

FRANCHISE DISCLOSURE DOCUMENT

**AmerisourceBergen Drug Corporation**

A Delaware Corporation
1 West First Avenue, Conshohocken, PA, 19428
(610) 727-7000
www.AmerisourceBergen.com

The franchise offered ("GNP Premier Program") is for one or more retail outlets properly licensed as a retail pharmacy offering prescription services, over-the-counter health and beauty aids, and complementary services under the trade name of **Good Neighbor Pharmacy®** ("GNP Premier Pharmacy"). This offering is being made to pharmacies operating under a distribution agreement with us that sign a GNP Premier Agreement (Exhibit B).

The total investment necessary for an existing pharmacy to begin operating a GNP Premier Pharmacy franchise, depending on your pharmacy's existing fit-out, equipment and inventory, ranges from \$43,797 to \$556,405, which includes between \$1,797 to \$279,497 which must be paid to us or our affiliates.

For a start-up pharmacy, the total investment necessary to begin operating a GNP Premier Pharmacy franchise ranges from \$278,797 to \$575,205, which includes between \$81,797 to \$165,297 which must be paid to us or our affiliates.

This Disclosure Document is required by law and summarizes certain provisions of your GNP Premier Agreement and other information in plain English. Read this Disclosure Document and all accompanying agreements carefully. You must receive this Disclosure Document at least 14 calendar days before you sign a binding agreement with, or make any payment to, the franchisor or an affiliate in connection with the proposed franchise sale. **Note, however, that no governmental agency has verified the information contained in this document.**

You may wish to receive your Disclosure Document in another format that is more convenient for you. To discuss the availability of disclosures in different formats, contact your account representative or the Good Neighbor Pharmacy program at 1 West First Avenue, Conshohocken, PA, 19428. You can also e-mail programs@amerisourcebergen.com.

The terms of **your franchise agreement with us** (the "**GNP Premier Agreement**") will govern our franchise relationship. Do not rely on the Disclosure Document alone to understand your contract. Read your entire contract carefully. Show your contract and this Disclosure Document to an advisor, like a lawyer or an accountant.

Buying a franchise is a complex investment. The information in this Disclosure Document can help you make up your mind. More information on franchising, such as "A Consumer's Guide to Buying a Franchise," which can help you understand how to use this Disclosure Document, is available from the Federal Trade Commission. You can contact the FTC at 1-877-FTC-HELP or by writing to the FTC at 600 Pennsylvania Avenue, NW, Washington, D.C. 20580. You can also visit the FTC's home page at www.ftc.gov for additional information. Call your state agency or visit your public library for other sources of information on franchising.

There may also be laws on franchising in your state. Ask your state agencies about them.

Date of Issuance: December 18, 2025

How to Use This Franchise Disclosure Document

Here are some questions you may be asking about buying a franchise and tips on how to find more information:

QUESTION	WHERE TO FIND INFORMATION
How much can I earn?	Item 19 may give you information about outlet sales, costs, profits or losses. You should also try to obtain this information from others, like current and former franchisees. You can find their names and contact information in Item 20 or Exhibit D.
How much will I need to invest?	Items 5 and 6 list fees you will be paying to the franchisor or at the franchisor's direction. Item 7 lists the initial investment to open. Item 8 describes the suppliers you must use.
Does the franchisor have the financial ability to provide support to my business?	Item 21 or Exhibit E includes financial statements. Review these statements carefully.
Is the franchise system stable, growing, or shrinking?	Item 20 summarizes the recent history of the number of company-owned and franchised outlets.
Will my business be the only Good Neighbor Pharmacy business in my area?	Item 12 and the "territory" provisions in the franchise agreement describe whether the franchisor and other franchisees can compete with you.
Does the franchise have a troubled legal history?	Items 3 and 4 tell you whether the franchisor or its management have been involved in material litigation or bankruptcy proceedings.
What's it like to be a Good Neighbor Pharmacy franchisee?	Item 20 or Exhibit D lists current and former franchisees. You can contact them to ask about their experiences.
What else should I know?	These questions are only a few things you should look for. Review all 23 Items and all Exhibits in this disclosure document to better understand this franchise opportunity. See the table of contents.

What You Need To Know About Franchising *Generally*

Continuing responsibility to pay fees. You may have to pay royalties and other fees even if you are losing money.

Business model can change. The franchise agreement may allow the franchisor to change its manuals and business model without your consent. These changes may require you to make additional investments in your franchise business or may harm your franchise business.

Supplier restrictions. You may have to buy or lease items from the franchisor or a limited group of suppliers the franchisor designates. These items may be more expensive than similar items you could buy on your own.

Operating restrictions. The franchise agreement may prohibit you from operating a similar business during the term of the franchise. There are usually other restrictions. Some examples may include controlling your location, your access to customers, what you sell, how you market, and your hours of operation.

Competition from franchisor. Even if the franchise agreement grants you a territory, the franchisor may have the right to compete with you in your territory.

Renewal. Your franchise agreement may not permit you to renew. Even if it does, you may have to sign a new agreement with different terms and conditions in order to continue to operate your franchise business.

When your franchise ends. The franchise agreement may prohibit you from operating a similar business after your franchise ends even if you still have obligations to your landlord or other creditors.

Some States Require Registration

Your state may have a franchise law, or other law, that requires franchisors to register before offering or selling franchises in the state. Registration does not mean that the state recommends that franchise or has verified the information in this document. To find out if your state has a registration requirement, or to contact your state, use the agency information in Exhibit A.

Your state also may have laws that require special disclosures or amendments be made to your franchise agreement. If so, you should check the State Specific Addenda. See the Table of Contents for the location of the State Specific Addenda.

Special Risks to Consider About *This* Franchise

Certain states require that the following risk(s) be highlighted:

1. **Out-of-State Dispute Resolution**. The franchise agreement requires you to resolve disputes with the franchisor by mediation, arbitration, or litigation only in Pennsylvania. Out-of-state mediation, arbitration, or litigation may force you to accept a less favorable settlement for disputes. It may also cost more to mediate, arbitrate, or litigate with franchisor in Pennsylvania than in your own state.

Certain states may require other risks to be highlighted. Check the “State Specific Addenda” (if any) to see whether your state requires other risks to be highlighted.

**ADDENDUM TO AMERISOURCEBERGEN DRUG CORPORATION
DISCLOSURE DOCUMENT
FOR THE STATE OF MICHIGAN**

THE STATE OF MICHIGAN PROHIBITS CERTAIN UNFAIR PROVISIONS THAT ARE SOMETIMES IN FRANCHISE DOCUMENTS. IF ANY OF THE FOLLOWING PROVISIONS ARE IN THESE FRANCHISE DOCUMENTS, THE PROVISIONS ARE VOID AND CANNOT BE ENFORCED AGAINST YOU:

(A) A PROHIBITION ON THE RIGHT OF A FRANCHISEE TO JOIN AN ASSOCIATION OF FRANCHISEES.

(B) A REQUIREMENT THAT A FRANCHISEE ASSENT TO A RELEASE, ASSIGNMENT, NOVATION, WAIVER, OR ESTOPPEL WHICH DEPRIVES A FRANCHISEE OF RIGHTS AND PROTECTIONS PROVIDED IN THIS ACT. THIS SHALL NOT PRECLUDE A FRANCHISEE, AFTER ENTERING INTO A FRANCHISE AGREEMENT, FROM SETTling ANY AND ALL CLAIMS.

(C) A PROVISION THAT PERMITS A FRANCHISOR TO TERMINATE A FRANCHISE PRIOR TO THE EXPIRATION OF ITS TERM EXCEPT FOR GOOD CAUSE. GOOD CAUSE SHALL INCLUDE THE FAILURE OF THE FRANCHISEE TO COMPLY WITH ANY LAWFUL PROVISION OF THE FRANCHISE AGREEMENT AND TO CURE SUCH FAILURE AFTER BEING GIVEN WRITTEN NOTICE THEREOF AND A REASONABLE OPPORTUNITY, WHICH IN NO EVENT NEED BE MORE THAN 30 DAYS, TO CURE SUCH FAILURE.

(D) A PROVISION THAT PERMITS A FRANCHISOR TO REFUSE TO RENEW A FRANCHISE WITHOUT FAIRLY COMPENSATING THE FRANCHISEE BY REPURCHASE OR OTHER MEANS FOR THE FAIR MARKET VALUE AT THE TIME OF EXPIRATION, OF THE FRANCHISEE'S INVENTORY, SUPPLIES, EQUIPMENT, FIXTURES, AND FURNISHINGS. PERSONALIZED MATERIALS WHICH HAVE NO VALUE TO THE FRANCHISOR AND INVENTORY, SUPPLIES, EQUIPMENT, FIXTURES, AND FURNISHINGS NOT REASONABLY REQUIRED IN THE CONDUCT OF THE FRANCHISE BUSINESS ARE NOT SUBJECT TO COMPENSATION. THIS SUBSECTION APPLIES ONLY IF: (i) THE TERM OF THE FRANCHISE IS LESS THAN 5 YEARS; AND (ii) THE FRANCHISEE IS PROHIBITED BY THE FRANCHISE OR OTHER AGREEMENT FROM CONTINUING TO CONDUCT SUBSTANTIALLY THE SAME BUSINESS UNDER ANOTHER TRADEMARK, SERVICE MARK, TRADE NAME, LOGOTYPE, ADVERTISING, OR OTHER COMMERCIAL SYMBOL IN THE SAME AREA SUBSEQUENT TO THE EXPIRATION OF THE FRANCHISE OR THE FRANCHISEE DOES NOT RECEIVE AT LEAST 6 MONTHS ADVANCE NOTICE OF FRANCHISOR'S INTENT NOT TO RENEW THE FRANCHISE.

(E) A PROVISION THAT PERMITS THE FRANCHISOR TO REFUSE TO RENEW A FRANCHISE ON TERMS GENERALLY AVAILABLE TO OTHER FRANCHISEES OF THE SAME CLASS OR TYPE UNDER SIMILAR CIRCUMSTANCES. THIS SECTION DOES NOT REQUIRE A RENEWAL PROVISION.

(F) A PROVISION REQUIRING THAT ARBITRATION OR LITIGATION BE CONDUCTED OUTSIDE THIS STATE. THIS SHALL NOT PRECLUDE THE FRANCHISEE

FROM ENTERING INTO AN AGREEMENT, AT THE TIME OF ARBITRATION, TO CONDUCT ARBITRATION AT A LOCATION OUTSIDE THIS STATE.

(G) A PROVISION WHICH PERMITS A FRANCHISOR TO REFUSE TO PERMIT A TRANSFER OF OWNERSHIP OF A FRANCHISE, EXCEPT FOR GOOD CAUSE. THIS SUBDIVISION DOES NOT PREVENT A FRANCHISOR FROM EXERCISING A RIGHT OF FIRST REFUSAL TO PURCHASE THE FRANCHISE. GOOD CAUSE SHALL INCLUDE, BUT IS NOT LIMITED TO:

(i) THE FAILURE OF THE PROPOSED TRANSFEREE TO MEET THE FRANCHISOR'S THEN CURRENT REASONABLE QUALIFICATIONS OR STANDARDS.

(ii) THE FACT THAT THE PROPOSED TRANSFEREE IS A COMPETITOR OF THE FRANCHISOR OR SUBFRANCHISOR.

(iii) THE UNWILLINGNESS OF THE PROPOSED TRANSFEREE TO AGREE IN WRITING TO COMPLY WITH ALL LAWFUL OBLIGATIONS.

(iv) THE FAILURE OF THE FRANCHISEE OR PROPOSED TRANSFEREE TO PAY ANY SUMS OWING TO THE FRANCHISOR OR TO CURE ANY DEFAULT IN THE FRANCHISE AGREEMENT EXISTING AT THE TIME OF THE PROPOSED TRANSFER.

(H) A PROVISION THAT REQUIRES THE FRANCHISEE TO RESELL TO THE FRANCHISOR ITEMS THAT ARE NOT UNIQUELY IDENTIFIED WITH THE FRANCHISOR. THIS SUBDIVISION DOES NOT PROHIBIT A PROVISION THAT GRANTS TO A FRANCHISOR A RIGHT OF FIRST REFUSAL TO PURCHASE THE ASSETS OF A FRANCHISE ON THE SAME TERMS AND CONDITIONS AS A BONA FIDE THIRD PARTY WILLING AND ABLE TO PURCHASE THOSE ASSETS, NOR DOES THIS SUBDIVISION PROHIBIT A PROVISION THAT GRANTS THE FRANCHISOR THE RIGHT TO ACQUIRE THE ASSETS OF A FRANCHISE FOR THE MARKET OR APPRAISED VALUE OF SUCH ASSETS IF THE FRANCHISEE HAS BREACHED THE LAWFUL PROVISIONS OF THE FRANCHISE AGREEMENT AND HAS FAILED TO CURE THE BREACH IN THE MANNER PROVIDED IN SUBDIVISION (C).

(I) A PROVISION WHICH PERMITS THE FRANCHISOR TO DIRECTLY OR INDIRECTLY CONVEY, ASSIGN, OR OTHERWISE TRANSFER ITS OBLIGATIONS TO FULFILL CONTRACTUAL OBLIGATIONS TO THE FRANCHISEE UNLESS PROVISION HAS BEEN MADE FOR PROVIDING THE REQUIRED CONTRACTUAL SERVICES.

THE FACT THAT THERE IS A NOTICE OF THIS OFFERING ON FILE WITH THE ATTORNEY GENERAL DOES NOT CONSTITUTE APPROVAL, RECOMMENDATION, OR ENDORSEMENT BY THE ATTORNEY GENERAL.

ANY QUESTIONS REGARDING THIS NOTICE SHOULD BE ADDRESSED TO:

DEPARTMENT OF ATTORNEY GENERAL
CONSUMER PROTECTION DIVISION
G. Mennen Williams Building, 5th Floor
525 W. Ottawa Street
LANSING, MICHIGAN 48913
Telephone (517) 373-7117

TABLE OF CONTENTS

	<u>Page</u>
ITEM 1 THE FRANCHISOR AND ANY PARENTS, PREDECESSORS, AND AFFILIATES.....	2
ITEM 2 BUSINESS EXPERIENCE	10
ITEM 3 LITIGATION	11
ITEM 4 BANKRUPTCY	14
ITEM 5 INITIAL FEES.....	15
ITEM 6 OTHER FEES	17
ITEM 7 ESTIMATED INITIAL INVESTMENT	20
ITEM 8 RESTRICTIONS ON SOURCES OF PRODUCTS AND SERVICES	24
ITEM 9 FRANCHISEE'S OBLIGATIONS	29
ITEM 10 FINANCING	31
ITEM 11 FRANCHISOR'S ASSISTANCE, ADVERTISING, COMPUTER SYSTEMS AND TRAINING	31
ITEM 12 TERRITORY	35
ITEM 13 TRADEMARKS	36
ITEM 14 PATENTS, COPYRIGHTS AND PROPRIETARY INFORMATION	37
ITEM 15 OBLIGATION TO PARTICIPATE IN THE ACTUAL OPERATION OF THE FRANCHISE BUSINESS.....	38
ITEM 16 RESTRICTIONS ON WHAT THE FRANCHISEE MAY SELL	39
ITEM 17 RENEWAL, TERMINATION, TRANSFER AND DISPUTE RESOLUTION.....	40
ITEM 18 PUBLIC FIGURES	45
ITEM 19 FINANCIAL PERFORMANCE REPRESENTATIONS	45
ITEM 20 OUTLETS AND FRANCHISEE INFORMATION.....	49
ITEM 21 FINANCIAL STATEMENTS.....	66
ITEM 22 CONTRACTS.....	66
ITEM 23 RECEIPTS	67
EXHIBIT A STATE ADMINISTRATORS AND AGENTS FOR SERVICE OF PROCESS	
EXHIBIT B GNP PREMIER AGREEMENT	
EXHIBIT C TABLE OF CONTENTS OF GNP MANUAL(S)	
EXHIBIT D LIST OF CURRENT, TRANSFERRED & FORMER FRANCHISEES AS OF SEPTEMBER 30, 2025	
EXHIBIT E FINANCIAL STATEMENTS AND CENCORA GUARANTY	
EXHIBIT F STATE SPECIFIC ADDENDA TO AMERISOURCEBERGEN DRUG CORPORATION DISCLOSURE DOCUMENT	

ITEM 1

THE FRANCHISOR AND ANY PARENTS, PREDECESSORS, AND AFFILIATES

The Franchisor is AmerisourceBergen Drug Corporation. To simplify this Disclosure Document, AmerisourceBergen Drug Corporation is referred to as “ABDC”, “we”, “us” or “our”. “You” means the person or legal entity who buys the franchise, the franchisee (called a “Customer” in the agreements). If you are a corporation, limited liability company, partnership or any other type of legal entity, certain provisions of the GNP Premier Agreement (defined below) also will apply to, and be binding upon, certain of your owners (referred to as your “Principals”).

AmerisourceBergen Drug Corporation

We are a Delaware corporation, formed on June 24, 1985. We do business only under our corporate name, “**AmerisourceBergen Drug Corporation**”, and the names “**Good Neighbor Pharmacy**” and “**Elevate Provider Network**.” Our principal business address is 1 West First Avenue, Conshohocken, PA, 19428. Our agents for service of process are listed in Exhibit A. We have offered franchises since 2009. We have not conducted business nor offered franchises in any other line of business.

Our parent company is Cencora, Inc. (“Cencora”). Cencora is a Delaware corporation, formed on March 16, 2001 as AmerisourceBergen Corporation (and changed its name to Cencora, Inc. on August 30, 2023) in contemplation of the August 2001 merger of AmeriSource Health Corporation (“AHC”) and Bergen Brunswig Corporation (“BBC”). In August 2001, AHC and BBC became subsidiaries of Cencora. AHC and BBC continued as subsidiaries of Cencora until October 2002, at which time BBC was merged with and into AHC. AHC was the survivor and was renamed AmerisourceBergen Services Corporation (“ABSC”). ABSC survives today as a subsidiary of Cencora.

Cencora is one of the largest global pharmaceutical sourcing and distribution services companies, helping healthcare providers and pharmaceutical and biotech manufacturers improve patient access to products and enhance patient care. We deliver innovative programs and services designed to increase the effectiveness and efficiency of the pharmaceutical supply chain. More specifically, we distribute a comprehensive offering of brand-name and generic pharmaceuticals (including specialty pharmaceutical products), over-the-counter healthcare products, home healthcare supplies and equipment, and related services to a wide variety of healthcare providers located in the United States and select global markets, including retail chain and independent pharmacies, mail order pharmacies, acute care hospitals and health systems, physician practices, medical and dialysis clinics, long-term care and other alternate site pharmacies, and other customers. We also provide pharmacy services to certain specialty drug patients. Additionally, we furnish healthcare providers and pharmaceutical manufacturers with an assortment of related services, including reimbursement and pharmaceutical consulting services, niche premium logistics services, claim management services, and pharmacy management, along with retail strategies and front-end management, marketing and advertising services, digital media tools, and educational opportunities.

Our Predecessor and Affiliates

We acquired a substantial portion of our assets from Bergen Brunswig Drug Company (“BBDC”), which merged with and into AmeriSource Corporation (“ASC”) in October 2002. ASC was the survivor, under the name AmerisourceBergen Drug Corporation (us), and we acquired BBDC’s assets pursuant to the merger. In Puerto Rico, we operate through our wholly owned subsidiary, J.M. Blanco, Inc. (“Blanco”), a Delaware corporation, which maintains the same principal business address as us. In 2012, we acquired World Courier Group, Inc., which operates in over 50 countries and is a leading global specialty transportation and logistics provider for the biopharmaceutical industry. In February 2015, we acquired MWI Veterinary Supply, Inc. (“MWI”), a leading animal health distribution company in the United States

and in the United Kingdom. MWI sells pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and various other products to customers in both the companion animal and production animal markets. MWI also offers its customers a variety of value-added services, including its e-commerce platform, technology management systems, pharmacy fulfillment, inventory management system, equipment procurement consultation, special order fulfillment, and educational seminars. In June 2021, we acquired a majority of the Alliance Healthcare business from Walgreens Boots Alliance. Alliance Healthcare is one of the largest pharmaceutical wholesalers primarily in Europe and also operates retail pharmacies and provides manufacturer services in certain of its countries of operation. In January 2023, we acquired PharmaLex Holding GmbH, a leading provider of specialized services for the life sciences industry. In January 2025, we acquired Retina Consultants of America, a leading management services organization of retina specialists.

Although customers may, from time to time, choose to do business with our affiliates, other than Blanco, such business would not be connected with the GNP Premier Agreement.

Our affiliates, Alliance Healthcare Romania SRL and Alliance Healthcare Nederland B.V., make available pharmacy franchise offerings under the Alphega® brand in Romania and the Netherlands, respectively. Alliance Healthcare Romania SRL, which was incorporated in Romania and maintains its principal place of business at 7 Amilcar C. Sandulescu Street, 6th District, Bucharest, 060859 Romania, has made its pharmacy franchise offering available since September 1, 2016. As of the close of its 2025 fiscal year, there were 652 franchisees participating in Alliance Healthcare Romania SRL's pharmacy franchise offering. Alliance Healthcare Nederland B.V., which was incorporated in the Netherlands and maintains its principal place of business at Kempkens 2200, 5465 PR Veghel, Netherlands, has made its pharmacy franchise offering available since 2002. As of the close of its 2025 fiscal year, there were 77 franchisees participating in Alliance Healthcare Nederland B.V.'s pharmacy franchise offering. Except as described above, our predecessors, parents and affiliates do not provide products or services to our franchisees as part of the franchise relationship.

Our Legacy Voluntary Program

From 1982 until July 2019, we offered independent community pharmacies a license to operate under the Good Neighbor Pharmacy trade name ("Voluntary Pharmacy") on terms substantially different than those contained in the GNP Premier Agreement. As of July 2019, we no longer offer new independent pharmacies the opportunity to sign up as Voluntary Pharmacies; however, a significant number of legacy Voluntary Pharmacies continue to operate. As part of the Voluntary Pharmacy program, we provide products and services to independent community pharmacies, regional retail chain pharmacies and other healthcare providers, including hospitals, physician offices and clinics and other alternate care facilities. Voluntary Pharmacies did not sign the GNP Premier Agreement, which we began offering in 2009. As of September 30, 2025, there were 157 Voluntary Pharmacies and 2,204 GNP Premier Pharmacies (for a total of 2,361). See Item 20.

Description of the Franchise

We grant franchises for GNP Premier Pharmacies that operate under the "Marks," which include (i) the "Good Neighbor Pharmacy" and related service marks, (ii) the "Elevate Provider Network" service marks, (iii) the elements and components of a GNP Premier Pharmacy's trade dress, and (iv) any and all additional, different or replacement trade names, trademarks, service marks, logos and slogans that we adopt from time to time to identify the GNP Premier Program and products and services that can be offered by a GNP Premier Pharmacy or the GNP Premier Program, including Available Programs. Though we do not currently own or operate any GNP Premier Pharmacies, we reserve the right to own and/or operate GNP Premier Pharmacies.

ABDC, as a pharmaceutical distribution services company, delivers medicines and other products to thousands of retail customers on a just-in-time basis, which are then dispensed or sold to patients and consumers. We also provide business coaching services to help those customers who are GNP Premier Pharmacies improve their businesses and focus on their strengths. GNP Premier Pharmacies offer other retail products and services, including traditional drug store categories such as vitamins, cough and cold, first aid, and analgesics. Some GNP Premier Pharmacies carry home healthcare products, such as canes, walkers and other durable medical equipment.

We offer GNP Premier Agreements that grant to eligible customers the right to convert one or more existing or start-up pharmacies to each become a GNP Premier Pharmacy at a designated site ("Pharmacy Location"). The GNP Premier Agreement is attached to this Disclosure Document as Exhibit B. If you currently operate a pharmacy, we assume that you have an existing location, inventory, equipment and other items necessary to operate a pharmacy at the time you sign the GNP Premier Agreement. You have the right to terminate the GNP Premier Agreement at any time on 60 days' notice without cause.

To be eligible to participate in the GNP Premier Program, you must meet our minimum requirements ("Premier Minimum Requirements"), including having a computer system for pharmacy management that allows participation in our InSite from ABDC program and related Available Programs. For stores whose existing pharmacy management system does not enable participation in our InSite from ABDC program and related Available Programs, we estimate it would take two to four months for a store to plan, evaluate, purchase and install the required system. See Items 8 and 11.

You must operate your GNP Premier Pharmacy and utilize Available Programs in accordance with the GNP Premier Agreement and the standards we establish ("Standards"). The Standards are described in our manuals and other directives to you, whether on paper or electronic form ("GNP Manual"), which we revise and supplement from time to time. The Standards pertain to, among other things, purchases of prescription pharmaceuticals, over-the-counter products, including our GNP private label products ("GNP Private Label Products"), health and beauty care products, signage and layouts, equipment, specifications for products and services, training, methods of inventory control, advertising and marketing programs and information technology, all of which we may improve, further develop or otherwise modify from time to time.

GNP Premier Program

Among other things, the GNP Premier Agreement, which we began offering in 2009, provides an integrated bundle of programs and services ("Available Programs"), including programs and services fee such as Elevate Provider Network, InSite from ABDC, Claim Reconciliation, and Business Coaching. See description of the Available Programs under "Description of Available Programs" below in this Item, and in Term Sheets 1-10 of the GNP Premier Agreement (each, a "Term Sheet"). You must participate in certain Available Programs after your GNP Premier Agreement becomes effective and you may, from time to time, elect to enroll in others optional Available Programs, some of which have additional fees. See pages 3-4 and Term Sheets 1-10 of the GNP Premier Agreement (Exhibit B to this Disclosure Document). Term Sheets 1-10 of the GNP Premier Agreement describe Available Programs we currently offer or provide to you.

Terms and conditions for each Available Program are provided on applicable Term Sheets, which are agreed to as part of the GNP Premier Agreement (see Term Sheets 1-10 which are attached to the GNP Premier Agreement). In addition, you will sign a Data Authorization to the Master Program Agreement (which is attached to the GNP Premier Agreement), which we then provide to one or more of your designated system vendors and our Program Partners (as defined in Term Sheet 2) as authorization to enable us to receive your Pharmacy Data (as defined in the Data Protection Provisions; See Exhibit A to the GNP Premier Agreement).

You may be required to fulfill certain prerequisite conditions before the services offered in an Available Program are made available to you. For an Available Program that is Optional, you may (i) enroll during the Term by submitting applicable information required to set-up your participation and requesting that ABDC begin providing such Available Program and (ii) disenroll by requesting that ABDC discontinue providing such Available Program, pursuant to the terms of the corresponding Term Sheet. All Term Sheets incorporate provisions of the GNP Premier Agreement, including, without limitation, its respective Exhibits, by reference.

The following is a short description of the Available Programs. Also see Items 6, 8, 9 and 17 of this Disclosure Document for more information about the Available Programs.

The table below lists the Available Programs you must participate in under the GNP Premier Program. See Item 11 and relevant Term Sheets for more detailed descriptions.

<u>Required Programs</u>	<u>Term Sheet</u>
<p>Elevate Provider Network®</p> <p>We will enter into agreements on your behalf with Payors (as defined in Item 16) that offer pharmacy benefit plans to their members. Individual Payors process and pay covered service claims you submit. We receive centralized payments from Payors and disburse your funds to you (“Central Pay”). We provide help desk service and in general facilitate your participation in managed care networks to gain access to patients.</p> <p><i>Additional fees may apply for Network Providers that: (i) process more than 10,000 claims in a month; (ii) use alternative, approved switch service providers for Elevate Advanced Features; and/or (iii) elect to receive optional and/or enhanced Elevate Advanced Features services (e.g., enhanced reporting, etc.).</i></p>	Term Sheet 1
<p>Elevate Advanced Features (Included with Elevate Provider Network®)</p> <p>ABDC, together with Program Partners, has assembled a suite of data-driven services designed to assist you with your healthcare operations including treatment, payment, and healthcare operations activities. We will collect your Pharmacy Data directly from you and indirectly from Program Partners supporting or participating in the Available Programs, including without limitation your designated pharmacy system vendor, designated point-of-sale system vendor, designated reconciliation service provider, Change Healthcare (a part of Optum® [“Change Healthcare”]), or other switch service provider approved by ABDC in writing, EnlivenHealth (f/k/a FDS AMPLICARE, Inc.) (“EnlivenHealth”), Retail Insights and Outcomes Operating, Inc. (f/k/a Prescribe Wellness) (“Outcomes”).</p> <p><i>Additional fees may apply for Network Providers that: (i) process more than 10,000 claims in a month; (ii) use alternative, approved switch service providers for Elevate Advanced Features; and/or (iii) elect to receive optional and/or enhanced Elevate Advanced Features services (e.g., enhanced reporting, etc.).</i></p>	Term Sheet 2
<p>Pre & Post Edit Solutions (PPE) (Part of the Elevate Advanced Features)</p> <p>ABDC, together with our Program Partner Change Healthcare, offers pre- and post-edit and other claim services. Your pharmacy must use Change Healthcare as its pharmacy switch for routing claims to Payors (as defined in Term Sheet 1). You must contract directly with Change Healthcare for pharmacy switching services (or indirectly through your pharmacy management system vendor). Change Healthcare captures your claim transactions and furnishes a copy to us for use in those programs designed to aid your pharmacy in its treatment, payment, and healthcare operations activities.</p> <p>Optional services offered by Change Healthcare through ABDC include payer compliance re-billing and electronic medical claims billing for immunization services.</p>	Term Sheet 2A

Required Programs	Term Sheet
<p>Claim Reconciliation Services <i>(Part of the Elevate Advanced Features)</i></p> <p>ABDC, together with our Program Partner EnlivenHealth, extend our Central Pay services to include a self-service claims reconciliation solution through the use of a web-based portal so that your pharmacy staff can match claims to actual payments and generate various receivables reports. This program is designed to aid your pharmacy in its payment and healthcare operations activities.</p> <p>EnlivenHealth also offers an optional “Concierge Service” for an additional monthly fee. Customers may enroll in the optional service directly with EnlivenHealth.</p>	Term Sheet 2B
<p>InSite from ABDC <i>Pharmacy Management System Data</i></p> <p>We operate a proprietary data analytics system used to measure and compare pharmacy performance by organizing and analyzing detailed prescription and other business transaction data. Certain data is collected directly from you and other data indirectly with the collaboration of your designated system vendors and in cooperation with our Program Partners, including without limitation Change Healthcare (or other claims switching services provider approved by ABDC in writing), EnlivenHealth, Outcomes, and Retail Insights. We manage your data under the terms of our Data Protection Provisions (Exhibit A to the GNP Premier Agreement).</p> <p>Optional programs include InSite for Point-of-Sale System Data and the Five-Star Rebate Program.</p>	Term Sheet 3
<p>First to Shelf® <i>Front-End Products</i></p> <p>We will auto-ship to your pharmacy certain newly launched front-end products that we anticipate will be important products in the category. These products are often private label products or Rx-to-OTC switch items. You must promptly display the products.</p>	Term Sheet 5

Optional Programs

The following optional programs are available to GNP Premier Pharmacies, subject to the fees and conditions outlined in the following table and described in further detail in the relevant Term Sheets attached to your GNP Premier Agreement. You may (i) enroll during the Term by submitting applicable information required to activate your participation and requesting that ABDC begin providing such Available Program and (ii) disenroll by requesting that ABDC discontinue providing such Available Program, pursuant to the terms of the corresponding Term Sheet. See Item 11 and relevant Term Sheets for more detailed descriptions.

Optional Programs	Term Sheet
<p>Five-Star Rebate Program</p> <p>We offer the Five-Star Rebate program to recognize high performance in CMS Star Measures and to encourage continuous performance improvements. Based on pharmacy performance measures, your pharmacy will be eligible for a rebate of up to 100 basis points (1.00%) on your overall net purchases of rebateable PRxO Generics®. Unless agreed upon otherwise as between ABDC and your buying group (if any), the quarterly rebate is issued as a credit by us. As part of the program, you provide your consent to extract dispense usage data from your Pharmacy Data and make it available to our sales team to assist you in optimizing your purchase performance with ABDC. Requires participation in Elevate Advanced Features (Term Sheet 2). Further eligibility conditions apply (see Term Sheet 4) and may differ based on buying group affiliation; consult with your buying group for more details.</p> <p>No additional fees.</p>	Term Sheet 4
<p>Pre & Post Edit Solutions (PPE) (Part of Elevate Advanced Features)</p> <p>Customer may choose to participate in Change Healthcare's payer compliance re-billing and electronic medical claims billing for immunization services (where ABDC has signed network agreements with applicable Payors). Additional fees apply at the following negotiated pricing.</p> <p><u>Fees:</u> <u>Payer Compliance Claims:</u> \$1.00 per successful claim <u>MedRx Immunization Claims:</u> \$1.00 per successful claim <u>Other Services:</u> Prevailing rate</p>	Term Sheet 2A
<p>Claim Reconciliation Concierge Services</p> <p>This optional service is provided directly by EnlivenHealth who will assign a reconciliation analyst to you. This analyst will conduct those tasks normally handled by you or your staff in our self-service model. The analyst will regularly provide you reports on the state of your third-party receivables. You will sign a service agreement directly with EnlivenHealth to enroll in the optional Concierge program.</p> <p><u>Fees:</u> \$199/month for optional Concierge Services (No fee for self-service)</p>	Term Sheet 2B
<p>Outcomes Patient Care Services</p> <p>Outcomes makes available its Outcomes Premium Solution (as defined in Term Sheet 2C) offering real-time analytics and ongoing management tools designed to assist subscribing pharmacies in improving, among other things, patient health outcomes, patient adherence, and clinical services. The Outcomes Premium Solution is currently made available through Prescribe Wellness functionality but will be transitioned to Outcomes Premium. Subscribing customers will sign a service agreement directly with Outcomes to access certain modules or offerings available via this optional program. Applicable fees to be paid by Customer may vary and are dependent upon the manner in which Customer enrolls in the Outcomes Premium Solution and applicable Outcomes Premium Solution modules chosen by Customer. If Customer enrolls in the Outcomes Premium Solution directly through Outcomes, Customer will pay Outcomes' prevailing rates. Alternatively, if Customer enrolls in the Outcomes Premium Solution through ABDC and satisfies all applicable requirements (see Term Sheet 2C), Customer will pay the following rates, which may be increased by up to Five Percent (5%) annually, for the following Outcomes Premium Solution modules:</p> <p><u>Outcomes Premium:</u> \$49/store/month <u>Outcomes Premium + Vaccine:</u> \$129/store/month <u>Outcomes Premium + Vaccine + Engagement:</u> \$249/store/month</p>	Term Sheet 2C

Optional Programs	Term Sheet
<p>EnlivenHealth Patient Care Services</p> <p>EnlivenHealth makes available its Treat Solution (as defined in Term Sheet 2D) offering real-time analytics and ongoing management tools designed to assist subscribing pharmacies in improving, among other things, patient health outcomes, patient adherence, and clinical services. Subscribing customers will sign a service agreement directly with EnlivenHealth to access certain modules or offerings available via this optional program. Applicable fees to be paid by Customer may vary and are dependent upon the manner in which Customer enrolls in the Treat Solution and applicable Treat Solution bundles chosen by Customer. If Customer enrolls in the Treat Solution directly through EnlivenHealth, Customer will pay EnlivenHealth's prevailing rates. Alternatively, if Customer enrolls in the Treat Solution through ABDC and satisfies all applicable requirements (see Term Sheet 2D), Customer will pay the following rates for the following Treat Solution bundles:</p> <p><u>Essentials</u>: \$100/store/month</p> <p><u>Workflow</u>: \$100/store/month</p> <p><u>All-In</u>: \$185/store/month</p> <p><i>*Additional transaction fees may apply based on the bundle chosen, as provided under Customer's direct agreement with EnlivenHealth respecting the Treat Solution.</i></p>	Term Sheet 2D
<p>InSite for Point-of-Sale System Data</p> <p>We also accept the data from your point-of-sale system to measure and compare the performance of the front-end of your pharmacy to your peers. Certain data is collected directly from you and other data indirectly with the collaboration of your designated system vendors and in cooperation with our Program Partners, including without limitation Change Healthcare (or other claims switching services provider approved by ABDC in writing), EnlivenHealth, Outcomes, and Retail Insights. We manage your data under the terms of our Data Protection Provisions (Exhibit A to the GNP Premier Agreement).</p> <p>No additional fees.</p>	Term Sheet 3
<p>Planogram Services</p> <p>We regularly publish and update schematic diagrams, known as "Planograms," which specify the optimal layouts of traditional drug store front-end product categories. Planograms are designed based on industry and consumer research to increase product sales. If you enroll in Merchandising services, our team will implement the planograms as part of their scheduled visit in your store.</p> <p>No additional fees.</p>	Term Sheet 5
<p>Retail Product Zone Pricing</p> <p>We regularly publish and update suggested retail prices, based on competitive zones, for traditional drug store front-end products. Prices are set based on industry research. You will pick a specific price zone which is tied to targeted competitiveness.</p> <p>No additional fees.</p>	Term Sheet 5
<p>Front-End Support Kit</p> <p><i>Monthly in-store promotional materials</i></p> <p>As an integral component of the Good Neighbor Pharmacy program, ABDC provides in-store promotional materials in reasonable quantities in a monthly kit for you to promptly display in-store, consistent with directions from ABDC in Program Guides.</p>	Term Sheet 5

Optional Programs	Term Sheet
<p>Merchandising Services</p> <p>A Retail Merchandising Specialist visits your pharmacy periodically to match pharmacy product choice and placement to category Planograms which you maintain between visits. You must substantially comply with Planogram layouts and stock substantially all Planogram products. Requires participation in InSite for Point-of-Sale System Data.</p> <p>No additional fees.</p>	Term Sheet 5
<p>Digital Marketing</p> <p>We provide a set of interrelated programs designed to assist you in promoting your pharmacy through the use of digital marketing channels. Programs include a website, mobile application, social media resources, pay-per-click digital advertising and local listing management all designed to attract patients and other consumers and build loyalty.</p> <p><i>Additional optional digital advertising services, such as ad hoc digital marketing campaign opportunities, may be made available via separate enrollment form(s) and subject to additional terms, conditions, and fees (which may vary based on options selected).</i></p>	Term Sheet 6
<p>Business Coaching</p> <p>Using the data received by InSite as well as additional financial and operational information you provide, a Business Coaching Associate (as defined in Term Sheet 7) will assess your pharmacy's current state, help identify opportunities to enhance performance and make recommendations to you based on industry best practices. The recommendations are intended to be able to be implemented in a relatively short period of time and without significant capital investment.</p> <p>No additional fees.</p>	Term Sheet 7
<p>Pharmacy Data Services</p> <p>You may select which system data services you wish us to provide for your installed systems, including on-line order processing and item catalogs with price updates for your pharmacy management and point-of-sale systems.</p> <p>No additional fees.</p>	Term Sheet 8
<p>Unsaleable Returns</p> <p>To assist pharmacies in recovering the value of unsaleable products, we provide pharmacies with a comprehensive solution for disposal including all processing, shipping, and destruction costs. Premier pharmacies are eligible for onsite assistance and pre-funding based on the estimated recoverable value prior to returning the products.</p> <p>No additional fees.</p>	Term Sheet 9
<p>Statement of Work Services (Form)</p> <p>You may request that we provide other services that are beyond Available Programs. The Special Project Form, when agreed upon by the parties, would describe the terms and conditions under which those extra services will be provided.</p> <p>Fees: Determined on a case-by-case basis.</p>	Term Sheet 10

The General Market

We consider the market for pharmacies to be very well developed. GNP Premier Pharmacies offer most of their products and services to all types of consumers on a walk-in, retail basis. Some GNP Premier Pharmacies also serve long term care, assisted living, or similar facilities. Sales of prescription products are restricted by law to patients with a valid prescription. Sales of some products, both prescription and OTC, such as vaccines or cough and cold remedies, are generally seasonal.

Industry Specific Regulation

You must comply with all federal, state and local laws relating to the offer and sale of prescription medicines, as well as regulations adopted by state pharmacy boards and the U.S. Food and Drug Administration and U.S. Drug Enforcement Administration, including laws and regulations relating to whom prescription pharmaceuticals may be sold and the storage, security and disposal of prescription pharmaceuticals. You must comply with regulations under the federal Health Insurance Portability and Accountability Act of 1996, as amended, ("HIPAA"). See, for example, HIPAA Business Associate Agreement, Exhibit B of the GNP Premier Agreement (which is Exhibit B of this Disclosure Document).

Development and operation of your GNP Premier Pharmacy will also be subject to compliance with applicable zoning and environmental regulations as well as federal and state employment and health and safety laws, including minimum wage laws governing some of your employees. Some of your GNP Premier Pharmacy's personnel may be paid at rates related to the federal minimum wage and, accordingly, further increases in the federal, state or local minimum wage will affect your labor costs. There may be other laws or regulations affecting your GNP Premier Pharmacy.

We are not aware of any laws or regulations that would apply to a GNP Premier Pharmacy differently than those that already apply to you if you operate an existing pharmacy or that will apply to you if you are opening a new start-up pharmacy. We recommend that you check with your state and local agencies to determine which laws apply to the operation of a GNP Premier Pharmacy in your area. You should consider these laws and regulations when evaluating your decision to participate in the GNP Premier Program.

Competition

You will compete with other GNP Premier Pharmacies. You will also compete with other independent pharmacies and chain pharmacies in a variety of locations, such as grocery and mass merchandisers and in some instances, hospital and clinic facilities. With respect to non-pharmaceutical products, you will compete with grocery stores, drug stores, discount stores and similar retail outlets.

ITEM 2 **BUSINESS EXPERIENCE**

President and Chief Executive Officer: Robert P. Mauch

Mr. Mauch has been President and Chief Executive Officer of the Company and a member of the Board since October 2024. Prior to that, he served as Executive Vice President and Chief Operating Officer from October 2022 to September 2024. He served as Group President from February 2019 to September 2022. He served as Group President, Pharmaceutical Distribution & Strategic Global Sourcing from June 2017 to February 2019. He served as President, AmerisourceBergen Drug Corporation from February 2015 to June 2017. Mr. Mauch served as Senior Vice President and Chief Operating Officer, AmerisourceBergen Drug Corporation from March 2014 to February 2015. He was Senior Vice President, Operations, AmerisourceBergen Drug Corporation from April 2012 to March 2014. He was Senior Vice President of Sales and Marketing, AmerisourceBergen Drug Corporation from April 2011 to April 2012. He was Senior Vice President, Alternate Care Sales and Marketing, AmerisourceBergen Drug Corporation from May 2010 to April 2011. Mr. Mauch has been employed by the Company or one of its predecessors for over 25 years.

Executive Vice President and Chief Financial Officer: James F. Cleary

Mr. Cleary has been Executive Vice President since March 2015 and became Chief Financial Officer in November 2018. He served as Group President, Global Commercialization Services & Animal Health from June 2017 to November 2018. He previously served as President, MWI Animal Health from March 2015 to June 2017. Prior to joining the Company, he was President and Chief Executive Officer of MWI Veterinary Supply, Inc. from June 2002. Mr. Cleary has been employed by the Company or one of its predecessors for over 25 years.

Executive Vice President and Chief Legal Officer: Elizabeth Campbell

Ms. Campbell has been Executive Vice President and Chief Legal Officer since September 2021. She served as Senior Vice President and Deputy General Counsel from June 2020 to August 2021. Prior to that, Ms. Campbell served in a variety of roles within the Company's legal department with increased responsibility, including serving as Chief Litigator and Chief Compliance Counsel. Ms. Campbell has been employed by the Company for 15 years.

Executive Vice President and President, U.S. Pharmaceutical and Animal Health: Rich Tremonte

Mr. Tremonte has served as EVP & President of U.S. Pharmaceutical and Animal Health at Cencora since October 2022. Prior to this role, Mr. Tremonte served as EVP & President of Community & Specialty Pharmacy at Cencora beginning September 2018 and President of Strategic Global Sourcing from June 2017 until September 2018. This included leading global offices in Ireland and Switzerland.

Senior Vice President, Community & Specialty Pharmacy and Marketing Retail Executive Vice President: Franklin Harris

Mr. Harris has served as our Senior Vice President, Independent Community & Specialty Pharmacy Field and Inside Sales since July 2020. Mr. Harris joined Cencora in 1997 and has held roles within CSP sales, Strategic Global Sourcing as well as internationally where he worked within the Walgreens Boots Alliance Development Sourcing Group as the AmerisourceBergen Seconded. Mr. Harris is located in our office in Conshohocken, Pennsylvania.

Senior Vice President and President, Community Retail & Long-Term Care: Tim Cernohous

Mr. Cernohous has served as Senior Vice President and President of Community Retail and Long-Term Care Pharmacy since February 2024. Prior to this role, Mr. Cernohous served as SVP, Commercial Advancement and Operations at Cencora within the Health System and Government Services business unit. Before joining Cencora in 2023, Mr. Cernohous led Ambulatory Pharmacy Services at Essentia Health located in Duluth, Minnesota.

ITEM 3 **LITIGATION**

Cencora, our parent, is one of the largest global pharmaceutical sourcing and distribution services companies. As a result, at any given time, Cencora and its subsidiaries may be involved in lawsuits, administrative proceedings, government subpoenas and investigations which may be viewed as ordinary and routine. Such matters may allege or involve, among other things, fraud, unfair practices or comparable allegations.

Other than the matters below, at this time, we do not view these matters as material to prospective franchisees. Cencora's audited financial statements describe certain of these matters. See Note 12 and

Note 13 of Exhibit E to this Disclosure Document. Further, Cencora may have been involved in matters in which it was alleged to have violated antitrust or securities law or to have engaged in fraud, misrepresentation or similar behavior which may be considered other than routine in nature, but which we do not believe, at this time, are material to a prospective franchisee.

United States ex rel. Michael Mullen v. AmerisourceBergen Corporation, et al., Civil Action No. CV-10-4856 (E.D.N.Y); United States ex rel. Omni Healthcare Inc. v. AmerisourceBergen, et al., Civil Action No. CV-12- 1178 (E.D.N.Y); United States ex rel. Daniel Sypula and Kelly Hodge v. AmerisourceBergen Drug Corporation, et al., CV-13-10439 (E.D.MI.). In these three related cases, Cencora settled civil claims pertaining to a formerly operating subsidiary of AmerisourceBergen Specialty Group, LLC's alleged violation of the False Claims Act, 31 U.S.C. §3730(b). Cencora paid the sum of \$625 million to settle the cases without any admission of liability.

In re: National Prescription Opiate Litigation, Case Number 1:17-md-02804 (N.D. Ohio). A significant number of counties, municipalities, and other governmental entities in a majority of U.S. states and Puerto Rico, as well as numerous states and tribes, filed lawsuits in various federal, state and other courts against pharmaceutical wholesale distributors (including Cencora and certain subsidiaries, such as ABDC and H.D. Smith), pharmaceutical manufacturers, retail pharmacy chains, medical practices, and physicians relating to the distribution of prescription opioid pain medications.

Starting in December 2017, more than 2,000 cases were transferred to Multidistrict Litigation ("MDL") proceedings before the United States District Court for the Northern District of Ohio (the "MDL Court"). Since then, several cases filed by government and tribal plaintiffs that were selected as bellwether cases in the MDL have been resolved through trial or settlement. Following trial in two consolidated cases in the United States District Court for the Southern District of West Virginia, the Court entered judgment in favor of the defendants, including Cencora. The plaintiffs filed an appeal of the Court's decision in the United States Court of Appeals for the Fourth Circuit on August 2, 2022. On October 28, 2025, the Fourth Circuit issued its opinion in the case, vacated the District Court's judgment, and remanded the case back to the District Court for further proceedings consistent with the Fourth Circuit's opinion.

On July 21, 2021, Cencora announced that it and the two other national pharmaceutical distributors had negotiated a Distributor Settlement Agreement that, if all conditions were satisfied, would result in the resolution of a substantial majority of opioid lawsuits filed by state and local governmental entities. The Distributor Settlement Agreement became effective on April 2, 2022, and as of September 30, 2025, it included 48 of 49 eligible states (the "Settling States") as well as 99% by population of the eligible political subdivisions in the Settling States. The Distributor Settlement Agreement requires Cencora to comply with certain requirements, including the establishment of a clearinghouse that will consolidate data from all three national pharmaceutical distributors. The States of Alabama and West Virginia and their subdivisions and Native American tribes are not a part of the Distributor Settlement Agreement, and Cencora has reached separate agreements with those groups.

The MDL Court selected four cases filed by third-party payors to serve as additional litigation bellwethers. On May 31, 2024, the MDL Court severed and stayed these four cases against Cencora and the two other national pharmaceutical distributors, pursuant to ongoing settlement discussions to resolve litigation filed by a putative class of third-party payors. On August 29, 2024, Cencora and two other national pharmaceutical distributors entered into a proposed class action settlement agreement to resolve the opioid-related claims of a proposed settlement class of third-party payors. Pursuant to the agreement, Cencora recorded a \$93.0 million litigation expense accrual in Litigation and Opioid-Related Expenses (Credit), Net in its fiscal 2024 Consolidated Statement of Operations. The MDL Court granted a motion for preliminary approval of the proposed class action settlement on September 3, 2024. Following a time period for submission of any objections or requests to be excluded from the

settlement, the MDL granted final approval of the settlement during a fairness hearing held on January 13, 2025 and entered a final approval order on January 15, 2025. On February 13, 2025, the sole objector to the settlement filed a notice of appeal of the final approval order. A settlement agreement with the sole objector was entered into on June 12, 2025. On June 16, 2025, the MDL Court ruled that it would approve the settlement with the sole objector if remanded for that purpose. On July 25, 2025, the United States Court of Appeals for the Sixth Circuit granted a motion for limited remand. The MDL Court approved the settlement with the sole objector on August 8, 2025. The class action settlement became effective as of September 9, 2025.

In Maryland, a trial commenced on September 16, 2024 in a case filed by the Mayor and City Council of Baltimore in the Circuit Court for Baltimore City. On November 12, 2024, the jury returned a verdict finding ABDC (and another national distributor) liable for public nuisance and assessing approximately \$274 million total in compensatory damages, approximately \$74 million of which was assessed against ABDC. A second phase of the trial began on December 11, 2024 related to the City of Baltimore's request for an abatement remedy and proceeded as a bench trial. On June 12, 2025, the Court issued a ruling on the defendants' post-trial motions relating to the first phase of the trial. The Court upheld the jury's finding of liability, but granted the defendants a new trial on the extent of damages to correct certain errors and due to the excessive nature of the jury's damages award. In the alternative, the Court granted remittitur, through which the Court reduced the compensatory damages assessed against ABDC to approximately \$14.4 million. The Court issued its ruling regarding the City of Baltimore's request for abatement on August 8, 2025, assessing approximately \$28 million against ABDC for abatement measures, bringing the overall monetary award assessed against ABDC to approximately \$42.5 million. On August 14, 2025, the City of Baltimore informed the Court that it would accept the reduced damages award as reflected in the Court's post-trial ruling, in lieu of a new trial. On September 2, 2025, the Court entered final judgment. In October 2025, ABDC (and the other national distributor) filed a notice of appeal to the Appellate Court of Maryland, and the City of Baltimore filed a notice of cross-appeal. In November 2025, both the City of Baltimore and ABDC (and the other national distributor) filed petitions for a writ of certiorari (bypass) with the Supreme Court of Maryland. If the Court grants the petitions, then the appeal will proceed directly in that Court, instead of in the Appellate Court. The \$42.4 million is a component of Cencora's \$4.3 billion litigation liability as of September 30, 2025, as described above.

On September 26, 2024, Cencora and two other national pharmaceutical distributors entered into a proposed class action settlement agreement to resolve the opioid-related claims of a proposed settlement class of hospitals. Cencora recorded a \$120.9 million litigation expense accrual in Litigation and Opioid- Related Expenses (Credit), Net in its fiscal 2024 Consolidated Statement of Operations, representing Cencora's expected share of the potential class action settlement. On October 30, 2024, the United States District Court for the District of New Mexico granted a motion for preliminary approval of the proposed class action settlement. Following notice to class members, a time period for submission of any objections to the settlement or requests to be excluded from the settlement, and a fairness hearing on March 4, 2025, the Court granted final approval of the settlement and entered a final approval order. The settlement became effective on April 4, 2025.

Cencora's accrued litigation liability related to the Distributor Settlement Agreement, including the State of Alabama and an estimate for nonparticipating government subdivisions (with whom Cencora has not reached a settlement agreement), as well as other opioid-related litigation for which it has reached settlement agreements, as described above, was \$4.3 billion as of September 30, 2025 and \$4.9 billion as of September 30, 2024. The \$4.3 billion liability will be paid over 13 years. Cencora currently estimates that \$416.0 million will be paid prior to September 30, 2026, which is recorded in Accrued Expenses and Other on Cencora's Consolidated Balance Sheet. The remaining long-term liability of \$3.9 billion is recorded in Accrued Litigation Liability on Cencora's Consolidated Balance Sheet. While Cencora has accrued its estimated liability for opioid litigation, it is unable to estimate the range of

possible loss associated with the matters that are not included in the accrual. Because loss contingencies are inherently unpredictable and unfavorable developments or resolutions can occur, the assessment is highly subjective and requires judgments about future events. Cencora regularly reviews opioid litigation matters to determine whether its accrual is adequate. The amount of ultimate loss may differ materially from the amount accrued to date. Until such time as otherwise resolved, Cencora will continue to litigate and prepare for trial and to vigorously defend itself in all such matters. Since these matters are still developing, Cencora is unable to predict the outcome, but the result of these lawsuits could include excessive monetary verdicts and/or injunctive relief that may affect Cencora's operations. Additional lawsuits regarding the distribution of prescription opioid pain medications have been filed and may continue to be filed by a variety of types of plaintiffs, including lawsuits filed by non-governmental or non-political entities and individuals, among others. Cencora is vigorously defending itself in the pending lawsuits and intends to vigorously defend itself against any threatened lawsuits or enforcement proceedings.

Since July 2017, Cencora has received subpoenas from several U.S. Attorney's Offices, including grand jury subpoenas from the U.S. Attorney's Office for the District of New Jersey ("USAO-NJ") and the U.S. Attorney's Office for the Eastern District of New York ("USAO-EDNY"). Those subpoenas requested the production of a broad range of documents pertaining to Cencora's distribution of controlled substances through its various subsidiaries, including ABDC, and its diversion control programs. Cencora produced documents in response to the subpoenas and engaged in discussions with the various U.S. Attorney's Offices, including the Health Care and Government Fraud Unit of the Criminal Division of the USAO-NJ, the U.S. Department of Justice Consumer Protection Branch and the U.S. Drug Enforcement Administration, in an attempt to resolve these matters. On December 29, 2022, the Department of Justice filed a civil complaint (the "Complaint") against Cencora, ABDC, and Integrated Commercialization Services, LLC ("ICS"), a subsidiary of Cencora, alleging violations of the Controlled Substances Act. Specifically, the Complaint alleges that Cencora negligently failed to report suspicious orders to the Drug Enforcement Administration. In the Complaint, the Department of Justice seeks civil penalties and injunctive relief. This Complaint relates to the aforementioned and previously-disclosed investigations. On March 30, 2023, Cencora filed a motion to dismiss the Complaint in its entirety on behalf of itself, ABDC, and ICS. On November 6, 2023, the United States District Court for the Eastern District of Pennsylvania granted in part and denied in part the motion, dismissing with prejudice all claims for civil penalties for Defendants' alleged violations of the suspicious order reporting requirement prior to October 24, 2018, but otherwise denying the motion. On December 18, 2023, Cencora, ABDC and ICS filed an Answer and Affirmative Defenses to the Complaint. On July 15, 2025, the Court entered an Amended Scheduling Order setting the fact discovery deadline as June 12, 2026 and the expert discovery deadline as January 15, 2027. Cencora denies the allegations in the Complaint and intends to defend itself vigorously in the litigation.

In addition to the above-referenced matters, please see Cencora's SEC filings, which disclose additional lawsuits not directly related to the franchise offering or franchise system involving the manufacturing, administering, prescribing, distributing, or storing of pharmaceutical products where Cencora has been named as a defendant.

No other litigation information is required to be disclosed in this Item.

ITEM 4

BANKRUPTCY

No bankruptcy information is required to be disclosed in this Item.

ITEM 5

INITIAL FEES

Premier Agreement

Although we do not charge you an initial franchise fee, you may have to pay us or our affiliates for certain goods or services upon signing the Premier Agreement as described in the “Start of GNP Premier Program Billing” subsection below (existing store) or prior to your store’s opening date (start-up store).

Initial Inventory of Pharmaceutical and Front-End Products

For an existing pharmacy, no incremental inventory may be required other than the requirements for GNP Private Label Products described below. Accordingly, the low-end estimate for this cost for an existing pharmacy is \$0. Depending on your existing inventory of pharmaceutical and front-end products, we estimate in certain cases an existing pharmacy may be required to expend up to \$25,000 for an initial inventory of these products. For a start-up pharmacy, we estimate that before your opening date you will pay us \$50,000 to \$150,000 for an initial inventory of pharmaceutical and front-end products.

GNP Private Label Products

For an existing pharmacy that is already stocked with a broad selection of GNP Private Label Products, we anticipate little or no additional expenditure for GNP Private Label Products will be required. However, if you are a start-up franchisee or your existing pharmacy does not currently stock a broad selection, you must place an order for GNP Private Label Products with us in quantities you determine are reasonable to meet anticipated consumer demand. We estimate this amount may be \$0 to \$1,200 for existing stores that have regularly stocked GNP Private Label Products. We estimate that a store with no or minimal existing inventory of GNP Private Label Products may place an order ranging from \$5,000 to \$12,000 (see Item 7 and Item 8), depending on the size of the store, front-end categories carried, the number of facings, and the market where it is located.

Interior and Exterior Signage

We provide complimentary signage packages to all new franchisees that, when applied according to our standards, meet our minimum requirements (for an existing Voluntary Pharmacy converting to a GNP Premier Pharmacy we may provide only a partial package as compliant signage may already be installed). To encourage you to enhance the appearance of your GNP Premier Pharmacy and further apply the Good Neighbor Pharmacy trade dress at your location, we offer new franchisees a one-time purchase match of up to \$2,500 per location to order additional or enhanced signage and other trade dress that meets our specifications within 180 days of signing the Premier Agreement (the “Purchase Match Amount”). We will match your initial purchase, dollar for dollar, up to \$2,500 for qualified expenses which meet our specifications. For example:

- ▶ If you spend \$1,000, you will get a \$1,000 match
- ▶ If you spend \$2,500, you will get a \$2,500 match
- ▶ If you spend \$3,000, you will get a \$2,500 match

To obtain the Purchase Match Amount, you must place your signage order within 180 days of signing the Premier Agreement and order through our approved vendor (currently GoodNeighborPharmacySigns.com) or submit pre-approved estimates and copies of paid invoices, along with photos of the installed trade dress to the Good Neighbor Pharmacy department in our Conshohocken, PA office via email to programs@amerisourcebergen.com. If you terminate the Premier

Agreement for any reason other than an uncured default by ABDC prior to the end of the first full twelve (12) month period that the Premier Agreement is in effect, you will pay ABDC, in addition to any other amounts or damages that may be owed to ABDC under any other agreement and not as liquidated damages, an amount equal to the Purchase Match Amount.

Typically, all signage must be purchased from an approved vendor. From time to time, ABDC will pre-purchase signage from the approved vendor to facilitate delivery of signage, in which case you may be billed for signage originally purchased by ABDC from this outside vendor. The cost of the various signage and trade dress available for purchase from our approved vendors and according to our specifications will range between \$0 and \$25,000 depending on your choices. Since our complimentary signage package meets our minimum requirements the low estimate on expenses is \$0.

Leasehold Improvements

If you have an existing pharmacy, depending on the design and layout of your pharmacy, you may not need to incur any additional leasehold costs. If you do need to incur leasehold costs, these improvements vary substantially based on the location and condition of your existing pharmacy.

If you are opening a start-up pharmacy, the cost of leasehold improvements will vary based on the size and existing configuration of the premises as well as local factors such as wage rates and availability and price of materials. These costs may also vary if the landlord agrees to incur the costs and allocate them over the term of the lease.

Our pharmacy transformation services group can, at your option and upon the execution of a corresponding agreement, evaluate your existing pharmacy, recommend improvements and manage the project for you for a base fee ranging from \$1,500 to \$3,000 depending on the applicable services tier chosen. Additional fees may apply.

Optional Available Programs

At this time, certain Available Programs in which you elect to participate may require the payment of additional fees, as described in Term Sheets 1-10 of the GNP Premier Agreement (Exhibit B to this Disclosure Document).

Start of GNP Premier Program Billing

ABDC invoices any monthly fees, such as the Premier program fee, and initial fees (applicable to optional programs and promotional material) in arrears (typically on the 25th of the month), which such fees may be prorated as applicable. Typically, you will pay on the same terms on which you pay for other goods and services purchased from us or as we mutually agree (such as by the 10th of the following month).

Release from Claims

As part of your consideration for entering into the GNP Premier Agreement with us, you, your owners and affiliates agree to release us from any and all claims in connection with offering ABDC's Voluntary Pharmacy program. This release does not apply to any claim related to this offer of the GNP Premier Agreement.

The fees described above are uniform as to all customers who sign the GNP Premier Agreement and such fees are fully earned when paid and not refundable.

ITEM 6
OTHER FEES

Type of Fee	Amount	Due Date	Remarks, Definitions and Caveats
GNP Premier Fee	\$599	Monthly	If you are an existing pharmacy, you will begin paying this fee in the month after you sign the GNP Premier Agreement. If you are a start-up pharmacy, you will begin paying this fee the month after you open for business. We may increase the monthly fee upon 120 days' notice.
Claim Reconciliation Concierge Services	\$199/month	Monthly	\$199/month for optional Concierge Services (No fee for self-service)
Outcomes Patient Care Services (Outcomes Premium Solution)	<u>Outcomes Premium:</u> \$49/store/month <u>Outcomes Premium + Vaccine:</u> \$129/store/month <u>Outcomes Premium + Vaccine + Engagement:</u> \$249/store/month	Monthly	Subscribing customers will sign a service agreement directly with Outcomes to access certain modules or offerings available via this optional program. Applicable fees to be paid by Customer may vary and are dependent upon the manner in which Customer enrolls in the Outcomes Premium Solution and applicable Outcomes Premium Solution modules chosen by Customer. If Customer enrolls in the Outcomes Premium Solution directly through Outcomes, Customer will pay Outcomes' prevailing rates. Alternatively, if Customer enrolls in the Outcomes Premium Solution through ABDC and satisfies all applicable requirements (see Term Sheet 2C), Customer will pay the rates listed in this table, which may be increased by up to Five Percent (5%) annually, for the applicable Outcomes Premium Solution modules. Customer may not concurrently enroll in the Outcomes Premium Solution and EnlivenHealth Treat Solution via ABDC.

Type of Fee	Amount	Due Date	Remarks, Definitions and Caveats
EnlivenHealth Patient Care Services (Treat Solution)	<u>Essentials:</u> \$100/store/month <u>Workflow:</u> \$100/store/month <u>All-In:</u> \$185/store/month	Monthly	<p>Subscribing customers will sign a service agreement directly with EnlivenHealth to access certain modules or offerings available via this optional program. Applicable fees to be paid by Customer may vary and are dependent upon the manner in which Customer enrolls in the Treat Solution and applicable Treat Solution bundles chosen by Customer. If Customer enrolls in the Treat Solution directly through EnlivenHealth, Customer will pay EnlivenHealth's prevailing rates. Alternatively, if Customer enrolls in the Treat Solution through ABDC and satisfies all applicable requirements (see Term Sheet 2D), Customer will pay the rates listed in this table for the applicable Treat Solution bundles. Customer may not concurrently enroll in the Outcomes Premium Solution and EnlivenHealth Treat Services via ABDC.</p> <p>Additional transaction fees may apply based on the bundle chosen, as provided under Customer's direct agreement with EnlivenHealth respecting the Treat Solution.</p>
Special Projects	Varies	As incurred, 15 days from invoice date, or as otherwise agreed	We will charge for time and materials or at a fixed price, as negotiated, for any special projects not covered by a Term Sheet or other agreement.
Optional/Enhanced Services	Varies	As incurred, monthly, or as otherwise agreed	We make available certain optional, enhanced services (e.g., enhanced Elevate Advanced Features reporting, etc.) at specified rates.

Type of Fee	Amount	Due Date	Remarks, Definitions and Caveats
Indemnification Costs	Varies	As incurred	As more fully specified in Items 7 and 8, you must carry liability insurance that covers ABDC and its affiliates as additional insureds and if we or our affiliates are threatened with liability due to operation of your GNP Premier Pharmacy you must pay for the cost to defend us.
Late Fee	Lower of 0.05% per day (18%/360) or maximum rate permitted by law	As incurred	Payable so long as the respective payment remains unpaid.

Explanatory Notes

In addition to the initial fees in Item 5, and except as described above, all fees are uniformly imposed by and payable to us. All fees are non-refundable. We must provide 60 days' prior written notice to change fees on any Available Program and, you may terminate with 60 days' prior written notice.

Typically, you will pay on the same terms (such as weekly or semi-monthly) on which you currently pay us for other goods and services you purchase; otherwise, payments are due 15 days from invoice date unless noted otherwise above.

ITEM 7
ESTIMATED INITIAL INVESTMENT

A. Existing Pharmacy

Type of Expenditure	Amount	Method of Payment	When Due	To Whom Payment is Made
Leasehold Improvements ^(a)	\$0 to \$50,000	As arranged	As agreed	Third Party Contractors
Leasehold Improvement Management Services ^(a)	\$0 to \$1,500	As arranged	As agreed	ABDC
Furniture, Fixtures, and Equipment	\$0 to \$50,000	As arranged	As agreed	Third Party Vendors
Pharmacy Management System Hardware and Software ^(b)	\$0 to \$15,000	As arranged	As agreed	Third Party Vendors
Point of Sale System Hardware and Software ^(c)	\$0 to 35,000	As arranged	As agreed	Third Party Vendors
Interior and Exterior Signage ^(d)	\$0 to \$5,000 (interior) \$0 to \$20,000 (exterior)	As arranged	As agreed	ABDC or Approved Vendors
Fees for Optional Goods and Services ^(e)	\$0 to \$1,908 (3 months)	As arranged	As agreed	Vendors
Insurance ^(f)	\$1,500 to \$5,000	As arranged	As agreed	Third Party Insurance Company
Opening Inventory ^(g) (exclusive of GNP Private Label Products)	\$0 to \$250,000	As arranged	Net 10 days after semi-monthly billing	ABDC
GNP Private Label Products ^(h)	\$0 to \$1,200	As arranged	As agreed	ABDC
Pharmacy and Business Licenses ⁽ⁱ⁾	\$500 to \$3,000	As arranged	As agreed	Licensing Authorities

Additional Advertising and Marketing ^(j)	\$0 to \$15,000	As arranged	As agreed	Vendors
Additional Funds – 3 months ^(k)	\$40,000 to \$50,000	As arranged	As agreed	Vendors
GNP Premier Fee – 3 months	\$1,797	As arranged	As agreed	ABDC
Total^(l):	\$43,797 to \$556,405			

B. Start-Up Pharmacy

Type of Expenditure	Amount	Method of Payment	When Due	To Whom Payment is Made
Real Property Lease/Leasehold Improvements ^(a)	\$50,000 to \$110,000	As arranged	As agreed	Third Party Contractors
Leasehold Improvement Management Services ^(a)	\$0 to \$1,500	As arranged	As agreed	ABDC
Furniture, Fixtures, and Equipment	\$25,000 to \$75,000	As arranged	As agreed	Third Party Vendors
Pharmacy Management System Hardware and Software ^(b)	\$0 to \$15,000	As arranged	As agreed	Third Party Vendors
Point of Sale System Hardware and Software ^(c)	\$0 to 35,000	As arranged	As agreed	Third Party Vendors
Interior and Exterior Signage ^(d)	\$0 to \$5,000 (interior) \$0 to \$20,000 (exterior)	As arranged	As agreed	ABDC or Approved Vendors
Fees for Optional Goods and Services ^(e)	\$0 to \$1,908 (3 months)	As arranged	As agreed	Vendors
Insurance ^(f)	\$1,500 to \$5,000	As arranged	As agreed	Third Party Insurance Company
Opening Inventory ^(g) (exclusive of GNP Private Label Products)	\$75,000 to \$125,000	As arranged	Net 10 days after semi-monthly billing	ABDC

GNP Private Label Products ^(h)	\$5,000 to 12,000	As arranged	As agreed	ABDC
Pharmacy and Business Licenses ⁽ⁱ⁾	\$500 to \$3,000	As arranged	As agreed	Licensing Authorities
Additional Advertising and Marketing ^(j)	\$0 to \$15,000	As arranged	As agreed	Vendors
Additional Funds – 3 months ^(k)	\$120,000 to \$150,000	As arranged	As agreed	Vendors
GNP Premier Fee – 3 months	\$1,797	As arranged	As agreed	ABDC
Total^(l):	\$278,797 to \$575,205			

Explanatory Notes to Charts A and B.

- a) Real property lease, leasehold improvements, furniture, fixtures and equipment. If you have an existing pharmacy, depending on the design and layout of your pharmacy, you may not need to incur any additional leasehold costs. If you do need to incur leasehold costs, these improvements vary substantially based on the location and condition of your existing pharmacy. Our pharmacy transformation services group can, subject to execution of a corresponding agreement, evaluate your existing pharmacy, recommend improvements and manage the project for you; additional terms and conditions apply. If you are opening a start-up pharmacy, the cost of leasehold improvements will vary based on the size and existing configuration of the premises as well as local factors such as wage rates and availability and price of materials. These costs may also vary if the landlord agrees to incur the costs and allocate them over the term of the lease.
- b) Pharmacy Management Systems. Pharmacy management systems enable the prescription dispensing process including patient profiles, clinical screening, inventory replenishment, claim submissions and connectivity to e-prescribing networks. As discussed above, you must participate in InSite from ABDC, a proprietary pharmacy performance analytics system that measures pharmacy performance using data from your pharmacy management system. If your existing system is from one of the participating industry vendors with whom we have agreements to facilitate your participation in InSite, we anticipate you will incur minimal or no expense. The above estimate is for start-up pharmacies and for existing pharmacies that need to purchase or replace computer hardware, software and related services from a participating vendor.
- c) Point-of-Sale Systems. Point-of-sale systems enable retail checkout processes such as UPC scanning, credit and debit card processing, inventory replenishment, and sales reporting. Use of a point-of-sale system is not required under the GNP Premier Agreement but is highly recommended. As discussed above, we offer you optional participation to upload your sales transaction data into InSite from ABDC, a proprietary pharmacy performance analytics system that measures pharmacy performance using data from pharmacy management and point-of-sale systems. Uploading your sales transaction data into InSite may be required for participation in certain front-end retail programs such as merchandising services. If your existing point-of-sale system is from one of the participating industry vendors with whom we have agreements to facilitate your participation in InSite, we anticipate you will incur minimal or no expense. The above estimate is for start-up pharmacies and for existing pharmacies that

need to purchase or replace computer hardware, software and related services from a participating industry vendor.

- d) Interior and Exterior Signage. We provide complimentary signage packages to all new franchisees that meet our standard, minimum requirements at the time of application (for an existing Voluntary Pharmacy upgrading to a Premier Pharmacy we may provide only a partial package as compliant signage might already be installed). Therefore, we anticipate that you will have minimal or no initial expense for signage. The above estimates are provided in the event that you wish to further enhance the appearance of your location with Good Neighbor Pharmacy exterior signage and/or interior trade dress. In the event you choose to purchase or replace exterior signage, your costs will depend on the physical features of your location and whether you have architectural, municipal or lease restrictions on the signage you can use. In all cases, you must meet or exceed our specifications for your signage unless you are restricted by local ordinance or lease provisions from meeting our specifications. While such expenses vary widely, for purposes of comparison, we estimate you may spend up to \$5,000 if you choose to purchase additional interior trade dress and up to \$20,000 if you choose to enhance your exterior signage. For additional information on signage and trade dress, see Item 5 above.
- e) Optional Goods and Services. The low-end estimate assumes you do not enroll in any optional programs while the high-range estimate assumes you will choose to enroll and pay fees for optional products and services. See Item 6.
- f) Insurance. If you have an existing pharmacy, we anticipate you will incur no incremental expense for required insurance coverage. For start-up pharmacies, the amount in the table represents our best estimate of the annual premiums in the marketplace to provide the coverage/limits for commercial general liability and professional liability insurance that meet our requirements. See Item 8 for a more detailed description of insurance requirements. Costs for insurance may vary substantially based on the geographic location of your pharmacy.
- g) Opening Inventory. If you have an existing pharmacy, we anticipate you will incur modest incremental expenses (from \$0 - \$25,000) to meet our recommendations which may include categories carried, adjacencies and number of facings of product on your shelves. For start-up pharmacies we estimate a range of \$50,000 to \$150,000 or more depending on location, demographics, pharmacy type/specialty, expected growth rate, front-end size, and customer needs.
- h) GNP Private Label Products. If your pharmacy is an existing Voluntary Pharmacy, we anticipate you will incur little or no additional investment (\$0 - \$1,200) in GNP Private Label Product inventory. If you are a start-up pharmacy or an existing pharmacy with no GNP Private Label product on your shelves we estimate an investment of \$5,000 to \$12,000 so that, as you reasonably determine based on your experience, you can carry a representative assortment to meet consumer demand, taking into account, among other things, your Pharmacy's size and market. Any such initial inventory that is purchased from us will typically be on terms that are the same or substantially similar to those that would be available to you whether or not you are a GNP Premier Pharmacy.
- i) Pharmacy and Business Licenses. You must obtain certain business licenses and occupancy permits to operate a retail pharmacy. If you have an existing pharmacy, we assume you have all required licenses and, as such, will have minimal or no incremental expenses. For start-up pharmacies we estimate a range of \$500 to \$2,500 to obtain the licenses under state and federal law required to operate a pharmacy as well as permits. The costs will vary by state

and may be impacted by local ordinances. We assume that licenses or other fees for pharmacists, pharmacy technicians or other employees are not your expenses.

- j) Advertising and Marketing. If you have an existing pharmacy, you may feel you have no significant need for “new business” advertising in which case we have estimated no expense at the low end. In addition, we will expend certain amounts on advertising (see Item 11) to promote the Good Neighbor Pharmacy franchise system generally. However, we recommend that both start-up pharmacies and existing pharmacies also promote a grand opening for their new GNP Premier Pharmacy. Amounts for such promotions vary widely based on the extent to which you advertise and the media you elect to use. Accordingly, we have estimated \$15,000 at the high end. Advertising is suggested as a best practice regardless of when the pharmacy opened.
- k) Additional Funds. For start-up pharmacies and for purposes of comparison, we estimate that a typical pharmacy would incur the following on-going expenses over a three-month period of operation: phone (\$2,000-\$3,000); other utilities (\$15,000-\$20,000); rent (\$30,000-\$35,000); security (\$2,000-\$3,000); trash/waste removal (\$500-\$1,000); legal, accounting and other professional services (\$6,000-\$7,000); office systems (\$6,000-\$7,000); and miscellaneous/other (\$58,500-\$74,000); for a total of \$120,000 to \$150,000.
- l) Total Initial Investment. These figures are an estimate of your total opening and operating expenses for the initial three months of business. They are based on the experiences of pharmacy owners that have operated pharmacies over more than 10 years.

We do not offer, directly or indirectly, any financing arrangements for your initial investment in connection with the GNP Premier Pharmacy franchise relationship. To our knowledge, costs and expenses described above are not refundable.

ITEM 8

RESTRICTIONS ON SOURCES OF PRODUCTS AND SERVICES

To ensure that the quality of the products and services you offer under our Marks is consistent, the furniture, fixtures equipment, and signage used in connection with your GNP Premier Pharmacy, must meet the Standards we establish as contained in the GNP Premier Agreement and GNP Manual. We modify Standards (including those for vendors) by revisions to the GNP Manual and other periodic written directives to you. If your pharmacy is an existing Voluntary Pharmacy, we expect that you will have already acquired and installed a significant amount, if not all, of such items. We formulate and modify these Standards based on research, industry trends, guidance from regional and national advisory boards and our general business plan.

Restrictions on Programs

To be eligible to sign the GNP Premier Agreement and thereby participate in the GNP Premier Program, you must meet the Premier Minimum Requirements, which necessitate that you: (1) be an existing pharmacy or a start-up pharmacy; (2) have a Prime Vendor Agreement (PVA), or other applicable distribution agreement, with ABDC (where permitted by applicable law); (3) be willing to immediately implement the GNP signage requirements described below in this Item; (4) utilize a pharmacy management system from one of the participating industry vendors that enables connectivity with our Available Programs; (5) immediately enroll in Elevate Advanced Features and InSite from ABDC (which requires you to sign our Data Authorization to the Master Program Agreement and GNP Premier Agreement (see Exhibit B) to initiate our cooperation with your participating vendor); (6) unless otherwise approved by ABDC in writing, utilize Change Healthcare as your switch vendor (or immediately initiate the transition to Change Healthcare) to activate the capture and upload of your Pharmacy Data to InSite; See Items 1 and 11 and also Exhibit B. Additionally, you must comply with

prerequisites or other qualifications for the specific Available Programs you select, including any base Available Programs for which other Available Programs are enhancements, maintain the on-going obligations for those Available Programs as stated in the GNP Manual and applicable Term Sheets, and remain in compliance with our Standards, also as described in the GNP Manual. Where equipment, software and other items we determine are necessary for Available Programs you select, such costs are your responsibility. Certain third-party vendors utilized in the provision of Available Programs may pay ABDC a fee for pharmacies that enroll in additional program offerings by such vendor. You may only use the Available Programs at Pharmacy Locations that are covered under a GNP Premier Agreement.

You must comply with the Elevate Provider NetworkSM program terms (Term Sheet 1 of the GNP Premier Agreement, which is Exhibit B to this Disclosure Document), under which we will assist you to participate in and obtain payment from Payors (as defined in Item 16) that offer pharmacy benefit plans to their members. Under the Elevate Provider Network program, only we may negotiate and enter into Payor Contracts (as defined in Term Sheet 1 of the GNP Premier Agreement, which is Exhibit B to this Disclosure Document) with Payors on your behalf (unless you contract directly or through another pharmacy services administration organization (“PSAO”) that we approve) to provide covered services for all Payors with which ABDC has contracted so that we may promote the capabilities of all GNP Premier Pharmacies to Payors. Except as noted in the preceding sentence, you will not appoint any other PSAO or any other party to act as your contracting entity for Payor Contracts with Payors (although you may always contract directly). We regularly, as a course of business, add, discontinue and revise arrangements with Payors, typically in response to changes by Payors, and Payors regularly add, discontinue and modify pharmacy benefits plans and other related requirements. As applicable, we or the Payor will, to the extent permitted, give you notice of any such material changes and an opportunity to accept such new provisions or to withdraw from the affected Elevate Document (as defined in Term Sheet 1 of the GNP Premier Agreement, which is Exhibit B to this Disclosure Document) or the Elevate Provider Network.

Restrictions on Systems

You must use a pharmacy management system from one of the participating industry vendors that enables connectivity with our programs and: (1) sign our Data Authorization to the Master Program Agreement (Exhibit E of the GNP Premier Agreement which is attached to this Disclosure Document as Exhibit B) to initiate our cooperation with your participating vendor; and (2) have the capture and upload of your data to InSite in full operation. See Items 1 and 11 and also Exhibit B.

While use of a point-of-sale system is optional, some Available Programs require use of a point-of-sale system from one of the participating industry vendors that enables connectivity with InSitePOS (managed in conjunction with our Program Partner Retail Insights) and to have the capture and upload of your data to InSitePOS in full operation. We may add, discontinue or modify arrangements with participating industry vendors.

Restrictions on Signage and Trade Dress

Each Pharmacy must be identified as a participating “Good Neighbor Pharmacy®” as ABDC designates. At each pharmacy location, within 90 days after signing the GNP Premier Agreement, you must remove any and all non-GNP pharmacy-franchise-related signage and/or trade dress (if applicable) and install GNP signage and trade dress that meets our Standards. Our current signage Standards require: (i) at least one “GOOD NEIGHBOR PHARMACY” identification window decal; (ii) at least one “GOOD NEIGHBOR PHARMACY” logo, which is available in both standard and customized interior and exterior versions; (iii) “GOOD NEIGHBOR PHARMACY” member plaque; and (iv) any other signage required by ABDC, as set forth in the GNP Manual.

We provide complimentary signage packages to all new franchisees that when applied according to our standards meet our minimum requirements. If you are an existing Voluntary Pharmacy we may provide only a partial package as compliant signage may already be installed. You may purchase additional GNP signage which is typically purchased from an approved vendor that is not affiliated with ABDC. However, in order to facilitate administration, ABDC generally pays for signage ordered from its approved vendor and then invoices the pharmacy for such signage. ABDC may also pre-purchase signage from the approved vendor to facilitate delivery, in which case ABDC will also bill the pharmacy for signage purchased by ABDC from this outside vendor.

The GNP Manual describes Standards for appearance, placement and visibility of signs. You must keep the signage in good repair at all times. As discussed above, if you do not yet have required signage, you must do so within 90 days of signing the GNP Premier Agreement and should immediately begin taking necessary steps, such as initiating and pursuing permits and approvals. We may modify signage requirements and at that time you must comply with such modifications at your expense. You may not vary from any of the signage Standards unless we have approved the change in writing before you use any non-compliant signage. Variations and exceptions are reviewed and approved by the Good Neighbor Pharmacy department before use.

Restrictions on Internet Marketing

You may promote your GNP Premier Pharmacy and sell products using the Marks on the internet in accordance with the GNP Premier Agreement, GNP Manual and Standards, so long as you clearly identify your business and comply with all applicable laws. Specifically, you cannot identify your store as a Good Neighbor Pharmacy store without also clearly indicating the full name under which you are licensed or do business, as well as your geographic location. We do not require that you get our prior approval for any internet domain name, home page address or internet content. We may restrict use of an internet domain name, vanity URL, home page or other web address that includes a Mark (or require a separate license for such use), limit your use of hyperlinks or require use of hyperlinks or other material (including required links to the MyGNP Website) and restrict use of material in which any third party has any interest. However, your website, including any use of Marks on or in connection with it, must comply with applicable Standards, and you must modify or discontinue your website if we notify you that any use or material is disapproved. See sections 1(c), 8(a), and 8(b) of the GNP Premier Agreement (which is Exhibit B to this Disclosure Document). You are solely responsible for accuracy of content you provide on the internet.

Restrictions on Products

As a GNP Premier Pharmacy, except where prohibited by law, you must purchase from us brand and generic prescription ("Rx"), over-the-counter ("OTC") and health and beauty care ("HBC") products and GNP Private Label Products pursuant to a distribution agreement such as a prime vendor agreement ("PVA") or other buying arrangement through an approved group purchasing organization or retail buying group. Typically, distribution agreement terms are the same or substantially similar to those that would be available to you whether or not you are a GNP Premier Pharmacy. We will provide access to electronic catalogs of such products, which are typically updated daily. You must place orders using one of our then-current order systems, with purchases subject to terms in your distribution agreement or as otherwise agreed, including terms for payment, credit, liability, risk of loss, shortages, delays and compliance with law. All such orders will be at our standard then-current wholesale prices under your distribution agreement. You may purchase new products, including Rx and GNP Private Label Products, as they are available.

You must accept delivery of AutoShip products from us, sent without a corresponding order from you, and promote them as required in the Front-End Solution Program terms, Term Sheet 5 of the GNP Premier Agreement (which is Exhibit B to this Disclosure Document). "AutoShip" is a service that we

provide to make you more competitive and includes certain new market break items, line extensions, GNP Private Label Products, Rx-to-OTC switch and other OTC products. You must promote the products to consumers using promotional materials we have provided and display them according to our schematic diagrams (“Planograms”).

Additionally, you are required to support national advertising programs, for example by stocking products and providing services that are featured. Also, you must use shelf sign kits, shelf talkers and other promotional material that we provide, display advertising circulars in your GNP Premier Pharmacy and comply with Planograms.

Restrictions on Approved Suppliers

Purchases of GNP supplies and services are often restricted to approved vendors. In general, vendors we approve are those who demonstrate, to our continuing reasonable satisfaction, their ability to meet our Standards. All vendors we approve must have adequate quality controls and the capacity to supply the needs of GNP Premier Pharmacies promptly and reliably over an extended period of time at a competitive price. Currently, we are an approved supplier of brand and generic prescription (“Rx”), over-the-counter (“OTC”) and health and beauty care (“HBC”) products and GNP Private Label Products pursuant to a distribution agreement such as a prime vendor agreement (“PVA”) or other buying arrangement through an approved group purchasing organization or retail buying group. Except as otherwise disclosed in this Item, neither we nor our affiliates are currently approved suppliers.

We may designate other specific vendors and suppliers in the future. Let us know if you desire to purchase supplies or products from a supplier that is not already approved and we will evaluate the need to do so. Our prior written approval may take up to 90 days or more after we receive all requested information, including information regarding the supplier's fiscal strength, demonstrated customer service, product quality, product safety and market presence. We do not charge any fees related to obtaining alternate supplier approval. If GNP determines that a previously approved alternate supplier of GNP supplies and services no longer demonstrates to our satisfaction their ability to meet our Standards, such alternate supplier will be removed from our list of approved vendors.

We may receive revenue from the sale of items to GNP Premier Pharmacies and expect to contract with vendors that may provide volume discounts, rebates or other benefits based on aggregate purchases of supplies and products by GNP Premier Pharmacies. We expect to receive payment from third party vendors on the sale of certain logoed items (such as shirts and key chains) to GNP Premier Pharmacies. The payment from third party vendors on the sale of certain logoed items should not exceed 25% of the cost to acquire such logoed items. These items will not be offered for resale, and you are not required to buy them. However, if you choose to purchase these items, they must meet our Standards. We anticipate that most such benefits we receive based on your purchase of products and supplies related to the GNP Premier Program will be used to enhance and promote Available Programs or otherwise used to benefit GNP Premier Pharmacies generally. In certain cases, we may allocate such benefits directly and proportionally to participating GNP Premier Pharmacies and we may deduct our expenses to administer and coordinate suppliers. We reserve the right to receive revenue from the sale of items to you by others. In the GNP Premier Agreement, you assign to us for collection and for our account promotional and advertising allowances related to the GNP Premier Program and all related products and services. Additionally, ABDC charges outside reconciliation service vendors a data interchange fee (typically a monthly flat fee per location, currently \$55.00) as compensation for our consolidating remittance advices from multiple Payors into a single, consistent format. Except as described above, as of the date of this Disclosure Document, no third-party vendors are providing rebates, discounts or other benefits to us based on required purchases by GNP Premier Pharmacies from any third-party vendor, and there are no agreements in effect which would require them to do so.

Restrictions on Insurance

Because operation of each GNP Premier Pharmacy reflects on other GNP Premier Pharmacies and the goodwill of the GNP Premier Program, we expect that you and all other GNP Premier Pharmacies will use your best efforts to operate with diligence and vigor, and maintain the highest possible ethics, as well as maintain your Pharmacy and personnel in a manner that are a credit to the community and reflect the high standards and quality of the GNP Premier Program, including, without limitation, interacting with and treating all customers and ABDC personnel in a respectful and professional manner. However, with such interdependence, there is some increase in the risk that we, you, or other GNP Premier Pharmacies could be sued as the result of actions for which we are not responsible. As such, each GNP Premier Pharmacy must carry commercial general liability and professional liability insurance in the amounts and on terms required by Payors, with minimum requirements described in note (f) of Item 7. We anticipate this is comparable to insurance already in place for most existing pharmacies and, as such, there will be little or no incremental expense. Such insurance will be underwritten on an occurrence basis, covering activities and errors and omissions of your GNP Premier Pharmacy and your personnel, in each case naming ABDC and our affiliates as additional insureds and requiring at least 30 days' written notice to ABDC if such insurance is cancelled or coverage is reduced. You will provide ABDC with a copy of such policies upon request. Any pharmacist or other health care professional providing covered services who is not separately insured by policies with similar coverage and limits must be covered on your insurance. See Section 4(l), Elevate Provider Network program terms, Term Sheet 1 of the GNP Premier Agreement (which is Exhibit B to this Disclosure Document).

Licensing Requirements

As a condition to being a GNP Premier Pharmacy, including as a condition to providing any covered services to persons covered by Payor pharmacy benefit plans, you must be fully licensed at your Pharmacy Location. If you have an existing pharmacy, we anticipate all such licensing would already be in place and, as such, there will be little or no incremental expense. If you have a start-up pharmacy, please review our estimated licensing costs for start-up pharmacies provided within Item 7.

Other

None of our officers own any interest in any Payor (other than those times we function as the Payor) or other approved vendor.

We have not arranged any purchasing cooperatives for our franchisees, and, except as described above, we do not negotiate purchase arrangements with suppliers for your benefit. We also do not provide material benefits to our franchisees, such as renewal or granting additional franchises, based upon their purchases of particular products or services and their use of certain designated suppliers or vendors.

During fiscal year 2025, our parent company, Cencora, had revenues of \$ 321,332,819,000, which includes parts of its business other than ABDC. The US Healthcare Solutions Division of Cencora, which includes ABDC, had revenues during fiscal year 2025 of \$290,982,022,513.13. ABDC's revenues during fiscal year 2025 were \$277,303,688,430.26, of which about \$0.51 billion (approximately 0.18%) was derived from sales of products and services to Voluntary Pharmacies and about \$8.32 billion (approximately 3.00%) was derived from sales of products and services to GNP Premier Pharmacies.

We estimate that the purchases described above may be nominal (5% or less) of the cost to open a GNP Premier Pharmacy for an existing Voluntary Pharmacy. Typically, for purposes of comparison, the cost to purchase inventory for a community pharmacy can range from approximately 65% to 80% of ongoing operating expenses. We estimate that the ongoing required purchases of GNP Private Label

Products will be nominal (1% or less of total operating expenses for a GNP Premier Pharmacy), as determined by you in your reasonable discretion based on your general business experience.

ITEM 9 FRANCHISEE'S OBLIGATIONS

This table lists your principal obligations under the GNP Premier Agreement and its exhibits and Term Sheets. It will help you find more detailed information about your obligations in these agreements and in other items of this Disclosure Document.

Available Program Term Sheets

Key:	Elevate Provider Network	Term Sheet 1
	Elevate Advanced Features	Term Sheet 2
	Pre and Post Edit Solutions	Term Sheet 2A
	Claim Reconciliation Services	Term Sheet 2B
	Outcomes Patient Care Services	Term Sheet 2C
	EnlivenHealth Patient Care Services	Term Sheet 2D
	InSite from ABDC	Term Sheet 3
	Five-Star Rebate	Term Sheet 4
	The Front-End Solution Programs	Term Sheet 5
	Digital Marketing	Term Sheet 6
	Business Coaching	Term Sheet 7
	Pharmacy System Data Services	Term Sheet 8
	Unsaleable Returns	Term Sheet 9
	Statement of Work-Services (Form)	Term Sheet 10

Obligation	Section In GNP Premier Agreement	Item In Disclosure Document
a. Site selection and acquisition/ lease	Not Applicable	7, 11, 12
b. Pre-opening purchases/leases	Not Applicable	7, 8, 11
c. Site development and other pre- opening requirements	Not Applicable	5, 6, 7, 8, 11, 12
d. Initial and ongoing training	Term Sheet 1, Section 4 Term Sheet 2B, Section 4	7, 11
e. Opening	Not Applicable	5, 7, 11
f. Fees	Section 2, Summary and Signature Pages, Section 9(c), Exhibit E and; All Term Sheets Section 2, except: Term Sheet 5, Sections 2, 3, 4, 5, 6 and 7; Term Sheet 6, Section 2, 3, 4 and 5; Term Sheet 8, Sections 3, 4; and Term Sheet 9	5, 6, 7

Obligation	Section In GNP Premier Agreement	Item In Disclosure Document
g. Compliance with standards /GNP Manual	Sections 4, 5, and 8, Exhibit E, HIPAA Business Associate Agreement, Sections 2, 3; Term Sheet 1, Section 4; Term Sheet 2A, Sections 3, 6; Term Sheet 2B, Section 3; Term Sheet 2C, Section 3, Term Sheet 3, Sections 5, 7; Term Sheet 6, Section 10;	1, 8, 11
h. Trademarks and proprietary information	Sections 1(a), 1(d), 3(a), 4(k), 10; Term Sheet 1, Sections 4, 7; Term Sheet 2A, Sections 3, 5, 6; Term Sheet 2B, Section 3, 5; Term Sheet 2C, Section 3, Term Sheet 3, Sections 3, 5, 6;	13, 14
i. Restrictions on products/services offered	Section 1(d), 4(a), 4(g), and 4(h); Term Sheet 1, Section 4	11, 16
j. Warranty and customer service requirements	Not Applicable	Not Applicable
k. Territorial development and sales quotas	Not Applicable	12
l. Ongoing product/ service purchases	Sections 4(g), 6	8
m. Maintenance, appearance and remodeling requirements	Sections 3, 4(a)-(d), 4(l), 5	5
n. Insurance	Term Sheet 1, Section 4;	7, 8
o. Advertising	Sections 5, 8 and 9; Term Sheet 5, throughout	5, 6, 7, 11
p. Indemnification	Paragraph 6, Provisions, Exhibit C; HIPAA Business Associate Agreement, Paragraph 6; Term Sheet 1, Section 4; Term Sheet 7, Section 7; Term Sheet 8, Section 8	6
q. Owner's participation/ management/staffing	Section 4(e)	15

Obligation	Section In GNP Premier Agreement	Item In Disclosure Document
r. Records/reports	Paragraph 2, Provisions, Exhibit C Term Sheet 1, Sections 3, 6; Term Sheet 2A, Section 4	8
s. Inspections/audits	Paragraph 1, Provisions, Exhibit C; Term Sheet 1, Section 6;	11
t. Transfers	Section 11	17
u. Renewal	Section 7(a) Term Sheet 1, Section 9	17
v. Post-termination obligations	Section 13, Paragraph 5.2, Provisions, Exhibit C; Term Sheet 1, Section 9;	17
w. Non-competition covenants	Not Applicable	17
x. Dispute resolution	Paragraph 2, Provisions, Exhibit C; Section 15; Term Sheet 1, Sections 3, 4 Term Sheet 2A, Section 4 Term Sheet 2B, Sections 3, 7	17

ITEM 10 **FINANCING**

We do not offer direct or indirect financing other than the payment terms included in your ABDC distribution agreement. We do not guarantee your note, lease or any other financial obligation.

ITEM 11 **FRANCHISOR'S ASSISTANCE, ADVERTISING,** **COMPUTER SYSTEMS AND TRAINING**

Except as listed below, ABDC is not required to provide you with any assistance.

Pre-Conversion

After you execute the GNP Premier Agreement, but before you operate as a GNP Premier Pharmacy:

We will make accessible to you the GNP Manual, in electronic format, which contains our Standards. (Section 2(c) of the GNP Premier Agreement, which is Exhibit B to this Disclosure Document). The GNP Manual is currently 94 pages long, and the table of contents is attached to this Disclosure Document as Exhibit C.

Computer Systems

Computer hardware and software systems, which range in cost from \$0 to \$55,000, include a required pharmacy management system and an optional point-of-sale system. Pharmacy management systems enable the prescription dispensing process including patient profiles, clinical screening, inventory replenishment, claim submissions and connectivity to e-prescribing networks. Point-of-sale systems enable retail checkout processes such as UPC scanning, credit and debit card processing, inventory replenishment, and sales reporting. While capability, features and the type of data generated and stored on such systems vary among vendors that provide point-of-sale systems that meet program requirements, typically data includes a master file (items a store sells and their prices, including sale or other special prices), transaction information (item sold, its price, and how it was paid for, such as cash, credit card, etc.) and inventory information (number of units ordered, received, sold and on-hand). We will not have independent access to the information stored in your system. However, Select Vendors and participating vendors may have access to your system and directly or indirectly coordinate the transmission of certain information to us, subject to applicable law and agreements, including the Data Protection Provisions and any HIPAA Business Associate Agreement.

System vendors typically provide regular maintenance updates under support contracts which typically range from \$2,000 to \$5,000 per year depending on your system's size and the options you select. The costs associated with maintenance updates and support contracts are subject to the terms you negotiate with your system vendor.

Post-Conversion

After you become a GNP Premier Pharmacy, we will make accessible to you additions, modifications and supplements to the GNP Manual as they become available in electronic format. See Section 2(e) of GNP Premier Agreement. Additionally, we will provide the following services and assistance to you.

Our Assistance with Available Programs

We will provide Available Programs, including any optional programs that you select, consistent with applicable Term Sheets, industry standards and applicable laws, and subject to our right to modify or discontinue any particular Available Program (see GNP Premier Agreement, Section 3(a) and Paragraph 1 of Provisions, Exhibit C).

1. Elevate Provider Network (See Paragraphs 3(a)-(g) of Term Sheet 1 to the GNP Premier Agreement, which is Exhibit B to this Disclosure Document).

- Negotiate Payor Contracts on your behalf for paying and processing covered claims;
- Provide a help desk during normal business hours;
- Publish newsletters and other communications to assist in claim submission;
- Assist you in investigating Payor problems;
- Promote your GNP Premier Pharmacy to Payors;
- Offer direct deposit to your account for payments from Payors through our central payment service;
- Offer claim reconciliation service to you or alternatively, provide consolidated electronic remittance advices (RAs) to your selected outside vendor for reconciliation; and

- Update pharmacy plan specifications received from Payors.
2. Elevate Advanced Features (See Term Sheet 2, 2A, 2B, 2C, and 2D to GNP Premier Agreement).
- Collaborate with your designated system vendors and our Program Partners for the transmission of your business data to InSite from ABDC as necessary to facilitate your participation in PPE Solutions, Claim Reconciliation Services, the Outcomes Premium Solution, and the EnlivenHealth Treat Solution.
3. InSite from ABDC Program (See Term Sheet 3 to GNP Premier Agreement).
- Collaborate with your designated system vendors and our Program Partners for the transmission of your Pharmacy Data to InSite from ABDC to facilitate your participation in Available Programs;
 - Provide you with reports, studies, analyses and other compilations about your business performance, including various benchmark comparisons from our proprietary pharmacy performance analytics system, InSite; and
 - Protect your Pharmacy Data pursuant to the Data Protection Provisions.
4. The Front-End Solution Programs. Provide products, materials, marketing support and merchandising services with respect to non-prescription brand name and GNP Private Label Products we supply, as described under Advertising in this Item 11. See Term Sheet 5 to GNP Premier Agreement.
5. Digital Marketing. Provide an overall strategy to attract and engage patients and consumers online. Includes the following programs: MyGNP Website, MyGNP Mobile App, Digital and Social Media Marketing, and Local Listings Management. See Term Sheet 6 to the GNP Premier Agreement.
6. Business Coaching Program. Provide certain recommendations related to increasing your Pharmacy's performance through our representative, including gathering data, reporting and presenting our findings and recommendations to you by various means, guiding you in implementing the recommendations, providing on-going coaching, and helping to set goals for your Pharmacy. See Term Sheet 7 to GNP Premier Agreement.
7. Pharmacy System Data Services Program. Furnish certain system data services to assist with pharmacy computer applications, including pharmacy management and point-of-sale systems. Such system data services include electronic order entry and confirmation and catalog and price updates for prescription pharmaceuticals and OTC products, via on-line downloads or access to our secure website. See Term Sheet 8 to GNP Premier Agreement.
8. Unsaleable Returns. Provide quarterly on-site assistance including the processing of returns, packing and shipping of returned products, printing inventory manifest and requesting 222 forms and issue monthly checks based on the ERV before the product is returned to the manufacturer. See Term Sheet 9 to the GNP Premier Agreement.

Our Assistance with Ordering ABDC Products

We will provide access to electronic catalogs for our brand and generic prescription pharmaceuticals, over-the-counter, health and beauty care and our GNP Private Label Products, which we typically update daily. See Section 4(f) of GNP Premier Agreement.

Our Assistance with Site Selection

We do not offer any site selection services.

Our Assistance with Training

GNP Premier Pharmacies will be owners and operators of an existing or start-up pharmacy and, as such, we do not currently offer any initial training.

Our Assistance with Advertising and Promotions

The GNP Premier Agreement, the Front-End Solution Programs Term Sheet and Digital Marketing Term Sheet and (Term Sheets 5 and 6, respectively) describe advertising and marketing assistance that we provide and your obligations. The GNP Premier Agreement contains provisions regarding advertising on the internet. The Front-End Solution Program terms describe the various types of merchandising support that we offer to you (see Item 1 for a description).

Under the Front-End Solution Programs, we provide: (i) automatic shipment (without your order) of certain over-the-counter ("OTC") products to facilitate your prompt stocking of products to meet anticipated consumer demand (First To Shelf™); (ii) a set of schematic diagrams ("Planograms") with periodic updates showing recommended layout of specific product categories; (iii) periodic suggested retail prices for a broad range of health and beauty aids, OTC and other non-prescription products, based on various factors (Retail Product Zone Pricing Service); (iv) optional merchandising assistance; and (v) a point-of-sale data analytics system used to measure and compare the performance of pharmacy front-ends (InSitePOS from ABDC).

We are not obligated to conduct advertising, nor to spend any amount in connection with advertising in your area or territory. We do not currently require you to join a regional advertising cooperative or contribute to an advertising fund.

You may use your own advertising materials (including internet advertising, as described in Item 8), so long as the materials comply with our Standards.

Our Assistance with Advertising Council & National Advisory Boards

We do not currently have a franchisee advertising council that advises on advertising policies. We may form one in the future, but we have no obligation to do so. If we do, we will have the right to determine how its members are selected and the scope of its authority as well as the right to change or dissolve the franchisee advertising council.

We currently have a national advisory board consisting of owners/operators of GNP Premier Pharmacy owners. The number of members on the national advisory board may vary between 5 and 18, but currently includes 10 members. Members of the national advisory board provide us with advice and recommendations on issues related to the GNP Premier Program and its administration, participate in design of new and modified programs and value-added services, including Available Programs, make presentations to peers on the GNP Premier Program and related services, recommend new business opportunities for us and community pharmacies, and otherwise assist us. National advisory board members are nominated and selected by ABDC and agree to participate actively in the GNP Premier Program and comply with certain standards. Typically, they serve a 3-year term but may resign at any time and extensions may be offered. Advisory board members are not paid, although we may reimburse their expenses to attend in-person meetings in some circumstances.

Our Assistance with Internet Capability

We engage in advertising on the internet for consumers and control its design and contents, which we plan to maintain but may discontinue it at any time. See GNP Premier Agreement, Section 8(c).

We may establish and maintain a portal through which GNP Premier Pharmacies may communicate with each other and through which we may disseminate updates and supplements to the GNP Manual and other Confidential Information (“GNP Portal”). We will establish policies and procedures and other terms of use to address issues such as: (i) restrictions on the use of abusive, slanderous or otherwise offensive language; (ii) restrictions on communications that endorse or encourage breach of any agreement, including a GNP Premier Agreement; (iii) confidential treatment of materials contained in the GNP Portal; (iv) password protocols and other security precautions; (v) grounds and procedures for suspending or revoking your access to the GNP Portal; (vi) a privacy policy governing our access to and use of electronic communications that franchisees post on the GNP Portal; and (vii) compliance with laws, including antitrust laws and HIPAA. Your right to access the GNP Portal will continue until your GNP Premier Agreement’s expiration or termination. To increase usefulness of the GNP Portal, you must allow us to use, publish and copyright photographs of your GNP Premier Pharmacy and your statements with or without identifying information for editorial, promotional, advertising or other purposes, at any time and in any medium, including advertising on the internet for consumers and the GNP Portal. We plan to maintain the GNP Portal but have the right to discontinue it at any time. See GNP Premier Agreement, Section 8(d).

ITEM 12 **TERRITORY**

GNP Premier Agreement

Under the GNP Premier Agreement, we grant you the right to operate one or more GNP Premier Pharmacies under the Marks and our GNP Premier Program, each at an approved Pharmacy Location specified in the GNP Premier Agreement. Your use of the Marks or any element of the GNP Premier Program in the operation of a business at any other address or in any other channel of distribution without our express prior written authorization will constitute willful infringement of our rights in the Marks and the GNP Premier Program. We do not permit the relocation of an approved Pharmacy Location. In the event that you would like to change your approved Pharmacy Location or open an additional franchise, you must complete the same approval process used to establish your currently approved Pharmacy Location(s). Additionally, you must be in good standing with our wholesale distribution business and in compliance with the standards set forth by this Disclosure Document and the Premier Participation Agreement. We do not grant you any options, rights of first refusal or any similar right to obtain additional franchises under the GNP Premier Agreement.

You will not receive an exclusive territory. You may face competition from other franchisees, from outlets that we own, from other channels of distribution or competitive brands that we control.

You will have no competitive protection at all. We reserve rights to do any of the following without compensation to you, regardless of proximity to or competitive impact on you:

- (i) Allow others to establish and operate GNP Premier Pharmacies, Voluntary Pharmacies or other businesses, and do so ourselves;
- (ii) Offer and sell the GNP Premier Program and related products and services to other customers;



- (iii) Establish, operate, offer and sell other businesses, goods and services, or allow others to do so, including those that are the same, similar or different and using some, all or none of the Marks; and
- (iv) Advertise and promote the sale of any products and services in any area and advertise and promote franchises for other GNP Pharmacies.

We do not impose any restrictions on your right to use other channels of distribution in connection with the GNP Premier Pharmacy franchise relationship except as specified otherwise herein.

We have no obligation or duty to insulate or protect your revenues from erosion as the result of your GNP Premier Pharmacy's competition with other GNP Premier Pharmacies, with Voluntary Pharmacies or with other pharmacies not affiliated with us to whom we may provide goods and services.

ITEM 13 TRADEMARKS

We have registered the following principal Marks on the Principal Register of the United States Patent and Trademark Office ("USPTO"):

Mark Name	Registration Number	Registration Date
	4205108	9/11/2012
	4209193	9/18/2012
GOOD NEIGHBOR PHARMACY	1516842	12/13/1988
GOOD NEIGHBOR PHARMACY	5726298	4/16/2019
GOOD NEIGHBOR SCRIPT	5927822	12/3/2019
ELEVATE PROVIDER NETWORK	5115412	1/3/2017
LOCALLY OWNED. LOCALLY LOVED.	5449413	4/17/2018
MY GNP	7154791	9/5/2023
YOUR PARTNER IN DIABETES CARE	2937589	4/5/2005
DIABETES SHOPPE	2953807	5/17/2005

We filed all required affidavits and renewals for our trademark registrations related to Marks and for those classes of the Marks that are still in use and know of no superior prior rights or infringing uses of Marks that could materially affect their use.

You must notify us of any infringements of, or challenges to, the Marks that come to your attention and actively cooperate with us in the investigation of any infringement or challenge. We have the right to control any administrative proceedings or litigation involving the Marks and will take whatever action we deem appropriate.

Although we are not contractually obligated to defend the Marks, we intend to do so vigorously. We will defend and indemnify you against third party claims of infringement or unfair competition arising from your authorized use of the Marks that comply with the GNP Premier Agreement and Standards. Your indemnity of us will include an infringement claim arising from use that is not authorized or is not compliant. See Exhibit C, Paragraph 6, of the GNP Premier Agreement.

You may not use “GOOD NEIGHBOR PHARMACY”, “ELEVATE PROVIDER NETWORK” or any other Mark, or any abbreviation, acronym or variation as part of your corporate or other legal name without our express and written consent, and you must comply with our instructions in filing and maintaining trade name or fictitious name registrations. You must sign any documents we require to protect the Marks or to maintain their continued validity and enforceability. In addition, you may not directly or indirectly contest the validity of our ownership of the Marks, or of our rights in the Marks.

You may use the Marks in connection with advertising on the internet, subject to your compliance with the GNP Manual, our Standards and applicable law. Although we do not require that you get our prior approval for any internet domain name, vanity URL, home page or other web address or internet content, we may restrict use that includes a Mark (or require a separate license for its use), limit your use of hyperlinks or require use of hyperlinks or other material (including required links to our advertising on the internet for consumers), and restrict use of material in which any third party has any interest. You must discontinue any use if we notify you that any use or material is disapproved. You are responsible for the accuracy of all content.

Upon expiration or termination of your GNP Premier Agreement for any reason, you must immediately discontinue the use of all the Marks. You must take appropriate action to remove the Marks from your GNP Premier Pharmacy location and online presence.

There are no currently effective determinations of the U.S. Patent and Trademark Office, the Trademark Trial and Appeal Board or the trademark administrator of any state or any court, nor are there any pending infringement, opposition or cancellation proceedings involving the Marks. Nor is there any pending material federal or state court litigation regarding our use or ownership rights in the Marks. If we modify or discontinue the use of the Marks, you must promptly comply with and adopt all such modifications at your own expense.

ITEM 14

PATENTS, COPYRIGHTS AND PROPRIETARY INFORMATION

Neither we nor our affiliates currently own any required patents or registered copyrights that are material to the franchise. There are no pending patent applications that are material to the franchise.

The GNP Premier Program and its components, the contents of the GNP Manual and all of the employee training materials and computer applications developed by us or in accordance with our Standards and any confidential information that we impart to you with respect to a GNP Premier Pharmacy's operation or management, whether through the GNP Manual, Confidential Information, or otherwise (collectively, “Trade Secrets”) belong exclusively to us or our licensors, if applicable, and the ideas and information in the GNP Manual are our sole and exclusive property.

You and your Principals must hold the elements of the GNP Premier Program, the Trade Secrets and the contents of the GNP Manual in strict confidence, must not disclose any Trade Secret or any operating or management procedure to any person other than your Designated Manager (as defined in the GNP Premier Agreement) and your employees who must receive disclosure to understand their job duties, and you must instruct and routinely remind your employees that the GNP Premier Program, the Trade Secrets and the contents of the GNP Manual are confidential and may not be disclosed or appropriated. You may not disclose any element of the GNP Premier Program, any of the Trade Secrets or the contents of the GNP Manual, or make the GNP Manual available, to anyone who is not actively and regularly involved in your GNP Premier Pharmacy's management, including, if you are a business entity, a shareholder, director, officer, partner, member or manager (other than your Designated Manager) who is not actively managing your Pharmacy.

You and your Principals must not use any element of the GNP Premier Program, any of the Trade Secrets or the operating, management or marketing procedures in the GNP Manual in connection with the operation of any establishment or enterprise other than your GNP Premier Pharmacy, and must promptly discontinue use of the GNP Premier Program, the Trade Secrets and the operating, management and marketing procedures in the GNP Manual upon the expiration or termination of your GNP Premier Agreement.

You and your Principals must not, without our prior written consent, copy or permit any person to inspect, copy or reproduce any part of the GNP Manual and any other printed, graphic or audio/visual item designated by us as containing Trade Secrets or otherwise permit their use or inspection by any person other than you, your Designated Manager and your employees who need to be disclosed to in order to perform their job duties, and our authorized representatives.

All employee training materials (including videos, presentations, audio or web-based video programs) and all computer programs developed by us or by following our standards contain information, embody procedures or facilitate business practices that are proprietary to us and fall within the parameters of our Trade Secrets.

You must notify us of any infringements of or challenges to the copyrighted materials that come to your attention and actively cooperate with us in the investigation of any infringement or challenge. We have the right to control any administrative proceedings or litigation involving the copyrighted materials and will take whatever action we deem appropriate.

Although we are not contractually obligated to defend the copyrighted materials, we intend to do so vigorously. We will defend and indemnify you against third party claims of infringement or unfair competition arising from your authorized use of copyrighted material that complies with the GNP Premier Agreement and Standards. Your indemnity of us will include an infringement claim arising from use that is not authorized or is not compliant. See Exhibit C, Paragraph 6, of the GNP Premier Agreement.

If we modify or discontinue the use of any copyrighted materials, you must promptly comply with and adopt, at your own expense, all such modifications.

You, your GNP Business Coaching Associate and certain of your employees are bound by confidentiality provisions (see Item 17) concerning the proprietary information and may be required to enter into a confidentiality agreement (see Item 15).

If you develop or suggest an innovation or improvement that we decide to incorporate into the GNP Premier Program, either temporarily or permanently, the innovation or improvement will become our Confidential Information and property without compensation to you.

ITEM 15

OBLIGATION TO PARTICIPATE IN THE ACTUAL OPERATION OF THE FRANCHISE BUSINESS

You must appoint a Designated Manager to be your primary contact with us to administer and coordinate our relationship. As explained in Item 11, we do not currently offer any initial training, other than continuing education courses offered at our annual trade show and optional education available on Good Neighbor Pharmacy University. In the future, we may offer other training, at our option, with or without a fee.

Your Principals will be bound by certain provisions of the GNP Premier Agreement. Your "Principals" include each of your officers and directors and those of any of your affiliates and anyone with a direct

or indirect interest in you or your affiliates, the GNP Premier Agreement or the assets, revenues or income of your GNP Premier Pharmacy, each as we may determine. If the franchisee is a business entity, the Designated Manager is not required to have any equity interest in the franchisee's business. By signing the GNP Premier Agreement, you agree your Principals will be bound by provisions relating to confidential treatment of our Trade Secrets and use of our copyrighted material.

You also must ensure that your Designated Manager, other employees and other representatives are aware of their obligations and do not disclose any ABDC Confidential Information.

By signing the GNP Premier Agreement, you and your Principals agree to be bound by a HIPAA Business Associate Agreement (in Exhibit B of the GNP Premier Agreement, which is Exhibit B to this Disclosure Document, or as we may agree otherwise) in connection with Available Programs, such as Elevate Provider Network, Elevate Advanced Features, Pre and Post Edit Solutions, Claim Reconciliation Services, InSite from ABDC and Business Coaching, that involve access to protected health information. A HIPAA Business Associate Agreement requires that we, you and your Principals to comply with the federal Health Insurance Portability and Accountability Act of 1996, as amended, relating to privacy of protected health information, which describes the uses and limits of use on the covered health information.

ITEM 16

RESTRICTIONS ON WHAT THE FRANCHISEE MAY SELL

GNP Premier Pharmacy franchisees must participate in the Elevate Provider Network, our program that provides access to pharmacy benefit plans of Payors and provides for the processing and payment of covered claims you submit through the program (or through another pharmacy services administration organization ("PSAO") that we approve) in connection with your provision of covered services for all Payors with which ABDC has entered into Payor Contracts (as defined under Term Sheet 1 of the GNP Premier Agreement, which is Exhibit B to this Disclosure Document) on behalf of pharmacies in the Elevate Provider Network. A "Payor" is an entity that has entered or will enter into a Payor Contract with ABDC in connection with applicable covered services to be provided by participating Network Providers thereunder, such as: (i) a pharmacy benefit manager, health plan, or other third party that sponsors or administers prescription drug programs, health benefit plans, clinical services plans or programs, and/or is primarily responsible for processing and paying pharmacy claims; (ii) a prescription drug discount company; and/or (iii) a workers' compensation processing company. Additionally, From time to time under one or more Elevate Document (as defined under Term Sheet 1 of the GNP Premier Agreement, which is Exhibit B to this Disclosure Document), ABDC may also be a Payor that contracts with GNP Premier Pharmacies as part of providing its pharmacy benefit plan administration services. Payor Contracts typically require you to provide certain covered services to eligible persons covered by a Payor's pharmacy benefit plan specifications. These services include dispensing pharmaceuticals or devices to eligible persons and providing such other services for which you accept any co-payment and compensation from a Payor as full payment.

If you offer products and services described in a Term Sheet, you may do so only if you comply with the Standards and the GNP Manual, and acquire all equipment, software and other items required for the services covered by the selected Term Sheet. You may sell products and services on internet websites only as we authorize in the GNP Manual or otherwise.

A Term Sheet only applies to a GNP Premier Pharmacy's authorized Pharmacy Location covered under a GNP Premier Agreement. You may not enroll for one Pharmacy Location and then use Available Programs in another store even if you also own or control such other store unless it is otherwise permitted to do so.

You must comply with all laws, including maintaining all licenses and other required approvals and reporting or reflecting discounts, rebates and other price reductions relating to cost reports or claims submitted to federal or state healthcare programs. You must retain and make available upon request any invoices and related pricing documents.

You must feature the GNP Private Label Products as your preferred alternative to national brands and use your best efforts to promote and sell GNP Private Label Products. You must periodically order a representative assortment of GNP Private Label Products, as you determine is reasonable to meet anticipated consumer demand, based on your experience, taking into account, among other things, your Pharmacy's size and market. You must also accept automatic delivery of promotional and new products (see Item 8), and participate in the special promotions and new product introductions for those products.

We have the right to change the products and services without limitation, and you must promptly comply with the new requirements, unless you exercise your right to terminate the GNP Premier Agreement.

We regularly, as a course of business, add, discontinue and revise arrangements with Payors, typically in response to changes by Payors, and Payors regularly add, discontinue and modify pharmacy benefits plans and other related requirements. As applicable, we or the Payor will, to the extent permitted, give you notice of any such material changes and an opportunity to accept such new provisions or to withdraw from the affected Elevate Document (as defined in Term Sheet 1 of the GNP Premier Agreement, which is Exhibit B to this Disclosure Document) or the Elevate Provider Network.

ITEM 17

RENEWAL, TERMINATION, TRANSFER AND DISPUTE RESOLUTION

THE FRANCHISE RELATIONSHIP

This table lists certain important provisions of the GNP Premier Agreement, its exhibits and certain of the Term Sheets, including those for Elevate Provider Network and Business Coaching. You should read these provisions in the agreements attached to this Disclosure Document.

Available Program Term Sheets

Key:	Elevate Provider Network	Term Sheet 1
	Elevate Advanced Features	Term Sheet 2
	Pre and Post Edit Solutions	Term Sheet 2A
	Claim Reconciliation Services	Term Sheet 2B
	Outcomes Patient Care Services	Term Sheet 2C
	Enliven Health Patient Care Services	Term Sheet 2D
	InSite from ABDC	Term Sheet 3
	Five-Star Rebate	Term Sheet 4
	The Front-End Solution Programs	Term Sheet 5
	Digital Marketing	Term Sheet 6
	Business Coaching	Term Sheet 7
	Pharmacy System Data Services	Term Sheet 8
	Unsaleable Returns	Term Sheet 9
	Special Projects Form	Term Sheet 10

Provision	Section in Premier Agreement	Summary
a. Length of the term	Signature Page and Section 7(a)	Five years. Generally, Available Programs continue until GNP Premier Agreement terminates.
b. Renewal or extension of the term	Section 7(a)	Automatic renewals for 2-year terms, unless we or you give 120 days' notice of intent not to renew.
c. Requirements for franchisee to renew or extend	Section 7(a)	Automatic renewals for 2-year terms if in compliance with program requirements, unless you or we give notice to terminate or not renew. However, as noted in paragraph (d), you may terminate anytime without cause on 60 days' notice. When renewing you may be asked to sign a contract with materially different terms and conditions than your original contract.
d. Termination by franchisee	Section 7(b)	Termination without cause on 60 days' prior written notice to us. (subject to state law)
	Paragraph 5, Provisions, Exhibit C	Termination without cause on 60 days' prior written notice to us; Termination for cause for reasons described in 17.h below. On written notice to us, for Bankruptcy (as defined in Paragraph 5), failure to pay continuing 5 days after written notice, or failure to perform any other material obligation continuing for 30 days after written notice.
e. Termination by franchisor without cause	Section 7(b)	Termination without cause on 60 days prior written notice to you.
f. Termination by franchisor with cause	Sections 7(c), 7(d) and 11 Paragraph 5, Provisions, Exhibit C	You or a Principal (as defined in Section 7(c)(ii)) commits any one of several listed violations; and as provided in Section 5, Provisions.

Provision	Section in Premier Agreement	Summary
	Section 4(i) Term Sheet 1, Section 9	We may terminate if you designate another PSAO as your primary contracting entity without our prior written approval. We may terminate if you default under the Elevate Provider Network Term Sheet, a Pharmacy Addendum or Payor contract, and do not cure after 30 days written notice; we or the Payor may terminate without notice or cure if you provide substandard, inferior, contaminated or adulterated drug products, violate laws relating to drug products, your licenses are revoked or suspended or you or your employees are barred from providing Medicare, Medicaid or other health care services or you commit any act or omission for which a Payor may terminate any Pharmacy Addendum or contract you have signed with a Payor; or you are insolvent. Termination by us ends all Payor relationships for your GNP Premier Pharmacy.
g. “Cause” defined – curable defaults	Term Sheet 1, Section 9(b)	Any failure to perform, in any material respect, your obligations under Elevate Documents.
	Paragraph 5, Provisions, Exhibit C	On written notice to you, for Bankruptcy (as defined in the Paragraph 5), failure to pay continuing 5 days after written notice, or failure to perform any other material obligation continuing for 30 days after written notice.
	Term Sheet 1 Section 9(a)	We may terminate if you fail to cure a default under any of the Elevate Documents 30 days after written notice.
h. “Cause” defined – non-curable defaults	Section 7(c)	Breach of confidentiality, abandonment, conviction/guilty or no contest pleas to certain crimes or any other conduct any of which may adversely affect our goodwill, another GNP Premier Pharmacy or our Marks.
	Paragraph 5, Provisions, Exhibit C	On written notice, for Bankruptcy as defined in Paragraph 5.

Provision	Section in Premier Agreement	Summary
i. Franchisee's obligations on termination/non-renewal	Section 13	Discontinue use of the Marks, Copyrighted materials, the GNP Premier Program and Trade Secrets, and remove Trade Dress, cancel advertising and cease using all Available Programs, except as mutually agreed.
	Paragraph 5, Provisions, Exhibit C	Pay all amounts due, return Software, equipment and material, including GNP Manual.
	Term Sheet 1, Section 9(e);	Customer must discontinue use of all signage, Marks and trade dress.
j. Assignment of contract by franchisor	Section 11 Paragraph 8.3, Provisions, Exhibit C	You consent to our assignment of all or part of our obligations under the GNP Premier Agreement and to the grant of a security interest by us or our affiliate. We may assign with notice to you. We may assign all or part of our obligations to an affiliate or for financing or securitization purposes without notice to you.
k. "Transfer" by franchisee – defined	Section 11	Includes transfer of contract or assets or any change in control (including sale of 25% or more of your assets or equity).
l. Franchisor approval of transfer by franchisee	Section 11	We may terminate if you do not have our prior written consent.
m. Conditions for franchisor approval of transfer	Section 11	You must promptly notify us of changes in ownership, name, form or state of business, and your intent to sell, close, move or modify your operations.
n. Franchisor's right of first refusal to acquire franchisee's business	Not Applicable	Not Applicable.
o. Franchisor's option to purchase franchisee's business	Not Applicable	Not Applicable.
p. Death or disability of franchisee	Not Applicable	Not Applicable.
q. Non-competition covenants during the term of the franchise	Term Sheet 1, Section 4(f)	We are your exclusive PSAO (unless you contract directly or through another pharmacy services administration organization ("PSAO") that we approve to provide covered services for all Payors with which ABDC has contracted). (subject to state law)

Provision	Section in Premier Agreement	Summary
r. Non-competition covenants after the franchise is terminated or expires	Not Applicable	Not Applicable. (subject to state law)
s. Modification of the agreement	Section 4(g); Section 8.6, Provisions, Exhibit C; Section 5, Master Program Agreement, Exhibit E; Term Sheet 1 Section 5	Except for unilateral modifications by us permitted by the GNP Premier Agreement, the Master Program Agreement (Exhibit E of the GNP Premier Agreement), and its other Exhibits and Term Sheets, no modification except in writing signed by both parties. We may amend the GNP Premier Agreement, Master Program Agreement, and/or other Exhibits or Term Sheet if we determine it is appropriate or, respecting modification to applicable Elevate Documents, a Payor amends pharmacy plan specifications. We, or, respecting modification to applicable Elevate Documents, Payors, will give you notice and you may withdraw to the extent permitted under the affected documents if you don't agree.
t. Integration/ merger clause	Paragraph D	Only the terms of the franchise agreement and other related written agreements are binding (subject to state law). Any representations or promises made outside the disclosure document and franchise agreement may not be enforceable. Notwithstanding the foregoing, nothing in any agreement is intended to disclaim the express representations made in the Franchise Disclosure Document, its exhibits and amendments.
	Term Sheet 1, Section 5	Payor Contract controls if in conflict with the Elevate Provider Network Term Sheet.
u. Dispute resolution by arbitration or mediation	Section 15(c)	At ABDC's option, all claims or disputes which are not first resolved through the internal dispute resolution procedure will be submitted first to mediation to take place at ABDC's then-current corporate headquarters under the auspices of the American Arbitration Association ("AAA"), in accordance with AAA's Commercial Mediation Rules then in effect. (subject to state law)

Provision	Section in Premier Agreement	Summary
v. Choice of forum	Section 15(e)	Any actions arising out of or related to this Agreement must be initiated and litigated to conclusion exclusively in the state court of general jurisdiction closest to ABDC's then-current corporate headquarters. (subject to state law)
w. Choice of law	Paragraph 8.6, Provisions, Exhibit C; Section 15(a)	Pennsylvania law governs, subject to applicable state law.

A provision in the GNP Premier Agreement that terminates the agreement on your bankruptcy may not be enforceable under Title 11, United States Code Section 101.

ITEM 18

PUBLIC FIGURES

We do not currently employ any public figure or celebrity in our management.

ITEM 19

FINANCIAL PERFORMANCE REPRESENTATIONS

The FTC's Franchise Rule permits a franchisor to provide information about the actual or potential financial performance of its franchised and/or franchisor-owned outlets, if there is a reasonable basis for the information, and if the information is included in the Disclosure Document. Financial performance information that differs from that included in Item 19 may be given only if: (i) a franchisor provides the actual records of an existing outlet you are considering buying; or (ii) a franchisor supplements the information provided in this Item 19, for example, by providing information about possible performance at a particular location or under particular circumstances.

Background

This Item sets forth certain historical data pertaining to GNP Premier Pharmacies performance vs. industry statistics, GNP Premier Pharmacies participating in certain options programs as against non-participating GNP Premier Pharmacies, and GNP Premier Pharmacies own year-on-year performance for the measurement periods set forth in each of the notes below. The GNP Pharmacies are substantially similar to those offered in this Franchise Disclosure Document, where GNP Pharmacies participate in certain optional programs, those Pharmacies are noted and compared to those that do not participate. Information is what is reported to us from our franchisees for all GNP Premier Pharmacies that participated in the various programs for the time-period stated. We have not audited this information, nor independently verified this information. Written substantiation of the data used in preparing this information will be made available upon reasonable request. The information is for the periods set forth in the specific notes set forth below.

Clinical Services

1. Premier members administer on average 41.4% more vaccinations.

This is based on comparing Independent Premier Members (1,740 stores) and Independent Elevate Only members from (964 stores) during the months of September 2024 – August 2025. Premier members averaged 53 vaccinations per month (min: 9, max: 244) compared to Elevate only members who averaged 37 vaccinations per month (min: 11, max: 143) in the same period. 28% of Premier customers were above average (484 out of 1,740 customers) with a median of 28.

Elevate Members

2. Elevate members experienced 5.0% year-over-year growth compared to 1.2% for the independent class of trade and 2.3% for the overall retail pharmacy market (August 2025).

Based on information licensed from IQVIA: RXInsight dated August 2025 for the period of August 2023 – September 2024 vs. September 2024 - August 2025. IQVIA's Custom GNP Retail Prescription Report ("IQVIA Data") measures AmerisourceBergen's GNP Pharmacies in the Independent Class of Trade, in addition to benchmarks to the overall Independent Class of Trade and the Overall Retail Segment (Chain, Mass Merchandisers, Food Stores and Independents) and is based on information provided to IQVIA by the pharmacies.

Five-Star Rebate

3. PRxO Generics five-star rebate: \$926.94 average payout of Q2 2025 scoring 4.5 and higher.

1% maximum rebate. 776 stores participating full Q2 2024, 50% above average, median \$738.54. Highest performing member \$7,113.98 and lowest \$5.03.

4. 68.6% higher proportion of Premier customers achieving 4.5 or greater star rating compared to non-Premier in Q2 2025.

774 customers achieving 4.5 or greater five-star ratings participating full Q2 2025, 50% above average, median \$738.56. Highest performing member \$7,113 and lowest \$5.03.

5. 99.7% higher rebate earned for Premier customers compared to non-Premier customers across all payout tiers in Q2 2025.

1% maximum rebate. 2,284 stores participating in PRxO Generics five-star rebate for full Q2 2025, 37.6% above average, median \$440.53. Highest performing member \$9,560.51 and lowest \$5.03.

Front-End Purchases

6. 9.2% Increase in front-end purchases (YOY)

Average performance for GNP Pharmacies (October 1, 2024 - September 30, 2025) All 2,148 Pharmacies participating full year FY 2024 & FY 2025, 48% above average, median 7.9%. Highest performing Pharmacy +21,708.6% and lowest -286.15%.

Pharmacy Quality Performance

7. GNP Premier Pharmacies complete, on average, 121% more medication therapy management ("MTM") services per month.

This is based on comparing Independent Premier Members (2,282 stores) and Independent Elevate Only members from (1,579 stores) during the months of September 2024 – August 2025. Premier

members averaged 145 MTMs completed per month (min: 14, max: 359) compared to Elevate only members who averaged 86 MTMs completed per month (min: 9, max: 163) in the same period. 29% of Premier customers were above average (667 out of 2,282 customers) with a median of 93.

8. GNP Premier Pharmacies earn on average 252% more on enhanced services dollars per month.

This is based on comparing Independent Premier Members (2,313 stores) and pharmacies only participating in Elevate Provider Network (2,624 stores) during the months of October 2024 – September 2025. Premier members averaged \$25 Enhanced Services dollars earned per month compared to Elevate only pharmacies who averaged \$7 Enhanced Services dollars earned per month in the same period. 21% of Premier customers were above average (491 out of 2,313 customers) with a median of \$0.

9. GNP Pharmacies earn 28% more dollars in the Humana MAPD performance Quality Improvement Program.

This is based on comparing Independent Premier Members (1,184 stores) and independent Elevate Only members from (503) stores during the months of January 2024 – July 2025. Premier members captured an average of \$4,471 Humana MAPD Quality Improvement Program performance dollars compared to Elevate only members who averaged \$3,192. (min \$1,000, max: \$378,000) in the same period. 25% of Premier pharmacies were above average (305 out of 1,184 customers) with median of \$12,764.

Unsaleable Returns

10. \$9,021 per year in unsaleable returns recouped.

Average performance of participating Good Neighbor Pharmacies (October 1, 2024 – September 30, 2025). All 1,569 Pharmacies participating in the stated time-period, 50% above average, median \$5,977. Highest performing pharmacy returned \$1.0M in product and the lowest returned \$1.

Using a Business Coaching Associate

11. 2.9% increase in the average number of patients per pharmacy

Results are based on a comparison of 1,540 pharmacies working with a business coaching Associate from August 2023 through August 2025. 40.7% above average. median was a 2-patient increase. Highest performing member increased patients by 4,445 and lowest -1,523.

12. Pharmacies working with a Business Coaching Associate dispense 91 more prescriptions on average per month.

This is based on comparing GNP Premier Pharmacies (1,540 stores) working with a Business Coaching Associate and Independent Elevate Only members during the months of August 2023 through August 2025. Premier members working with a Business Coaching Associate averaged 91 more prescriptions per month (low: -924.4 per month, high: 1,446.5 per month) compared to Elevate only members in the same period. 43% of Premier customers achieved an increase of 91 or more prescriptions a month with a median increase of 20 prescriptions per month.

13. GNP Premier Pharmacies working with a Business Coaching Associate in Humana's Quality Improvement Program increased their payout by an average of \$5,220.

This is based on 399 same store GNP Premier Pharmacies working with a Business Coaching Associate participating in the Quality Improvement Program comparing January 2024 - July 2024 vs. January 2025 – July 2025. The average dollar increase was \$5,220 (min: \$179,501 decrease, max: \$50,747 increase) 128 (32.1%) of the participating pharmacies had payouts that exceeded the average. The median increased payout was \$4,474.

Private Label

14. GNP Premier Pharmacies make 126.5% more private label product purchases per month.

This is based on comparing measured GNP Premier Pharmacies (2,092 stores) and pharmacies only participating in Elevate Provider Network (1,935 stores) during the months of September 2024 – August 2025. Measured GNP Premier Pharmacies averaged \$903.74 in private label product purchases per month (min: \$773.49; max: \$1,195.13) compared to measured Elevate-only pharmacies, who averaged \$398.92 in private label product purchases per month (min: \$360.44; max: \$456.08) in the same period. 34% of GNP Premier Pharmacies measured were above average (706 out of 2,092); median of \$651.

Pet Meds

15. GNP Premier Pharmacies have 110.7% higher pet health purchases per month.

This is based on comparing GNP Premier Pharmacies (1,478 stores) and Independent Elevate Only members from (715 stores) during the months of September 2024 – August 2025. Premier members averaged \$65.92 in pet health purchases per month (min: \$52.83, max: \$76.27) compared to Elevate only members who averaged \$31.28 in private label purchases per month (min: \$27.05, max: \$38.48) in the same period. 42.1% of Premier customers were above average (622 out of 1,478 customers) with a median of \$48.50.

Merchandise

16. GNP Premier Pharmacies that placed all shelf talkers were 25% higher than those that did not place any shelf talkers.

This is based on GNP Premier Pharmacies that participated in shelf talkers (1,240 stores) from December 2024 - July 2025 compared to GNP Premier Pharmacies that did not place any shelf talkers. Median sales for participating pharmacies were \$532 (min: \$1, max \$13,786.48). 408 (33%) participating pharmacies exceeded the average. 53% of pharmacies that placed at least 1 shelf talker exceeded the median figure.

Some outlets sold these amounts. Your individual results may differ. There is no assurance you will sell as much.

Other than the preceding financial performance representation, we do not make any representations about a franchisee's future financial performance or the past financial performance of GNP Premier Pharmacies. We also do not authorize our employees or representatives to make any such representations either orally or in writing. If you are purchasing an existing GNP Premier Pharmacy, however, we may provide you with the actual records of that pharmacy. If you receive any other financial performance information or projections of your future income, you should report it to the franchisor's management by contacting Michael Nachman at (610) 727-7000, Cencora, 1 West First Avenue, Conshohocken, PA, 19428, Attn: Michael Nachman, Esq. (Legal Department), the Federal Trade Commission, and the appropriate state regulatory agencies.

ITEM 20
OUTLETS AND FRANCHISEE INFORMATION

We did not offer franchises for the operation of GNP Premier Pharmacies prior to 2009 but, since 1982, have permitted Voluntary Pharmacies the opportunity to operate using the Good Neighbor Pharmacy trade name. As of July 2019, we are no longer offering new independent pharmacies the opportunity to operate as Voluntary Pharmacies, though the legacy Voluntary Pharmacies described in the Tables below continue to operate. Tables 1 and 3 are broken out to describe Voluntary Pharmacies and GNP Premier Pharmacies separately to provide information on both our franchises and the legacy Voluntary Pharmacy program. Please note that our fiscal year ends September 30.

TABLE NO. 1
VOLUNTARY PHARMACIES
SYSTEMWIDE OUTLET SUMMARY
FOR FISCAL YEARS 2023 TO 2025

Outlet Type	Year	Voluntary at the Start of the Year	Voluntary at the End of the Year	Voluntary Net Change	Outlets that Converted to Premier	Outlets at Year Start Including Premier	Outlets at Year End Including Premier	Net Change including Premier
Licensed	2023	240	199	-41	11	2515	2497	-18
	2024	199	182	-17	0	2497	2476	-21
	2025	182	157	-25	0	2476	2361	-115
Company Owned	2023	0	0	0	0	0	0	0
	2024	0	0	0	0	0	0	0
	2025	0	0	0	0	0	0	0
Totals	2023	240	199	-41	11	2515	2497	-18
	2024	199	182	-17	0	2497	2476	-21
	2025	182	157	-25	0	2476	2361	-115

GNP PREMIER PHARMACIES
SYSTEMWIDE OUTLET SUMMARY
FOR FISCAL YEARS 2023 TO 2025

Outlet Type	Year	Premier at the Start of the Year	Premier at the End of the Year	Premier Net Change
Franchise	2023	2275	2298	23
	2024	2298	2294	-4
	2025	2294	2204	-90
Company Owned	2023	0	0	0
	2024	0	0	0
	2025	0	0	0

Totals	2023	2275	2298	23
	2024	2298	2294	-4
	2025	2294	2204	-90

TABLE NO.2
TRANSFERS OF OUTLETS FROM FRANCHISEES TO NEW OWNERS
(OTHER THAN THE FRANCHISOR)
FOR FISCAL YEARS 2023 TO 2025

State	Year	Transfers
Alabama	2023	0
	2024	3
	2025	1
Alaska	2023	0
	2024	0
	2025	0
Arizona	2023	0
	2024	1
	2025	0
Arkansas	2023	1
	2024	5
	2025	1
California	2023	0
	2024	31
	2025	7
Colorado	2023	0
	2024	0
	2025	0
Connecticut	2023	0
	2024	0
	2025	3
Delaware	2023	0
	2024	0
	2025	0
District of Columbia	2023	0
	2024	0
	2025	0
Florida	2023	0
	2024	11
	2025	1
Georgia	2023	0
	2024	4

State	Year	Transfers
	2025	2
Guam	2023	0
	2024	0
	2025	0
Hawaii	2023	0
	2024	0
	2025	0
Idaho	2023	0
	2024	1
	2025	0
Illinois	2023	0
	2024	2
	2025	1
Indiana	2023	0
	2024	0
	2025	3
Iowa	2023	0
	2024	1
	2025	1
Kansas	2023	0
	2024	3
	2025	1
Kentucky	2023	0
	2024	6
	2025	2
Louisiana	2023	0
	2024	6
	2025	0
Maine	2023	0
	2024	2
	2025	0
Maryland	2023	0
	2024	3
	2025	0
Massachusetts	2023	0
	2024	3
	2025	0
Michigan	2023	0
	2024	10
	2025	0
Minnesota	2023	0

State	Year	Transfers
	2024	0
	2025	0
Mississippi	2023	1
	2024	1
	2025	1
Missouri	2023	0
	2024	5
	2025	0
Montana	2023	0
	2024	0
	2025	0
Nebraska	2023	0
	2024	1
	2025	0
Nevada	2023	0
	2024	1
	2025	0
New Hampshire	2023	0
	2024	0
	2025	0
New Jersey	2023	0
	2024	16
	2025	1
New Mexico	2023	0
	2024	0
	2025	0
New York	2023	0
	2024	4
	2025	0
North Carolina	2023	1
	2024	3
	2025	1
North Dakota	2023	0
	2024	0
	2025	0
Northern Mariana Islands	2023	0
	2024	0
	2025	0
Ohio	2023	0
	2024	0
	2025	2

State	Year	Transfers
Oklahoma	2023	0
	2024	0
	2025	0
Oregon	2023	0
	2024	0
	2025	0
Pennsylvania	2023	0
	2024	4
	2025	0
Puerto Rico	2023	13
	2024	2
	2025	0
Rhode Island	2023	0
	2024	0
	2025	0
South Carolina	2023	0
	2024	7
	2025	4
South Dakota	2023	0
	2024	1
	2025	0
Tennessee	2023	0
	2024	4
	2025	3
Texas	2023	13
	2024	11
	2025	3
Utah	2023	0
	2024	0
	2025	0
Vermont	2023	0
	2024	1
	2025	0
Virgin Islands	2022	0
	2024	0
	2025	0
Virginia	2023	0
	2024	5
	2025	3
Washington	2023	0
	2024	1

State	Year	Transfers
	2025	2
West Virginia	2023	0
	2024	0
	2025	2
Wisconsin	2023	0
	2024	0
	2025	0
Wyoming	2023	0
	2024	0
	2025	0
Totals	2023	29
	2024	159
	2025	45

TABLE NO. 3

**OUTLETS STATUS SUMMARY
FOR FISCAL YEARS 2023 TO 2025**

We did not offer franchises for the operation of GNP Premier Pharmacies prior to 2009 but, since 1982, have permitted Voluntary Pharmacies the opportunity to operate using the Good Neighbor Pharmacy trade name. As of July 2019, we are no longer offering new independent pharmacies the opportunity to operate as Voluntary Pharmacies, though the legacy Voluntary Pharmacies described in the Tables below continue to operate. For purposes of comparison, the following list summarizes the number of Voluntary Pharmacies in recent years, by state. Other than stores that became GNP Premier, we do not have records to indicate whether stores that discontinued being Voluntary Pharmacies did so because we terminated them, they chose to not renew, or they went out of business, were sold or otherwise discontinued operations. We have not purchased or operated any GNP Premier Pharmacies.

**VOLUNTARY PHARMACIES
FOR FISCAL YEARS 2023 TO 2025**

State	Year	Outlets at Start of Year	Outlets Opened	Converted to GNP Premier	Termination Non-Renewal, and Other	Reacquired by Franchisor	Reverted from GNP Premier	Outlets at End of Year
Alabama	2023	3	0	0	1	0	0	2
	2024	2	0	0	0	0	0	2
	2025	2	0	0	0	0	0	2
Alaska	2023	0	0	0	0	0	0	0
	2024	0	0	0	0	0	0	0
	2025	0	0	0	0	0	0	0
Arizona	2023	0	0	0	0	0	0	0
	2024	0	0	0	0	0	0	0
	2025	0	0	0	0	0	0	0

Arkansas	2023	1	0	0	0	0	0	1
	2024	1	0	0	0	0	0	1
	2025	1	0	0	0	0	0	1
California	2023	15	0	2	1	0	0	12
	2024	12	0	0	0	0	0	12
	2025	12	0	0	1	0	0	11
Colorado	2023	1	0	0	0	0	0	1
	2024	1	0	0	0	0	0	1
	2025	1	0	0	0	0	0	1
Connecticut	2023	1	0	0	0	0	0	1
	2024	1	0	0	0	0	0	1
	2025	1	0	0	0	0	0	1
Delaware	2023	0	0	0	0	0	0	0
	2024	0	0	0	0	0	0	0
	2025	0	0	0	0	0	0	0
District of Columbia	2023	0	0	0	0	0	0	0
	2024	0	0	0	0	0	0	0
	2025	0	0	0	0	0	0	0
Florida	2023	5	0	0	2	0	0	3
	2024	3	0	0	0	0	0	3
	2025	3	0	0	1	0	0	2
Georgia	2023	1	0	0	0	0	0	1
	2024	1	0	0	0	0	0	1
	2025	1	0	0	0	0	0	1
Guam	2023	9	0	0	1	0	0	8
	2024	8	0	0	5	0	0	3
	2025	3	0	0	0	0	0	3
Hawaii	2023	1	0	0	0	0	0	1
	2024	1	0	0	0	0	0	1
	2025	1	0	0	0	0	0	1
Idaho	2023	0	0	0	0	0	0	0
	2024	0	0	0	0	0	0	0
	2025	0	0	0	0	0	0	0
Illinois	2023	0	0	0	0	0	0	0
	2024	0	0	0	0	0	0	0
	2025	0	0	0	0	0	0	0
Indiana	2023	0	0	0	0	0	0	0

	2024	0	0	0	0	0	0	0
	2025	0	0	0	0	0	0	0
Iowa	2023	2	0	0	0	0	0	2
	2024	2	0	0	0	0	0	2
	2025	2	0	0	1	0	0	1
Kansas	2023	1	0	0	0	0	0	1
	2024	1	0	0	0	0	0	1
	2025	1	0	0	0	0	0	1
Kentucky	2023	2	0	1	0	0	0	1
	2024	1	0	0	0	0	0	1
	2025	1	0	0	0	0	0	1
Louisiana	2023	59	0	0	2	0	0	57
	2024	57	0	0	2	0	0	55
	2025	55	0	0	4	0	0	51
Maine	2023	1	0	0	0	0	0	1
	2024	1	0	0	0	0	0	1
	2025	1	0	0	0	0	0	1
Maryland	2023	2	0	0	0	0	0	2
	2024	2	0	0	1	0	0	1
	2025	1	0	0	0	0	0	1
Massachusetts	2023	0	0	0	0	0	0	0
	2024	0	0	0	0	0	0	0
	2025	0	0	0	0	0	0	0
Michigan	2023	5	0	0	1	0	0	4
	2024	4	0	0	1	0	0	3
	2025	3	0	0	0	0	0	3
Minnesota	2023	0	0	0	0	0	0	0
	2024	0	0	0	0	0	0	0
	2025	0	0	0	0	0	0	0
Mississippi	2023	9	0	0	0	0	0	9
	2024	9	0	0	0	0	0	9
	2025	9	0	0	6	0	0	3
Missouri	2023	5	0	0	0	0	0	5
	2024	5	0	0	1	0	0	4
	2025	4	0	0	0	0	0	4
Montana	2023	0	0	0	0	0	0	0
	2024	0	0	0	0	0	0	0
	2025	0	0	0	0	0	0	0

Nebraska	2023	0	0	0	0	0	0	0
	2024	0	0	0	0	0	0	0
	2025	0	0	0	0	0	0	0
Nevada	2023	2	0	0	1	0	0	1
	2024	1	0	0	0	0	0	1
	2025	1	0	0	0	0	0	1
New Hampshire	2023	0	0	0	0	0	0	0
	2024	0	0	0	0	0	0	0
	2025	0	0	0	0	0	0	0
New Jersey	2023	4	0	0	1	0	0	3
	2024	3	0	0	0	0	0	3
	2025	3	0	0	0	0	0	3
New Mexico	2023	1	0	0	0	0	0	1
	2024	1	0	0	0	0	0	1
	2025	1	0	0	0	0	0	1
New York	2023	18	0	3	3	0	0	12
	2024	12	0	0	1	0	0	11
	2025	11	0	0	0	0	0	11
North Carolina	2023	6	0	1	0	0	0	5
	2024	5	0	0	0	0	0	5
	2025	5	0	0	1	0	0	4
North Dakota	2023	0	0	0	0	0	0	0
	2024	0	0	0	0	0	0	0
	2025	0	0	0	0	0	0	0
Northern Mariana Islands	2023	3	0	0	0	0	0	3
	2024	3	0	0	0	0	0	3
	2025	3	0	0	0	0	0	3
Ohio	2023	6	0	0	1	0	0	5
	2024	5	0	0	1	0	0	4
	2025	4	0	0	0	0	0	4
Oklahoma	2023	4	0	0	0	0	0	4
	2024	4	0	0	1	0	0	3
	2025	3	0	0	0	0	0	3
Oregon	2023	0	0	0	0	0	0	0
	2024	0	0	0	0	0	0	0
	2025	0	0	0	0	0	0	0
Pennsylvania	2023	5	0	0	0	0	0	5

	2024	5	0	0	0	0	0	5
	2025	5	0	0	1	0	0	4
Puerto Rico	2023	32	0	1	12	0	0	19
	2024	19	0	0	2	0	0	17
	2025	17	0	0	2	0	0	15
Rhode Island	2023	0	0	0	0	0	0	0
	2024	0	0	0	0	0	0	0
	2025	0	0	0	0	0	0	0
South Carolina	2023	0	0	0	0	0	0	0
	2024	0	0	0	0	0	0	0
	2025	0	0	0	0	0	0	0
South Dakota	2023	3	0	1	1	0	0	1
	2024	1	0	0	0	0	0	1
	2025	1	0	0	0	0	0	1
Tennessee	2023	3	0	0	0	0	0	3
	2024	3	0	0	0	0	0	3
	2025	3	0	0	0	0	0	3
Texas	2023	27	0	2	3	0	0	22
	2024	22	0	0	2	0	0	20
	2025	20	0	0	8	0	0	12
Utah	2023	0	0	0	0	0	0	0
	2024	0	0	0	0	0	0	0
	2025	0	0	0	0	0	0	0
Vermont	2023	0	0	0	0	0	0	0
	2024	0	0	0	0	0	0	0
	2025	0	0	0	0	0	0	0
Virgin Islands	2023	1	0	0	0	0	0	1
	2024	1	0	0	0	0	0	1
	2025	1	0	0	0	0	0	1
Virginia	2023	1	0	0	0	0	0	1
	2024	1	0	0	0	0	0	1
	2025	1	0	0	0	0	0	1
Washington	2023	0	0	0	0	0	0	0
	2024	0	0	0	0	0	0	0
	2025	0	0	0	0	0	0	0
West Virginia	2023	0	0	0	0	0	0	0
	2024	0	0	0	0	0	0	0

	2025	0	0	0	0	0	0	0
Wisconsin	2023	0	0	0	0	0	0	0
	2024	0	0	0	0	0	0	0
	2025	0	0	0	0	0	0	0
Wyoming	2023	1	0	0	0	0	0	1
	2024	1	0	0	0	0	0	1
	2025	1	0	0	0	0	0	1
Totals	2023	240	0	11	30	0	0	199
	2024	199	0	0	17	0	0	182
	2025	182	0	0	25	0	0	157

As noted above, we did not offer franchises for operation of GNP Premier Pharmacies until 2009. The above table reflects only Voluntary Pharmacies, and the following table reflects only GNP Premier Pharmacies, showing the number of stores at the beginning and end of each year and how many opened, were terminated, did not renew or are otherwise no longer operating.

GNP PREMIER PHARMACIES FOR FISCAL YEARS 2023 TO 2025

State	Year	Outlets at Start of Year	Outlets Opened	Terminations	Non-Renewal	Reacquired by Franchisor	Other	Outlets at End of Year
Alabama	2023	25	4	6	0	0	0	23
	2024	23	2	2	0	0	0	23
	2025	23	8	1	0	0	0	30
Alaska	2023	6	0	1	0	0	0	5
	2024	5	1	1	0	0	0	5
	2025	5	0	0	0	0	0	5
Arizona	2023	4	3	1	0	0	0	6
	2024	6	0	0	0	0	0	6
	2025	6	0	0	0	0	0	6
Arkansas	2023	86	11	6	0	0	0	91
	2024	91	5	6	0	0	0	90
	2025	90	4	1	0	0	0	93
California	2023	252	33	18	0	0	0	267
	2024	267	30	28	0	0	0	269
	2025	269	17	46	0	0	0	240
Colorado	2023	9	5	1	0	0	0	13
	2024	13	0	0	0	0	0	13
	2025	13	4	1	0	0	0	16
Connecticut	2023	12	1	2	0	0	0	11

	2024	11	1	1	0	0	0	11
	2025	11	5	2	0	0	0	14
Delaware	2023	2	0	0	0	0	0	2
	2024	2	0	0	0	0	0	2
	2025	2	0	0	0	0	0	2
District of Columbia	2023	1	0	0	0	0	0	1
	2024	1	0	0	0	0	0	1
	2025	1	0	0	0	0	0	1
Florida	2023	120	9	14	0	0	0	115
	2024	115	11	21	0	0	0	105
	2025	105	9	18	0	0	0	96
Georgia	2023	158	12	8	0	0	0	162
	2024	161	10	7	0	0	0	164
	2025	164	14	12	0	0	0	166
Guam	2023	0	0	0	0	0	0	0
	2024	0	0	0	0	0	0	0
	2025	0	0	0	0	0	0	0
Hawaii	2023	36	2	5	0	0	0	33
	2024	33	0	4	0	0	0	29
	2025	29	2	4	0	0	0	27
Idaho	2023	22	0	5	0	0	0	17
	2024	17	1	1	0	0	0	17
	2025	17	0	3	0	0	0	14
Illinois	2023	40	5	1	0	0	0	44
	2024	44	3	3	0	0	0	44
	2025	44	6	6	0	0	0	44
Indiana	2023	34	4	3	0	0	0	35
	2024	35	0	3	0	0	0	32
	2025	32	4	6	0	0	0	30
Iowa	2023	33	2	4	0	0	0	31
	2024	31	1	3	0	0	0	29
	2025	29	0	3	0	0	0	26
Kansas	2023	32	6	8	0	0	0	30
	2024	30	3	2	0	0	0	31
	2025	31	1	3	0	0	0	29
Kentucky	2023	112	11	6	0	0	0	117
	2024	117	4	10	0	0	0	111
	2025	111	10	6	0	0	0	115
Louisiana	2023	16	4	2	0	0	0	18

	2024	18	3	3	0	0	0	18
	2025	18	0	2	0	0	0	16
Maine	2023	11	1	0	0	0	0	12
	2024	12	1	1	0	0	0	12
	2025	12	0	4	0	0	0	8
Maryland	2023	34	1	10	0	0	0	25
	2024	25	7	3	0	0	0	29
	2025	29	0	5	0	0	0	24
Massachusetts	2023	23	3	4	0	0	0	22
	2024	22	1	3	0	0	0	20
	2025	20	0	1	0	0	0	19
Michigan	2023	108	12	9	0	0	0	111
	2024	111	4	4	0	0	0	111
	2025	111	7	20	0	0	0	98
Minnesota	2023	21	0	1	0	0	0	20
	2024	20	0	1	0	0	0	19
	2025	19	1	2	0	0	0	18
Mississippi	2023	30	5	4	0	0	0	31
	2024	32	3	3	0	0	0	32
	2025	32	4	2	0	0	0	34
Missouri	2023	52	3	6	0	0	0	49
	2024	49	4	5	0	0	0	48
	2025	48	2	9	0	0	0	41
Montana	2023	3	0	0	0	0	0	3
	2024	3	0	0	0	0	0	3
	2025	3	0	0	0	0	0	3
Nebraska	2023	19	3	1	0	0	0	21
	2024	21	0	0	0	0	0	21
	2025	21	1	4	0	0	0	18
Nevada	2023	4	0	0	0	0	0	4
	2024	4	0	4	0	0	0	0
	2025	0	0	0	0	0	0	0
New Hampshire	2023	0	0	0	0	0	0	0
	2024	0	0	0	0	0	0	0
	2025	0	2	1	0	0	0	1
New Jersey	2023	127	11	12	0	0	0	126
	2024	126	15	22	0	0	0	119
	2025	119	8	19	0	0	0	108
New Mexico	2023	14	0	3	0	0	0	11

	2024	11	1	0	0	0	0	12
	2025	12	1	0	0	0	0	13
New York	2023	66	13	8	0	0	0	71
	2024	71	25	8	0	0	0	88
	2025	88	3	4	0	0	0	87
North Carolina	2023	102	19	10	0	0	0	111
	2024	111	2	2	0	0	0	111
	2025	111	3	10	0	0	0	104
North Dakota	2023	12	2	1	0	0	0	13
	2024	13	1	0	0	0	0	14
	2025	14	0	1	0	0	0	13
Northern Mariana Islands	2023	0	0	0	0	0	0	0
	2024	0	0	0	0	0	0	0
	2025	0	0	0	0	0	0	0
Ohio	2023	89	3	8	0	0	0	84
	2024	84	4	11	0	0	0	77
	2025	77	3	12	0	0	0	68
Oklahoma	2023	14	1	1	0	0	0	14
	2024	14	3	0	0	0	0	17
	2025	17	0	0	0	0	0	17
Oregon	2023	10	1	1	0	0	0	10
	2024	10	0	1	0	0	0	9
	2025	9	1	0	0	0	0	10
Pennsylvania	2023	77	4	7	0	0	0	74
	2024	74	13	10	0	0	0	77
	2025	77	5	11	0	0	0	71
Puerto Rico	2023	14	0	1	0	0	0	13
	2024	13	5	0	0	0	0	18
	2025	18	0	2	0	0	0	16
Rhode Island	2023	0	0	0	0	0	0	0
	2024	0	0	0	0	0	0	0
	2025	0	1	0	0	0	0	1
South Carolina	2023	59	8	0	0	0	0	67
	2024	67	15	5	0	0	0	77
	2025	77	15	7	0	0	0	85
South Dakota	2023	2	2	0	0	0	0	4
	2024	4	1	0	0	0	0	5
	2025	5	0	1	0	0	0	4
Tennessee	2023	64	8	3	0	0	0	69

	2024	69	6	4	0	0	0	71
	2025	71	7	8	0	0	0	70
Texas	2023	186	17	25	0	0	0	178
	2024	178	8	18	0	0	0	168
	2025	168	15	15	0	0	0	168
Utah	2023	16	1	0	0	0	0	17
	2024	17	3	3	0	0	0	17
	2025	17	0	0	0	0	0	17
Vermont	2023	0	0	0	0	0	0	0
	2024	0	0	0	0	0	0	0
	2025	0	0	0	0	0	0	0
Virgin Islands	2023	0	0	0	0	0	0	0
	2024	0	0	0	0	0	0	0
	2025	0	0	0	0	0	0	0
Virginia	2023	49	1	2	0	0	0	48
	2024	48	3	5	0	0	0	46
	2025	46	6	4	0	0	0	48
Washington	2023	24	2	4	0	0	0	22
	2024	22	1	2	0	0	0	21
	2025	21	2	5	0	0	0	18
West Virginia	2023	22	3	2	0	0	0	23
	2024	23	3	1	0	0	0	25
	2025	25	2	3	0	0	0	24
Wisconsin	2023	17	3	2	0	0	0	18
	2024	18	3	0	0	0	0	21
	2025	21	1	0	0	0	0	22
Wyoming	2023	6	0	0	0	0	0	6
	2024	6	0	0	0	0	0	6
	2025	6	0	0	0	0	0	6
Totals	2023	2275	239	216	0	0	0	2298
	2024	2298	207	211	0	0	0	2294
	2025	2294	174	264	0	0	0	2204

**TABLE NO. 4
COMPANY-OWNED OUTLETS STATUS SUMMARY
FOR FISCAL YEARS 2023 TO 2025**

State	Year	Outlets at Start of Year	Outlets Opened	Outlets Reacquired From Franchisee	Outlets Closed	Outlets Sold to Franchisee	Outlets At End of Year
Totals	2023	0	0	0	0	0	0
	2024	0	0	0	0	0	0
	2025	0	0	0	0	0	0

**TABLE NO. 5
PROJECTED FRANCHISEE OPENINGS AS OF SEPTEMBER 30, 2025**

State	GNP Premier Agreements Signed But Outlet Not Opened	Projected New Franchised Outlets in the Next Fiscal Year	Projected New Company Owned Outlets in the Next Fiscal Year
Alabama	0	3	0
Alaska	0	1	0
Arizona	0	2	0
Arkansas	0	8	0
California	0	32	0
Colorado	0	3	0
Connecticut	0	1	0
Delaware	0	0	0
District of Columbia	0	0	0
Florida	0	10	0
Georgia	0	11	0
Hawaii	0	1	0
Idaho	0	1	0
Illinois	0	4	0
Indiana	0	2	0
Iowa	0	2	0
Kansas	0	5	0
Kentucky	0	7	0
Louisiana	0	4	0
Maine	0	1	0
Maryland	0	4	0
Massachusetts	0	2	0
Michigan	0	8	0
Minnesota	0	0	0
Mississippi	0	4	0
Missouri	0	3	0
Montana	0	0	0
Nebraska	0	2	0

State	GNP Premier Agreements Signed But Outlet Not Opened	Projected New Franchised Outlets in the Next Fiscal Year	Projected New Company Owned Outlets in the Next Fiscal Year
Nevada	0	0	0
New Hampshire	0	0	0
New Jersey	0	13	0
New Mexico	0	1	0
New York	0	19	0
North Carolina	0	11	0
North Dakota	0	2	0
Ohio	0	4	0
Oklahoma	0	2	0
Oregon	0	1	0
Pennsylvania	0	9	0
Rhode Island	0	0	0
South Carolina	0	12	0
South Dakota	0	1	0
Tennessee	0	7	0
Texas	0	13	0
Utah	0	2	0
Vermont	0	0	0
Virginia	0	2	0
Washington	0	2	0
West Virginia	0	3	0
Wisconsin	0	3	0
Wyoming	0	0	0
Puerto Rico	0	2	0
Guam	0	0	0
Northern Mariana Islands	0	0	0
Virgin Island	0	0	0
Totals	0	230	0

List of Current Franchisees

A list of current franchisees is provided in Exhibit D.

List of Former Franchisees and Licensees

We did not offer franchises for the operation of GNP Premier Pharmacies or otherwise until 2009 and have never refused to renew a franchise (other than as part of a total account closure for non-franchise related reasons such as credit concerns); 45 franchisees transferred ownership during FY 2025, and no franchisee has failed to communicate with us during the 10 weeks preceding the date of this Disclosure Document. If you buy this franchise, your contact information may be disclosed to other buyers when you leave the franchise system. Former franchisees are listed in Exhibit D.

If you enter into a GNP Premier Agreement, information about your agreement may be disclosed to others who are interested in the GNP Premier Program if you leave the GNP Premier Program.

Purchase of Previously Owned Franchise

If you are purchasing a previously owned GNP Premier Pharmacy or Voluntary Pharmacy from us, we will provide you additional information on this previously owned pharmacy in an addendum to this Disclosure Document, but only to the extent we have such information.

Confidentiality Clauses

During the last three fiscal years, we have not signed any agreements with Voluntary Pharmacies or GNP Premier Pharmacies that contain confidentiality clauses that would restrict their ability to speak openly about their experience (or we will agree to waive any such restriction upon request).

Trademark-Specific Franchisee Organizations

We are not currently aware of any trademark-specific franchisee organizations associated with the franchise GNP Premier Program which we have created, sponsored or endorsed, or any independent franchisee organizations that have asked to be included in this Disclosure Document. As noted above, there are regional and national GNP Advisory Boards. See Item 11.

ITEM 21 **FINANCIAL STATEMENTS**

Attached to this Disclosure Document as Exhibit E are the financial statements for Cencora, our parent. Our financial information is consolidated within that of Cencora.

Audited Financial Statements

The Consolidated Financial Statements are the consolidated financial position of Cencora on September 30, 2025 and 2024, and the consolidated results of their operations and their cash flows for each of the three years in the period ending on September 30, 2025.

Our parent, Cencora, has agreed to absolutely and irrevocably guarantee all obligations of ABDC to any franchisee under the GNP Premier Agreement and related agreements in this Disclosure Document. The guarantee is included in Exhibit E following the financial statements.

ITEM 22 **CONTRACTS**

Depending on Available Programs in which you elect to participate, you will sign the GNP Premier Agreement and the Data Authorization Supplement and agree to terms in some or all of its exhibits, all of which are attached as exhibits to this Disclosure Document.

Exhibit B - GNP Premier Agreement (with Data Authorization Supplement):

Exhibit A -	Data Protection Provisions
Exhibit B -	HIPAA Business Associate Agreement
Exhibit C -	Provisions
Exhibit D -	State-Specific Amendments/Addenda

Exhibit E - Master Program Agreement

Program Selection and Data Authorizations:

Term Sheet 1 -	Elevate Provider Network
Term Sheet 2 -	Elevate Advanced Features
Term Sheet 2A -	Pre & Post Edit Solutions (PPE)
Term Sheet 2B -	Claim Reconciliation Services
Term Sheet 2C -	Outcomes Patient Care Services
Term Sheet 2D -	EnlivenHealth Patient Care Services
Term Sheet 3 -	InSite from ABDC
Term Sheet 4 -	Five-Star Rebate
Term Sheet 5 -	The Front-End Solution Programs
Term Sheet 6 -	Digital Marketing
Term Sheet 7 -	Business Coaching
Term Sheet 8 -	Pharmacy System Data Services
Term Sheet 9 -	Unsaleable Returns
Term Sheet 10 -	Statement of Work for Special Projects (Form)

ITEM 23
RECEIPTS

Please sign two copies of the Receipt attached as the last two pages to this Disclosure Document. After execution, you keep one copy and provide the other to us.

**EXHIBIT A
STATE ADMINISTRATORS AND
AGENTS FOR SERVICE OF PROCESS**

STATE ADMINISTRATORS

CALIFORNIA

Department of Financial Protection and
Innovation
320 West 4th Street, Suite 750
Los Angeles, California 90013
(866) 275-2677 or (213) 576-7500

HAWAII

Department of Commerce and Consumer
Affairs
Business Registrations Division
335 Merchant Street, Room 203
Honolulu, Hawaii 96813
(808) 586 2722

ILLINOIS

Office of Attorney General
500 South Second Street
Springfield, Illinois 62706
(217) 782 4465

INDIANA

Franchise Section
Securities Division
302 W. Washington St., Room E 111
Indianapolis, Indiana 46204
(317) 232 6681

KENTUCKY

Office of the Attorney General
1024 Capital Center Drive
Frankfort, Kentucky 40602
(502) 696 5300

MARYLAND

Office of Attorney General
Securities Division
200 St. Paul Place
Baltimore, Maryland 21202
(410) 576 7042

MICHIGAN

Office of the Attorney General
Corporate Oversight Division
Franchise Section
G. Mennen Williams Building, 5th Floor
525 W. Ottawa Street
Lansing, Michigan 48909
(517) 373-7117

MINNESOTA

Department of Commerce
85 7th Place East, Suite 280
St. Paul, Minnesota 55101-2198
(651) 539-1600

NEBRASKA

Department of Banking and Finance
1200 N Street, Suite 311
P.O. Box 95006
Lincoln, Nebraska 68509
(402) 471 3445

NEW YORK

Office of the Attorney General
Investor Protection Bureau
28 Liberty Street, 21st Floor
New York, NY 10005
Tel: 212-416-8222

NORTH DAKOTA

North Dakota Securities Department
600 East Blvd., Fifth Floor
Bismarck, North Dakota 58505
(701) 328 4712

OREGON

Division of Consumer and Business
Services
Finance and Corporate Securities
350 Winter Street N.E.
Labor and Industries Building, Room 21
Salem, Oregon 97310
(503) 378 4387

RHODE ISLAND

Securities Division
1511 Pontiac Avenue
John O. Pastore Complex – Building 69-1
Cranston, Rhode Island 02920
(401) 222 3048

SOUTH DAKOTA

Division of Insurance
Securities Regulation
124 Euclid, Suite 104
Pierre, South Dakota 57501
(605) 773 3563

TEXAS

Statutory Document Section
Secretary of State
P.O. Box 12887
Austin, Texas 78711
(512) 475 1769

UTAH

Division of Consumer Protection
Utah Department of Commerce
160 East Three Hundred South
P.O. Box 146704
Salt Lake City, Utah 84114 6704
(801) 530 6601

VIRGINIA

State Corporation Commission
Division of Securities and Retail Franchising
1300 East Main Street, 9th Floor
Richmond, Virginia 23219
(804) 371 9051

WASHINGTON

Department of Financial Institutions
Securities Division
150 Israel Road, S.W.
Tumwater, Washington 98501
(360) 902 8760

WISCONSIN

Division of Securities
Department of Financial Institutions
P.O. Box 1768
Madison, Wisconsin 53701 or
345 W. Washington, 4th Floor
Madison, Wisconsin 53703
(608) 266 8559

AGENTS FOR SERVICE OF PROCESS

CALIFORNIA

Commissioner of ion
Department of Financial Protection and
Innovation
320 West 4th Street, Suite 750
Los Angeles, California 90013-1105

HAWAII

Commissioner of Securities
Department of Commerce and Consumer
Affairs
Business Registrations Division
335 Merchant Street, Room 203
Honolulu, Hawaii 96813

ILLINOIS

Illinois Attorney General
500 South Second Street
Springfield, Illinois 62706

INDIANA

Secretary of State
201 State House
200 W. Washington Street
Indianapolis, Indiana 46204

MARYLAND

Maryland Securities Commissioner
Office of the Attorney General
200 St. Paul Place
Baltimore, Maryland 21202-2020

MICHIGAN

Michigan Department of Attorney General
Corporate Oversight Division
G. Mennen Williams Bldg., 5th Floor
525 W. Ottawa Street
Lansing, Michigan 48913

MINNESOTA

Commissioner of Commerce
85 7th Place East, Suite 280
St. Paul, Minnesota 55101-2198

NEW YORK

New York Secretary of State
New York Department of State
One Commerce Plaza,
99 Washington Avenue, 6th Floor
Albany, NY 12231-0001
(518) 473-2492

NORTH DAKOTA

Securities Commissioner
North Dakota Securities Department
600 East Boulevard, Fifth Floor
Bismarck, North Dakota 58505

OREGON

Director
Department of Consumer and Business Services
Division of Finance and Corporate Securities
Labor and Industries Building
Salem, Oregon 97310

RHODE ISLAND

Director
Department of Business Regulation
1511 Pontiac Avenue
John O. Pastore Complex – Building 69-1
Cranston, Rhode Island 02920

SOUTH DAKOTA

Department of Labor and Regulation
Division of Securities
125 Euclid, Suite 104
Pierre, South Dakota 57501
(605) 773 3563

VIRGINIA

Clerk of the State Corporation Commission
1300 East Main Street, 1st Floor
Richmond, Virginia 23219

WASHINGTON

Director of Financial Institutions
Securities Division
150 Israel Rd. S.W.
Tumwater, Washington 98501

WISCONSIN

Commissioner of Securities
Fourth Floor
345 West Washington Avenue
Madison, Wisconsin 53703

GNP PREMIER AGREEMENT

Good Neighbor Pharmacy[®]
Premier Participation Agreement
Summary & Signature Page

This Good Neighbor Pharmacy[®] Premier Participation Agreement (“**Agreement**”) between AmerisourceBergen Drug Corporation, a Delaware corporation with offices at 1 West First Avenue, Conshohocken, PA 19428 (“**ABDC**”) and Customer (identified below and also referred to herein as “**you**” or “**your**”) is effective as of the effective date indicated below on this page (“**Effective Date**”) if it is accepted by ABDC.

CUSTOMER

Legal Name: _____

D/B/A: _____

Address 1: _____

Address 2: _____

City, State, Zip: _____

Attach list as Exhibit F for multiple locations or if pharmacy address is different.

ENTITY

Check one: ☐ Corporation ☐ Partnership
☐ Limited Liability Company ☐ Individual
☐ Limited Partnership ☐ Other:

State of Formation: _____

ACCOUNT

NCPDP No: _____ *For Single Locations Only*

PROGRAM

Effective Date: _____

Term: 5 years (with 60-day “no cause” termination in Section 7)

Customer’s Designated Manager: _____

Initial Fee: None

Monthly Fee: \$599 per Pharmacy Location

Available Program Participation: See Sections 4(g) and 4(h), Exhibit E and Term Sheets 1 to 10

Disclosure Compliance Franchise Disclosure Document Delivery Date: _____

Each party’s authorized officer, partner or principal signed this Good Neighbor Pharmacy[®] Premier Participation Agreement as of the date indicated and such Agreement shall be effective as of its Effective Date.

Customer

ABDC

By: _____

By: _____

Name: _____

Name: _____

Title: _____

Title: _____

Date Signed: _____

Date Signed: _____

Do Not Sign Before: _____

TABLE OF CONTENTS

Table of Contents

1. Grant.....	1
2. Fees.....	2
3. Modifications of GNP Premier Program and Marks	2
4. Customer’s Obligations	3
5. Required Signage	5
6. GNP Private Label Products.....	5
7. Term and Termination.....	6
8. Internet Operations	6
9. Trademarks and Intellectual Property	7
10. Transfers.....	9
11. GNP License Program Release	9
12. Post-Termination Obligations	9
13. Program Master Terms	10
14. Dispute Resolution.....	12
15. Miscellaneous.....	14
Exhibit A – Data Protection Provisions	15
Exhibit B – HIPAA Business Associate Agreement	18
Exhibit C – Provisions	21
Exhibit D – State-Specific Amendments	24
Exhibit E – Master Program Agreement	31
Available Program Enrollment Form & Data Authorization	37
Term Sheet 1 – Elevate Provider Network®	40
Term Sheet 2 – Elevate Advanced Features	47
Term Sheet 2A – Pre & Post Edit Solutions.....	49
Term Sheet 2B – Claim Reconciliation Services.....	52
Term Sheet 2C – Outcomes PCS Services.....	55
Term Sheet 2D – Enliven Health Patient Care Services	57
Term Sheet 3 – InSite from ABDC / InSite for POS System	60
Term Sheet 4 – Five-Star Rebate Program	62
Term Sheet 5 – First to Shelf / Planogram Services / Merchandising Services Retail Product Zone Pricing / Front-End Support Kit	64
Term Sheet 6 – Digital Marketing	65
Term Sheet 7 – Business Coaching	67
Term Sheet 8 – Pharmacy Data Services	69
Term Sheet 9 – Unsaleable Returns.....	70
Term Sheet 10 – Statement of Work-Services (Form) for Special Projects	72
<i>Current Term Sheets are posted on AB Central</i>	
<i>(https://abcorder.amerisourcebergen.com)</i>	

Good Neighbor Pharmacy® Premier Participation Agreement

A. ABDC, a nationwide wholesaler of pharmaceuticals and sundries, and its Corporate Affiliates (as defined below) have, with expenditure of time, skill, effort and money, developed an advertising and merchandising program, “Good Neighbor Pharmacy” for community pharmacies. As used in this Agreement, a “**Corporate Affiliate**” means a person or entity that controls, is controlled by or is under common control with another person or entity, either by virtue of equity ownership, by contract or by other means.

B. Customer owns and operates one or more community pharmacies (each a “**Pharmacy**”) and desires to obtain the right to use the Good Neighbor Pharmacy® Premier program (“**GNP Premier Program**”) in operating each Pharmacy pursuant to this Agreement, which such right ABDC is willing to grant subject to the terms and conditions provided herein.

C. Customer is joining the GNP Premier Program to promote and advertise its Pharmacy, to contribute to the collective goodwill of the GNP Premier Program and to actively participate in its programs.

D. This Agreement, including its Addenda, Exhibits, Term Sheets, as well as their respective enrollment forms and Data Authorizations, each as may be amended from time to time as permitted herein, is the entire agreement between the parties related to the GNP Premier Program (excluding only the disclosure document described in Recital G below) and is independent of any unrelated business relationships between the parties. This Agreement supersedes any Master Program Agreement entered into by and between the parties for so long as the customer is party to this Agreement; provided, however, that any obligations outstanding as of the Effective Date originating from the Master Program Agreement, any Available Program (as defined in Section 4(g)) selections, any Data Authorization forms relating to Available Programs, and any other terms or agreements the context of which show the parties intended them to survive, shall carry over into this Agreement and shall survive, and such Master Program Agreement shall be reinstated upon termination of this Agreement. Nothing in this Agreement or in any related agreement will disclaim ABDC’s representations in the Franchise Disclosure Document that was furnished to you.

E. Customer confirms that, as reflected on the Summary and Signature Page, it received (1) a complete copy of this Agreement, including its exhibits, with all blanks filled in, at least seven days before execution, and (2) the Franchise Disclosure Document, required by the Trade Regulation Rule of the Federal Trade Commission entitled “Disclosure Requirements and Prohibitions Concerning Franchising,” at least fourteen (14) days before execution.

1. Grant.

- (a) Use of Marks & GNP Premier Program. Subject to this Agreement, ABDC hereby grants and Customer accepts certain non-exclusive rights to use all or part of the GNP Premier Program. In turn, Customer will use the “Good Neighbor Pharmacy” and related trademarks, service marks and their successors (collectively, “**Marks**”) to operate Pharmacy under the GNP Premier Program, and to advertise and promote Pharmacy using the Marks, all as required by this Agreement. Customer’s use of the Marks is subject to the conditions set forth in Section 9 of this Agreement.
- (b) Pharmacy Locations. Pursuant to this Agreement, Customer may operate each Pharmacy as a GNP Pharmacy at its existing Pharmacy location, where Customer was previously operating its pharmacy business, or new Pharmacy location, where Customer is a start-up pharmacy (each such location, a “**Pharmacy Location**”). In granting rights under this Agreement, ABDC makes no assurance, express or implied, about suitability of such location for a pharmacy, or any other purpose, and ABDC will not be responsible if Pharmacy does not meet Customer’s expectations for revenue, operations or other criteria.
- (c) Internet Operations. Customer may sell products and services using internet websites only as expressly permitted herein or as otherwise authorized by ABDC in writing.
- (d) Unapproved Operations. Customer may not use any Mark or other distinctive or unique elements of the GNP Premier Program to operate any business other than Pharmacy at the Pharmacy Location, without

ABDC's express prior written approval. Customer understands and acknowledges that such use constitutes willful infringement of the Marks and the GNP Premier Program.

- (e) Non-Exclusivity. Customer's rights with respect to the GNP Premier Program are not exclusive. ABDC may among other things: (1) establish and operate GNP Pharmacies (defined in Section 4(a)) and allow others to do so, including ones in the GNP Premier Program; (2) offer and sell the GNP Premier Program and related products and services to other customers; and (3) establish, operate, offer and sell other businesses, goods and services, or allow others to do so, including those that are the same, similar or different and using some, all or none of the Marks, in each case regardless of proximity to or competitive impact on GNP Pharmacies.
- (f) Administration. In certain instances, ABDC receives revenue from the sale of items (other than ABDC's core distribution items such as Rx, OTC, etc.) related to the GNP Premier Program that are purchased by GNP Pharmacies from third parties, such as volume discounts, rebates or other benefits based on GNP Pharmacies' aggregate purchases. Such benefits will be used to generally enhance and promote the GNP Premier Program or to benefit GNP Pharmacies generally. This provision is not meant to circumvent or eliminate opportunities for revenue sharing with GNP Pharmacies, and in such cases ABDC may allocate such benefits directly and proportionally to participating GNP Pharmacies and deduct expenses to administer and coordinate suppliers. In connection with programs for GNP Pharmacies and related products and services, Customer hereby assigns ABDC the right to collect related promotional and advertising allowances.

2. Fees.

- (a) Initial Fee. In consideration of Customer's anticipated initial expenditures which may be required to meet GNP Premier Program requirements, ABDC does not charge an initial fee associated with its granting of rights as provided in this Agreement.
- (b) Periodic Fees. In consideration for Customer's continuing use of the Marks and the GNP Premier Program and participating in Available Programs that are Required or Optional (each as defined in Section 4(g)-(h)), Customer agrees to pay ABDC for each Pharmacy Location the GNP Premier monthly fee provided on the Summary and Signature Page ("**Monthly Fee**") which such Monthly Fees may be prorated as applicable. ABDC will add to the billed amount applicable fees for Available Programs and applicable sales, use or other tax or charges. Unless otherwise agreed, payment is due pursuant to payment terms under Customer's PVA (defined in Section 4(f)). ABDC may increase the Monthly Fee upon sixty (60) days' notice.
- (c) GNP Manual. ABDC will provide to Customer the GNP Manual (defined in Section 4(a)), in electronic format, and additions and supplements to the GNP Manual as they become available. Notwithstanding the foregoing, Customer understands and agrees that the current version of the GNP Manual on file in ABDC's offices is the standard, official version for purposes of resolving any question or dispute concerning GNP Manual contents.

3. Modification of GNP Premier Program and Marks.

- (a) Modifications. ABDC may modify the GNP Premier Program and Marks, including: (i) adding, changing or discontinuing them; (ii) changing decorative, non-functional components that provide Pharmacy a distinctive, memorable appearance ("**Trade Dress**"); and (iii) adding, changing or discontinuing "Good Neighbor Pharmacy" brand private label product ("**GNP Private Label Product**"). Customer will comply with and adopt, at its expense, any and all such changes, including changing Trade Dress, signage and Pharmacy operations items.
- (b) Innovations. The GNP Premier Program is continually enhanced through feedback provided by GNP Pharmacies, including sharing of successful and innovative uses of the GNP Premier Program. If Customer suggests, enhances or develops an innovation or improvement related to any aspect of the GNP Premier Program and ABDC incorporates it into its programs for use in or by other GNP Pharmacies

(whether on a temporary or permanent basis and whether applicable to some or all GNP Pharmacies): (i) such innovation or improvement will become part of such programs without compensation to Customer or any other party; and (ii) Customer hereby irrevocably assigns to ABDC all right, title, and interest in and to such enhancements, innovations, and improvements, including all intellectual property rights and proprietary rights attributable thereto, and agrees to take any additional steps ABDC may request in connection with ABDC's ownership of the same.

4. Customer's Obligations.

- (a) Pharmacy Operation. Operation and appearance of each pharmacy that operates under the "Good Neighbor Pharmacy" trademark and other Marks, including those in the GNP Premier Program and pharmacies operating under a Good Neighbor Pharmacy Voluntary License (collectively, "**GNP Pharmacies**"), reflect on other GNP Pharmacies and goodwill of the GNP Premier Program. Customer will use best efforts to operate its business at each Pharmacy with diligence and vigor, and maintain the highest possible ethics and maintain Pharmacy and personnel in a manner that are a credit to the community and reflect the high standards and quality of the GNP Premier Program, including interacting with and treating all customers and ABDC personnel in a respectful and professional manner. GNP prescribes or recommends standards, practices, procedures, policies and advice relating to the appearance, operations, management and marketing of GNP Pharmacies (collectively, "**Standards**"), as updated by ABDC from time to time and provided in the materials it provides or makes available to you ("**GNP Manual**"). Customer shall become active and compliant with all required Available Programs within one hundred twenty (120) days after the Effective Date; provided, however, that Customer understands and acknowledges that it may take four (4) to six (6) weeks for a third-party Payor to recognize that Customer is authorized to provide Covered Services to its Members (each as defined under Term Sheet 1). Customer will operate Pharmacy and perform its obligations hereunder in accordance with applicable law, this Agreement, the GNP Manual, and Standards and other agreements.
- (b) Pharmacy Appearance and Integrity. Customer will maintain all interior and exterior areas at each Pharmacy Location in a safe and sanitary condition. Customer will keep equipment, decorations, fixtures, furnishings and improvements in good order and promptly repair or replace those that are damaged, worn or obsolete. Customer will provide appropriate training for Pharmacy personnel on proper use and display of Marks under this Agreement, the GNP Manual and Standards.
- (c) Signage. Customer will purchase exterior and interior signage from suppliers meeting Standards to ABDC's reasonable satisfaction and display all required signage at each Pharmacy in accordance with the Standards.
- (d) Placard. Customer will display in a reasonably visible manner in each Pharmacy Location a notice stating, "This business is independently owned and operated by [insert name of Customer]." Customer shall not make any statement or representation contrary to Paragraph 8.5 of the Provisions (Exhibit C).
- (e) Designated Manager. Customer will designate one (1) owner, partner or other authorized person as Customer's primary contact ("**Customer's Designated Manager**") with ABDC and its staff to administer and coordinate the relationship under this Agreement.
- (f) Prime Vendor Agreement. Customer will purchase brand and generic prescription (Rx), over-the-counter (OTC), health and beauty care (HBC), and GNP Private Label Products from ABDC pursuant to a prime vendor agreement or other applicable distribution agreement ("**PVA**"), which shall be executed separately. Separately, animal health products may be purchased from MWI Veterinary Supply Co., an affiliate of ABDC, pursuant to a GNP - Animal Health Purchase Agreement or other applicable distribution agreement. ABDC will provide access to electronic catalogs of such products, which are typically updated daily including new products as they are available. Customer will place orders using one of ABDC's available order systems, with purchases subject to the PVA or as otherwise agreed, including terms for payment, credit, liability, risk of loss, shortages, delays and compliance with law. All such orders will be at ABDC's standard then-current wholesale prices under the PVA.

- (g) **Available Programs.** ABDC offers a variety of programs and services (“**Available Programs**”) in which pharmacies may participate to improve their operational and financial performance. General terms for Available Programs are provided in the Master Program Agreement (Exhibit E) and the Provisions (Exhibit C), with specific descriptions, terms, and conditions respecting each Available Program provided in Term Sheets 1 to 10 (“**Term Sheets**”). ABDC may unilaterally amend this Agreement, including, without limitation, developing new or modifying existing Exhibits hereto and/or Available Programs and their respective policies, procedures, and corresponding Term Sheets, which any such amendments are effective sixty (60) days after they are available or any shorter period specified in a Term Sheet, as applicable. As noted in the Master Program Agreement, Customer may incur additional expenses for Available Programs. Current Term Sheets are posted on AB Central (<https://abcorder.amerisourcebergen.com>). ABDC will provide notice via fax or email respecting any unilateral amendment to this Agreement as provided herein.
- (h) **Required & Optional Programs.** Each GNP Premier Program participant must participate in certain Available Programs (“**Required**”) and has the option to participate in others that are included with or without an additional cost (“**Optional**”). Customer enrollment and onboarding in Required Available Programs will begin as of the Effective Date; provided, however, that Customer may be required to fulfill certain prerequisite conditions before the services offered in such Available Program are made available to Customer, and some Available Programs may not be immediately available to Customer. For an Available Program that is Optional, Customer may (i) enroll during the Term by submitting applicable information required to set-up Customer's participation and requesting that ABDC begin providing such Available Program and (ii) disenroll by requesting that ABDC discontinue providing such Available Program, pursuant to the terms of the respective Term Sheet. All Term Sheets incorporate the provisions of this Agreement, including all Exhibits attached hereto, by this reference. Currently, the following are Available Programs:

	AVAILABLE PROGRAMS	
Required Required Required Optional Optional Optional	Managed Care <ul style="list-style-type: none"> <input type="checkbox"/> Elevate Provider Network <input type="checkbox"/> Elevate Advanced Features <input type="checkbox"/> Pre & Post Edit Solutions (PPE) <input type="checkbox"/> Claim Reconciliation Services <input type="checkbox"/> Outcomes Patient Care Services Solution <input type="checkbox"/> EnlivenHealth Patient Care Services Solution 	Term Sheet 1 Term Sheet 2 Term Sheet 2A Term Sheet 2B Term Sheet 2C Term Sheet 2D
Required Optional Optional	Data Analytics and Pharmacy Performance <ul style="list-style-type: none"> <input type="checkbox"/> InSite for Pharmacy Management System Data <input type="checkbox"/> InSite for Point-of-Sale System Data <input type="checkbox"/> Five-Star Rebate 	Term Sheet 3 Term Sheet 4
Required Optional Optional Optional Optional	Front-End Solution Programs <ul style="list-style-type: none"> <input type="checkbox"/> First-to-Shelf – AutoShip New OTC & GNP Private Label Products <input type="checkbox"/> Planogram Services <input type="checkbox"/> Retail Product Zone Pricing Service <input type="checkbox"/> Front-End Support Kit <input type="checkbox"/> Merchandising Services 	Term Sheet 5
Optional Optional Optional Optional	Digital Marketing <ul style="list-style-type: none"> <input type="checkbox"/> My GNP Website <input type="checkbox"/> My GNP Mobile App <input type="checkbox"/> Social Media Marketing <input type="checkbox"/> Local Listings Management 	Term Sheet 6
Optional	Business Coaching <ul style="list-style-type: none"> <input type="checkbox"/> Business Coaching 	Term Sheet 7

	AVAILABLE PROGRAMS	
Optional Optional Optional	Miscellaneous <input type="checkbox"/> Pharmacy Data Services <input type="checkbox"/> Unsaleable Returns <input type="checkbox"/> Statement of Work-Service (Form) for Special Projects	Term Sheet 8 Term Sheet 9 Term Sheet 10

- (i) Elevate Provider NetworkSM. GNP Premier Program participants each participate in the Elevate Provider Network[®] (“**Elevate Provider Network**”), pursuant to which ABDC will assist Customer to participate in and obtain payment from certain Payors (as defined in Term Sheet 1). Customer must designate the Elevate Provider Network as its primary contracting entity and may not appoint any other pharmacy services administration organization (“**PSAO**”) or other party to act as its primary agent/contracting entity for agreements with Payors without ABDC’s prior written approval or ABDC may terminate this Agreement. Such termination will be effective at the earlier of the date on which Customer’s designation of another PSAO is effective or thirty (30) days after Customer’s receipt of ABDC’s termination notice under this Section 4(i). Participation in Elevate Advanced Features is required notwithstanding Customer’s designation of an alternative PSAO.
- (j) Business Coaching. Within six (6) months of Customer completing all prerequisite conditions necessary to enroll in the Required Available Programs, Customer will be enrolled in the Business Coaching Available Program and assigned a Business Coaching Associate (as defined in Term Sheet 7), who will provide to Customer certain recommendations related to increasing Pharmacy’s performance. Business Coaching is provided at no additional cost to Pharmacies enrolled in the GNP Premier Program.
- (k) Confidential Information. Customer will maintain in strict confidence all ABDC Confidential Information (as defined in and in accordance with Paragraph 4 of the Provisions (Exhibit C) and Term Sheets) and take all necessary action to ensure that its employees and other representatives do not disclose any ABDC Confidential Information except as expressly permitted herein.
- (l) Display of Material. Customer will display at each Pharmacy Location: (i) Good Neighbor Pharmacy product identification material; (ii) point-of-purchase promotional material; (iii) promotional memorabilia and merchandise; and (iv) other advertising and marketing material that ABDC requires Customer to use in operating Pharmacy, in each case in accordance with this Agreement and in such manner as ABDC may otherwise periodically designate.

5. Required Signage.

- (a) Initial Signage. Each Pharmacy Location must be prominently identified as a participating “Good Neighbor Pharmacy[®]” member as ABDC designates. At each Pharmacy Location, within ninety (90) days after signing the GNP Premier Agreement, Customer must install GNP signage and Trade Dress that meets the Standards. ABDC’s current signage Standards require: (i) at least one (1) “GOOD NEIGHBOR PHARMACY” identification window decal; (ii) at least one (1) “GOOD NEIGHBOR PHARMACY” logo, which is available in both standard and customized interior and exterior versions; (iii) “GOOD NEIGHBOR PHARMACY” member plaque; and (iv) any other signage required by ABDC, as set forth in the GNP Manual. All signage must meet applicable Standards, including Standards relating to appearance, placement and visibility of signs, as provided in the GNP Manual and be kept in good repair. Customer will use best efforts to maximize visibility of exterior “GOOD NEIGHBOR PHARMACY” signs subject to any legal limitations. For each Pharmacy Location, Customer will obtain all required approvals, including government permits, before installing or removing any signs, structures or other items associated with the Marks.
- (b) Initial Signage Allowance. ABDC provides complimentary signage packages to all new franchisees that, when applied according to the Standards, meet applicable minimum requirements; provided, however, that for an existing Voluntary Pharmacy converting to a GNP Premier Pharmacy, ABDC may provide only a partial package as compliant signage may already be installed. To encourage you to enhance the

appearance of your GNP Premier Pharmacy and further apply the Good Neighbor Pharmacy Trade Dress at your Pharmacy Location, ABDC offers new franchisees up to Two Thousand Five Hundred dollars (\$2,500.00) in matching funds as a one-time allowance of up to Two Thousand Five Hundred dollars (\$2,500.00) per Pharmacy Location to install additional or enhanced exterior signage and other Trade Dress that meets the Standards within one hundred eighty (180) days of executing this Agreement. If Customer terminates this Agreement for any reason, other than an uncured default by ABDC, within twelve (12) months of executing the Agreement, Customer will reimburse ABDC, in addition to any other amounts or damages that may be owed to ABDC under this Agreement or any other agreement, the full amount ABDC paid to Customer in matching funds under this provision. Customer acknowledges and agrees that the foregoing reimbursement does not constitute liquidated damages, and is not exclusive of any other rights or remedies that may be available to the parties. ABDC associates are unable to assist with measuring or installation of any signage items.

- (c) Compliance Exceptions. If Customer needs to vary signage from the applicable requirements under this Agreement or the GNP Manual, variations will be documented on a GNP Compliance Exception Request Form to be reviewed and approved by ABDC in its sole discretion. Such approval must be given by ABDC in writing prior to Customer's use of non-conforming signage.

6. GNP Private Label Products. Customer will periodically purchase and offer for sale a representative assortment of GNP Private Label Products in quantities reasonably anticipated to meet consumer demand, taking into account, among other things, Pharmacy's size and market, as determined by Customer in its reasonable discretion based on its general business experience. Customer will feature the GNP Private Label Products as its preferred alternative to national brands and will use best efforts to promote and sell GNP Private Label Products. Customer hereby authorizes ABDC to initiate commercially reasonable orders on its behalf for new GNP Private Label Products as they are introduced.

7. Term and Termination.

- (a) Initial & Renewal Terms. The initial term of this Agreement begins on its Effective Date on the Summary and Signature Page and, subject to earlier termination, ends five (5) years after the Effective Date ("**Initial Term**"). Thereafter, the Term will renew automatically for additional, consecutive two-year periods (each, a "**Renewal Term**" and, together with the Initial Term, the "**Term**") unless either party gives the other party one hundred twenty (120) days' prior written notice of its intent to not renew the Term.
- (b) Mutual Termination. Either party may terminate this Agreement with respect to one or more Pharmacy Locations with or without cause upon sixty (60) days' prior written notice to the other party. Termination for less than all Pharmacy Locations will not terminate this Agreement with respect to a Pharmacy Location that is not named in the termination notice. Termination of this Agreement will not, by itself, terminate any other agreement between the parties.
- (c) Termination for Breaching GNP Obligations. ABDC may terminate this Agreement immediately upon notice to Customer and without providing Customer the opportunity to cure if (i) Customer or a Principal (as defined below) breaches its obligations to protect Confidential Information; (ii) breaches its obligations relating to use of the Marks or ABDC's online portal maintained in connection with the GNP Premier Program (the "**GNP Portal**"); or (iii) Customer or a Principal is convicted of or pleads guilty or no contest to a felony or any other offense that ABDC determines may adversely affect other GNP Pharmacies, Available Programs, related programs, or goodwill of the Marks or the GNP Premier Program, such as fraud, sexual harassment, battery, drug possession and crimes of moral turpitude. "**Principal**" means each officer, director or owner of Customer or any Corporate Affiliate.
- (d) Default. Additionally, either party may terminate this Agreement for cause pursuant to Paragraph 5 of the Provisions (Exhibit C).

8. Internet Operations.

- (a) General. Customer may promote Pharmacy and sell products using the Marks on the internet pursuant to the GNP Manual and Standards. Any such internet operation will clearly identify Customer's community pharmacy business and be incidental to and an extension of such business. Internet operations must comply fully with applicable federal and state laws, including laws in states in which patients reside. Notwithstanding the foregoing, ABDC may: (i) restrict use of an internet domain name, vanity URL, home page or other web address that includes a Mark (or require a separate license for such use); and/or (ii) limit or require use of hyperlinks (such as required links to ABDC websites) or other material, including material such as text, images, photographs, video, and/or sound that ABDC or a third party owns or has the right to use or limit the use of. Customer must promptly discontinue any such use if ABDC notifies Customer it is disapproved.
- (b) Customer Responsible. Notwithstanding ABDC's right to disapprove content of Customer's website, Customer is solely responsible for accuracy of information it provides on the internet or otherwise.
- (c) ABDC Websites. ABDC may advertise GNP Pharmacies on the internet and in other media in its discretion, including design and content, and discontinue some or all such advertising without liability. ABDC may create interior pages on websites with information about Pharmacy and link to any Customer website, including advertising or other opportunities.
- (d) Publicity. Customer hereby authorizes ABDC to use, publish, and copyright photographs of the Pharmacy Locations and Customer's statements made during the Term for editorial, promotional, advertising or other purposes, with or without Customer's name or other identifying information, in any media, including on ABDC's websites and the GNP Portal. ABDC will, upon Customer's request, remove from ABDC's websites or the GNP Portal any such photographs or statements that identify Customer.

9. Trademarks and Intellectual Property.

- (a) Right to Use Marks and Copyrighted Material. Customer may use the Marks only as necessary for operation and promotion of Pharmacy and only for a Pharmacy Location, including advertising. Customer may not use the Marks: (i) other than in compliance with Standards and such other quality controls as ABDC adopts to promote and defend the Mark's goodwill; or (ii) in connection with developing or operating any business other than Pharmacy, including any additional pharmacy owned or operated by Customer that is not a GNP Pharmacy. Customer will promptly discontinue any advertising or other use of Marks or Copyrighted Material (defined in Section 9(b)) if ABDC notifies Customer that such use is disapproved. Customer agrees that ABDC owns all right, title and interest in and to the Marks and Copyrighted Material. Customer acquires no right, title, or interest in the Marks or Copyrighted Material other than the right to use them pursuant to this Agreement and the GNP Manual and Standards. ABDC expressly reserves any and all rights not otherwise specified herein.
- (b) Prohibitions Concerning the Marks and Copyrighted Material. Customer understands ABDC is authorized by law to prevent unauthorized use of the Marks, to control quality of associated goods and services, and to control the copying and distribution of the Copyrighted Material. "**Copyrighted Material**" means any material produced by or for ABDC, including works derived from other Copyrighted Material, including (1) program guides and manuals used in Pharmacy's operation and marketing activities, including the GNP Manual; (2) training material, including printed, audio, video, or electronic material; (3) signage plans and specifications; (4) product posters, photographs, and graphics; (5) advertising and marketing material; (6) labels, forms, and reports; (7) computer software developed or provided by ABDC; (8) all Trade Dress and Trade Dress elements; and (9) any other material protected by copyright law or marked or identified by ABDC as protected by copyright. Without limiting the foregoing, Customer agrees to the following:
 - (i) As between ABDC and Customer, ABDC is the lawful owner of each Mark and all Copyrighted Material, with the right to use them and license Customer to use them, with Customer's interest solely as a licensee, and with Customer's use inuring to ABDC's benefit. Customer hereby unconditionally disclaims any ownership interest in any Mark or Copyrighted Material.

- (ii) Customer may not use any Marks, including “Good Neighbor Pharmacy”, or any abbreviation, acronym or variation of them as part of its name or as part of the name of any business entity. However, Customer may file an assumed name or fictitious name certificate to the extent that Customer is operating Pharmacy under a trade name that includes the “Good Neighbor Pharmacy” Mark in accordance with the GNP Manual.
 - (iii) Customer may only use Marks and Copyrighted Material in advertising, promotion, sale, and distribution of products and services offered by Pharmacy as ABDC has expressly permitted in writing.
 - (iv) Customer may use Marks or Copyrighted Material on the internet only as permitted by Section 8 and this Section 9.
 - (v) Customer will, if it adopts and uses any additional trade names, trademarks, brand names, Copyrighted Material, slogans, commercial symbols, and/or logos that ABDC develops related to the GNP Premier Program: (A) use all the Marks in the precise form ABDC prescribes; (B) observe ABDC directions regarding the use, copying and distribution of the Copyrighted Material, presentation and manner of the Marks’ display and use; and (C) not copy or distribute any Copyrighted Material in violation of this Agreement.
 - (vi) Customer will not knowingly permit, and will promptly report to ABDC upon becoming aware of, any apparent unauthorized use of a Mark and any apparent unauthorized use or copying of any Copyrighted Material by any person, or use by any person of a trade name, trademark, service mark, or symbol that might be construed as an infringement of any Mark or as unfair competition or passing-off at common law, and will actively cooperate with ABDC in investigating and prosecuting any infringement claims. ABDC may make any determination on infringement or other unlawful use, including whether to pursue or settle such claims.
 - (vii) Customer may not challenge validity of any Mark or ABDC’s rights in or to them, and Customer may not make any written or oral admission that a Mark or any Copyrighted Material is invalid or infringes rights of any person. Customer will promptly notify ABDC of any allegation of invalidity or infringement of which Customer becomes aware. ABDC does not warrant that its ownership of any Mark or Copyrighted Material is incontestable or that they do not infringe or conflict with rights of any other party but ABDC will indemnify Customer for any third party Claim as defined in and pursuant to Paragraph 6 of the Provisions (Exhibit C) relating to infringement by a Mark or any Copyrighted Material.
- (c) GNP Premier Program, ABDC Confidential Information and GNP Manual. Customer acknowledges that the GNP Premier Program and all ABDC Confidential Information (as defined in Exhibit C, Section 4) belong exclusively to ABDC and that, as between ABDC and Customer, ideas and information in the GNP Manual are ABDC’s exclusive property. Customer further understands and acknowledges that unauthorized use or disclosure of ABDC Confidential Information, including any part of the GNP Premier Program, an ABDC Trade Secret (as defined below) or other information in the GNP Manual, may adversely affect the business, competitive position and/or goodwill of ABDC, the GNP Premier Program, and other GNP Pharmacies. “**Trade Secret**” means information that derives actual or potential independent economic value from not being generally well known to, and not being readily ascertainable by proper means by, other persons who can obtain economic value from its disclosure or use and that is subject to reasonable efforts to maintain its secrecy. For avoidance of doubt, in assessing whether information is “Confidential Information” or a “Trade Secret,” the parties intend to exclude information that a licensed pharmacist, with background and experience comparable to Customer, would know without access to ABDC’s material. Accordingly, Customer agrees to the following, each of which survive termination of this Agreement and perpetually bind Customer and its Principals:
- (i) Customer must hold all ABDC Confidential Information, including elements of the GNP Premier Program and GNP Manual, in strict confidence and limit disclosing ABDC Trade Secrets and operating or management procedures as required by ABDC, including to Customer’s Designated Manager or to Pharmacy bona fide employees or others to whom such disclosure is necessary for their

duties. Customer will instruct and routinely remind such people that the GNP Premier Program, ABDC Confidential Information, and GNP Manual contents are confidential and may not be disclosed or appropriated.

- (ii) Customer may not use any element of the GNP Premier Program or operating, management, or marketing procedures provided in the GNP Manual in connection with any business other than Pharmacy and only for a Pharmacy Location.
- (iii) Customer may not, without ABDC's prior written consent, download, copy, or permit any person to download or copy any part of the GNP Manual or other printed, graphic, audio, or visual item that contains ABDC Confidential Information. Customer may not otherwise permit their use or inspection by any person other than Customer's Designated Manager and bona fide Pharmacy employees to whom such disclosure is necessary in relation to their duties, and authorized ABDC representatives.
- (iv) All training material, including videos, audios, and computer programs related to the GNP Premier Program, contain ABDC Confidential Information, including procedures and business practices.
- (d) Internet Domain Names. Customer acknowledges that ABDC is the sole owner of internet domain names related to the GNP Premier Program, including "GoodNeighborPharmacy.com" and "mygnp.com". Customer hereby unconditionally disclaims any ownership interest in or to: (i) any such phrase or colorably or confusingly similar internet domain name; (ii) any such domain name and any domain names that may be colorably or confusingly similar to them; and (iii) the words "Good Neighbor" and "Good Neighbor Pharmacy" and any abbreviation, acronym, or variation of such words, including "GNP". Customer may not register any internet domain name in any class or category that contains "Good Neighbor", "Good Neighbor Pharmacy", or "GNP", or any abbreviation, acronym, or variation of those words.
- (e) Equitable Relief. In addition to other rights, ABDC may obtain injunctive relief, without bond, against Customer and any Principal restraining unauthorized or prohibited use of any Mark, Copyrighted Material, ABDC Confidential Information, or ABDC Trade Secret, with or without terminating this Agreement.

10. Transfers. Customer will notify ABDC of changes in ownership, name, business form (e.g., sole proprietorship, partnership, corporation, etc.), state of incorporation or formation, or any intent to sell, close, move or modify its operations prior to such change, sale, closure or modification, and provide other information ABDC reasonably requests. ABDC may immediately terminate this Agreement upon or following any sale or transfer of Customer's business, in whole or in part, or sale of 25% or more of Customer's assets or equity to a: (i) pharmaceutical wholesale distributor; (ii) franchisor or licensor of a pharmacy advertising or merchandising program; (iii) chain of ten (10) or more pharmacies doing business under the same or a substantially similar name; or (iv) Corporate Affiliate. This Agreement inures to the benefit of and binds heirs, successors, and assigns of each party. Customer hereby consents to ABDC's: (a) assigning part or all of its obligations hereunder to any ABDC Corporate Affiliate; and (b) granting a security interest in this Agreement in connection with any financing or securitization by ABDC or any Corporate Affiliate thereof, in either case without prior written notice to Customer.

11. GNP License Program Release. If Customer participated with ABDC's prior voluntary program related to pharmacies operating under the name "Good Neighbor Pharmacy" ("**ABDC's Prior Program**") and its related programs and agreements, each party, their Principals and Corporate Affiliates hereby release each other and their Principals and Corporate Affiliates from claims or other obligations they may have against any others now or in the future, but only to the extent they relate to an offer or sale of ABDC's Prior Program or its related programs and agreements, including fraudulent inducement claims or sales law violations. This Section 11 does not affect any claim related, directly or indirectly, to: (i) the offer, sale or execution of this Agreement; (ii) performance by anyone under ABDC's Prior Program or its related programs and agreements; or (iii) other agreements between the parties.

12. Post-Termination Obligations.

- (a) Use of Marks. If this Agreement expires or is terminated for a Pharmacy Location: (i) Customer's right and privilege to use the GNP Premier Program, Marks, Copyrighted Material, ABDC Confidential Information, and all components of the GNP Manual will absolutely and unconditionally cease for such Pharmacy Location, effective as of the applicable expiration or termination effective date, provided, however, such termination or expiration will not, by itself, affect Customer's right to buy products under its PVA; and (ii) ABDC may remove information about such Pharmacy Location from websites, including the GNP Portal, and suspend or terminate Customer's access to the GNP Portal. During the sixty (60) days prior to expiration or cause-free termination of this Agreement, Customer will immediately begin to comply with the following for such Pharmacy Location so that such steps are completed by the end of the Term (and will do so promptly if this Agreement is terminated for cause), and Customer's failure to comply fully with the following requirements by such date shall constitute willful trademark and copyright infringement:
 - (i) Discontinue use of the GNP Premier Program, Marks, Copyrighted Material, ABDC Confidential Information, and all components of the GNP Manual;
 - (ii) Return to ABDC all parts of the GNP Manual or any other printed, graphic, audio, or visual item designated by ABDC as containing ABDC Confidential Information (Customer may elect to completely destroy all parts of the GNP Manual, whether in physical or electronic form, in lieu of returning same to ABDC);
 - (iii) Remove from each Pharmacy Location all interior and exterior GNP signage and other uses of the Marks;
 - (iv) Cancel all advertising arrangements relating to Customer's use of Marks or Copyrighted Material, including "yellow pages" or similar listings, as soon as reasonably possible, and promptly cancel any assumed or fictitious name filings related to the Marks; and
 - (v) Alter Pharmacy's interior to remove all Trade Dress items and otherwise eliminate the distinctive features of the GNP Premier Program.
- (b) Goodwill for Marks. Upon expiration or termination of this Agreement, all goodwill associated with the Marks and Copyrighted Material will inure to ABDC.
- (c) ABDC Rights. If Customer does not comply with Section 12(a), in addition to other rights, ABDC may, at Customer's expense, enter the applicable Pharmacy Location(s) on seven (7) days' notice to effect compliance with such obligations, including removal and storage of signs and alteration or removal of Trade Dress items.
- (d) Payment. In addition to other rights, ABDC may recover all amounts owed to ABDC in connection with this Agreement, plus interest and late fees under Paragraph 2.2 of the Provisions (Exhibit C), with or without terminating this Agreement. For any obligation referred to an attorney for collection or collected through a judicial proceeding, Customer will pay ABDC attorneys' fees and costs and for ABDC's staff and administrative time.
- (e) Equitable Relief. In addition to other rights, ABDC will be entitled to injunctive relief, without bond, to enforce compliance with requirements of this Section 12.
- (f) Damages. In addition to other rights, ABDC may recover damages from Customer and any Principal for: (i) unauthorized or prohibited use of any Mark, Copyrighted Material, or ABDC Trade Secret; and/or (ii) any loss of customer or future goodwill associated with the Marks or GNP Premier Program.
- (g) Survival. The parties' obligations, the context of which show the parties intended them to survive, will remain in effect after the Term, including indemnification, confidentiality and choice of law obligations. Without limiting the foregoing, the parties' other business relationships, including the PVA, are independent of this Agreement and the Available Programs hereunder. Except as agreed: (i) performance under this Agreement or its expiration or termination will not affect such other agreements; and (ii) performance under such other agreements or their expiration or termination will not affect this Agreement.

13. Available Program Terms.

- (a) Term. In addition to other applicable terms and conditions provided herein, Customer's enrollment and participation in Available Programs is subject to the following terms:
- (i) Respecting any Available Programs that are Required and in which Customer is not previously enrolled, Customer will begin enrollment and onboarding steps beginning on the Effective Date of this Agreement, to the extent immediately available and subject to satisfaction of any prerequisite conditions, and such participation shall terminate upon the expiration or earlier termination of this Agreement; provided, however, Available Programs may continue thereafter subject to applicable provisions of this Agreement, or, if adopted by the parties following termination of this Agreement, ABDC's Master Program Agreement, until such Available Program is terminated pursuant to Paragraph 5 of Exhibit C (Provisions) or as provided in this Section 13.
 - (ii) Either party may terminate one or more Available Programs at one or more Pharmacies, with or without cause, at any time upon sixty (60) days' written notice to the other party; provided, however (A) termination of specific Available Programs may be subject to restrictions or termination obligations; (B) Customer may not terminate any Available Program that is Required unless Customer also terminates this Agreement; and (C) ABDC will use commercially reasonable efforts to give Customer at least sixty (60) days' prior written notice before terminating any Available Program that is Required and the option for Customer to exercise its right to terminate this Agreement on the date such Available Program is to be terminated, notwithstanding Customer's other notice requirements. Termination of less than all Available Programs at all Pharmacy Locations will not terminate Customer's rights or obligations pursuant to the Master Program Agreement (Exhibit E) nor any Term Sheets not explicitly terminated by Customer or ABDC, unless Customer executes a replacement Master Program Agreement to supersede the version attached hereto.
 - (iii) To the extent immediately available and subject to satisfaction of any prerequisite conditions, Optional Available Programs commence and terminate as of the date on which Customer enrolls or disenrolls as provided in Section 4(h).
 - (iv) Notwithstanding the foregoing, ABDC may immediately and at any time terminate or modify, as applicable, any Pharmacy Location's participation in any Available Program that includes eligibility qualifications, requirements, and/or criteria, as provided in applicable Term Sheets and/or enrollment forms, that such Pharmacy Location does not satisfy.
- (b) Fees. Each Term Sheet states applicable per-Pharmacy fees, which such fees may be prorated as applicable. Some Available Programs require Customer to incur other expenses, which are Customer's responsibility. "**Premier**" fees apply to GNP Pharmacies under the GNP Premier Program, including Customer. Fees for GNP and Others (each as defined below), which apply to non-Premier GNP Pharmacies ("**GNP**") and Pharmacies that are not Premier or GNP Pharmacies ("**Others**"), respectively, are not applicable to Customer. Applicable fees may be increased on sixty (60) days' prior written notice.
- (c) ABDC Commitments.
- (i) Programs and Services. ABDC will use commercially reasonable efforts to provide Available Programs in which Customer enrolls from time to time pursuant to terms in the applicable Term Sheet, industry standards, laws and the GNP Manual. In addition to written material, ABDC or others, including Payors (as defined under Term Sheet 1), may, to the extent permitted by applicable agreements between ABDC and Payors, publish the GNP Manual, Standards, policies, procedures, and updates to each of these on AB Central or other websites they maintain, or make them available on request. A listing of current Available Programs and applicable Term Sheets are accessible on AB Central or from Customer's ABDC sales representative.
 - (ii) Statements of Work. From time-to-time, Customer may engage ABDC to provide other goods and services including custom work or a special project, terms of which will be as agreed pursuant to a Statement of Work (Term Sheet 10) and governed by this Agreement.

- (iii) Privacy. ABDC will protect and only use Pharmacy Data (as defined in Exhibit A) provided by, or on behalf of, Customer, pursuant to the Data Protection Provisions (Exhibit A) in connection with any Available Program that involves access to Pharmacy Data and, in connection with any Available Program that involves access to protected health information (PHI as defined in Exhibit B), such as Elevate Provider Network, InSite, Pre & Post Edit Solutions, Claim Reconciliation Services, Business Coaching, and the ABDC Order Monitoring Program, pursuant to the HIPAA Business Associate Agreement (Exhibit B or as otherwise agreed) under the Health Insurance Portability and Accountability Act of 1996 (“**HIPAA**”), the HITECH Act, and implementing regulations including the Privacy, Security, and Breach Notification Rules (each defined in Exhibit B).

(d) Customer Commitments.

- (i) Compliance. Customer will comply with this Agreement, all laws, Term Sheets and the GNP Manual, including qualifications Customer must meet to be eligible for each Available Program in which Customer is enrolled, including, without limitation, all Required Available Programs. If Customer does not, it may not participate in such Available Program or, if it is participating, its right to do so may be revoked. Customer is responsible for acquiring and maintaining all equipment, software and other items specified as necessary in Program Guides, as updated from time to time. Such items must be purchased from suppliers meeting Standards to ABDC’s reasonable satisfaction.
- (ii) Use of Programs. Customer may only use an Available Program for its own Pharmacy business and only at a Pharmacy Location for which Customer has enrolled in such Available Program. Nothing supplied by ABDC pursuant to this Agreement, including performance measurements, business advice, cost or price data is a substitute for Customer’s business and professional judgment or will dictate to Customer at what price to sell pharmaceuticals or other merchandise, except to the extent Customer agrees (e.g., under Elevate Provider Network). Customer is solely responsible for use of data and advice obtained through Available Programs and must keep confidential and not disclose, redistribute, supply, license, or sell any data or information, including reports and methods, relating to Available Programs.

14. Dispute Resolution

- (a) Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the Commonwealth of Pennsylvania, without reference to its conflict of laws principles.
- (b) Dispute Resolution. Customer must first bring any claim or dispute between Customer and ABDC to ABDC’s management, after providing notice as set forth in Section 14(f) of this Agreement, and make every effort to resolve the dispute internally. Customer must exhaust this internal dispute resolution procedure before Customer may bring Customer’s dispute before a third party. This agreement to first attempt resolution of disputes internally shall survive termination or expiration of this Agreement. If the parties are unable to resolve any claim or dispute internally within ninety (90) days, Customer agrees that any controversy or claim arising out of or relating to this Agreement, or the breach thereof, shall be determined by final and binding arbitration administered by the American Arbitration Association (“AAA”) under its Commercial Arbitration Rules and Mediation Procedures to take place in Philadelphia, Pennsylvania. Any arbitration award or decision may be filed in a court of competent jurisdiction for enforcement. Notwithstanding the foregoing, the parties will not be required to first attempt to resolve a controversy, dispute, or claim through mediation as set forth in this Section 14(b) if such controversy, dispute, or claim concerns an allegation that a party has violated (or threatens to violate, or poses an imminent risk of violating): (i) any federally protected intellectual property rights or other rights in or to the Marks, ABDC’s franchise system, or any Confidential Information or other ABDC information; (ii) any of the restrictive covenants contained in this Agreement; and (iii) any of Customer’s payment obligations under this Agreement.
- (c) Injunctive Relief. Customer acknowledges and agrees that irreparable harm could be caused to ABDC by Customer’s violation of certain provisions of this Agreement and, as such, in addition to any other relief

available at law or equity, ABDC shall be entitled to obtain in any court of competent jurisdiction, without bond, restraining orders or temporary or permanent injunctions in order to: (i) enforce, among other items, the provisions of this Agreement relating to: (A) Customer's use of the Marks and Confidential Information (including any proprietary software used in connection with the GNP Premier Program); (B) the in-term covenant not to compete, as well as any other violations of the restrictive covenants set forth in this Agreement; (C) Customer's obligations on termination or expiration of this Agreement; (D) disputes and controversies based on or arising under the Lanham Act, or otherwise involving the Marks, as now or hereafter amended; and/or (E) disputes and controversies involving enforcement of the ABDC's rights or Customer's obligations with respect to confidentiality under this Agreement; and (ii) prohibit any act or omission by Customer or its employees that constitutes a violation of applicable law, threatens ABDC's franchise system, or threatens other customers of ABDC. Customer's only remedy if such an injunction is entered will be the dissolution of the injunction, if appropriate, and Customer hereby waives any and all claims for damages if the injunction is wrongfully issued.

(d) Venue. Subject to Sections 14(b), 14(c), 14(f), and 14(h) of this Agreement, the parties agree that any actions arising out of or related to this Agreement must be initiated and litigated to conclusion exclusively in the state court of general jurisdiction closest to ABDC's then-current corporate headquarters or, if appropriate, the United States District Court for the Eastern District of Pennsylvania. Customer acknowledges that this Agreement has been entered into in the Commonwealth of Pennsylvania, and that Customer is to receive valuable and continuing services emanating from ABDC's headquarters in Pennsylvania, including but not limited to training, assistance, support and the development of ABDC's franchise system. In recognition of such services and their origin, Customer hereby irrevocably consents to the personal jurisdiction of the state and federal courts of Pennsylvania as set forth in this Section.

(e) Third Party Beneficiaries. ABDC's officers, directors, shareholders, agents and/or employees are express third party beneficiaries of the provisions of this Agreement, including the dispute resolution provisions set forth in this Section 14, each having authority to specifically enforce the right to mediate/arbitrate claims asserted against such person(s) by Customer.

(f) Notice Requirement. As a condition precedent to commencing an action for damages or for violation or breach of this Agreement, Customer must notify ABDC within thirty (30) days after the occurrence of the violation or breach, and failure to timely give such notice shall preclude any claim for damages.

(g) No Withholding of Payments. Customer shall not withhold all or any part of any payment to ABDC or any of its affiliates on the grounds of ABDC's alleged nonperformance or as an offset against any amount ABDC or any of ABDC's affiliates allegedly may owe Customer under this Agreement or any related agreements.

(h) Limitation of Actions. Without in any way limiting the foregoing, Customer further agrees that no cause of action arising out of or under this Agreement may be maintained by Customer against ABDC unless Customer brings an action/suit against ABDC before the expiration of one (1) year after the act, transaction or occurrence upon which such action is based or the expiration of one (1) year after Customer becomes aware of facts or circumstances reasonably indicating that Customer may have a claim against ABDC hereunder, whichever occurs sooner. Any action or suit that Customer does not bring within this period shall be barred as a claim, counterclaim, defense, or set-off. Customer hereby waives the right to obtain any remedy based on alleged fraud, misrepresentation, or deceit by ABDC, including, without limitation, rescission of this Agreement, in any mediation, judicial, or other adjudicatory proceeding arising hereunder, except upon a ground expressly provided in this Agreement.

(i) Waiver of Punitive Damages. TO THE FULLEST EXTENT PERMITTED BY LAW, CUSTOMER HEREBY WAIVES ANY RIGHT TO OR CLAIM FOR ANY PUNITIVE, EXEMPLARY, INCIDENTAL, INDIRECT, SPECIAL OR CONSEQUENTIAL DAMAGES (INCLUDING, WITHOUT LIMITATION,

LOST PROFITS) AGAINST ABDC ARISING OUT OF ANY CAUSE WHATSOEVER (WHETHER SUCH CAUSE BE BASED IN CONTRACT, NEGLIGENCE, STRICT LIABILITY, OTHER TORT OR OTHERWISE), EVEN IF ABDC WAS ADVISED AS TO THE POSSIBILITY OR LIKELIHOOD OF SUCH DAMAGES, AND AGREES THAT IN THE EVENT OF A DISPUTE, CUSTOMER'S RECOVERY SHALL BE LIMITED TO ACTUAL DIRECT DAMAGES. If any other term of this Agreement is found or determined to be unconscionable or unenforceable for any reason, the foregoing provisions shall continue in full force and effect, including, without limitation, the waiver of any right to claim any consequential damages. Nothing in this Section or any other provision of this Agreement shall be construed to prevent ABDC from claiming and obtaining expectation or consequential damages, including lost future royalties for the balance of the term of this Agreement if such termination is due to Customer's default, which the parties agree and acknowledge ABDC may claim under this Agreement.

(j) WAIVER OF JURY TRIAL. THE PARTIES HEREBY AGREE TO WAIVE TRIAL BY JURY IN ANY ACTION, PROCEEDING OR COUNTERCLAIM, WHETHER AT LAW OR EQUITY, REGARDLESS OF WHICH PARTY BRINGS SUIT. THIS WAIVER SHALL APPLY TO ANY MATTER WHATSOEVER BETWEEN THE PARTIES WHICH ARISES OUT OF OR IS RELATED IN ANY WAY TO THIS AGREEMENT, THE PERFORMANCE OF EITHER PARTY, AND/OR CUSTOMER'S PURCHASE FROM ABDC OF THE FRANCHISE AND/OR ANY GOODS OR SERVICES.

(k) WAIVER OF CLASS ACTIONS. THE PARTIES AGREE THAT ALL PROCEEDINGS ARISING OUT OF OR RELATED TO THIS AGREEMENT, OR THE SALE OF THE FRANCHISED BUSINESS, WILL BE CONDUCTED ON AN INDIVIDUAL, NOT A CLASS-WIDE BASIS, AND THAT ANY PROCEEDING BETWEEN CUSTOMER, CUSTOMER'S GUARANTORS OR PRINCIPALS, AND/OR ABDC OR ITS AFFILIATES, OFFICERS, OR EMPLOYEES MAY NOT BE CONSOLIDATED WITH ANY OTHER PROCEEDING BETWEEN ABDC AND ANY OTHER THIRD PARTY.

15. Miscellaneous

- (a) Exhibit A (Data Protection Provisions), Exhibit B (HIPAA Business Associate Agreement), Exhibit C (Provisions to this Agreement), Exhibit D (State-Specific Amendments), Exhibit E (Master Program Agreement) and Term Sheets 1 to 10 (Term Sheets), each as may be amended from time to time, are incorporated herein by this reference.
- (b) References to "**Master Program Agreement**" or Customer's "**Premier Agreement**" in this Agreement, Exhibits, and Term Sheets mean this Agreement, including the Exhibits, Term Sheets, and their respective enrollment forms and Data Authorizations, each as amended from time to time as permitted herein. Nothing in this Agreement, related agreements, exhibits, and/or Term Sheets is intended to disclaim the express representations made in the Franchise Disclosure Document.
- (c) Customer consents to receiving notices, advertisements, and other marketing materials by fax or email from ABDC and its Corporate Affiliates.
- (d) References in Term Sheets to "**Program Guides**" mean the GNP Manual and Standards and to "**GNP License**" mean GNP pharmacies that are not in the GNP Premier Program.
- (e) Definition of certain capitalized terms may be found as follows:

ABDC	Opening paragraph	Manager	
ABDC's Prior Program Agreement	Section 11	Effective Date	Opening paragraph
Available Programs	Opening paragraph	GNP Manual	Section 4(a)
Copyrighted Material	Section 4(g)	GNP Pharmacy	Section 4(a)
Corporate Affiliate	Section 9(b)	GNP Premier Program	Recital B
Customer	Recital A	GNP Private Label Products	Section 3(a)
Customer's Designated	Opening paragraph	GNP Portal	Section 7(c)
	Section 4(e)	Marks	Section 1(a)



Monthly Fee	Section 2(b)	PVA	Section 4(f)
Optional (Available Programs)	Section 4(h)	Required (Available Programs)	Section 4(h)
Pharmacy	Recital B	Standards	Section 4(a)
Principal	Section 7(c)	Term	Section 7(a)
		Term Sheets	Section 4(g)
PSAO (pharmacy services administration organization)	Section 4(i)	Trade Dress	Section 3(a)
		Trade Secret	Section 9(c)



DATA PROTECTION PROVISIONS

Overview

ABDC has developed these Data Protection Provisions to protect Pharmacy Data collected from each Pharmacy participating in Available Programs under the Agreement. In these provisions, “**Pharmacy Data**” means the financial, operational, performance, business, pharmacy, and patient data that ABDC receives directly or indirectly from Customer or from Customer’s system vendor, switch vendor, Payors (as defined in Term Sheet 1), or other Program Partners. Pharmacy Data may include but is not limited to point-of-sale transaction data, prescription data, or claim reimbursement data. Pharmacy Data includes any information, regardless of the format it is in (for example, paper, electronic, or films).

1.0 Restrictions on Access to Pharmacy Data. ABDC will protect Pharmacy Data by maintaining logical access controls (such as unique user identification and dual factor authentication for remote access) and as set forth in Paragraph 4.0. Access to Pharmacy Data will be provided on a “business need-to-know” basis so users are granted the least amount of access required to successfully fulfill their job requirements. Access that is not explicitly defined is not allowed.

1.2 Limited or Specific Use and Disclosure. Use and disclosure of Pharmacy Data and Business Contact Information (as defined below) will be restricted to only the purposes: (i) set forth in this Agreement and/or applicable Term Sheets in connection with the Available Programs in which Customer participates; (ii) set forth in Customer’s distribution agreement with ABDC to measure and help improve purchase performance and as well as compliance with, Customer’s contractual requirements with ABDC; and (iii) as may be otherwise agreed upon in writing. ABDC also uses and/or discloses Pharmacy Data and Business Contact Information to: (1) identify, validate, and/or develop programs, solutions or actions that might benefit Customer’s business; (2) evaluate, manage, and improve Available Programs in which Customer participates; and (3) conduct outreach campaigns in connection with the foregoing, including sharing with: (a) ABDC’s affiliates; (b) members of ABDC’s sales team; (c) and Customer’s buying group, aggregation group, or group purchasing organization (if any). In addition, other people Customer specifically authorizes may access Pharmacy Data and Business Contact Information, but only to the extent Customer so authorizes. Customer releases IQVIA and any other third-party data aggregators to share with ABDC, information that IQVIA or applicable third parties receive under data supply agreements with Customer, as well as information received from other data sources. Customer consents to IQVIA’s and other third-party aggregator’s use of Customer’s information, including Business Contact Information, to produce reports and provide them to

ABDC and acknowledges that the reports may include pharmacy and product names and purchasing dollars.

1.3 Business Contact Information. Customer and ABDC acknowledge that each party is an independent data controller with respect to Business Contact Information. “**Business Contact Information**” is personal data of each party’s employees, independent contractors, and workforce personnel processed by the other party for the purpose of facilitating the Available Programs under this Agreement and maintaining the business relationship with the other party. ABDC further uses and discloses Business Contact Information as described in Section 1.2 of this Exhibit A and in accordance with its privacy policy, available at <https://www.cencora.com/global-privacy-statementoverview> as may be updated from time to time. Customer and ABDC agree to comply with the California Consumer Privacy Act, as amended (“CCPA”), as may be applicable to Business Contact Information. Each party grants the other party the right to take reasonable and appropriate steps to ensure each party’s use of Business Contact Information is consistent with the party’s obligations under the CCPA, as applicable. With respect to Business Contact Information, each party will notify the other party if it determines that it cannot fulfill its obligations under the CCPA, as applicable, in which case the other party will have the right to take reasonable and appropriate steps to stop and remediate unauthorized use of Business Contact Information.

2.0 No Restrictions on Derivative Works. Except as otherwise agreed-upon by the parties, ABDC may create, use, and/or disclose de-identified, aggregated Pharmacy Data and/or Business Contact Information, or other derivative works created by ABDC using Pharmacy Data and/or Business Contact Information, as long as Customer cannot be specifically identified, such as comparative financial analyses by business type or analyses of manufacturer market share, and any PHI that has been appropriately de-identified. This provision is not meant to circumvent or eliminate opportunities for revenue sharing through data sales or similar programs or offerings.

3.0 Required Disclosure of Pharmacy Data. There may be times when ABDC becomes obligated to disclose Pharmacy Data or other information to other parties not referenced in Paragraph 1.0. For instance, ABDC may be requested or may become legally compelled to answer oral questions, interrogatories, requests for information or documents, subpoenas, civil investigative demands or similar processes and to disclose Pharmacy Data. Nothing in these provisions prevents ABDC from responding to any such disclosure requests or obligations, taking reasonable steps to prevent fraud or other illegal activity, or disclosing information about activities it reasonably believes are illegal.

4.0 Security of Pharmacy Data. ABDC employs industry standard information security and physical security (“IT Security”) safeguards, procedures and practices to protect the privacy and security of Pharmacy

Data ABDC receives, accesses, uses, creates, or discloses pursuant to this Agreement. These security safeguards are: (a) at least equal to industry standards; (b) in accordance with the Health Insurance Portability and Accountability Act of 1996 (“HIPAA”) and the Health Information Technology for Economic and Clinical Health Act (“HITECH”); and (c) reasonably appropriate to protect against accidental or unlawful destruction, loss, alteration or unauthorized third-party disclosure or access of Pharmacy Data.

5.0 Physical Safeguards. All Pharmacy Data is stored in a physically and logically secure environment that protects it from unauthorized access, modification, theft, misuse or destruction. ABDC maintains appropriate levels of physical security controls over ABDC facilities, including alarm systems, visitor access procedures, security guards, cameras, and video surveillance. ABDC ensures that the facilities have proper environmental controls including power, connectivity, temperature controls, fire suppression, uninterruptible power supply and backup generator to support availability of the Services. ABDC maintains an active and up-to-date anti-malware program to protect the ABDC system, software and Pharmacy Data and Services.

6.0 Data Encryption. ABDC uses encryption to the extent required by HIPAA regulations to receive, transmit, and store all PHI. Although there cannot be a guaranty of the security of Pharmacy Data, ABDC utilizes adequate security for Pharmacy Data transmitted across public networks – at a minimum, TLS 1.2 128 bit is used for web traffic and 256 bit or better for bulk data transfer, with the exception of electronic mail transmission. Transmission of data may include, but is not limited to, file transfer methods, file upload or file download, and file exports.

7.0 License and Retention of Data. Customer hereby grants to ABDC an irrevocable, non-exclusive, royalty-free license to use and/or disclose Pharmacy Data and Business Contact Information as permitted hereunder and as may be necessary for ABDC or the Program Partners to provide Customer with the Available Programs or as otherwise may be required by law. ABDC uniformly retains Pharmacy Data and Business Contact Information for all participating Pharmacies for as long as is reasonably necessary or appropriate for the fulfillment of Available Programs under the Agreement, including InSite from ABDC, or as necessary for legal and/or compliance purposes. ABDC maintains strict change control processes for both hardware and software changes and ensures that all ABDC personnel are familiar with and utilize this process. ABDC securely and completely disposes of Pharmacy Data and Business Contact Information residing on ABDC equipment that will be retired. When Pharmacy Data or Business Contact Information is no longer required to fulfill those purposes, ABDC will use reasonable efforts to have it destroyed, erased or made anonymous.

8.0 Disaster Recovery and Data Backup. ABDC shall maintain and implement disaster recovery procedures in accordance with ABDC’s written Disaster Recovery Plan. ABDC’s Disaster Recovery Plan shall contain procedures designed to safeguard Pharmacy Data and the availability of the services and solutions included in the Available Programs in which Customer participates hereunder.

8.1 Testing. ABDC periodically performs disaster recovery testing on its electronic systems associated with the services provided in connection with the Available Programs in which Customer participates hereunder.

8.2 Software Lifecycle. ABDC shall use commercially reasonable efforts to identify vulnerabilities, risks and threats as early as possible at any time during the software lifecycle. The software lifecycle shall mean from development, management, and updates through retirement of such application. ABDC shall maintain a strict change control process for ABDC software development lifecycle.

8.3 Data Management. ABDC deploys certain techniques on its electronic systems associated with the services being offered in connection with the Available Programs in which Customer participates hereunder that are intended to safeguard Pharmacy Data, including vulnerability scanning tools, data loss prevention monitoring, penetration testing, implementation of a security information and event management system, and maintenance of a formal risk management program. Confirmed vulnerabilities are prioritized based upon risk level.

8.4 Data Backups. ABDC performs daily backups of Pharmacy Data. ABDC agrees to store all backup Pharmacy Data as part of its designated backup and recovery processes using a commercially supported encryption solution. Data backups are retained for twelve (12) days should the need to restore from data backups arise. ABDC shall be responsible for periodically testing that backup processes are working to ensure that data can be recovered in a reasonable timeframe in the instance of an outage or disaster on the primary infrastructure.

9.0 Incident Response. ABDC shall maintain a program plan to detect and respond to data security incidents. The program shall include identification, containment, mitigation and remediation of an incident (security breach or attack) and communication to Customer of any data security incident resulting in a Breach (as defined by HIPAA) of Pharmacy Data. ABDC shall meet Federal and applicable regulatory requirements for breach notification. ABDC shall cooperate and coordinate with Customer and authorities should a confirmed security breach of Pharmacy Data occur. Without limiting the generality of the foregoing, ABDC will take all reasonable measures to secure and defend ABDC locations and equipment both physically and logically against “hackers” and others who may seek, without authorization, to

modify or access the ABDC systems or the information found therein.

10.0 Employee Screening and Security Awareness.

Prior to employment, each ABDC employee undergoes a formal security clearance review that includes a criminal background check. Any past activity that would subject confidential information and critical systems to risk is cause to restrict an ABDC employee's access to Pharmacy Data. To ensure security awareness by its employees, ABDC: (a) maintains policies or codes of conduct documenting responsibilities regarding data security practices; (b) requires its employees to acknowledge and review these documents at least biennially; (c) provides security awareness and HIPAA training to its workforce as part of ABDC's overall awareness program; (d) requires confidentiality agreements to be completed as part of hiring process to ensure that ABDC's workforce understands their responsibilities regarding the protection of Pharmacy Data.

ABDC believes that its security policies and safeguards are reasonable and appropriate to adequately protect such information, regardless of the format in which such information is held. ABDC intends to review and update its security policies and safeguards on a regular basis. ABDC requires that its employees keep all Pharmacy Data and Business Contact Information confidential.



HIPAA BUSINESS ASSOCIATE AGREEMENT

This HIPAA Business Associate Agreement (“**BA Agreement**”) is effective as of the Effective Date of the agreement (GNP Premier Participation Agreement or Master Program Agreement, including all Exhibits, Amendments, Attachments, Term Sheets, Schedules, and Addenda thereto, as applicable) for Available Programs (“**Agreement**”) between AmerisourceBergen Drug Corporation (“**Business Associate**”) and Customer, as defined in the Agreement (“**Covered Entity**” and, collectively with Business Associate, the “**Parties**”). This BA Agreement amends the Agreement only to the extent the Parties use, disclose or create Protected Health Information as a Business Associate or Covered Entity, respectively.

WHEREAS, Business Associate provides Services to Covered Entity that may involve the use, disclosure and/or creation of Protected Health Information.

WHEREAS, Covered Entity and Business Associate desire to enter into this BA Agreement to address certain requirements that are now or will become applicable to Covered Entity (and, in certain instances, Business Associate) pursuant to the Health Insurance Portability and Accountability Act of 1996 (“**HIPAA**”) (Pub. L. 104-191), as amended by, among other authorities, the Health Information Technology for Economic and Clinical Health Act (“**HITECH Act**”) (42 U.S.C. §17921 et seq.) and implementing regulations, including, as defined below, the Privacy Rule, Security Rule and Breach Notification Rule.

NOW THEREFORE, in consideration of the mutual covenants and agreements contained in this BA Agreement and for other good and valuable consideration, the receipt and sufficiency of which are acknowledged by the Parties, the Parties hereby agree as follows:

1. DEFINITIONS.

Any citations in the definitions below shall reference the provision as currently drafted and as it is subsequently updated, amended or revised, as applicable. Capitalized terms or phrases used, but not otherwise defined, in this BA Agreement shall have the same meaning as those terms or phrases in the Privacy Rule, Security Rule or Breach Notification Rule, as applicable.

1.1 **Breach** is defined in 45 C.F.R. §164.402.

1.2 **Breach Notification Rule** means the final rule related to Breach notification for Unsecured Protected Health Information at 45 C.F.R. Parts 160 and 164.

1.3 **Business Associate** means AmerisourceBergen Drug Corporation in its capacity as a business associate as defined in 45 C.F.R. §160.103.

1.4 **Covered Entity** means Customer in its capacity as a covered entity as defined in 45 C.F.R. §160.103.

1.5 **Designated Record Set** is defined in 45 C.F.R. §164.501.

1.6 **Electronic Protected Health Information** and **ePHI** are defined in 45 C.F.R. §160.103, limited to the information created or received by Business Associate from or on behalf of Covered Entity.

1.7 **Individual** is defined in 45 C.F.R. §160.103 and shall include a person who qualifies as a personal representative in accordance with 45 C.F.R. §164.502(g).

1.8 **Health Care Operations** is defined in 45 C.F.R. §164.501.

1.9 **Privacy Officer** is defined in 45 C.F.R. §164.530(a)(1).

1.10 **Privacy Rule** means the Standards for Privacy of Individually Identifiable Health Information, codified at 45 C.F.R. Parts 160 and 164, Subparts A and E.

1.11 **Protected Health Information** and **PHI** have the meaning they are given in 45 C.F.R. §160.103, limited to the information created or received by Business Associate from or on behalf of Covered Entity.

1.12 **Reproductive Health Care** includes, but is not limited to, an individual’s receipt of contraception, management of pregnancy and pregnancy-related conditions, miscarriage management, pregnancy termination, fertility or infertility diagnosis and treatment, assistive reproductive technology, and other diagnoses, treatment and care that affect the reproductive system, where the care or services are lawfully obtained.

1.13 **Required by Law** is defined in 45 C.F.R. §164.103.

1.14 **Security Rule** means the Security Standards for Protection of Electronic Protected Health Information, codified at 45 C.F.R. §164 Subparts A and C.

1.15 **Secretary** means the Secretary of the Department of Health and Human Services or his or her designee.

1.16 **Security Incident** is defined in 45 C.F.R. §164.304.

1.17 **Substance Abuse Disorder (SUD)** means a treatable mental disorder that affects a person’s brain and behavior, leading to their inability to control their use of substances like legal or illegal drugs, alcohol, or medications. Symptoms can be moderate to severe, with addiction being the most severe form of SUD.

1.18 **Tracking Technology** is defined as any tracking technology utilized by Business Associate including, but not limited to cookies, pixels, codes, fingerprinting scripts, web beacons, etc., whether collected via user authenticated web pages, unauthenticated pages, or mobile applications, as set forth in the December 1, 2022, Office for Civil Rights Bulletin on Requirements under HIPAA for Online Tracking Technologies to Protect the Privacy and Security of Health Information.

1.19 **Unsecured PHI** is defined in the Breach Notification Rule at 45 C.F.R. §164.402.

2. PERMITTED USES AND DISCLOSURES OF PROTECTED HEALTH INFORMATION BY BUSINESS ASSOCIATE.

2.1 **Services.** Pursuant to the Agreement, Business Associate provides services (“**Services**”) for, or on behalf of, Covered Entity that involve the use, disclosure and/or creation of PHI. Except as otherwise specified herein, Business Associate may make any and all uses and disclosures of PHI necessary to perform its obligations under the Agreement. All other uses and disclosures not authorized by this BA Agreement are prohibited. Moreover, Business Associate may use and disclose PHI for the purposes authorized by this BA Agreement only: (i) to its employees, subcontractors and agents, in accordance with Paragraph 3.5; (ii) as directed by Covered

Entity; or (iii) as otherwise permitted by the terms of this BA Agreement including, but not limited to, Paragraphs 2.2 and 2.3.

2.2 Uses and Disclosures by Business Associate. Unless otherwise limited herein, Business Associate may:

2.2.1 Use, consistent with 45 C.F.R. §164.504(e)(4), the PHI in its possession if necessary (i) for its proper management and administration and/or (ii) to carry out any present or future legal responsibilities of Business Associate provided that such uses are permitted under state and federal confidentiality laws.

2.2.2 Disclose, consistent with 45 C.F.R. §164.504(e)(4), the PHI in its possession to third parties for the purpose of its proper management and administration and/or to carry out any present or future legal responsibilities of Business Associate, provided that Business Associate represents to Covered Entity, in writing, that (i) the disclosures are Required by Law, as provided for in 45 C.F.R. §164.103; or (ii) Business Associate has received from the third party written assurances regarding its confidential handling of such PHI as required under 45 C.F.R. §164.504(e)(4) and the third party notifies Business Associate of any breaches in the confidentiality of the PHI.

2.3 Additional Activities of Business Associate. In addition to using and disclosing the PHI to perform the Services and the purposes enumerated in Paragraph 2.2, Business Associate may:

2.3.1 If the Agreement is for data aggregation services, consistent with 45 C.F.R. §164.504(e)(2)(i)(B), aggregate the PHI in its possession with the PHI of other covered entities that Business Associate has in its possession through its capacity as a business associate to said other covered entities provided that the purpose of such aggregation is to provide Covered Entity with data analyses relating to the Health Care Operations of Covered Entity. Under no circumstances may Business Associate disclose PHI of Covered Entity to another entity, including a covered entity, absent the explicit authorization of Covered Entity.

2.3.2 De-identify any and all PHI provided that the de-identification substantially conforms to the requirements of 45 C.F.R. §164.514(b). Pursuant to 45 C.F.R. §164.502(d)(2), de-identified information does not constitute PHI and is not subject to the terms of this BA Agreement.

2.3.3 Use and/or disclose PHI to report violations of law to appropriate federal and State authorities, consistent with 45 C.F.R. §164.502(j)(1).

3. PRIVACY RULE AND HITECH ACT RESPONSIBILITIES OF THE BUSINESS ASSOCIATE. With regard to its use and/or disclosure of PHI, Business Associate hereby agrees to do the following:

3.1 Use and/or disclose the PHI only as permitted or required by this BA Agreement, including as permitted in Paragraph 2.2 and 2.3, or as otherwise permitted or Required by Law.

3.2 Report to Covered Entity's designated Privacy Officer, in writing, any use and/or disclosure of the PHI that is not permitted or required by this BA Agreement of which Business Associate becomes aware within fifteen (15) days of Business Associate becoming aware of such unauthorized use and/or disclosure.

3.3 Establish procedures for mitigating, to the extent practicable, any deleterious effects from any improper use and/or disclosure of PHI that Business Associate reports to Covered Entity.

3.4 To the extent that Business Associate is to carry out one or more of Covered Entity's obligations under Subpart E of 45 C.F.R. Part 164, comply with the requirements of Subpart E that apply to Covered Entity in the performance of such obligations, including the use of appropriate safeguards to prevent unauthorized use and/or disclosure of PHI.

3.5 Require all of its subcontractors and agents that create, receive, maintain, or transmit PHI on behalf of Business Associate to agree, in writing, to adhere to substantially similar restrictions and conditions (in all material respects) on the use and/or disclosure of PHI and other restrictions and requirements that relate to PHI that apply to Business Associate pursuant to Paragraphs 2.0 through 5.0.

3.6 Make available all records, books, agreements, policies and procedures relating to the use and/or disclosure of PHI to the Secretary for purposes of determining Covered Entity's compliance with the Privacy Rule, subject to attorney-client and other applicable legal privileges.

3.7 Within fifteen (15) days of receiving a written request from Covered Entity, provide to Covered Entity such information as is requested by Covered Entity to permit Covered Entity to respond to a request by an Individual to inspect and obtain a copy of PHI about the Individual that is maintained in a Designated Record Set by Business Associate, for as long as the PHI is maintained in the Designated Record Set by Business Associate, in accordance with 45 C.F.R. §164.524; to amend PHI or a record about the Individual maintained in a Designated Record Set by Business Associate, for as long as PHI is maintained in the Designated Record Set by Business Associate, in accordance with 45 C.F.R. §164.526; and for an accounting of the disclosures of the Individual's PHI in accordance with 45 C.F.R. §164.528. The Parties agree and acknowledge that it is Covered Entity's responsibility to respond to all such requests.

3.8 Disclose to its subcontractors, agents or other third parties, and request from Covered Entity, only the minimum PHI necessary to perform or fulfill a specific function required or permitted hereunder, unless the disclosure is not subject to the minimum necessary standard in 45 C.F.R. §164.502(b).

3.9 Comply with Confidentiality of Substance Use Disorder (SUD) Patient Records under 42 CFR Part 2 in alignment with HIPAA regulations as stated in the Federal Register, Vol. 89, No. 33, February 16, 2024.

3.10 Comply with the HIPAA Privacy Rule to Support Reproductive to provide protection for individuals who receive reproductive health care when the care is provided lawfully, without risk of an individual's identity or health information being disclosed for purposes of state criminal, civil or administrative investigations.

3.10.1 Business Associate is prohibited from the disclosure of PHI to conduct or assist with a criminal, civil, or administrative investigation into or impose criminal, civil, or administrative liability on any person for the mere act of seeking, obtaining, providing, or facilitating reproductive health care, where such health care is lawful under the circumstances in which it is provided.

3.11 Update its applicable Notice of Privacy Practices (if any) to support reproductive health care privacy and Confidentiality of Substance Use Disorder (SUD) Patient Records.

4. SECURITY RULE AND HITECH ACT RESPONSIBILITIES OF THE BUSINESS ASSOCIATE.

With regard to its use and/or disclosure of ePHI, Business Associate hereby agrees to do the following:

4.1 Comply with 45 C.F.R. §§164.308, 164.310, 164.312 and 164.316, with respect to ePHI, to prevent use or disclosure of ePHI other than as provided for by this BA Agreement.

4.2 Require all of its subcontractors and agents that create, receive, maintain, or transmit ePHI on behalf of the BA to agree, in writing, to adhere to substantially similar restrictions and conditions (in all material respects) concerning ePHI that apply to Business Associate pursuant to this Paragraph 4.0.

4.3 Report to Covered Entity any Security Incident of which it becomes aware that involves the Confidentiality, Integrity or Availability of the ePHI that it creates, receives, maintains or transmits for or on behalf of Covered Entity. This Paragraph satisfies any reporting required by Business Associate of attempted but Unsuccessful Security Incidents (as defined below) for which the parties agree no additional report shall be required. “**Unsuccessful Security Incidents**” include activity such as “pings” and other broadcast attacks on Business Associate's firewall, port scans, unsuccessful log-on attempts, denials of service and any other attempts to penetrate such computer networks or systems that do not result in unauthorized access, use or disclosure of ePHI. Separate from the requirements related to Security Incident reporting, Business Associate shall also make the reports to Covered Entity as set forth in Paragraph 5.0, related to a Breach of Unsecured PHI.

4.4 In the event Business Associate utilizes Tracking Technology with respect to its Services, Business Associate is prohibited from using or disclosing any such data resulting from the Tracking Technology for purposes other than as delineated in this Agreement. For the avoidance of doubt, this BA Agreement prohibits Business Associate's Use of PHI or other data obtained from utilizing such Tracking Technology for its own use and/or benefit.

4.5 Authorize termination of this BA Agreement by Covered Entity if Covered Entity determines that Business Associate has violated a material term of this BA Agreement, in accordance with Paragraph 6.2.

5. BREACH NOTIFICATION RULE OBLIGATIONS.

5.1 Business Associate will notify Covered Entity within fifteen (15) business days of the discovery of a Breach of Unsecured PHI.

5.2 Any notice pursuant to Paragraph 5.1 will include, to the extent possible, the identification of each Individual whose Unsecured PHI has been, or is reasonably believed by Business Associate, to have been accessed, acquired or disclosed during such Breach. Business Associate will also provide Covered Entity other available information that Covered Entity is required to include in its notification to the Individual.

6. TERM AND TERMINATION.

6.1 **Term.** This BA Agreement is effective on the Effective Date of the Agreement and shall continue in effect

until all obligations of the Parties have been met, unless terminated as provided in this Paragraph 6.0. In addition, certain provisions and requirements of this BA Agreement shall survive its expiration or other termination in accordance with Paragraph 7.1.

6.2 **Termination by Covered Entity.** As provided for under 45 C.F.R. §164.504(e)(2)(iii), Covered Entity may immediately terminate this BA Agreement, any other provision of the Agreement notwithstanding, if Covered Entity determines that Business Associate has breached a material term of this BA Agreement; provided that Covered Entity (i) provides Business Associate with written notice of the existence of an alleged breach; and (ii) affords Business Associate an opportunity to cure said alleged breach. Failure to cure in the manner set forth in this Paragraph 6.2 is grounds for the immediate termination of this BA Agreement and the Agreement by Covered Entity, any other provision of the Agreement notwithstanding, but termination of the Agreement may be allowed only to the extent that the use, disclosure and/or creation of PHI is required in order for Business Associate to carry out its responsibilities under the Agreement.

6.3 **Termination by Business Associate.** Business Associate shall have the same rights and options related to termination as set forth in Paragraph 6.2 with respect to Covered Entity.

6.4 **Effect of Termination.** Upon the event of termination pursuant to this Paragraph 6.0, Business Associate agrees to return or destroy all PHI pursuant to 45 C.F.R. §164.504(e)(2)(ii)(J), if it is feasible to do so. Prior to doing so, Business Associate further agrees to recover any PHI in the possession of its subcontractors or agents. If it is not feasible for Business Associate to return or destroy said PHI, Business Associate agrees to extend any and all protections, limitations and restrictions contained in this BA Agreement to Business Associate's use and/or disclosure of any PHI retained after the termination of this BA Agreement, and to limit any further uses and/or disclosures to the purposes that make the return or destruction of the PHI infeasible. If it is infeasible for Business Associate to obtain, from a subcontractor or agent any PHI in the possession of the subcontractor or agent, Business Associate shall require the subcontractors and agents to agree to extend any and all protections, limitations and restrictions contained in this BA Agreement to the subcontractors' and/or agents' use and/or disclosure of any PHI retained after the termination of this BA Agreement, and to limit any further uses and/or disclosures to the purposes that make the return or destruction of the PHI infeasible.

7. MISCELLANEOUS.

7.1 **Part 2 Compliance.** If, and only to the extent applicable to Business Associate, Business Associate acknowledges that if its Services under the Agreement require it to access, use, disclose, maintain, or transmit information that is protected by Confidentiality of Substance Use Disorder Patient Records law and its implementing regulations set forth at 42 U.S.C. §290dd-2 and 42 C.F.R. Part 2 (“Part 2”), Business Associate is a Qualified Service Organization and is fully bound by the Part 2 regulations. If necessary, Business Associate will resist in judicial proceedings any efforts to obtain access to patient records protected by Part 2 except as expressly permitted by 42 C.F.R. §§2.1-2.68. Business Associate further acknowledges that any records it receives from Covered Entity that are protected by Part 2 are subject to protections that may

prohibit Business Associate from disclosing such information to subcontractors or agents without the specific written consent of the individual and that any unauthorized disclosure of information is a federal criminal offense.

7.2 **Survival.** The respective rights and obligations of Business Associate and Covered Entity under the provisions of Paragraphs 2, 3, 4, 5, 6.4 and 7.1, solely with respect to PHI Business Associate retains in accordance with Paragraph 6.4 because it is not feasible to return or destroy such PHI, shall survive termination of this BA Agreement indefinitely.

7.3 **No Third Party Beneficiaries.** Nothing express or implied in this BA Agreement is intended to confer, nor shall anything herein confer, upon any person other than the Parties and the respective successors or assigns of the Parties, any rights, remedies, obligations, or liabilities whatsoever.

7.4 **Notices.** Any notices to be given hereunder to a Party shall be made via U.S. Mail or express courier to such Party's address given below.

If to Business Associate, to:
Cencora, Inc., Attn: Privacy Officer

1 W. First Ave.
Conshohocken, PA, 19428

If to Covered Entity, to:
To address on Signature Page of agreement for Available Programs (GNP Premier or Master Program Agreement)
Attn: Privacy Officer

Each Party named above may change its address and that of its representative for notice by the giving of notice thereof in the manner hereinabove provided.

7.5 **Counterparts; Facsimiles.** This BA Agreement may be executed in any number of counterparts, delivered by facsimile transmission or by electronic delivery in portable document format or other similar format, each of which shall be deemed an original.

7.6 **Limitation of Liability.** Neither Party will be liable to the other Party for any incidental, indirect, exemplary, consequential, special or punitive damages with respect to the matters addressed in this BA Agreement.

7.7 **Severability.** Should any provision of this BA Agreement be held illegal, invalid or unenforceable by any governmental body or court of competent jurisdiction, such holding shall not diminish the validity or enforceability of any other provision of this BA Agreement.

7.8 **Governing Law.** This BA Agreement shall be governed by and construed in accordance with the internal laws of the Commonwealth of Pennsylvania without regard to its conflict of laws provisions.

7.9 **Notice of Privacy Practice Limitations.** Covered Entity shall promptly notify Business Associate, in writing, of any limitations in its notice of privacy practices under 45 C.F.R. §164.520, to the extent that such limitations may affect Business Associate's Use or Disclosure of PHI.

❖❖❖

PROVISIONS

Capitalized terms used but not otherwise defined in this Exhibit C will have the meaning ascribed to such terms in the GNP Premier Agreement.

The following Provisions apply to the GNP Premier Agreement and each of the Available Programs.

1. DUTIES OF ABDC. ABDC will use commercially reasonable efforts to provide requested Available Programs, which may be subject to restrictions or requirements. Available Programs in Hawaii, Alaska, U.S. territories and foreign countries may be unavailable or subject to higher prices.

2. DUTIES OF CUSTOMER

2.1 Disclosure. Customer will maintain all certificates licenses, permits, registrations and other required approvals and report and reflect discounts, rebates and other price reductions pursuant to 42 USC Sec. 1320a-7b(b)(3)(A) on cost reports or claims submitted to federal or state healthcare programs, retain invoices and related pricing documentation and make them available on request. ABDC may suspend Available Programs, payments and services immediately upon the loss, restriction or suspension of any certificate, license, permit, registration or other approval that Customer is required to maintain under this Agreement or any agreement with a Payor. ABDC may suspend Available Programs, payments and services immediately upon the exclusion of Customer or any of its pharmacists, pharmacy technicians or other employees from Medicare, Medicaid or any other federal or state healthcare program.

2.2 Distribution Agreement. Available Programs are intended for Customer's locations operating in good standing under a distribution agreement that designates ABDC as its prime vendor for sourcing prescription products.

2.2 Payments. Available Program payments must be received by ABDC on the date due. If payment is delinquent, ABDC may suspend Available Programs and services or withhold payments to Customer and assess a per-day late payment fee of the lower of 0.05% (18%/360) or the maximum legal rate on the outstanding balance until paid, beginning on the first business day after such due date.

3. NO WARRANTIES; LIMITATION OF LIABILITY. ABDC DISCLAIMS ALL WARRANTIES, EXPRESS OR IMPLIED, INCLUDING THOSE OF MERCHANTABILITY, TITLE, NON-INFRINGEMENT AND FITNESS FOR A PARTICULAR PURPOSE, FOR PROGRAMS, PRODUCTS AND SERVICES. NO ORAL OR WRITTEN INFORMATION PROVIDED BY ABDC, ITS EMPLOYEES OR OTHER REPRESENTATIVES WILL CREATE ANY SUCH WARRANTY. IN NO EVENT WILL ABDC, ITS AFFILIATES (OR THEIR RESPECTIVE OWNERS, DIRECTORS, OFFICERS, EMPLOYEES, SUBCONTRACTORS OR REPRESENTATIVES) BE LIABLE FOR ANY SPECIAL, INCIDENTAL, INDIRECT, CONSEQUENTIAL, EXEMPLARY OR PUNITIVE DAMAGES, OR LOST PROFITS IN CONNECTION WITH OR RELATED TO THIS AGREEMENT, AVAILABLE PROGRAMS, OR ANY PRODUCTS OR SERVICES PROVIDED BY ABDC HEREUNDER, EVEN IF ABDC OR ANOTHER PERSON IS NOTIFIED OF THE LIKELIHOOD THAT DAMAGES MAY OCCUR. **Unless otherwise specified in a Term Sheet, liability of ABDC and its affiliates with respect to any and all direct and/or third party**

Claims related to this Master Program Agreement (including any and all Exhibits and Addendums) or any Available Program, whether in contract, in tort, under a warranty or otherwise, will not exceed the total fees paid by Customer during the twelve (12) month period immediately preceding the Claim accrual date for the Available Programs to which such Claim is related, less any credits or refunds by ABDC to Customer. Unless ABDC's decisions and actions are inconsistent with Customer's express rights and obligations, ABDC may exercise its business judgment in assessing the best interest of Available Programs, including terms, commitments, and requirements for all of its customers generally and in the aggregate, without specifically considering Customer's individual interest. ABDC decisions and actions will be reasonable if any business justification is based on the best interests of Available Programs or customers generally. This disclaimer of warranties and limitation of liability shall survive the expiration of this Agreement.

4. CONFIDENTIALITY. Customer, its employees and representatives will protect and keep strictly confidential all proprietary and confidential information ("**Confidential Information**") disclosed by ABDC and not use or disclose it except in connection with Available Programs or as agreed. Subject to such exception, Confidential Information specifically includes this Agreement, Term Sheets, Program Guides, ABDC's methods of doing business, pricing, payment and other related financial terms, and other information related to any Available Program. Confidential Information does not include information that: (i) at the time of disclosure by ABDC, is generally available to the public; (ii) after disclosure by ABDC, becomes generally available to the public other than as a result of a breach of this Agreement by Customer; (iii) Customer can establish via written records: (1) was already in Customer's possession at the time the information was disclosed by ABDC; and (2) with respect to such information and the source thereof, was not otherwise subject to confidentiality obligations; (iv) Customer receives from a third party without obligation of confidentiality with respect to such information or otherwise applicable to such third party; or (v) Customer can establish via written records was developed independently by Customer without direct or indirect use or reference of any Confidential Information. In the event Customer becomes obligated to disclose this Agreement and/or any Confidential Information, including, without limitation, disclosures required by applicable law, upon becoming aware of any such disclosure obligation: (a) Customer will immediately notify ABDC in writing and reasonably cooperate with ABDC in connection therewith; (b) Customer will comply with Payor and other third party advance notice requirements prior to disclosure of Confidential Information; and (c) Customer will request the highest level of confidential treatment available under applicable law if it discloses this Agreement or Confidential Information.

5. TERMINATION OF MASTER PROGRAM AGREEMENT

5.1 Default. In addition to other available remedies for Available Programs, either party may immediately terminate this Master Program Agreement for cause upon written notice to the other party upon the other party's (a)(i) filing an application for or consenting to appointment of a trustee, receiver or custodian of its assets; (ii) having an order for relief entered in Bankruptcy Code proceedings; (iii) making a general assignment for the benefit of

creditors; (iv) having a trustee, receiver or custodian of its assets appointed unless proceedings and the person appointed are dismissed within 30 days; (v) insolvency within the meaning of Uniform Commercial Code Section 1-201 or failing generally to pay its debts as they become due within the meaning of Bankruptcy Section 303(h)(1) (11 U.S.C. §303(h)(1)), as amended; or (vi) certification in writing of its inability to pay its debts as they become due (and either party may periodically require the other to certify its ability to pay its debts as they become due) (collectively, “**Bankruptcy**”); (b) failure to pay any amount due and such failure continues five days after written notice; or (c) failure to perform any other material obligation of this Master Program Agreement or any other agreement between the parties or their affiliates and such failure continues for 30 days after it receives notice of such breach from the non-breaching party.

5.2 Survival Upon Termination. Within five days of expiration or earlier termination of this Master Program Agreement for any reason, amounts owed by either party to the other will be immediately due and paid to the other party. Customer will return all Available Program materials, including Term Sheets, Program Guides and Licensed Material, or pay to ABDC their replacement cost. Obligations in Paragraphs 4.0, 5.2, 6.0 and 8.0 and any provision the context of which shows the parties intended it to survive will remain in effect after the Term.

6. **INDEMNIFICATION.** Each party (“**Indemnifying Party**”) will indemnify, defend, and hold harmless the other, its affiliates, its employees and representatives (“**Indemnified Party**”) against all claims and damages (including expenses and attorneys’ fees) (“**Claim**”) to the extent arising out of Indemnifying Party’s obligations hereunder, but only to the extent permitted by law (with any such limits applying equally to the parties). Failure to give prompt written notice of a Claim will not relieve Indemnifying Party of liability except to the extent caused by such failure. Indemnifying Party will defend Claims with counsel reasonably satisfactory to Indemnified Party and Indemnified Party will cooperate fully in such defense. Without limiting the foregoing, Customer’s obligations include any Claim arising from its infringement or other violation of a patent, trademark, copyright or other proprietary right owned or controlled by ABDC or any third party except to the extent arising from use that complies with this Agreement.

7. COMPUTER APPLICATIONS, SOFTWARE & DATA

7.1 License. ABDC grants Customer a non-exclusive, limited, nontransferable, non-sublicenseable, and revocable license to use computer applications, including websites, software and data related to Available Programs and related documentation (“**Licensed Material**”). Customer may not make, or allow others to make, copies of the Licensed Material except one backup copy. Customer must include all proprietary notices in permitted copies of Licensed Material. Customer may not modify Licensed Material, create derivative works, or otherwise translate, reverse engineer, disassemble or decompile the Licensed Material.

7.2 Limited Warranty. ABDC warrants that the Licensed Material will perform substantially in accordance with its documentation if the Licensed Material is operated as directed, no modification of the Licensed Material is made by any person other than ABDC and only the most current release of the Licensed Material is used. ABDC DISCLAIMS ALL OTHER WARRANTIES, EXPRESS OR IMPLIED, INCLUDING THOSE OF MERCHANTABILITY, TITLE, NON-INFRINGEMENT AND FITNESS FOR A PARTICULAR PURPOSE, FOR LICENSED MATERIAL, AND ACCURACY OF ANY DATA.

ALL DATA IS PROVIDED “AS IS.” DUE TO THE NATURE OF SOFTWARE AND DATA, ERRORS AND INTERRUPTIONS MAY OCCUR AND CUSTOMER HAS ALL RISKS FOR QUALITY AND PERFORMANCE. No oral or written information provided by ABDC, its employees or other representatives will create any warranty.

7.3 Remedy. If ABDC breaches a warranty in Paragraph 7.2, as Customer’s sole remedy (other than the indemnity for third party Claims under Paragraph 6.0), ABDC will, at its option and expense (i) repair or replace Licensed Material so it performs substantially in accordance with its documentation; or (ii) advise Customer how to achieve substantially the same functionality using different procedures.

8. MISCELLANEOUS

8.1 Force Majeure. ABDC may reduce, delay, suspend or eliminate any Available Program, in whole or in part, without liability or obligation if ABDC’s performance is prevented, delayed or otherwise affected by any cause beyond its control, including labor disputes, fire, terrorism, acts of God, unavailability of an Available Program, or material component thereof, loss of access to data, delays by suppliers, loss of facilities or internet, telecommunication or electrical systems, pandemic, voluntary foregoing a right in order to comply with or accommodate government orders or requests, or compliance with any law or otherwise.

8.2 Notices. Except as provided otherwise herein, notices must be in writing and personally delivered or sent by certified mail, prepaid, return receipt requested; by overnight delivery; or, by facsimile or email as provided in this Section 8.2. Notices will be deemed delivered (i) upon delivery when personally delivered or sent by certified mail or overnight delivery; (ii) upon delivery if sent by facsimile or email during normal business hours of the receiving party (or, otherwise, on the following business day) with a confirming copy sent by U.S. mail or overnight delivery; or (iii) upon delivery if sent by facsimile or email (with no confirming copy required) for notices by ABDC of updates to this Agreement, Term Sheets or other Available Program documentation.

To Customer: Customer’s address on the Agreement signature page.

To ABDC : AmerisourceBergen Drug Corporation
1 W. First Ave.
Conshohocken, PA 19428
Attn: Sr. Director - Strategic Program Operations

With copy to: Cencora, Inc.
1 W. First Ave.
Conshohocken, PA 19428
Attn: Legal Department

8.3 Assignment. Neither party may assign this Master Program Agreement without the other party’s prior written consent, and attempted assignment in contravention of this Agreement shall be void and of no effect. Valid assignment of this Agreement will inure to the benefit of and be binding upon each party and its heirs, successors and assigns. Notwithstanding the foregoing, ABDC may, without notice, assign part or all of its obligations hereunder to any affiliate or may do so (or grant a security interest herein) in connection with any financing or securitization by ABDC or any corporate affiliate. Customer will notify ABDC of changes in ownership, name, business form (e.g.,

sole proprietorship, partnership or corporation), state of incorporation or formation, or any intent to sell, close, move or modify its operations prior to such change, sale, closure or modification, and provide other information ABDC reasonably requests.

8.4 EEO Requirements. ABDC and Customer each warrant it does not and will not discriminate against any employee or applicant for employment because of race, creed, color, national origin, religion, gender, sexual preference, veteran status, handicap or as otherwise prohibited by law and will meet affirmative action obligations imposed by law.

8.5 Independent Parties. This Master Program Agreement will not create a partnership, joint venture, agency, employment, fiduciary or other special relationship between ABDC and Customer or its employees or representatives. No representation to the contrary will be binding.

8.6 Attorneys' Fees; Choice of Law. The successful party in any legal action may recover all costs it incurs, including reasonable attorneys' fees. Pennsylvania law governs this Agreement without reference to its conflict of laws provisions.

8.7 Dispute Resolution. Customer must first bring any claim or dispute under this Agreement to ABDC's management and make every effort to resolve the dispute internally before bringing a dispute before a third party. If the parties are unable to resolve any claim or dispute internally within 90 days, Customer agrees that any controversy or claim arising out of or relating to this Agreement, or the breach thereof, shall be determined by final and binding arbitration administered by the American Arbitration Association under its Commercial Arbitration Rules and Mediation Procedures. Any arbitration award or decision may be filed in a court of competent jurisdiction for enforcement.

8.8 Third Party Beneficiaries. Other than ABDC's officers, directors, and/or employees, there are no other third party beneficiaries.

8.9 WAIVER OF CLASS ACTIONS. Customer waives the right to litigate in court or arbitrate any claim or dispute as a class action, either as a member of a class, or as a representative.

8.10 Compliance with Law; Healthcare Exclusions. Each party will comply with all laws, and maintain its eligibility to participate in Medicare, Medicaid and other federal and state healthcare programs. Customer will promptly disclose if it (or any of its pharmacists or pharmacy technicians or other employees) becomes an excluded entity or individual on an HHS-OIG or comparable list for Medicare, Medicaid or other federal or state healthcare programs.

8.11 Setoff. Without limiting ABDC's other legal rights, ABDC and its affiliates may withhold, delay, or setoff any amounts owed to Customer pursuant to this Agreement or an Available Program, or take any other lawful actions, to: (i) recover any amount (including, but not limited to, principal, interest, costs, and reasonable attorneys' fees) owed by Customer to ABDC or its affiliates under this Agreement, any Available Program, or any other agreement, including but not limited a distribution agreement, credit agreement, and/or any other master program agreement between Customer and ABDC or its affiliates; and/or (ii) satisfy, or remit payment towards the satisfaction of, any amount (including, but not limited to, principal, interest, costs, and reasonable attorneys' fees) owed by Customer to a third party creditor (e.g., Internal Revenue Service, etc.) pursuant to which ABDC becomes legally obligated to remit such amounts otherwise owed to Customer.

8.12 Ownership. Customer must disclose to ABDC, in writing, the identity of any and all Payors that, directly or

indirectly, own an interest in Customer's business and/or otherwise exercise control over Customer's management.

8.13 Miscellaneous. Any forbearance or delay in the exercise of any right or remedy hereunder or as otherwise afforded by law will not be a waiver of or preclude the exercise of any such right or remedy. All provisions are severable. This Agreement supersedes prior oral or written agreements by the parties that relate to its subject matter. This Agreement only benefits the parties hereto and will not, except as expressly provided herein, create or convey a benefit to anyone who is not a party hereto. Captions are intended for convenience of reference only. "**Including**" means "including but not limited to." Except as provided otherwise herein, the parties may not modify this Agreement other than by a subsequent writing signed by each party. This Master Program Agreement will be interpreted as if written jointly by the parties. In the event of a conflict between the terms of this Master Program Agreement and any Term Sheet, the terms of this Master Program Agreement will control except to the extent expressly and specifically amended by or provided otherwise in such Term Sheet. Any such modification will be valid only for that particular Term Sheet and will not amend this Master Program Agreement generally.

❖❖❖

STATE-SPECIFIC AMENDMENTS

Each provision of these state-specific amendments (“Amendments”) to this GNP Premier Participation Agreement (“Agreement”) will be effective only to the extent that jurisdictional requirements of such respective states’ laws applicable to the Agreement are met independently of these Amendments. These Amendments have no effect if jurisdictional requirements are not met.

CALIFORNIA

The California Department of Corporations requires that certain provisions in franchise documents be amended to be consistent with California law, including the California Franchise Investment Law, CAL. CORPORATIONS CODE Section 31000 et seq., and the California Franchise Relations Act, CAL. BUS. & PROF. CODE Section 20000 et seq. To the extent the Agreement has provisions that are inconsistent with the following, such provisions are hereby amended:

- a. California Business and Professions Code Sections 20000 through 20043 provide rights to Customer concerning nonrenewal and termination of the Agreement. The Federal Bankruptcy Code also provides rights to Customer concerning termination of the Agreement upon certain bankruptcy-related events. To the extent the Agreement has a provision is inconsistent with these laws, these laws will control.
- b. If Customer is required in the Agreement to execute a release of claims, such release will exclude claims arising under the California Franchise Investment Law and the California Franchise Relations Act with respect to the offer or sale of the Agreement and the Premier Candidate Agreement.
- c. If the Agreement requires payment of liquidated damages that is inconsistent with California Civil Code Section 1671, the liquidated damage clause may be unenforceable.
- d. If the Agreement has a covenant not to compete which extends beyond the expiration or termination of the Agreement, the covenant may be unenforceable under California law.
- e. If the Agreement requires litigation, arbitration or mediation to be conducted in a forum other than the State of California, the requirement may be unenforceable under California law.
- f. If the Agreement requires that it be governed by a state’s law, other than the State of California, such requirement may be unenforceable.
- g. Section 8.6 of Exhibit C of the Agreement is hereby amended to state that the representations made in the Franchise Disclosure Document are not excluded from that on which Customer may rely.

HAWAII

- a. No release language set forth in the GNP Premier Agreement shall relieve the franchisor or any other party, directly or indirectly, from liability imposed by the laws concerning franchising in the State of Hawaii.
- b. The GNP Premier Agreement is hereby supplemented with the following provision:

Hawaii Law. Pursuant to Section 482E-6(3) of the Hawaii Revised Statutes, for so long as such statute remains in effect and so provides, upon termination or refusal to renew the franchise, Franchisee shall be compensated for the fair market value, at the time of termination or expiration of the franchise, of Franchisee’s inventory, supplies, materials and furnishings purchased from the Franchisor or a supplier designated by the Franchisor, exclusive of personalized materials which have no value to the Franchisor. If the Franchisor refuses to renew a franchise for the purpose of converting the franchised business to one owned by the Franchisor, the Franchisor, in addition to the remedies provided in this paragraph, shall compensate Franchisee for the loss of goodwill. The Franchisor may deduct from such compensation reasonable costs incurred in removing, transporting and disposing of Franchisee’s inventory, supplies, materials and furnishings pursuant to this paragraph, and may offset from such compensation any moneys due to the Franchisor.
- c. Notwithstanding anything contained in the Franchise Agreement or Area Development Agreement to the contrary, you do not have to pay us the Initial Franchise Fee until we perform our pre-opening obligations under the Franchise Agreement and your first Franchised Business is open. Once we complete this obligation and you are open, you must immediately pay us all initial fees we deferred.

ILLINOIS**ILLINOIS ADDENDUM TO THE PARTICIPATION (FRANCHISE) AGREEMENT**

Illinois law governs the Participation (Franchise) Agreement.

In conformance with Section 4 of the Illinois Franchise Disclosure Act, any provision in a franchise agreement that designates jurisdiction and venue in a forum outside of the State of Illinois is void. However, a franchise agreement may provide for arbitration to take place outside of Illinois.

Franchisees' rights upon Termination and Non-Renewal are set forth in sections 19 and 20 of the Illinois Franchise Disclosure Act.

Any condition, stipulation or provision purporting to bind any person acquiring any franchise to waive compliance with the Illinois Franchise Disclosure Act or any other law of Illinois is void.

While the Franchisor's Parent company has guaranteed to assume the duties and obligations of the Participation (Franchise) Agreement if the Franchisor is unable to do so – the Parent company's financial condition calls into question its ability to fulfill such a guarantee. Notwithstanding anything contained in the Franchise Agreement to the contrary, you do not have to pay us the Initial Franchise Fee until we perform our pre-opening obligations under the Franchise Agreement and your Franchised Business has commenced business operations. The Illinois Attorney General's Office imposed this deferral requirement due to Franchisor's financial condition.

Nothing in the Premier Participation Agreement (Franchise Agreement), related agreements, exhibits and Term Sheets are intended to disclaim the express representations made in the Franchise Disclosure Document.

There is no training program for this franchise opportunity.

AmerisourceBergen Drug Corporation

Franchisee: _____

By: _____

By: _____

Title: _____

Title: _____

INDIANA

- a. Any Franchise Agreement executed in and operative within the State of Indiana shall be governed by applicable Indiana franchise laws and the right of any franchisee to institute a civil action or initiate proceedings within the State of Indiana shall not be deemed to have been abridged in any form or manner by any provisions contained in the Franchise Agreement.
- b. In compliance with Indiana Code section 23-2-2.7-1(9), any provisions in the Franchise Agreement relating to non-competition upon the termination or non-renewal of the Franchise Agreement shall be limited to a geographic area not greater than the territory granted in the Franchise Agreement and shall be construed in accordance with Indiana Code section 23-2-2.7-1(9).
- c. Indiana Code section 23-2-2.7-1(10) prohibits the choice of an exclusive forum other than Indiana.
- d. Indiana Code section 23-2-2.7-1(10) prohibits the limitation of litigation. The Indiana Secretary of State has interpreted this section to prohibit provisions in contracts regarding liquidated damages. Accordingly, any provisions in the Franchise Agreement regarding liquidated damages may not be enforceable. To the extent that any provision of the Franchise Agreement conflicts with Indiana Code section 23-2-2.7-1 (10), Indiana law will control.
- e. Indiana Code sections 23-2-2.7-1 (1) and 23-2-2.5-30 impose different time limitations for litigation brought for breach of the Agreement or violation of Indiana law in connection with the Agreement. To the extent that any provision of the Agreement conflicts with Indiana law, Indiana law will control.
- f. In compliance with Indiana Code section 23-2-2.7-1 (10), any inference contained in the Franchise Agreement to the effect that the Franchisor "is entitled" to injunctive relief shall, when applicable to a Franchise Agreement executed

in and operative within the State of Indiana, hereby be deleted, understood to mean and replaced with the words "may seek."

- g. Indiana Code sections 23-2-2.5 and 23-2-2.7 supersede the choice of law clauses of the Franchise Agreement.
- h. Indiana Code section 23-2.2.7-1 makes it unlawful for a franchisor to terminate a franchise without good cause or to refuse to renew a franchise on bad faith.
- i. In compliance with Indiana Code section 23-2-2.7-1 (5), any requirement that the Franchisee must execute a release upon termination of the Franchise Agreement shall not be mandatory and is hereby made discretionary. However, Franchisee shall execute all other documents necessary to fully rescind all agreements between the parties.

MARYLAND

The Maryland Securities Division requires that certain provisions in franchise documents be amended to be consistent with Maryland law, including the Maryland Franchise Registration and Disclosure Law, Md. Code Ann., Bus. Reg. §§ 14-201 - 14-233 (2004 Repl. Vol. and Supp. 2008) (the "Maryland Franchise and Disclosure Law"). To the extent that the Agreement has provisions that are inconsistent with the following, such provisions are hereby amended:

- a. If Customer is required in the Agreement to execute a release of claims and/or to acknowledge facts that would negate or remove from judicial review any statement, misrepresentation or action that would violate Maryland Franchise and Disclosure Law, or a rule or order under the Maryland Franchise and Disclosure Law, such release will exclude claims arising under the Maryland Franchise and Disclosure Law, and such acknowledgments will be void with respect to claims under the Maryland Franchise and Disclosure Law relating to the offer and sale of the Agreement and related agreements.
- b. If the Agreement requires litigation to be conducted in a forum other than the State of Maryland, the requirement will not be interpreted to limit any rights Customer may have under the Maryland Franchise and Disclosure Law to bring suit in the state of Maryland.
- c. Any general release required as a condition of renewal, sale, and/or assignment/transfer will not apply to any liability under the Maryland Franchise and Disclosure Law.
- d. The Agreement is hereby amended to reflect that any claims arising under the Maryland Franchise and Disclosure Law must be brought within 3 years after the grant of the franchise.
- e. Based upon the financial information submitted, the Commissioner has determined that all fees paid to the franchisor by the franchisee, including payment for goods and services received from the franchisor before the business opens, shall be deferred pending satisfaction of all of the franchisor's pre-opening obligations to the franchisee.
- f. The Maryland Franchise and Disclosure Law prohibits a franchisor from requiring a prospective franchisee to assent to any release, estoppel or waiver of liability as a condition of purchasing a franchise. The Agreement requires prospective franchisees to disclaim the occurrence and/or acknowledge the non-occurrence of acts that would constitute a violation of the Maryland Franchise and Disclosure Law. Such representations are not intended to nor will they act as a release, estoppel or waiver of any liability incurred under the Maryland Franchise and Disclosure Law resulting from the offer or sale of the franchise.
- g. No statement, questionnaire, or acknowledgment signed or agreed to by a franchisee in connection with the commencement of the franchise relationship shall have the effect of (i) waiving any claims under any applicable state franchise law, including fraud in the inducement, or (ii) disclaiming reliance on any statement made by any franchisor, franchise seller, or other person acting on behalf of the franchisor. This provision supersedes any other term of any document executed in connection with the franchise.

MINNESOTA

The Commissioner of Commerce for the State of Minnesota requires that certain provisions in franchise documents be amended to be consistent with Minnesota Franchise Act, Minn. Stat. Section 80.01 et seq., and of the Rules and Regulations promulgated under the Act (collectively the "Minnesota Act"). To the extent that the Agreement and Franchise Disclosure Document have provisions that are inconsistent with the following, such provisions are hereby amended:

- a. The Minnesota Department of Commerce requires that ABDC indemnify Minnesota franchisees against liability to third parties resulting from claims by third parties that a franchisee's use of the Marks infringes trademark rights of the third party. ABDC does not indemnify against the consequences of Customer's use of the Marks except in accordance with the requirements of the Agreement, and, as a condition to indemnification, Customer must provide notice to ABDC of any such claim within ten (10) days after the earlier of (i) actual notice of the claim or (ii) receipt of written notice of the claim, and must therein tender the defense of the claim to ABDC. If ABDC accepts the tender of defense, ABDC has the right to manage the defense of the claim including the right to compromise, settle or otherwise resolve the claim, and to determine whether to appeal a final determination of the claim. If either the Agreement or the Franchise Disclosure Document has a provision that is inconsistent with the Minnesota Act, such provision will be superseded by the Minnesota Act's requirements and will have no force or effect.
- b. Minnesota Act, Sec. 80C.14, Subd. 4., requires, except in certain specified cases, that Customer be given written notice of ABDC's intention not to renew 180 days prior to expiration of the franchise and that Customer be given sufficient opportunity to operate the franchise in order to enable Customer the opportunity to recover the fair market value of the franchise as a going concern. If either the Agreement or the Franchise Disclosure Document has a provision that is inconsistent with the Minnesota Act, such provision will be superseded by the Minnesota Act's requirements and will have no force or effect.
- c. Minnesota Act, Sec. 80C.14, Subd. 3., requires, except in certain specified cases, that Customer be given 90 days notice of termination (with 60 days to cure). If either the Agreement or the Franchise Disclosure Document has a provision that is inconsistent with the Minnesota Act, such provision will be superseded by the Minnesota Act's requirements and will have no force or effect.
- d. Minn. Rule 2860.4400(D) prohibits ABDC from requiring Customer to assent to a general release. If either the Agreement or the Franchise Disclosure Document requires Customer to execute a release of claims or to acknowledge facts that would negate or remove from judicial review any statement, misrepresentation or action that would violate the Franchise Act, such release will exclude claims arising under the Minnesota Act, and such acknowledgments will be void with respect to claims under the Minnesota Act.
- e. Minnesota Statutes, Section 80C.21 and Minn. Rule 2860.4400(J) prohibit ABDC from requiring litigation to be conducted outside Minnesota, requiring waiver of a jury trial or requiring Customer to consent to liquidated damages, termination penalties or judgment notes. In addition, nothing in the Agreement or the Franchise Disclosure Document can abrogate or reduce Customer's rights under Minnesota Statutes, Chapter 80C or Customer's rights to any procedure, forum or remedies provided for by the laws of the jurisdiction.
- f. Notwithstanding anything contained in the Franchise Agreement to the contrary, you do not have to pay us the Initial Franchise Fee until we perform our pre-opening obligations under the Franchise Agreement and your Franchised Business is open. Once we complete this obligation and you are open, you must immediately pay us all initial fees we deferred.

NEW YORK

The New York Department of Law requires that certain provisions in franchise documents be amended to be consistent with New York law, including the General Business Law, Article 33, Sections 680 through 695 (1989). To the extent that the Agreement has provisions that are inconsistent with the following, such provisions hereby amended:

- a. If the Agreement requires Customer to execute a release of claims or to acknowledge facts that would negate or remove from judicial review any statement, misrepresentation or action that would violate the General Business Law, or any regulation, rule or order under the Law, such release will exclude claims arising under the New York General Business Law, Article 33, Section 680 through 695 and the regulations promulgated thereunder, and such acknowledgments will be void. It is the intent of this provision that non-waiver provisions of Sections 687.4 and 687.5 of the General Business Law be satisfied.
- b. If the Agreement requires that it be governed by a state's law, other than the State of New York, the choice of law provision will not waive any rights conferred upon Customer under the New York General Business Law, Article 33, Sections 680 through 695.

NORTH DAKOTA

The North Dakota Securities Commissioner requires that certain provisions in franchise documents be amended to be consistent with North Dakota law, including the North Dakota Franchise Investment Law, North Dakota Century Code Annotated Chapter 51-19, Sections 51-19-01 through 51-19-17 (1993) (the “Law”). To the extent that the Agreement has provisions that are inconsistent with the following, such provisions are hereby amended:

- a. If Customer is required in the Agreement to execute a release of claims or to acknowledge facts that would negate or remove from judicial review any statement, misrepresentation or action that would violate the Law, or a rule or order under the Law, such release will exclude claims arising under the North Dakota Franchise Investment Law, and such acknowledgments will be void with respect to claims under the Law, as to the offer and sale of the Agreement.
- b. Covenants not to compete during the term of and upon termination or expiration of the Agreement are enforceable only under certain conditions according to North Dakota law. If the Agreement has a covenant not to compete that is inconsistent with North Dakota law, the covenant may be unenforceable.
- c. The Commissioner has held that requiring franchisees to consent to the jurisdiction of courts outside of North Dakota is unfair, unjust or inequitable within the intent of Section 51-19-09 of the North Dakota Franchise Investment Law.
- d. If the Agreement requires that law of a state other than North Dakota govern it, to the extent that such law conflicts with the North Dakota law, North Dakota law will control.
- e. If the Agreement requires litigation, mediation or arbitration to be conducted in a forum other than North Dakota, the requirement may be unenforceable under the Law. Arbitration involving a franchise purchased in North Dakota must be held either in a location mutually agreed upon prior to the arbitration or if the parties cannot agree on a location, the location will be determined by the arbitrator.
- f. If the Agreement requires payment of a termination penalty, the requirement may be unenforceable under the Law.

RHODE ISLAND

The Rhode Island Securities Division requires that certain provisions in franchise documents be amended to be consistent with Rhode Island law, including the Franchise Investment Act, R.I. Gen. Law. ch. 395 Sec. 19-28.1-1 -19-28.1-34 (the “Rhode Island Act”). To the extent that the Agreement has provisions that are inconsistent with the following, such provisions are hereby amended:

- a. If the Agreement requires litigation to be conducted in a forum other than Rhode Island, the requirement is void under Rhode Island Act Sec. 19-28.1-14.
- b. If the Agreement requires that it be governed by law of a state other than Rhode Island, to the extent that such law conflicts with the Rhode Island Act it is void under Sec. 19-28.1-14.
- c. If Customer is required in the Agreement to execute a release of claims or to acknowledge facts that would negate or remove from judicial review any statement, misrepresentation or action that would violate the Rhode Island Act, or a rule or order under the Rhode Island Act, such release will exclude claims arising under the Rhode Island Act, and such acknowledgments will be void with respect to claims under the Rhode Island Act, as to the offer and sale of the Agreement.

SOUTH DAKOTA

- a. Neither the franchisor nor any person identified in Item 2 has any material arbitration proceeding pending, or has during the 10-year period immediately preceding the date of this Disclosure Document been a party to concluded material arbitration proceedings.
- b. Although the Franchise Agreement requires all arbitration proceedings to be held where the American Arbitration Association designates, the site of any arbitration started pursuant to the Franchise Agreement will be at a site mutually agreed upon by you and us.
- c. We may not terminate the Franchise Agreement for a breach, for failure to meet performance and quality standards and/or for failure to make royalty payments unless you receive thirty (30) days prior written notice from us and you

are provided with an opportunity to cure the defaults. Covenants not to compete upon termination or expiration of the Franchise Agreement are generally unenforceable in the State of South Dakota.

- d. The laws of the State of South Dakota will govern matters pertaining to franchise registration, employment, covenants not to compete, and other matters of local concern; but as to contractual and all other matters, the Franchise Agreement will be subject to the applications, construction, enforcement and interpretation under the governing law of Pennsylvania.
- e. Any provision in the Franchise Agreement restricting jurisdiction or venue to a forum outside of the State of South Dakota or requiring the application of the laws of another state is void with respect to a claim otherwise enforceable under the South Dakota Franchise Act.
- f. Any provision that provides that the parties waive their right to claim punitive, exemplary, incidental, indirect, special or consequential damages may not be enforceable under South Dakota law.

VIRGINIA

The Virginia State Corporation Commission's Division of Securities and Retail Franchising requires us to defer payment of the initial franchise fee and other initial payments owed by franchisees to the franchisor until the franchisor has completed its pre-opening obligations under the franchise agreement.

WASHINGTON

In the event of a conflict of laws, the provisions of the Washington Franchise Investment Protection Act, Chapter 19.100 RCW will prevail.

RCW 19.100.180 may supersede the franchise agreement in your relationship with the franchisor including the areas of termination and renewal of your franchise. There may also be court decisions which may supersede the franchise agreement in your relationship with the franchisor including the areas of termination and renewal of your franchise.

In any arbitration or mediation involving a franchise purchased in Washington, the arbitration or mediation site will be either in the state of Washington, or in a place mutually agreed upon at the time of the arbitration or mediation, or as determined by the arbitrator or mediator at the time of arbitration or mediation. In addition, if litigation is not precluded by the franchise agreement, a franchisee may bring an action or proceeding arising out of or in connection with the sale of franchises, or a violation of the Washington Franchise Investment Protection Act, in Washington.

A release or waiver of rights executed by a franchisee may not include rights under the Washington Franchise Investment Protection Act or any rule or order thereunder except when executed pursuant to a negotiated settlement after the agreement is in effect and where the parties are represented by independent counsel. Provisions such as those which unreasonably restrict or limit the statute of limitations period for claims under the Act, or rights or remedies under the Act such as a right to a jury trial, may not be enforceable.

Transfer fees are collectable to the extent that they reflect the franchisor's reasonable estimated or actual costs in effecting a transfer.

Pursuant to RCW 49.62.020, a noncompetition covenant is void and unenforceable against an employee, including an employee of a franchisee, unless the employee's earnings from the party seeking enforcement, when annualized, exceed \$100,000 per year (an amount that will be adjusted annually for inflation). In addition, a noncompetition covenant is void and unenforceable against an independent contractor of a franchisee under RCW 49.62.030 unless the independent contractor's earnings from the party seeking enforcement, when annualized, exceed \$250,000 per year (an amount that will be adjusted annually for inflation). As a result, any provisions contained in the franchise agreement or elsewhere that conflict with these limitations are void and unenforceable in Washington.

RCW 49.62.060 prohibits a franchisor from restricting, restraining, or prohibiting a franchisee from (i) soliciting or hiring any employee of a franchisee of the same franchisor or (ii) soliciting or hiring any employee of the franchisor. As a result, any such provisions contained in the franchise agreement or elsewhere are void and unenforceable in Washington. The undersigned does hereby acknowledge receipt of this addendum.

In lieu of an impound of franchise fees, the Franchisor will not require or accept the payment of any initial franchise fees until the franchisee has (a) received all initial training that it is entitled to under the franchise agreement or offering circular, and (b) is open for business.

WISCONSIN

The Wisconsin Department of Financial Institutions requires that certain provisions in franchise documents be amended to be consistent with Wisconsin Law, including The Wisconsin Fair Dealership Law, ch. 135, Wis. Stats. (the “Wisconsin Act”). To the extent that the Agreement has provisions that are inconsistent with the following, such provisions are hereby amended:

- a. The Wisconsin Fair Dealership Law supersedes any provisions contained in the Agreement that are inconsistent with the Wisconsin Act.

MASTER PROGRAM AGREEMENT

1. TERM. The term of this Agreement (“**Term**”) starts on its Effective Date and continues until all Available Programs have been terminated pursuant to Paragraph 5.0 of Exhibit C of the GNP Premier Agreement or as follows. Either party may terminate this Master Program Agreement or one or more Available Programs at one or more Pharmacies, with or without cause, at any time upon sixty (60) days' prior written notice, although termination of specific Available Programs may be subject to restrictions or termination obligations provided on the applicable Term Sheet. Notwithstanding the preceding sentence, ABDC may immediately and at any time terminate or modify, as applicable, any Pharmacy's participation in any Available Program that includes eligibility qualifications, requirements, and/or criteria, as provided in applicable Term Sheets and/or enrollment forms, that such Pharmacy does not satisfy. Termination of less than all Available Programs at all Pharmacies will not terminate this Agreement with respect to any Available Program and/or Pharmacy that is not named in the termination notice.

2. FEES. Each Term Sheet states applicable per-Pharmacy fees, which such fees shall apply during the term of Customer's participation in each corresponding Available Program and may be prorated as applicable. Some Available Programs require Customer to incur other expenses, which are Customer's responsibility. “**Premier**” fees apply to Pharmacy locations under a Good Neighbor Pharmacy Premier Participation Agreement (“**Premier Agreement**”). “**GNP**” fees apply to Pharmacies under a Good Neighbor Pharmacy Voluntary License (“**GNP License**”). “**Other**” fees apply to Pharmacies that do not participate in the Good Neighbor Pharmacy program and may be higher. Applicable fees may be increased on sixty (60) days' prior written notice.

3. ABDC COMMITMENTS.

(a) **Programs and Services.** ABDC will promptly provide Available Programs (subject to roll-out schedules and sequential program activation) in which Customer enrolls from time to time pursuant to applicable industry standards, laws, Term Sheets, and program materials ABDC provides or makes available to Customer that prescribe or recommend standards, practices, procedures, policies and guidance relating to the Available Program (“**Program Guides**”). In addition to written material, ABDC and others, including Payors (as defined under Term Sheet 1), may publish Term Sheets, Program Guides, policies, procedures, and updates to each of these on AB Central or other websites they maintain, or make them available on request. A listing of current Available Programs and applicable Term Sheets are accessible on AB Central or from Customer's ABDC sales representative.

(b) **Statements of Work.** From time-to-time, Customer may engage ABDC to provide other goods and services, such as custom work or a special project, pursuant to a "statement of work" hereunder. Each statement of work will be subject to the terms and conditions of this Agreement, will be attached hereto, and is hereby incorporate into and made a part of this Agreement.

(c) **Data Protection.** ABDC will protect and only use Pharmacy Data and Business Contact Information provided by or on behalf of Customer pursuant to Exhibit A in connection with any Available Program that involves access to such information and, in connection with any Available Program that involves access to protected health information (PHI in Exhibit B), pursuant to the Business Associate Agreement (Exhibit B or as otherwise agreed).

4. CUSTOMER COMMITMENTS.

(a) **Program Agreement.** During the Term, Customer may request to enroll a Pharmacy in an Available Program by submitting the required Available Program enrollment form(s) to request that ABDC begin providing the Available Program. For Available Programs that involve access to Pharmacy Data, Customer will sign a Data Authorization as part of enrollment.

(b) **Compliance.** Customer will comply with this Agreement, Term Sheets and Program Guides, including qualifications or other actions Customer must meet to be eligible, each as amended by ABDC from time to time. If Customer does not comply, it may not participate in such Available Program or, if it is participating, its right to do so may be revoked. Customer is responsible for acquiring and maintaining all equipment, software and services, including claims switch services provided by “Change Healthcare”, or such services provided by another claims switch services provider approved by ABDC in writing, as may be required for Available Program participation. Such items and services must be purchased from vendors meeting Available Program specifications to ABDC's reasonable satisfaction.

(c) **Payment.** Unless otherwise agreed, ABDC will bill fees monthly and add to the billed amount any applicable sales, use or other tax or charges, with payment due under terms of Customer's prime vendor agreement or ABDC's standard terms.

(d) **Use of Available Programs.** Customer may only use an Available Program for its own business and only at a Pharmacy that Customer has enrolled in such Available Program. Nothing supplied by ABDC under this Agreement, including performance measurements, business advice, or cost or price data, is a substitute for Customer's business and professional judgment or will dictate to Customer at what price to sell services, pharmaceuticals or other merchandise, except to the extent Customer and a third party each agree (including as a part of the Elevate Provider Network). Customer is solely responsible for use of data and advice obtained through Available Programs. Except as expressly permitted otherwise herein respecting disclosures required by law,

Customer must keep confidential and not disclose, redistribute, reverse engineer, supply, license or sell any analyses, processes, advice or any other intellectual property of ABDC, including reports and methods, relating to Available Programs.

5. PROVISIONS AND POLICIES. ABDC may unilaterally amend this Agreement, including, without limitation, developing new or modifying existing Exhibits hereto and/or Available Programs and their respective policies, procedures, and corresponding Term Sheets, which any such amendments are effective sixty (60) days after they are made available or any shorter period specified in a Term Sheet, as applicable. Customer consents to receiving notices, advertisements and other marketing materials by fax or email from ABDC and its corporate affiliates. ABDC will provide notice via fax or email respecting any unilateral amendment to this Agreement as provided herein. Participation in an Available Program and all Term Sheets incorporate this Agreement, including all Exhibits attached hereto, by this reference.

STATE-SPECIFIC ADDENDA TO MASTER PROGRAM AGREEMENT

MARYLAND

The Maryland Insurance Administration requires that certain provisions in pharmacy services administrative contracts (as defined in Md. Code, Ins. § 15-2001(d)) between pharmacy services administrative organizations (as defined in Md. Code, Ins. § 15-2001(e)) and independent pharmacies (as defined in Md. Code, Ins. § 15-2001(b)) be amended to be consistent with applicable Maryland law. To the extent that Customer is a pharmacy or owns certain pharmacies that satisfy the definition of “independent pharmacy” as defined in Md. Code, Ins. § 15-2001(b), the following Maryland State Addendum to the Master Agreement applies and amends the terms of the Agreement, as follows:

MARYLAND STATE ADDENDUM TO MASTER PROGRAM AGREEMENT

This Maryland State Addendum to Master Program Agreement (this “**Addendum**”) is incorporated in its entirety into, and made a part of, that certain Master Program Agreement, including all term sheets, exhibits, addenda, schedules and amendments thereto (collectively, the “**Agreement**”) entered into by and between AmerisourceBergen Drug Corporation d/b/a Elevate Provider Network (“**ABDC**”) and Customer (as defined in the Agreement), effective as of the Effective Date (as defined in the Agreement). ABDC and Customer are also referred to in this Addendum as a “**Party**” and, collectively, the “**Parties**”.

RECITALS

- A. WHEREAS, ABDC is a pharmacy services administrative organization and operates a network of pharmacies, including Customer, that have authorized ABDC to enter into and bind the pharmacies to certain Payor Contracts on their behalf.
- B. WHEREAS, the Parties entered into the Agreement as of the Effective Date.
- C. WHEREAS, Customer is a pharmacy or owns certain pharmacies that satisfy the definition of “**independent pharmacy**” as defined in Md. Code, Ins. § 15-2001(b).
- D. WHEREAS, in order to comply with applicable provisions of the Insurance Article, Annotated Code of Maryland, including, without limitation, Title 15, Subtitles 15 and 20 of the Insurance Article, Annotated Code of Maryland, including, without limitation, Insurance Article §§ 15-1611, 15-1628, 15-1628.1, 15-1628.2, 15-1628.3, 15-1629, 15-1631, 15-1633, 15-1634, 15-1635, 15-1636, 15-1637, 15-1638, 15-1639, 15-2011, 15-2013(c), 15-2014(c), 15-2015, and 15-2016, Annotated Code of Maryland, and the corresponding regulations promulgated in connection therewith, including, without limitation, the Code of Maryland Regulations (collectively, the “**MD Laws**”), the Parties desire to mutually amend the Agreement as provided herein.

NOW THEREFORE, the Parties agree as follows:

- 1. **Incorporation**. The initial paragraph and Recitals to this Addendum are hereby incorporated herein and made a part hereof.
- 2. **Scope**. For independent pharmacies (as defined in Md. Code, Ins. § 15-2001(b)) receiving services in the State of Maryland, this Addendum modifies the Agreement with respect to the Parties’ performance and activities in accordance with certain legislative and regulatory requirements applicable to the Parties in the State of Maryland. Notwithstanding anything to the contrary contained herein or in the Agreement, in the event of any conflict between the terms of this Addendum and the Agreement, the terms of this Addendum shall control.
- 3. **Definitions**.
 - a. “**Brand Drug**” or “**Brand Name Drug**” shall be as defined in Health Occupations Article, §12-504, Annotated Code of Maryland.
 - b. “**Generic Drug**” shall be as defined in Health Occupations Article, §12-504, Annotated Code of Maryland.
 - c. “**Multisource Generic Drug**” means a generic drug as defined in Health-General Article, §21-2C-01(f), Annotated Code of Maryland, for which there is at least one other drug and does not include a Brand Name Drug.
 - d. For the purposes of this Addendum, the term “**Pharmacy(ies)**” shall include Customer and/or Customer’s pharmacies, as applicable, in the State of Maryland that satisfy the definition of “independent pharmacy” as defined in Md. Code, Ins. § 15-2001(b).
 - e. All capitalized terms contained but not otherwise defined herein shall be defined as set forth in the Agreement.

4. **Compliance.** ABDC shall comply with, and may not engage in any activity that is prohibited pursuant to, the MD Laws. To the extent that the Agreement contains any provisions, or portions thereof, in violation of the MD Laws, such provisions, or portions thereof, are deleted in their entirety. Without in any way limiting the foregoing, ABDC's obligations pursuant to the MD Laws shall include the following:
- a. Pharmacies will not be directly or indirectly charged or held responsible for a fee or performance-based reimbursement related to adjudication of a Claim or an incentive program.
 - b. ABDC may not make or allow any reduction in payment to the Pharmacies for pharmacy services or directly or indirectly reduce, or allow the reduction of, a payment to the Pharmacies for a pharmacy service under a reconciliation process to an effective rate of reimbursement, including generic effective rates, brand effective rates, direct and indirect remuneration fees, or any other reduction or aggregate reduction of payments.
 - c. Except to the extent expressly provided otherwise under the MD Laws, if a Claim has been approved through adjudication, ABDC may not retroactively deny or modify, or allow the retroactive denial or modification of, reimbursement to a Pharmacy or Pharmacy's pharmacist(s), as applicable, for the approved Claim.
 - d. Pharmacy and/or Pharmacy's pharmacist(s), as applicable, are not prohibited from providing or discussing retail prices or cost sharing with beneficiaries.
 - e. ABDC may not reimburse, or allow the reimbursement of, a covered drug in an amount that differs, including zero, based on the identity of the wholesale distributor used by a Pharmacy for acquisition of the covered drug.
 - f. Except for instances of error or fraud, ABDC may not, nor may ABDC allow a pharmacy benefits manager to, reclassify, recategorize, or recharacterize an adjudicated Claim.
 - g. Pharmacy and/or Pharmacy's pharmacists are not in any way prohibited or restricted from filing a complaint with the Maryland Insurance Commissioner.
 - h. ABDC's internal appeals procedures regarding the investigation and resolution of disputes filed against ABDC by a Pharmacy shall be as provided in the Agreement; provided, however, that such procedures shall only apply to the extent not otherwise prohibited by the MD Laws.

5. **Miscellaneous.**

- a. **Changes in Law.** This Addendum will, without the need for further action from the Parties, be deemed automatically amended to incorporate any and all changes to the MD Laws, including any additional provisions required to be included herein pursuant to the MD Laws, effectuated after the Effective Date.
- b. **Governing Law.** For independent pharmacies receiving services in the State of Maryland, each of the Agreement and this Addendum will be interpreted and governed by the laws of the State of Maryland without regard to its choice-of-law principles.
- c. **Ownership Disclosure.** Customer acknowledges that ABDC exists and functions as a fictitiously named subdivision operating under AmerisourceBergen Drug Corporation, a prescription drug, biologics, and medical device distribution company. ABDC will notify Customer within 5 days of any material change in its ownership or control as it relates to the foregoing.
- d. **Disclosure to Customer.** ABDC will provide copies of Payor Contracts, including any payment schedules or reimbursement rates applicable thereto, in addition to any amendments thereto, to Customer within five (5) business days following the execution thereof. For the avoidance of doubt, any and all Payor Contracts provided hereunder shall constitute Confidential Information and, without in any way limiting Customer's other confidentiality obligations in connection with the same, may not be disclosed to ABDC's competitors.
- e. **No Purchase Required.** Nothing in the Agreement shall in any way require Customer to purchase drugs, biologics, or medical devices from ABDC.

SOUTH CAROLINA

The South Carolina Department of Insurance requires that certain provisions in PSAO-pharmacy contracts (as defined in S.C. Code § 38-71-2310(6)) between pharmacy services administrative organizations (as defined in S.C. Code § 38-71-2310(5)) and pharmacies (as defined in S.C. Code § 38-71-2310(2)) be amended to be consistent with applicable South Carolina law. To the extent that Customer is a pharmacy or owns certain pharmacies that satisfy the definition of “pharmacy” as defined in S.C. Code § 38-71-2310(2), the following South Carolina State Addendum to the Master Agreement applies and amends the terms of the Agreement, as follows:

SOUTH CAROLINA STATE ADDENDUM TO MASTER PROGRAM AGREEMENT

This South Carolina State Addendum to Master Program Agreement (this “**Addendum**”) is incorporated in its entirety into, and made a part of, that certain Master Program Agreement, including all Term Sheets, Exhibits, Addenda, Schedules and Amendments thereto, (collectively, the “**Agreement**”) entered into by and between AmerisourceBergen Drug Corporation d/b/a Elevate Provider Network (“**ABDC**”) and Customer (as defined in the Agreement), effective as of the Effective Date (as defined in the Agreement). ABDC and Customer are also referred to in this Addendum as a “**Party**” and, collectively, the “**Parties**”.

RECITALS

- A. ABDC is a pharmacy services administrative organization and operates a network of pharmacies, including Customer, that have authorized ABDC to enter into and bind the pharmacies to certain Payor Contracts on their behalf.
- B. The Parties entered into the Agreement as of the Effective Date.
- C. Customer is a pharmacy or owns certain pharmacies that satisfy the definition of “pharmacy” as defined in S.C. Code § 38-71-2310(2).
- D. In order to comply with applicable provisions of the South Carolina Code of Laws, including, without limitation, Title 38, Chapter 71 of the South Carolina Code of Laws, including, without limitation, Insurance Article §§ 38-71-2310, 38-71-2320, 38-71-2330, 38-71-2340, and 38-71-2350, South Carolina Code of Laws, and the corresponding regulations promulgated in connection therewith, including, without limitation, the South Carolina Code of State Regulations (collectively, the “**SC Laws**”), the Parties desire to amend the Agreement as provided herein.

NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties agree to be legally bound as follows:

- 1. **Incorporation.** The initial paragraph and Recitals to this Addendum are hereby incorporated herein and made a part hereof.
- 2. **Scope.** For pharmacies (as defined in S.C. Code § 38-71-2310(2)) receiving services in the State of South Carolina, this Addendum modifies the Agreement with respect to the Parties’ performance and activities in accordance with certain legislative and regulatory requirements applicable to the Parties in the State of South Carolina. Notwithstanding anything to the contrary contained herein or in the Agreement, in the event of any conflict between the terms of this Addendum and the Agreement, the terms of this Addendum shall control.
- 3. **Definitions.**
 - a. For the purposes of this Addendum, the term “**Pharmacy(ies)**” shall include Customer and/or Customer’s pharmacies, as applicable, in the State of South Carolina that satisfy the definition of “pharmacy” as defined in S.C. Code § 38-71-2310(2).
 - b. All capitalized terms contained but not otherwise defined herein shall be defined as set forth in the Agreement.
- 4. **Compliance.** ABDC shall comply with, and may not engage in any activity that is prohibited pursuant to, the SC Laws.

5. **Miscellaneous.**

- a. **Changes in Law.** The Parties agree to take any and all actions with respect to this Addendum as may be necessary to comply with any and all changes to the SC Laws, as may be amended from time to time, including, without limitation, amending this Addendum to incorporate any additional provisions required to be included herein or amending this Addendum to amend or remove any provisions included herein required to be amended or removed.
- b. **Governing Law.** For pharmacies receiving services in the State of South Carolina, each of the Agreement and this Addendum will be interpreted and governed by the laws of the State of South Carolina without regard to its choice-of-law principles.
- c. **Ownership Disclosure.** Customer acknowledges that ABDC exists and functions as a fictitiously named subdivision operating under AmerisourceBergen Drug Corporation, a prescription drug, biologics, and medical device distribution company. ABDC will notify Customer within five (5) days of any material change in its ownership or control as it relates to the foregoing.
- d. **Disclosure to Customer.** ABDC will provide copies of Payor Contracts, including any payment schedules or reimbursement rates applicable thereto, in addition to any amendments thereto, to Customer within three (3) days following the execution thereof. For the avoidance of doubt, any and all Payor Contracts provided hereunder shall constitute Confidential Information and, without in any way limiting Customer's other confidentiality obligations in connection with the same, may not be disclosed to ABDC's competitors.
- e. **No Purchase Required.** Nothing in the Agreement shall in any way require Customer to purchase drugs, biologics, or medical devices from ABDC.

AVAILABLE PROGRAM ENROLLMENT FORM & DATA AUTHORIZATION

Eligibility for Available Programs

This Available Program Enrollment Form & Data Authorization (this “Enrollment Form”) is used to initiate the enrollment process respecting the Available Programs provided herein. Enrollment is not complete unless all requirements, including, without limitation, activation and onboarding steps, are met. Term Sheets outline applicable eligibility criteria, requirements, and prerequisites. AmerisourceBergen Drug Corporation (“ABDC”) may immediately and at any time terminate or modify, as applicable, any of Customer’s, or any of its Pharmacy’s, participation in any Available Program that includes eligibility qualifications, requirements, and/or criteria, as provided in applicable Term Sheets and/or enrollment forms, that Customer, or any of its Pharmacies, does not satisfy. Available Programs are intended for Customer’s locations operating in good standing under a distribution agreement that designates ABDC as its prime vendor.

☐ Elevate Provider NetworkSM (Term Sheet 1)

By selecting Elevate Provider Network, Customer hereby grants its authority to ABDC to serve as its contracting agent to negotiate and execute Payor Contracts on behalf of Customer, pursuant to which Customer’s pharmacy locations will be bound and comply with all such terms and conditions. Members not enrolled in the GNP Premier Program pay a monthly fee ranging from \$249 - \$575 per location, dependent upon the nature of the member’s Master Program Agreement with ABDC, as elected by the member in writing and/or otherwise confirmed by ABDC in writing, as follows: (1) *Standard*: \$249/location/month; (2) *Enhanced*: \$399/location/month; (3) *Enhanced Plus*: \$575/location/month. *See Term Sheet 1 for additional terms and conditions.*

☐ Elevate Advanced Features (Term Sheet 2 – 3)

Elevate Advanced Features is a suite of services made available by ABDC and/or certain of the Program Partners (as defined below) and designed to assist Customer with its healthcare operations, including treatment, payment, and healthcare operations activities. Fee is included for Elevate Provider Network members. Members not enrolled in the GNP Premier Program pay monthly fee of \$249. Additional fees may apply if Customer: (i) processes more than 10,000 claims in a month; (ii) uses an alternative, approved switch service provider for Elevate Advanced Features; and/or (iii) elects to receive optional and/or enhanced Elevate Advanced Features services (e.g., enhanced reporting, etc.). Excludes enrollment in patient care services solutions offerings via ABDC which require the execution of a separate enrollment form, direct agreement with the respective Program Partner, and payment of additional fees (which vary depending on the method of enrollment utilized). *See Term Sheet 2 for additional terms and conditions.*

☐ Includes PPE Solutions (Term Sheet 2A)

Powered by Change Healthcare, participation in Pre and Post Edit Solutions requires Customer to have or execute an agreement with Change Healthcare for claims switching services. *See Term Sheet 2A for additional terms and conditions.*

☐ Includes Claim Reconciliation Services (Term Sheet 2B)

Powered by EnlivenHealth, the self-service option is included; Customer may upgrade to Concierge Service directly with EnlivenHealth or use an outside reconciliation vendor at additional fees. *See Term Sheet 2B for additional terms and conditions.*

☐ Optional: Outcomes Patient Care Services (Term Sheet 2C)

Outcomes makes available its Outcomes Premium Solution offering real-time analytics and ongoing management tools designed to assist subscribing pharmacies in improving, among other things, patient health outcomes, patient adherence, and clinical service; requires separate enrollment. *See Term Sheet 2C for additional terms and conditions.*

☐ Optional: EnlivenHealth Patient Care Services (Term Sheet 2D)

EnlivenHealth makes available its Amplicare Treat Solution offering real-time analytics and ongoing management tools designed to assist subscribing pharmacies in improving, among other things, patient health outcomes, patient adherence, and clinical services; requires separate enrollment. *See Term Sheet 2D for additional terms and conditions.*

☐ Includes in InSite from ABDC (Term Sheet 3)

A proprietary data analytics system used to measure and compare pharmacy performance by organizing and analyzing Pharmacy Data (as defined below). Fee is included with Elevate Advanced Features. *See Term Sheet 3 for additional terms and conditions.*

☐ Optional: Enroll my Pharmacy (LTC NCPDP only) in InSite from ABDC (Term Sheet 3)

A proprietary data analytics system used to measure and compare pharmacy performance by organizing and analyzing Pharmacy Data (as defined below). Fee is included with Elevate Advanced Features. *See Term Sheet 3 for additional terms and conditions.*

☐ **Five-Star Rebate (Term Sheet 4)**

A PRxO Generics rebate that recognizes and rewards performance in pharmacy quality measures. In exchange, Customer provides consent to extract dispense usage data from Pharmacy Data (as defined below) and, unless restricted by Customer's designated buying group agreement (if any), share it with ABDC sales and other associates to identify missed opportunities and to assist Customer in optimizing purchase performance. Five-Star rebate is only available to retail NCPDP accounts. *See Term Sheet 4 for additional terms and conditions.*

Front-End Solution programs (Term Sheet 5)

The following interrelated programs are designed to assist Customer in promoting traditional drugstore non-prescription product categories. *See Term Sheet 5 for additional terms and conditions.* Certain services are available only to Premier and GNP Pharmacies. Please identify your selections below:

☐ **Planogram services**

Premier: Included; no additional fee
GNP: No additional fee
Other: \$55 per month (\$89 combined with Zone Pricing)

☐ **Retail Product Zone Pricing Service**

Premier: Included; no additional fee
GNP: No additional fee
Other: \$45 per month (\$89 with Planograms)

☐ **First To Shelf™ (AutoShip New OTC)**

Premier: Required; no additional fee
GNP: No additional fee
Other: Not available

☐ **Front-End Support Kit**

Premier: Optional; no additional fee
GNP: No additional fee
Other: Not available

☐ **Merchandising Services**

Premier: Included; no additional fee
GNP: Limited availability (pricing based on scope of work)
Other: Limited availability (pricing based on scope of work)

Digital Marketing programs (Term Sheet 6)

The following interrelated programs are part of an overall strategy to attract and engage patients and consumers online. *See Term Sheet 6 for additional terms and conditions.*

☐ **MyGNP Website**

Premier: Included; no additional fee
GNP: Included; no additional fee
Other: Not available

☐ **My GNP Mobile App**

Premier: Included; no additional fee
GNP: Included; no additional fee
Other: Not available

☐ **Digital and Social Media Marketing**

Premier: Included; additional fees apply to optional digital advertising services in which Customer enrolls
GNP: Not available
Other: Not available

☐ **Local Listings Management**

Premier: Included; no additional fee
GNP: Included; no additional fee
Other: Not available

Business Coaching (Term Sheet 7)

ABDC assigns a business coach to Customer who will assess the current performance and practices of Customer's pharmacy locations and recommend new practices and opportunities to improve profitability. *See Term Sheet 7 for additional terms and conditions.*

☐ **Business Coaching**

Premier: Included; no additional fee
GNP: Not available
Other: Not available

Pharmacy Data Services (Term Sheet 8)

ABDC will furnish the selected data services to Customer to assist with pharmacy computer applications, including pharmacy management and point-of sale systems. Multi-location computer systems, whether or not connected, will be charged per Pharmacy or other location. *See Term Sheet 8 for additional terms and conditions.*

☐ **Catalog & Price Update Service - OTC**

Premier: Included; no additional fee
GNP: \$55 per month
Other: \$55 per month

☐ **Catalog & Price Update Service - Rx**

Premier: Included; no additional fee
GNP: \$55 per month
Other: \$55 per month

Unsaleable Returns (Term Sheet 9)

ABDC will assist you in recovering the value of unsaleable products by providing a comprehensive solution for disposal including all processing, shipping, and destruction costs. *See Term Sheet 9 for additional terms and conditions.*

☐ Unsaleable Returns

Premier: Included; no additional fee
GNP: Included; no additional fee
Other: Not available

☐ On-Site Assistance

Premier: Included; no additional fee
GNP: Not available
Other: Not available

Additional Terms

Data Authorization Consent

These programs (“Available Programs”) are designed to aid Customer’s pharmacy locations in its treatment, payment, and healthcare operations activities. In order for ABDC and its Program Partners (as described below) to provide Customer with the Available Programs, Customer, by signing below: (i) authorizes ABDC to receive financial, operational, pharmacy, performance, business, operational, pharmacy, and patient data, including protected health information, on behalf of Customer (“Pharmacy Data”) directly from Customer or indirectly from third parties supporting or participating in the Available Programs, including without limitation Customer’s designated pharmacy system vendor, designated point-of-sale system vendor, designated reconciliation service provider, Payors (as defined under Term Sheet 1), IQVIA, InSite, IntrinsicQ Specialty Solutions, Inc., Change Healthcare (a part of Optum®) or other claims switching service provider approved by ABDC in writing, EnlivenHealth (f/k/a FDS AMPLICARE), Retail Insights and Outcomes Operating, Inc. (f/k/a/ Prescribe Wellness) or other patient services provider approved by ABDC in writing (collectively, “Program Partners”); and (ii) authorizes and directs ABDC and the Program Partners to exchange Pharmacy Data on Customer’s behalf to support Customer’s participation in the Available Programs.

This data authorization is intended to constitute Customer’s written consent under the applicable HIPAA Business Associate Agreement or similar document between Customer, ABDC and/or Program Partners for the exchange of Pharmacy Data on Customer’s behalf. ABDC’s receipt and use of Pharmacy Data is subject to the terms of the program documentation applicable to the specific Available Programs in which Customer enrolls (“Program Documentation”), such as the parties’ MPA (as defined below) and accompanying Exhibits and Term Sheets. Customer acknowledges that in conformance with the Program Documentation, ABDC associates with a need to know may access and use Pharmacy Data including protected health information to assist Customer in its treatment, payment, and healthcare operations activities. This authorization will automatically terminate thirty (30) days after Customer ceases its participation in the Available Programs.

Business Coach Data Authorization Consent

Customer will furnish certain business, operational and financial data regarding its Pharmacy location, including protected health information, (“Coaching Data”) to its Business Coaching Associate. ABDC’s receipt and use of Coaching Data is subject to the terms of the applicable Program Documentation, such as the parties’ MPA (as defined below) and accompanying Exhibits and related Term Sheets. This Coaching Data authorization is intended to constitute Customer’s written consent under the applicable HIPAA Business Associate Agreement or similar document between Customer and ABDC and/or Program Partners for the exchange of Coaching Data on Customer’s behalf. This Coaching Data authorization is in addition to and supplements Customer’s Data Authorization Consent for Pharmacy Data previously executed and provided to ABDC. Customer acknowledges that in conformance with the Program Documentation, ABDC associates with a need to know may access and use Coaching Data, including protected health information, to assist Customer in its treatment, payment, and healthcare operations activities. This authorization will automatically terminate thirty (30) days after Customer ceases its participation in the Available Programs.

Acknowledgment of Terms

Customer represents and warrants that: (i) it has executed or will execute a Master Program Agreement or GNP Premier Agreement (as applicable, the “Agreement”) with ABDC; (ii) it has the full power and authority to enter into this Enrollment Form; (iii) the individual executing this Enrollment Form on Customer’s behalf is fully authorized and empowered to legally bind Customer hereto; (iv) it has obtained any and all consents, approvals, and/or authorizations necessary to permit ABDC’s and the Program Partners’ receipt, use, disclosure, maintenance, and exchanging of Pharmacy Data as contemplated herein and the Agreement, including, without limitation, all necessary authorizations and/or consents from its customers and patients, which such activities are necessary to facilitate ABDC’s provision of services to Customer pursuant to the Agreement; and (v) Customer’s entering into this Enrollment Form does not conflict with any contract or agreement to which Customer is a party. If

Customer has not yet executed an Agreement, this Enrollment Form and related Term Sheets will become effective on the effective date of the Agreement. This Enrollment Form is incorporated into, and made a part of, the Agreement and is binding upon the parties. Capitalized terms used but not separately defined herein shall have the same meaning as provided in the Agreement.

PHARMACY

NCPDP ID: _____

D/B/A: _____

Address: _____

Customer

By: _____

Name: _____

Title: _____

Date Signed: _____



Fax completed form to 877-687-8699

or, email to

or, mail to AmerisourceBergen Drug Corporation • 1 West First Avenue, Conshohocken, PA 19428

**Elevate Provider NetworkSM
Term Sheet**

All other terms and conditions of the Master Program Agreement, including all Exhibits thereto, are hereby incorporated by reference into this Term Sheet. Certain capitalized words applicable to the Elevate Network (as defined below) are defined at the end of this Term Sheet. Capitalized words not herein defined have the meaning set forth in the Master Program Agreement and Exhibits thereto.

1. Program Description

a) Negotiated Payor Contracts and Central Pay. On behalf of Network Providers that join the Elevate Provider Network (“Elevate Network”), ABDC negotiates and enters into written agreements with Payors (“Payor Contracts”). By entering into the Elevate Network as a Network Provider, Customer hereby authorizes ABDC to negotiate and enter into Payor Contracts with Payors on behalf of Network Provider, and Network Provider agrees to be bound by such Payor Contracts. Payor Contracts encompass a variety of areas, including, but not limited to, pharmaceutical-product and/or clinical service reimbursement rates that may be tied to an individual Network Provider, one (1) or more pharmacists affiliated with and/or performing on behalf of a Network Provider, or Elevate Network-wide aggregate performance metrics (such as STAR quality measures) or financial metrics (such as network-wide aggregate brand or generic effective rates), for Network Providers to provide Covered Services to Members. Most Payors pay Network Providers for Covered Services through Central Pay.

b) Elevate Advanced Features. Network Providers will be concurrently enrolled in the Elevate Advanced Features (Term Sheet 2) which requires Network Providers to utilize Claims switch services provided by Change Healthcare (a part of Optum® and hereinafter, “Change Healthcare”) or other Claims switch service provider approved by ABDC in writing. Network Providers may request to opt out of Elevate Advanced Features, which Elevate Network may, in its sole discretion, allow without reduction in the monthly fee. Please see the Term Sheets specific to the Elevate Advanced Features for program descriptions and terms and conditions.

2. Pricing and Availability

Participation fees respecting this Available Program vary dependent upon the nature of Customer’s Master Program Agreement with ABDC, as elected by Customer and/or otherwise confirmed by ABDC in writing, as follows:

Standard

Premier: Required; no additional fee
GNP: \$249/month (incl. Elevate Advanced Features)
Other: \$249/month (incl. Elevate Advanced Features)

Enhanced

GNP: \$399/month (incl. Elevate Advanced Features)
Other: \$399/month (incl. Elevate Advanced Features)

Enhanced Plus

GNP: \$575/month (incl. Elevate Advanced Features)

Other: \$575/month (incl. Elevate Advanced Features)

**Additional fees may apply for Network Providers that: (i) process more than 10,000 Claims in a month; (ii) use alternative, approved switch service providers for Elevate Advanced Features; and/or (iii) elect to receive optional and/or enhanced Elevate Advanced Features services (e.g., enhanced reporting, etc.).*

3. ABDC Responsibilities

a) Payor Contracts. ABDC enters into Payor Contracts on behalf of participating Network Providers for Payor Contract participation and arranges for payment of Claims through Central Pay. Payor Contracts, take effect for each applicable Network Provider as Payors recognize its participation. ABDC makes no representation or warranty, including any implied warranty, about Payors, financial viability of individual rates or networks, or applicability of any particular Payor Contract to any particular Network Provider, and ABDC assumes no fiscal responsibility for any Claims. ABDC is not a surety or guarantor for Claim payment; nor is ABDC a fiduciary beyond what has been expressly granted in Section 4 (a). In no event shall ABDC be obligated to pay Customer for any services rendered by each Network Provider if ABDC has not received monies from Payor with respect to the Network Provider that is sufficient to pay for such services.

b) Help Desk and Other Services. ABDC provides help desk service during normal business hours, publishes newsletters, provides certain other Claims-related assistance, and provides or makes available other offerings, which may be subject to additional terms and conditions, in connection with Network Providers’ participation in the Elevate Network, including an online portal through which Network Providers may access certain information relating to Elevate Network participation.

c) Disputes. Nominal fees paid by Network Providers are for simplified access to Payor Contracts through the Elevate Network. Fees are not sufficient, nor does this Available Program have resources, to resolve reimbursement, payment, audit and other disputes arising among Customer, its Network Providers, Payors and/or others, including current or Former Participants and other network providers. Customer will comply with each Payor’s respective dispute resolution processes, including Network Provider rights and obligations in connection therewith, as provided in the applicable Elevate Documents. As a courtesy, ABDC may assist with initial investigations of such disputes to clarify their nature and attempt prompt resolution. Customer authorizes ABDC to provide information related to such disputes to Payors, including invoices from ABDC’s records and supporting material provided by Customer, and to receive information and documents related to disputes from Payors.

d) Promote Elevate Network. ABDC promotes the Elevate Network to Payors, including reporting to Payors specific capabilities, services and accreditations of individual Network Providers.

e) Central Pay. ABDC makes EFT deposits to Customer's account(s) after ABDC matches payment received from a Payor on Customer's Network Provider(s)' behalf with corresponding electronic EOBs, less fees and any other charges, withholds, or offsets imposed under the Agreement. For Network Providers in good standing with ABDC and Payors, ABDC makes commercially reasonable efforts to wire bank instructions within one (1) business day after receiving funds and matching EOBs. Notwithstanding the foregoing, ABDC may reduce the frequency of payments made to Former Participants and/or Network Providers that are not in good standing with ABDC and/or Payors, including without limitation, using commercially reasonable efforts to wire bank instructions within one (1) week after receiving funds and matching EOBs.

f) Central Pay System. ABDC makes available a web-based portal with defined security protocols, for Customer to access, print and download EOBs, including Claim, payment and deposit detail for up to the prior thirty-six (36) months by Network Provider. Network Providers may also receive Claim reimbursement information via email or fax. Former Participants will lose access to Central Pay twelve (12) months after the last payment is received by a Payor.

g) Outside Reconciliation Vendors. As an alternative to the reconciliation services included under Elevate Advanced Features, ABDC collaborates with other pharmacy system and reconciliation service providers that meet ABDC's specifications ("Outside Reconciliation Vendors") and provides automated EOBs to Network Provider's Outside Reconciliation Vendor or for direct import into Network Provider's pharmacy system (not widely available). ABDC charges each Network Provider or its Outside Reconciliation Vendor an additional monthly fee, which such fee can be confirmed by ABDC upon written request, to provide automated EOBs.

4. Customer Responsibilities

a) Grant Authorization to ABDC. By enrolling in this Available Program, Customer represents and warrants that it has: (i) executed a Master Program Agreement with ABDC; and (ii) the legal authority to enter into the Master Program Agreement and all related Term Sheets for each Network Provider. Customer hereby grants its authority to ABDC: (1) to serve as its contracting agent to negotiate and execute Payor Contracts on behalf of Network Provider(s) pursuant to which Network Provider(s) will be bound and comply with all such terms and conditions; (2) to collect and receive on Network Provider's behalf, accounts receivable generated by billings and Claims for reimbursement; and (3) to deposit into ABDC's Central Pay account any remuneration provided under or in connection with Payor Contracts on behalf of Network Provider(s).

b) Acceptable Star Ratings. Certain Payors may use aggregate performance network-wide Star ratings as determinants in reimbursement formulas. Network Provider(s) must use

reasonable efforts to achieve and retain an average star rating of 3.0 or higher.

c) Licensing, Training & Elevate Documents. Each Network Provider will comply with the Elevate Documents and with this Term Sheet. Elevate Documents and updates may be published on one or more web-based portals maintained by ABDC or Payors. Upon request, and upon Network Provider's execution of a non-disclosure form, ABDC will provide current copies of Elevate Documents applicable to Network Provider's participation hereunder, including applicable Payor Contracts, or direct Network Provider to online resources. As part of its applicable obligations required to remain in good standing: (i) each Network Provider, its pharmacists, and other employees will maintain and keep current all applicable licenses, authorizations, approvals, permits, certifications, and training necessary to provide Covered Services, including, without limitation, unrestricted licensure, accreditation, and/or certification from the U.S. Drug Enforcement Agency, each applicable board of pharmacy, and as otherwise required under Payor Contracts; (ii) Customer will: (1) maintain and timely update any and all such information in Network Provider's NCPDP profile; and (2) timely provide evidence of any of the foregoing to ABDC or Payors upon request; and (iii) respecting specialized Covered Services, such as long-term care, compounding, home infusion, mail order, specialty drug or immunization, and/or other clinical services permitted by law, each Network Provider and its employees, including, without limitation, any pharmacist(s) affiliated with and/or performing on behalf of Network Provider, must: (1) meet applicable licensing, accreditation, certification, training and other requirements; and (2) otherwise comply with applicable laws and obligations under the Elevate Documents.

d) Enrollment. Where Payor Contract enrollment requires additional materials to be submitted, Customer will promptly and accurately complete enrollment materials, initiate access for each authorized user, prevent disclosure or misuse of passwords, and promptly validate receipt of test deposits to its account for each Network Provider. Customer will promptly update such information on request and upon changes in Network Provider's ownership, licensing, disciplinary history, banking, payment instructions, or other information provided in enrollment materials and updates and otherwise comply with Program Guides. Not all Payors use Central Pay, and some require separate enrollment materials.

e) Outside Reconciliation Services. By directing ABDC to provide EOBs to its Outside Reconciliation Vendor, Customer authorizes ABDC as its business associate to provide protected health information and other Pharmacy Data and warrants to ABDC that it has all required agreements in effect for each Network Provider, including business associate agreements. Customer will promptly notify ABDC if any such agreement terminates so ABDC discontinues disclosure. Except as otherwise agreed upon by and between Customer and ABDC in writing, Outside Reconciliation Vendors are solely responsible for determining applicable pricing and features, which Customer must determine are compatible with its systems.

f) Dispute Liability. While ABDC may provide courtesy assistance with disputes under Paragraph 3(c), each Network Provider is solely responsible for its relationships with Payors,

including responding to, defending and resolving any and all Payor disputes, whether relating to matters respecting payment or otherwise, including paying applicable legal expenses and any amounts owed as a result of a dispute. Customer must comply with applicable notice requirements in connection with Payor disputes as provided in Section 8 herein. Any such dispute notice shall include, without limitation, a description of the nature and extent of the dispute.

g) Central Payments and Offsets. As part of its applicable obligations required to remain in good standing, Customer agrees to not incur a negative balance in its Central Pay account with Elevate Network. Customer acknowledges and agrees that ABDC may withhold, delay, or offset Central Pay amounts owed to Network Provider(s) in the event of an audit, investigation, network and individual obligations related to Payor Contracts, or other disputed amount between the Payor and a Network Provider. Customer agrees to reimburse ABDC in full and to indemnify ABDC for any offset taken by a Payor against a Network Provider. In addition, ABDC may, in advance, reduce, delay, or offset any payments to a Network Provider, including without limitation payments from another Payor, if in ABDC's reasonable determination an anticipated offset by a Payor may result in a negative balance for such Network Provider. In such a case, Customer expressly authorizes ABDC, at its discretion and based on its best judgement and information, to withhold an amount of funds which may be at issue between Network Provider and Payor. If Customer incurs a negative balance under Central Pay, ABDC may, at its option: (i) withhold funds from future payments until such time as such Network Provider's balance under Central Pay is zero dollars or above, (ii) debit Network Provider's bank account for the negative amount, or (iii) invoice Network Provider for such negative amount, which sum will be due and payable with five (5) days following Network Provider's receipt of invoice. Finally, without limiting ABDC's other legal rights, ABDC and its affiliates may withhold, delay or setoff Central Pay amounts owed to Network Provider, or take any other lawful actions, to: (x) recover any amount (including, but not limited to, principal, interest, costs, and reasonable attorneys' fees) owed by Customer to ABDC or its affiliates under this or any other agreement, including but not limited to a distribution agreement, credit agreement, and/or any other master program agreement between Customer and ABDC's affiliates; and/or (y) satisfy, or remit payment towards the satisfaction of, any amount (including, but not limited to, principal, interest, costs, and reasonable attorneys' fees) owed by Customer to a third party creditor (e.g., Internal Revenue Service, etc.) pursuant to which ABDC becomes legally obligated to remit such Central Pay amounts otherwise owed to Network Provider. Any forbearance or delay in the exercise of any right or remedy hereunder or as otherwise afforded by law will not be a waiver of or preclude the exercise of any such right or remedy.

h) Network-wide Aggregate Performance Payor Contracts. Customer acknowledges that reimbursement rates can be tied to individual and network-wide performance or financial metrics (such as brand and/or generic effective rates) that may result in periodic or post-year-end recoupments from Network Provider(s) to meet individual or aggregate network-wide financial obligations under certain Payor Contracts.

Accordingly, if a Network Provider's performance under a network-wide Payor Contract has a materially adverse impact on the Elevate Network as a whole, Elevate may either initiate holds as outlined above to mitigate the adverse impact or seek to de-affiliate Network Provider from the Payor Contract or the Elevate Network as a whole. Network Providers that terminate prior to the end of the calendar year will be reconciled by ABDC pursuant to Section 10(c) below.

i) Elevate Network Goodwill. Because operation and appearance of each Network Provider reflects on other network providers and the Elevate Network, Customer will use its best efforts to operate each Network Provider with diligence and vigor, maintain the highest possible ethics, and maintain its facilities and personnel in a manner that is a credit to the community and reflects the high standards and quality of the Elevate Network, including, without limitation, interacting with and treating all customers and ABDC personnel in a respectful and professional manner.

j) Exclusivity; Payor Contracts. By enrolling as a Network Provider, Customer authorizes ABDC to be Network Provider(s)'s exclusive contracting entity for Payor Contracts and Central Pay for such Network Provider. A Network Provider may contract directly with certain Payors but ABDC may terminate this Term Sheet if an enrolled Network Provider designates another pharmacy services administration organization (PSAO) or other party as a contracting entity for Payor Contracts and Central Pay without ABDC's prior written approval, with termination effective at the earlier of the date such designation is effective or thirty (30) days after ABDC's termination notice under this Paragraph 4(j).

k) Covered Services. Network Provider must provide Covered Services to all Members in accordance with the Elevate Documents and applicable laws.

l) Accept Payor Reimbursements. Customer authorizes ABDC to receive payment and EOBs from Payors for each Network Provider and make deposits to Customer's account(s) and initiate adjustments for entries as determined by ABDC or a Payor through a Network Provider audit or for obligations related to Payor Contracts, as determined by ABDC or a Payor in accordance with a Payor Contract. Customer will accept negotiated compensation, inclusive of copayments and charges, as full payment for Network Provider providing Covered Services.

m) Protect Confidential Information. Customer must protect all Confidential Information of ABDC and Payors, including methods of doing business, any information related to performance under Elevate Documents, and any lists of customers, clients, Payors, claim processors or other network providers, as required pursuant to Paragraph 7 of this Term Sheet, Paragraph 4.0 of Exhibit C (Provisions) and the Elevate Documents, and Customer may only use and disclose such Confidential Information as expressly permitted by the Elevate Documents. Except as expressly permitted by the Elevate Documents, Customer may not use or disclose any such Confidential Information for its own benefit, for the benefit of any other party, or for any other reason without ABDC's and/or Payors' prior written consent, as applicable.

n) Insurance Coverage. Customer will for each Network Provider maintain and provide evidence of commercial general

liability insurance and professional liability insurance (including druggist's liability coverage) with limits of at least \$1,000,000 per incident and \$3,000,000 annual aggregate (or such higher limits as ABDC may reasonably require) for claims arising out of bodily injury, property damage, personal injury, advertising injury, and Covered Services, as well as such other insurance as required by Payors or applicable law. Such insurance will be underwritten on an "occurrence" basis covering activities, acts and omissions of Network Provider(s) and its personnel and will include ABDC and its corporate affiliates as additional insured. During the Term, such insurance will be evidenced by a certificate of insurance that provides ABDC with at least thirty (30) days' written notice of cancellation, non-renewal or material change. Customer will:

(i) provide ABDC, or any Payor upon such Payor's request, with a copy(ies) of such policy(ies) and each renewal prior to expiration; and (ii) as part of its applicable obligations required to maintain in good standing, maintain and timely update such information in Network Provider's NCPDP profile. Any pharmacist or other healthcare professional providing Covered Services who is not separately insured by policies with similar coverage and limits must be covered on Network Provider's insurance. Lower limits in any Payor Contract or related material do not override coverage limits in this Paragraph 4(n).

o) EEO Requirements. Customer warrants that it's Network Provider(s) does not and will not discriminate against any employee or applicant for employment because of race, creed, color, national origin, religion, gender, sexual orientation or preference, veteran status, handicap or as otherwise prohibited by law and will meet affirmative action obligations imposed by law.

p) Compliance with Distribution Agreement. Participation as a Network Provider is intended for Customers operating under a distribution agreement with ABDC naming ABDC as Network Provider's primary vendor of pharmaceutical products. Customer must be in compliance with the terms of its distribution agreement or Network Provider(s)'s participation in Elevate Network may be revoked.

q) Maintenance of NCPDP Profile; NPI Registry. As part of its applicable obligations required to remain in good standing, Customer will maintain and timely update: (i) each Network Provider's National Council for Prescription Drug Programs ("NCPDP") Service Provider Profile, Parts I and Parts II (as applicable per NCPDP); and (ii) the national provider identifier ("NPI") and corresponding National Plan and Provider Enumeration System ("NPES") registry information associated with each pharmacist that is affiliated with Network Provider and provides Covered Services comprising clinical services in connection with applicable Payor Contract participation, in each case as required by applicable law, ABDC, Payors, and the Elevate Documents.

5. Changes to Elevate Documents

a) Terms. Customer's Network Provider(s) will comply with Elevate Documents which ABDC or a Payor may, as applicable, amend as it determines is appropriate in its sole discretion. As applicable, ABDC or the Payor will give Customer notice of material changes and an opportunity to accept such new provisions or to withdraw from the affected Elevate Document (to the extent permitted) or the Elevate

Network. Elevate Documents and this Term Sheet are the entire agreement related to Customer's and its Network Provider's participation in the Elevate Network.

b) Conflicts, Superiority. For any conflict between this Term Sheet and any Elevate Document, the order of precedence (with the first being controlling) is: (i) the Elevate Documents comprising Payor materials; (ii) all other Elevate Documents; and (iii) this Term Sheet, unless specifically stated otherwise that this Term Sheet supersedes such conflict.

6. Payor Contract Obligations. Customer's obligations respecting Payor Contracts include but are not limited to the following:

a) Maintain Records. Customer will maintain for each Network Provider all records and other information required by law and the Elevate Documents. Without limiting the preceding sentence, Customer will maintain for each Network Provider adequate records and other information related to Covered Services provided to Members for seven (7) years or any longer period required by law or Elevate Documents.

b) Confidentiality. Customer and ABDC will each: (i) safeguard confidentiality of Member health records as required by the Agreement, Payor Contracts, and applicable law; and (ii) ensure that any subcontractors do so as required. Customer will ensure that each Network Provider complies with all applicable confidentiality requirements. As required, ABDC and Customer entered into a HIPAA Business Associate Agreement (Exhibit B or as otherwise agreed).

c) Access to Records. To the extent permitted by the respective Payor Contract or other Elevate Document, Payors may examine and audit Network Provider's records and other information that relates to Network Provider's participation in the Elevate Network.

d) General Compliance. Without in any way limiting Customer's obligations as otherwise provided herein, Customer shall comply with any and all Payor Contract requirements, including, without limitation, requirements respecting insurance and credentialing as provided in this Term Sheet and the Elevate Documents.

7. Use of Information

a) Ownership of Confidential Information. As among Customer, ABDC and Payors, each party is the sole owner of its Confidential Information.

b) Use of Certain Data. Payors provide performance data for Covered Services, for both the Elevate Network in its entirety and individual Network Providers, to ABDC. Such information is Confidential Information that may be used and disclosed by ABDC if it safeguards confidentiality of Member health records.

c) Marketing and Benefit Information. ABDC and Payors may use, disclose, and reproduce each Network Provider's name, address, trademarks, logos, and other contact information in communications related to available benefits and information about Covered Services for Members. Customer may only refer to or list ABDC, Elevate Network, or Payors in advertising, media announcements or promotional or other material in compliance with this Term Sheet and Elevate Documents.

Customer will promptly discontinue any such use if ABDC notifies Customer it is disapproved.

d) Pharmacy Data Authorization. Without in any way limiting, and in accordance with, Exhibit A of the Agreement: (i) Customer understands, acknowledges, and agrees that: (1) ABDC may receive and retain Pharmacy Data (including, without limitation, Claims and payment detail received from Payors) in the InSite pharmacy performance management system from ABDC for all Network Providers; and (2) de-identified data may be disclosed to third parties if Network Provider(s) is unidentifiable as its source; and (ii) Customer authorizes: (1) ABDC to receive Pharmacy Data from Payors and other Program Partners for each Network Provider, and to use, disclose, and exchange such Pharmacy Data to and among Payors and other Program Partners in connection with Payor Contract activities; (2) access to and use of Pharmacy Data by ABDC and its managed care specialists in order to assist Customer, file a MAC price appeal with a Payor, measure Payor and Network Provider compliance and performance, improve negotiations and assist and promote Network Providers with Payors; (3) ABDC, as its business associate, to combine Pharmacy Data with similar data received as a business associate of multiple covered entities, and to use such cumulative data to prepare reports, analyses and compilations relating to business performance and market trends to benchmark Customer and other covered entities against peer groups to improve all parties' overall efficiency and performance of healthcare operations.

e) EQUIPP® Data Authorization. Customer authorizes ABDC to receive EQUIPP performance data from Pharmacy Quality Solutions, Inc. and to share the findings with members of ABDC's sales force and Customer's buying group (if any).

8. General

a) Independent Parties. Pursuant to Paragraph 8.5 of Exhibit C (Provisions), Network Provider, ABDC and each Payor are independent contractors. Customer is solely responsible for operating and maintaining its Network Provider's facilities, equipment and software and for providing Covered Services to Members. All medical, clinical and related decisions with respect to Covered Services are made solely by Customer and its personnel and not by ABDC or others. The relationship between a Member and Network Provider is subject to all requirements and privileges of the pharmacist-patient relationship.

b) Adverse Actions. In addition to fraud, waste and abuse or other periodic compliance attestations and any reporting obligations under Elevate Documents, Customer must immediately notify ABDC, via email at Elevate_audits@amerisourcebergen.com, if: (i) Customer or Network Provider initiates, anticipates, or otherwise becomes subject to an appeal, dispute, or other legal process, including, without limitation, state or federal governmental investigation, arbitration, or other legal action, involving a Payor or otherwise relating to participation in an Available Program, or otherwise is or becomes obligated to produce documents, testimony, and/or information in connection therewith, whether pursuant to a subpoena, state or federal governmental demand (e.g., civil

investigative demand, etc.), or otherwise; (ii) its Network Provider's pharmacy license is suspended, challenged, or otherwise threatened; (iii) any action or restriction, such as actions or restrictions implemented by governmental agencies, bodies or other instrumentalities (e.g., law enforcement seizure, etc.), may affect Network Provider(s)' ability to meet its obligations, such as those required by a Payor, licensing agency (board of pharmacy, DEA, etc.), or other regulatory body; (iv) it or any owner, Network Provider, or employee is or becomes an excluded entity or individual on an HHS-OIG or comparable federal or state list(s) for Medicare, Medicaid, General Services Administration (GSA) System for Award Management (SAM) and other healthcare services; or (v) any other occurrence may adversely impact Network Provider's participation under a Payor Contract or ability to perform its obligations and/or otherwise comply with the Elevate Documents (collectively, "**Adverse Actions**"). Without limiting the foregoing, Customer must also comply with any separate reporting obligations required of Network Providers by Payors with respect to Adverse Actions or other events as provided in the Elevate Documents.

9. Termination

a) Termination. In addition to termination without cause under the Agreement, the parties may terminate for cause pursuant to Paragraph 4(h) of this Term Sheet or Paragraph 5.0 of Exhibit C (Provisions). Additionally, ABDC may terminate for cause upon written notice to Customer if Customer or its Network Provider(s) fails to perform, in any material respect, its obligations under Elevate Documents and its failure is not cured within 30 days (or any shorter cure period in a Payor Contract or related material). Such notice will describe the nature of the failure and action required to cure the default, if a cure is possible. ABDC may immediately and in its sole discretion terminate a Payor Contract with respect to a Network Provider upon notice to Network Provider(s) ("De-Affiliation"). Upon Network Provider's De-Affiliation from a particular Payor Contract, such Network Provider will no longer receive Central Payments from that Payor and will need to contract directly with such Payor to remain in the Payor's network.

b) Immediate Termination. Notwithstanding anything to the contrary contained herein, ABDC or a Payor may terminate an Elevate Document immediately with respect to a Network Provider, and ABDC may terminate this Term Sheet immediately, without advanced notice, if Network Provider: (i) provides a product or service to any Member that is contaminated, adulterated or does not otherwise meet legal or professional standards; (ii) violates any federal, state or local law applicable to compounding, sale, dispensing, storage, packaging or use of products or services to Members; (iii) cannot provide Covered Services due to an Adverse Action or otherwise; (iv) commits an act or omission that gives a Payor the right to immediately terminate Network Provider from a Payor Contract as determined by the Elevate Documents; or (v) incurs a negative balance in its Central Pay account with Elevate Network.

c) Effect. Termination of this Term Sheet in its entirety by ABDC will terminate Network Provider as to all Payor Contracts. Termination by ABDC or a Payor of one or more

Network Providers will not cause termination of other Network Providers. Termination by one Payor of a Network Provider will not result in termination of other Payors as to that Network Provider. Termination of this Term Sheet or a Payor Contract with respect to either a Network Provider or a Former Participant for any reason shall not affect the rights and obligations of the Payor, Network Provider, and/or Former Participant arising out of any transactions occurring prior to the effective date of such termination. In the event a Network Provider and/or Former Participant(s) has incurred financial obligations to a Payor under a Payor Contract, such Network Provider and/or Former Participant acknowledges and agrees that such applicable Payor is permitted to deduct such financial obligations from its then current financial obligations to such Former Participant or Network Provider.

10. Termination Obligations

a) Withholding for Payor Obligations. Upon notice of termination to a Network Provider of this Term Sheet for any reason, ABDC will withhold: (i) a security deposit of \$10,000 or 10% of such Network Provider's prior 12-month average deposits, whichever is greater ("Security Deposit"), to cover typical post-termination Payor adjustments and obligations; and (ii) any amounts necessary to satisfy Former Participant's reasonably anticipated or then outstanding liabilities to ABDC or a Payor under Paragraphs 4(g), (h) and (l) (e.g., audit, Claim reversals, BER, GER, and/or DIR, etc.) based on best available data.

b) Post-Termination Deposits and Security Deposits.

Notwithstanding Paragraph 5.2 of Exhibit C (Provisions), ABDC will make EFT deposits under Paragraph 3(e) to Former Participant to extent that the net balance exceeds its Security Deposit and any amounts withheld under Paragraphs 4(g), (h), (l), and 10(a)(2). ABDC may charge Former Participant a nominal processing fee for each deposit after termination.

Subject to reduction or delay under this Paragraph 10(b) or Paragraphs 4(g), (h), and (l), ABDC will pay Former Participant any remaining Security Deposit once there has been no account activity for 120 days, and any outstanding obligations have been satisfied, or invoice Former Participant any negative amount, which Former Participant shall promptly pay. Any new Payor activity post termination will restart the 120-day time period. By way of example, if there is Payor activity at day 119 following Former Participant's termination from the Elevate Network, the 120-day clock will begin again, and will continue to be reset each time there is new Payor activity. Notwithstanding anything herein to the contrary, in ABDC's discretion, at the end of the initial 120 days, ABDC may evaluate the account's activity and reduce some or all of Former Participant's Security Deposit.

c) Reconciliation of Aggregate Network-Wide Performance Payor Contracts. The amount owed by Former Participant shall be determined by ABDC based on data provided to ABDC by the applicable Payor(s). ABDC's resulting calculation shall constitute the final allocation of financial liabilities owed by such Former Participant to a Payor under such Payor Contract for the applicable time period.

ABDC has the discretion to initiate a final allocation of all Former Participant's liabilities owed to a Payor under an aggregate network-wide performance Payor Contract.

The financial liabilities owed by a Former Participant to a Payor may be recouped by ABDC through: (i) withholding funds under Section 4(g) or Section 10; (ii) invoicing a Former Participant; and/or (iii) permitting the direct recoupment by a Payor from the Former Participant's then current payments.

Upon ABDC's final allocation to a Former Participant, in the event that any previously withheld funds under Section 10(a)(ii) exceed the amount of ABDC's final allocation of financial liabilities and all other liabilities owed, ABDC will release any excess funds to Former Participant.

Remainder of page left intentionally blank

11. Definitions

a) **Central Pay** is the centralized payment system implemented by Elevate Network to receive, on behalf of Network Providers, funds from or on behalf of Payors.

b) **Covered Service** is a Network Provider's (i) dispensing of a covered drug or device to a Member under a Payor Contract, pursuant to a prescription when required by law; and/or (ii) providing of such other covered services and/or benefits under a Payor Contract (e.g., clinical services, etc.) in accordance with applicable law, in each case pursuant to Elevate Documents and for which Customer accepts Payor's compensation and any cost share amount as full payment.

c) **Claim** is a Network Provider's claim to be paid for providing a Covered Service to a Member.

d) **Elevate Documents** means the Master Program Agreement and related Exhibits, and Program Guides, Payor Contracts and related material, including Payors' provider manuals and Provider Plan Specifications.

e) **EOBs** mean explanation of benefits/remittance advice, 835 file or other electronic remittance advice.

f) **Former Participant** is a former Network Provider of the Elevate Network.

g) **Member** is an eligible person covered by Provider Plan Specifications, including primary beneficiaries and, if permitted, their eligible and enrolled dependents.

h) **Network Provider** means, as applicable: (i) Customer's Pharmacy(ies) and other dispensing site(s), as identified by NCPDP number; and/or (ii) those pharmacist(s), as identified by NPI number, affiliated with Customer's Pharmacy(ies) that provide(s) Covered Services comprising reimbursable clinical services in connection with participation in applicable Payor Contracts.

i) **Payor** is an entity that has entered or will enter into a Payor Contract with ABDC in connection with applicable Covered Services to be provided by participating Network Providers thereunder, including: (i) a pharmacy benefit manager, health plan, or other third party that sponsors or administers prescription drug programs, health benefit plans, clinical services plans or programs, and/or is primarily responsible for processing and paying Claims; (ii) a prescription drug discount company; and/or (iii) a workers' compensation processing company. From time to time under one or more Elevate Document, ABDC may also be a Payor that contracts with Network Providers as part of providing its pharmacy benefit plan administration services.

j) **Provider Plan Specifications** are written descriptions of a Payor's pharmacy benefit plan describing Covered Services, coverage exclusions, service limits and other requirements. ABDC or a Payor may add new Provider Plan Specifications or amend existing ones on 30 calendar days' notice to Customer or such other period specified in a Payor Contract.



Elevate Advanced Features Term Sheet

1. Program Description

Elevate Advanced Features is a suite of services designed to assist Customer with its healthcare operations including treatment, payment, and healthcare operations activities. In order for ABDC and its Program Partners (as defined below) to provide Customer with the services under this Term Sheet, Customer must authorize ABDC to receive Customer's Pharmacy Data directly from Customer or indirectly from third parties supporting or participating in the Available Programs, including, without limitation, Customer's designated pharmacy system vendor, Customer's designated point-of-sale system vendor, Customer's designated reconciliation service provider, Change Healthcare (a part of Optum®, "Change Healthcare"), or other claims switching services provider approved by ABDC in writing, Payors, Intrinsic Specialty Solutions, Inc., EnlivenHealth, IQVIA, InSite, Retail Insights and Outcomes Operating, Inc. (formerly known as Prescribe Wellness, "Outcomes") or other patient services provider approved by ABDC in writing (collectively, "**Program Partners**"). ABDC reserves the right to change Program Partners at any time.

2. Pricing

Premier: Included; no additional fee.

GNP: \$249/month or included under Elevate Provider Network.

Other: \$249/month or included under Elevate Provider Network.

Additional fees may apply for Network Providers that: (i) process more than 10,000 claims in a month; (ii) use alternative, approved switch service providers for Elevate Advanced Features; and/or (iii) elect to receive optional and/or enhanced Elevate Advanced Features services (e.g., enhanced reporting, etc.).

3. Program Prerequisites

a) Claims Switching. ABDC's current Program Partner for claims switching services is Change Healthcare. Unless otherwise approved in advance and in writing by ABDC, Customer's Network Provider(s) must utilize Change Healthcare as its claims switching services provider and is responsible for claim switching service fees from Change Healthcare or other approved claim switching services provider (or indirectly through its participating system vendor). Notwithstanding anything to the contrary contained herein, if ABDC approves Customer's use of an alternative claims switching services provider, such approved alternative vendor shall constitute ABDC's respective Program Partner for the purposes of Customer's provision of Pharmacy Data and participation in applicable Available Programs. Claim switching service fees are not included as a part of this Available Program.

b) System Vendor Collaboration. Customer's Network Provider(s) designated pharmacy system vendor and designated point-of-sale system vendor must be

participating system vendors with ABDC and must collaborate with ABDC and ABDC's Program Partners.

c) Customer System Configuration. Customer must cooperate with its participating system vendor and ABDC's Program Partners to initiate and maintain the configuration changes necessary to meet applicable Available Program requirements.

d) HIPAA Compliance. As required, ABDC and Customer have entered into a HIPAA Business Associate Agreement (Exhibit B or as otherwise agreed).

4. Data Authorization

a) Authorization to Receive Pharmacy Data. Customer authorizes ABDC to receive Pharmacy Data provided by or on behalf of Customer either directly from Customer or indirectly from the Program Partners.

b) Authorization and Direction to Exchange Data. Customer authorizes and directs ABDC and the Program Partners to use and exchange Pharmacy Data on Customer's behalf to support Customer's participation in the Available Programs.

c) Written Consent. Enrolling in and activating the Available Program services constitutes Customer's written consent under the applicable HIPAA Business Associate Agreement or similar document between Customer, ABDC and/or Program Partners and participating system vendors for the use and exchange of Pharmacy Data on Customer's behalf.

d) Receipt and Use of Pharmacy Data. ABDC's receipt and use of Pharmacy Data is subject to the terms of the program documentation applicable to the specific Available Programs in which Customer enrolls (collectively, "**Program Documentation**"), such as the parties' Master Program Agreement and accompanying Data Protection Provisions, HIPAA Business Associate Agreement and Term Sheets. Customer acknowledges that in conformance with the Program Documentation, ABDC associates with a need to know may access and use Pharmacy Data including protected health information to assist Customer in its treatment, payment, and healthcare operations activities. This authorization will automatically terminate thirty (30) days after Customer's Network Provider(s) cease its participation in the Available Programs.

5. Advanced Features Description

a) PPE and Data Capture Services from Change Healthcare. ABDC works with Change Healthcare to enhance and extend its pre and post edit services with custom edits. Claim transactions are captured and furnished to ABDC. In addition, Change Healthcare makes portions of the solutions accessible through a web-based portal and offers optional services such as payer compliance re-billing and electronic medical claims billing for immunization services. See Term Sheet 2A.

b) Claim Reconciliation Services from EnlivenHealth. ABDC works with EnlivenHealth to provide claims reconciliation and related services through a web-based portal to track and resolve the accurate payment of third-party claims. See Term Sheet 2B.

c) Outcomes Premium from Outcomes. ABDC works with Outcomes to provide an optional, web-based patient care services solution offering real-time analytics and ongoing management tools designed to assist subscribing pharmacies in improving, among other things, patient health outcomes, patient adherence, and clinical services. See Term Sheet 2C.

d) EnlivenHealth Tools and Treat Solution. ABDC works with EnlivenHealth to provide a web-based tool providing consolidated information relating to the practice of pharmacy and an optional, web-based patient care services solution designed to assist subscribing pharmacies in improving, among other things, patient health outcomes and offering new patient care services. See Term Sheet 2D.

e) InSite from ABDC. Pharmacy Data received by or on behalf of Customer is loaded to InSite from ABDC, a proprietary data analytics system used to measure and compare pharmacy performance. See Term Sheet 3.

All other terms and conditions of the Master Program Agreement, including all Exhibits thereto, are hereby incorporated by reference into this Term Sheet. Capitalized words not defined in this Term Sheet have the meaning defined in the Master Program Agreement or Elevate Provider Network Term Sheet, as applicable.



PPE Solutions Term Sheet

1. Program Description

ABDC has been appointed as a reseller of pre and post-edit and other services of “**Change Healthcare**” and works with Change Healthcare (a part of Optum®), as a Program Partner, to enhance and extend these services through means such as the use of custom edits and data capture for participation in ABDC programs (“**PPE Solutions**”). ABDC and Change Healthcare provide the PPE Solutions to assist Customer with its healthcare operations including aiding in the accurate submission of claims for third party reimbursement. PPE Solutions consists of a series of edits providing financial, administrative and legal compliance reviews on prescription claims prior to being forwarded to, and another series of edits on responses received from, Payors. In addition to the integration of PPE Solutions with Customer’s systems, Change Healthcare makes portions of the solutions accessible through web-based tools, including on-demand reports. Optional services of Change Healthcare offered through ABDC include payer compliance re-billing and electronic medical claims billing for immunization services, and are also subject to this Term Sheet.

2. Pricing

a) The fees for PPE Solutions are covered as part of the Advanced Features of the Elevate Provider Network (Term Sheet 2). Additional fees may apply for stores processing more than 10,000 claims in a month.

b) If Customer opts to participate in Change Healthcare’s optional services respecting payer compliance re-billing, electronic medical claims billing for immunization services, or other services, additional fees will apply at the following negotiated pricing:

- Payer Compliance Claims: \$1.00 per successful claim
- MedRx Immunization Claims: \$1.00 per successful claim
- Other Services: Prevailing rate

3. Obligations of Customer

a) To participate in PPE Solutions, Customer must utilize Change Healthcare as its switch provider and participate in InSite from ABDC (Term Sheet 3).

b) Customer is responsible for claim switching service fees from Change Healthcare (or indirectly through its participating system vendor), which fees are not included as a part of this Program.

c) Customer must cooperate with its participating system vendor and Change Healthcare to initiate the configuration changes that participating system vendor has made to meet program requirements.

d) Customer appoints ABDC and Change Healthcare as its agents for providing and performing the PPE Solutions.

e) Customer will transmit all prescription claims and transactions in compliance with the procedures, data element standards, formats, codes, protocols, rules and edits set forth in

the then relevant specifications agreed upon by Change Healthcare and ABDC for implementation of the PPE Solutions (“**PPE Specifications**”).

f) Customer shall conform Customer’s system to changes in the PPE Specifications resulting from any non-optional feature, enhancement, product or module furnished to Customer without charge by Change Healthcare, and Customer must comply with the applicable timeline designated by Change Healthcare (which cannot be less than ninety (90) days).

g) Customer will use the PPE Solutions in accordance with applicable laws and regulations, this Term Sheet, the PPE Specifications and other conditions established by ABDC and Change Healthcare from time to time as set forth in any manuals, materials, documents, or instructions furnished by ABDC or Change Healthcare to Customer (“**PPE Materials**”).

h) Customer will ensure that all data supplied by Customer is correct, complete, and in the proper format as set forth in the PPE Specifications and PPE Materials. Customer is responsible for correcting any incorrect, incomplete or non-formatted data (or reimbursing Change Healthcare for its reasonable costs to do the same).

i) Customer will comply with ABDC’s and Change Healthcare’s procedures to secure any authorizations then required by applicable law or industry practice in connection with its transmission process, and to maintain prescription claims data transmitted through the PPE Solutions and afford access thereto in accordance with procedures then required by applicable law or industry practice.

j) Customer will permit ABDC and Change Healthcare to confirm Customer’s compliance with Customer’s obligations pursuant to this Term Sheet.

k) With regard to the use and/or disclosure of “Protected Health Information” (as defined in Title 45 parts 160 through 164 of the United States Code of Federal Regulations) by ABDC or Change Healthcare, Customer will: (i) obtain any consent, authorization or permission that may be required by the Privacy Regulation (as defined in Section 6 below) or any other applicable federal, state or local laws and/or regulations prior to furnishing ABDC or Change Healthcare the Protected Health Information pertaining to an individual; and (ii) not furnish to Change Healthcare any Protected Health Information that is subject to any arrangements permitted or required of Customer, including but not limited to, arrangements agreed to by Customer under 45 C.F.R. § 164.522 that may impact in any manner the use and/or disclosure of Protected Health Information by Change Healthcare under this Term Sheet.

l) Customer represents and warrants that its notice of privacy practices permits Customer to use and disclose Protected Health Information in the manner that ABDC and Change Healthcare are authorized to use and disclose Protected Health Information under this Term Sheet.

4. Obligations of Change Healthcare

a) Change Healthcare will provide the PPE Solutions as provided in the PPE Specifications and PPE Materials and in accordance with applicable laws and regulations.

b) Change Healthcare shall have no responsibility for determining the accuracy of any claim submitted, for settling disputed claims, for settling disputed payments, for settling disagreements or disputes between a third party payor or plan and Customer, for any liability for the acts of a third party payor or plan and/or Customer that violate the Social Security Act and related regulations and/or guidelines, or for any liability foreseeable or otherwise occurring beyond Change Healthcare's transmission of data.

c) Change Healthcare will:

(i) maintain and make available its internal practices, books and records relating to the use and/or disclosure of Protected Health Information to the Secretary of HHS for purposes of determining Customer's compliance with the Privacy Regulation;

(ii) document and, within thirty (30) days of receiving a written request from Customer, make available to Customer such information necessary for Customer to make an accounting of disclosures of an individual's Protected Health Information in accordance with 45 C.F.R. § 164.528 and, as of the date compliance is required by final regulations, 42 U.S.C. § 17935(c);

(iii) within fifteen (15) days of receiving a written request from Customer, make available Protected Health Information, in accordance with 45 C.F.R. § 164.524, as necessary for Customer to respond to individuals' requests for access to Protected Health Information about them, including, as of September 23, 2013, providing or sending a copy to a designated third party and providing or sending a copy in electronic format, to the extent that the Protected Health Information in Change Healthcare's possession constitutes a Designated Record Set; and

(vi) within thirty (30) days of receiving a written request from Customer, incorporate any amendments or corrections to the Protected Health Information in accordance with 45 C.F.R. § 164.526, to the extent that the Protected Health Information in Change Healthcare's possession constitutes a Designated Record Set.

d) Upon the termination of the PPE Solutions, Change Healthcare will return or destroy all Protected Health Information, including such information in the possession of Change Healthcare's subcontractors, if it is feasible to do so. If return or destruction of said Protected Health Information is not feasible, Change Healthcare will extend any and all protections, limitations and restrictions contained in this Term Sheet to Change Healthcare's use and/or disclosure of any Protected Health Information retained after the termination of the PPE Solutions, and limit any further uses and/or disclosures to the purposes that make the return or destruction of the Protected Health Information infeasible.

5. License

Subject to this Term Sheet, Change Healthcare hereby licenses to Customer a personal, nonexclusive, nontransferable end user license for so long as Customer utilizes the PPE Solutions in compliance with the PPE Specifications and PPE Materials.

6. Compliance

a) Change Healthcare, ABDC and Customer desire to meet their obligations, to the extent applicable, under the Standards for Privacy of Individually Identifiable Health Information (the "**Privacy Regulation**") and the Health Insurance Reform: Security Standards (the "**Security Regulation**") published by the U.S. Department of Health and Human Services ("**HHS**") at 45 C.F.R. parts 160 and 164 under the Health Insurance Portability and Accountability Act of 1996, as amended ("**HIPAA**").

b) Except as otherwise specified herein, Change Healthcare and ABDC may make any and all uses and disclosures of Protected Health Information created, maintained or transmitted from or on behalf of a Customer necessary to perform the PPE Solutions. Change Healthcare may perform Data Aggregation services for the Health Care Operations of Customer.

c) Unless otherwise limited herein, Change Healthcare and ABDC may: (i) consistent with 45 C.F.R. § 164.504(e)(4), use and disclose the Protected Health Information in its possession for its proper management and administration and to fulfill any present or future legal responsibilities of Change Healthcare or ABDC, provided that (a) the disclosures are required by law; or (b) any third party to which Change Healthcare or ABDC discloses Protected Health Information for those purposes provides reasonable assurances that the information will be held confidentially and used or further disclosed only as required by law or for the purpose for which it was disclosed to the third party, and the third party promptly will notify Change Healthcare and ABDC of any instances of which it becomes aware in which the confidentiality of the information has been breached; and (ii) de-identify any and all Protected Health Information in accordance with 45 C.F.R. § 164.514(b).

d) Customer acknowledges and agrees that de-identified information is not Protected Health Information and that each of Change Healthcare and ABDC on behalf of itself and/or its affiliates may use such de-identified information for any lawful purpose and consistent with this Term Sheet.

e) ABDC may amend this Term Sheet to give effect to any amendment to any provision of HIPAA, or its implementing regulations set forth at 45 C.F.R. parts 160 through 164, or other applicable law.

f) The parties' obligations under this Term Sheet will be construed in light of any interpretation and/or guidance on HIPAA, the Privacy Regulation and/or the Security Regulation issued by HHS from time to time. Regulatory citations are to the United States Code of Federal Regulations Title 45 parts 160 through 164, as interpreted and amended from time to time by HHS, for so long as such regulations are in effect. Unless otherwise specified, all capitalized terms not otherwise defined shall have the meaning established for purposes of Title 45

parts 160 through 164 of the United States Code of Federal Regulations, as amended from time to time.

7. Warranties and Limitations

a) ABDC, on behalf of Change Healthcare, warrants that the PPE Solutions will substantially conform in all material respects to its published specifications. Customer's sole remedy for breach of the foregoing warranty is for ABDC to use reasonable efforts to cause Change Healthcare to use commercially reasonable efforts to attempt to correct such flaw in a timely manner, to the extent that such flaw is due to the malfunction of Change Healthcare's computer, operating systems, programs, or to errors by Change Healthcare's employees. This warranty does not apply to any media or documentation which has been subjected to damage or abuse or to any claim which results, in whole or in part, from changes in the operating characteristics of computer hardware or computer operating systems made after the release of the applicable PPE Solutions, or which results from problems in the interaction of PPE Solutions with non-Change Healthcare software or equipment, or from a breach by Customer of any of its obligations hereunder.

b) EXCEPT FOR THE WARRANTIES CONTAINED IN THIS SECTION 7, THERE ARE NO OTHER WARRANTIES OF ANY KIND WITH RESPECT TO THE PPE SOLUTIONS, EXPRESSED OR IMPLIED OR STATUTORY, INCLUDING WITHOUT LIMITATION, ANY WARRANTY OF MERCHANTABILITY OR OF FITNESS FOR A PARTICULAR PURPOSE, ALL OF WHICH ARE EXPRESSLY DISCLAIMED.

8. Exclusions of Consequential Damages and Limitations of Liability

a) NEITHER ABDC NOR CHANGE HEALTHCARE GUARANTEES THE PAYMENT OR THE TIMING OF PAYMENT OF ANY CLAIMS SUBMITTED THROUGH THE PPE SOLUTIONS. PAYMENT REMAINS THE RESPONSIBILITY OF THE PARTICULAR PAYOR OF HEALTH CARE SERVICES AND/OR SUPPLIER TO WHICH THE CUSTOMER IS SUBMITTING.

b) CUSTOMER ACKNOWLEDGES THAT THE PPE SOLUTIONS ARE PROVIDED SOLELY BY CHANGE HEALTHCARE.

c) NEITHER ABDC NOR CHANGE HEALTHCARE SHALL BE LIABLE FOR INCIDENTAL, CONSEQUENTIAL OR SPECIAL DAMAGES ARISING OUT OF THE PPE SOLUTIONS AND CUSTOMER'S USE OF THE PPE SOLUTIONS EVEN IF SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.

d) ABDC'S AND CHANGE HEALTHCARE'S AGGREGATE LIABILITY TO CUSTOMER UNDER THIS TERM SHEET AND WITH RESPECT TO THE PPE SOLUTIONS (WHETHER UNDER CONTRACT, TORT, OR ANY OTHER THEORY OF LAW OR EQUITY) SHALL NOT EXCEED, UNDER ANY CIRCUMSTANCES, THE VALUE OF THE PPE SOLUTIONS GIVING RISE TO THE

CLAIM. THE FOREGOING LIMITATION OF LIABILITY REPRESENTS THE ALLOCATION OF RISK OF FAILURE AMONG THE PARTIES AS REFLECTED IN THE PRICING HEREUNDER AND IS AN ESSENTIAL ELEMENT OF THE BASIS OF THE BARGAIN AMONG THE PARTIES.

e) NOTWITHSTANDING ANYTHING TO THE CONTRARY HEREIN, NOTHING IN THIS TERM SHEET OR THE MASTER PROGRAM AGREEMENT SHALL LIMIT CHANGE HEALTHCARE'S LIABILITY FOR (I) FRAUDULENT MISREPRESENTATION, (II) GROSS NEGLIGENCE OR INTENTIONAL MISCONDUCT, OR (III) ANY OTHER LIABILITY THAT CANNOT BE EXCLUDED OR LIMITED UNDER APPLICABLE LAW.

f) Any claim against ABDC or Change Healthcare by Customer must be asserted in writing within thirty (30) days after Change Healthcare should have transmitted information received from a Customer or the transmission of inaccurate information on which the claim is based, whichever is applicable. Customer hereby agrees to promptly supply to Change Healthcare documentation reasonably requested by Change Healthcare to support any claim of Customer.

g) No party will be responsible for delays or failures in performance resulting from acts or events beyond its control, including but not limited to, acts of nature, governmental actions, fire, labor difficulties or shortages, civil disturbances, transportation problems, interruptions of power, supply or communications or natural disasters, provided such party takes reasonable efforts to minimize the effect of such acts or events.

h) The provisions of this Section 8 shall control over any conflicting provision elsewhere in the Master Program Agreement.

All other terms and conditions of the Master Program Agreement, including all Exhibits thereto, are hereby incorporated by reference into this Term Sheet. Capitalized words not defined in this Term Sheet have the meaning defined in the Master Program Agreement or Elevate Provider Network Term Sheet, as applicable.

◆◆◆

Claim Reconciliation Services Term Sheet

1. Program Description

a) ABDC works with EnlivenHealth (formerly known as FDS AMPLICARE, Inc.) (“**EnlivenHealth**”), as a Program Partner, to provide claims reconciliation and related services through a web-based portal for review of claim reconciliation opportunities (“**Reconciliation Services**”) for up to the prior 24 months by Network Provider. ABDC and EnlivenHealth provide this solution to aid Customer in its payment and healthcare operations activities including measuring the accuracy of third-party claim payments (“**Healthcare Operations**”). ABDC and EnlivenHealth make portions of the solutions accessible through web-based tools, including on-demand reports and training materials. Through the Elevate Help Desk, ABDC also provides email templates that enable a Pharmacy to dispute a claim that has not been paid or that has been underpaid and helpful hints based on the context of the activity of the user to help Customer identify possible reasons for disputed claims.

b) ABDC will furnish to EnlivenHealth the claims data Customer’s Network Provider(s) submits through the Change Healthcare claims switch services, or other claims switching services provider approved by ABDC in writing, via Network Provider’s system vendor (“**Claims Data**”) to match Network Provider’s claims to Network Provider’s payment remittance data received by ABDC from various Payors (“**Remittance Data**”).

c) An optional service offered by EnlivenHealth provides enhanced reconciliation services in which a EnlivenHealth analyst will conduct activities normally conducted by a Network Provider’s staff including chasing certain underpaid claims on behalf of Customer (“**EnlivenHealth Concierge Solutions**”). EnlivenHealth Concierge Solutions are subject to the terms and conditions agreed upon directly between Customer and EnlivenHealth.

2. Pricing and Availability

Premier: Included; no additional fee
GNP: Included in Elevate Advanced Features
Elevate: Included in Elevate Advanced Features
Other: Not available

Additional fees may apply for Network Providers processing more than 10,000 claims in a month.

a) Should Customer request reconciliation for previous Claims Data or Remittance Data dating prior to the beginning of the provision of Reconciliation Services to Customer, EnlivenHealth will attempt to retrieve such data and EnlivenHealth will invoice Customer directly for any costs associated with such retrieval.

b) If Customer opts to have its Network Provider(s) participate in EnlivenHealth Concierge Solutions, Customer will enter into an agreement directly with EnlivenHealth and be invoiced directly by EnlivenHealth for EnlivenHealth Concierge Solutions. The Fees for EnlivenHealth Concierge Solutions are in addition to the fees charged for Advanced Features, and can be confirmed by ABDC upon written request.

3. Customer Obligations

a) Unless specifically authorized otherwise, Network Provider(s) must participate in InSite from ABDC (Term Sheet 3) and PPE Solutions (Term Sheet 2A).

b) Customer authorizes and directs ABDC to furnish Claims Data and Remittance Data to EnlivenHealth for Network Provider(s) for the purpose of providing Reconciliation Services. Customer further authorizes ABDC to use its data, including Claims Data and Remittance Data and PHI, for program administration, including measuring Payor compliance across ABDC customers. Customer acknowledges and agrees that de-identified information is not PHI and that each of EnlivenHealth and ABDC on behalf of itself and/or its affiliates may use such de-identified information for any lawful purpose and consistent with the terms and conditions of this Term Sheet.

c) Customer represents and warrants that its notice of privacy practices permits Customer to use and disclose PHI in the manner that ABDC and EnlivenHealth are authorized to use and disclose PHI under this Term Sheet.

d) Customer will comply with ABDC’s and EnlivenHealth’s procedures to secure any authorizations then required by applicable law or industry practice in connection with its transmission process.

e) For claims submitted to Payors not contracted with Elevate, EnlivenHealth will obtain electronic remittance advices directly based on the Payor’s ability and willingness to provide such remittance advices.

f) Customer acknowledges that EnlivenHealth will only be able to reconcile remittance advices received directly by the Customer if uploaded or keyed in manually by Customer to the EnlivenHealth system.

g) Customer will use the Reconciliation Services in accordance with applicable laws and regulations and the reasonable conditions, rules, and regulations established by ABDC and EnlivenHealth from time to time and as set forth in any manuals, materials, documents, or instructions furnished by ABDC or EnlivenHealth to Customer, provided the same are not in conflict with any provisions of the Master Program Agreement or this Term Sheet (“**Reconciliation Materials**”).

h) Notwithstanding the provision of Reconciliation Services under this Term Sheet, Network Provider is ultimately responsible for submitting accurate claims to and receiving accurate reimbursement from Payors, and for responding to, defending and resolving such disputes (including legal expenses).

4. EnlivenHealth and ABDC Obligations

a) EnlivenHealth will provide the Reconciliation Services as provided in this Term Sheet and the Reconciliation Materials and in accordance with applicable laws and regulations.

b) EnlivenHealth will use due care in performing all Reconciliation Services and will use its best efforts to correct any errors to the extent that such errors are due to the malfunction of EnlivenHealth’s systems or to errors by EnlivenHealth’s

employees or agents. Corrections shall be limited to rerunning of jobs or recreation of data or program files.

c) EnlivenHealth will make webinars or similar training opportunities available to Customer on the use of Reconciliation Services.

d) If Network Provider participates in EnlivenHealth's commercial reconciliation offering prior to joining Elevate or signing up for Reconciliation Services, Customer authorizes ABDC and EnlivenHealth to terminate its then current agreement with EnlivenHealth and to enroll Network Provider in Reconciliation Services. EnlivenHealth will release Network Provider from any existing agreement.

e) ABDC will provide assistance with Reconciliation Services through its Elevate help desk, available during normal business hours.

5. License

Subject to this Term Sheet, EnlivenHealth hereby licenses to Customer a personal, nonexclusive, nontransferable end user license for each Network Provider for so long as such Network Provider utilizes the Reconciliation Services in compliance with the Reconciliation Materials.

6. Warranties and Limitations

a) ABDC, on behalf of EnlivenHealth, warrants that the Reconciliation Services will substantially conform in all material respects to its published specifications. Customer's sole remedy for breach of the foregoing warranty is for ABDC to use reasonable efforts to cause EnlivenHealth to use commercially reasonable efforts to attempt to correct such flaw in a timely manner, to the extent that such flaw is due to the malfunction of EnlivenHealth's computer, operating systems, programs, or to errors by EnlivenHealth's employees. This warranty does not apply to any media or documentation which has been subjected to damage or abuse or to any claim which results, in whole or in part, from changes in the operating characteristics of computer hardware or computer operating systems made after the release of the applicable Reconciliation Services, or which results from problems in the interaction of Reconciliation Services with non-EnlivenHealth software or equipment, or from a breach by Customer of any of its obligations hereunder.

b) EXCEPT FOR THE WARRANTIES CONTAINED IN THIS SECTION 6, THERE ARE NO OTHER WARRANTIES OF ANY KIND WITH RESPECT TO THE RECONCILIATION SERVICES, EXPRESSED OR IMPLIED OR STATUTORY, INCLUDING WITHOUT LIMITATION, ANY WARRANTY OF MERCHANTABILITY OR OF FITNESS FOR A PARTICULAR PURPOSE, ALL OF WHICH ARE EXPRESSLY DISCLAIMED.

7. Exclusions of Consequential Damages and Limitations of Liability

a) ABDC and EnlivenHealth shall not be liable for any errors occurring as a result of failure by Customer to comply with this Term Sheet or the Reconciliation Materials.

b) EnlivenHealth and ABDC shall have no responsibility for determining the accuracy of any claim submitted, for settling disputed claims, for settling disputed payments, for settling disagreements or dispute between a Payor and Customer, for any

liability for the acts of a Payor and/or Customer that violate the Social Security Act and related regulations and/or guidelines, or for any liability foreseeable or otherwise occurring beyond EnlivenHealth's transmission of data.

c) NEITHER ABDC NOR ENLIVENHEALTH GUARANTEES THE PAYMENT OR THE TIMING OF PAYMENT OF ANY CLAIMS SUBMITTED THROUGH THE RECONCILIATION SERVICES. PAYMENT REMAINS THE RESPONSIBILITY OF THE PARTICULAR PAYOR OF HEALTH CARE SERVICES AND/OR SUPPLIER TO WHICH THE CUSTOMER IS SUBMITTING.

d) CUSTOMER ACKNOWLEDGES THAT THE ENLIVENHEALTH CONCIERGE SOLUTIONS ARE PROVIDED SOLELY BY ENLIVENHEALTH.

e) NEITHER ABDC NOR ENLIVENHEALTH SHALL BE LIABLE FOR INCIDENTAL, CONSEQUENTIAL OR SPECIAL DAMAGES ARISING OUT OF THE RECONCILIATION SERVICES AND CUSTOMER'S USE OF THE RECONCILIATION SERVICES EVEN IF SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.

ABDC'S AND ENLIVENHEALTH'S AGGREGATE LIABILITY TO CUSTOMER UNDER THIS TERM SHEET AND WITH RESPECT TO THE RECONCILIATION SERVICES (WHETHER UNDER CONTRACT, TORT, OR ANY OTHER THEORY OF LAW OR EQUITY) SHALL NOT EXCEED, UNDER ANY CIRCUMSTANCES, THE VALUE OF THE RECONCILIATION SERVICES GIVING RISE TO THE CLAIM. THE FOREGOING LIMITATION OF LIABILITY REPRESENTS THE ALLOCATION OF RISK OF FAILURE AMONG THE PARTIES AS REFLECTED IN THE PRICING HEREUNDER AND IS AN ESSENTIAL ELEMENT OF THE BASIS OF THE BARGAIN AMONG THE PARTIES.

f) NOTWITHSTANDING ANYTHING TO THE CONTRARY HEREIN, NOTHING IN THIS TERM SHEET OR THE MASTER PROGRAM AGREEMENT SHALL LIMIT ENLIVENHEALTH'S LIABILITY FOR (I) FRAUDULENT MISREPRESENTATION, (II) GROSS NEGLIGENCE OR INTENTIONAL MISCONDUCT, OR (III) ANY OTHER LIABILITY THAT CANNOT BE EXCLUDED OR LIMITED UNDER APPLICABLE LAW.

g) Any claim against ABDC or EnlivenHealth by Customer must be asserted in writing within thirty (30) days after EnlivenHealth should have processed information received from a Customer or the transmission of inaccurate information on which the claim is based, whichever is applicable. Customer hereby agrees to promptly supply to EnlivenHealth documentation reasonably requested by EnlivenHealth to support any claim. No party will be responsible for delays or failures in performance resulting from acts or events beyond its control, including but not limited to, acts of nature, governmental actions, fire, labor difficulties or shortages, civil disturbances, transportation problems, interruptions of power, supply or communications or natural disasters, provided such party takes reasonable efforts to minimize the effect of such acts or events.

h) No party will be responsible for delays or failures in performance resulting from acts or events beyond its control, including but not limited to, acts of nature, governmental actions,

fire, labor difficulties or shortages, civil disturbances, transportation problems, interruptions of power, supply or communications or natural disasters, provided such party takes reasonable efforts to minimize the effect of such acts or events.

i) The provisions of this Section 7 shall control over any conflicting provision elsewhere in the Master Program Agreement.

All other terms and conditions of the Master Program Agreement, including all Exhibits thereto, are hereby incorporated by reference into this Term Sheet. Capitalized words not defined in this Term Sheet have the meaning defined in the Master Program Agreement or the Elevate Provider Network Term Sheet.



Outcomes Patient Care Services

Term Sheet

1. Program Description

a) ABDC works with Outcomes, as a Program Partner, to provide an optional web-based patient care services solution (the “Outcomes Premium Solution”) offering real-time analytics and ongoing management tools designed to assist subscribing pharmacies in improving, among other things, patient health outcomes, patient adherence, and clinical services. The Outcomes Premium Solution is currently made available through Prescribe Wellness functionality but will be transitioned to Outcomes Premium.

b) Enrollment in the Outcomes Premium Solution is optional, and Customer may enroll through ABDC or directly through Outcomes, as provided more fully in this Term Sheet; provided, however, that Customer may not enroll in the Outcomes Premium Solution through ABDC to the extent that Customer is enrolled in the Ampicare Clinical Solution (as defined under Term Sheet 2D) through ABDC. Enrollment in the Outcomes Premium Solution requires, among other things, the execution of an agreement directly with Outcomes and completion of an applicable enrollment form with ABDC.

2. Pricing

a) Fees for the Outcomes Premium Solution are in addition to the fees charged for Elevate Advanced Features (see Term Sheet 2), will be invoiced directly by Outcomes, and may be increased by up to Five Percent (5%) annually. Applicable fees to be paid by Customer may vary and are dependent upon the manner in which Customer enrolls in the Outcomes Premium Solution and applicable Outcomes Premium Solution modules chosen by Customer. If Customer enrolls in the Outcomes Premium Solution directly through Outcomes, Customer will pay Outcomes’ prevailing rates. Alternatively, to the extent that Customer enrolls in the Outcomes Premium Solution through ABDC, remains affiliated with ABDC, maintains on file with ABDC an active and valid Outcomes Premium Solution enrollment form, and otherwise satisfies all applicable requirements, including, without limitation, utilization requirements provided under Section 3(h) below, Customer will pay the following rates for the following Outcomes Premium Solution modules:

- Outcomes Premium:
\$49/store/month
- Outcomes Premium + Vaccine: \$129/store/month
- Outcomes Premium + Vaccine + Engagement:
\$249/store/month

b) For the avoidance of doubt, the fees to be paid by Customer for the Outcomes Premium Solution are subject to increase if Customer enrolls in the Outcomes Premium Solution through ABDC and fails to satisfy the conditions and requirements provided in Section 2(a) above.

3. Obligations of Customer

a) To access the Outcomes Premium Solution, Customer must sign a HIPAA Business Associate Agreement directly with Outcomes and timely pay all applicable amounts due.

b) Customer must complete all applicable enrollment requirements, including, without limitation, completion of an applicable enrollment form with ABDC.

c) Unless specifically authorized otherwise by ABDC in writing, Customer must participate in Elevate Advanced Features (Term Sheet 2).

d) Customer authorizes ABDC and Outcomes to utilize Pharmacy Data to measure and improve the performance, or the future development of any Outcomes product, and to use and disclose to third parties de-identified Pharmacy Data aggregated across other ABDC and/or Outcomes customers, as applicable. Customer represents and warrants that its notice of privacy practices permits Customer to use and disclose Protected Health Information in the manner that ABDC and Outcomes are authorized to use and disclose Protected Health Information under this Term Sheet.

e) Customer will use the Outcomes Premium Solution in accordance with: (i) applicable laws and regulations; (ii) the reasonable conditions, rules, and requirements established by ABDC and/or Outcomes from time to time and as set forth in any manuals, materials, documents, or instructions furnished by ABDC or Outcomes to Customer (collectively the “Outcomes Premium Materials”); and (iii) any other agreement between Outcomes and Customer respecting the Outcomes Premium Solution.

f) Customer will take strict measures to protect the security of its assigned Outcomes Premium Solution account and corresponding username and password and agrees that all consequences resulting from the use of said account shall be the sole responsibility of Customer. Customer is solely responsible for all information submitted through the Outcomes Premium Solution via its assigned account.

g) Customer may not rent, disclose, publish, sell, assign, lease, sublicense, market or transfer any content of ABDC or Outcomes nor use it in any manner not expressly authorized by this Term Sheet or the Outcomes Premium Materials.

h) In order to remain eligible for the pricing terms provided under Section 2(a) above respecting Outcomes Premium Solution enrollment through ABDC, Customer must access and utilize the Outcomes Premium Solution, on average during each month, at least one (1) time. If Customer’s use fails to meet such frequency requirement, the fees to be paid by Customer shall be subject to increase, as provided under Section 2 above, for the periods during which such failure occurs.

4. Grant of Rights and IP Rights

a) To the extent permitted by law, ABDC grants to Customer a limited, non-transferable, non-exclusive right to use the Outcomes Premium Solution subject to the

Outcomes Premium Materials, this Term Sheet, and any other agreement between Outcomes and Customer respecting the Outcomes Premium Solution. Customer's use of the Outcomes Premium Solution is restricted to Customer's own internal business purposes. Customer shall have no right to resell, distribute or otherwise transfer or permit usage of the Outcomes Premium Solution by any other person. Title to the Outcomes Premium Solution and all rights of copyright, patent or other intellectual property therein are and shall at all times remain solely and exclusively with ABDC or Outcomes, as applicable. Customer shall keep its use of the Outcomes Premium Solution free and clear of all liens, claims and encumbrances. ABDC and Outcomes, respectively and as applicable, reserve any and all rights not expressly granted herein.

b) Customer acknowledges and agrees that all content, products, programs and/or technology on and accessible through the Outcomes Premium Solution (excluding Pharmacy Data provided by Customer) is the property of either Outcomes or ABDC, and Customer shall not claim any interest in such property.

c) Customer will not alter or remove any copyright or trademark notice or proprietary legend contained in or on any content of the Outcomes Premium Solution. Any trademark, logos and marks displayed on the Outcomes Premium Solution, whether registered or unregistered, are property of their respective owners.

5. Warranties and Limitations

a) THE OUTCOMES PREMIUM SOLUTION IS PROVIDED "AS-IS" AND WITHOUT ANY WARRANTY OR CONDITION WHATSOEVER. NEITHER ABDC NOR OUTCOMES MAKES ANY WARRANTY, EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION, ANY IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE OR INFORMATION SECURITY, IN RELATION TO THE USE OF THE OUTCOMES PREMIUM SOLUTION. FURTHER, AND WITHOUT LIMITING THE FOREGOING, NEITHER ABDC NOR OUTCOMES MAKES ANY WARRANTY THAT ACCESS TO OR USE OF THE OUTCOMES PREMIUM SOLUTION WILL BE UNINTERRUPTED OR ERROR-FREE, OR AS TO ANY RESULTS THAT MAY BE OBTAINED BY USE OF THE OUTCOMES PREMIUM SOLUTION BY CUSTOMER AND/OR ANY PERSON, IRRESPECTIVE OF WHETHER ABDC OR OUTCOMES HAS BEEN INFORMED OF, KNEW OF OR SHOULD HAVE KNOWN OF THE LIKELIHOOD OF SUCH DAMAGES.

6. Exclusions of Consequential Damages and Limitations of Liability

a) ABDC and Outcomes shall not be liable for any errors occurring as a result of failure by Customer to comply with this Term Sheet, the Outcomes Premium Materials, or any other agreement between Outcomes and Customer respecting the Outcomes Premium Solution.

b) CUSTOMER UNDERSTANDS AND ACKNOWLEDGES THAT: (I) THE OUTCOMES SERVICES AND OFFERINGS ARE PROVIDED SOLELY BY OUTCOMES; (II) ABDC DOES NOT OWN, OPERATE OR MAINTAIN THE OUTCOMES PREMIUM SOLUTION; (III) USE OF THE OUTCOMES PREMIUM SOLUTION IS AT CUSTOMER'S SOLE RISK AND DISCRETION; AND (IV) EXCEPT AS EXPRESSLY PROVIDED IN THIS TERM SHEET, ALL TERMS AND CONDITIONS APPLICABLE TO THE OUTCOMES PREMIUM SOLUTION ARE DETERMINED SOLELY BY OUTCOMES.

c) NEITHER ABDC NOR OUTCOMES SHALL BE LIABLE FOR INCIDENTAL, CONSEQUENTIAL OR SPECIAL DAMAGES ARISING OUT OF THE OUTCOMES PREMIUM SOLUTION AND CUSTOMER'S USE OF THE OUTCOMES PREMIUM SOLUTION, EVEN IF SUCH PARTY HAS BEEN INFORMED OF, KNEW OF, OR SHOULD HAVE KNOWN OF THE LIKELIHOOD OF SUCH DAMAGES.

d) ABDC'S AND OUTCOMES' AGGREGATE LIABILITY TO CUSTOMER UNDER THIS TERM SHEET AND WITH RESPECT TO THE OUTCOMES PREMIUM SOLUTION (WHETHER UNDER CONTRACT, TORT, OR ANY OTHER THEORY OF LAW OR EQUITY) SHALL NOT EXCEED, UNDER ANY CIRCUMSTANCES, THE VALUE OF THE SERVICES RELATING TO THE OUTCOMES PREMIUM SOLUTION GIVING RISE TO THE CLAIM. THE FOREGOING LIMITATION OF LIABILITY REPRESENTS THE ALLOCATION OF RISK OF FAILURE AMONG THE PARTIES AS REFLECTED IN THE PRICING HEREUNDER AND IS AN ESSENTIAL ELEMENT OF THE BASIS OF THE BARGAIN AMONG THE PARTIES.

e) No party will be responsible for delays or failures in performance resulting from acts or events beyond its control, including but not limited to, acts of nature, governmental actions, fire, labor difficulties or shortages, civil disturbances, transportation problems, interruptions of power, supply or communications or natural disasters, provided such party takes reasonable efforts to minimize the effect of such acts or events.

f) The provisions of this Section 6 shall control over any conflicting provision elsewhere in the Master Program Agreement.

All other terms and conditions of the Master Program Agreement, including all Exhibits thereto, are hereby incorporated by reference into this Term Sheet. Capitalized words not defined in this Term Sheet have the meaning defined in the Master Program Agreement, Elevate Provider Network Term Sheet, or Elevate Advanced Features Term Sheet, as applicable.



EnlivenHealth Patient Care Services Term Sheet

1. Program Description

a) ABDC works with EnlivenHealth, as a Program Partner, to make available for enrollment a web-based patient care services solution (the “**Treat Solution**”) offering real-time analytics and ongoing management tools designed to assist subscribing pharmacies in improving, among other things, patient health outcomes, patient adherence, and clinical services. Enrollment in the Treat Solution is optional, and Customer may enroll through ABDC or directly through EnlivenHealth, as provided more fully in this Term Sheet; provided, however, that Customer may not enroll in the Treat Solution through ABDC to the extent that Customer is enrolled in the Outcomes Premium Solution (as defined under Term Sheet 2C) through ABDC. Enrollment in the Treat Solution requires, among other things, the execution of an agreement directly with EnlivenHealth and completion of an applicable enrollment form with ABDC.

b) ABDC also works with EnlivenHealth to provide access to its Pharmacy Clinical Practice by State tools (collectively, the “**EnlivenHealth Tools**”) for all Good Neighbor Pharmacy and Elevate Provider Network pharmacy members.

2. Pricing

a) Access to the EnlivenHealth Tools is provided at no additional cost.

b) Fees for the Treat Solution are in addition to the fees charged for Elevate Advanced Features (see Term Sheet 2) and will be invoiced directly by EnlivenHealth. Applicable fees to be paid by Customer may vary and are dependent upon the manner in which Customer enrolls in the Treat Solution and applicable Treat Solution bundles chosen by Customer. If Customer enrolls in the Treat Solution directly through EnlivenHealth, Customer will pay EnlivenHealth’s prevailing rates. Alternatively, to the extent that Customer enrolls in the Treat Solution through ABDC, remains affiliated with ABDC, maintains on file with ABDC an active and valid Treat Solution enrollment form, and otherwise satisfies all applicable requirements, Customer will pay the following rates for the following Treat Solution bundles:

- Essentials: \$100/store/month
- Workflow: \$100/store/month
- All-in: \$185/store/month

**Additional transaction fees may apply based on the bundle chosen, as provided under Customer’s direct agreement with EnlivenHealth respecting the Treat Solution.*

c) For the avoidance of doubt, the fees to be paid by Customer for the Treat Solution are subject to increase if Customer enrolls in the Treat Solution through ABDC and fails to satisfy the conditions and requirements provided in Section 2(b) above.

3. Obligations of Customer

a) To access the Treat Solution, Customer must sign a HIPAA Business Associate Agreement directly with EnlivenHealth.

b) To access the EnlivenHealth Tools, Customer must acknowledge and agree to applicable terms and conditions provided by ABDC and/or EnlivenHealth and timely pay all amounts due.

c) Customer must complete all applicable enrollment requirements, including, without limitation, completion of an applicable enrollment form with ABDC.

d) Unless specifically authorized otherwise by ABDC in writing, Customer must participate in Elevate Advanced Features (Term Sheet 2) and InSite from ABDC (Term Sheet 3).

e) Customer will use the EnlivenHealth Tools and Treat Solution in accordance with: (i) applicable laws and regulations and the reasonable conditions, rules, and regulations established by ABDC and EnlivenHealth from time to time and as set forth in any manuals, materials, documents, or instructions furnished by ABDC or EnlivenHealth to Customer (collectively, the “EnlivenHealth PCS Materials”); and (ii) any other agreement between EnlivenHealth and Customer respecting the Treat Solution and/or EnlivenHealth Tools.

f) Customer will take strict measures to protect the security of its assigned Treat Solution and EnlivenHealth Tools accounts and corresponding usernames and passwords and agrees that all consequences resulting from the use of said accounts shall be the sole responsibility of Customer. Customer is solely responsible for all access, use, and/or information submitted through the EnlivenHealth Tools and Treat Solution via its assigned accounts. Customer understands and acknowledges that its accounts may be disabled, suspended, or terminated in the event of unauthorized use of any such account.

g) Customer may not rent, disclose, publish, sell, assign, lease, sublicense, market or transfer any content of ABDC or EnlivenHealth nor use it in any manner not expressly authorized by this Term Sheet or the EnlivenHealth PCS Materials.

4. Grant of Rights and IP Rights

a) To the extent permitted by law, ABDC grants to Customer a limited, non-transferable, non-exclusive right to use the EnlivenHealth Tools, subject to the EnlivenHealth PCS Materials, this Term Sheet, and any other agreement between EnlivenHealth and Customer respecting the EnlivenHealth Tools, including, without limitation, terms and conditions of use determined by EnlivenHealth. Customer’s use of EnlivenHealth Tools and Treat Solution is restricted to Customer’s own internal business purposes. Customer shall have no right to resell, distribute or otherwise transfer or permit usage of the EnlivenHealth Tools and/or Treat Solution by any

other person. Title to the EnlivenHealth Tools and Treat Solution and all rights of copyright, patent or other intellectual property therein are and shall at all times remain solely and exclusively with ABDC or Enliven Health, as applicable. Customer shall keep its use of the EnlivenHealth Tools and Treat Solution free and clear of all liens, claims and encumbrances. ABDC and EnlivenHealth, respectively and as applicable, reserve any and all rights not expressly granted herein.

b) Customer acknowledges and agrees that all content, products, programs and/or technology on and accessible through the EnlivenHealth Tools and/or Treat Solution (excluding Pharmacy Data provided by Customer) is the property of EnlivenHealth and Customer shall not claim any interest in such property.

c) Customer will not alter or remove any copyright or trademark notice or proprietary legend contained in or on any content of the EnlivenHealth Tools and/or Treat

Solution. Any trademark, logos and marks displayed on the EnlivenHealth Tools and/or Treat Solution, whether registered or unregistered, are property of their respective owners.

5. Warranties and Limitations

a) Customer understands and acknowledges that, with respect to the EnlivenHealth Tools: (i) the EnlivenHealth Tools do not include information concerning every circumstance available nor does ABDC or EnlivenHealth engage in the practice of medicine; (ii) neither ABDC nor the EnlivenHealth Tools provide any business, medical, pharmaceutical, or other professional advice in connection with the Agreement or as part of or because of the provision of the EnlivenHealth Tools; and (iii) neither ABDC nor the EnlivenHealth Tools have the ability to determine: (1) the legality of utilizing the EnlivenHealth Tools in the state in which the EnlivenHealth Tools are being utilized by Customer; (2) the appropriateness of the use of the EnlivenHealth Tools by or for Customer; or (3) whether Customer understands the information provided in the EnlivenHealth Tools.

b) THE ENLIVENHEALTH TOOLS AND TREAT SOLUTION ARE PROVIDED “AS-IS” AND WITHOUT ANY WARRANTY OR CONDITION WHATSOEVER. NEITHER ABDC NOR ENLIVENHEALTH MAKES ANY WARRANTY, EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION, ANY IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE OR INFORMATION SECURITY, IN RELATION TO THE USE OF THE TREAT SOLUTION OR ENLIVENHEALTH TOOLS, AND ABDC AND ENLIVENHEALTH DISCLAIM ALL REPRESENTATIONS, WARRANTIES, AND CONDITIONS OF ANY KIND OR NATURE, EXPRESS OR IMPLIED, ARISING OUT OF OR RELATED TO THE ENLIVENHEALTH TOOLS OR TREAT SOLUTION, OR RESULTS DERIVED THEREFROM, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OR CONDITIONS REGARDING ACCURACY, QUALITY, CORRECTNESS, COMPLETENESS, COMPREHENSIVENESS, AND SUITABILITY AND/OR

ANY WARRANTY THAT THE ENLIVENHEALTH TOOLS OR TREAT

SOLUTION, OR THE CONTENTS THEREIN, WILL MEET ANY PARTICULAR REQUIREMENTS OF OR GUARANTEE REIMBURSEMENT FOR CUSTOMER OR THAT ACCESS TO OR USE OF THE ENLIVENHEALTH TOOLS OR TREAT SOLUTION WILL BE UNINTERRUPTED OR ERROR-FREE. FURTHER, AND WITHOUT LIMITING THE FOREGOING, NEITHER

ABDC NOR ENLIVENHEALTH MAKES ANY WARRANTY AS TO ANY RESULTS THAT MAY BE OBTAINED BY USE OF THE TREAT SOLUTION OR ENLIVENHEALTH TOOLS BY CUSTOMER AND/OR ANY PERSON, IRRESPECTIVE OF

WHETHER ABDC OR ENLIVENHEALTH HAS BEEN INFORMED OF, KNEW OF OR SHOULD HAVE KNOWN OF THE LIKELIHOOD OF SUCH DAMAGES.

6. Exclusions of Consequential Damages and Limitations of Liability

a) ABDC and Enliven Health shall not be liable for any errors occurring as a result of failure by Customer to comply with this Term Sheet, the EnlivenHealth PCS Materials, or any other agreement between EnlivenHealth and Customer respecting the EnlivenHealth Tools and/or Treat Solution.

b) CUSTOMER UNDERSTANDS AND ACKNOWLEDGES THAT: (I) THE ENLIVENHEALTH SERVICES AND OFFERINGS ARE PROVIDED SOLELY BY ENLIVENHEALTH; (II) ABDC DOES NOT OWN, OPERATE, OR MAINTAIN THE ENLIVENHEALTH TOOLS OR TREAT SOLUTION; (III) USE OF THE ENLIVENHEALTH TOOLS AND TREAT SOLUTION IS AT CUSTOMER’S SOLE RISK AND DISCRETION; AND (IV) EXCEPT AS EXPRESSLY PROVIDED IN THIS TERM SHEET, ALL TERMS AND CONDITIONS APPLICABLE TO THE ENLIVENHEALTH TOOLS AND TREAT SOLUTION ARE DETERMINED SOLELY BY ENLIVENHEALTH.

c) NEITHER ABDC NOR ENLIVEN HEALTH SHALL BE LIABLE FOR INCIDENTAL, CONSEQUENTIAL OR SPECIAL DAMAGES ARISING OUT OF THE TREAT SOLUTION, ENLIVEN HEALTH TOOLS, AND/OR CUSTOMER’S USE THEREOF, EVEN IF SUCH PARTY HAS BEEN INFORMED OF, KNEW OF, OR SHOULD HAVE KNOWN

OF THE LIKELIHOOD OF SUCH DAMAGES.

d) ABDC’S AND ENLIVENHEALTH’S AGGREGATE LIABILITY TO CUSTOMER UNDER THIS TERM SHEET AND WITH RESPECT TO THE TREAT SOLUTION AND ENLIVENHEALTH TOOLS (WHETHER UNDER CONTRACT, TORT, OR ANY OTHER THEORY OF LAW OR EQUITY) SHALL NOT EXCEED, UNDER ANY CIRCUMSTANCES, THE VALUE OF THE SERVICES RELATING TO THE TREAT SOLUTION OR ENLIVENHEALTH TOOLS GIVING RISE TO THE CLAIM. THE FOREGOING LIMITATION OF LIABILITY

REPRESENTS THE ALLOCATION OF RISK OF FAILURE AMONG THE PARTIES AS REFLECTED IN THE PRICING HEREUNDER AND IS AN ESSENTIAL ELEMENT OF THE BASIS OF THE BARGAIN AMONG THE PARTIES.

e) No party will be responsible for delays or failures in performance resulting from acts or events beyond its control, including but not limited to, acts of nature, governmental actions, fire, labor difficulties or shortages, civil disturbances, transportation problems, interruptions of power, supply or communications or natural disasters, provided such party takes reasonable efforts to minimize the effect of such acts or events.

f) The provisions of this Section 6 shall control over any conflicting provision elsewhere in the Master Program Agreement.

All other terms and conditions of the Master Program Agreement, including all Exhibits thereto, are hereby incorporated by reference into this Term Sheet. Capitalized words not defined in this Term Sheet have the meaning defined in the Master Program Agreement, Elevate Provider Network Term Sheet, or Elevate Advanced Features Term Sheet, as applicable.



InSite from ABDC Term Sheet

1. Program Description

a) InSite from ABDC is a proprietary data analytics system used to measure and compare pharmacy performance by organizing and analyzing detailed prescription and other business transaction data, including Pharmacy Data.

b) InSitePOS from ABDC is a proprietary data analytics system used to measure and compare the performance of pharmacy front ends by organizing and analyzing detailed business transaction data collected from point-of-sale systems, including Pharmacy Data. ABDC collaborates with its Program Partner, Retail Insights, on the collection and cleansing of the data.

c) TruVuPOS is an ABDC service offered to consumer goods manufacturers, in collaboration with ABDC's Program Partner, Retail Insights, to gain access for participating pharmacies to manufacturer offerings, and to provide funding to help support the programs.

These programs are designed to aid Customer in its treatment, payment, and healthcare operations activities, and are collectively referred to as "InSite from ABDC".

2. Pricing

Premier: Included; no additional fee

GNP: Included in Elevate Advanced Features

Other: Included in Elevate Advanced Features

Additional fees may apply for Network Providers that: (i) process more than 10,000 Claims in a month; (ii) use alternative, approved switch service providers for Elevate Advanced Features; and/or (iii) elect to receive optional and/or enhanced Elevate Advanced Features services (e.g., enhanced reporting, etc.).

3. Data Authorization & Program Partners

a) Customer authorizes ABDC to receive Pharmacy Data provided by or on behalf of Customer directly or indirectly from Customer or ABDC's Program Partners in connection with the Permitted Uses (as defined below).

b) Without in any way limiting the scope of such definition as provided under the Agreement and/or Term Sheet 2 (Elevate Advanced Features), ABDC's Program Partners respecting this Available Program include but are not limited to:

(i) Change Healthcare (a part of Optum®). Provides pre and post edit and data capture services.

(ii) EnlivenHealth. Provides central payment services, claim reconciliation services, and the EnlivenHealth Tools (as defined under Term Sheet 2D) and hosts and makes available for enrollment through ABDC the Treat Solution (as defined under Term Sheet 2D).

(iii) Outcomes. Hosts and makes available for enrollment through ABDC the Outcomes PCS Solution (as defined under Term Sheet 2C).

(iv) Retail Insights. Collects, organizes, and analyzes transaction data from point-of-sale systems and operates the TruVuPOS program with ABDC and consumer goods

manufacturers to assist pharmacies in gaining access to promotional monies and other retail programs.

c) Customer represents and warrants that its notice of privacy practices permits Customer to use and disclose protected health information in the manner that ABDC is authorized to use and disclose protected health information under the Agreement and this Term Sheet.

4. Advanced Features

InSite from ABDC is included in, and required for participation in each of, the Advanced Features (Term Sheet 2) of the Elevate Provider Network (Term Sheet 1), which include Pre and Post Edit Services and data capture from Change Healthcare (Term Sheet 2A), Claim Reconciliation Services from EnlivenHealth (Term Sheet 2B), Outcomes Premium Solution from Outcomes (Term Sheet 2C), and Patient Care Services from EnlivenHealth (Term Sheet 2D). To participate in one (1) or more Advanced Features, Customer must enroll and comply with the terms and conditions in the applicable Term Sheet(s).

5. Customer Responsibilities

a) Procure Systems. To participate, Customer must acquire systems from one or more participating system vendors and is responsible for the costs to acquire, maintain and update its systems, which vary based on Customer's choices.

b) Data Flow. Customer will comply with instructions of ABDC, ABDC's Program Partners and system vendors to ensure the quality and timely receipt of all Pharmacy Data, including cash or private pay claims as required, by InSite and will use reasonable efforts to resolve any process failures or missing data. Customer will obtain all necessary authorizations from its customers/patients to transmit Pharmacy Data to ABDC and its Program Partners. Claims data capture and corresponding switching services through Change Healthcare are required unless otherwise approved by ABDC in writing, in which case such approved alternative vendor shall constitute ABDC's respective Program Partner for the purposes of Customer's provision of Pharmacy Data and participation in applicable Available Programs.

c) HIPAA Compliance. As required, ABDC and Customer entered into a HIPAA Business Associate Agreement (Exhibit B or as otherwise agreed).

6. ABDC Responsibilities

a) System Vendors. ABDC will collaborate with certain system vendors that Customer may designate to facilitate the delivery of Pharmacy Data provided by or on behalf of Customer and the implementation of various business initiatives, including Available Programs.

b) InSite. Using InSite, ABDC will provide Customer with reports, analyses and other compilations about business performance, including various benchmark comparisons against peer groups of similar pharmacies using de-identified Pharmacy Data and other data to assess

and improve overall efficiency and performance of healthcare operations.

c) Report Availability. Certain reports and performance measurements are provided to all participating Pharmacies. Some reports or features have additional fees or are only available as part of another Available Program.

d) Protection of Customer Data. ABDC will protect Pharmacy Data provided by or on behalf of Customer pursuant to the Data Protection Provisions (Exhibit A), which describes steps ABDC takes to safeguard Pharmacy Data. ABDC may only use Pharmacy Data provided by or on behalf of Customer as set forth in the Master Program Agreement (including this Term Sheet and Term Sheets applicable to other Available Programs in which Customer enrolls) and as authorized by Customer in writing.

7. Use of Pharmacy Data

a) Pharmacy Data License. Customer hereby grants to ABDC an irrevocable, non-exclusive license to use, reproduce, create derivative works from, and market and distribute those derivative works from any and all Pharmacy Data captured directly or indirectly from Customer, Program Partners, or Payors for the Permitted Uses specified in Section 7(b) below.

b) Permitted Uses. Consistent with applicable laws and regulations, Customer authorizes ABDC to use, reproduce, and create derivative works from Pharmacy Data, and market and distribute those derivative works for the following purposes (collectively, “**Permitted Uses**”):

(i) providing Customer with reports, studies, analyses and other compilations relating to Customer's business performance to assist Customer in its treatment, payment, and healthcare operations activities;

(ii) in such a manner that Customer is unidentifiable as the source of the data and any protected health information is appropriately de-identified, combining Pharmacy Data with similar data received by ABDC as a business associate of multiple covered entities and using such cumulative data to prepare reports, analyses and compilations relating to business performance and market trends to benchmark Customer and other covered entities against peer groups to improve all parties' overall efficiency and performance of treatment, payment, and healthcare operations activities;

(iii) supporting Customer's participation in Advanced Features and other Available Programs by furnishing Pharmacy Data (including PHI), to Program Partners in connection with Advanced Features and other Available

Programs to assist Customer in its treatment, payment, and healthcare operations activities;

(iv) supporting Customer's participation in InSite POS and TruVuPOS and other business offerings under The Front-End Solution (Term Sheet 5), whereby ABDC and Retail Insights furnish point-of-sale Pharmacy Data to manufacturers to support Customer's participation in manufacturer-sponsored promotions and related offerings;

(v) identifying validating, and/or developing programs, solutions or actions that might benefit Customer's business, evaluating, managing, and/or improving the Available Programs in which Customer participates, and conducting outreach campaigns in connection with the foregoing, including sharing with ABDC's affiliates, members of ABDC's sales team, and Customer's Business Coaching Associate (as defined in Term Sheet 7), buying group, aggregation group, or group purchasing organization (if any); and

(vi) any other lawful use for which ABDC obtains the express written consent of Customer.

ABDC may not market or otherwise provide Pharmacy Data derivative works that include protected health information or, unless otherwise agreed by ABDC and Customer, that identify Customer as the source of specific data.

8. No Representations

Participating system vendors and Program Partners were chosen in part because of their established record in successfully developing, marketing, installing and supporting systems used by community pharmacies. However, ABDC has not performed any financial or other due diligence and makes no warranty, including any implied warranty, about any system vendor or Program Partner or its financial viability or responsibility. ABDC is not acting as a guarantor for any system vendor or Program Partner. Notwithstanding anything to the contrary contained herein or in the Agreement, ABDC reserves the right to change Program Partners at any time.

All other terms and conditions of the Master Program Agreement, including all Exhibits thereto, are hereby incorporated by reference into this Term Sheet. Capitalized words not defined in this Term Sheet have the meaning defined in the Master Program Agreement, Elevate Provider Network Term Sheet, or Elevate Advanced Features Term Sheet, as applicable.



Five-Star Rebate Program Term Sheet

1. Program Description

This program is offered to recognize high performance in adherence and other pharmacy performance measures and to aid Customer in its healthcare operations activities, including meeting its purchasing obligations under its agreements with ABDC.

2. Data Consent

By enrolling in this Available Program, Customer hereby authorizes ABDC to derive dispense usage data from Pharmacy Data and to use and share such data, including pharmacy performance and benchmarking data, with ABDC's Sales and other associates, as well as Customer's designated buying group, for the purposes of aiding Customer in its healthcare operations activities, including meeting its purchasing obligations under its agreements with ABDC, as well as improving the overall effectiveness of the PRxO Generics program. In all cases, ABDC's use of Pharmacy Data will be in accordance with ABDC's Data Protection Provisions and applicable laws and regulations including HIPAA. The foregoing consent applies to Pharmacy Data captured through any Available Program in which Customer is enrolled as of or enrolls in subsequent to the Effective Date, notwithstanding any limitations of use in any such authorization. Customer may withdraw such consent at any point by providing written notice to ABDC, at which time Customer will no longer be eligible for the Five-Star Rebate.

3. Performance Measurements and Rebate Table

Currently, Star Measure Ratings used for the rebate calculation are based upon, and determined at such time as, the most recent ratings data provided to AmerisourceBergen by EQUIPP® and where necessary directly from MTM providers and others. ABDC calculates the average score used for the Five-Star Rebate calculation. Where rating thresholds vary between MAPD and PDP plans, the higher of the two is used. Where ratings are not available from EQUIPP a rating of 3.0 is used. In the future, ABDC may adopt alternative sources of STAR measures, directly calculate the measures using Pharmacy Data, as well as use alternative techniques to stratify pharmacy performance such as percentiles.

4. Eligibility

The Five-Star Rebate is available to retail, independent pharmacies not affiliated with a buying group, or whose buying group participates in this Available Program, that meet all applicable eligibility criteria. Eligibility requirements vary by participating buying group affiliation (if any), and Customer may consult with its buying group for additional eligibility requirements. Customer must be a franchisee under the Premier program (including participation in Elevate Provider Network) or separately

enrolled and active in Elevate Provider Network (Term Sheet 1) to be eligible to participate in this Available Program. Customer must also be in compliance with all other required terms to be eligible and otherwise submit all required data for each quarter being measured in full, as applicable respecting each measurement period of participation.

5. Data Requirements

- a) Elevate Advanced Features (Term Sheet 2)
- b) Pre and Post Edits and data capture with Change Healthcare (Term Sheet 2A) or data capture via other claims switching services provider approved by ABDC in writing
- c) InSite from ABDC (Term Sheet 3).

To be eligible for the Five-Star Rebate, Customer must submit its third-party claims through the PPE program, or other claims switching services provider approved by ABDC in writing.

6. Helping Improve Purchase Performance

In coordination with Customer's buying group (if any), ABDC equips its teams and Customer's buying group with the results of matching dispensed quantities to wholesale purchase quantities so ABDC can collectively work with Customer to identify missed opportunities and assist Customer in optimizing its purchase performance and rebate opportunities.

7. ABDC Generics Rebate Table

Only one level of Five-Star Rebate is paid per pharmacy. Rebate performance will be measured at the end of each calendar quarter and, unless agreed-upon otherwise as between ABDC and Customer's buying group (if any), credits issued directly to Customer within six weeks of quarter end. Rebates are based and credited on net purchases of rebatable ABDC generics products during the quarter under Customer's applicable generics program.

Standard Calculation

Average Star Rating 0.00 to 2.99	0.25%
Average Star Rating 3.00 to 3.99	0.50%
Average Star Rating 4.00 to 4.49	0.75%
Average Star Rating 4.50 to 5.00	1.00%

8. Other

- a) Distribution Agreement. Customer must be in compliance with the terms of its distribution agreement with ABDC when credits are issued.
- b) Other PRxO Generics Rebates. This Five-Star Rebate is in addition to all other discounts, rebates or other incentives related to PRxO Generics purchases.
- c) Discount Reporting and Safe Harbor. Customer agrees to comply with all laws, including reporting on reflecting

discounts, rebates and other price reductions, including this rebate, pursuant to 42 U.S.C. § 1320a-7b(b)(3)(A) and 42 CFR 1001.952(h) on cost reports or claims submitted to federal or state healthcare programs, retaining invoices and related pricing documentation and making them available on request to healthcare program representatives.

d) ABDC may modify or terminate this Five-Star Rebate Program at any time on 30 days' notice prior to the start of the next calendar quarter. In the event of termination of the Five-Star Rebate Program, ABDC's provision of rebates under this Available Program will cease concurrently upon the effective date of such termination, unless otherwise agreed to in writing by ABDC.

All other terms and conditions of the Master Program Agreement, including all Exhibits thereto, are hereby incorporated by reference into this Term Sheet. Capitalized words not defined in this Term Sheet have the meaning defined in the Master Program Agreement, Elevate Provider Network Term Sheet, or Elevate Advanced Features Term Sheet, as applicable.



Front-End Solution Programs Term Sheet

1. Program Description

The following interrelated front-of-store services and programs (collectively, the “**Front-End Solution Programs**”) are designed to assist Customer in promoting traditional drugstore non-prescription product categories. Certain services are available only to Premier and GNP Pharmacies. Separate enrollment is required for each Front-End Solution Program.

2. Planogram Services

ABDC regularly publishes and updates schematic diagrams (“**Planograms**”) that specify optimal layouts of traditional drug store non-prescription product categories, designed to maximize consumer interest and increase Customer's sales. Customer must substantially comply with Planogram layouts and stock substantially all Planogram products.

Premier: Included; no additional fee

GNP: No additional fee

Other: \$55 per month (\$89 combined with Zone Pricing)

3. Retail Product Zone Pricing Service

ABDC regularly publishes and updates suggested retail price files for traditional drug store non-prescription products. Zone prices are based on factors, such as product, product category and targeted competitiveness. Customer is solely responsible for determining the extent to which it uses and/or implements any such suggested retail prices.

Premier: Included; no additional fee

GNP: No additional fee

Other: \$45 per month (\$89 combined with Planograms)

4. First To Shelf™ (AutoShip New OTC)

With First To Shelf™, ABDC delivers to Customer, without a corresponding order (“**AutoShip**”), commercially reasonable quantities of certain OTC products to facilitate prompt stocking of such products by Customer in anticipation of new or increased consumer demand. Such products may include new market break items, GNP Private Label Products and Rx-to-OTC switch items. Customer will accept and pay for such products and promptly display them for sale consistent with the Planogram.

Premier: Required; no additional fee

GNP: No additional fee

Other: Not available

5. Front-End Support Kit

As an integral component of the Good Neighbor Pharmacy program, ABDC provides in-store promotional materials in reasonable quantities in a monthly kit. Customer will promptly display in-store promotional materials consistent with directions from ABDC in Program Guides.

Premier: Option to opt-in during customer onboarding; no additional fee

GNP: Option to opt-in during customer onboarding; no additional fee

Other: Not available

6. Merchandising Services

ABDC will make reasonable efforts to assign a Retail Merchandising Specialist within six (6) months of Customer completing all Premier requirements. ABDC may reasonably limit time and resources devoted to Merchandising services. To continue receiving merchandising services Customer must allow the representative to execute the Planogram and requires Customer to maintain the Planogram sections in between visits by ABDC's representative.

Premier: Included; no additional fee

GNP: Limited availability (pricing based on scope of work)

Other: Limited availability (pricing based on scope of work)

7. InSite POS from ABDC

Customer, if using InSite from ABDC, authorizes limited use and exchange of Pharmacy Data by and among (a): (i) ABDC, including merchandisers and sales associates; (ii) Customer's buying group, aggregation group, or group purchasing organization (if any); and (iii) ABDC's Program Partners, to assist Customer and to enhance the Front-End Solutions Program and related Available Programs through means such as measuring the effectiveness of promotions and other promotional material; and (b) manufacturers who partner with ABDC, or ABDC's Program Partners, to enable access to promotional offerings and to provide funding to help support the Front-End Solutions Program and related Available Programs.

All other terms and conditions of the Master Program Agreement, including all Exhibits thereto, are hereby incorporated by reference into this Term Sheet. Capitalized words not defined in this Term Sheet have the meaning defined in the Master Program Agreement, Elevate Provider Network Term Sheet, or Elevate Advanced Features Term Sheet, as Applicable.



Digital Marketing Programs Term Sheet

1. Program Description

The following interrelated programs (“**Digital Marketing Programs**”) are part of an overall strategy to attract and engage patients and consumers online. Separate enrollment is required for each Digital Marketing Program.

2. MyGNP Website

ABDC hosts a consumer website designed to attract patients and other consumers (“**Visitors**”) and build their loyalty for Premier and GNP Pharmacies (“**Website**”), currently www.MyGNP.com. This Available Program includes an individual subdomain (“**Local Page**”) and Local Page subdomain name, maintenance, user data, licensed content, and prescription refill requests.

Premier: Included; no additional fee

GNP: Included; no additional fee

Other: Not available

3. MyGNP Mobile App

ABDC publishes a Good Neighbor Pharmacy branded application available for consumers to download and use on mobile phones. The application includes prescription refill requests.

Premier: Included; no additional fee

GNP: Included; no additional fee

Other: Not available

4. Social Media and Online Reviews

ABDC provides, through its respective Program Partner, a platform designed for online review and multi-network social media management, including a robust content library, performance statistics, and reputation management. Content may be posted by Customer or on behalf of Customer. Customer is solely responsible for any and all content posted by Customer, including, without limitation, content generated or altered by Customer through the use of artificial intelligence or related technology.

Premier: Included; no additional fee.

GNP: Not available

Other: Not available

5. Local Listings Management

ABDC assists Customer to claim and manage online business listings so that local consumers using search engines are presented full and accurate pharmacy information such as location, hours and contact information.

Premier: Included; no additional fee

GNP: Included; no additional fee

Other: Not available

6. Digital Marketing

ABDC runs or makes available certain pay-per-click advertising campaigns, such as pay-per-click advertising campaigns through internet search engine advertising platforms.

Premier: Included; no additional fee

GNP: Not available

Other: Not available

Additional optional digital advertising services, such as ad hoc digital marketing campaign opportunities, may be made available via separate enrollment form(s) and subject to additional terms, conditions, and fees (which may vary based on options selected). Except as otherwise specified, to participate in additional advertising, a minimum advertising contribution of \$100 is required in addition to agency and administrative fees.

7. Program Prerequisites

a) Good Neighbor Pharmacy. Customer must be a Premier or GNP Pharmacy in good standing.

b) Platform Permissions. Customer must enable and configure its social media accounts to allow ABDC to provide the services.

c) Interactive App Refill Service. ABDC, through its Program Partner Outcomes, offers an interactive mobile-application-based refill service for consumers ordering prescription refills through the “MyGNP” mobile application. Customer’s eligibility to use the interactive prescription refill service is subject to Customer’s enrollment in the Outcomes PCS Solution (Term Sheet 2C), the participation of its designated pharmacy system vendor, and other eligibility requirements provided in the Program Guides. Fax service is used for prescription refill requests that cannot be delivered through the interactive service.

d) HIPAA Compliance. As required, ABDC and Customer have entered into a HIPAA Business Associate Agreement (Exhibit B or as otherwise agreed).

8. ABDC Responsibilities

a) Hosting. ABDC through its service providers and Program Partners hosts or makes available the Website and Local Pages and publishes the mobile application.

b) ABDC Content. All materials provided by ABDC to Customer for the Digital Marketing Programs, including templates, content, data, graphics, design, information, computer software, logos, trademarks, processes, methodologies, know-how, or any other proprietary materials provided by ABDC or its licensors, (collectively, the “ABDC Content”) are the sole and exclusive property of ABDC or its licensors. ABDC grants Customer a non-exclusive, limited license to use and display ABDC Content on the applicable application while Customer participates in this Available Program. ABDC controls and owns all rights to registered domain and subdomain names.

c) Templates. ABDC provides templates that allow Customer to provide limited content, in a format specified by ABDC, for the applicable program pursuant to this Term Sheet.

d) Visitor Data. ABDC collects certain click stream and similar data on Visitor usage, which it may choose to make available to Customer periodically. As between ABDC and Customer, information collected from the

AmerisourceBergen

Digital Marketing Programs are the sole and exclusive property of ABDC, including email addresses provided by Visitors.

9. Customer Responsibilities

a) Customer Authorization and Content. Customer is responsible for all content and materials provided by Customer for use in any of the Digital Marketing Programs (“**Customer Content**”). Customer Content must be related to Customer’s GNP business and comply with Program Guides. Customer must update and modify Customer Content so it is fresh and current. ABDC may remove, or demand that Customer remove, content that is not consistent with Program Guides.

b) Customer hereby authorizes and consents to ABDC’s use and access to Customer’s social media accounts, website, and any other digital resources of Customer such as may be necessary for ABDC to carry out its responsibilities pursuant to this Term Sheet. Customer hereby consents to ABDC and Program Partners’ use, access to, and exchange of business, operational, and financial data regarding Customer’s Pharmacy (collectively, “**Business Data**”) during the performance of its obligations. This Business Data authorization is in addition to and supplements Customer’s data authorization and consent for Pharmacy Data previously executed and provided to ABDC for all other Terms Sheets associated with the MPA between the parties.

c) Notwithstanding anything to the contrary contained in the Agreement, Customer hereby authorizes ABDC to receive, use, create, use and disclose derivative works of, and disclose to Customer’s Business Coach (as defined in Term Sheet 7) and ABDC’s and its affiliates’ employees, affiliates, and Program Partners supporting the Digital Marketing Programs, as applicable, any and all Pharmacy Data (excluding PHI) and/or other data (if any) resulting from Customer’s participation in the Digital Marketing Programs, including receipt, use, creation of derivative works, and/or disclosure in formats that may identify Customer as the source of such data, for the purposes of analysis, benchmarking, reporting, and as Customer may otherwise agree in writing.

d) Legal Compliance. Customer represents and warrants that: (i) it owns the Customer Content or is authorized to include it in emails and/or in its use of the Digital Marketing Programs; and (ii) no Customer Content will be inaccurate, deceptive, fraudulent; infringe on any third-party intellectual property rights; or otherwise violate any law.

e) License. Customer hereby grants to ABDC a non-exclusive, royalty-free license to publish, transmit, modify, display, distribute, translate, and adapt Customer Content in connection with its performance under this Available Program.

f) Privacy. Customer must comply with privacy laws for information collected from its use of the Digital Marketing Programs, including notices required by HIPAA for protected health information. Personal and non-personal information collected, used, or disclosed is subject to ABDC’s privacy policy posted on the Website. The Website privacy policy does not apply, and ABDC is not responsible, when a Visitor is redirected to any other internet site.

10. Disclaimers

The Digital Marketing Programs may be unavailable due to scheduled maintenance and required repairs or due to causes beyond the control of ABDC or its hosting Program Partner. Pursuant to Paragraphs 3 and 7.2 of Exhibit C (Provisions) of the Premier Agreement, ABDC DOES NOT GUARANTEE AVAILABILITY OF THE DIGITAL MARKETING PROGRAMS AND DISCLAIMS ANY AND ALL LIABILITY FOR DIRECT, INDIRECT OR CONSEQUENTIAL DAMAGES ARISING FROM OR RELATED TO CUSTOMER’S OR VISITOR’S USE OF THE WEBSITE OR LOCAL PAGES, INCLUDING ANY INTERRUPTION OR UNAVAILABILITY.

All other terms and conditions of the Master Program Agreement, including all Exhibits thereto, are hereby incorporated by reference into this Term Sheet. Capitalized words not defined in this Term Sheet have the meaning defined in the Master Program Agreement, Elevate Provider Network Term Sheet, or Elevate Advanced Features Term Sheet, as applicable.



Business Coaching Term Sheet

1. Program Description

- a) ABDC will provide to Customer certain recommendations of industry best practices related to increasing Pharmacy's performance ("**Business Coaching**") through its representative ("**Business Coaching Associate**").
- b) Business Coaching value depends on Customer providing complete and accurate information to the Business Coaching Associate and implementing recommended industry best practices as Customer determines are appropriate to its operations. Business Coaching focuses primarily on assessing Pharmacy's current performance and practices and identifying opportunities to improve performance with high impact changes that can be implemented in reasonable timeframes, based upon complexity of applicable changes, without significant capital investment.
- c) This Available Program is not comprehensive business consulting, nor is it designed to build long-term business plans or investigate every potential opportunity for improvement; it is based on a specific set of performance indicators that ABDC found increased performance at other community pharmacies.

2. Pricing

Premier: Included; no additional fee

GNP: Not available

Other: Not available

3. Program Prerequisites

- a) Pharmacy Data. Customer must be a Premier Pharmacy and must participate in Elevate Advanced Features (Term Sheet 2) and InSite from ABDC (Term Sheet 3).
- b) HIPAA Compliance. As required, ABDC and Customer entered into a HIPAA Business Associate Agreement (Exhibit B or as otherwise agreed).

4. Duration of Program

ABDC will make reasonable efforts to assign a Business Coaching Associate within six (6) months of Customer completing all Premier requirements and to provide ongoing Business Coaching support as long as Customer is active in this Available Program, including, without limitation, remaining actively engaged with the assigned Business Coaching Associate. ABDC may reasonably limit time and resources devoted to Business Coaching.

5. ABDC Responsibilities

- a) Startup. Business Coaching Associate will work with Customer, or with other authorized Pharmacy personnel identified by customer (collectively, "**Authorized Pharmacy Personnel**"), to gather a defined set of business data, including financial and operational data, and data available through InSite from ABDC to enable the Business Coaching Associate and business analysts to analyze Pharmacy performance ("Coaching Data").
- b) Recommendations. Based on the information provided by Customer and/or Authorized Pharmacy Personnel, data

available through InSite from ABDC, comparisons with similar pharmacies, and information from other resources, such as local demographics, Business Coaching Associate and supporting business analysts will develop a report detailing their findings and include a set of recommended industry best practices related to increasing Pharmacy's performance.

c) Presentation of Findings and Recommendations. Business Coaching Associate will present and review the findings and recommendations in a series of discussions conducted face-to-face, using interactive internet presentations, or by telephone, the objective of which is to increase Customer's understanding of its business performance and enable Customer to select from all recommendations those that Customer determines are most appropriate for its business. Detailed findings may include benchmarking and comparisons of analytics with similar pharmacies, analysis of patient loyalty, assessment of product offerings and pricing strategies, or specific observations regarding inventory management, financial management, operational systems, labor and productivity, managed care reimbursements, hours of operation, patient care services, prescriber and patient marketing strategies, and front-end effectiveness. Presentation and review will be conducted directly with Customer or with applicable Authorized Pharmacy Personnel as agreed.

d) Implementation. Customer may implement the priority recommendations selected by Customer or Authorized Pharmacy Personnel, as applicable. Business Coaching Associate may also offer additional recommendations to mitigate issues Customer may experience in implementing the recommendations.

e) On-Going Coaching. As recommendations are implemented, Business Coaching Associate may encourage Customer or Authorized Pharmacy Personnel, as applicable, to pursue additional performance improvements based on previous findings.

f) Goal Setting. Business Coaching Associate will assist Customer or Authorized Pharmacy Personnel, as applicable, in establishing strategic, operational and growth goals for its coming year.

g) Authorization; Privacy of Customer Data. Customer authorizes limited use, disclosure, and exchange of Pharmacy Data by and among ABDC and Program Partners, including its associates and subcontractors who provide Business Coaching and analysis, pursuant to the Data Protection Provisions (Exhibit A) to assist Customer and improve the overall effectiveness of this Available Program. For greater clarity, except as set forth above, as may be applicable to Authorized Pharmacy Personnel, or as otherwise authorized by Customer, no other person will have access to Customer's Coaching Data, including members of ABDC's pharmacy distribution sales force engaged in selling products to Customer's Pharmacy. This enhanced privacy for Coaching Data supersedes any otherwise authorized uses under the Master Program Agreement.

CONSTITUTE OR REFLECT LEGAL, MEDICAL, OR OTHER PROFESSIONAL ADVICE.

6. Customer Responsibilities

a) Gather Data. Prior to the initial meeting, Customer will gather a pre-defined list of business reports, to be supplemented as reasonably requested by Business Coaching Associate, including: (i) Financial statements: 12-month profit and loss statements, balance sheets, and payroll information; (ii) Operational data: inventory, labor and other information not available in InSite; and (iii) Other information: as deemed necessary. Full-scope business coaching services may not be able to commence until customer data is provided.

b) Customer Action. Customer will implement recommendations that Customer determines are appropriate to its operations, and monitor the operational and financial impact of such recommendations.

c) Customer Responsibility. Customer acknowledges and agrees that it is solely responsible for: (i) the decision to implement and the implementation of the industry best practices recommended by the Business Coaching Associate; and (ii) all actions, inactions, and/or other activity by its Authorized Pharmacy Personnel. ALL RISKS ASSOCIATED WITH BUSINESS COACHING, THE RESULTS THEREOF, OR OTHERWISE IN CONNECTION WITH THIS AVAILABLE PROGRAM, ARE EXPRESSLY ASSUMED BY CUSTOMER, AND ALL BUSINESS COACHING IS PROVIDED “AS-IS”, WITHOUT REPRESENTATION OR WARRANTY OF ANY KIND, AND IS NOT INTENDED TO

All other terms and conditions of the Master Program Agreement, including all Exhibits thereto, are hereby incorporated by reference into this Term Sheet. Capitalized words not defined in this Term Sheet have the meaning defined in the Master Program Agreement, Elevate Provider Network Term Sheet, or Elevate Advanced Features Term Sheet, as applicable.

◆◆◆

Pharmacy Data Services Term Sheet

1. Program Description

ABDC will furnish to Customer the following data services (“**Data Services**”) to assist with pharmacy computer applications, including pharmacy management and point-of-sale systems. Data Services are only available to ABDC customers. Multi-location computer systems, whether or not connected, will be charged per Pharmacy or other location.

2. Electronic Order Entry and Confirmation

ABDC accepts electronic purchase orders directly from Customer's computer system and provides electronic confirmation that an order has been received and that stock is allocated to fill the order. Confirmation is sent directly to Customer's systems when enabled by Customer's system vendors. There are no fees for electronic order entry and confirmation.

3. Catalog and Price Updates–Rx Products

ABDC provides electronic product descriptions and pricing data that Customer may download to its pharmacy management and point of sale systems, including basic drug description fields, Customer's invoice cost, contract price, and standard reference benchmarks such as average wholesale price (“**AWP**”) or Suggested Wholesale Price (“**SWP**”) for prescription pharmaceuticals. ABDC currently obtains Data Services information from First Databank (“**FDB**”) and, where FDB does not provide standard benchmarks available from other publishers, ABDC may supplement it by using an industry standard calculation (for example, 1.2 times FDB's WAC for brand Rx). Initial file loads may include all eligible products or be based on Customer's purchase history.

Premier:	Included; no additional fee
GNP:	\$55 per month
Other:	\$55 per month

4. Catalog and Price Updates–OTC Products

ABDC provides electronic pricing data for point-of-sale systems relating to Customer's invoice acquisition cost, contract prices, and retail selling prices for over-the-counter and other non-prescription products. Initial file loads can include all eligible products or be based on Customer's purchase history.

Premier:	Included; no additional fee
GNP:	\$55 per month
Other:	\$55 per month

5. Delivery Options

- a) EDI File Download. Subject to capabilities of Customer's systems, allows unattended exchange of EDI documents to support all three Data Services.
- b) Secure Web Site. A secure directory for downloading catalog and price update files (Rx and OTC).

6. Compendia Sources and Benchmark Prices

a) First Databank. ABDC obtains certain industry and benchmark price data for use in Data Services from FDB. Where FDB does not provide standard reference benchmarks (such as AWP) available from other publishers, ABDC may supplement it by using an industry standard calculation (for example, 1.2 times FDB's WAC for brand Rx).

b) Medi-Span. ABDC obtains certain industry and standard reference benchmarks from Medi-Span.

7. Disclaimers

ABDC uses reasonable care in collecting and transmitting Data Services information. ABDC obtains some Data Services information from other parties it believes are reliable, such as SWP from FDB. However, pursuant to Paragraph 7.2 of Exhibit C (Provisions), ABDC does not warrant accuracy of codes, prices or other Data Services information. Data Services information is intended as a supplement to, and not a substitute for, knowledge, expertise, skill and judgment of Customer and Customer's pharmacists and other professionals. ABDC strongly encourages Customer to regularly review its systems to identify and address incorrect application of Data Services information, such as different assumptions about package size, case quantities, units of measure or units of use.

8. 340B Program

Notwithstanding any contrary provisions herein, if Customer is eligible to participate in the 340B drug purchase program established pursuant to the Veterans Health Care Act of 1992 as part of Public Law 102-585 (“**340B Program**”) and uses the services of a third party (“**340B Service Provider**”) to assist with its participation in the 340B Program, in the event that Customer requests ABDC to provide Data Services to its 340B Service Provider, Customer will: (i) enter into an agreement with its 340B Service Provider containing confidentiality and other provisions that are similar in form and substance to those set forth herein with respect to the Data Services; and (ii) indemnify ABDC with respect to any Data Services ABDC provides to a 340B Service Provider at Customer's request.

All other terms and conditions of the Master Program Agreement, including all Exhibits thereto, are hereby incorporated by reference into this Term Sheet. Capitalized words not defined in this Term Sheet have the meaning defined in the Master Program Agreement, Elevate Provider Network Term Sheet, or Elevate Advanced Features Term Sheet, as applicable.



Unsaleable Returns Term Sheet

1. Program Description

ABDC's unsaleable returns program provides pharmacies with a comprehensive solution for the proper disposal of unsaleable pharmaceutical products and includes all processing, shipping, and disposal costs, while allowing pharmacies to optimize the recoverable value of returned products. This Available Program is available to retail, independent community pharmacies and long-term care pharmacies.

2. Contract Returns Processor

ABDC utilizes a third party as its designated "**Contract Returns Processor**" (currently Inmar Inc., hereinafter referred to as "**Inmar**"). Customer must be authorized by ABDC to participate in this Available Program. Customer must use the portal to administer and process returns which are shipped directly to Inmar and processed once per month for potential manufacturer credit. Returns received after the published cutoff dates are processed the following month. Unsaleable products should be returned during the month the product expires as printed on the container as certain manufacturers do not issue credit for products returned before the expiration date. Customer is solely responsible for tracking and monitoring returns activity on the portal including details of products deemed eligible for manufacturer credit and reasons for products deemed not eligible for credit. Reports are on the portal.

3. Credit Valuation

a) **Base Program.** Credit issued to Customer is based on the actual credit received from the manufacturer less Available Program fees to cover all shipping charges, processing and disposal costs, and financial reconciliation costs incurred by ABDC. Customer will receive a check for 80% of the manufacturer credit for eligible prescription products and 70% of the manufacturer credit for eligible non-prescription healthcare products.

b) **GNP Premier Program.** If Customer is a GNP Premier member, Customer may be issued a credit in advance of ABDC receiving credits from the manufacturer based on the Estimated Recovery Value ("ERV"). The ERV is calculated by ABDC based on the applicable manufacturer's return goods policies (which vary) and the manufacturer's credit issuance practices. Customer will receive a credit in the form of a check for the equivalent of 80% of the ERV for eligible prescription products and 70% of the ERV for eligible non-prescription healthcare products. The reduction of the ERV amount reflects a fee retained by ABDC for its services and costs incurred to manage this Available Program including shipping charges, processing and disposal costs, and financial reconciliation costs.

c) ABDC may adjust the ERV and credit amount at its discretion to reflect changes in manufacturer credit valuations, credit issuance policies, and distribution terms respective the products being returned. The amount credited to the Customer is not contingent on manufacturer

issuing credit to ABDC, excluding the following conditions ("**Exclusions**"): unusually large quantities of products that are returned through this Available Program; MRNA and flu vaccine products subject to manufacturer return restrictions; returned products not purchased from ABDC; manufacturer making payments directly to Customer; and manufacturer selling products to distributors on a non-returnable basis. Adjustments to reported ERV subsequent to product return receipt and processing by Contract Returns Processor may alter check issuance dates and amounts paid to Customer for such Exclusions.

d) Contract Returns Processor's on-line portal may not always reflect most current ERV but provides the final credit amount issued to Customer in the form of a check. The products not eligible for ERV credit may be accepted by the Contract Returns Processor for disposal (but will not be returned to Customer). ABDC may adjust the fees retained or implement ancillary fees for certain services as necessary.

4. Payments

a) **Base Program.** Customer receives a monthly check that includes all manufacturer credits issued, on Customer's behalf, to ABDC during the previous month.

b) **GNP Premier Program.** If Customer is a GNP Premier member, Customer receives a single check for the eligible products returned to the Contract Return Processor during the monthly return period. The check will be issued within 45 days of the close of the return period when processed returns are eligible for credit, reported by the Contract Returns Processor, and not subject to Exclusions.

5. Premier Franchisee Benefits

a) **On-Site Assistance.** On-site assistance is available to *Good Neighbor Pharmacy* Premier Members that are in good standing. On-site services include processing of returns, packing and shipping of returned products, printing inventory manifests, and requesting Form 222 for CII Products. Such services are provided by Retail Merchandising Specialists and are optional. Eligible products may be returned directly to the Contract Returns Processor between on-site visits.

b) **Prefunded Value.** Customer's check amount is based on the credit valuation described in Section 3 and is issued within 45 days of the end of the Contract Returns Processor's reporting period. Customer is not required to reconcile the return claims to the manufacturers and the payment issued by manufacturers, which can take several months, enhancing cash flow and reducing expense.

6. Products Included

- a) Prescription products, including controlled substances.
- b) Full and partial containers.
- c) Over-the-counter healthcare products in full containers.

Agreement, Elevate Provider Network Term Sheet, or Elevate Advanced Features Term Sheet, as applicable.



7. Products Not Eligible for Credit

- a) Products not purchased from ABDC and ineligible per manufacturer return goods policy or credit issuance practices.
- b) Products not in manufacturer's original container.
- c) Products returned outside manufacturer allowable dates.
- d) Products that are private labeled (e.g., *Good Neighbor Pharmacy* private label products, etc.).
- e) Products that are non-pharmaceuticals such as medical equipment and home healthcare aids.

8. Recalled Products

- a) Recalled products may be returned by Customer directly to manufacturers or the manufacturer's returns processor according to the manufacturer's recall instructions issued at the time of the recall.
- b) Recalled products may also be returned through this Available Program, and credit received according to the credit valuation terms in Section 3.

9. Other Terms

- a) Other terms and conditions provided or required by the Contract Returns Processor (e.g., no acceptance of products that are leaking, broken, tampered with, contaminated, or otherwise soiled, etc.) may apply.
- b) This Available Program does not cover unsaleable products returned to Customer's servicing distribution center.
- c) This Available Program does not cover saleable products, flu vaccines, or Good Neighbor Pharmacy private label products, each of which should be returned directly to Customer's servicing distribution center in accordance with ABDC's standard returns policy.
- d) Customer must comply with shipping, product handling and disposal, and return authorization requirements, including but not limited to DOT, DEA, FDA, HIPAA, and EPA requirements and applicable federal, state, and local laws.

10. Long-Term Care Pharmacies

Non-prescription products and excessive returns not in original manufacturer's packaging are not eligible for return.

11. Customers located in the State of Georgia

To comply with Georgia regulations, the following terms apply: (i) invoice credits are issued within 60 days after processing; (ii) prescription healthcare products must be purchased from ABDC to be eligible for credit; (iii) non-prescription healthcare products may be returned for disposal, but no credit is issued; (iv) products must be returned after the product expiration date and must be processed by Contracts Returns Processor within six months after the expiration date; and (v) the credit amount is based on Customer's purchase price from ABDC less a 7% fee.

All other terms and conditions of the Master Program Agreement, including all Exhibits thereto, are hereby incorporated by reference into this Term Sheet. Capitalized words not defined in this Term Sheet have the meaning defined in the Master Program

Statement of Work-Services (Form)
For Special Projects

AmerisourceBergen Drug Corporation ("ABDC") will furnish the following special services ("Services") to Customer pursuant to this Statement of Work ("SOW"). This SOW is effective as of _____ ("SOW Effective Date").

1. Description of Work. ABDC will perform the following Services:

A. Description: _____

B. Schedule: _____

C. ABDC Training: _____

D. Performance of all Services will be concluded by: _____

2. Compensation. Customer will compensate ABDC as follows for Services.

- A. Option 1—Time and materials. ABDC will issue invoices at the end of each [day/week/month] for Services performed in the previous [day/week/month]. Invoices will itemize charges with reasonable detail. Payment is due within 15 days from the applicable invoice date.

Customer will pay ABDC \$ _____ per _____ [day/week/month] per person.

- B. Option 2—Fixed price. ABDC will invoice Customer for fixed amounts below. Invoices will itemize charges in reasonable detail. Payment is due within 15 days from the applicable invoice date.

Customer will pay ABDC \$ _____ as follows: _____ % upon execution of this SOW;
 _____ % upon completion of:

_____ % upon completion of:

_____ % upon full completion of Services.

3. Expenses. Customer will reimburse ABDC for reasonable documented expenses incurred consistent with ABDC's travel and expense policy.

4. Incorporation of Terms. All other terms and conditions of the Master Program Agreement, including all Exhibits thereto, are hereby incorporated by reference into this SOW. Capitalized words not defined in this SOW have the meaning defined in the Master Program Agreement, Elevate Provider Network Term Sheet, or Elevate Advanced Features Term Sheet, as applicable.

IN WITNESS WHEREOF, each party's authorized officer, partner or principal has signed this Statement of Work as of the SOW Effective Date.

Customer

ABDC

By: _____ By: _____

Name: _____ Name: _____

Title: _____

Title: _____

Date Signed: _____

Date Signed: _____

NOTE: This form applies to special projects and other work that is outside the scope of any other Available Program and agreed upon by ABDC and Customer. Using this SOW Form allows the parties to quickly and easily agree on work to be done for Customer, as well as price and other terms. Special projects must be priced at full fair market value.

EXHIBIT C
TABLE OF CONTENTS OF GNP MANUAL(S)

Table of Contents

<i>Good Neighbor Pharmacy Overview</i>	3	<i>Elevate Provider Network</i>	61
<i>Good Neighbor Pharmacy Brand Guidelines</i>	7	<i>Business performance</i>	68
<i>Good Neighbor Pharmacy Central</i>	27	<i>Pet health</i>	70
<i>In-Store Experience</i>	28	<i>Marketplace Overview</i>	71
<i>The Front-End solution, retail pricing, planograms and merchandising</i>	30	<i>Blood pressure management</i>	72
<i>Good Neighbor Pharmacy private label products</i>	31	<i>Expo RX Card</i>	73
<i>Good Neighbor Pharmacy private label autoshipments</i>	32	<i>Credit card processing</i>	75
<i>Free Vitamin Program</i>	33	<i>Good Neighbor Pharmacy prescription bags</i>	76
<i>Pharmacy and point of sale systems</i>	34	<i>On-hold messaging services</i>	77
<i>PRxO Generics</i>	37	<i>Photo service</i>	78
<i>Unsaleable returns program</i>	41	<i>Retailer gift cards and other popular prepaid cards</i>	79
<i>Good Neighbor Pharmacy University</i>	42	<i>Travel and trial size items</i>	80
<i>Marketing</i>	55	<i>Vials and caps</i>	81
<i>Marketing offerings and resources</i>	57	<i>Good Neighbor Pharmacy programs and resources</i>	91
<i>Protect your independence</i>	59		

EXHIBIT D
LIST OF CURRENT AND FORMER FRANCHISEES AS OF SEPTEMBER 30, 2025
CURRENT FRANCHISEES

ACTIVE PREMIER FRANCHISEES

Account Name	Business Street Address	Business Address City	Business Address State	Zip Code	Business Phone
Barnett's Drug	1661 East Lee Street	Rogersville	Alabama	35652	(256) 247-5451
Beauregard Drugs, Inc	7667 Alabama Hwy 51 Suite A	Opelika	Alabama	36804	(334) 364-9993
Boone's Pharmacy	203 Lafayette Street	Livingston	Alabama	35470	(205) 652-7022
Borden Family Pharmacy	3190 Alabama Highway 157	Cullman	Alabama	35058	(256) 734-7535
Chads Payless Pharmacy Inc	501 West College Street	Florence	Alabama	35630	(256) 766-3298
Chandler Drugs	914 7th St South	Clanton	Alabama	35045-3718	(205) 755-8009
Ed Holcombe Discount Pharmacy	106 2nd Avenue Southwest	Cullman	Alabama	35055	(256) 734-1083
Fort Payne Pharmacy	1614 Glenn Blvd SW	Fort Payne	Alabama	35968-3522	(256) 845-3402
Fred's Pharmacy	797 Military Street South	Hamilton	Alabama	35570	(205) 921-3193
Gadsden City Pharmacy	911 RAINBOW DR	GADSDEN	Alabama	35901	(256) 547-4479
Hackleburg Pharmacy	34863 Highway 43	Hackleburg	Alabama	35564	(205) 935-3392
J&M Pharmacy and Compounding Center LLC	301 2nd Ave W.	Oneonta	Alabama	35121	(205) 274-2740
Jackson Apothecary	12755 Hwy 22E	New Site	Alabama	36256	(256) 392-3448
Jackson Drugs	1974 Cherokee Road	Alexander City	Alabama	35010-3437	(256) 234-2538
Killen Corner Drug	1621 Highway 72	Killen	Alabama	35645	(256) 757-2166
Mill Street Pharmacy	10639 Alabama Highway 168	Boaz	Alabama	35957	(256) 593-5279
Payless Drugs	2512 31st Avenue North	Birmingham	Alabama	35207	(205) 252-4179
Payless Drugs	460 Walker Rd	Springville	Alabama	35146-0252	(205) 467-7988
Payless Drugs	4901 Gary Avenue	Fairfield	Alabama	35064-5064	(205) 785-4343
Payless Drugs	585 Morris Majestic Rd	Morris	Alabama	35116	(205) 647-0515

Payless Drugs	1310 Eastern Valley Rd	Bessemer	Alabama	35020	(205) 425-5258
Riverside Pharmacy	405 S 1st St	Gadsden	Alabama	35901-5358	(256) 546-3784
Shoals Pharmacy	859 E Hobson St	Tuscumbia	Alabama	35674-1773	(256) 389-9800
Southside Pharmacy	11964 Escue Drive Suite A	Tanner	Alabama	35671	(256) 232-6588
The Drug Store	464 N DEAN RD	AUBURN	Alabama	36830	(334) 821-4493
The Drug Store At Stevenson	205 Kentucky Avenue	Stevenson	Alabama	35772	(256) 437-6500
The Pill Box Pharmacy	2422 Danville Rd SW Suite J	Decatur	Alabama	35603	(256) 353-1121
The Pill Box Pharmacy	474 Highway 67 South	Decatur	Alabama	35603	(256) 353-0100
Young's Drug and General Store	24460 HIGHWAY 48	WOODLAND	Alabama	36280-5204	(256) 449-2372
Young Drug Store	88960 Hwy 9	Lineville	Alabama	36266	(256) 396-5632
Alaska Family Pharmacy	167 South Santa Claus Lane	North Pole	Alaska	99705	(907) 488-8555
Alaska Family Pharmacy	1001 Noble Street	Fairbanks	Alaska	99701	(907) 452-2556
Harry Race Pharmacy	106 Lincoln Street	Sitka	Alaska	99835	(907) 313-6883
Petersburg Rexall Drug	215 N Nordic Drive	Petersburg	Alaska	99833	(907) 772-3265
White's Pharmacy	705 Halibut Point Road	Sitka	Alaska	99835	(907) 313-6881
Desert Sky Pharmacy	6750 W Thunderbird Rd Suite 103	Peoria	Arizona	85381	(623) 209-0870
Potter's House Apothecary	21585 North 77th Avenue Suite 1500	Peoria	Arizona	85382	(623) 362-9322
Walton Drug	1520 West Thatcher Boulevard	Safford	Arizona	85546	(928) 428-6366
Walton Drug of Morenci	408 Burro Alley	Morenci	Arizona	85540	(928) 865-9946
White Mountain Pharmacy	4461 South White Mountain Road Suite E1	Show Low	Arizona	85901-7783	(928) 537-8555
White Mountain Pharmacy 2	2841 Highway 260 Box 2217	Overgaard	Arizona	85933	(928) 535-4300
American Drug	1 East Main Street	Greenbrier	Arkansas	72058	(501) 679-2211
American Home Pharmacy	454 Ingram Street	Clinton	Arkansas	72031-6609	(501) 745-4266
Amity Road Pharmacy	810 Amity Road Suite 101	Conway	Arkansas	72032	(501) 358-3863
Beebe Drug Inc	703 Dewitt Henry Drive	Beebe	Arkansas	72012	(501) 882-5402
Berry Drug of Dardanelle	417 Union Street	Dardanelle	Arkansas	72834	(479) 229-4811
Bono Family Pharmacy	10040 North Highway 63 Suite 4	Bono	Arkansas	72416	(870) 277-1543

C & D Drug Store	121 North Commerce Avenue	Russellville	Arkansas	72801	(479) 968-2456
Caldwell Pharmacy 1	804 S Falls Blvd	Wynne	Arkansas	72396	(870) 238-7085
Cave City Pharmacy	301 South Main Street Suite C	Cave City	Arkansas	72521	(870) 283-5589
City Drug	1512 Linwood Dr	Paragould	Arkansas	72450-5814	(870) 236-8501
City Pharmacy	606 South Park Street	Pocahontas	Arkansas	72455	(870) 892-5517
Clarks Family Pharmacy	621 Commerce Street	Earle	Arkansas	72331	(870) 792-7177
Clarksville Family Pharmacy	510 South Rogers Street Suite 3	Clarksville	Arkansas	72830	(479) 647-3138
Clinic Drug Store, Inc.	1700 Harrison Street, Suite D	Batesville	Arkansas	72501	(870) 793-5170
Collier Drug-Dickson	100 West Dickson Street	Fayetteville	Arkansas	72701	(479) 442-6262
Collier Drug-Prairie Grove	801 East Douglas Street	Prairie Grove	Arkansas	72753	(479) 846-2195
Conway MedCare Pharmacy	2521 College Avenue	Conway	Arkansas	72034	(501) 358-3498
Corner Drug Store	830 East Main Street	Melbourne	Arkansas	72556	(870) 368-7171
Crawford Pharmacy	107 Crawford Street	Hot Springs	Arkansas	71913	(501) 624-4636
Deans Pharmacy #1	1640 South Whitehead Drive	Dewitt	Arkansas	72042	(870) 946-2381
Debbie's Family Pharmacy	5403 W Pinnacle Point Dr	Rogers	Arkansas	72758-8118	(479) 271-6300
East End Express Pharmacy	21019 Highway 167, Suite 100	Hensley	Arkansas	72065	(501) 486-4100
East End Pharmacy	20381 Arch Street Pike	Little Rock	Arkansas	72206	(501) 888-2830
Family Clinic Pharmacy	1208 West Main Street	Walnut Ridge	Arkansas	72476	(870) 886-8100
Family Medical Center Pharmacy	3016 S. University Ste 120	Little Rock	Arkansas	72204	(501) 562-3314
Food Giant Discount Pharmacy	605 North Illinois Street	Harrisburg	Arkansas	72432	(870) 578-5200
Forrest City Family Pharmacy	1111 N Washington St	Forrest City	Arkansas	72335-1800	(870) 581-9029
Gammel's Clinic Pharmacy	909 Unity Road	Crossett	Arkansas	71635	(870) 364-5100
Garner Family Pharmacy LLC	765 East Matthew Avenue	Jonesboro	Arkansas	72401-3103	(870) 558-5488
Greenbrier Pharmacy	61A South Broadview Street	Greenbrier	Arkansas	72058-9161	(501) 402-4906
Hawkins Lakeside Pharmacy	902 Central Boulevard	Bull Shoals	Arkansas	72619	(870) 445-7188
Health-Care Pharmacy	10 Hospital Drive	Morrilton	Arkansas	72110	(501) 354-1460
Hickory Hill Pharmacy	109 Hickory Hill Drive	Helena	Arkansas	72342	(870) 338-8351

Hilltop Family Pharmacy	1706 Visions Avenue	Jonesboro	Arkansas	72401	(870) 336-8310
Horseshoe Health & Medicine	600 Market Street	Horseshoe Bend	Arkansas	72512	(870) 670-4580
Hudson Pharmacy	1609 Main St	Van Buren	Arkansas	72956-4735	(479) 474-1193
Hyde Pharmacy Inc	1001 W Kings Hwy	Paragould	Arkansas	72450-4638	(870) 239-4036
iCareRx Pharmacy - Newport	1117 McLain Street Suite 400	Newport	Arkansas	72112	(870) 523-5555
Imboden Medical Pharmacy	110 North Walnut Street	Imboden	Arkansas	72434	(870) 869-2046
Joe's Pharmacy Express	2412 E Race Ave Suite F	Searcy	Arkansas	72143-4730	(501) 268-9400
Kavanaugh Pharmacy	5200 KAVANAUGH BLVD	LITTLE ROCK	Arkansas	72207	(501) 664-3844
Landmark Pharmacy	3401 Atwood Road, Suite E	Little Rock	Arkansas	72206	(501) 888-2223
Marion Family Pharmacy	134 Block Street	Marion	Arkansas	72364	(870) 739-1111
Mark's Pharmacy	205 E Main	Melbourne	Arkansas	72556	(870) 368-5355
Mayflower Family Pharmacy	616B Highway 365	Mayflower	Arkansas	72106-9630	(501) 470-9898
McCoy Tygart Drug Store Inc	821 North Rock	Sheridan	Arkansas	72150	(870) 942-5121
McHaney Drug PA	1400 W Hunt St	Paragould	Arkansas	72450-3574	(870) 236-3180
Medic Pharmacy	306 North Reynolds Road	Bryant	Arkansas	72022	(501) 847-3596
Medi Quik Pharmacy	810 West Commercial Street	Ozark	Arkansas	72949	(479) 667-4145
Medi-Quik Pharmacy	1531 East Main Street	Booneville	Arkansas	72927	(479) 675-3900
Medi-Sav Pharmacy #1	621 E Main St	Charleston	Arkansas	72933	(479) 965-2244
Medisav Pharmacy #2	8820 Rogers Avenue	Fort Smith	Arkansas	72903	(479) 452-0278
Medisav Pharmacy #3	1910 S Zero St., Suite A	Fort Smith	Arkansas	72901	(479) 646-2971
MedRelief Pharmacy	2895 State Highway 77 South Suite 3	Marion	Arkansas	72364	(870) 739-1700
Miller's Drug Store	231 S Main St	Malvern	Arkansas	72104-3736	(501) 332-2351
Mitchell's Main Street Pharmacy	214 EAST MAIN STREET	Mountain View	Arkansas	72560	(870) 269-3253
Mitchell's Medi Mart	1523 South Main Street	Hope	Arkansas	71801	(870) 777-5555
Mitchell's Park Street Pharmacy	526 Park St. PO Box 569	Calico Rock	Arkansas	72519	(870) 297-8107
Nashville Family Pharmacy	330 S Main St	Nashville	Arkansas	71852-2410	(870) 912-0858
National Family Pharmacy	1615 Dodson Avenue	Fort Smith	Arkansas	72901	(479) 783-6135

Newton's Pharmacy	715 West Main Street	Russellville	Arkansas	72801	(479) 968-1157
Palace Drug	270 Main Street	Mammoth Spring	Arkansas	72554	(870) 625-3222
Palace Drug of Salem, LLC	106 West Highway 62	Salem	Arkansas	72576	(870) 895-3811
Piggott Pharmacy	648 E Main St	Piggott	Arkansas	72454	(870) 598-3183
Prescriptions Corner Drug	320 W Kingshighway	Paragould	Arkansas	72450-4229	(870) 239-9535
Prince Pharmacy	211 E Stadium Dr	Magnolia	Arkansas	71753	(870) 234-7292
Randolph County Drug	567 Highway 67 South Suite A	Pocahontas	Arkansas	72455	(870) 202-2536
Rector Downtown Drug	316 East 9th Street	Rector	Arkansas	72461	(870) 595-3523
ReedHutchins Pharmacy	408 West Main Street	Heber Springs	Arkansas	72543-3017	(501) 270-8888
Remedy Drug	8511 West Markham Street	Little Rock	Arkansas	72205	(501) 313-4480
Rison Pharmacy	301 Main St	Rison	Arkansas	71665-8835	(870) 325-6262
Rose Drug	211 E Main St	Clarksville	Arkansas	72830-3723	(479) 754-2180
Rose Drug Dover	8880 Market Street	Dover	Arkansas	72837	(479) 331-2133
Rose Drug of Dardanelle	1176 State Hwy 22 West Suite A	Dardanelle	Arkansas	72834	(479) 229-4040
Sheridan Family Pharmacy	677 Heritage Drive	Sheridan	Arkansas	72150	(870) 484-4488
Smith Drug / The Corner Gifts	695 E Third St	Gentry	Arkansas	72734-0629	(479) 736-2241
Smith Drug and Compounding, Inc	1629 Airport Road Suite D	Hot Springs	Arkansas	71913	(501) 767-2220
Smith Drug and Compounding, Inc. #3	1500 Albert Pike Rd	Hot Springs	Arkansas	71913-4023	(501) 767-2230
Smith Drug and Compounding Inc	117 Piper Street Suite A	Hot Springs	Arkansas	71901	(501) 760-0808
Smith Drug And Compounding Inc.	1 Mercy Lane Street Suite 103	Hot Springs	Arkansas	71913-6408	(501) 624-2900
Sullivan Pharmacy	731 N MAIN ST STE B	HARRISON	Arkansas	72601	(870) 741-2119
Tanglewood Drug Store	6815 Cantrell Road	Little Rock	Arkansas	72207	(501) 664-4444
THE PHARMACY AT FLIPPIN STATION	109 N 1ST ST	FLIPPIN	Arkansas	72634	(870) 493-7367
The Prescription Pad Pharmacy	539 Highway 425 South	Monticello	Arkansas	71655	(870) 367-4227
Village Pharmacy	500 West Commercial Street	Ozark	Arkansas	72949	(479) 667-2101
Vilonia Family Pharmacy Inc	1122 Main Street Suite 14	Vilonia	Arkansas	72173	(501) 796-2204
Walden Drug	3104 W Kingshighway	Paragould	Arkansas	72450	(870) 236-6118
Watson Pharmacy	802 W 4th Street	Fordyce	Arkansas	71742	(870) 352-2161

Wilson Wil-Sav Pharmacy	5 Allen Chapel Road	Batesville	Arkansas	72501	(870) 251-2432
Winningham Pharmacy	232 W Main St #112	Bradford	Arkansas	72020	(501) 344-2763
Woodsprings Pharmacy	1807 Woodsprings Road	Jonesboro	Arkansas	72401	(870) 972-8310
Wynne Apothecary Inc	500 Falls Blvd N	Wynne	Arkansas	72396	(870) 238-8511
Dean's Pharmacy # 3	311 West Chestnut Street	Marianna	Arkansas	72360	(870) 295-4100
A1Care Pharmacy	2001 E 4th St Suite 112	Santa Ana	California	92705-3916	(714) 541-3900
Absolute Wellness Pharmacy	19720 Ventura Boulevard Unit 100	Woodland Hills	California	91364	(818) 912-6800
Access Medical Pharmacy	1271 Westwood Boulevard	Los Angeles	California	90024	(310) 873-6565
ACE Medical Pharmacy	9171 Wilshire Boulevard Suite B	Beverly Hills	California	90210	(310) 385-9128
A Family Pharmacy Apple Valley	15863 Kasota Rd Suite C	Apple Valley	California	92307	(760) 242-5452
Alhambra Professional Pharmacy	330 South Garfield Avenue, Suite 104	Alhambra	California	91801	(626) 458-8909
AllCare Pharmacy	12998 Hesperia Road Suite 102	Victorville	California	92395-8317	(760) 241-0508
AllCare Pharmacy	331 Main Street	Salinas	California	93901	(831) 424-8053
Alpha-1 Pharmacy	341 East Main Street Suite #104	San Jacinto	California	92583-4206	(951) 225-4244
Alta Care Pharmacy	1004 W FOOTHILL BLVD SUITE 101	UPLAND	California	91786	(909) 360-8352
Altamed Pharmacy West Covina	1300 South Sunset Avenue Room 100	West Covina	California	91790-3342	(888) 499-9303
Amcare Pharmacy	760 S WASHBURN AVENUE SUITE 01/02	CORONA	California	92882	(951) 268-6486
AndersonRx, Inc	2940 East Street	Anderson	California	96007	(530) 378-5566
Apollo Pharmacy	29645 Rancho California Road Suite 129	Temecula	California	92591-5285	(951) 506-4006
Arden Medical Pharmacy	435 West Arden Avenue Suite 110	Glendale	California	91203	(818) 247-1842
Arianna Medical Pharmacy	3600 North Verdugo Road Suite 103	Glendale	California	91208	(818) 957-9200
Arka Pharmacy	621 East Glenoaks Boulevard Suite C	Glendale	California	91207	(818) 937-9394
Armen Pharmacy	1025 East Broadway	Glendale	California	91205	(818) 551-0082
Audrey Pharmacy	9741 Bolsa Avenue, Suite 116	Westminster	California	92683	(714) 531-1983
Audrey Pharmacy #2	9822 Bolsa Ave Suite G	Westminster	California	92683-6870	(714) 531-1244

Avalon Pharmacy	58471 29 Palms Highway, Suite 301	Yucca Valley	California	92284	(760) 365-7621
B&B Pharmacy	10244 Rosecrans Avenue	Bellflower	California	90706	(562) 866-8363
Balboa Pharmacy	6465 Balboa Avenue Suite 101	San Diego	California	92111	(858) 278-0111
Barrington Wilshire Pharmacy	11701 Wilshire Boulevard, Suite 3	Los Angeles	California	90025	(310) 473-3323
Bascom Pharmacy	105 North Bascom Avenue, Suite 101	San Jose	California	95128	(408) 995-6020
Beach Terrace Pharmacy	12282 Beach Blvd	Stanton	California	90680-3970	(714) 786-8222
Bear Creek Pharmacy	24046 Clinton Keith Rd Suite 107	Wildomar	California	92595	(951) 677-4880
Beeman's Rx Pharmacy	355 East 21st Street	San Bernardino	California	92404	(909) 882-3719
Beemans Highland Pharmacy	399 East Highland Avenue	San Bernardino	California	92404	(909) 886-6851
Best Care Pharmacy	1306 Main Street Suite 102	Ramona	California	92065	(760) 440-0550
Beverly Glen Pharmacy	2946 North Beverly Glen Circle	Los Angeles	California	90077	(310) 475-0568
BJRX Pharmacy	1801 East March Lane Suite B280	Stockton	California	95210-6653	(209) 474-2888
Brent Air Pharmacy	134 South Barrington Avenue	Los Angeles	California	90049	(310) 476-2211
Brentwood Pharmacy	2530B SAN VICENTE BLVD	Santa Monica	California	90402	(310) 393-0201
Bright La Mirada Pharmacy	12675 La Mirada Boulevard Suite 100	La Mirada	California	90638	(562) 777-8175
Brimhall Pharmacy	8305 Brimhall Rd Suite 1603	Bakersfield	California	93312-2243	(661) 588-5555
Broadway Pharmacy	7600 Pacific Ave	Lemon Grove	California	91945-1605	(619) 717-8990
BT Pharmacy	14262 Beach Blvd	Westminster	California	92683	(714) 622-5992
Burbank Compounding Pharmacy	201 S BUENA VISTA ST	Burbank	California	91505	(818) 563-2120
Burt's Pharmacy	2900 Townsgate Road Suite 105	Westlake Village	California	91361	(805) 371-4000
Burt's Pharmacy	2333 Borchard Road	Newbury Park	California	91320	(805) 498-6675
Burt's Pharmacy Moorpark	865 Patriot Drive Suite 103	Moorpark	California	93021-3407	(805) 552-4500
Bushards Pharmacy	244 Forest Avenue	Laguna Beach	California	92651	(949) 494-1059
Cabrillo Pharmacy	146 North Brent Street	Ventura	California	93003	(805) 643-9939
Camden Pharmacy and Gift Emporium	414 North Camden Drive	Beverly Hills	California	90210	(310) 273-3363
Campus Pharmacy	100 UCLA Medical Plaza Suite 150	Los Angeles	California	90024	(310) 208-2340
Capital City Pharmacy	339 Georgia St	Vallejo	California	94590-5906	(707) 644-2272

Capsmart Pharmacy	2557 Mowry Ave Suite 11	Fremont	California	94538-1614	(510) 896-8121
Care Pharmacy	302 East Bullard Avenue	Fresno	California	93710	(559) 261-9888
Catinat Pharmacy	9549 Bolsa Avenue Suite A	Westminster	California	92683	(714) 531-3560
Central Avenue Pharmacy	133 15th Street	Pacific Grove	California	93950	(831) 373-1225
Central Drugs	520 West La Habra Boulevard	La Habra	California	90631	(562) 691-6754
Central Drugs #2	1955 Sunnycrest Dr Suite 100	Fullerton	California	92835-3627	(714) 515-1530
Century City Medical Plaza Pharmacy	2080 Century Park East Suite 102	Los Angeles	California	90067	(310) 553-3434
Ceres Drug Store	2929 4th Street	Ceres	California	95307	(209) 537-0718
Chula Vista Pharmacy	384 H Street Suite 100	Chula Vista	California	91910	(619) 781-8177
Coachella Valley Pharmacy	77-932 Country Club Dr Suite 2-2	Palm Desert	California	92211-3407	(760) 223-7188 Ext 0
College Pharmacy	90 North Ashwood Avenue	Ventura	California	93003	(805) 642-4135
Cooley Health Pharmacy	1091 S Mt Vernon Ave., # J	Colton	California	92324-3932	(909) 514-1730
Croal's Rexall Drugs	901 East Williams Street	Barstow	California	92311	(760) 256-8968
Daniels Pharmacy	943 Geneva Avenue	San Francisco	California	94112	(415) 584-2210
Delta Pharmacy	407 N Main St	Rio Vista	California	94571-1616	(707) 374-5135
Desert Hospital Outpatient Pharmacy	1180 North Indian Canyon Drive Suite E140	Palm Springs	California	92262	(760) 323-1001
Diablo Pharmacy	12677 Alcosta Blvd Suite 145	San Ramon	California	94583-4423	(925) 237-9939
DK Pharmacy	10431 Lemon Avenue, Suite G	Rancho Cucamonga	California	91737	(909) 493-1500
Dollar Drug	1055 West College Avenue, Suite C	Santa Rosa	California	95401	(707) 575-1313
Dorado Pharmacy	13003 Van Nuys Boulevard Suite E	Pacoima	California	91331-8324	(818) 485-5554
Dorado Pharmacy 2	13678 Van Nuys Boulevard	Pacoima	California	91331-3616	(747) 274-1055
Drug Co Pharmacy	307 North Ash Street	Escondido	California	92027	(760) 745-6672
Elevate Pharmacy	8631 West 3rd Street Suite 320 E	Los Angeles	California	90048	(310) 657-4090
El Monte Pharmacy	3948 North Peck Road	El Monte	California	91732	(626) 448-2507
Family First Pharmacy	4859 E. Cesar Chavez Blvd	Fresno	California	93727-3811	(559) 493-5566
Farmacia Anaheim	941 South Euclid Street	Anaheim	California	92802	(714) 215-4740
Farmacia Del Pueblo	653 Main Street	Brawley	California	92227	(760) 344-2000

Farmacia Del Pueblo	801 E Birch St Suite 4	Calexico	California	92231	(760) 768-6000
Farmacia Del Pueblo	1692 S 4th St Suite F	El Centro	California	92243	(760) 353-9000
Farmacia Estrella	5020 South C Street	Oxnard	California	93033	(805) 240-9962
Farmacia Familiar	1126 S Bristol St	Santa Ana	California	92704-3420	(714) 486-2277
Farmacia Santa Ana	307 East 1st Street Suite D	Santa Ana	California	92701-5302	(714) 542-5444
Finley's Rexall Drug	8554 Sierra Avenue	Fontana	California	92335	(909) 822-2288
Foothill Remedy Drugs	6253 Foothill Boulevard	Tujunga	California	91042	(818) 236-2500
Fox Drug of Torrance	1327 El Prado	Torrance	California	90501	(310) 328-7244
Freeman Medical Pharmacy	301 North Prairie Avenue, Suite 110	Inglewood	California	90301	(310) 672-7000
Friendly #1 Pharmacy	485 Lewis Road, Suite D	San Jose	California	95111	(408) 226-0200
Friendly #2 Pharmacy	639 Tully Road, Suite A	San Jose	California	95111	(408) 279-8188
Fullerton Pharmacy	1820 Fullerton Avenue Suite 105	Corona	California	92881	(951) 496-4222
Galaxy Pharmacy	1801 W Romneya Dr Suite 108	Anaheim	California	92801-1824	(714) 833-5723
Galaxy Pharmacy	1295 East Anaheim Street	Long Beach	California	90813	(562) 599-1301
GALAXY PHARMACY	1360 E ANAHEIM ST STE 106	LONG BEACH	California	90813-5516	(562) 336-1200
Gateway Pharmacy	1330 Gateway Boulevard Suite B-2	Fairfield	California	94533	(707) 422-0500
GKN Rx Inc	1471 B St Suite R	Livingston	California	95334-1432	(209) 398-2035
Golden Gate Pharmacy	1836 Noriega Street	San Francisco	California	94122	(415) 661-0790
Gonzales Rx Pharmacy	18 Fourth St	Gonzales	California	93926-0808	(831) 675-3643
Grove Pharmacy	8283 Grove Avenue Suite 108-109	Rancho Cucamonga	California	91730-3137	(909) 480-4401
Haig Pharmacy	1112 South Glendale Avenue	Glendale	California	91205	(818) 500-0800
Haller's Pharmacy and Medical Supply	37323 Fremont Boulevard	Fremont	California	94536-5098	(510) 797-2772
Healthcare Pharmacy	14642 Newport Avenue	Tustin	California	92780	(714) 669-4000
Hendricks Pharmacy	137 North Harvard Ave	Claremont	California	91711	(909) 624-1611
Hepps Prescription Pharmacy	240 S La Cienega Blvd	Beverly Hills	California	90211-3375	(310) 652-0550
High Street Pharmacy	4248 Macarthur Boulevard	Oakland	California	94619	(510) 530-1335

Hinas Home Care Pharmacy	9508 Stockdale Highway Suite 130	Bakersfield	California	93311	(661) 664-7979
Hinas Pharmacy	6300 White Lane Suite N	Bakersfield	California	93309	(661) 282-8805
Holy Cross Specialty Pharmacy	11550 Indian Hills Rd Suite 130	Mission Hills	California	91345-1200	(818) 898-1628
Hospital Dr Valley Pharmacy	7600 Hospital Dr Suite A	Sacramento	California	95823-5406	(916) 423-2098
Imperial Pharmacy	1530 Palm Avenue	San Diego	California	92154	(619) 343-0095
Imperial Valley Pharmacy	1487 Ocotillo Dr	El Centro	California	92243-4212	(760) 970-5800
Indio Medical Pharmacy	81893 Doctor Carreon Boulevard, Suite 7	Indio	California	92201	(760) 347-0659
Inland Pharmacy	1001 E Latham Ave Suite P	Hemet	California	92543-4435	(951) 658-7111
Irvine Medical Center Pharmacy	16300 Sand Canyon Avenue, Suite 101	Irvine	California	92618	(949) 453-9789
Ivy Pharmacy	16854 Ivy Avenue Suite C	Fontana	California	92335-1504	(909) 321-5588
Jeff Goodman Special Care Pharmacy	1625 Schrader Boulevard, 1st Floor	Los Angeles	California	90028-6213	(323) 993-7513
Jonathan's Pharmacy	19341 Bear Valley Road Suite 103	Apple Valley	California	92308	(760) 983-2599
Kanan Pharmacy and Medical Supplies	5847 Kanan Rd	Agoura Hills	California	91301	(818) 889-3070
KML Pharmacy Inc	1655 S De Anza Blvd Suite 2	Cupertino	California	95014	(408) 873-8123
Komoto Medical Pharmacy	2110 Truxtun Avenue, Suite 100	Bakersfield	California	93301	(661) 327-7524
Komoto Pharmacy, Inc	1017 Ellington St	Delano	California	93215-2621	(661) 725-9489
Kovacs-Frey Pharmacy	2860 Artesia Boulevard	Redondo Beach	California	90278	(310) 371-7541
Kramers Pharmacy	29525 Canwood Street	Agoura Hills	California	91301	(818) 706-8099
Kyoto Pharmacy	420 E 3rd St Suite 6	Los Angeles	California	90013-1645	(213) 253-5999
La Buena Vida Pharmacy	51335 Cesar Chavez Street Suite 116	Coachella	California	92236	(760) 398-8866
Lanvy Pharmacy	14971 Brookhurst Street Suite A	Westminster	California	92683	(714) 531-2828
Lark Drugs Pharmacy	16251 Main Street	Guerneville	California	95446	(707) 869-9055
Larson's Pharmacy	142 West H Street	Colton	California	92324	(909) 825-1950
Linda Rx Pharmacy	1569 Lexann Avenue, Suite 130	San Jose	California	95121	(408) 270-2828
Linda Vista Pharmacy	4300 Rose Drive Suite D	Yorba Linda	California	92886	(714) 528-3610

Lindhurst Pharmacy	5991 Lindhurst Ave	Marysville	California	95901	(530) 741-9800
Los Alamitos Pharmacy	3801 Katella Avenue Suite 120	Los Alamitos	California	90720	(562) 431-2505
Lucerne Pharmacy, Inc.	6244 East Highway 20	Lucerne	California	95458-1316	(707) 274-6643
Maggies Pharmacy	2315 KUEHNER DR UNIT 107	SIMI VALLEY	California	93063	(805) 770-1001
Magnolia Pharmacy	7130 Magnolia Ave Suite C	Riverside	California	92504-3864	(951) 327-7770
Maico Pharmacy	10161 Bolsa Avenue Suite 105B	Westminster	California	92683	(714) 531-7000
Manor Drug Medical & Mobility	5795 North First Street	Fresno	California	93710	(559) 431-4142
Market Pharmacy	9250 Reseda Blvd Unit 2C	Northridge	California	91324	(818) 701-7777
McCarthy Drugs	12025 San Vicente Blvd	Los Angeles	California	90049	(310) 452-1105
Medical Arts Pharmacy	1320 Maricopa Highway Suite J	Ojai	California	93023-3154	(805) 646-7211
Medical Pavilion Pharmacy	9460 No Name Uno Suite 100	Gilroy	California	95020	(408) 842-2001
Med-Rx Pharmacy and Compounding	1031 East Vista Way	Vista	California	92084	(760) 724-7125
Meiji Pharmacy	1630 W Redondo Bch Blvd Suite 14	Gardena	California	90247	(310) 538-2885
Mendocino Coast Pharmacy	350 Cypress Street	Fort Bragg	California	95437-5408	(707) 962-0800
Mexicare Pharmacy	9670 Magnolia Avenue Suite 107	Riverside	California	92503-3684	(951) 588-6727
Mickey Fine Pharmacy	433 North Roxbury Drive	Beverly Hills	California	90210-4280	(310) 271-6123
Mickey Fine Pharmacy & Snack Shop	2000 AVENUE OF THE STARS	LOS ANGELES	California	90067-4700	(310) 277-6123
Ming & H Drugs	1717 MING AVE	BAKERSFIELD	California	93304-4595	(661) 444-8880
Ming Plaza Pharmacy	2726 Ming Avenue Suite A	Bakersfield	California	93304	(661) 545-6464
Montebello Professional Pharmacy	265 East Beverly Boulevard, Suite B	Montebello	California	90640	(323) 722-1999
Mowry Medical Pharmacy	1999 Mowry Avenue Suite 2A	Fremont	California	94538	(510) 793-5011
Mowry Plaza Pharmacy	668 Mowry Avenue	Fremont	California	94536	(510) 745-9900
Myers Medical Pharmacy	260 Hospital Drive, Suite 111	Ukiah	California	95482	(707) 468-1866
New Care	12384 Palmdale Road Suite 105	Victorville	California	92392	(909) 726-7890
Newport Lido Pharmacy	351 Hospital Rd Suite 107	Newport Beach	California	92663	(949) 764-6580
Nhan Ai Pharmacy Inc	14516 Brookhurst St	Westminster	California	92683-5750	(714) 852-3789

Nogales Pharmacy Inc	18702 Colima Rd Suite 103	Rowland Heights	California	91748-2991	(626) 810-2240
North Chester Pharmacy	1822 North Chester Avenue	Bakersfield	California	93308	(661) 399-3337
North Lake Medical Pharmacy #1	5136 Hill Road 3	Lakeport	California	95453	(707) 263-6192
North Lake Medical Pharmacy #2	347 Lakeport Boulevard	Lakeport	California	95453	(707) 263-1328
Nuevo Pharmacy	75 West Nuevo Road Suite H	Perris	California	92571	(951) 322-4700
Oakdale Pharmacy	5400 Balboa Boulevard Suite 100	Encino	California	91315	818-788-0770
Olivehurst Drug Store	4897 Olivehurst Avenue	Olivehurst	California	95961	(530) 743-5451
Orange Plaza Pharmacy - New	1010 W La Veta Ave Suite 130	Orange	California	92868-4301	(714) 550-9798
Oxnard Drug	105 West 5th Street	Oxnard	California	93030	(805) 483-2115
Panama Pharmacy	6348 Ashe Rd STE 300-400	Bakersfield	California	93313-9490	(661) 527-0000
Parke Vista Pharmacy	3838 Sherman Dr Suite 1	Riverside	California	92503-4088	(951) 687-4203
Parkside Pharmacy	4404 Del Rio Rd	Sacramento	California	95822	(916) 452-2200
Parkview Medical Plaza Pharmacy	3975 Jackson Street Suite 109	Riverside	California	92503	(951) 637-0180
Pearsons Medical Group Pharmacy	1700 N Waterman Ave	San Bernardino	California	92404-5115	(909) 883-3088
Plaza Pharmacy	430 E Avenida de los Arboles Suite 103	Thousand Oaks	California	91360-2934	(805) 492-2451
Primera Care Pharmacy	17500 Foothill Boulevard Suite A-7A	Fontana	California	92335-3736	(909) 222-6944
Prime RX Rowland Heights	18399 COLIMA RD. STE. A	ROWLAND HEIGHTS	California	91748-2797	(626) 295-2515
Puente Hills Pharmacy	1850 S Azusa Ave Suite 101	Hacienda Heights	California	91745-6854	(626) 912-3311
Queens Pharmacy	12677 Hesperia Road Suite 180	Victorville	California	92395	(760) 962-1200
Queens Pharmacy	18522 Highway 18 Suite 103	Apple Valley	California	92307	(760) 946-4700
Raincross Pharmacy	4646 Brockton Avenue	Riverside	California	92506	(951) 788-4646
Ramsay Rexall Drug	2246 Newport Boulevard	Costa Mesa	California	92627	(949) 646-7744
Rancho Drugs	17798 Wika Road	Apple Valley	California	92307	(760) 242-4900
Red Cross Pharmacy	525 5th Street Suite A	Eureka	California	95501-1032	(707) 440-0460
Reliance Pharmacy	11333 N.SEPULVEDA BLVD.STE1200	Mission Hills	California	91345	(818) 365-3986

Right Care Pharmacy	39872 Los Alamos Road Suite A10	Murrieta	California	92562	(951) 677-1114
RMC Pharmacy Brockton	7117 Brockton Avenue	Riverside	California	92506-2658	951-899-8199
RMC Pharmacy Temescal Valley	21634 Retreat Parkway Suite 100	Temescal Valley	California	92883-6100	(951) 963-3330
Rogers Drug Store	402 H Street	Modesto	California	95351	(209) 522-5229
Royalty Pharmacy	1902 Royalty Drive Suite 110	Pomona	California	91767	(909) 620-8008
RS Pharmacy	24990 Alessandro Blvd Suite J	Moreno Valley	California	92553-3915	(951) 414-3100
Rubio Pharmacy	16550 Ventura Blvd Suite 100	ENCINO	California	91436-2004	(818) 990-5100
Safesave Pharmacy	737 Colusa Avenue	Yuba City	California	95991	(530) 674-3550
Saint Johns Plaza Pharmacy	1301 20th Street Suite 120	Santa Monica	California	90404-2094	(310) 453-6553
Sanborn Pharmacy	323 North Sanborn Road	Salinas	California	93905-2247	(831) 287-6833
Santa Monica Medical Plaza Pharmacy	1260 15th Street Suite 100	Santa Monica	California	90404	(310) 393-6767
Savco Pharmacy	455 O'Conner Drive, Suite 190	San Jose	California	95128	(408) 298-6190
Save More Pharmacy	349 East Main Street Suite 101	Alhambra	California	91801-7909	(626) 282-8633
Sea View Pharmacy	665 Camino de Los Mares Suite 101	San Clemente	California	92673	(949) 496-0123
Sebastopol Family Pharmacy, Inc.	652 Petaluma Avenue Suite I1	Sebastopol	California	95472-4266	(707) 824-1876
Selam Pharmacy LLC	2447 Telegraph Ave	Oakland	California	94612-2404	(510) 984-1429
Sherman's Apothecary Pharmacy	1212 South Main Street, Suite 101	Salinas	California	93901	(831) 422-5988
Sierra Pharmacy	210 South Grand Avenue Suite 116	Glendora	California	91741	(626) 335-2300
Silverado Pharmacy	1473 Lincoln Ave Suite D	Calistoga	California	94515-1702	(707) 942-5115
Skinner's Pharmacy	905 Deep Valley Drive	Rolling Hills Estates	California	90274	(310) 377-4871
Smith's St Helena Pharmacy	1390 Railroad Ave	Saint Helena	California	94574-1194	(707) 963-2794
Soledad Pharmacy and Wellness Center	537 Front Street	Soledad	California	93960	(831) 677-6100
SORTPAK PHARMACY	655 North Central Avenue 22nd Floor	Glendale	California	91203	(877) 570-7787
South Gate Pharmacy - SF	8200 LONG BEACH BLVD UNIT D-2	SOUTH GATE	California	90280	(323) 537-2837
Southwood Pharmacy	22220 Palos Verdes Boulevard	Torrance	California	90505-2017	(424) 350-7995
Spectrum Pharmacy	9430 Warner Ave Suite G	Fountain Valley	California	92708-2826	(657) 616-0976

Stans Drug	3001 S Saviers Rd	Oxnard	California	93033-5395	(805) 486-2678
Sun Pharmacy	2559 S King Rd Suite B10	San Jose	California	95122-1894	(408) 440-2077
Sunshine Center Pharmacy	1166 Old Mission Road	South San Francisco	California	94080-1303	(650) 589-4133
Super Care Pharmacy	24825 Alessandro Blvd Suite 2	Moreno Valley	California	92553	(951) 243-2530
Sutter Pharmacy	501 Plumas St Suite 104	Yuba City	California	95991	(530) 821-5110
Teplow Drugs	404 E MAIN ST	BARSTOW	California	92311-2326	(760) 256-2726
The Prescription Center	9730 Wilshire Boulevard Suite 103 and 114	Beverly Hills	California	90212	(310) 274-7113
The Prescription Shop	1215 West Whittier Boulevard	Montebello	California	90640	(323) 728-8127
Thu Van Pharmacy	10362 Bolsa Avenue, Suite 108	Westminster	California	92683	(714) 775-0772
Tormed Pharmacy	3440 Lomita Boulevard Suite 149	Torrance	California	90505	(310) 326-7706
Total Care Pharmacy	1657 E 6th St	Beaumont	California	92223-5765	(951) 769-3105
Town Square Pharmacy, Inc	81 709 Doctor Carreon Boulevard Suite E3	Indio	California	92201-5526	(760) 342-4933
Tri City RX Pharmacy Inc	15940 QUANTICO RD SUITE 100	APPLE VALLEY	California	92307	(760) 946-1414
Truxtun Pharmacy	5925 Truxtun Ave Suite B	Bakersfield	California	93309-0434	(661) 324-7979
Truxtun Pharmacy Delano	1228 Jefferson Street	Delano	California	93215-9225	(661) 778-0111
USC Medical Plaza Pharmacy	1510 San Pablo Street, Suite 144	Los Angeles	California	90033	(323) 442-5770
USC Pharmacy	1025 W 34th St (KOH) Suite 105	Los Angeles	California	90089-0028	(213) 821-6100
USC Verdugo Hills Professional Pharmacy	1808 Verdugo Boulevard Suite 111	Glendale	California	91208	(818) 952-2223
Valley Care Pharmacy	11441 HEACOCK ST STE D	MORENO VALLEY	California	92557	(951) 200-4592
Valley Medical Pharmacy	630 Main Street	Brawley	California	92227	(760) 344-6303
Valley Pharmacy	560 W Putnam Ave Suites 6 & 7	Porterville	California	93257-3269	(559) 854-7500
Valley Pharmacy	10400 Main St. Suite D	Lamont	California	93241	(661) 735-7077
Ventura County Pharmacy	3350 Loma Vista Road	Ventura	California	93003-3024	(805) 765-6046
Versailles Pharmacy	2801 Encinal Avenue	Alameda	California	94501	(510) 523-4907
Via Lido Drugs	3445 Via Lido	Newport Beach	California	92663-3996	(949) 723-8921

Villa Park Pharmacy	17821 Santiago Boulevard	Villa Park	California	92861	(714) 998-3030
Vine Discount Pharmacy and Medical Supply	1253 North Vine Street	Los Angeles	California	90038	(323) 957-9446
Vineyard Pharmacy & Gifts	1900 McHenry Avenue	Escalon	California	95320	(209) 838-0511
Vo Pharmacy	12464 East Washington Boulevard	Whittier	California	90602-1005	(562) 646-3339
Wagner Pharmacy	1224 East McFadden Avenue	Santa Ana	California	92705	(714) 547-3590
Wards Pharmacy	653 Long Beach Boulevard	Long Beach	California	90802	(562) 437-0678
Western Ave Pharmacy	501 Western Avenue	Glendale	California	91201	(818) 242-5887
Westside Drug	1101 O Street	Firebaugh	California	93622	(559) 659-2159
West Care Pharmacy	5353 Balboa Blvd.	Encino	California	91316	(818) 788-2411
White Memorial Medical Plaza Pharmacy	1701 East Cesar E Chavez Avenue Suite 109	Los Angeles	California	90033	(323) 221-6000
Woodbridge Pharmacy	4950 Barranca Parkway Suite 102	Irvine	California	92604	(949) 857-2141
Your Drug Store	2303 Niles Point	Bakersfield	California	93306-4021	(661) 325-2487
Zweber Apothecary	11411 Brookshire Avenue, Suite 107	Downey	California	90241	(562) 923-1256
Basalt Clinic Pharmacy	110 Midland Avenue	Basalt	Colorado	81621	(970) 927-3833
Bayfield Pharmacy	871 County Road 501	Bayfield	Colorado	81122	(970) 884-9133
Byers Pharmacy	568 US HWY 36	Byers	Colorado	80103	(303) 822-9371
Capitol Heights Pharmacy	1200 Madison Street	Denver	Colorado	80206	(303) 388-3679
ClearSpring Pharmacy	8031 Southpark Cir Suite B	Littleton	Colorado	80120-5724	(303) 707-1500
ClearSpring Pharmacy, Ltd	201 University Blvd Suite 105	Denver	Colorado	80206	(303) 333-2010
Downtown Drug	825 Grand Avenue	Glenwood Springs	Colorado	81601	(970) 945-7987
Gem Pharmacy	191 East Orchard Road, Suite 100	Littleton	Colorado	80121	(303) 795-3154
La Jara Pharmaceutical Center	412 Main Street	La Jara	Colorado	81140	(719) 274-5109
Lorenzo Apothecary	306 Main Street	Sterling	Colorado	80751-4345	(970) 522-0828
Mesa Pharmacy	25140 East Highway 50	Pueblo	Colorado	81006	(719) 544-1371
Palace Drug	601 Main Street	Canon City	Colorado	81212	(719) 275-3375
Palace Drug Silver Cliff	94 Main St	Silver Cliff	Colorado	81252	(719) 371-9402

Platte Valley Pharmacy	1610 PRAIRIE CENTER PKWY STE 2110	BRIGHTON	Colorado	80601	(303) 483-7455
The Pharmacy at St Michaels	2914 67th Avenue Suite 101	Greeley	Colorado	80634	(970) 978-4557
TKS Pharmacy	4809 Argonne St Suite 155	Denver	Colorado	80249-6801	(720) 583-2110
Bailey's Pharmacy	1137 MAIN Street Suite 100	East Hartford	Connecticut	06108-2236	(860) 206-5737
Beacon Prescriptions	543 W Main St	New Britain	Connecticut	06053-3915	(860) 225-6487
Beacon Prescriptions	25 Collins Road	Bristol	Connecticut	06010	(860) 589-5587
Beacon Prescriptions	609 North Main Street	Southington	Connecticut	06489	(860) 628-3972
Beacon Prescriptions	875 Foxon Road	East Haven	Connecticut	06513	(203) 467-2600
Beacon Prescriptions South St.	57 South Street	Bristol	Connecticut	06010	(860) 583-1006
Danielson Pharmacy	77 Westcott Road	Danielson	Connecticut	06239	(860) 774-0050
Hancock Pharmacy & Surgical	840 E MAIN ST	MERIDEN	Connecticut	06450	(203) 235-6323
Kent Station Pharmacy	38 North Main Street	Kent	Connecticut	06757	(860) 927-3725
Medical Arts Pharmacy	461 Monroe Tpke	Monroe	Connecticut	06468-2338	(203) 590-3737
Medical Pharmacy	1213 Main Street	Willimantic	Connecticut	06226	(860) 423-1661
MSP	2117 Boston Ave	Bridgeport	Connecticut	06610-3030	(203) 212-3800
Rotary Drug	1030 Barnum Avenue	Stratford	Connecticut	06614	(203) 378-9394
Visels Pharmacy - New Haven, CT	714 Dixwell Ave	New Haven	Connecticut	06511-1097	(203) 562-6878
Darley Pharmacy	111 Darley Road	Claymont	Delaware	19703	(302) 798-0202
Dover Community Pharmacy	1035 South Governors Avenue	Dover	Delaware	19904	(302) 724-9323
Mt Pleasant Care Pharmacy	3169 Mount Pleasant Street Northwest	Washington	District of Columbia	20010-2798	(202) 387-3100
A-1 Pharmacy	815-3 South Moody Road	Palatka	Florida	32177	(386) 385-3987
Ace Pharmacy & Discount	1572 West 37th Street	Hialeah	Florida	33012	(305) 558-1499
ACME Pharmacy	1548 E Fowler Ave Suite 102	Tampa	Florida	33612-5416	(813) 971-6565
Acquaviva's Pharmacy	1555 Port Malabar Northeast, Suite 101	Palm Bay	Florida	32905	(321) 725-7188
Andres Pharmacy and Discount	7167 Southwest 8th Street	Miami	Florida	33144	(305) 261-2822

A Plus Pharmacy	4750 East Moody Boulevard Suite 107	Bunnell	Florida	32110	(386) 313-6959
Bailey's Pharmacy	3850 W. Commercial Blvd. Suite 6	Tamarac	Florida	33309-3316	(954) 766-4090
Bailey's Pharmacy	3065 34TH Street N Suite B	Saint Petersburg	Florida	33713-2401	(727) 256-1410
Bailey's Pharmacy	780 Us Highway 1 Suite 101	Vero Beach	Florida	32962-1661	(772) 492-8559
Bailey's Pharmacy	5156 South Orange Avenue Suite B	Pine Castle	Florida	32809	(407) 930-3102
Baya Pharmacy East	780 SE Baya Dr	Lake City	Florida	32025	(386) 755-6677
Baya Pharmacy West	1465 West US Highway 90 Suite 110	Lake City	Florida	32055	(386) 755-2233
Bay Street Pharmacy	7746 Bay St	Sebastian	Florida	32958	(772) 589-2043
Better Life Pharmacy #1	180 Patricia Ave	Dunedin	Florida	34698-8103	(727) 900-6404
Black & White Pharmacy	8381 Bird Road	Miami	Florida	33155	(305) 545-2108
Brownings Pharmacy	141 East Hibiscus Boulevard	Melbourne	Florida	32901	(321) 723-6520
Cali Pharmacy & Discount	1924-26 West 60th Street	Hialeah	Florida	33012	(305) 558-5055
Cardenas Pharmacy	2741 Coral Way	Miami	Florida	33134	(305) 529-0003
Careplus Pharmacy	701 West Dr Martin Luther King Jr Boulevard Suite 1	Tampa	Florida	33603	(813) 849-0991
Care Rx Pharmacy	1167 E Tennessee St	Tallahassee	Florida	32308-6913	(850) 577-1890
Charles Pharmacy	5081 Okeechobee Boulevard	West Palm Beach	Florida	33417	(561) 507-5300
Choice Pharmacy Inc	5913 North Armenia Avenue	Tampa	Florida	33603	(813) 870-6426
Cocoa Beach Discount Pharmacy	291 West Cocoa Beach Causeway	Cocoa Beach	Florida	32931	(321) 799-2030
Community Pharmacy	897 N. Summit Street	Crescent City	Florida	32112	(386) 698-2666
Continental Rx	505 Southwest 8th Street	Miami	Florida	33130	(305) 856-2211
Cypress Wellness Pharmacy	9451 Cypress Lake Dr	Fort Myers	Florida	33919	(239) 481-7322
Davis Islands Pharmacy	232 E Davis Blvd	Tampa	Florida	33606-3795	(813) 254-1888
Delray Shores Pharmacy	124 Northeast 5th Avenue	Delray Beach	Florida	33483	(561) 272-2124
Duval Pharmacy	2386 Dunn Avenue Suite 117	Jacksonville	Florida	32218	(904) 696-8882
Duval Pharmacy 201	7077 Normandy Blvd Suite 5	Jacksonville	Florida	32205-6294	(904) 900-7700

Elite Pharmacy	11216 West Hillsborough Avenue	Tampa	Florida	33635	(813) 444-4493
Empath Health Pharmacy #1	3050 1st Ave S Pharmacy Dept	St Petersburg	Florida	33712-1010	(727) 209-3500
Empath Health Pharmacy #3	4703 N Florida Ave	Tampa	Florida	33603-3734	(727) 523-2550
Empath Health Pharmacy #6	5771 Roosevelt Blvd Building 410-466	Clearwater	Florida	33760	(727) 523-2575
E P Medical Equipment Pharmacy	6440 SW 117TH AVE	MIAMI	Florida	33183	(305) 630-9307
FamilyCare Discount Pharmacy	514 E Colonial Dr	Orlando	Florida	32803-4504	(407) 216-3474
Farmacia Julia Discount	3000 NW 7th St	Miami	Florida	33125	(305) 642-6211
Farmacia Julia Discount #2	3197 SW 18th St	Miami	Florida	33145-1803	(305) 448-6523
Five Points Pharmacy and Wellness	1108 Lake Drive	Cocoa	Florida	32922	(321) 806-3951
Flagler Pharmacy	200 Moody Boulevard	Flagler Beach	Florida	32136	(386) 777-0777
Fort Myers Prescription Shop	13195 Metro Parkway Suite 3	Fort Myers	Florida	33966	(239) 939-0249
GLS Pharmacy LLC	15680 Southwest 72nd Street	Miami	Florida	33193-1923	(786) 391-3618
Gulf Breeze Apothecary	1177 Gulf Breeze Pkwy	Gulf Breeze	Florida	32561-4835	(850) 677-9340
Gulf Gate Pharmacy	2134 Gulf Gate Drive	Sarasota	Florida	34231	(941) 493-6500
Gulfport Pharmacy	5004 Gulfport Boulevard S	Gulfport	Florida	33707	(727) 223-1075
Heartland Discount Pharmacy	407 South Parrott Avenue	Okeechobee	Florida	34974	(863) 763-7633
Infinity Pharmacy	7551 West Hillsborough Avenue	Tampa	Florida	33615	(813) 462-2777
Island Family Pharmacy	600 PLANTATION ISLAND DR S UNIT 3	ST AUGUSTINE	Florida	32080	(904) 461-1081
J's Pharmacy	6416 Ridge Road	Port Richey	Florida	34668	(727) 847-2211
Kabs Pharmacy #01	2812 E Bearss Ave	Tampa	Florida	33613	(813) 988-4000
Key Pharmacy	614 Crandon Boulevard	Key Biscayne	Florida	33149	(305) 361-5445
King Pharmacy & Compounding LLC	31201 US Highway 19 North Suite 1	Palm Harbor	Florida	34684-4422	(727) 772-6868
La Cubana Pharmacy Discount	5965 SW 8th St Suite A	Miami	Florida	33144	(305) 267-6767
Little Road Pharmacy	4211 Little Road Unit #4	New Port Richey	Florida	34655	(727) 372-5222
Logos Pharmacy	7543 W Waters ave	Tampa	Florida	33615	(813) 886-2800

Manatee Discount Pharmacy	1802 59th Street West	Bradenton	Florida	34209	(941) 209-1234
Marquez Pharmacy	5901 West 16th Avenue	Hialeah	Florida	33012	(305) 558-8002
Med-Care Infusion Services	3085 West 80th Street	Hialeah	Florida	33018	(305) 863-4277 Ext 2903
Medical Arts Pharmacy	4417 Bee Ridge Road	Sarasota	Florida	34233	(941) 706-1777
Medicine Maxx	646 South Dillard Street	Winter Garden	Florida	34787	(407) 656-0081
Medplus Pharmacy	1690 Jeremiah St Unit 107	Middleburg	Florida	32068-8428	(904) 214-3105
MedzDirect Inc #1	1065 NE 125th St Suite 207	North Miami	Florida	33161-5821	(786) 347-0365
Merit Pharmacy	2464 N State Rd 7	Lauderdale Lakes	Florida	33313	(954) 739-4666
Moultrie Pharmacy	3690 US 1 South	St. Augustine	Florida	32086	(904) 794-1399
New Life Pharmacy	22149 S Dixie Highway	Miami	Florida	33170	(305) 960-7176 Ext 22162
Next Dose Pharmacy	6802 West Hillsborough Avenue Suite 12	Tampa	Florida	33634	(813) 930-9300
Oaks Pharmacy	1905 West State Road 434	Longwood	Florida	32750	(407) 350-5925
Orlando Pharmacy	2909 North Orange Avenue Suite 112	Orlando	Florida	32804	(407) 898-1331
Ortux Pharmacy LLC	9134 NW 25th St	Doral	Florida	33172	(786) 542-5007
Pathway Pharmacy	202 Southwest 17th Street Suite A	Ocala	Florida	34471	(352) 624-2779
PDL Pharmacy	3255 NW 7 St	Miami	Florida	33125	(305) 266-3705
Perkins Indian River Pharmacy	3721 10th Court	Vero Beach	Florida	32960	(772) 567-2555
PharmacyGo	20041 S Tamiami Trail Suite 13	Estero	Florida	33928-2228	(239) 908-3187
Prime Rx Pharmacy	10010 Cross Creek Blvd.	Tampa	Florida	33647-2595	(813) 955-7777
QuickRx@Bartow	1140 E Van Fleet Dr	Bartow	Florida	33830-7626	(863) 537-6910
Rx Express Pharmacy	8986 Ortega Park Dr	Navarre	Florida	32566	(850) 936-6446
Savers Drug Mart	200 Ocean Avenue	Melbourne Beach	Florida	32951-2350	(321) 725-5492
Save Rx Pharmacy	231 Del Prado Boulevard South Suite 11	Cape Coral	Florida	33990-5707	(239) 288-2244
Scripts Direct Pharmacy	8313 West Hillsborough Avenue Suite 260	Tampa	Florida	33615	(813) 868-1999
St. Mary Pharmacy	1290 West Bay Drive	Largo	Florida	33770	(727) 585-1333
Starcare Pharmacy	7200 RIDGE RD STE 106	Port Richey	Florida	34668	(727) 312-4888
St Mary Pharmacy II	30606 US Highway 19 North	Palm Harbor	Florida	34684	(727) 773-9000

Sun Discount Pharmacy	3600 S Tuttle Ave	Sarasota	Florida	34239-7116	(941) 556-9622 Ext 0
Sun Pharmacy of Bradenton	415 53rd Ave W	Bradenton	Florida	34207-3416	(941) 444-9656 Ext 0
Sun Pharmacy of Venice	1214 E Venice Ave Suite C	Venice	Florida	34285-7165	(941) 584-2080
Sunshine Pharmacy	5040 West SR 46 Suite 1126	Sanford	Florida	32771	(407) 878-4272
Super Discount Pharmacy	1423 S Collins St	Plant City	Florida	33563	(813) 752-1133
Union Pharmacy and Medical Supplies	6456 West Flagler Street	Miami	Florida	33144	(305) 262-4646
Union Pharmacy and Medical Supplies	2501 SW 67th Ave	Miami	Florida	33155-2968	(305) 661-8800
University Pain Management Center Pharmacy	3220 Cove Bend Drive	Tampa	Florida	33613	(813) 615-0742
Vida Pharmacy	7250 West 24th Avenue, Suite 19/20	Hialeah	Florida	33016	(305) 822-8234
Village Pharmacy	9408 SW 87th Ave Suite 105	Miami	Florida	33176	(305) 274-8955
Wellness Rx LLC	7640 Northwest 25th Street Suite 105	Miami	Florida	33122	(305) 384-7600
Winships Pharmacy	5643 South East Crooked Oak Avenue Seabranh Square	Hobe Sound	Florida	33455	(772) 324-8381
Winships Prescription Center	721 Northlake Boulevard	North Palm Beach	Florida	33408	(561) 842-2444
Scripts Pharmacy	2352 Bruce B Downs Blvd Suite 103	Wesley Chapel	Florida	33544-9203	(813) 751-3377 Ext 0
Abundant Life Pharmacy	117 North Main Street	Baxley	Georgia	31513	(912) 367-8404
Adams Drug Store	408 B 16th Ave E	Cordele	Georgia	31015	(229) 273-3433
Adams Family Pharmacy	98 Peachtree Street	Cuthbert	Georgia	39840-5807	(229) 732-2077
Adams Family Pharmacy	6381 Hamilton Street	Preston	Georgia	31824	(229) 828-2273
ADD Drug	1695 South Lumpkin Street	Athens	Georgia	30606	(706) 548-2239
Allcare Pharmacy and Compounding	112 South Oxley Drive	Lyons	Georgia	30436	(912) 526-3200
Altama Pharmacy	5711 Altama Ave Suite G	Brunswick	Georgia	31525	(912) 264-2622
Apollo Pharmacy	418 West Broughton Street	SAVANNAH	Georgia	31401-3218	(912) 999-6101
Apollo Pharmacy #2	111 Canal Street Suite 101	Pooler	Georgia	31322-4054	(912) 988-7185
Augusta Pharmacy	1944 Walton Way Suite C	Augusta	Georgia	30904-6711	(706) 287-2700

Bainbridge Pharmacy	1420 East Evans Street	Bainbridge	Georgia	39819	(229) 246-7200
Ball Ground Pharmacy	470 Valley Street	Ball Ground	Georgia	30107	(770) 735-6161
Barber's Pharmacy	731 Cameron Drive	Blackshear	Georgia	31516	(912) 449-4444
Barnes Drug Store	200 South Patterson Street	Valdosta	Georgia	31601	(229) 242-1925
Batts Drug Company Inc	115 Commerce Street	Hawkinsville	Georgia	31036	(478) 892-9021
Baxley Wellness Pharmacy Inc	160 Azalia Road	Baxley	Georgia	31513	(912) 705-3784
Beasley Drug Company	933 Center Street	Conyers	Georgia	30012	(770) 483-7211
Ben Hill Pharmacy	3740 Campbellton Rd SW	Atlanta	Georgia	30331-5222	(404) 565-0252
Bennett's Hometown Pharmacy	26826 Highway 82	Waynesville	Georgia	31566	(912) 778-3784
Bennett's Hometown Pharmacy	13202 Cleveland Street West, Suite 100	Nahunta	Georgia	31553	(912) 462-3784
Bennett's Hometown Pharmacy	4402 North Second Street Suite C	Folkston	Georgia	31537	(912) 496-3784
Bonaire Pharmacy	810 SR 96 Suite 1800	Warner Robins	Georgia	31088	(478) 287-2169
Brasstown Professional Pharmacy, Inc.	23B Murphy Highway	Blairsville	Georgia	30512	(706) 745-2303
Brooke's Pharmacy	812 South Park Street Suite 5A	Carrollton	Georgia	30117	(770) 834-9050
Brooklet Drug	102 Parker Avenue South	Brooklet	Georgia	30415	(912) 842-9886
Brownings Pharmacy	1919 Alice Street	Waycross	Georgia	31501	(912) 283-5504
Buchanan Drugs	106 Courthouse Square	Buchanan	Georgia	30113	(770) 646-3570
C & C Pharmacy	621 West Memorial Drive	Dallas	Georgia	30132-4120	(770) 445-2600
Center Drugs	133 2nd Ave SE	Cairo	Georgia	39828	(229) 377-2777
Chapman Drug Co Inc	615 North Central Avenue	Hapeville	Georgia	30354	(404) 761-1136
Chapman Healthcare Pharmacy	305 Maple Drive	Vidalia	Georgia	30474	(912) 538-0053
Citizens Pharmacy	5325 Atlanta Highway	Flowery Branch	Georgia	30542	(770) 967-3324
City Pharmacy of Zebulon PC	460 Thomaston Street	Zebulon	Georgia	30295	(770) 567-8844
Clark Drug Company	206 West 6th Street	Waynesboro	Georgia	30830-1460	(706) 558-3400
Clinic Pharmacy	58 Big A Road Suite 101	Toccoa	Georgia	30577	(706) 886-2151

Coastal Drug Company	90 Butler St Suite A	Midway	Georgia	31320	(912) 884-9255
Coliseum Park Professional Pharmacy	380 Hospital Drive, Suite 175 A	Macon	Georgia	31217	(478) 745-5431
Colony Discount Drugs	502 South Grant Street	Fitzgerald	Georgia	31750-3398	(229) 423-9801
Colquitt Pharmacy	215 West Main Street	Colquitt	Georgia	39837	(229) 600-0524
Connect Care Pharmacy	2191 Highway 247 Connector	Byron	Georgia	31008	(478) 654-5222
CONYERS PHARMACY	1179 West Avenue	Conyers	Georgia	30012	(770) 929-1414
Cox Pharmacy Inc	300 2nd Avenue Southeast	Cairo	Georgia	39828	(229) 377-9017
CRAWFORD-BREAZEALE DRUG CO	125 North Washington Street	Lincolnton	Georgia	30817-1784	(706) 359-3343
Dennard Drugs	794 2nd Street	Soperton	Georgia	30457	(912) 529-4545
Dykes Pharmacy	134 N Second St	Cochran	Georgia	31014-1619	(478) 934-6344
Eastman Drugs	1221 Plaza Avenue, Suite B	Eastman	Georgia	31023	(478) 374-6670
Economy Discount Pharmacy	9881 Commerce Street Suite A	Summerville	Georgia	30747	(706) 808-1100
Farmer's Prescription Shop	279 North Broad Street Ste B	Winder	Georgia	30680	(770) 867-9072
Fievet Pharmacy	115 East Robert Toombs Avenue	Washington	Georgia	30673	(706) 678-2260
First Choice Primary Care	400 Poplar Street	MACON	Georgia	31201	(478) 309-1744
Five Points Pharmacy	217 N Camellia Blvd	Fort Valley	Georgia	31030	(478) 822-0555
Folkston Pharmacy	3885 Main Street	Folkston	Georgia	31537	(912) 496-2044
Forest Heights Pharmacy	4439 Country Club Road	Statesboro	Georgia	30458	(912) 489-7979
Friendly City Pharmacy	1202 US Highway 41 North	Tifton	Georgia	31794	(229) 586-8193
Fulghum Drugs	73 Southwest Park Avenue	Baxley	Georgia	31513	(912) 367-2488
Georgetown Drug Company	1080 King George Blvd	Savannah	Georgia	31419	(912) 920-1500
Glenn's Corner Pharmacy	631 East Franklin Street	Sylvester	Georgia	31791	(229) 776-3600
Golden Isles Pharmacy	3010 Altama Avenue	Brunswick	Georgia	31520	(912) 266-8140
Golden Isles Pharmacy	615 South Palisade Drive	Brunswick	Georgia	31523-8211	(912) 400-2929
Graves Pharmacy	770 Pine Street, Suite 100	Macon	Georgia	31201	(478) 745-0476
Hall Drug Co	90 Court Square	Blakely	Georgia	39823	(229) 723-3441
Haney's Drug Corner	623 Dixie Street	Carrollton	Georgia	30117	(770) 834-3393

Hawkinsville Drug Company	153 Commerce Street	Hawkinsville	Georgia	31036-8420	(478) 783-0555
Health Delivery Pharmacy	1326 Eisenhower Drive Building 1	Savannah	Georgia	31406	(912) 200-9250
Hinesville Pharmacy	481 Elma G Miles Parkway	Hinesville	Georgia	31313	(912) 876-8125
Hogan's Pharmacy	2704 North Oak Street Suite B-1	Valdosta	Georgia	31602	(229) 244-5353
Hometown Pharmacy	236 West Clinton Street	Gray	Georgia	31032	(478) 986-4827
IHS Pharmacy & Gifts	150 South Leroy Street	Metter	Georgia	30439	(912) 685-2803
IHS Pharmacy #3	13762 Highway 80	Jeffersonville	Georgia	31044	(478) 945-3500
Jackson Pharmacy	170 JOHN RANDOLPH DR	HOSCHTON	Georgia	30548-1502	(706) 658-0064
Jennings Mill Drug Company	1360 Caduceus Wy Bldg 400 Suite 105	Watkinsville	Georgia	30677-7300	(706) 621-5996
Jones Prescription Shop	101 Peachtree Street	Jesup	Georgia	31545	(912) 427-8825
King's Hometown Pharmacy	33 SCHOOL CIRCLE SUITE A	BLAIRSVILLE	Georgia	30512-2984	(706) 400-5043
Knight's Pharmacy	2 E William Wainwright St	Reynolds	Georgia	31076	(478) 847-3666
Lacey Drug Company	4797 South Main Street	Acworth	Georgia	30101	(770) 974-3131
Laceys Marietta Pharmacy	790 Church St Suite 210	Marietta	Georgia	30060-7289	(770) 424-3131
Lane Drug Co.	19427 Hartford Street	Edison	Georgia	39846	(229) 835-2212
Lee-Goodrum Pharmacy	40 Hospital Road	Newnan	Georgia	30263-1200	(770) 253-1121
Lily's Pharmacy	11670 Jones Bridge Road Suite E	Johns Creek	Georgia	30005	(678) 964-5459
Live Oak Pharmacy	98 Oakland Avenue East	Camilla	Georgia	31730	(229) 336-2255
Lo Cost Pharmacy	612 East 69th Street	Savannah	Georgia	31405	(912) 352-0375
Ludowici Drugs	11 West Cypress Street	Ludowici	Georgia	31316	(912) 545-2125
Lula Pharmacy and Foothills Gift Shop	6102 Banks Street	Lula	Georgia	30554	(770) 869-3616
Madden's Pharmacy, Inc.	101 College Avenue	Elberton	Georgia	30635-1705	(706) 283-1701
Maddox Drugs	1330 Big A Road	Toccoa	Georgia	30577	(706) 886-3119
Madison Drug Company	213 NORTH MAIN STREET	MADISON	Georgia	30650	(706) 342-1722
Magnolia Drug Co Inc	112 North Church Street	Homerville	Georgia	31634	(912) 470-7277
Max Brown Pharmacy	809 North Jefferson Street	Dublin	Georgia	31021	(478) 272-8086
McCaysville Drug Center Inc	131 Blue Ridge Drive	McCaysville	Georgia	30555	(706) 492-4126
Medical Arts Pharmacy Inc	650 North Cobb Street	Milledgeville	Georgia	31061	(478) 452-1222

Medical Park Pharmacy	2406 Bellevue Rd	Dublin	Georgia	31021	(478) 272-8065
Medicine Stop	1544 Watson Boulevard	Warner Robins	Georgia	31093	(478) 922-2067
Medi-Save Pharmacy	800 South Slappey Boulevard	Albany	Georgia	31701	(229) 435-1306
MediThrift Pharmacy	324 West Patton Street	Lafayette	Georgia	30728	(706) 638-3114
Mid-City Pharmacy	196 E Main St	Canton	Georgia	30114-2799	(770) 479-5533
Midtown Pharmacy	2660 Buena Vista Road Suite A	Columbus	Georgia	31906	(706) 596-8871
Misty's Pharmacy	149 NW Broad St	Jesup	Georgia	31545	(912) 427-3726
Mitch's Pharmacy	5 E Coffee St	Hazlehurst	Georgia	31539	(912) 699-3784
Morris Drug Co	646 Main Street North	Pearson	Georgia	31642	(912) 422-3631
Mount Vernon Drug Company	115 West Spring Street	Mount Vernon	Georgia	30445	(912) 616-9922
Moyes Drug Store	162 East Railroad Street South East	Pelham	Georgia	31779	(229) 294-4058
Murrayville Pharmacy	5304 Thompson Bridge Rd	Murrayville	Georgia	30564	(770) 534-2245
North Columbus Pharmacy	6490 Veterans Parkway Suite B	Columbus	Georgia	31909	(706) 327-5125
Northside Drugs	1109 HWY 19 NORTH	THOMASTON	Georgia	30286	(706) 648-2181
OCILLA PHARMACY	515 North Irwin Avenue	OCILLA	Georgia	31774-1542	(229) 468-5929
PeachRx Pharmacy	610 Shurling Drive	Macon	Georgia	31211	(478) 314-7993
Pembroke Pharmacy	137 East Bacon Street	Pembroke	Georgia	31321	(912) 653-2772
Phillips Pharmacy	306 West First Street	Vidalia	Georgia	30474	(912) 537-3049
Pillar Drug Company	1 Hidden Creek Drive	Guyton	Georgia	31312	(912) 772-9100
Pooler Pharmacy	1557 POOLER PARKWAY SUITE 400	POOLER	Georgia	31322	(912) 348-4420
Powells Northside Pharmacy	440 Charter Boulevard Suite 1107	Macon	Georgia	31210	(478) 474-6767
Powells Pharmacy	4839 Bloomfield Road	Macon	Georgia	31206-4399	(478) 781-1213
Premier Drugstore	8446 Campbellton Street	Douglasville	Georgia	30134	(770) 635-8509
Prescription Shop	710 Medical Center Dr	Eastman	Georgia	31023	(478) 374-5514
Quick Rx Drugs #6	504 N LAUREL ST	SPRINGFIELD	Georgia	31329	(912) 754-6444
Richmond Hill Pharmacy	2409 US Highway 17	Richmond Hill	Georgia	31324	(912) 756-3331
Riggins Pharmacy	12240 Augusta Road	Lavonia	Georgia	30553	(706) 356-8863

Riverside Pharmacy Inc	935 Green St NE	Gainesville	Georgia	30501	(770) 532-6253
Robins Pharmacy	150 South Houston Lake Road Suite 300	Warner Robins	Georgia	31088-9056	(478) 333-6767
Rome Community Pharmacy	501 East 2nd Avenue	Rome	Georgia	30161-3249	(706) 622-2063
Rose City Pharmacy	616 South Broad Street	Thomasville	Georgia	31792-5551	(229) 233-7733
Ross Drug	127 North Main Street	Sylvania	Georgia	30467	(912) 564-7002
Sanders Drugs	61 Falls Road	Toccoa	Georgia	30577	(706) 297-0111
Sandersville Drug Co.	528 Sparta Road	Sandersville	Georgia	31082	(478) 552-7333
Satilla Wellness Pharmacy	515 South City Boulevard Suite D & E	Waycross	Georgia	31501	(912) 514-4111
Sawnee Drug Co	2515 Business Drive	Cumming	Georgia	30028	(770) 889-8900
Silver Creek Pharmacy	4450 Rockmart Highway	Silver Creek	Georgia	30173	(706) 292-0106
Smith's Pharmacy	141 Eighth St.	McRae Helena	Georgia	31037	(229) 868-2580
SOUTHERN DRUG CO-DARIEN	1001 North Way	Darien	Georgia	31305	(912) 437-6353
Southern Drug Co - Jesup	918 S 1st St.	Jesup	Georgia	31545	(912) 559-2961
Southern Drug Company	4075 East First Street	Blue Ridge	Georgia	30513	(706) 632-4448
St Simons Drug Company	209 Longview Plaza	St Simons Is	Georgia	31522	(912) 638-8676
Swan Pharmacy Inc	48 N Main St	Wadley	Georgia	30477	(478) 252-5252
Tallapoosa Drug	2066 US Hwy 78	Tallapoosa	Georgia	30176-1464	(770) 574-2339
Temple Pharmacy	285 Sage St	Temple	Georgia	30179-0608	(770) 562-3268
THE MEDICINE CABINET	102 S PIERCE ST	ALMA	Georgia	31510	(912) 383-0634
THE MEDICINE CABINET	2607 PLANT AVENUE	WAYCROSS	Georgia	31501	(912) 490-6337
The Medicine Cabinet	300 MOOTY BRIDGE RD STE 112	LAGRANGE	Georgia	30240-1881	(706) 298-4930
The Medicine Cabinet	1704 ROANOKE RD	LAGRANGE	Georgia	30240-3803	(706) 298-6460
The Medicine Cabinet	1194 WARM SPRINGS HWY	MANCHESTER	Georgia	31816	(706) 846-2002
The Medicine Cabinet	205 VERNON STREET	LAGRANGE	Georgia	30240	(706) 298-4928
The Medicine Cabinet of Brunswick LLC	2500 Starling St Suite 102	Brunswick	Georgia	31520	(912) 265-7000

The Medicine Cabinet of Douglas	722 Shirley Avenue	Douglas	Georgia	31533	(912) 383-8510
The Medicine Cabinet of Dublin LLC	1819 RICE AVE	DUBLIN	Georgia	31021-0537	(478) 272-1822
The Medicine Cabinet of Waycross - Downtown, LLC	620 Tebeau St	Waycross	Georgia	31501	(912) 283-2772
The Medicine Cabinet - Ward Street, LLC	223 W ASHLEY ST	DOUGLAS	Georgia	31533-3124	(912) 383-6337
The Pharmacy Place	2035 Commerce Dr N	Peachtree City	Georgia	30269-3538	(678) 271-3970
Thomson Drug Company	501 Mount Pleasant Road	Thomson	Georgia	30824	(706) 595-6126
Thrifty Mac Pharmacy	218 S Main St	Madison	Georgia	30650	(706) 342-4141
Tomlinson Pharmacy	108 Rowe St	Dublin	Georgia	31021	(478) 272-7722
Towne Pharmacy	6014 Highway 21 South Suite P	Rincon	Georgia	31326	(912) 826-0250
Trenton Pharmacy	11969 S Main St	Trenton	Georgia	30752-2855	(706) 500-1301
Trumarx Drugs	501 Gordon Avenue	Thomasville	Georgia	31792	(229) 226-8700
Twin City Drug Co	507 South Railroad Avenue	Twin City	Georgia	30471-0040	(478) 763-2151
Unadilla Drug Company	413 2nd Street	Unadilla	Georgia	31091	(478) 627-3041
Valurite Discount Pharmacy	1006 Professional Boulevard	Dalton	Georgia	30720	(706) 217-2700
Village Drug Shop of Athens	740 Prince Avenue	Athens	Georgia	30606-2296	(706) 548-4444
Villa Rica Drugs	222 W Wilson St	Villa Rica	Georgia	30180-1807	(770) 456-4663
Walker Pharmacy & Gifts Inc	2425 Northside Drive West	Statesboro	Georgia	30458	(912) 764-6175
Walker Pharmacy Market District	1198 Merchants Way	Statesboro	Georgia	30458	(912) 681-3784
Wauka Mountain Pharmacy	5233 Cleveland Highway	Clermont	Georgia	30527	(770) 983-9556
Wayne Drug Co	192 North First Street	Jesup	Georgia	31545	(912) 427-4288
West End Pharmacy	824 West Avenue	Cartersville	Georgia	30120	(770) 606-0697
WOODBINE PHARMACY	908 GEORGIA AVE	WOODBINE	Georgia	31569	(912) 576-6998
WYATT'S PHARMACY	10671 Veterans Memorial Hwy.	Lithia Springs	Georgia	30122	(770) 948-8825
Young Life Pharmacy	1769 Candler Road	Decatur	Georgia	30032-3276	(404) 549-9671
5 Minute Pharmacy	94-216 Farrington Highway, Suite B1-102	Waipahu	Hawaii	96797	(808) 677-5550

5 MINUTE PHARMACY DOWNTOWN	928 NUUANU AVE # 1-B	HONOLULU	Hawaii	96817-5190	(808) 809-6661
5 MINUTE PHARMACY LONG TERM CARE	94-449 Akoki St #102	WAIPAHU	Hawaii	96797-1922	(808) 671-5511
Don Quijote Drugs	801 Kaheka St	Honolulu	Hawaii	96814	(808) 973-6661
Family Pharmacy INC	1451 South King Street Suite 203 A	Honolulu	Hawaii	96814	(808) 379-2347
KTA Kamuela Pharmacy	65-1158 Mamalahoa Highway	Kamuela	Hawaii	96743	(808) 885-0033
KTA Keauhou Pharmacy	78-6831 Alii Drive	Kailua-Kona	Hawaii	96740	(808) 322-2511
KTA Ponahawai Pharmacy	670 Ponahawai Street Suite 211	Hilo	Hawaii	96720	808-865-0505
KTA Puainako Pharmacy	50 E Puainako St	Hilo	Hawaii	96720-5243	(808) 959-8700
KTA Waikoloa Village Pharmacy	68-3916 Paniolo Avenue	Waikoloa	Hawaii	96738	(808) 883-8434
Maui Clinic Pharmacy	22 Hana Hwy, Suite B	Kahului	Hawaii	96732	(808) 877-6222
Medipharm Pharmacy	891 Ululani Street Suite 113	Hilo	Hawaii	96720	(808) 969-9163
Medipharm Pharmacy	197 Sand Island Access Road, Suite 208	Honolulu	Hawaii	96819-4901	(808) 744-9080
Pharmacare No. 4	99 128 Aiea Heights Drive Suite 103	Aiea	Hawaii	96701	(808) 840-5681
Rainbow Pharmacy	431 Seventh Street	Lanai City	Hawaii	96763	(808) 565-9332
Times Pharmacy #1	1772 S King St	Honolulu	Hawaii	96826	(808) 973-5851
Times Pharmacy #10	47 388 Hui Iwa St	Kaneohe	Hawaii	96744	(808) 239-3204
Times Pharmacy #11	1425 Liliha St	Honolulu	Hawaii	96817	(808) 522-5082
Times Pharmacy #12	98 1264 Kaahumanu Street	Pearl City	Hawaii	96782	(808) 483-3078
Times Pharmacy #18	94 615 Kupuohi St	Waipahu	Hawaii	96797	(808) 677-5999
Times Pharmacy #2	1173 21st Avenue	Honolulu	Hawaii	96816	(808) 733-2031
Times Pharmacy #24	3350 Lower Honoapiilani Rd	Lahaina	Hawaii	96761-8402	(808) 661-8008
Times Pharmacy #25	1620 North School Street	Honolulu	Hawaii	96817	(808) 853-2268
Times Pharmacy #4	45 934 Kamehameha Hwy	Kaneohe	Hawaii	96744	(808) 233-4601
Times Pharmacy #6	94 766 Farrington Highway	Waipahu	Hawaii	96797	(808) 677-1513
Times Pharmacy #9	99 115 Aiea Heights Drive	Aiea	Hawaii	96701	(808) 483-3071

Kaleo's Pharmacy LLC	4475 Papalina Rd Suite C1	Kalaheo	Hawaii	96741-8503	(808) 431-4455
Jacks Pharmacy Inc	103 East College Avenue	St Maries	Idaho	83861	(208) 245-4578
London Drug	6 S Main	Grace	Idaho	83241	(208) 425-3766
Maag Prescription and Medical Supply	333 West Center Street	Pocatello	Idaho	83204	(208) 233-2063
Medicine Man Athol Pharmacy	30585 North Roberts Road	Athol	Idaho	83801	(208) 683-1309
Medicine Man Bonners Ferry Pharmacy	6452 Main Street	Bonners Ferry	Idaho	83805	(208) 267-4021
Medicine Man Hayden Pharmacy	240 West Hayden Avenue	Hayden	Idaho	83835	(208) 772-3311
Medicine Man North Pharmacy	305 West Kathleen Avenue	Coeur D' Alene	Idaho	83815	(208) 765-2268
Medicine Man Prairie Pharmacy	8093 Cornerstone Drive	Hayden	Idaho	83835	(208) 762-9355
Mike's Pharmacy & Compounding	180 S Holmes Ave	Idaho Falls	Idaho	83401	(208) 525-8700
SavMor Drug	139 Main Ave W	Twin Falls	Idaho	83301-6194	(208) 733-8323
The Prescription Pad	1620 N Whitley Dr	Fruitland	Idaho	83619-2271	(208) 452-7075
Valley Apothecary	201 North Washington Avenue	Ketchum	Idaho	83340	(208) 726-2679
Vic's Family Pharmacy	118 South Midland Boulevard	Nampa	Idaho	83686	(208) 442-1000
Vic's Family Pharmacy	1513 12th Avenue Road	Nampa	Idaho	83686	(208) 465-7000
Alwood Pharmacy	211 South 1st Street	Alpha	Illinois	61413	(309) 629-4506
Armitage Pharmacy, Inc.	3650 West Armitage Avenue Suite 100	Chicago	Illinois	60647	(773) 486-8800
Benivex Pharmacy	370 West Indian Trail	Aurora	Illinois	60506	(630) 800-1636
Bond County Pharmacy	224A E Harris Ave	Greenville	Illinois	62246-2150	(618) 690-5000
Byrd-Watson Drug #2	1071 West Broadway	Centralia	Illinois	62801-5309	(618) 532-2200
Cains Drug Store	1401 North 8th Street	Vandalia	Illinois	62471	(618) 283-0196
Community Pharmacy of Chicago Ridge	9830 South Ridgeland	Chicago Ridge	Illinois	60463	(708) 229-2100
Crescent Pharmacy	7261 West 87th Street	Bridgeview	Illinois	60455-1821	(708) 598-0505
Curry's Family Pharmacy	1275 North 7th Street	Riverton	Illinois	62561	(217) 629-7001
Dick's Pharmacy	122 S. Walnut St	Arthur	Illinois	61911	(217) 543-2913

Dundee Pharmacy	2750 Dundee Road, Suite 9	Northbrook	Illinois	60062	(847) 480-1000
Harrys Pharmacy Inc	620 East Jackson	Auburn	Illinois	62615	(217) 438-6141
HUDSON DRUG SHOP	108 N MARKET	Paxton	Illinois	60957	(217) 379-4858
Illini Clinic Pharmacy	855 Illini Drive, Suite 200	Silvis	Illinois	61282	(309) 792-7002
Katsaros Pharmacy	1521 East 53rd Street	Chicago	Illinois	60615	(773) 288-8700
Kremer Pharmacy	206A North Pearl Street	Teutopolis	Illinois	62467- 1134	(217) 857-3000
KREMER PHARMACY ALTAMONT	12 N 3RD ST	ALTAMONT	Illinois	62411- 1271	(618) 483-5100
Kwikrx Pharmacy	13015 West 143rd Street	Homer Glen	Illinois	60491	(708) 292-0043
Mexicare Pharmacy	3200 West 26th Street	Chicago	Illinois	60623	(773) 890-1800
Moreland & Devitt Inc	124 North Congress Street	Rushville	Illinois	62681	(217) 322-3335
Moreland & Devitt Pharmacy	201 South State Street	Beardstown	Illinois	62618- 1219	(217) 909-4333
Morton Alwan Pharmacy	419 Maxine Drive	Morton	Illinois	61550	(309) 291-0180
Oakwood Apothecary	17 N HAMILTON ST	SULLIVAN	Illinois	61951	(217) 728-2760
OGDEN PHARMACY	2040 Ogden Avenue Suite 117	Aurora	Illinois	60504- 7205	(630) 320-8600
Orion Family Pharmacy LLC	201 11th Avenue	Orion	Illinois	61273	(309) 526-8008
Pearman Pharmacy	116 West Court Street	Paris	Illinois	61944	(217) 465-8455
Plum Street Pharmacy	311 Plum Street	Carmi	Illinois	62821	(618) 382-8400
Prime Plus Pharmacy	2955 W 95th St	Evergreen Park	Illinois	60805- 2409	(708) 741-7501
Princeville Pharmacy	206 East Main	Princeville	Illinois	61559	(309) 385-4955
Rigg FamilyCare Pharmacy	37 W MAIN ST	ALBION	Illinois	62806- 1006	(618) 445-2581
Scotts Family Pharmacy	220 N Sangamon Ave	Gibson City	Illinois	60936- 1397	(217) 784-8241
Sears Pharmacy	1003 Madison St	Oak Park	Illinois	60302- 4499	(708) 386-6304
Sherman's Pharmacy	91 Knoxville Avenue	Brimfield	Illinois	61517	(309) 446-3292
Silver Pharmacy	1890 Silver Cross Boulevard Suite 120	New Lenox	Illinois	60451- 9528	(815) 800-3100
Southwest Express Pharmacy	11164 Southwest Highway	Palos Hills	Illinois	60465- 2709	(708) 541-1000
St. Jude Pharmacy	301 Madison Street Suite 114	Joliet	Illinois	60435	(815) 900-9000

Staywell Pharmacy	912 East Northwest Highway	Palatine	Illinois	60074-6506	(847) 496-5559
Tablets Pharmacy Inc	9603 S Pulaski Rd	Evergreen Park	Illinois	60805	(708) 272-1212
Vorac Pharmacy LLC	114 S State St	Geneseo	Illinois	61254-1348	(309) 944-2166
Wear Drug	408 Walnut Street	Carthage	Illinois	62321	(217) 357-9327
Wellcreek Pharmacy - Bethalto	333 West Bethalto Drive Suite B	Bethalto	Illinois	62010	(618) 377-5356
WellCreek Pharmacy-Charleston	1 West Lincoln Avenue	Charleston	Illinois	61920	(217) 512-2816
Xpress Pharmacy Inc	6700 W 95th St Suite 150	Oak Lawn	Illinois	60453-2106	(708) 598-5000
Alwan Pharmacy and Compounding Center	311 North Western Avenue	Peoria	Illinois	61604	(309) 676-6333
Cloverdale Drugs	900 North Main Street	Cloverdale	Indiana	46120	(765) 795-4100
Cowan Drugs	112 North Lebanon Street	Lebanon	Indiana	46052	(765) 482-0180
Dr Aziz Pharmacy	7320 East 82nd Street	Indianapolis	Indiana	46256	(317) 842-5771
George's Family Pharmacy	326 South Washington Street Suite 22	Versailles	Indiana	47042	(812) 689-0200
George's Family Pharmacy	124 West Indian Trail Suite C	Milan	Indiana	47031	(812) 654-6251
George's Family Pharmacy	480 Main Street	Brookville	Indiana	47012	(765) 647-6251
George's Family Pharmacy	24128 State Line Road	Lawrenceburg	Indiana	47025	(812) 637-6251
George's Family Pharmacy, Inc.	1198 State Road 46 East	Batesville	Indiana	47006	(812) 932-6251
George's Family Pharmacy, Inc.	330 East 5th Street	Connersville	Indiana	47331-2604	(765) 825-6251
George's Pharmacy East Side	5543 E Washington St	Indianapolis	Indiana	46219-6448	(317) 359-8278
Herbst Apothecary Inc	201 N Dixon Rd	Kokomo	Indiana	46901-4097	(765) 457-1191
Herbst Pharmacy	300 E Southway Blvd Suite E	Kokomo	Indiana	46902-6411	(765) 455-5418
Herbst Pharmacy	710 W Main St	Greentown	Indiana	46936	(765) 628-3446
JR Pharmacy LLC 2	15 Southland Shopping Cntr	Terre Haute	Indiana	47802	(812) 232-6655
JR Pharmacy Poplar LLC	1101 Poplar St	Terre Haute	Indiana	47807-4565	(812) 235-7373
JR Pharmacy Rockville LLC 4	1330 N Lincoln Rd	Rockville	Indiana	47872-1215	(765) 569-6900
JR Scripts Pharmacy No 1 LLC	2902 Poplar St	Terre Haute	Indiana	47803-2661	(812) 478-1006

Mathes Pharmacy	1621 Charlestown Road	New Albany	Indiana	47150	(812) 944-3612
Medicine Plus	2412 West 16th Street	Bedford	Indiana	47421	(812) 275-3383
MedWorks Pharmacy	2123 Intelliplex Drive	Shelbyville	Indiana	46176-8538	(317) 421-2020
Millers Pharmacy	420 South Detroit Street	Lagrange	Indiana	46761	(260) 463-7464
Parkside Pharmacy	1639 North Lebanon Street	Lebanon	Indiana	46052	(765) 482-1600
Paul's Pharmacy	2345 W Franklin St	Evansville	Indiana	47712-5172	(812) 425-4364
Paul's Pharmacy East	1150 South Green River Road	Evansville	Indiana	47715	(812) 962-3500
PAULS PHARMACY	3408 N 1ST AVE	EVANSVILLE	Indiana	47710-3302	(812) 422-8255
Pharmacy 1 Express	730 West 2nd Street	Bloomington	Indiana	47403	(812) 331-7979
Seifert Drug #2	100 N Elkhart St	Wakarusa	Indiana	46573	(574) 862-1454
Seifert Drug #3	2102 North Main Street Suite 100	Nappanee	Indiana	46550	(574) 773-8280
Seifert Healthcare LLC #1	222 Harrison St	Elkhart	Indiana	46516-3120	(574) 295-4333
Webb's Family Pharmacy	724 Main Street	Rochester	Indiana	46975	(574) 223-2216
Brehme Drug	220 E Main St	Manchester	Iowa	52057	(563) 927-3509
Carroll Apothecary	425 W US Hwy 30 Suite 140	Carroll	Iowa	51401	(712) 792-2671
Cherokee Main Street Pharmacy	218 E Main St	Cherokee	Iowa	51012	(712) 225-2320
Clarks Pharmacy	1946 42nd Street NE	Cedar Rapids	Iowa	52402	(319) 393-3210
Clinic Pharmacy	1115 South Marshall Street	Boone	Iowa	50036	(515) 432-7123
Eagle Grove Pharmacy	311 W Broadway St	Eagle Grove	Iowa	50533	(515) 448-3814
Holstein Community Pharmacy	108 North Main Street	Holstein	Iowa	51025-7754	(712) 368-0010
Koerner-Whipple Pharmacy	104 First Street Northwest	Hampton	Iowa	50441	(641) 456-2510
Larry's Pharmacy 1	1310 10th Ave N	Humboldt	Iowa	50548-1112	(515) 332-1627
Mahaska Drug, Inc	205 North E Street	Oskaloosa	Iowa	52577	(641) 673-3439
Main Street Drug	204 N Main St	Charles City	Iowa	50616-2017	(641) 228-3519
Medical Associates Pharmacy	120 South Story Street	Boone	Iowa	50036	(515) 432-3460
Mercy Family Pharmacy-Clear Lake	1410 6th Avenue South Suite 200	Clear Lake	Iowa	50428	(641) 231-8900
Mercy Family Pharmacy - Greene	104 East Traer Street	Greene	Iowa	50636	(641) 816-3013

MercyOne FOREST PARK PHARMACY	1010 4th Street Southwest Suite 110	Mason City	Iowa	50401	(641) 428-6100
MercyOne Northwood Pharmacy	98 North 10th Street	Northwood	Iowa	50459- 1438	(641) 324-2116
MercyOne Regency Pharmacy	621 South Illinois Avenue Suite 101	Mason City	Iowa	50401	(641) 428-6940
MercyOne Sheffield Pharmacy	115 Gilman	Sheffield	Iowa	50475	(641) 892-4640
MercyOne Westside Pharmacy	910 North Eisenhower Avenue	Mason City	Iowa	50401	(641) 428-5630
Meyer Pharmacy	110 10th St SW	Waverly	Iowa	50677	(319) 352-3120
North Scott Pharmacy	225 East LeClaire Road	Eldridge	Iowa	52748	(563) 285-2001
Sergeant Bluff Pharmacy	105 Gaul Drive Suite A	Sergeant Bluff	Iowa	51054	(712) 943-1494
Smart Pharmacy #22	616 North 8th Street	Osage	Iowa	50461	(641) 732-5806
South Side Drug	337 Church Street	Ottumwa	Iowa	52501	(641) 682-3467
Spring City Pharmacy LLC	101 N WALNUT ST	COLFAX	Iowa	50054	(515) 674-3784
Summit Pharmacy	300 West Burlington Avenue	Fairfield	Iowa	52556- 3241	(641) 472-7987
B & C Drug Company	702 12TH Street	Belleville	Kansas	66935	(785) 527-2146
Bachman Drug	129 South Fowler	Meade	Kansas	67864	(620) 873-2641
Barrys Drug Center	414 Poyntz Avenue	Manhattan	Kansas	66502- 6086	(785) 776-8833
Clark Pharmacy	104 S Main St	Cimarron	Kansas	67835- 9998	(620) 855-2242
Continental Pharmacy LLC	821 Southwest 6th Street	Topeka	Kansas	66603- 3130	(785) 232-6975
Doug's Pharmacy	430 Main Street	Rossville	Kansas	66533	(785) 584-6722
Dunne's Pharmacy Inc	2429 Claflin Rd	Manhattan	Kansas	66502- 2785	(785) 539-2345
Ferguson Rexall Drugs	713 5th Street	Clay Center	Kansas	67432	(785) 632-3121
Gatlin Medical Arts Pharmacy	420 Country Club Road	Pratt	Kansas	67124	(620) 672-7447
Gibson's Pharmacy	2401 Central Avenue	Dodge City	Kansas	67801	(620) 227-8193
Grant County Drug	219 N Main St	Ulysses	Kansas	67880- 2130	(620) 356-1446
Greeley County Drug	422 Broadway Avenue	Tribune	Kansas	67879- 7701	(620) 376-4224
Hamilton County Drug	302 East Avenue A	Syracuse	Kansas	67878	(620) 384-7424
Humboldt Pharmacy	204 South Ninth Street	Humboldt	Kansas	66748- 1908	(620) 473-2520
Iola Pharmacy	109 East Madison	Iola	Kansas	66749	(620) 365-3176
Kellstrom Pharmacy	1860 Claflin Rd	Manhattan	Kansas	66502- 3492	(785) 776-1200

Ken's Sunflower Pharmacy	7222 West 80th Street	Overland Park	Kansas	66204	(913) 341-7244
Moffet Drug	102 South State	Norton	Kansas	67654	(785) 877-2721
Newman Community Rx 1430	1400 W 12th Ave	Emporia	Kansas	66801	(620) 342-1242
S and S Drugs	110 South Mill Street	Beloit	Kansas	67420	(785) 738-2285
Silver Creek Pharmacy & Gifts	945 Market St	La Cygne	Kansas	66040	(913) 757-4744
St Marys Pharmacy	520 W Bertrand Ave	Saint Marys	Kansas	66536-1698	(785) 437-2967
Stockton Pharmacy	402 Main Street	Stockton	Kansas	67669	(785) 425-7172
Taylor Drug	201 South Summit Street	Arkansas City	Kansas	67005-2895	(620) 442-3500
The Downtown Drug Store	516 East 4th Street	Tonganoxie	Kansas	66086	(913) 369-3800
The Medicine Store	760 Northstar Court	Tonganoxie	Kansas	66086-0580	(913) 369-2100
The Medicine Store	15415 Pinehurst Drive	Basehor	Kansas	66007	(913) 724-3666
Wamego Drug Store	501 Lincoln St	Wamego	Kansas	66547-1633	(785) 456-9292
Ward Drug	142 South Penn Avenue	Oberlin	Kansas	67749	(785) 475-2285
Adair Drug	510 Burkesville Street Suite 1	Columbia	Kentucky	42728	(270) 384-9999
Benton Pharmacy	2606 Main St	Benton	Kentucky	42025	(270) 527-1409
Berea Drug	402 Richmond Road Suite A	Berea	Kentucky	40403	(859) 986-4521
Betsy Layne Pharmacy Inc	11105 US Highway 23 South	Betsy Layne	Kentucky	41605	(606) 478-9474
Blanks Pharmacy	272 Pike Street	Covington	Kentucky	41011	(859) 261-1313
Bluegrass Apothecary	3000 Alvey Park Drive West	Owensboro	Kentucky	42303	(270) 926-4080
Bowling Family Pharmacy	314 Treuhaft Boulevard	Barbourville	Kentucky	40906	(606) 546-2210
Burgess Drug Store Inc. #2	19 Medical Loop Suite 2	Whitley City	Kentucky	42653	(606) 376-5043
Burgess Drug Store Inc # 3	2157 South Highway 27	Stearns	Kentucky	42647	(606) 376-9662
Calvert City Pharmacy	906 E 5th Ave	Calvert City	Kentucky	42029-0365	(270) 395-4350
Care More Pharmacy	151 Dorton Jenkins Hwy	Dorton	Kentucky	41520	(606) 639-2273
CDS #10 Pharmacy	1308 Ashley Cir	Bowling Green	Kentucky	42104-3339	(270) 781-5661
Clark Drugs	500 Main St	Munfordville	Kentucky	42765-0127	(270) 524-3669
Clay Community Pharmacy	118 Clay CO S/C	Manchester	Kentucky	40962	(606) 599-0209
Clays Pharmacy	3513 Court Street	Catlettsburg	Kentucky	41129-1011	(606) 865-2025

Clinic Pharmacy	203 North 2nd Street	Central City	Kentucky	42330	(270) 754-4300
Columbia Pharmacy	803 Burkesville Street	Columbia	Kentucky	42728	(270) 384-2118
Commonwealth Pharmacy	5425 North Mayo Trail, Suite 102	Pikeville	Kentucky	41501	(606) 437-0701
Cull Family Pharmacy	965 Highway 127 North	Owenton	Kentucky	40359	(502) 484-3046
Cynthiana Hometown Pharmacy	1134 US Highway 27 South	Cynthiana	Kentucky	41031	(859) 234-5600
Davis Drugs	250 Lone Oak Road	Paducah	Kentucky	42001	(270) 443-1442
Draffenville Pharmacy	153 US Hwy 68 E	Benton	Kentucky	42025	(270) 527-1404
Duncan Clinic Pharmacy	1111 Medical Center Circle	Mayfield	Kentucky	42066	(270) 247-7000
Duncan Prescription Center	1520 Cuba Road	Mayfield	Kentucky	42066	(270) 247-3345
Eastridge-Phelps Pharmacy Campbellsville	500 N BYPASS RD	Campbellsville	Kentucky	42718	(270) 789-0577
Eastridge-Phelps Pharmacy Greensburg	460 Commerce Dr	Greensburg	Kentucky	42743-7758	(270) 299-2333
Economy Drug Company Inc	180 Town Mountain Road Suite 115	Pikeville	Kentucky	41501	(606) 437-7333
Elkhorn Drug	105 East Elkhorn Street	Elkhorn City	Kentucky	41522	(606) 754-0221
Ely Drug of Bowling Green	4863 Scottsville Road	Bowling Green	Kentucky	42104	(270) 467-5225
Ely Drugs #2	415 Happy Vly Rd	Glasgow	Kentucky	42141	(270) 651-8359
Faith Pharmacy	140 Adams Lane, Suite 500	Pikeville	Kentucky	41501	(606) 509-6337
Family Pharmacy	412 Central Avenue	South Williamson	Kentucky	41503	(606) 237-7430
Family Pharmacy of Jackson	265 KY Hwy 15 South, Suite 2	Jackson	Kentucky	41339	(606) 666-5519
Gibson's Pharmacy	1206 Paris Road	Mayfield	Kentucky	42066	(270) 247-1055
Glenn's Apothecary	520 West Gum Street	Marion	Kentucky	42064	(270) 965-4101
Glenn's Prescription Center	119 East Main Street	Salem	Kentucky	42078	(270) 988-3226
Good Neighbor Pharmacy	60 Cassady Avenue Suite 3	Danville	Kentucky	40422	(859) 936-1222
Green River Pharmacy	50 DILLON ST	Liberty	Kentucky	42539	(606) 787-2100
Greenville Pharmacy	117 North Main Street	Greenville	Kentucky	42345	(270) 338-3800
H & N Drug Inc	515 Memorial Drive Suite 2	Manchester	Kentucky	40962	(606) 598-5025
Health First Pharmacy	111 S Main St	Greensburg	Kentucky	42743	(270) 299-2467

Heritage Pharmacy	870 Parkway Drive	Salyersville	Kentucky	41465	(606) 349-7733
Highland Pharmacy	301 Rogers Road	Glasgow	Kentucky	42141	(270) 629-4300
Hometown Pharmacy of Jackson	95 Jackson Heights	Jackson	Kentucky	41339	(606) 666-5500
Horton Brothers and Brown Pharmacy LLC	201 East Main St	Grayson	Kentucky	41143	(606) 474-5655
Irvine Health Care Pharmacy	1325 Richmond Road	Irvine	Kentucky	40336	(606) 723-5446
J&R PHARMACY	34 US Hwy 68 E Unit A	Benton	Kentucky	42025	(270) 527-3135
J & R Pharmacy	817 Main St	Benton	Kentucky	42025	(270) 527-9374
Jamestown Pharmacy	1417 North Main Street, Suite A	Jamestown	Kentucky	42629	(270) 343-4443
Jay's Pharmacy Inc	400 South Highway 27	Somerset	Kentucky	42501	(606) 678-2784
Jeff's Prescription Shop	2415 Ring Rd	Elizabethtown	Kentucky	42701	(270) 765-2157
Kimper Pharmacy	9711 State Highway 194 East	Kimper	Kentucky	41539	(606) 631-3327
King Drug and Home Care	1156 Carter Road	Owensboro	Kentucky	42301	(270) 683-7010
Knight's Pharmacy	191 Glades Road	Berea	Kentucky	40403	(859) 986-0500
Lewis County Primary Care Center	211 Kentucky 59	Vanceburg	Kentucky	41179	(606) 796-2686
Liberty Drug	256 N Wallace Wilkinson Blvd	Liberty	Kentucky	42539-3014	(606) 448-2469
Lincoln Parkway Pharmacy	117 Lincoln Drive	Hodgenville	Kentucky	42748	(270) 358-2117
Lone Oak Pharmacy	3535 Lone Oak Road	Paducah	Kentucky	42001	(270) 554-7944
Louisa Drug Store	408 North Lock Avenue	Louisa	Kentucky	41230	(606) 638-4155
Madison Drug	110 Big Hill Avenue	Richmond	Kentucky	40475	(859) 624-1565
Maysville OB/GYN Family Health Center Pharmacy	927 Kenton Station Drive	Maysville	Kentucky	41056	(606) 759-1189
Mccays Total Pharmacy	260 Boggs Lane	Richmond	Kentucky	40475-2591	(859) 623-4216
MED EXPRESS PHARMACY	212 South Mayo Trail	Paintsville	Kentucky	41240	(606) 789-1444
Medical Arts Pharmacy	300 S 8th St	Murray	Kentucky	42071-2883	(270) 753-2011
Medical Center Pharmacy	1010 Medical Center Drive	Powderly	Kentucky	42367	(270) 338-9993
MEDICINE CABINET PHARMACY	230 STATE HIGHWAY 2	OLIVE HILL	Kentucky	41164	(606) 286-2035

Metcalfe Drugs	115 East Stockton Street	Edmonton	Kentucky	42129	(270) 432-3051
Midtown Pharmacy Express	500 North Main Street	Beaver Dam	Kentucky	42320	(270) 274-9224
Optimum Wellness Center	716 Broadway Street	Paintsville	Kentucky	41240	(606) 220-2553
Parkland Drugs	209 N Dixie Hwy	Cave City	Kentucky	42127	(270) 773-3152
Parkview Pharmacy, Inc	8274 Kentucky Rte 122	Minnie	Kentucky	41651	(606) 377-2117
Parkway Pharmacy	186 Breanna Blvd, Suite 400	Salyersville	Kentucky	41465	(606) 349-4400
Pharmacy Arts	31 Burnley Road	Scottsville	Kentucky	42164	(270) 618-4444
Pharmacy Express	415 South L. Rogers Wells Boulevard	Glasgow	Kentucky	42141	(270) 651-7948
Pikeville Medical Center Outpatient Pharmacy	911 Bypass Rd Bldg E, Ste 1	Pikeville	Kentucky	41501	(606) 218-3576
Plaza Drug of London	731 North Laurel Road	London	Kentucky	40741	(606) 657-5245
Professional Pharmacy	419 Town Mountain Road Suite 101	Pikeville	Kentucky	41501	(606) 432-0196
Professional Pharmacy of Somerset	342 Bogle Street	Somerset	Kentucky	42503	(606) 679-1169
Reidland Pharmacy	5433 Reidland Rd	Paducah	Kentucky	42003-0368	(270) 898-7313
Rite Value Pharmacy	2673 Highway 644	Louisa	Kentucky	41230	(606) 638-9627
Rite-Value Pharmacy	94 Board Walk Suite 2	Inez	Kentucky	41224	(606) 298-2080
Riverview Pharmacy	201 South Water Street	Louisa	Kentucky	41230	(606) 638-9218
Russell Springs Pharmacy	92 Joe T. Petty Drive, Suite 100	Russell Springs	Kentucky	42642	(270) 866-2778
Save Discount Drugs	716 Madison Avenue	Covington	Kentucky	41011	(859) 431-2857
Save More Drugs	2208 Fort Campbell Boulevard	Hopkinsville	Kentucky	42240	(270) 885-5515
Shelbyville Pharmacy	182 Frankfort Road	Shelbyville	Kentucky	40065	(502) 437-3008
Smithland Drugs	203 East Adair Street	Smithland	Kentucky	42081	(270) 928-2161
Stovalls Prescription Shop	202 South Court Street	Scottsville	Kentucky	42164	(270) 237-5402
Strawberry Hills Pharmacy	2670 New Holt Road Suite D	Paducah	Kentucky	42001	(270) 444-7070
Stultz Pharmacy	1615 Ashland Road	Greenup	Kentucky	41144	(606) 473-7346
Sutton Pharmacy	330 W Maple St	Lancaster	Kentucky	40444-1058	(859) 792-4611
Taylor Pharmacy	109 Fairgrounds Road	Hardinsburg	Kentucky	40143	(270) 756-5222

The Prescription Pad	465 Keene Centre Drive	Nicholasville	Kentucky	40356	(859) 887-2841
Thompson's Pharmacy	1064 North College Street	Harrodsburg	Kentucky	40330	(859) 734-3004
Thrifty Pharmacy	127 East Main Street	Providence	Kentucky	42450	(270) 667-2049
Tompkinsville Drug Company	1513 Edmonton RD	Tompkinsville	Kentucky	42167	(270) 487-6155
Total Care Pharmacy #1	209 South Main Cross Street	Flemingsburg	Kentucky	41041	(606) 845-2101
Total Care Pharmacy #2	118 Clark Street	Flemingsburg	Kentucky	41041	(606) 845-3421
Total Care Pharmacy #4	700 Violet Road	Crittenden	Kentucky	41030	(859) 428-0900
Total Care Pharmacy #5	45 Klee Way Suite A	Falmouth	Kentucky	41040	(859) 654-3232
Total Care Pharmacy #7	206 West Main Street	Morehead	Kentucky	40351	(606) 784-4491
Total Pharmacy Care	533 Hambley Boulevard	Pikeville	Kentucky	41501	(606) 433-0555
Total Pharmacy Care #3	420 North Lake Drive	Prestonberg	Kentucky	41653	(606) 889-8570
Total Pharmacy Care #4	263 KY ROUTE 122	Martin	Kentucky	41649	(606) 949-1555
Total Pharmacy Care #5	13380 Phelps 632 Road	Phelps	Kentucky	41553	(606) 456-3446
Total Pharmacy Care #6	6162 Zebulon Highway	Pikeville	Kentucky	41501	(606) 631-9137
Total Pharmacy Care of Belfry	20 State Highway 319	Belfry	Kentucky	41514	(606) 237-0555
Town and Country Pharmacy	736 East Main Street	Glasgow	Kentucky	42141	(270) 629-4633
Versailles Independent Pharmacy	166 Frankfort Street	Versailles	Kentucky	40383	(859) 879-0199
Walter's Family Pharmacy	604 S 12th St	Murray	Kentucky	42071-2916	(270) 753-7688
Weathers Drugs	44 Public Square	Elkton	Kentucky	42220	(270) 265-2155
West Knox Pharmacy, LLC	14161 North US Highway 25 East	Corbin	Kentucky	40701-6183	(606) 258-1111
Yates Pharmacy LLC	432 Hopkinsville Road	Russellville	Kentucky	42276	(270) 726-8451
Your Hometown Pharmacy Taylorsville	913 Taylorsville Road	Taylorsville	Kentucky	40071	(502) 477-1973
Mountain Apothecary	834 South Mayo Terrace	Paintsville	Kentucky	41240	(606) 789-6150
ARON'S PHARMACY	1209 NORTH 18TH ST	MONROE	Louisiana	71201	(318) 323-2242
Book's Pharmacy	1158 Logan Sewell Drive	Vidalia	Louisiana	71373-3342	(318) 414-2616
Community Pharmacy LLC	2904 Forsythe Ave	Monroe	Louisiana	71201	(318) 398-2100

Community Pharmacy of Sterlington	200 Scott Drive	Sterlington	Louisiana	71280	(318) 667-0197
Community Pharmacy of Winnsboro	3326 Front Street Suite D	Winnsboro	Louisiana	71295	(318) 435-9681
E.W. Thomson Drug Co	213 Depot St	Delhi	Louisiana	71232	(318) 878-2261
East Jefferson Medical Pharmacy #1	1301 Williams Blvd	Kenner	Louisiana	70062-6303	(504) 468-2361
Gem Drugs	139 Central Avenue	Reserve	Louisiana	70084	(985) 536-3957
Gem Drugs Gramercy	1635 Highway 3125	Gramercy	Louisiana	70052	(225) 869-3651
J & K Drug	7190 Highway 165 South	Columbia	Louisiana	71418	(318) 649-0825
Minsky Drug Store	405 Lake Street	Lake Providence	Louisiana	71254	(318) 559-2400
Morgans Pharmacy	1806 FOURTH STREET	JONESVILLE	Louisiana	71343	(318) 339-8532
Russo's Pharmacy	7902 Highway 23	Belle Chasse	Louisiana	70037	(504) 394-4444
Scott's Pharmacy	114 Serio Boulevard	Ferriday	Louisiana	71334	(318) 757-3035
Village Pharmacy #3	7659 Gilbert St Suite A	Gilbert	Louisiana	71336-3410	(318) 907-2077
Williams Family Pharmacy, LLC	1058 Tanglewood Drive	Franklinton	Louisiana	70438-5673	(985) 839-7200
Bangor Drug Company	711 Broadway Suite 1	Bangor	Maine	04401-3225	(207) 922-3849
Carroll Drug Store	3 Village Green Way	Southwest Harbor	Maine	04679-1306	(207) 244-5588
City Drug Store	159 Academy Street	Presque Isle	Maine	04769	(207) 764-4424
Hebert Rexall Pharmacy	31 MAIN ST	Van Buren	Maine	04785	(207) 868-2242
Mars Hill Pharmacy Inc	106 Main Street	Mars Hill	Maine	04758	(207) 425-4431
Milbridge Pharmacy	11 Main Street	Milbridge	Maine	04658-0458	(207) 546-2304
Presque Isle Pharmacy	797 Main St	Presque Isle	Maine	04769	(207) 760-9100
Spruce Mountain Pharmacy Inc.	148 Main Street	Jay	Maine	04239	(207) 897-9080
AGH RediScripts Pharmacy	9733 Healthway Dr	Berlin	Maryland	21811	(410) 641-9241
Broadneck Pharmacy	269 Peninsula Farm Road	Arnold	Maryland	21012	(410) 544-3733
Clear Spring Pharmacy	34 Mulberry Street	Clear Spring	Maryland	21722	(301) 842-2774
Co-Op Pharmacy	121 Center way	Greenbelt	Maryland	20770	(301) 474-4400
Deale Pharmacy	5809 Deale Churchton Road	Deale	Maryland	20751	(410) 867-2455
Drug City Pharmacy	2805 North Point Road	Baltimore	Maryland	21222	(410) 284-2424

Fallston Pharmacy	2112 Belair Road Suite 11	Fallston	Maryland	21047	(410) 879-9000
Greensboro Pharmacy	102 South Main Street	Greensboro	Maryland	21639	(410) 482-6256
Hereford Pharmacy and Gift Shop	216 Mount Carmel Road	Parkton	Maryland	21120	(410) 329-6209
High Street Discount Pharmacy	30 High Street	Waldorf	Maryland	20602-1846	(240) 448-3301
Jarrettsville Pharmacy	3714 Norrisville Rd	Jarrettsville	Maryland	21084	(410) 557-7717
Karemore Pharmacy	12085 North Somerset Avenue Suite 5	Princess Anne	Maryland	21853	(410) 651-3980
Laplata Pharmacy	6501 Crain Highway	La Plata	Maryland	20646-4268	(301) 934-4050
Medsurg Pharmacy	3037 Marshall Hall Road	Bryans Road	Maryland	20616-3240	(240) 903-3949
Meritus Medical Center	11116 Medical Campus Rd Ste 2460	Hagerstown	Maryland	21742-6700	3017909281
Mt Carmel Pharmacy	111 Mount Carmel Road	Parkton	Maryland	21120	(410) 343-0110
Northern Pharmacy and Med Equipment	6701 Harford Road	Baltimore	Maryland	21234-7707	(410) 254-2055
Pittsville Pharmacy	34205 Old Ocean City Road Unit E	Pittsville	Maryland	21850-2083	(410) 835-8585
Steves Pharmacy	16117 McMullen Highway Southwest	Cumberland	Maryland	21502	(301) 729-2600
Ultra Care Pharmacy	12619 Wisteria Drive Suite A	Germantown	Maryland	20874-5259	(301) 569-6464
Ultra Care Pharmacy	4419 Falls Road Suite B	Baltimore	Maryland	21211-1295	(410) 878-1031
Ultra Care Pharmacy-Columbia	10798 Hickory Ridge Road Suite A	Columbia	Maryland	21044-3646	(410) 997-0005
Whiteford Pharmacy	2338 Whiteford Road	Whiteford	Maryland	21160	(410) 452-5221
Williamsport Pharmacy	100 E Potomac St	Williamsport	Maryland	21795	(301) 223-4101
Ayer Family Pharmacy	13 Park Street	Ayer	Massachusetts	01432-1120	(978) 391-4061
Bouvier Pharmacy Inc	515 Lincoln Street	Marlborough	Massachusetts	01752	(508) 485-0432
Conlin's Pharmacy	30 Lawrence Street	Methuen	Massachusetts	01844	(978) 552-1700
Cure-Aid Pharmacy	101 Amesbury Street Suite 207	Lawrence	Massachusetts	01840-1510	(978) 984-5285
Dans Pharmacy	110 Pleasant St	Nantucket	Massachusetts	02554	(508) 825-9100
Dedham Pharmacy & Medical Supply	596 Providence Highway	Dedham	Massachusetts	02026-6804	(781) 326-7007
EssentialRx	123 Summer St Suite 365	Worcester	Massachusetts	01608-1216	(508) 363-6602

FAIRHAVEN PHARMACY	72 MAIN ST	FAIRHAVEN	Massachusetts	02719-3014	(508) 525-4455
Flynns Pharmacy	173 Elm St	Pittsfield	Massachusetts	01201-6589	(413) 445-5567
Hingham Centre Pharmacy	294 Main St	Hingham	Massachusetts	02043	(781) 749-1277
Margolis Pharmacy	447 Broadway	Chelsea	Massachusetts	02150	(617) 884-3524
Nantasket Pharmacy Inc	480 Nantasket Avenue	Hull	Massachusetts	02045	(781) 925-1270
Norwood Pharmacy	54 Broadway	Norwood	Massachusetts	02062	(781) 349-8895
Pepperell Family Pharmacy	74 Main Street	Pepperell	Massachusetts	01463	(978) 433-6130
Scituate Pharmacy	384 Gannett Road	Scituate	Massachusetts	02066	(781) 545-1020
Standard Pharmacy @ Healthfirst	387 Quarry St	Fall River	Massachusetts	02723-1007	(774) 322-1335
Walpole Pharmacy	699 Main Street	Walpole	Massachusetts	02081	(508) 645-8866
Walsh Pharmacy	202 Rock Street	Fall River	Massachusetts	02720	(508) 679-1300
Whittier Health Pharmacy Inc	1012 Tremont Street	Roxbury	Massachusetts	02120-3432	(617) 541-6846
Advanced Care Pharmacy Services	2136 Robinson Road, Suite 2	Jackson	Michigan	49203	(517) 750-2180
Advanced Health Pharmacy	7916 Oakland Drive	Portage	Michigan	49024	(269) 324-1100
Alexander's Drug Store	211 East Main Street	Fennville	Michigan	49408	(269) 561-4411
All Care Pharmacy	7125 Allen Rd	Allen Park	Michigan	48101	(313) 386-2273
Alliance Specialty Pharmacy	25301 Van Dyke Avenue	Center Line	Michigan	48015	(248) 230-8044
Anderson Pharmacy	1108 Marquette Ave	Bay City	Michigan	48706-4000	(989) 684-8905
Apollo Pharmacy of Wyandotte	2000 Eureka Rd	Wyandotte	Michigan	48192-6004	(734) 550-0850
Azaal Discount Pharmacy	9834 Conant Street	Hamtramck	Michigan	48212	(313) 872-0021
Azaal Pharmacy II LLC	15120 Michigan Avenue	Dearborn	Michigan	48126	(313) 733-8034
Bay Pharmacy	112 South State Street	St Ignace	Michigan	49781	(906) 643-7725
Best Care Pharmacy Plus	31500 Dequindre Rd Suite 300	Warren	Michigan	48092	(586) 999-5544
Big Brothers Pharmacy	4801 Fenton Road	Flint	Michigan	48507	(810) 820-8685
Bobs Drugs	194 North Division Street	Hesperia	Michigan	49421	(231) 854-6605
Bosticks Drug Store	117 West Main Street	Manton	Michigan	49663	(231) 824-6465
Brothers Pharmacy	118 West Pierson Road	Flint	Michigan	48505	(810) 785-7770
Bunte's Pharmacy	115 East Main Avenue	Zeeland	Michigan	49464	(616) 772-4685
Cadillac Family Pharmacy	108 North Mitchell	Cadillac	Michigan	49601	(231) 775-8200

Carerx Specialty Pharmacy AP	13201 Stephens Road Suite G	Warren	Michigan	48089-4378	(734) 656-4082
Cedar Springs Pharmacy	14111 White Creek Avenue Northeast Suite 12	Cedar Springs	Michigan	49319-8170	(616) 439-2779
Central Drug Store Inc	301 Bridge Street	Charlevoix	Michigan	49720-1414	(231) 547-2424
Clio Community Pharmacy	4180 West Vienna Road Suite 4	Clio	Michigan	48420-9497	(810) 547-7201
Coleman Family Pharmacy	211 East Railway Street	Coleman	Michigan	48618	(989) 465-6661
CORNER DRUGS	154 River Street	Elk Rapids	Michigan	49629	(231) 264-8033
Davison Pharmacy	1509 South State Road Suite F	Davison	Michigan	48423-1966	(810) 412-4666
Delton Family Pharmacy	338 N Grove St	Delton	Michigan	49046	(269) 623-5250
Downtown Drugs	121 E Broadway	Mt Pleasant	Michigan	48858-2368	(989) 773-5544
Dynamic Care Pharmacy	4121 West 13 Mile Road	Royal Oak	Michigan	48073	(248) 850-1802 Ext 1
Eagle Pharmacy	109 West Main Street	Farwell	Michigan	48622	(989) 588-2900
Fenkell Rx Pharmacy	18360 Fenkell Ave	Detroit	Michigan	48223-2314	(313) 519-5700
Flint Family Pharmacy	G4444 Fenton Road	Flint	Michigan	48507	(810) 235-7995
Fred's Pharmacy	121 West Prairie Street	Vicksburg	Michigan	49097	(269) 649-0660
Freds Pharmacy	808 West Michigan Avenue	Three Rivers	Michigan	49093	(269) 278-2355
Gateway Pharmacy	1048 North McEwan Street	Clare	Michigan	48617	(989) 386-2900
Gilberts Drug Store	212 S State St	Oscoda	Michigan	48750	(989) 739-7585
Grand Blanc Pharmacy	2227 East Hill Road	Grand Blanc	Michigan	48439-5000	(810) 498-4334
Grand Value Pharmacy	10920 Grand River Avenue	Detroit	Michigan	48204	(313) 931-0010
Grayling Pharmacy	500 N James St	Grayling	Michigan	49738	(989) 348-2000
Great Lakes Pharmacy of Midland	1120 Eastman Avenue	Midland	Michigan	48640	(989) 835-7911
Gun Lake Pharmacy	71 124th Ave	Shelbyville	Michigan	49344	(269) 672-7774
Harbor Drug	114 South Huron Avenue	Harbor Beach	Michigan	48441	(989) 315-8605
Harrison Family Pharmacy	182 North Second Street	Harrison	Michigan	48625	(989) 539-2900
HealthPlus Pharmacy of Brighton	2305 Genoa Business Park, Suite 140	Brighton	Michigan	48114	(810) 229-4420
HealthPlus Pharmacy of Howell	1225 South Latson Road Suite 100	Howell	Michigan	48843	(517) 579-2797

Hemmingsen Drug Store	132 West Michigan Avenue	Marshall	Michigan	49068	(269) 781-3411
Highland Pharmacy	4000 Highland Road Suite 113	Waterford	Michigan	48328	(248) 977-1394
Holihans Drug Store	128 N Main St	Evart	Michigan	49631	(231) 734-2551
Holly Pharmacy	4048 Grange Hall Road Suite D	Holly	Michigan	48442-1193	(248) 467-8003
HUDSON PHARMACY, INC.	325 Railroad Street Suite D	Hudson	Michigan	49247	(517) 448-3111
Huron Market Pharmacy	1116 West Huron Street	Waterford	Michigan	48328-3734	(248) 977-4848
Jill's Genuine Care Pharmacy	23603 Farmington Rd	Farmington	Michigan	48336-3102	(248) 987-5940
Kingsley Pharmacy and Compounding Center	114 South Brownson Avenue	Kingsley	Michigan	49649	(231) 263-7701
Kronner Pharmacy	778 W Houghton Lake Dr	Prudenville	Michigan	48651-9451	(989) 366-7611
Lapeer Pharmacy	944 Baldwin Road Suite B	Lapeer	Michigan	48446	(810) 245-9600
LC Family Pharmacy	57 North Morey Road	Lake City	Michigan	49651	(231) 559-0005
Lefave Pharmacy & Compounding	1202 W Chisholm St	Alpena	Michigan	49707-1620	(989) 354-3189
Leroy Pharmacy	1280 North Leroy Street	Fenton	Michigan	48430-2760	(810) 373-5808
Maple Pharmacy	5829 West Maple Road Suite 129	West Bloomfield	Michigan	48322	(248) 757-2503
McBain Family Pharmacy	119 North Roland Street	Mc Bain	Michigan	49657	(231) 825-8175
Medcenter Pharmacy	7210 North Main Street, Suite 102	Clarkston	Michigan	48346	(248) 625-3885
Mesick Pharmacy	112 Mesick Avenue	Mesick	Michigan	49668	(231) 885-1751
Miller Pharmacy	206 North Broadway Street	Union City	Michigan	49094	5177413604
Millington Pharmacy	4729 Main Street	Millington	Michigan	48746	(989) 871-2820
Mills Pharmacy & Apothecary	1744 West Maple Suite A	Birmingham	Michigan	48009	(248) 644-5060
Mission Pharmacy	926 South Mission Street	Mount Pleasant	Michigan	48858	(989) 773-8200
Monroe Pharmacy	2507 Monroe Street	Dearborn	Michigan	48124	(313) 274-9141
Moore Family Pharmacy Allegan	100 Monroe Street, Suite B	Allegan	Michigan	49010	(269) 673-6749
Moore Family Pharmacy Hamilton	3416 M40	Hamilton	Michigan	49419-9512	(269) 751-8482
Moore Family Pharmacy South Haven	08337 M 140 Unit 2	South Haven	Michigan	49090	(269) 637-3222
Niles Wellcare Pharmacy	70 E Main St	Niles	Michigan	49120-2200	(269) 262-4343

Noor Pharmacy	4092 East 14 Mile Road Suite 200	Warren	Michigan	48092	(586) 268-3900
Park Pharmacy SCS	20225 East 9 Mile Road Suite 100	Saint Clair Shores	Michigan	48080-1775	(586) 999-8200
Pharmacy Care	4652 N M37 Hwy	Middleville	Michigan	49333-0159	(269) 795-7936
Pontiac Pharmacy	1925 North Perry Street	Pontiac	Michigan	48340-2237	(248) 499-6070
Professional Pharmacy	9175 Cherry Valley	Caledonia	Michigan	49316	(616) 891-1116
Rexall Pharmacy	8483 Holly Road Suite 202	Grand Blanc	Michigan	48439	(810) 344-6422
Rogers Pharmacy	316 West Nepessing Street	Lapeer	Michigan	48446	(810) 664-0600
Saginaw Valley Pharmacy	5618 State Street	Saginaw	Michigan	48603	(989) 220-1718
Saugatuck Drug Store	201 Butler St	Saugatuck	Michigan	49453	(269) 857-2300
Schmidt & Sons Pharmacy of Tecumseh Inc	120 East Chicago Boulevard	Tecumseh	Michigan	49286	(517) 423-3250
Sheba Discount Pharmacy	10136 Vernor Highway	Dearborn	Michigan	48120	(313) 841-8820
Shelby Family Pharmacy	48887 Hayes Road	Shelby Township	Michigan	48315	(586) 461-2900
Shores Specialty Pharmacy	29306 Harper Avenue	Saint Clair Shores	Michigan	48081	(586) 200-1824
SRX Specialty Care Pharmacy	3412 West 13 Mile Road	Royal Oak	Michigan	48073-6708	(248) 607-3110
St. Charles Pharmacy	1008 N Saginaw St	Saint Charles	Michigan	48655-1401	(989) 865-9971
State Street Pharmacy & Wellness Center Inc	192 North State Street	Caro	Michigan	48723	(989) 672-3500
Sterling Heights Pharmacy	38924 Dequindre Road	Sterling Heights	Michigan	48310	(586) 983-9740
Sunshine Pharmacy	43009 Hayes Road	Sterling Heights	Michigan	48313	(586) 286-5005
Swartz Creek Pharmacy	8021 Miller Road	Swartz Creek	Michigan	48473-1342	(810) 635-3355
Taylor Discount Drugs	9320 Telegraph Road	Taylor	Michigan	48180	(313) 299-8810
Thompson Pharmacy and Medical	324 South Union Street	Traverse City	Michigan	49684	(231) 947-4212
TLC Pharmacy	2959 South Telegraph Road	Dearborn	Michigan	48124	(313) 274-0800
Ubly Pharmacy	2031 East Main Street	Ubly	Michigan	48475-9726	(989) 658-3324
USA Pharmacy	47315 Van Dyke Ave	Shelby Township	Michigan	48317-3363	(586) 326-0006
Wackerly Pharmacy	957 West Midland Road	Auburn	Michigan	48611	(989) 662-7773
WARE'S PHARMACY	304 South Jefferson Street	Mason	Michigan	48854	(517) 676-9199

Watkins Pharmacy & Surgical Supply	1391 East Sherman Boulevard	Muskegon	Michigan	49444	(231) 739-7158
We Care Pharmacy Plus	1412 South Lapeer Road	Lake Orion	Michigan	48360	(248) 690-9686
Yinger Pharmacy Shoppe	1704 South Custer Road	Monroe	Michigan	48161	(734) 243-5451
Blue Earth Drug	125 South Grove Street Suite 1	Blue Earth	Minnesota	56013	(507) 526-2121
Corner Drug	101 Main St S Suite 115	Le Sueur	Minnesota	56058-1915	(507) 665-3301
Kennedy Drug	223 South Lakeshore Drive	Lake City	Minnesota	55041	(651) 345-3411
Mackenthun Beck Pharmacy Inc	851 Market Place Dr	Waconia	Minnesota	55387	(952) 442-4407
Sterling	700 Division Street South	Northfield	Minnesota	55057	(507) 645-4455
Sterling Drug	410 Hoffman Drive	Owatonna	Minnesota	55060	(507) 451-0240
Sterling Drug #04	400 South State Street 50	Fairmont	Minnesota	56031	(507) 238-2797
Sterling Drug #08	511 10th Street	Worthington	Minnesota	56187	(507) 372-7533
Sterling Drug #20	209 Maine Avenue, Suite 105	Adrian	Minnesota	56110	(507) 483-2332
Sterling Drug #24	115 West Jessie Street	Rushford	Minnesota	55971	(507) 864-2153
Sterling Drug #26	615 West Esch Drive	Caledonia	Minnesota	55921	(507) 725-3328
Sterling Drug #29	306 Main Street Suite 103	La Crescent	Minnesota	55947	(507) 895-8784
Sterling Pharmacy	1109 W Oakland Ave	Austin	Minnesota	55912	(507) 433-7123
Trumm Drug Clinic Pharmacy	610 30th Ave West	Alexandria	Minnesota	56308-0397	(320) 763-3116
Trumm Drug Downtown	600 Fillmore Street	Alexandria	Minnesota	56308	(320) 763-3111
Trumm Drug Elbow Lake	11 Central Avenue South	Elbow Lake	Minnesota	56531	(218) 685-4471
Trumm Drug Glenwood	7 Fourth Avenue SE	Glenwood	Minnesota	56334	(320) 634-4434
Trumm Drug Parkers Prairie	114 E Soo St	Parkers Prairie	Minnesota	56361	(218) 338-2661
ANDERSON'S PHARMACY	112 East Main Street	North Carrollton	Mississippi	38947	(662) 237-9294
Booneville Community Pharmacy	206 North Second Street	Booneville	Mississippi	38829	(662) 728-1951
Brick City Drugs	159 Fountains Boulevard	Madison	Mississippi	39110	(769) 231-1400
Byhalia Drug Company, LLC	7984 Hwy 178 W	Byhalia	Mississippi	38611	(662) 838-3784
Caleb's Hometown Pharmacy	801 Main Street	Collins	Mississippi	39428	(601) 765-5055
City Drug Pharmacy and Gifts	113 Bobo Drive	Crystal Springs	Mississippi	39059	(601) 892-4121

City Drug Pharmacy and Gifts	27190 Highway 28 Suite 100	Hazlehurst	Mississippi	39083-2224	(601) 892-4124
Condon East Union Pharmacy	1403 East Union	Greenville	Mississippi	38703	(662) 332-0941
Cox-Blythe Drug Co	122 West College Street	Booneville	Mississippi	38829-3498	(662) 728-5732
Fairview Pharmacy & Compounding	500 Katie Avenue	Hattiesburg	Mississippi	39401	(601) 544-4871
Freedom Pharmacy	3902 Hardy St	Hattiesburg	Mississippi	39402-1541	(601) 450-6979
Friendship Pharmacy	5532 Highway 15 Suite 1	Ecu	Mississippi	38841	(662) 488-0317
Greenwood Drugs	400 West Park Avenue	Greenwood	Mississippi	38930	(662) 477-0700
Guy's Pharmacy of Crystal Springs	512 West Marion Avenue	Crystal Springs	Mississippi	39059	(601) 647-0030
Guy's Pharmacy of Tylertown	3000 Plaza Drive Suite B	Tylertown	Mississippi	39667	(601) 377-1982
Guys Pharmacy of Brookhaven	1005 West Congress Street	Brookhaven	Mississippi	39601	(601) 833-6333
Guys Pharmacy of Hazlehurst	212 Caldwell Drive	Hazlehurst	Mississippi	39083	(601) 524-4897
Haire Drug Center	805 1st Street	Cleveland	Mississippi	38732-2309	(662) 843-4211
LITTLE'S PHARMACY	122 Main Street	Raleigh	Mississippi	39153	(601) 782-4552
Macon Primary Pharmacy	34 Hospital Road	Macon	Mississippi	39341	(662) 788-4398
McGuffee Drug	102 North Main Street	Mendenhall	Mississippi	39114	(601) 847-2511
Medical Center Pharmacy	312 Marion Avenue	Mc Comb	Mississippi	39648	(601) 684-9602
North Sunflower Medical Center Pharmacy	860 North Oak Avenue	Ruleville	Mississippi	38771	(662) 756-4381
Okolona Pharmacy	210 W Main St	Okolona	Mississippi	38860-1608	(662) 447-0300
Park Place Pharmacy	46 Parkway Lane	Petal	Mississippi	39465	(601) 450-3673
Pearsons Discount Drugs LLC	101 E Washington St	Houston	Mississippi	38851-2225	(662) 456-2551
Sav- Mor Drugs and Gifts	1967 Commerce Street	Grenada	Mississippi	38901	(662) 226-6741
Stepp-Saver Pharmacy	203 North Newberger Avenue	Bruce	Mississippi	38915-0656	(662) 983-4011
Stricklands Cash And Save Discount Pharmacy	703 Front St N	Richton	Mississippi	39476	(601) 788-6332
Sunflower Greenwood Pharmacy	201 West Park Avenue	Greenwood	Mississippi	38930-3008	(662) 219-2733
The Pharmacy of Quitman	125 Main Street	Quitman	Mississippi	39355	(601) 776-6282
Wards Pharmacy	122 South Front Street	Ellisville	Mississippi	39437-3118	(601) 477-8587

Williams Tylertown Pharmacy LLC	201 Hospital Drive	Tylertown	Mississippi	39667-2019	(601) 222-1770
Winona Drugs	500 North Applegate Street Suite A	Winona	Mississippi	38967	(662) 535-0800
Advance Pharmacy	110 South Oak	Advance	Missouri	63730	(573) 722-3562
Albers Medical Pharmacy	4400 Broadway Suite 106	Kansas City	Missouri	64111	(816) 931-0100
Beauton Drug	124 North Washington	East Praire	Missouri	63845	(573) 649-3923
Bond Pharmacy	703 West Buchanan	California	Missouri	65018	(573) 796-3145
Bruner Pharmacy	321 East Broadway Street	Monett	Missouri	65708	(417) 235-3139
Butler Drug Store	222 East Main Street	Portageville	Missouri	63873	(573) 379-5469
Chaffee Drug Store	211 West Yoakum Avenue	Chaffee	Missouri	63740	(573) 887-3622
Cole Camp Pharmacy	512 West Main Street	Cole Camp	Missouri	65325	(660) 668-4646
Countryside Pharmacy	402 E Price Ave	Savannah	Missouri	64485	(816) 324-5111
E & S Pharmacy	1105 Walnut Street	Doniphan	Missouri	63935	(573) 996-7157
EAST SIDE DISCOUNT PHARMACY	400 EAST PINE STREET	POPLAR BLUFF	Missouri	63901	(573) 686-7238
Family Pharmacy	806 North Sturgeon	Montgomery City	Missouri	63361	(573) 564-2273
Flow's Pharmacy	303 North Keene Street	Columbia	Missouri	65201	(573) 447-8093
Flow's Pharmacy	1506 E BROADWAY	COLUMBIA	Missouri	65201	(573) 449-5366
Gosney Pharmacy	911 Highway 24/36 East	Monroe City	Missouri	63456	(573) 735-1130
Grand Pharmacy	733 Grand Avenue	Hannibal	Missouri	63401	(573) 221-2792
Greenfield Pharmacy	105 N GRAND STE 1	GREENFIELD	Missouri	65661	(417) 637-2909
Harris Pharmacy	1224 First St	Kennett	Missouri	63857	(573) 888-6006
Hayden Pharmacy	1200 Ward Avenue	Caruthersville	Missouri	63830	(573) 333-4606
Iman's Pharmacy INC	2360 East 12th Street	Kansas City	Missouri	64127-1237	(816) 569-6310
Jones Drug Store	125 Court Street	Jackson	Missouri	63755	(573) 243-3524
Key Drugs	910 North Westwood Boulevard	Poplar Bluff	Missouri	63901	(573) 785-8218
Kinlead Pharmacy	105 South Allen Street	Centralia	Missouri	65240	(573) 682-2155
L & S Pharmacy	406 South Main Street	Charleston	Missouri	63834	(573) 683-3307
Lakeland Pharmacy #1	18565 Business 13	Branson West	Missouri	65737	(417) 272-8064
Lakeland Pharmacy #2	1232 Branson Hills Pkwy Suite 205	Branson	Missouri	65616	(417) 336-4701

Lakeland Pharmacy #3	104 Cortney Lane	Crane	Missouri	65633	(417) 723-5241
Lakeland Pharmacy #4	16269 US Hwy 160	Forsyth	Missouri	65653-7122	(417) 546-5151
Lakeland Pharmacy #7	110 Bear Dr Suite 4	Willow Springs	Missouri	65793-1512	(417) 469-9009
Lindenwood Drug	6903 Lansdowne	St. Louis	Missouri	63109	(314) 781-2445
New Madrid Pharmacy	457 Main Street	New Madrid	Missouri	63869	(573) 748-3080
Pill Box Pharmacy	304 East Jackson Street 2D	Willard	Missouri	65781	(417) 742-3508
Rogersville Pharmacy	317 South Main Street	Rogersville	Missouri	65742	(417) 753-7774
Saults Drug Store Inc	505 Court Street	Fulton	Missouri	65251	(573) 642-4186
Scotland County Pharmacy	445 East Grand Avenue	Memphis	Missouri	63555	(660) 465-2400
Scott Family Pharmacy	414 West Grand Avenue	Campbell	Missouri	63933	(573) 246-2514
Sterling Pharmacy	808 Hunter Avenue Suite 1A	Sikeston	Missouri	63801	(573) 475-1900
Sterling Retail KC	3338 Northeast Ralph Powell Road, Suite E	Lees Summit	Missouri	64064	(816) 788-7928
Summit Pharmacy	140 Northstar Drive	Holts Summit	Missouri	65043-1123	(573) 826-4151
Twin City Pharmacy	106 North First Street	Marble Hill	Missouri	63764	(573) 238-4177
Hils Pharmacy	800 North Morley Street	Moberly	Missouri	65270-2617	(660) 263-4457
Missoula Pharmacy, Inc.	1211 South Reserve Street, Suite 102	Missoula	Montana	59801	(406) 728-5650
Sykes Pharmacy	202 2nd Ave West	Kalispell	Montana	59901-4463	(406) 257-4806
Sykes Pharmacy Columbia Falls	500 12th Ave W Suite 1A	Columbia Falls	Montana	59912-3818	(406) 206-7277
Burwell Pharmacy	137 Grand Avenue	Burwell	Nebraska	68823-0520	(308) 346-4747
Clabaugh Pharmacy	501 Court Street	Beatrice	Nebraska	68310	(402) 223-3591
GLOBAL REXALL DRUG	424 E ST	FAIRBURY	Nebraska	68352-2535	(402) 729-2620
Manion's Drug Store	719 Main Street	Creighton	Nebraska	68729	(402) 358-3535
Medicine Man Pharmacy	748 North Main Street	North Bend	Nebraska	68649	(402) 652-3217
Medicine Man Pharmacy	15615 Pacific Street Suite 8	Omaha	Nebraska	68118	(402) 496-9757
Medicine Man Pharmacy	122 WEST 16TH STREET	SCHUYLER	Nebraska	68661	(402) 352-3020
MEDICINE MAN PHARMACY	526 NORTH LINDEN STREET	WAHOO	Nebraska	68066	(402) 443-4167
Nein Pharmacy	1012 Main Street	Bridgeport	Nebraska	69336	(308) 262-1070

O'Neill Family Pharmacy	317 E Douglas St	Oneill	Nebraska	68763-1829	(402) 336-2660
ONEWORLD PHARMACY	4920 S 30TH ST STE 105	OMAHA	Nebraska	68107	(402) 502-5832
Plainview Family Pharmacy	103 S Main St	Plainview	Nebraska	68769-0217	(402) 582-4202
Steffen Drug	214 North Broadway	Hartington	Nebraska	68739-0248	(402) 254-3549
Sutton Pharmacy	210 N Saunders Ave	Sutton	Nebraska	68979	(402) 773-4300
ViaRx	825 North 90th Street	Omaha	Nebraska	68114	(402) 614-6363
Weaver Pharmacy	1014 G Street	Geneva	Nebraska	68361	(402) 759-4433
Wells Drug	113 S 4th St	Albion	Nebraska	68620-1215	(402) 395-2184
Western Drug	806 Illinois	Sidney	Nebraska	69162	(308) 254-2032
Fisherville Pharmacy	219 Fisherville Rd Suite C	Penacook	New Hampshire	03303-2074	(603) 565-0210
Advanced Pharmacy	288 Smith Street	Perth Amboy	New Jersey	08861	(732) 324-4490
Allentown Pharmacy	2 S Main St	Allentown	New Jersey	08501-9501	(609) 259-6121
Allstar Pharmacy	105 Terhune Ave	Lodi	New Jersey	07644-2805	(973) 473-2243
Angelo Pharmacy	492 Ferry Street	Newark	New Jersey	07105	(973) 589-6530
AR-EX Pharmacy	370 New Brunswick Avenue	Fords	New Jersey	08863	(732) 738-1085
Bayshore Pharmacy	2 Bayshore Plaza	Atlantic Highlands	New Jersey	07716	(732) 291-2900
Bell Pharmacy	1907 Route 27	Edison	New Jersey	08817	(732) 985-1211
Boro Hall Pharmacy	565 Bound Brook Road	Middlesex	New Jersey	08846	(732) 968-0414
Boyd's Pharmacy of Florence	306 Broad Street	Florence	New Jersey	08518	(609) 499-0100
Boyd's Pharmacy of Mansfield	23202 Columbus Road Suite E	Columbus	New Jersey	08022	(609) 298-7474
Boyd's Pharmacy of Medford	5-100 Wilkins Station Road	Medford	New Jersey	08055	(609) 975-8197
Boyd's Pharmacy of Bordentown	118 Farnsworth Avenue	Bordentown	New Jersey	08505	(609) 298-1811
Boyd's Pharmacy of Pemberton	17 Fort Dix Road	Pemberton	New Jersey	08068	(609) 894-8288
Boyt Drugs	411 Main Street	Metuchen	New Jersey	08840	(732) 548-2125
Briarmill Pharmacy	1820 Lanes Mill Road	Brick	New Jersey	08724	(732) 840-1800
Buckleys Drug Store	35 East Palisade Avenue	Englewood	New Jersey	07631-2932	(201) 569-1345
Bunting Family Pharmacy	1337-A New Road	Northfield	New Jersey	08225	(609) 484-0026
Burgess Chemist	559 FRANKLIN AVENUE	NUTLEY	New Jersey	07110	(973) 235-0909
Butler Pharmacy	2301 Bridge Avenue	Point Pleasant	New Jersey	08742	(732) 892-4488

Camacho Pharmacy	509 Elizabeth Avenue	Elizabeth	New Jersey	07206	(908) 355-1784
Campbell's Pharmacy	2175 Highway 35	Sea Girt	New Jersey	08750	(732) 974-2929
Center Pharmacy	1108 Liberty Avenue	Hillside	New Jersey	07205	(908) 354-3169
CENTRAL JERSEY PHARMACY	275 HOBART ST	PERTH AMBOY	New Jersey	08861-3396	(732) 979-2410
Centrastate Specialty Script	901 W Main Street (Main Lobby)	Freehold	New Jersey	07728-2537	(732) 414-1977
CLOVER PHARMACY	3100 Quakerbridge Road	Mercerville	New Jersey	08619	(609) 588-5445
Colonial Pharmacy	828 Clifton Avenue	Clifton	New Jersey	07013	(973) 473-4000
Colts Neck Pharmacy	420 State Route 34 Suite 309	Colts Neck	New Jersey	07722	(732) 780-5480
CrossKeys Pharmacy	468 Hurffville Cross Keys Road Unit 2	Sewell	New Jersey	08080	(856) 716-6149
Damiano Pharmacy	270 Parker Avenue	Clifton	New Jersey	07011	(973) 546-6700
Devine's Pharmacy	1949 Oak Tree Road	Edison	New Jersey	08820	(732) 549-7117
Edgewood Pharmacy	62 B Mountain Blvd	Warren	New Jersey	07059	(908) 754-4400
FARMACIA SAN ANTONIO	2319 Federal Street	Camden	New Jersey	08105	(856) 964-4600
Franklyn Pharmacy	204 WARREN AVE	Hohokus	New Jersey	07423	(201) 444-5550
Future Pharmacy	979 Route 9 N	Howell	New Jersey	07731-3365	(732) 431-8170
Future Pharmacy 3	680 Route 33 E Unit 8	East Windsor	New Jersey	08520	(609) 632-2170
Future Pharmacy 4	700 Tennent Rd Suite 9	Manalapan	New Jersey	07726-3148	(732) 851-7100
Future Pharmacy II	72 Route 34	Old Bridge	New Jersey	08857	(732) 952-5550
Garden Pharmacy	2467 State Hwy 33	Neptune	New Jersey	07753-3762	(732) 922-4121
Georgies Family Pharmacy	332 W St Georges Ave	Linden	New Jersey	07036	(908) 925-4567
Georgies Outpatient Pharmacy	6 Earlin Avenue Suite 130	Browns Mills	New Jersey	08015	(609) 726-5800
Georgies Parlin Pharmacy	499 Ernston Rd	Parlin	New Jersey	08859-1406	(732) 952-3022
Get Rx Help Pharmacy	688 Westwood Ave Ste 3	River Vale	New Jersey	07675-6375	(201) 666-6100
Goodale Pharmacy	16 North Sussex Street	Dover	New Jersey	07801	(973) 366-0976
Good Health Pharmacy	530 Joralemon St.	Belleville	New Jersey	07109	(973) 759-2761
Haworth Apothecary	169 Terrace Street	Haworth	New Jersey	07641	(201) 384-7171
Hazlet Pharmacy	2874 Highway 35 South	Hazlet	New Jersey	07730	(732) 264-3310

HB Pharmacy	98 Ridge Road	North Arlington	New Jersey	07031	(201) 997-2010
Health Fair Pharmacy	315 Willow Avenue	Hoboken	New Jersey	07030-3807	(201) 222-6968
Heights Specialty Pharmacy	450 Boulevard	Hasbrouck Heights	New Jersey	07604	(201) 288-0404
Heller's Pharmacy	664 Mount Prospect Avenue	Newark	New Jersey	07104	(973) 482-5353
High Touch Pharmacy	344 West Grand Street	Elizabeth	New Jersey	07202-1202	(908) 353-2000
HOPEWELL PHARMACY	1 West Broad Street	Hopewell	New Jersey	08525	(609) 466-1960
Jersey Drugs	286 Central Avenue	Jersey City	New Jersey	07307	(201) 656-4392
Jersey Shore Pharmacy	580 North Main Street	Barnegat	New Jersey	08005	(609) 660-1111
Kennedy Pharmacy	42 E Laurel Rd Suite 1900	Stratford	New Jersey	08084-1350	(856) 346-3535
Levys Pharmacy	299 Stuyvesant Ave	Lyndhurst	New Jersey	07071-1838	(201) 438-1026
Liberty Drug and Surgical	195 Main Street	Chatham	New Jersey	07928	(973) 635-6200
Lifeline Rx LLC	9252 KENNEDY BLVD UNIT 3	NORTH BERGEN	New Jersey	07047	(201) 624-8015
Liss Pharmacy	794 Mt Prospect Ave	Newark	New Jersey	07104-3295	(973) 483-4749
Little Silver Family Pharmacy	10 Church Street	Little Silver	New Jersey	07739	(732) 741-1121
LiveWell Pharmacy	477 State Route 10 Unit 13	Randolph	New Jersey	07869-2142	(973) 775-9818
Loving Care Pharmacy	1653 Lincoln Highway	Edison	New Jersey	08817	(732) 832-2862
Madison Pharmacy	66 Main Street	Madison	New Jersey	07940	(973) 377-0075
Madura Pharmacy	115 North Broadway	South Amboy	New Jersey	08879	(732) 721-1732
Market Street Pharmacy	10 Market Street	Belvidere	New Jersey	07823-1444	(908) 475-1421
Medical Mall Pharmacy	9 Hospital Dr Suite B3	Toms River	New Jersey	08755	(732) 244-4747
Middletown Family Pharmacy	877 Main St	Belford	New Jersey	07718	(732) 471-9100
Middle Village Pharmacy	393 Piaget Avenue	Clifton	New Jersey	07011	(973) 478-0600
Midtown Pharmacy	581 Kearny Avenue	Kearny	New Jersey	07032	(201) 991-3454
Miguel's Pharmacy	1787 River Road	Camden	New Jersey	08105	(856) 757-0200
Montclair Pharmacy	732 Valley Road	Upper Montclair	New Jersey	07043	(973) 744-2113
Morris Plains Pharmacy	712 Speedwell Avenue	Morris Plains	New Jersey	07950-2231	(973) 539-3635
Newport Pharmacy	165 Erie Street	Jersey City	New Jersey	07302	(201) 963-1903
North Warren Pharmacy and Gift	155 Route 94	Blairstown	New Jersey	07825	(908) 362-5156 Ext 4
Novecks Pharmacy	7823 Bergenline Avenue	North Bergen	New Jersey	07047-4996	(201) 869-1235

Olssons Pharmacy	576 Lafayette Ave	Hawthorne	New Jersey	07506-2400	(973) 427-1700
Paramount Drug	54 East Scott Street	Riverside	New Jersey	08075	(856) 461-0953
Parkview Pharmacy	1430 Queen Anne Rd	Teaneck	New Jersey	07666-3518	(201) 837-6368
PERFECT CARE PHARMACY	1727 JOHN F KENNEDY BLVD	Jersey City	New Jersey	07305	(201) 984-2585
Peter Pan Pharmacy	2125 Park Avenue	South Plainfield	New Jersey	07080	(908) 754-7607
Pharmacy Town	1590 State Highway 35	Ocean	New Jersey	07712	(732) 493-5100
Plumsted Pharmacy	28 Brindletown Road	New Egypt	New Jersey	08533	(609) 758-8829
Plymouth Park Pharmacy Inc	11 12 Saddle River Road	Fair Lawn	New Jersey	07410	(201) 797-0006
Preston Drugs & Surgicals	127 Hawkins Place	Boonton	New Jersey	07005	(973) 334-3460
Princeton Pike Rx LLC	3100 Princeton Pike Suite 4B	Lawrenceville	New Jersey	08648-2376	(609) 450-3740
Quick Mart Pharmacy	100 Ryders Lane	Milltown	New Jersey	08850	(732) 745-7222
Raritan Valley Pharmacy	1055 Route 202 N	Branchburg	New Jersey	08876	(908) 429-5544
Reading Ridge Pharmacy	8 Reading Road, Suite 206	Flemington	New Jersey	08822	(908) 782-7576
Reef Family Pharmacy	1037 S Route 9	Cape May Court House	New Jersey	08210	(609) 465-0004
Richards Pharmacy	207 Broad Avenue	Palisades Park	New Jersey	07650	(201) 944-0863
Riverview Pharmacy	2405 Hamburg Turnpike Suite C	Wayne	New Jersey	07470	(973) 831-4080
Robinson Wellness Pharmacy	27 E Main St	Mendham	New Jersey	07945-1505	(973) 543-2525
S.RESES PHARMACY	269 West White Horse Pike	Pomona	New Jersey	08240	(609) 965-3600
Scott Drugs	701 Park Avenue	Plainfield	New Jersey	07060	(908) 754-1600
Siegels Pharmacy	1201 S Broad St	Trenton	New Jersey	08610-6231	(609) 394-8111
SILVERTON PHARMACY	1824 Hooper Avenue	Toms River	New Jersey	08753	(732) 255-3121
Skaff's Corner Pharmacy	1112 Saint Georges Avenue	Rahway	New Jersey	07065	(732) 381-4144
Somerset Park Pharmacy	900 Easton Avenue Suite 26	Somerset	New Jersey	08873	(732) 846-6666
Springview Pharmacy	4 Elmwood Avenue	Irvington	New Jersey	07111	(973) 372-1300
THE ROBBINS PHARMACY	2108 PENNINGTON RD	TRENTON	New Jersey	08638-1498	(609) 882-2404
Tiffany Natural Pharmacy	1115 South Avenue West	Westfield	New Jersey	07090	(908) 233-2200
Twin City Pharmacy	1708 Park Avenue	South Plainfield	New Jersey	07080	(908) 755-7696
Union Avenue Legend Pharmacy	433 West Union Avenue	Bound Brook	New Jersey	08805	(732) 356-3113

Valley Pharmacy	75 Washington Valley Road	Bedminster	New Jersey	07921	(908) 658-4900
Value Mart Pharmacy	314 Main Street	Orange	New Jersey	07050	(973) 676-0866
Village Pharmacy	1278 Yardville Allentown Rd Suite 5	Allentown	New Jersey	08501	(609) 259-2202
West Milford Pharmacy	1495 Union Valley Road	West Milford	New Jersey	07480	(973) 728-1400
Westminster Pharmacy	577 North Broad Street	Elizabeth	New Jersey	07208	(908) 352-7111
CHRISTUS St. Vincent Outpatient Pharmacy	465 Saint Michaels Drive Suite 112	Santa Fe	New Mexico	87505-7621	(505) 913-5000
Fairview Pharmacy	734 N Riverside Dr	Espanola	New Mexico	87532	(505) 753-2209
FarmaKeio NM	2100 Louisiana Blvd NE Suite 460	Albuquerque	New Mexico	87110-5419	(505) 705-3540
Kare Drug #4	100 North Church Street, Suite A	Bloomfield	New Mexico	87413	(505) 632-3324
Kare Drug - Aztec	100 Llano Street	Aztec	New Mexico	87410	(505) 334-6411
La Tienda Pharmacy	1301 South Canal Street	Carlsbad	New Mexico	88220	(575) 628-0637
Mesilla Valley Pharmacy & Consulting	4119 White Sage Arc Suite F	Las Cruces	New Mexico	88011	(575) 323-2093
Mt Cristo Pharmacy LLC	1155 McNutt Rd Suite 110	Sunland Park	New Mexico	88063-9175	(575) 332-9393
Nowell Pharmacy LLC	122 W Adams	Lovington	New Mexico	88260	(575) 396-4242
Pinon Family Pharmacy	2300 East 30th Street, Suite B-101	Farmington	New Mexico	87401	(505) 327-4826
Roden-Smith Pharmacy	305 E Llano Estacado Boulevard	Clovis	New Mexico	88101	(575) 762-3848
Route 66 Pharmacy	117 Camino de Vida Suite 200	Santa Rosa	New Mexico	88435	(575) 472-5666
Sierra Blanca Pharmacy	1206 Mechem Drive	Ruidoso	New Mexico	88345	(575) 258-2456
86th Street Community Pharmacy Corp	2789 86th Street	Brooklyn	New York	11223	(718) 266-2137
90th Street Pharmacy	1262 Madison Ave	New York	New York	10128-0590	(212) 289-9168
Aliton's Pharmacy Home Healthcare Centers	12 Sussex St	Port Jervis	New York	12771-2253	(845) 856-8314
ASG Rx Corp	10216 Liberty Avenue	Ozone Park	New York	11417	(347) 960-8788
Baldwin Pharmacy LLC	1927 Grand Avenue	North Baldwin	New York	11510-2818	(516) 544-4454
BBRx Pharmacy	6013 7th Avenue Unit B	Brooklyn	New York	11220	7184390502
Better Health Rx Corp	503 W 125th St	New York	New York	10027-3402	(212) 222-8600

Big Apple Rx Inc	220 Saint Nicholas Avenue	New York	New York	10027-6237	(646) 609-6300
Castle Hill Drugs Inc	674 Castle Hills Avenue	Bronx	New York	10473	(718) 239-5400
Central Valley Pharmacy	228 Route 32, Suite 103	Central Valley	New York	10917	(845) 928-1117
Confucius Pharmacy	7 Bowery Street, Store #A-104	New York	New York	10002	(212) 966-4420
Corona Pharmacy Inc	10409A Corona Avenue	Corona	New York	11368-2923	(718) 685-2388
Crystal Run Pharmacy	731 Route 211 E Ste 108	Middletown	New York	10941	(845) 692-7628
Drug Loft Pharmacy	1408 Madison Avenue	New York	New York	10029	(212) 996-9499
Drug Shoppe Llc	2074 8th Ave	New York	New York	10026	(212) 222-3652
Drug World #28	55 Chestnut St	Cold Spring	New York	10516	(845) 265-6352
ELTON PHARMACY	2992 FULTON ST	Brooklyn	New York	11208	(718) 827-8943
Esther Pharmacy	71 South Broadway	Yonkers	New York	10701-4004	(914) 965-2661
Falak Pharmacy	2730 E Tremont Ave	Bronx	New York	10461-2877	(718) 597-5230
Franklin Pharmacy	94-31 59th Ave	Elmhurst	New York	11373-5168	(718) 592-7200
Frederick Community Pharmacy	2450 Frederick Douglas Boulevard	New York	New York	10029	(212) 690-5202
Freds Granville Pharmacy	75 Quaker Street	Granville	New York	12832	(518) 642-3733
Gotham Pharmacy Inc	2258 3rd Avenue	New York	New York	10035	(212) 289-7800
Hazard's Pharmacy	290 Main Street	Cornwall	New York	12518-1579	(845) 534-4345
Healthcare Pharmacy	1825 Madison Avenue	New York	New York	10035	(212) 369-5555
Health Max Pharmacy	80-07 Jamaica Avenue	Woodhaven	New York	11421	(718) 296-0400
Health Source Plus Pharmacy, LLC	118-07 Metropolitan Avenue	Kew Gardens	New York	11415	(718) 849-6700
Hicksville Pharmacy	495 South Broadway Unit 16	Hicksville	New York	11801	(516) 396-0608
Holbrook Pharmacy & Surgical	233 Union Avenue	Holbrook	New York	11741	(631) 585-7092
Hudson Pharmacy	40 Spring Street	Ossining	New York	10562	(914) 941-4476 Ext 121
Hylan Medicine Cabinet	1988 Hylan Boulevard	Staten Island	New York	10306	(718) 667-4300
Islip Pharmacy and Surgical	437 Main Street	Islip	New York	11751	(631) 581-8077
J Drugs	1205 Avenue J	Brooklyn	New York	11230	(718) 258-6686
J Drugs II	3402 Avenue N	Brooklyn	New York	11234	(718) 258-5858

J RX Pharmacy	6515 Fresh Pond Road	Ridgewood	New York	11385	(718) 366-0626
K & K Pharmacy	187 Mill Street	Liberty	New York	12754	(845) 292-3430
Kingsbay Chemists Inc.	3610 Nostrand Avenue	Brooklyn	New York	11229	(718) 891-3447
Koblin's Pharmacy	96 Main Street	Nyack	New York	10960	(845) 358-0688
Kruticks Pharmacy	589 Crescent Street	Brooklyn	New York	11208	(718) 277-0573
Laurelton Pharmacy	22412 Merrick Boulevard	Laurelton	New York	11413	(718) 977-0700
Lenox Pharmacy	27 Lenox Avenue	New York	New York	10026	(212) 678-9722
Lenox Terrace Drug	20 West 135th Street	New York	New York	10037	(212) 234-2050
Mannings 8th Ave Pharmacy	6402 8th Avenue Suite G103	Brooklyn	New York	11220	(718) 238-3850
Matthews Pharmacy	101 Canal St	Ellenville	New York	12428-1400	(845) 647-6222
Medi Center Pharmacy	1262 Boston Road	Bronx	New York	10456	(347) 699-6006
Medrite Pharmacy	7316 Roosevelt Ave	JACKSON HEIGHTS	New York	11372-6336	(917) 832-6035
MEDS	1104 2ND AVENUE	NEW YORK	New York	10022-2007	(212) 371-6000
Middleport Family Health Center	81 Rochester Road	Middleport	New York	14105	(716) 735-3261
Middletown Pharmacy	149 Wickham Avenue	Middletown	New York	10940	(845) 342-5566
Naples Apothecary Inc	129 South Main Street	Naples	New York	14512-9574	(585) 374-5040
NEVINS DRUGS	739 Fulton St	Brooklyn	New York	11217	(718) 422-0100
New Age Pharmacy	2918 Avenue J	Brooklyn	New York	11210	(718) 253-1700
New York Ave Pharmacy	3424 Church Avenue	Brooklyn	New York	11203	(718) 856-8048
Ocean Breeze Pharmacy	1817 Hylan Boulevard	Staten Island	New York	10305-1918	(718) 987-2525
Palmer Pharmacy	2 East Main Street	Johnstown	New York	12095	(518) 762-8319
Parkdale Pharmacy	945 Rosedale Road	Valley Stream	New York	11581	(516) 791-6500
Pine Plains Pharmacy, Inc.	2965 Church St	Pine Plains	New York	12567-5547	(518) 398-5588
Plus Pharmacy	5223 7th Avenue	Brooklyn	New York	11220	(718) 851-0817
Prescription Center	296 Route 59	Tallman	New York	10982	(845) 368-9700
Prescription Center of Ossining	162 Croton Avenue	Ossining	New York	10562	(914) 941-1661
Prescription Centre & Surgicals	35H Middle Country Road	Coram	New York	11727	(631) 698-2868
Queens Drugs & Surgical	146-14 Jamaica Avenue	Jamaica	New York	11435	(718) 297-0099
Queens Drugs & Surgical	80-04 Baxter Avenue	Elmhurst	New York	11373	(718) 457-0099
Ridgewood Pharmacy	389 Onderdonk Avenue	Ridgewood	New York	11385	(718) 381-3622
Rosebank Pharmacy	500 Tompkins Ave	Staten Island	New York	10305-1798	(718) 727-0426

Rossi Pharmacy	1891 Eastern Parkway	Brooklyn	New York	11233	(718) 346-2506
Rx Box Pharmacy	3265 Richmond Avenue	Staten Island	New York	10312-2123	(718) 500-3269
Rye Beach Pharmacy	464 Forest Ave	Rye	New York	10580-3645	(914) 967-0856
Saldo Drugs	384 Graham Avenue	Brooklyn	New York	11211	(718) 389-8015
Schultz Pharmacy	150 West Railroad Avenue	Garnerville	New York	10923	(845) 429-5075
South Fulton Pharmacy Inc.	301 S Fulton Ave	Mount Vernon	New York	10553-1715	(914) 667-7772
St. George Pharmacy	99 Stuyvesant Place	Staten Island	New York	10301	(718) 447-0333
Stony Point Pharmacy	69 South Liberty Drive	Stony Point	New York	10980	(845) 942-1373
Super Health Pharmacy	6390 Amboy Road	Staten Island	New York	10309	(718) 967-4600
The Medicine Cabinet Pharmacy	273 New Main Street	Yonkers	New York	10701-1318	(914) 377-2334
Tower Drugs	272-68 Grand Central Parkway	Floral Park	New York	11005	(718) 631-9300
Triangle Pharmacy	119-01 Jamaica Avenue	Richmond Hill	New York	11418	(718) 847-9850
TruCare Pharmacy	358 Route 202 North	Pomona	New York	10970	(845) 364-5300
Upper Eastside Chemists INC	855 Lexington Avenue #1	New York	New York	10065	(212) 734-5678
V-Care Pharmacy Inc	59 East Eckerson Rd	Spring Valley	New York	10977	(845) 371-2018
Village Drug	126 Main St	Penn Yan	New York	14527	(315) 536-0100
Washingtonville Pharmacy	32 West Main Street Unit 2	Washingtonville	New York	10992	(845) 496-8001
Water Street Pharmacy	14 Water St	Dundee	New York	14837-1086	(607) 243-8114
Wellness Pharmacy	144 West 72nd Street	New York	New York	10023-3344	(212) 439-4718
West Hempstead Pharmacy	449 Hempstead Avenue	West Hempstead	New York	11552	(516) 292-6161
West Islip Pharmacy	432 Montauk Highway	West Islip	New York	11788	(631) 482-9209
Wurlitzer Family Pharmacy Inc	521 DIVISION ST	NORTH TONAWANDA	New York	14120-4403	(716) 260-1131
Adler Pharmacy	3806 A North Church Street	Greensboro	North Carolina	27405	(336) 897-3810
Archdale Drug Co Inc	11220 North Main St	Archdale	North Carolina	27263	(336) 434-2776
Asheville Discount Pharmacy	76 Patton Ave	Asheville	North Carolina	28801	(828) 258-8511
Avery Pharmacy & Health Care	436 Hospital Drive	Linville	North Carolina	28646	(828) 737-7476
B & B Pharmacy	462 Haywood Rd	Asheville	North Carolina	28806	(828) 252-2718

Banner Drug Co	308A Mocksville Highway	Statesville	North Carolina	28625	(704) 878-6681
Banner Drug of Harmony	111 West Memorial Highway	Harmony	North Carolina	28634-0436	(704) 546-5885
Banner Elk Pharmacy	110 Park Avenue	Banner Elk	North Carolina	28604	(828) 898-4271
Bayboro Pharmacy	702 Main St	Bayboro	North Carolina	28515	(252)745-5539
Beach Pharmacy of Avon	41934 Highway 12	Avon	North Carolina	27915	(252) 995-3811
Beach Pharmacy of Hatteras	57353 Highway 12	Hatteras	North Carolina	27943	(252) 986-2400
Boone Drug and Health Care	345 Deerfield Road	Boone	North Carolina	28607	(828) 264-3055
Boone Drug at Greenway	579 Greenway Road Suite 100	Boone	North Carolina	28607	(828) 355-3350
Boone Drug at King Street	202 W King St	Boone	North Carolina	28607-3516	(828) 264-8929
Boone Drug at New Market	245 New Market Center	Boone	North Carolina	28607	(828) 264-9144
Carrboro Family Pharmacy	104 Hwy 54 W Bypass Unit J Carrboro Plz	Carrboro	North Carolina	27510	(919) 933-7629
Carroll Pharmacy	840 S Brightleaf Blvd	Smithfield	North Carolina	27577-4377	(919) 934-7164
Cashiers Valley Pharmacy	52 Cashiers Shopping Center Highway 64 East	Cashiers	North Carolina	28717	(828) 743-3114
Crossroads Pharmacy	7605-B NC Highway 68 North	Oak Ridge	North Carolina	27310	(336) 441-4041 Ext 1
Deep River Drug	2401 B Hickswood Dr	High Point	North Carolina	27265	(336) 454-3784
Dempsey's Drugs Jackson Heights	2717 NC Highway 11/55	Kinston	North Carolina	28504	(252) 686-5295
Dempsey's Drugs La Grange	603 East Washington Street	La Grange	North Carolina	28551	(252) 582-3600
DREXEL DISCOUNT DRUG, LLC	2728 Highway 70 East	Morganton	North Carolina	28655	(828) 433-6777
DrugCare Pharmacy	132 Whitfield Street	Enfield	North Carolina	27823	(252) 445-3414
East Burke Pharmacy, Inc.	300 Main Avenue West	Hildebran	North Carolina	28637	(828) 397-3420
Eastover Drug	3591 Dunn Road	Eastover	North Carolina	28312	(910) 483-4555
Family Pharmacy	2124 Fayetteville Road Suite E	Rockingham	North Carolina	28379	(910) 895-7775
Friendly Pharmacy	3712-G Lawndale Drive	Greensboro	North Carolina	27455	(336) 790-7343
Galloway-Sands Pharmacy #2	1513 North Howe Street Suite 8	Southport	North Carolina	28461	(910) 454-9090
Gibsonville Pharmacy	220 Burlington Avenue	Gibsonville	North Carolina	27249	(336) 449-5501
Guys Family Pharmacy Inc	817 Randolph Street	Thomasville	North Carolina	27360	(336) 476-5632

Halsey Drug Company	55 South Main Street	Sparta	North Carolina	28675	(336) 372-5599
Health Care Connections	402 South Main Street Suite 100	Raeford	North Carolina	28376	(910) 848-0630
Health Park Pharmacy	8300 Health Park Suite 227	Raleigh	North Carolina	27615	(919) 847-7645
Healthridge Pharmacy	3130 US 70 Highway	Black Mountain	North Carolina	28711	(828) 669-9970
Hermitage Pharmacy	1509 South Cannon Boulevard	Kannapolis	North Carolina	28083	(704) 298-0435
Hogan's Pharmacy	815 West Front Street	Lillington	North Carolina	27546	(910) 893-4544
Hospital Drive Pharmacy	409 Altapass Road	Spruce Pine	North Carolina	28777	(828) 765-2025
Island Pharmacy	210 South Highway 64	Manteo	North Carolina	27954	(252) 473-5801
Island Pharmacy	2181-A Old Mountain Rd	Statesville	North Carolina	28625	(704) 873-0000
Jefferson Drug Store	418 East Main Street	Jefferson	North Carolina	28640	(336) 246-9492
Kim's Pharmacy	479 Dellwood Rd	Waynesville	North Carolina	28786	(828) 452-2313
King's Pharmacy	16 Wayne Brooks Lane	Hayesville	North Carolina	28904	(828) 516-9950
King's Pharmacy	30 Peachtree Street	Murphy	North Carolina	28906	(828) 837-7474
KING DRUG CO LLC	142 SOUTH MAIN STREET	KING	North Carolina	27021-0426	(336) 983-3147
Kinston Clinic Pharmacy North	701 Doctors Drive Suite P	Kinston	North Carolina	28501	(252) 523-3187
LAKESIDE PHARMACY	9615 SHERRILL ESTATES ROAD SUITE B	HUNTERSVILLE	North Carolina	28078	(980) 441-8600
Lakeside Specialty Pharmacy	480 River Highway, Suite A	Mooreville	North Carolina	28117-6958	(704) 360-2029
Mabrys Drug Store	41 West Main Street	Hamlet	North Carolina	28345	(910) 582-1776
Madison Pharmacy & Gifts Inc	4401 US HWY 25 70	MARSHALL	North Carolina	28753	(828) 380-6527
Madison Pharmacy and Homecare	125 West Murphy Street	Madison	North Carolina	27025	(336) 548-0049
Market Street Pharmacy	1612 Market Street	Wilmington	North Carolina	28401	(910) 763-0845
Mast Family Drug	418 Dabney Drive	Henderson	North Carolina	27536	(252) 438-4158
Mast Pharmacy	307 West Boulevard	Williamston	North Carolina	27892	(252) 792-1015
McDowell's Pharmacy	1004 Main Street	Scotland Neck	North Carolina	27874	(252) 826-4137
Medical Arts Pharmacy of Lenoir	202 Harper Ave NW Suite A	Lenoir	North Carolina	28645-5196	(828) 758-2356
Medical Center Pharmacy	805 S Long Dr	Rockingham	North Carolina	28379	(910) 997-4471

Medical Park Pharmacy	921 S Long Dr Suite 105	Rockingham	North Carolina	28379	(910) 417-3490
Medical Village Pharmacy	517 Lauchwood Rd	Laurinburg	North Carolina	28352-5595	(910) 276-1154
Moose Drug Company	8374 West Franklin Street	Mount Pleasant	North Carolina	28124	(704) 436-9613
Moose Pharmacy of Kannapolis	1113 North Main Street	Kannapolis	North Carolina	28081	(704) 932-9111
Moose Pharmacy of Locust	1750 West Main Street	Locust	North Carolina	28097	(704) 888-2114
Moose Pharmacy of Monroe	215 East Jefferson Street	Monroe	North Carolina	28112	(704) 283-8131
Moose Pharmacy of Mt. Holly	125 West Central Avenue	Mount Holly	North Carolina	28120	(704) 827-2211
Moose Pharmacy of Salisbury	1408 West Innes Street	Salisbury	North Carolina	28144	(704) 636-6340
Moose Professional Pharmacy	740 Church Street N	Concord	North Carolina	28025	(704) 784-9613
North Main Pharmacy	901 North Main Street	Mount Airy	North Carolina	27030	(336) 756-7855
North Village Pharmacy	1493 Main St	Yanceyville	North Carolina	27379	(336) 694-4104
Old Main Pharmacy	407 West 3rd Street	Pembroke	North Carolina	28372	(910) 521-5600
Pharmville Drug	3754 South Main Street	Farmville	North Carolina	27828-8546	(252) 787-5990
Pike's Pharmacy Inc	2133 Shamrock Drive	Charlotte	North Carolina	28205	(704) 563-2286
Pineville Pharmacy	311 South Polk Street Suite 80	Pineville	North Carolina	28134-8631	(704) 275-8791
Port City Pharmacy	6756 Gordon Rd., Suite 130	Wilmington	North Carolina	28411-8440	(910) 444-3300
Prescriptions Plus	703-1 East King Street	Kings Mountain	North Carolina	28086	(704) 739-4519
Prescriptions Plus	1614 West Franklin Boulevard	Gastonia	North Carolina	28052	(704) 867-3518
Price Pharmacy	110 East Bank Street	Granite Quarry	North Carolina	28072	(704) 279-2579
Price Pharmacy	422 North Highway 29	China Grove	North Carolina	28023	(704) 856-2579
Professional Pharmacy	140 Roxboro Rd	Oxford	North Carolina	27565	(919) 693-8555
PSA Clinic Pharmacy	2294 US Highway 70	Swannanoa	North Carolina	28778-2907	(828) 686-3804
QwikMed Pharmacy	204 Westwood Shopping Cntr	Fayetteville	North Carolina	28314-1528	(910) 676-7570
Red Springs Old Main	300 South Main Street	Red Springs	North Carolina	28377-1624	(910) 227-2425
Roan Mountain Pharmacy of Bakersville	604 South 226 Highway	Bakersville	North Carolina	28705-8809	(828) 820-8058
Rocky Mount Medical Park Pharm	901 North Winstead Avenue Suite 100	Rocky Mount	North Carolina	27804-8760	(252) 443-7979

Rocky Point Pavilion Pharmacy	7910 US Highway 117 Suite 110	Rocky Point	North Carolina	28457	(910) 210-2030
Roosevelt Pharmacy	1606 E Roosevelt Blvd Suite 103	Monroe	North Carolina	28112-4049	(704) 774-1313
Rowland Old Main Pharmacy	101 South Bond Street	Rowland	North Carolina	28383	(910) 422-3774
Scotland Drug Company	140 South Main Street	Laurinburg	North Carolina	28352	(910) 276-3001
Seashore Drugs	10227 Beach Drive Southwest	Calabash	North Carolina	28467	(910) 579-3200
Seven Lakes Prescription Shoppe Inc	120 Mac Dougall Dr	West End	North Carolina	27376	(910) 673-7467
Spindale Drug	109 W Main Street	Spindale	North Carolina	28160	(828)286-3746
Stedman Drug Center	7445 Clinton Road	Stedman	North Carolina	28391-8901	(910) 323-4555
Sunshine Family Pharmacy	1187 Duck Road	Duck	North Carolina	27949	(252) 715-0170
TAR HEEL DRUG	316 South Main Street	Graham	North Carolina	27253	(336) 227-2093
The Apothecary at St James	2571 ST JAMES DR UNIT 102-C	SOUTHPORT	North Carolina	28461-8201	(910) 946-7999
The Drug Store	104 North Henry Street	Stoneville	North Carolina	27408-0258	(336) 573-2200
Thomas Drugs	7917 E Oak Island Dr	Oak Island	North Carolina	28465	(910) 278-6050
Thomas Drugs	4750 Main St	Shallotte	North Carolina	28470	(910) 754-4720
Thomas Drug Store	609 East Cumberland Street	Dunn	North Carolina	28334	(910) 892-2114
Thorne Discount Drug	2900 North Main Street	Tarboro	North Carolina	27886-1921	(252) 823-5655 Ext 124
Village Pharmacy	14057 Highway 17 Suite 100	Hampstead	North Carolina	28443	(910) 319-6050
Warren's Drug Store, Inc	943 South Fifth Street	Mebane	North Carolina	27302	(919) 563-3102
Warrensville Drug Store	5121 North Carolina Highway 88 West	Warrensville	North Carolina	28693	(336) 384-3900
Whispering Pines Prescription Shoppe	7305 NC Highway 22	Carthage	North Carolina	28327-8512	(910) 949-3700
Your Pharmacy of Lexington	100 West Third Street	Lexington	North Carolina	27292	(336) 249-0322
BOTTINEAU CLINIC PHARMACY	314 OHMER ST	BOTTINEAU	North Dakota	58318	(701) 228-2220
CARRINGTON DRUG INC	415 MAIN	CARRINGTON	North Dakota	58421	(701) 652-2521
CENTRAL PHARMACY	4 8TH STREET NORTH	NEW ROCKFORD	North Dakota	58356	(701) 947-5313
CENTRAL PHARMACY INC	990 MAIN ST	CARRINGTON	North Dakota	58421	(701) 652-2651

COOPERSTOWN DRUG	901 BURREL AVE SE	COOPERSTOWN	North Dakota	58425	(701) 797-2414
Hankinson Drug	323 Main Avenue S	Hankinson	North Dakota	58041	(701) 242-7414
HILLSBORO DRUG	13 N MAIN ST	HILLSBORO	North Dakota	58045-4202	(701) 636-5231
LAKOTA DRUG	117 MAIN ST	LAKOTA	North Dakota	58344	(701) 247-2781
LANGDON COMMUNITY DRUG	805 3RD ST	LANGDON	North Dakota	58249	(701) 256-3330
LARIMORE DRUG AND GIFT INC	203 TOWNER AVE	LARIMORE	North Dakota	58251-0438	(701) 343-2461
Northport Drug	2522 Broadway N	Fargo	North Dakota	58102	(701) 235-5543
Northwood Drug	10 NORTH MAIN STREET	NORTHWOOD	North Dakota	58267	(701) 587-5271
Skips Budget Drug	2015 Library Circle #102	Grand Forks	North Dakota	58201	(701) 772-4805
A&B Sunset Pharmacy	4201 Sunset Boulevard	Steubenville	Ohio	43952	(740) 264-1669
Adrien Pharmacy	7023 Miami Ave	Cincinnati	Ohio	45243-2636	(513) 561-7700
Aries Pharmacy	8200 State Route 366	Russells Point	Ohio	43348-9670	(937) 843-3700
Arlington Pharmacy	106 North Main Street	Arlington	Ohio	45814	(419) 365-5202
Barr's Pharmacy	28 West Main	Xenia	Ohio	45385-2938	(937) 347-1200
Barr's Pharmacy of Blanchester	601 West Main Street	Blanchester	Ohio	45107-1141	(937) 625-1238
BARR'S PHARMACY OF HILLSBORO	119 South High Street	Hillsboro	Ohio	45133	(937) 840-0136
BARR'S PHARMACY OF SABINA	12459 East US Route 22 3	Sabina	Ohio	45169	(937) 584-2424
Brewster Family Pharmacy	360 North Wabash Avenue	Brewster	Ohio	44613	(330) 767-3436
Buckeye Pharmacy	15549 State Route 170 Suite 1	East Liverpool	Ohio	43920	(330) 382-7726
C & R Pharmacy	204 North Detroit Street	West Liberty	Ohio	43357	(937) 650-3333
Church Square Pharmacy	1956 E 79th St	Cleveland	Ohio	44103	(216) 721-1772
Clark LowCost Pharmacy	3107 Clark Avenue	Cleveland	Ohio	44109-1145	(216) 651-8685
Cleveland Lowcost Pharmacy	14529 Puritas Avenue	Cleveland	Ohio	44135	(216) 476-1400
COAL GROVE PHARMACY	600 MARION PIKE	IRONTON	Ohio	45638	(740) 533-2479
Davies Drug Inc	6046 Whipple Ave NW	North Canton	Ohio	44720	(330) 305-9075
Davies Pharmacy #1	2915 West Tuscarawas Street	Canton	Ohio	44708	(330) 454-5151

Diamond Pharmacy	503 Cadiz Road	Wintersville	Ohio	43953	(740) 264-6500
Elyria Lowcost Pharmacy	401 Cleveland Street	Elyria	Ohio	44035-6143	(440) 309-4036
Erie Drug	4502 Lewis Avenue	Toledo	Ohio	43612	(419) 476-4322
Ernie's Pharmacy	54 West High Street Suite A	London	Ohio	43140	(740) 852-5131
Essentra Pharmacy	73 Sportmans Drive Suite B	Marengo	Ohio	43334	(419) 253-0632
Fulton Drugs	1657 25th St NW	Canton	Ohio	44709	(330) 456-2476
Garfield Lowcost Pharmacy	5050 Turney Road	Garfield Heights	Ohio	44125	(216) 510-5649
Gerdes Pharmacy	245 Main Street	Conneaut	Ohio	44030	(440) 593-2578
HealingSprings Pharmacy	2449 Ross Millville Road, Suite 185	Hamilton	Ohio	45013-8952	(513) 863-8000
Henderson Pharmacy Services	186 West Main Street	Chillicothe	Ohio	45601-3106	(740) 702-1181
Herche Bloor Pharmacy	104 East 5th Street	East Liverpool	Ohio	43920	(330) 385-0825
Hicksville Pharmacy and Home Medical	116 East High Street	Hicksville	Ohio	43526	(419) 542-6218
Hoffmans Pharmacy	2323 Lake Avenue	Ashtabula	Ohio	44004-3109	(440) 992-3000
Holzer Family Pharmacy	90 Jackson Pike	Gallipolis	Ohio	45631	(740) 446-5236
Holzer Family Pharmacy	280 Pattonville Road	Jackson	Ohio	45640	(740) 395-8870
Holzer Family Pharmacy Athens	2131 East State Street	Athens	Ohio	45701	(740) 589-3181
Home Town Pharmacy	3899 Indian Ripple Road Suite A	Beavercreek	Ohio	45440	(937) 320-1500
Hursh Drugs	90 North Diamond Street	Mansfield	Ohio	44902	(419) 524-0521
IHS Pharmacy-Jamestown	4940 Cottonville Road	Jamestown	Ohio	45335-1522	(937) 675-6500
Kahler Pharmacy	1941 Airport Highway	Toledo	Ohio	43609	(419) 382-2911
Kratzer's Hometown Pharmacy Mount Orab	155 North Point Drive	Mount Orab	Ohio	45154	(937) 444-0135
Lorain Lowcost Pharmacy	12940 Lorain Avenue	Cleveland	Ohio	44111-2612	(216) 999-7120
McFadden Pharmacy	115 East Main Street	Bainbridge	Ohio	45612	(740) 634-3231
Medicine And More	100 Fort Jefferson Avenue	Greenville	Ohio	45331	(937) 547-1642
Medicine Center of Canton	2526 W Tuscarawas St	Canton	Ohio	44708	(330) 455-5422
Medicine Center Pharmacy	251 East St	Minerva	Ohio	44657	(330) 868-6200

Medicine Center Pharmacy	700 West Main Street	Louisville	Ohio	44641	(330) 875-5525
Monroe Pharmacy	4122 Monroe Street	Toledo	Ohio	43606	(419) 473-1531
North Olmsted Lowcost Pharmacy	26901 BROOKPARK ROAD EXT	NORTH OLMSTED	Ohio	44070-3176	(440) 741-7044
Okuley's Pharmacy Inc	102 S Main St	Continental	Ohio	45831-9194	(419) 596-3898
Prospect Pharmacy	171 South Main Street	Prospect	Ohio	43342	(740) 494-2663
Quays Drugs	2 PUBLIC SQ	GALION	Ohio	44833	(419) 468-3044
Richwood Pharmacy	24 West Ottawa Street	Richwood	Ohio	43344	(740) 943-2233
Roselawn Pharmacy	7601 Reading Road	Cincinnati	Ohio	45237	(513) 761-1212
Saint Paris Pharmacy	122 SOUTH SPRINGFIELD STREET	SAINT PARIS	Ohio	43072-0563	(937) 663-6001
Sand Run Pharmacy	40 Sand Run Rd	Akron	Ohio	44313-6288	(330) 864-2138
Save Rite Pharmacy	3235 Belmont Street	Bellaire	Ohio	43906	(740) 676-3433
Sheliga Drug	6025 St. Clair Avenue	Cleveland	Ohio	44103	(216) 431-1035
St. Elizabeth's Pharmacy	1 Elizabeth Place Suite 1015	Dayton	Ohio	45417	(937) 424-4599
St. Luke's Lowcost Pharmacy	11201 Shaker Boulevard Suite 126	Cleveland	Ohio	44104-3833	(216) 795-4000
Stewart's Pharmacy	1013 Jefferson Street	Greenfield	Ohio	45123	(937) 981-3245
Swisher & Lohse Pharmacy	636 East Main Street	Pomeroy	Ohio	45769	(740) 992-2955
The Drug Store of Perrysburg	580 Craig Dr Unit 12	Perrysburg	Ohio	43551	(419) 873-9100
The DrugStore on East State	934 E State St	Athens	Ohio	45701	(740) 566-4690
TOWNE PHARMACY	283 Cline Ave	Mansfield	Ohio	44907	(419) 756-6032
Towne Pharmacy	849 Smith Road	Ashland	Ohio	44805	(419) 281-4040
Uptown Pharmacy	23 North State Street	Westerville	Ohio	43081	(614) 882-2392
Valley View Pharmacy	11141 State Route 800 Northeast	Magnolia	Ohio	44643	(330) 866-3380
Wexler's Lake Milton Pharmacy	17674 Mahoning Avenue	Lake Milton	Ohio	44429	(330) 654-3792
Xtra Care Pharmacy	7920 South Mason Montgomery Road	Mason	Ohio	45040-8249	(513) 770-0084
ZEIGLER PHARMACY	159 West Main Street	Wilmington	Ohio	45177	(937) 382-0921
Broken Arrow Family Drug	3359 South Elm Place	Broken Arrow	Oklahoma	74012	(918) 451-3784
Broken Arrow Family Drug North	1030 East Lansing Street	Broken Arrow	Oklahoma	74012-7010	(918) 251-3784

CITY HEALTHMART DRUG	128 E Cherokee Ave	Nowata	Oklahoma	74048	(918) 273-3825
Community Pharmacy	212 East 8TH Street	Beaver	Oklahoma	73932	(580) 625-3646
Ernie's Pharmacy and Wellness Center Inc	410 South 32nd Street	Muskogee	Oklahoma	74401	(918) 683-0611
Fikes Pharmacy	101 East Second	Grandfield	Oklahoma	73546	(580) 479-5696
Harrison Discount Pharmacy	1442 North Harrison St	Shawnee	Oklahoma	74801-5208	(405) 273-9906
Holder Drug	513 Barnes	Alva	Oklahoma	73717-2288	(580) 327-3332
Lakeside Pharmacy	605 North Main Street	Eufaula	Oklahoma	74432	(918) 689-9940
Main Street Drug	225 West Main	Wilburton	Oklahoma	74578	(918) 465-9300
Owl Drug and The Gift House	418 West Cherokee St	WAGONER	Oklahoma	74467-5220	(918) 485-2722
Rogers Drug Company	326 East Cherokee Street	Wagoner	Oklahoma	74467	(918) 485-2317
Rose Rock Pharmacy	12100 S. Yukon Ave Suite A	Glenpool	Oklahoma	74033-6621	(918) 552-1040
Sooner Pharmacy of Oklahoma LLC	815 West Broadway Street	Sulphur	Oklahoma	73086	(580) 622-2200
Stroud Drug	406 West Main	Stroud	Oklahoma	74079	(918) 968-2323
Thrifty Pharmacy	10904 - L.N. May Avenue	Oklahoma City	Oklahoma	73120	(405) 751-2852
Westminster Family Drug	10911 Northeast 23rd Street	Nicoma Park	Oklahoma	73066	(405) 769-8585
Ashland Drug	53 North Second Street	Ashland	Oregon	97520	(541) 482-3366
Bowmans Hillsdale Pharmacy	6256 SW Capitol Hwy	Portland	Oregon	97239	(503) 244-7582
Broadway Pharmacy	2790 Broadway Ave	North Bend	Oregon	97459-2216	(541) 449-9190
Gold Beach Pharmacy	94202 2nd St	Gold Beach	Oregon	97444-7767	(541) 727-3300
Gold Hill Pharmacy	808 Second Avenue	Gold Hill	Oregon	97525	(541) 855-1544
Gordon's Pharmacy and Gifts	314 S. Main Street	Canyonville	Oregon	97417	(541) 839-4452
Harrisburg Pharmacy	230 North 3rd Street Suite 106	Harrisburg	Oregon	97446	(541) 995-9711
Malheur Drug	198 A Street West	Vale	Oregon	97918	(541) 473-3333
Sempert's Drug	735 Spruce Street	Myrtle Point	Oregon	97458	(541) 572-5010
Stayton Pharmacy	102 Martin Drive, Suite A	Stayton	Oregon	97383	(503) 769-2616 Ext 4
Adams-Cumberland Pharmacy	3463 Biglerville Road	Biglerville	Pennsylvania	17307	(717) 486-8606
Alberts Pharmacy	201 South Main Street Suite 2	Pittston	Pennsylvania	18640	(570) 299-5150
Alexa Pharmacy	919 Tyson Avenue	Philadelphia	Pennsylvania	19111	(215) 437-7573

Andrew Browns Drug Store Inc	1502 Pittston Avenue	Scranton	Pennsylvania	18505	(570) 346-7319
Appleby Drug Store	133 E Shirley St	Mount Union	Pennsylvania	17066	(814) 542-4412
Asti's South Hills Pharmacy	250 Mt Lebanon Blvd	Pittsburgh	Pennsylvania	15234	(412) 561-2347
Bechtels Pharmacy	302 Main Street	Slatington	Pennsylvania	18080	(610) 767-4121
BETTER HEALTH PHARMACY & WELLNESS	518 Burke Bypass	Olyphant	Pennsylvania	18447	(570) 383-6700
Brown's Pharmacy	63 Canton Street	Troy	Pennsylvania	16947	(570) 297-5400
Browns Pharmacy	121 Sullivan Street	Canton	Pennsylvania	17724	(570) 673-4372
Centennial Pharmacy Services	1020 North Delaware Avenue Suite 200	Philadelphia	Pennsylvania	19125-4334	(267) 534-5025
Custom Care Pharmacy	57 S Front St	Milton	Pennsylvania	17847-1110	(570) 246-5700
Davis Pharmacy	4523 Baltimore Avenue	Philadelphia	Pennsylvania	19143	(215) 222-3349
Dougs Family Pharmacy	101 Darby Square	Elverson	Pennsylvania	19520	(610) 286-0496
Ellis Prescription Pharmacy	2441 West Brown Street	Philadelphia	Pennsylvania	19130	(215) 765-1903
Express Care Pharmacy	1727 West Liberty Street Unit 2	Allentown	Pennsylvania	18104	(610) 351-2273
Famcare Pharmacy	1429 Burgettstown Plaza	Burgettstown	Pennsylvania	15021	(724) 947-7000
Family Prescription Counter	335 Main Street	Duryea	Pennsylvania	18642	(570) 457-6789
First National Pharmacy	143 North First Street	Lehighton	Pennsylvania	18235	(610) 377-0450
Gateway Pharmacy	165 Nutt Rd	Phoenixville	Pennsylvania	19460-3999	(610) 933-2609
Gaughns Drug Store	348 Pennsylvania Avenue West	Warren	Pennsylvania	16365	(814) 723-2840
Harrolds Pharmacy Inc	250 Old River Road	Wilkes Barre	Pennsylvania	18702-1614	(570) 822-5794
Heights Terrace Pharmacy	475 South Poplar Street	Hazleton	Pennsylvania	18201	(570) 454-8748
Holly Pharmacy	31 North Baltimore Avenue	Mt. Holly Springs	Pennsylvania	17065-1302	(717) 486-5321
Horsham Square Pharmacy	575 Horsham Road Unit C20	Horsham	Pennsylvania	19044	(215) 674-5050
Katz Pharmacy	2 East Eagle Road	Havertown	Pennsylvania	19083	(610) 446-4040
Langhorne Pharmacy	172 N Pine St	Langhorne	Pennsylvania	19047	(215) 752-1100
Lifestream Pharmacy	847 EASTON ROAD SUITE 2775	WARRINGTON	Pennsylvania	18976	(215) 491-0999
Marple Pharmacy	2070 Sproul Road	Broomall	Pennsylvania	19008	(610) 356-6491
Mauch Chunk Pharmacy	1204 North Street	Jim Thorpe	Pennsylvania	18229	(570) 325-5020

Max-Well Pharmacy Services	375 West Street Road	Warminster	Pennsylvania	18974	(215) 956-9280
Medmart Pharmacy	2618-A Memorial Boulevard	Connellsville	Pennsylvania	15425	(724) 628-7500
Morrison's Pharmacy	6113 Ridge Avenue	Philadelphia	Pennsylvania	19128	(215) 482-2697
Nazareth Outpatient Pharmacy	2601 Holme Ave Suite 100	Philadelphia	Pennsylvania	19152-2007	(215) 335-7985
Neighborhood Pharmacy	5701 Chestnut St	Philadelphia	Pennsylvania	19139	(215) 307-3609
New Falls Pharmacy	2235 Veterans Highway	Levittown	Pennsylvania	19056-3001	(215) 269-7000
Newhard Pharmacy	1001 Main Street	Northampton	Pennsylvania	18067	(610) 262-6721
Nucare Pharmacy	7960 Verree Road	Philadelphia	Pennsylvania	19111	(215) 342-0100
Paoli Pharmacy Inc	1564 Lancaster Ave	Paoli	Pennsylvania	19301	(610) 644-3880
Park Avenue Pharmacy Inc	220 PARK AVE	CHAMBERSBURG	Pennsylvania	17201-1230	(717) 264-7312
Parvin's Pharmacy	30 North Bryn Mawr Avenue	Bryn Mawr	Pennsylvania	19010	(610) 525-0443
Pharmacy of America	1500 East Erie Avenue	Philadelphia	Pennsylvania	19124	(215) 289-9500
Pharmacy of America II	5872 Oxford Avenue	Philadelphia	Pennsylvania	19149	(215) 613-7900
Pharmacy of America III	217 W Lehigh Ave Store #2	Philadelphia	Pennsylvania	19133	(215) 279-7981
Pharmacy of America IV	1900 North 9th Street	Philadelphia	Pennsylvania	19122	(215) 787-9999
Pharmacy of America IX Inc	1000 Cottman Ave	Philadelphia	Pennsylvania	19111-3644	(215) 770-7869
Pharmacy of America V	232 West Girard Avenue	Philadelphia	Pennsylvania	19123-1538	(267) 858-4279
Pharmacy of America VI	919 Levick Street	Philadelphia	Pennsylvania	19111-5421	(215) 535-0555
Pharmacy of America VII	4654 North 5th Street	Philadelphia	Pennsylvania	19140	(267) 900-5858
Pharmacy of America VIII Inc	7522 Frankford Ave	Philadelphia	Pennsylvania	19136-3533	(215) 914-6911
Quality Care Pharmacy	1 Sprint Drive	Carlisle	Pennsylvania	17015	(717) 249-5691
Quik-Stop Pharmacy	3506 East Lincoln Highway	Thorndale	Pennsylvania	19372	(610) 384-6100
Rann Pharmacy	377 Main Street	Harleysville	Pennsylvania	19438-2309	(215) 256-4146
RIOS PHARMACY	35 South Morton Avenue	Morton	Pennsylvania	19070	(610) 543-1858
RiteChoice Pharmacy at 11th Street	850 N 11th St Floor 1 Room 148	Philadelphia	Pennsylvania	19123-1957	(215) 769-2155
Shafer's Pharmacy	408 East Broad Street	Tamaqua	Pennsylvania	18252	(570) 668-0290
Sheehans Pharmacy	79 E Carey St	Plains	Pennsylvania	18705-2007	(570) 823-3151

Shop and Carry Pharmacy	1301 Lindley Avenue	Philadelphia	Pennsylvania	19141-2747	(267) 297-5030
Springfield Pharmacy	1154 Baltimore Pike	Springfield	Pennsylvania	19064	(610) 544-4645
St. Clare Pharmacy	1203 Langhorne Newtown Road	Langhorne	Pennsylvania	19047	(215) 710-7427
Standard Drug Store	322 South Hancock Street	McAdoo	Pennsylvania	18237	(570) 929-1130
Stephens Pharmacy	1101 Main Street	Honesdale	Pennsylvania	18431	(570) 253-7770
Summit Health Pharmacy LLC	3400 Edgmont Avenue	Brookhaven	Pennsylvania	19015-2804	(610) 872-5418
The Prescription Center	310 Adams Avenue	Scranton	Pennsylvania	18503	(570) 343-2448
Village Pharmacy at Spring House	1121 North Bethlehem Pike Suite 40	Spring House	Pennsylvania	19477-1011	(215) 646-1691
Waltmire Pharmacy	1435 Spring Garden Avenue	Pittsburgh	Pennsylvania	15212	(412) 323-1801
West Perry Pharmacy	1102 Montour Road	Loysville	Pennsylvania	17047	(717) 789-3093
West Reading Drug Store	538 Penn Avenue	West Reading	Pennsylvania	19611	(610) 375-4366
Woodlyn Pharmacy	1301 Jefferson Avenue	Woodlyn	Pennsylvania	19094	(610) 833-5600
Yorke Pharmacy	5524 New Falls Road	Levittown	Pennsylvania	19056	(215) 945-5700
Professional Pharmacy of Pennsburg/Red Hill	931 Main Street	Pennsburg	Pennsylvania	18073	(215) 679-9700
FARMACIA ABIMAR	CARR 780 KM 6.5 BO ANONES	NARANJITO	Puerto Rico	00719	(787) 869-2021
FARMACIA CARIBE	CARRETERA #3 KM 26.3	RIO GRANDE	Puerto Rico	00745	(787) 888-1888
Farmacia Caribe	Centro Comercial Villas De Rio Grande	Rio Grande	Puerto Rico	00745	(787) 887-3060
Farmacia Caribe II	Calle K #HH17Y18, URB Alturas De Rio Grande	Rio Grande	Puerto Rico	00745	(787) 887-4444
Farmacia Carraizo	Carretera 844 KM 5.6	Trujillo Alto	Puerto Rico	00928	(787) 760-2650
Farmacia Farmahorros	Local 101 Centro Comercial Villa Del Carmen	Cidra	Puerto Rico	00739	(787) 739-3522
Farmacia Guayabal	Carr. #1 KM 113.60 Bo. Cintrona	Juana Diaz	Puerto Rico	00795	(787) 260-3804
Farmacia Los Maestros	Calle Muniz Souffront #459, Urb. Los Maestros	San Juan	Puerto Rico	00923	(787) 765-8811
Farmacia Magda	UU48 Calle 37	Bayamon	Puerto Rico	00956-4789	(787) 786-0755
Farmacia Martin	Calle Ruiz Belvis # 22	San German	Puerto Rico	00683	(787) 892-1122

Farmacia Nueva	Calle Munoz Rivera #16	Camuy	Puerto Rico	00627	(787) 820-6892
Farmacia Reyes 3	1320 San Alfonso Avenue	San Juan	Puerto Rico	00921-3621	(787) 782-6403
Farmacia Villas De Castro	Calle 2 A18 Villas De Castro	Caguas	Puerto Rico	00725	(787) 390-0990
NUEVA FARMACIA SANTA ANA	CALLE 1 B3 URBANIZACION SANTA ANA	VEGA ALTA	Puerto Rico	00692	(787) 270-2503
Su Farmacia Amiga Inc.	Ave Las Americas BU-1 Residencial Bairoa	Caguas	Puerto Rico	00725	(787) 743-6434
Super Farmacia Lizette	Calle Guillermo Esteves #103	Jayuya	Puerto Rico	00664	(787) 828-0755
Matt's Local Pharmacy	88 East Main Road	Middletown	Rhode Island	02842-4912	(401) 619-5020
Aynor Family Pharmacy	240 8th Avenue	Aynor	South Carolina	29511	(843) 358-3520
Black River Pharmacy	32A North Williamsburg County Highway	Kingstree	South Carolina	29556	(843) 355-5656
Blythewood Pharmacy and Home Medical Equipment	710-C University Village Drive	Blythewood	South Carolina	29016	(803) 786-8110
Brunson's Pharmacy	12 North Brooks Street	Manning	South Carolina	29102	(803) 435-2511
Buford Street Drug Store	115 N Granard St	Gaffney	South Carolina	29341-2342	(864) 488-3036
Chapin Pharmacy	138A Amicks Ferry Rd	Chapin	South Carolina	29036	(803) 345-1114
Chester Family Pharmacy	1645 J A Cochran Bypass Suite G	Chester	South Carolina	29706-3102	(803) 581-1095
Corner Drug Store	205 West Cedar Rock Street	Pickens	South Carolina	29671	(864) 878-6357
Daniels Pharmacy of Barnwell	178 Wren Street	Barnwell	South Carolina	29812	(803) 259-1234
Delta of Charleston #3	346 East Bay St	Charleston	South Carolina	29401	(843) 937-0960
Delta of Elloree	2611 Cleveland St	Elloree	South Carolina	29047	(843) 761-5255
Delta of Eutawville	226 Porcher Ave	Eutawville	South Carolina	29048	(803) 492-9201
Delta of Moncks Corner	402 East Main St	Moncks Corner	South Carolina	29461	(843) 761-5255
Delta Pharmacy & Medical Supply #5	901 Island Park Dr Suite 103	Daniel Island	South Carolina	29492-8034	(843) 471-2870
Delta Pharmacy & Medical Supply #6	1400 Palm Blvd	Isle of Palms	South Carolina	29451-2280	(843) 885-8008
Delta Pharmacy & Medical Supply #7	6251 Hwy 162	Hollywood	South Carolina	29449-5782	(843) 564-5720
Delta Rx - Litchfield	115 Willowbrook Boulevard Unit A	Pawleys Island	South Carolina	29585-6542	(854) 600-1006
Dillon Community Pharmacy	200 W Harrison St Suite A	Dillon	South Carolina	29536-3331	(843) 774-4749

Dillon Family Pharmacy	603 North 6th Avenue	Dillon	South Carolina	29536	(843) 774-1816
Dottie's Pharmacy	325 Folly Road Suite 101	Charleston	South Carolina	29412	(843) 501-9500
Elgin Pharmacy	1107 Ross Street	Elgin	South Carolina	29045	(803) 438-5735
Family Pharmacy South Aiken	110 Price Avenue	Aiken	South Carolina	29803	(803) 648-1776
Fowler's Pharmacy	1908 Laurens Road	Greenville	South Carolina	29607	(864) 288-5920
Gaston Family Pharmacy	1118 Mack St	Gaston	South Carolina	29053	(803) 939-8489
Giant Discount Pharmacy	6611 Savannah Highway	Neeses	South Carolina	29107	(803) 247-2135 Ext 3
GILDER & WEEKS PHARMACY	200 N MAIN STREET	JOANNA	South Carolina	29351	(864) 697-6580
Great Falls Pharmacy	503 Chester Avenue Suite A	Great Falls	South Carolina	29055	(803) 482-2249
Harleyville Drug	108 West Main Street	Harleyville	South Carolina	29448	(843) 462-7646
Herold's Pharmacy	2057 Charlie Hall Boulevard Suite C	Charleston	South Carolina	29414	(843) 637-3037
Hibbitts Drug Company LLC	735 North Main Street	New Ellenton	South Carolina	29809	(803) 443-0077
Honea Path Pharmacy	309 East Greer Street	Honea Path	South Carolina	29654-1818	(864) 369-5337
Irmo Drug	1009 Lake Murray Blvd, Suite B	Irmo	South Carolina	29063	(803) 749-7485
Kash and Karry Pharmacy	101 Pete Hollis Boulevard	Greenville	South Carolina	29601	(864) 232-6711
Kershaw Family Pharmacy	401 South Hampton Street	Kershaw	South Carolina	29067-1832	(803) 475-6979
Lake Murray Drug Company	105 Snapdragon Court Suite A	Chapin	South Carolina	29036-8343	(803) 345-9999
Lake Murray Drug Company of Irmo	2 Palmetto Wood Parkway Suite 100	Irmo	South Carolina	29063	(803) 212-9999
Lake Wylie Pharmacy	221 Latitude Lane Suite 109	Lake Wylie	South Carolina	29710	(803) 831-2044
Landy's Pharmacy	835 Sparkleberry Lane	Columbia	South Carolina	29229-6544	(803) 567-3107
Lee's Inlet Apothecary	3579 Hwy 17 B	Murrells Inlet	South Carolina	29576	(843) 651-7979
Liberty Family Pharmacy	115 West Main Street	Liberty	South Carolina	29657-0063	(864) 843-9207
Lorex Drugs	1310 Wilson Road	Newberry	South Carolina	29108	(803) 276-0990
McLeskey Todd Pharmacy of Greer Inc	109 North Main Street	Greer	South Carolina	29650	(864) 877-0753
Medicine Mart of West Columbia #1	1300 Sunset Blvd	West Columbia	South Carolina	29169	(803) 791-7043
Medicine Mart Pharmacy	1401 Main Street	Conway	South Carolina	29526	(843) 248-4609

Medicine Mart Pharmacy of Lexington	348 B Columbia Ave	Lexington	South Carolina	29072	(803) 957-5969
MediSave Pharmacy	1025 W Dekalb St	Camden	South Carolina	29020-4162	(803) 424-0064
Mobley Drugs Inc	1073 West Meeting Street	Lancaster	South Carolina	29720-2321	(803) 285-2021
Nyes Pharmacy	1600 10th Avenue	Conway	South Carolina	29526	(843) 248-5015
Peak Pharmacy	22 River Street	Peak	South Carolina	29122	(803) 345-1707
Pickwick Pharmacy	3219 Augusta Road	Greenville	South Carolina	29605	(864) 277-4180
Piedmont Family Pharmacy	600 Anderson Street	Piedmont	South Carolina	29673-1418	(864) 832-9520
Pine Ridge Pharmacy	634 A Pine Ridge Drive	West Columbia	South Carolina	29172	(803) 955-3404
Powdersville Family Pharmacy	11061 Anderson Road	Piedmont	South Carolina	29673-8203	(864) 373-9229
Prescriptions Plus	311-C Chesnee Highway	Gaffney	South Carolina	29341	(864) 649-5371
Prof Pharmacy of Greer Inc	320 Memorial Drive	Greer	South Carolina	29650	(864) 877-3386
Prosperity Drug Company	101 North Main Street	Prosperity	South Carolina	29127	(803) 364-2310
Prosperity Drug of Batesburg-Leesville	317 Village Square Drive	Batesburg Leesville	South Carolina	29070-7055	(803) 580-2400
R & J Drugs	4633 Savannah Highway	North	South Carolina	29112	(803) 247-2133 Ext 5
Regenes Health Care Pharmacy	750 South Church Street	Spartanburg	South Carolina	29306	(864) 699-3283 Ext 8864
ReGenesis Health Care Pharmacy	460 Langdon St	Spartanburg	South Carolina	29302-1614	(864) 285-9867
Regenes Health Care Pharmacy #3	1663 E MAIN ST	Duncan	South Carolina	29334	(864) 416-7933
Regenes Organization Community Health Center #2	1341 North Limestone Street	Gaffney	South Carolina	29340-4733	(864) 582-2411 Ext 1011
Reidville Road Pharmacy	2660 Reidville Road Suite 8	Spartanburg	South Carolina	29301-3512	(864) 435-9400
Reynolds Drug Store Inc	7 South Morgan Avenue	Andrews	South Carolina	29510	(843) 264-5454
Richburg Discount Pharmacy	3191 Lancaster Highway Suite H	Richburg	South Carolina	29729	(803) 500-2998
Rileys Drugs Inc	1207 West Main Street	Lexington	South Carolina	29072	(803) 359-2587
Sadler Hughes Apothecary	102 Jacobs Hwy	Clinton	South Carolina	29325-2599	(864) 833-4000
Santee Drug Center	3931-D Byrnes Dr	Saint Stephen	South Carolina	29479-0910	(843) 567-3291
South End Pharmacy	1401 Albright Rd	Rock Hill	South Carolina	29730	(803) 366-3784

Stuckey Pharmacy	207 South Main Street	Hemingway	South Carolina	29554	(843) 558-1010
Sweetgrass Pharmacy	1477 Long Grove Dr Suite 101	Mt Pleasant	South Carolina	29464	(843) 654-4013
Sweetgrass Pharmacy Carolina Park	3485 Park Avenue Blvd	Mt Pleasant	South Carolina	29466	(843) 800-7007
Tega Cay Pharmacy	1741 Gold Hill Road Suite 106	Fort Mill	South Carolina	29708	(803) 547-6100
The Pharmacy	2500 Hoffmeyer Road	Florence	South Carolina	29501-7407	(843) 773-2821
Triangle Pharmacy	1239 D Avenue	West Columbia	South Carolina	29169	(803) 794-4840
True Pharmacy	623 Beltline Blvd	Columbia	South Carolina	29205-1847	(803) 849-1500
True Pharmacy of Easley	5809 Calhoun Memorial Highway Suite A	Easley	South Carolina	29640	(864) 810-5161
Union Family Pharmacy LLC	528 A Rice Ave	Union	South Carolina	29379	(864) 427-3700
Wall Drugs of Pamplico Inc	616 South Walnut Street	Pamplico	South Carolina	29583	(843) 905-0200
Wannamaker Drug	107 West Blvd	Chesterfield	South Carolina	29709-1528	(843) 623-2999
Wannamaker Drug	700 Chesterfield Hwy	Cheraw	South Carolina	29520	(843) 537-3221
Waterway Pharmacy	3373 Highway 9 East	Little River	South Carolina	29566	(843) 734-0612
Westbury Pharmacy	701 North Parler Ave	Saint George	South Carolina	29477	(843) 563-9384
Woodruff Health Mart Pharmacy	10195 Highway 221 Suite 5	Woodruff	South Carolina	29388-9358	(864) 670-8150
Yorkville Pharmacy	822 B East Liberty Street	York	South Carolina	29745	(803) 628-7934
Dakotamart	120 West Sioux Avenue	Pierre	South Dakota	57501-1158	(605) 224-7396
Haisch Pharmacy	303 E 5th St	Canton	South Dakota	57013-1735	(605) 987-2661
Lynn's Dakotamart Pharmacy - Belle Fourche	600 National Street	Belle Fourche	South Dakota	57717	(605) 892-2666
Lynns Dakotamart Pharmacy - Hot Springs	509 Jensen Hwy	Hot Springs	South Dakota	57747	(605) 745-3110
Alphacare Specialty Pharmacy	1510 Gunbarrel Road Suite 500	Chattanooga	Tennessee	37421-7175	(423) 888-9568
Anderson Crossing Pharmacy	3318 Andersonville Highway	Andersonville	Tennessee	37705	(865) 494-8444
Apothecare Pharmacy	1006 Main St	Wartburg	Tennessee	37887	4233467800
Apple Discount Drug	520 Clinch Avenue	Clinton	Tennessee	37716-4228	(865) 457-0300
Baggett Pharmacy Inc	133 East Race Street	Kingston	Tennessee	37763	(865) 376-6452

Bakers Family Pharmacy	200 West Main street	Jackson	Tennessee	38301	(731) 265-6555
Belew Drug Choto	1616 Choto Markets Way	Knoxville	Tennessee	37922-5760	(865) 766-4424
Belew Drugs	2021 N Broadway St	Knoxville	Tennessee	37917	(865) 525-4189
Belew Drugs Asheville Highway	8622 Asheville Highway	Knoxville	Tennessee	37924-4107	(865) 933-3441
Belew Drugs Washington Pike	5908 Washington Pike Suite 102	Knoxville	Tennessee	37918-7012	(865) 525-4967
Brainerd Pharmacy	3602 Brainerd Road	Chattanooga	Tennessee	37411	(423) 305-1858
Campbell's Hometown Pharmacy	272 Highway 11 E	Bulls Gap	Tennessee	37711	(423) 235-6263
City Drug	1612 East Lamar Alexander Parkway	Maryville	Tennessee	37804	(865) 982-7162
City Drug	630 RB Wilson Drive	Huntingdon	Tennessee	38344	(731) 986-2228
Crescent Center Drugs	228 North Fairmont Avenue	Morristown	Tennessee	37814	(423) 586-6263
Dannys Drugs	20029 Alberta Ave	Oneida	Tennessee	37841-4129	(423) 569-8652
DAYTON DRUG AND WELLNESS	6985 RHEA COUNTY HWY	Dayton	Tennessee	37321	(423) 775-5511
Dover Family Pharmacy	1307 Donelson Parkway	Dover	Tennessee	37058	(931) 232-0123
DOWN HOME PHARMACY LLC AP	1034 Main Street	Bean Station	Tennessee	37708	(865) 993-4074
DUNLOP PHARMACY	620 DUNLOP LN STE 110	CLARKSVILLE	Tennessee	37040-6440	(931) 278-6422
EAGLE DEN DISCOUNT DRUG	11510 CHAPMAN HWY	SEYMOUR	Tennessee	37865	(865) 299-4044
East Tennessee Discount Drug	524 Andrew Johnson Highway	Strawberry Plains	Tennessee	37871	(865) 933-4149
Family Pharmacy	6 Hospital Drive	Lexington	Tennessee	38351	(731) 968-6979
Family Pharmacy Milan	6078 South 1st Street	Milan	Tennessee	38358-3131	(731) 238-3800
Family Pharmacy Scotts Hill	10091 Highway 100	Scotts Hill	Tennessee	38374	(731) 549-2887
Family Wellness Pharmacy	330 North Oak Avenue	Cookville	Tennessee	38501-2440	(931) 559-6337
Hamilton Discount Pharmacy	6851 Shallowford Road	Chattanooga	Tennessee	37421	(423) 892-5955
Hermitage Pharmacy	3786 Central Pike Suite 120	Hermitage	Tennessee	37076	(615) 454-3300
Herndon Pharmacy	175 West Main Street	Camden	Tennessee	38320-1621	(731) 584-4711
Hixson Pharmacy	5508 Hixson Pike Suite 1	Hixson	Tennessee	37343	(423) 498-5900
Hoskins Drug Store #2	111 N Main St	Clinton	Tennessee	37716	(865) 457-4340

JABOS PHARMACY, INC.	602 East Broadway	Newport	Tennessee	37821	(423) 623-3088
Jeff Co Drug Center	127 West Meeting Street	Dandridge	Tennessee	37725	(865) 397-2868
John Smith Professional Pharmacy	100 Lantana Road, Suite 201	Crossville	Tennessee	38555	(931) 484-1434
LAFAYETTE PHARMACY	526 Highway 52 Bypass West	Lafayette	Tennessee	37083	(615) 666-4444
Loretto Drugs LLC	106 Church Street	Loretto	Tennessee	38469	(931) 853-5910
Mac's Pharmacy	2419 Washington Pike	Knoxville	Tennessee	37917	(865) 524-3453
Mac's Pharmacy at South Peters	125 S Peters Rd	Knoxville	Tennessee	37923-5202	(865) 381-2500
Mac's Pharmacy Oak Ridge	45 New York Avenue	Oak Ridge	Tennessee	37830-6410	(865) 298-8657
MAC'S PHARMACY TOWNSEND	7959 E LAMAR ALEXANDER PKWY	TOWNSEND	Tennessee	37882-4033	(865) 421-6227
MARKS FAMILY PHARMACY	205 East 3rd Ave	Oneida	Tennessee	37841-5885	(423) 569-7800
Max Discount Pharmacy	4531 Highway 58 Suite 105	Chattanooga	Tennessee	37416	(423) 803-5990
McMinnville Drug Center	1500 Sparta St	McMinnville	Tennessee	37110-1343	(931) 473-4471
Morristown Pharmacy	925 West 4th North Street	Morristown	Tennessee	37814	(423) 587-4949
Mountain City Pharmacy	1641 South Shady St	Mountain City	Tennessee	37683-2015	(423) 727-0038
Munsey Pharmacy	106 Administration Road	Oak Ridge	Tennessee	37830	(865) 483-8429
Newbern Drug #439	625 W Main St Suite A	Newbern	Tennessee	38059	(731) 627-9573
NPS Pharmacy	275 Cumberland Bend	Nashville	Tennessee	37228	(615) 743-1617
Nunally Drug Store	226 Main Street	Baxter	Tennessee	38544	(931) 858-3714
Olde Towne Pharmacy	102 West Jackson Boulevard	Jonesborough	Tennessee	37659	(423) 753-4446
Phipps Pharmacy, Huntingdon	20190 Main Street, East	Huntingdon	Tennessee	38344	(731) 535-3522
Phipps Pharmacy #1	15385 Highland Dr	Mckenzie	Tennessee	38201	(731) 352-0820
Phipps Pharmacy #4	19 Hughes Drive	Jackson	Tennessee	38305	(731) 668-9072
Preferred Pharmacy Sevierville	1024 Middle Creek Road Suite 1	Sevierville	Tennessee	37862	(865) 366-1770
Riggs Drug Jacksboro	2636 Jacksboro Pike	Jackboro	Tennessee	37757	(423) 566-1967
River City Pharmacy	5564 Little Debbie Parkway Suite 102	Ooltewah	Tennessee	37363-4356	(423) 521-7279
Roan Mountain Pharmacy	8251 Highway 19E	Roan Mountain	Tennessee	37687	(423) 772-3591

Roark's Pharmacy	19118 Alberta Street	Oneida	Tennessee	37841	(423) 569-9000
Southland Pharmacy	482 Interstate Drive Suite K	Manchester	Tennessee	37355-3486	(931) 563-0008
Stop-N-Go Discount Pharmacy	3984 Ringgold Road	East Ridge	Tennessee	37412	(423) 468-7161
Terry's Pharmacy Inc	310 East Central Avenue	La Follette	Tennessee	37766	(423) 562-4928
Terry's Pharmacy Jacksboro	2715 Jacksboro Pike	Jacksboro	Tennessee	37757	(423) 563-7455
The Drug Store at South Pittsburg	335 South Cedar Avenue	South Pittsburg	Tennessee	37380	(423) 837-6855
Tinsley Bible Drug Co Inc #316	1224 Gay St	Dandridge	Tennessee	37725-0280	(865) 397-3444
Town and Country Pharmacy	651 BROWN ST	CELINA	Tennessee	38551-4019	(931) 243-6850
US Pharmacy 001	440 Saint Andrews Drive	Murfreesboro	Tennessee	37128	(615) 295-2301
Val-U-Pharmacy	2811 West Market Street	Johnson City	Tennessee	37604	(423) 928-8004
Village Pharmacy	841 E 10th St	Cookeville	Tennessee	38501-1903	(931) 400-0841
WellCare Pharmacy	2130 West Poplar Avenue Suite 104	Collierville	Tennessee	38017	(901) 542-8001
Wilsons Sav-Mor Drugs	265 East Main Street	Newport	Tennessee	37821	(423) 623-3456
Abernathy Drug & Mercantile	318 Main St Unit A	Abernathy	Texas	79311	(806) 298-2222
Alameda Thrifty Pharmacy	4900 Alameda Ave	El Paso	Texas	79905-2802	(915) 772-5331
AM Pharmacy	10401 Anderson Mill Road Suite 112B	Austin	Texas	78750	(512) 270-4899
Anderson's Gibson Pharmacy	600 S Palestine St Suite 100	Athens	Texas	75751-2260	(903) 675-7069
Arapaho Pharmacy	57 Arapaho Village	Richardson	Texas	75080	(972) 235-7133
B & B Pharmacy	300 North Ballard	Pampa	Texas	79065	(806) 665-5788
Bailey's Pharmacy	6700 W Vickery Blvd Suite B	Fort Worth	Texas	76116-9156	(817) 862-7412
Bastrop Medicine Shop	1110 Main Street, Suite A	Bastrop	Texas	78602	(512) 350-4836
Bay Pharmacy	7407 W FM 2147	Horseshoe Bay	Texas	78657	(830) 598-1900
Beach Street Pharmacy	7630 North Beach Street Suite 170	Fort Worth	Texas	76137	(817) 427-8774
Biocare Pharmacy	10603 Bellaire Boulevard Suite B114	Houston	Texas	77072	(281) 530-5800
Bi-Wize Pharmacy	902 Main Street	Friona	Texas	79035	(806) 250-2270
Boomtown Drug	514 South Oklahoma Cutoff	Burkburnett	Texas	76354	(940) 569-5600
BrightMed Pharmacy	9630 Clarewood Drive Suite A-3	Houston	Texas	77036	(713) 772-7700

Brookshire Bros. Pharmacy of Kirbyville	1005 South Margaret	Kirbyville	Texas	75956	(409) 423-2248
Brown's Pharmacy	2021 N Macarthur Blvd Suite 120	Irving	Texas	75061-2170	(972) 254-8156
CareFusion Pharmacy	10 Medical Pkwy Suite 107	Farmers Branch	Texas	75234-7869	(469) 502-3881
Care Rx Pharmacy #1	4501 Hale Ave Suite 1	Harlingen	Texas	78550-9296	(956) 365-4677
Catching's Prescriptions LTD	1900 South Coulter Street Suite F	Amarillo	Texas	79106	(806) 355-2924
Celina Drug	701 North Preston Road Suite 210	Celina	Texas	75009	(972) 382-2832
Center Pharmacy	105 North Smith Street	Pleasanton	Texas	78064	(830) 569-2512
Circle Drug	3211 Robinson Drive	Waco	Texas	76706	(254) 662-0774
City Drug	232 E JEFFERSON	Van Alstyne	Texas	75495	(903) 482-5279
City Drug Store	104 East Belknap	Jacksboro	Texas	76458	(940) 567-5576
Clear Lake Professional Building Pharmacy	251 Medical Center Boulevard, Suite 100	Webster	Texas	77598	(281) 332-2496
Collingsworth Pharmacy	1016 16TH Street	Wellington	Texas	79095	(806) 447-1184
Comfort Pharmacy	404 Highway 27	Comfort	Texas	78013	(830) 995-3300
Cub Drug Inc	116 East Main Street	Olney	Texas	76374-1922	(940) 564-5551
Cypress Pharmacy	17330 Spring Cypress Road, Suite 160	Cypress	Texas	77429	(281) 213-3490
Daniel Drug Inc	3409 W 7th St	Fort Worth	Texas	76107-2718	(817) 332-6386
Davila Pharmacy	1423 Guadalupe Street Suite 108	San Antonio	Texas	78207	(210) 226-5293
Davy Crockett Drug Inc	107 South Fourth Street	Crockett	Texas	75835	(936) 544-2275
DEVINE'S CRAWFORD RX	200 S. Teel Drive	Devine	Texas	78016	(830) 455-5071
DIMMITT PHARMACY	201 NW 2ND ST	DIMMITT	Texas	79027	(806) 647-3151
Dorado Pharmacy	4060 Faudree Road Suite 101	Odessa	Texas	79765	(432) 614-6828
Dripping Springs Pharmacy	100 Commons Road Suite 1	Dripping Springs	Texas	78620	(512) 858-7935
DUFFEY DRUG	311 North Center Street	Franklin	Texas	77856	(979) 828-3536
Dyer Drug Store	133 McKinney Street	Farmersville	Texas	75442	(972) 782-6262
East Austin Medicine Shop	1909 E 38th 1/2 St Suite C2	Austin	Texas	78723-5749	(512) 643-0999
Economy Drug	511 East Garland Street	Grand Saline	Texas	75140	(903) 962-3900
Edgewood Pharmacy	186 S Friendswood Dr	Friendswood	Texas	77546	(281) 993-4779

Elgin Medicine Shop	199 Highway 290 East Suite A	Elgin	Texas	78621	(512) 285-6308
English Pharmacy	2600 10th Street	Wichita Falls	Texas	76309	(940) 723-6060
Express Care Pharmacy	3648 Old Denton Road Suite 104	Carrollton	Texas	75007	(214) 800-5526
Family Pharmacy of Pottsboro	563 W FM 120	Pottsboro	Texas	75076	(903) 786-2006
Fiesta MLK Pharmacy	3230 Martin Luther King	Dallas	Texas	75210	(214) 421-1067
Friendly Pharmacy	2176 East Garrison Street Suite D	Eagle Pass	Texas	78852	(830) 752-6088
Frisco Pharmacy	14550 State Highway 121 Suite 150	Frisco	Texas	75035	(469) 305-7058
Gail's Pharmacy	810 Woodrow Wilson Ray Circle	Bridgeport	Texas	76426	(940) 683-4011
GeneRx Discount Pharmacy	1235 South Josey Lane Suite 533	Carrollton	Texas	75006	(972) 417-8895
Glen Rose Discount Drug	906 North East Big Bend Trail	Glen Rose	Texas	76043	(254) 897-2711
Greenbriar Pharmacy	250 East FM 2449	Ponder	Texas	76259	(940) 479-0111
Green Cross Pharmacy	1305 Airport Freeway Ste 110	Bedford	Texas	76021	(817) 354-7771
Guardian Angel Pharmacy	1537 North Zaragoza Road Suite 1A	El Paso	Texas	79936	(915) 850-0713
Hale Center Clinical Pharmacy	601 Avenue G	Hale Center	Texas	79041	(806) 839-2466
Hansford Pharmacy	710 S Roland St	Spearman	Texas	79081-3499	(806) 659-2226
HAWK PHARMACY	120 West Park	Iowa Park	Texas	76367	(940) 592-4191
Healthville Pharmacy	7215 Mcpherson Rd	Laredo	Texas	78041	(956) 701-3349
Henrietta Pharmacy	124 North Bridge	Henrietta	Texas	76365	(940) 538-4361
Hereford Pharmacy	809 South 25 Mile Avenue	Hereford	Texas	79045	(806) 364-3400
Heritage Pharmacy	3529 Heritage Trace Parkway Suite 141	Keller	Texas	76244	(817) 741-7100
Highland Drug	504 East Avenue Unit E	Alpine	Texas	79830	(432) 837-3931
Hillcrest Pharmacy	1015 Hillcrest Drive, Suite B	Vernon	Texas	76384	(940) 552-5414
Hodges & Sargent Pharmacy	206 South Key Avenue	Lampasas	Texas	76550	(512) 556-3392
Hometown Pharmacy	201 East Commerce	Fairfield	Texas	75840	(903) 389-2541
Hometown Pharmacy	2800 Highway 22 West	Corsicana	Texas	75110	(903) 872-3784
Hometown Pharmacy	310 Charlie Dr	Whitesboro	Texas	76273	(903) 564-1234

Hometown Pharmacy	101 Medical Drive	Palestine	Texas	75801	(903) 729-3100
Hometown Pharmacy Gainesville	1201 Olive St	Gainesville	Texas	76240	(940) 668-7384
Hylands Pharmacy LLC	108 West Oklahoma Avenue	Wheeler	Texas	79096	(806) 826-5561
Jordan Pharmacy	1332 Hwy 16 S	Graham	Texas	76450	(940) 549-1011 Ext 0
Joshua Pharmacy	504 North Broadway	Joshua	Texas	76058	(817) 295-8531
K & K Pharmacy	1411 West American Blvd	Muleshoe	Texas	79347	(806) 272-7511
Kitch Pharmacy	10501 Quaker Avenue Suite 300	Lubbock	Texas	79424-8312	(806) 370-7311
KK's Pharmacy #251	980 North Walnut Creek Drive #118	Mansfield	Texas	76063	(817) 453-5700
KK's Pharmacy #51	2480 W Illinois Avenue	Dallas	Texas	75233	(214) 337-7770
Kraege Drug Store	113 East Main Street	Yorktown	Texas	78164-2030	(361) 564-2216
Lake Worth Pharmacy	4701 BOAT CLUB RD SUITE 115	Fort Worth	Texas	76135	(817) 237-7877
Lamar Plaza Drug Store	1509 South Lamar Boulevard Suite 550	Austin	Texas	78704	(512) 442-6777
Leonard Pharmacy	122 West Collins Street	Leonard	Texas	75452	(903) 587-3363
Lifetime Pharmacy	26795 US Hwy 380 E Suite 800	Aubrey	Texas	76227-7852	(972) 999-1772
Lindberg Pharmacy	5203 S McColl Rd	Edinburg	Texas	78539	(956) 687-6204
Lone Star Pharmacy	1395 Sattler Rd Suite 8	New Braunfels	Texas	78132	(830) 964-3615
Lone Star Pharmacy	13230 Fm 1764 Rd STE B	Santa Fe	Texas	77510	(409) 925-9995
Lynn's La Vega Pharmacy	2401 E Waco Drive	Waco	Texas	76705	(254) 799-4949
Lynn's Pharmacy Hewitt	511 N Hewitt Dr Suite 1	Hewitt	Texas	76643-3093	(254) 666-5000
Magnolia Pharmacy	18230 FM 1488, Suite 100	Magnolia	Texas	77354	(281) 356-9089
Malakoff Pharmacy	409 W Royall Blvd	Malakoff	Texas	75148	(903) 489-1909
Maloney Prescription Pharmacy	1405 Hailey Street	Sweetwater	Texas	79556	(325) 236-6394
Martin Tipton Pharmacy Hillside	5901 Bell St Unit 30	Amarillo	Texas	79109-6263	(806) 310-6255
Martin Tipton Pharmacy LLC	1501 South Tyler Street	Amarillo	Texas	79101	(806) 373-2812
Maxwell Pharmacy	626 North Highway 155	Frankston	Texas	75763	(903) 876-2323
Meadowbrook Pharmacy	6624 Meadowbrook Drive	Fort Worth	Texas	76112	(817) 451-6900

Medcenter Pharmacy	1419 East Bustamante Street	Laredo	Texas	78041	(956) 791-1991
Medical Plaza Pharmacy	615 North Third Street, Suite 1	Longview	Texas	75601	(903) 757-3477
Medicine Chest Pharmacy	814 Montgomery Rd	Graham	Texas	76450	(940) 549-8360
Meridian Pharmacy Group	1110 E Pleasant Run Rd Suite A	Desoto	Texas	75115-4202	(214) 333-1600
Mid Valley Pharmacy	400 E Expressway 83	Mercedes	Texas	78570	(956) 565-4111
Monahans Pharmacy	801 East 4th Street	Monahans	Texas	79756	(432) 943-4212
Moore's Pharmacy	200 S Rachal St	Sinton	Texas	78387-2552	(361) 364-1416
Moore Than Medicine	105 Southwest 2nd Street	Tulia	Texas	79088	(806) 995-3551
MS Pharmacy	27721 Tomball Parkway Suite 400	Tomball	Texas	77375	(832) 698-4522
Norman's Pharmacy	2105 South Day Street	Brenham	Texas	77833-5512	(979) 836-5264
NuCare Pharmacy	6050 Lake Worth Boulevard	Lake Worth	Texas	76135	(817) 238-7773
Ochoa's Pharmacy Central	1002 South 10TH Avenue Suite A	Edinburg	Texas	78539	(956) 381-0967
Palacios Prescription Shoppe	321 Main Street	Palacios	Texas	77465-5461	(361) 972-3608
Palmer Pharmacy Plus	2731 West Northwest Highway Suite 105	Dallas	Texas	75220	(214) 765-9238
Parkers City Pharmacy	1005 E Court St	Seguin	Texas	78155	(830) 379-1450
Payne Family Pharmacy	200 South Main Street	Floydada	Texas	79235	(806) 983-5111
PCF Pharmacy	2615 Strawberry Road	Pasadena	Texas	77502	(713) 947-6767
Pecan Discount Drug	9203 Plantation Drive Suite 1	Granbury	Texas	76049	(817) 573-9344
Pelzel's Hometown Pharmacy	1340 North Highway 377, Suite 100	Pilot Point	Texas	76258	(940) 686-0123
Peoples Pharmacy #1	4018 North Lamar Boulevard	Austin	Texas	78756	(512) 459-9090
Peoples Pharmacy #2	3801 B South Lamar Boulevard	Austin	Texas	78704	(512) 444-8866
Peoples Pharmacy #3	4201 Westbank Drive	Austin	Texas	78746	(512) 327-8877
Peoples Pharmacy #4	13860 US Hwy 183 N Suite C	Austin	Texas	78750	(512) 219-9499
Perrone Legend Pharmacy	3921 Benbrook Highway	Fort Worth	Texas	76116	(817) 738-2135
PETS AND PEOPLE PHARMACY	9215 BROADWAY ST STE 113 SUITE 113	PEARLAND	Texas	77584-8987	(281) 741-5825

Pharmacia Sana	102 East Danielsdale Road Suite 100	Duncanville	Texas	75137	(469) 513-2499
Pharmcare	1834 Broadway Street Suite 106	Pearland	Texas	77581	(281) 996-7500
Pipeline Pharmacy	328 East Pipeline Road	Hurst	Texas	76053- 5831	(817) 494-3606
Pleasant Grove Pharmacy	3302 Richmond Road	Texarkana	Texas	75503- 2134	(903) 832-4545
Popular Pharmacy	5326 East US Highway 83 Suite A # 5	Rio Grande City	Texas	78582- 9409	(956) 317-1112
Popular Pharmacy 3	2849 East Grant Street	Roma	Texas	78584- 8914	(956) 847-9000
Powers Pharmacy No 1 Inc	702 West Houston Street	Linden	Texas	75563	(903) 756-7923
Prescription Shop Inc	909 E Holland Ave	Alpine	Texas	79830	(432) 837-3498
Preston Road Apothecary Inc	9301 North Central Parkway Suite 110	Dallas	Texas	75231	(214) 361-6172
Preston Road Pharmacy	6901 Preston Road	Dallas	Texas	75205	(214) 521-9991
Primemed Pharmacy	10500 Vista Del Sol Dr Suite A	El Paso	Texas	79925- 7925	(915) 595-1300
QUALITY CARE PHARMACY	2300 West FM 544 Suite 130	Wylie	Texas	75098	(972) 442-5333
Red's Pharmacy, LLC	3102 Garrett Drive	Perryton	Texas	79070	(806) 435-3759
Richard's Pharmacy	1112 East Griffin Parkway Suite B	Mission	Texas	78572	(956) 581-4200
Richard's Pharmacy	605 N Main Street Suite E	Donna	Texas	78537	(956) 464-4131
Richard's Pharmacy	4630 S Closner Blvd	Edinburg	Texas	78539	(956) 289-1880
Ridgmar Pharmacy	2524 Mall Circle	Fort Worth	Texas	76116	(817) 737-7377
Robinson Family Pharmacy	213 North Pinecrest Drive	Atlanta	Texas	75551	(903) 796-1730
Rodger's Pharmacy	1909 Grand Avenue	Liberty	Texas	77575	(936) 776-5228
S & J Argyle Pharmacy	101 Old Town Boulevard Suite 102	Argyle	Texas	76226	(940) 464-4500
S&J Pharmacy	801 West Chapman Drive Suite 100	Sanger	Texas	76266	(940) 458-4448
San Augustine Drug Co.	104 East Columbia	San Augustine	Texas	75972	(936) 275-3401
Savon Drugs	123 Leveridge	East Bernard	Texas	77435	(979) 335-4810
Schulz and Wroten Pharmacy	122 N Washington St	Beeville	Texas	78102	(361) 358-1150
Shavano Oaks Pharmacy	12602 TOEPPERWEIN RD STE 118	San Antonio	Texas	78233	(210) 448-9080

Shavano Oaks Pharmacy @ Westover Hills	3903 Wiseman Blvd Suite 101	San Antonio	Texas	78251-4401	(210) 441-4501
Southern Star Pharmacy	6101 WINDHAVEN PARKWAY STE 125	PLANO	Texas	75093	(844) 290-7034
Spring Green Pharmacy 1	6144 Sienna Ranch Road Suite 200	Missouri City	Texas	77459-7120	(346) 341-7148
Stockton Pharmacy	616 W Dickinson Blvd	Fort Stockton	Texas	79735	(432) 336-2200
Sullivan Pharmacy	1140 Grand Avenue	Bacliff	Texas	77518	(281) 339-4577
Super Value Pharmacy	720 North Industrial Boulevard	Euless	Texas	76039	(817) 283-5308
Texas Professional Pharmacy-Magnolia	18602 FM 1488 STE 700	Magnolia	Texas	77355	(281) 356-2216
The Drug Store	19 County Road 4114 Suite 1	Pittsburg	Texas	75686	(903) 708-7500
The Med-Shop Pharmacy	111 East 2nd Street	Hughes Springs	Texas	75656	(903) 639-3508
Thornhill's Pharmacy	6823 82nd Street Suite 600	Lubbock	Texas	79424	(806) 368-8400
Thornhill's Pharmacy	600 8th Street	Shallowater	Texas	79363-5726	(806) 832-0300
Thurman's Pro-Med Pharmacy	402 North Madison Avenue	Mount Pleasant	Texas	75455	(903) 572-6337
Thurman's Pro-Med Pharmacy Morris County	201 Main Street	Naples	Texas	75568-9765	(903) 897-0011
Total Pharmacy Ennis	329 N SHILOH RD	Garland	Texas	75042	(972) 276-7071
Town and Country Drug	2616 N Grandview	Odessa	Texas	79761-1608	(432) 366-2868
Trinity Pharmacy	1925 East Rosemeade Parkway	Carrollton	Texas	75007-2499	(972) 492-4411
Tru Med Pharmacy	720 Avenue F N Suite 1	Bay City	Texas	77414	(979) 429-4044
Tyler Rx Pharmacy	2415 East 5th Street	Tyler	Texas	75701	(903) 593-1400
Valu-Rite Pharmacy	709 Woodrow Wilson Ray Circle	Bridgeport	Texas	76426	(940) 683-2950
Vina Pharmacy	11207 N Lamar Blvd Suite A	Austin	Texas	78753-3056	(512) 977-8844
VIP Pharmacy	10970 BEN CREWSHAW DR STE 107	El Paso	Texas	79935	(915) 629-2020
WeCare Pharmacy	4732 Sugar Grove Blvd Suite 203	Stafford	Texas	77477	(281) 783-8300
Whitewright Pharmacy	2065 Beasley Blvd, Suite 200	Whitewright	Texas	75491	(903) 364-5537

Yoakum Discount Pharmacy	1200 Carl Ramert Drive Suite A	Yoakum	Texas	77995	(361) 293-6881
Yoakum Discount Pharmacy	210 Nelson Street, Suite E	Yoakum	Texas	77995	(361) 741-7455
Central Valley Community Pharmacy	152 West 1500 North	Nephi	Utah	84648	(435) 623-3700
FAMILY PLAZA PHARMACY	3570 W 9000 S STE 150	WEST JORDAN	Utah	84088-8872	(801) 569-0175
Island View Pharmacy	2038 West 1900 South	Syracuse	Utah	84075	(801) 773-7899
Mears Pharmacy	1050 Shepard Lane Suite 1	Farmington	Utah	84025-2716	(801) 447-9484
Medical Center Pharmacy	1050 East South Temple	Salt Lake City	Utah	84102	(801) 350-8140
North View Pharmacy	2121 North Robbins Drive	Layton	Utah	84041	(801) 773-5666
Park View Pharmacy	425 West 100 South	Layton	Utah	84041	(801) 682-8708
Professional Plaza Pharmacy, Inc	2065 North Robins Drive	Layton	Utah	84041-1133	(801) 773-3863
Ridge View Pharmacy	3443 W 5600 South	Roy	Utah	84067	(801) 825-6400
Salem Hills Pharmacy	118 N Main	Salem	Utah	84653	(801) 723-0570
Salmon Pharmacy	865 N 980 W	Orem	Utah	84057	(801) 225-2150
Sky View Pharmacy	1750 East 3100 North	Layton	Utah	84040	(385) 405-2252
Stucki Family Pharmacy	568 West Telegraph Street #3	Washington	Utah	84780-1596	(435) 627-8848
The Apothecary Shoppe #1	82 S 1100 E Suite 104	Salt Lake City	Utah	84102-1525	(801) 521-6353
Tibbitts Family Pharmacy	2940 North Church Street, Suite 201	Layton	Utah	84040	(801) 771-0363
University Pharmacy	1320 E 200 South	Salt Lake City	Utah	84102	(801) 582-7624
Walker Drug	290 South Main Street	Moab	Utah	84532	(435) 259-5959
Carlin Springs Pharmacy	611 South Carlin Springs Road Suite 105	Arlington	Virginia	22204	(703) 379-4000
Claypool Hill Pharmacy	12252 Governor George C Peery hwy	Pounding Mill	Virginia	24637	(276) 963-3502
Colonial Pharmacy	7510 Mechanicsville Pike	Mechanicsville	Virginia	23111	(804) 746-7997
Cornerstone Pharmacy	205 Kilbourne Avenue	Appalachia	Virginia	24216	(276) 565-3434
Dans Wellness Pharmacy	418 Garrisonville Road Suite 100	Stafford	Virginia	22554	(540) 657-0006
Denbigh Pharmacy	13349 Warwick Boulevard	Newport News	Virginia	23602	(757) 877-0253
Dillwyn Pharmacy	1054 Main Street	Dillwyn	Virginia	23936	(434) 983-2013

Elkton Family Pharmacy	111 S Stuart Ave	Elkton	Virginia	22827-1525	(540) 298-9090
Family Drug Center	517 West Front Street	Coeburn	Virginia	24230	(276) 395-2257
Family Drug Center	110 West Main Street Suite 1	Lebanon	Virginia	24266	(276) 889-1919
Fork Union Pharmacy	4316B James Madison Highway	Fork Union	Virginia	23055	(434) 842-3208
Godwin Pharmacy	3061 Godwin Blvd Suite 109	Suffolk	Virginia	23434-6662	(757) 861-0080
Greene Pharmacy	331 Main Street	Stanardsville	Virginia	22973	(434) 985-3424
Haysi Drug Center	23906 Dickenson Highway	Haysi	Virginia	24256	(276) 865-5135
Hiddenwood Pharmacy, Inc	35 Hiddenwood Shopping Center	Newport News	Virginia	23606	(757) 595-1151
Hometown Pharmacy	196 Amelon Square	Madison Heights	Virginia	24572-5990	(434) 929-1000
Hometown Pharmacy	199 Old Courthouse Rd	Appomattox	Virginia	24522	(434) 352-3784
Jefferson Good Neighbor Pharmacy	194 B Turkeysag Trail	Palmyra	Virginia	22963	(434) 589-7902
Jones & Counts Pharmacy	251 Main Street	Haysi	Virginia	24256	(276) 865-5560
Lawrence Pharmacy	1156 North George Washington Highway	Chesapeake	Virginia	23323	(757) 487-3458
Lee Davis Pharmacy	7016 Lee Park Rd Suite 400	Mechanicsville	Virginia	23111	(804) 730-9200
Loudoun Community Pharmacy	19415 Deerfield Avenue Suite 116	Lansdowne	Virginia	20176-8470	(571) 499-4303
Lovettsville Pharmacy	11 Town Center Dr Suite 195	Lovettsville	Virginia	20180-8569	(540) 306-5839
Madison Drug Company Inc	114 North Main Street	Madison	Virginia	22727	(540) 948-4400
Marshall's Drug Store	50 Cross Street	Urbanna	Virginia	23175	(804) 758-5344
McGuire Park Pharmacy	2106 East Main Street	Richmond	Virginia	23223	(804) 344-4444
Medical Park Pharmacy	1503 Slate Creek Road	Grundy	Virginia	24614	(276) 935-6455
Montpelier Pharmacy	17128 Mountain Road	Montpelier	Virginia	23192	(804) 883-6363
Olde Virginia Pharmacy, Inc	1592 Fincastle St Tpke	Tazewell	Virginia	24651	(276) 988-7977
Orange Pharmacy #2	130 W Main St	Orange	Virginia	22960	(540) 661-5006
Purcellville Pharmacy	609 East Main Street Suite Q	Purcellville	Virginia	20132	(540) 751-9750
REMINGTON DRUG CO	207 East Main Street	Remington	Virginia	22734	(540) 439-3247
Scottie Pharmacy	1951 Second Street	Richlands	Virginia	24641	(276) 963-0284

Smith's Pharmacy	111 South Broad Street	Kenbridge	Virginia	23944	(434) 676-2266
Spencers Drug Store Inc	100 North Main Street	Blackstone	Virginia	23824-1424	(434) 292-3132
Stone Ridge Pharmacy	24560 Southpoint Dr Unit 190	Aldie	Virginia	20105-3505	(703) 345-1046
Strasburg Pharmacy	33820 Old Valley Pike Suite 7	Strasburg	Virginia	22657-3793	(540) 465-5001
Stuarts Draft Family Pharmacy	2929 Stuarts Draft Highway Suite 101	Stuarts Draft	Virginia	24477	(540) 337-3776
Temple Avenue Pharmacy	2000 Snead Avenue	Colonial Heights	Virginia	23834-2428	(804) 526-1000
Top Notch Family Pharmacy	943 Preston Avenue	Charlottesville	Virginia	22903	(434) 995-5595
True Blue Pharmacy Inc	12235 Grapefield Road Suite 1	Bastian	Virginia	24314	(276) 688-2424
Valley Pharmacy	351 Valley Health Way Suite 210	Front Royal	Virginia	22630	(540) 635-0736
Valley Pharmacy	190 Campus Blvd Suite 110	Winchester	Virginia	22601	(540) 536-8899
Walnut Hill Pharmacy	1950 South Sycamore Street	Petersburg	Virginia	23805	(804) 733-7711
Westbury Apothecary	8903 Three Chopt Road	Henrico	Virginia	23229	(804) 285-3428
Westwood Pharmacy	5823 Patterson Avenue	Richmond	Virginia	23226	(804) 288-1933
Your Gordonsville Pharmacy	400 Gordon Avenue Ste D	Gordonsville	Virginia	22942	(540) 832-0000
Family Drug	1755 Lovers Gap Rd	Vansant	Virginia	24656	(276) 597-2419
Davenport Pharmacy	525 Morgan St	Davenport	Washington	99122	(509) 725-1151
Don's Pharmacy	1151 Water Street	Port Townsend	Washington	98368	(360) 385-0969
Fairway Drug	1758 Front Street Suite 106	Lynden	Washington	98264	(360) 354-1226
Family Pharmacy	7315 212th St W Suite 100	Edmonds	Washington	98026-7610	(425) 778-7778
Hart and Dilatush Pharmacy	601 West Riverside Suite 140	Spokane	Washington	99201	(509) 624-2111
Kelley-Ross Pharmacy at the Polyclinic	904 7th Avenue Suite 103	Seattle	Washington	98104	(206) 324-6990
LAKETOWN PHARMACY	1550 S PIONEER WAY STE 105	MOSES LAKE	Washington	98837	(509) 765-8891
Lincoln Pharmacy	821 South 38th Street	Tacoma	Washington	98418	(253) 473-1155
Neil's Pharmacy	512 West Franklin	Shelton	Washington	98584	(360) 426-3327
Rx Pharmacy	800 Swift Boulevard Suite 140	Richland	Washington	99352-3559	(509) 713-7444
SOUTH KITSAP PHARMACY	1397 OLNEY AVE SE STE 109	PORT ORCHARD	Washington	98366	(360) 876-5594
Sumas Drug	1143 Cherry Street	Sumas	Washington	98295	(360) 988-2681

Tekoa Pharmacy	124 North Crosby Street	Tekoa	Washington	99033	(509) 284-4205
Tieton Village Drug	3708 Tieton Drive	Yakima	Washington	98902	(509) 966-6850
Tri-Area Pharmacy	93 Oak Bay Road	Port Hadlock	Washington	98339	(360) 379-9800
Valley Drug	208 East Main Street	Everson	Washington	98247	(360) 966-3481
Whole Health Pharmacy	800 South Pearl Street Suite 1	Ellensburg	Washington	98926-3646	(509) 925-6800
Tallmans Pharmacy	4 West Main Street	Walla Walla	Washington	99362	(509) 525-1010
Bison Rx Inc	20442 Charleston Road	Buffalo	West Virginia	25033	(304) 937-3000
Charlie's Pharmacy of Mullens LLC	224 Howard Avenue	Mullens	West Virginia	25882	(304) 294-5447
Clark's Family Pharmacy Inc	4501 Maccorkle Ave SW Suite 101	South Charleston	West Virginia	25309-1444	(304) 766-8484
Cox Family Pharmacy	2012 Garfield Avenue Suite C	Parkersburg	West Virginia	26101	(304) 893-9100
Crab Orchard Pharmacy	1299 Robert C Byrd Dr	Crab Orchard	West Virginia	25827	(304) 253-7474
Four Seasons Pharmacy	300 Morrison Drive	Princeton	West Virginia	24740-2765	(304) 487-0015
Goodykoontz Drug Store	2924 E Cumberland Rd	Bluefield	West Virginia	24701	(304) 325-7121
Griffith and Feil Drug	1405 Chestnut Street	Kenova	West Virginia	25530	(304) 453-2381
Hurley Drug Company Inc	210 Logan Street	Williamson	West Virginia	25661	(304) 235-3535
Iaeger Pharmacy	4381 Coal Heritage Rd, US Rte 52	Iaeger	West Virginia	24844	(304) 938-2819
J & B Drugstore	352 Main Street	Grantsville	West Virginia	26147	(304) 354-7737
Main Street Pharmacy	435 West Main Street Suite 1	Oak Hill	West Virginia	25901	(304) 465-7200
Med Rx	620 National Rd Suite 400	Wheeling	West Virginia	26003	(304) 232-4984
Moundsville Pharmacy	118 North Lafayette Avenue	Moundsville	West Virginia	26041	(304) 845-0390
New Martinsville Pharmacy	193 N STATE ROUTE 2	New Martinville	West Virginia	26155	(304) 455-2171
Pattersons Drug Store	311 Medical Ct Unit A	Martinsburg	West Virginia	25401	(304) 267-8903
Pine Grove Pharmacy	13030 Shortline Hwy	Pine Grove	West Virginia	26419	(304) 889-3131
Reed's Pharmacy 5	2830 Northwestern Pike	Capon Bridge	West Virginia	26711	(304) 856-2901
Renegade Pharmacy Inc	18 Logan Street	Oceana	West Virginia	24870	(304) 682-0444
Riverside Pharmacy	22 Larry Joe Harless Drive	Gilbert	West Virginia	25661	(304) 664-3343
Shepherdstown Pharmacy	7670 Martinsburg Pike Suite 2	Shepherdstown	West Virginia	25443	(304) 876-9966
Sistersville Pharmacy	312 Diamond St	Sistersville	West Virginia	26175	(304) 652-3711

Spring Mills Pharmacy	5759 Williamsport Pike Suite 105	Matinsburg	West Virginia	25404	(681) 242-3997
Waterfront Family Pharmacy	215 Don Knotts Boulevard Suite 120	Morgantown	West Virginia	26501	(304) 225-7979
Brownstone Rx	114 West Bayfield Street	Washburn	Wisconsin	54891	(715) 373-5588
Crivitz Pharmacy	710 Main Avenue	Crivitz	Wisconsin	54114	(715) 854-7425
Eannelli Pharmacy	405 Water Street	Prairie Du Sac	Wisconsin	53578	(608) 643-3396
Elkhorn Pharmacy	603 E GENEVA ST	ELKHORN	Wisconsin	53121	(262) 723-8444
Gwidt Pharmacy	203 East Westgor Avenue	Wittenberg	Wisconsin	54499-0253	(715) 253-2164
Heike Pharmacy	213 West Main Street	Durand	Wisconsin	54736	(715) 672-5202
Infinity Pharmacy	2700 South 60th Street	Milwaukee	Wisconsin	53219	(414) 988-0008
Lakeside Pharmacy	536 5th Ave	Antigo	Wisconsin	54409	(715) 623-2631
Manitowoc Pharmacies	919 South 8th Street	Manitowoc	Wisconsin	54220	(920) 684-6789
Nicolet Pharmacy	15481 Commercial Rd	Lakewood	Wisconsin	54138	(715) 276-3646
Oconto Falls Pharmacy	323 East Highland Drive	Oconto Falls	Wisconsin	54154	(920) 848-3721
Oconto Pharmacy	1008 Main Street	Oconto	Wisconsin	54153-0073	(920) 834-4455
Peshtigo Pharmacy	220 French Street	Peshtigo	Wisconsin	54157	(715) 582-4237
Pulaski Pharmacy	121 North Saint Augustine Street	Pulaski	Wisconsin	54162	(920) 822-3011
Smith Pharmacy	1800 Freedom Road Unit D	Little Chute	Wisconsin	54140	(920) 788-8888
Sniteman Pharmacy	N3708 River Ave STE A	Neillsville	Wisconsin	54456-7218	(715) 743-3500
The Apothecary	1470 Webb Street	Cumberland	Wisconsin	54829	(715) 822-2424
UPTOWN PHARMACY & WELLNESS	3512 N OAKLAND AVE	SHOREWOOD	Wisconsin	53211-2701	(414) 372-0700
Valucare Center	1378 Main Street	Marinette	Wisconsin	54143	(715) 732-0717
WellCreek Pharmacy Middleton	2532 Allen Blvd	Middleton	Wisconsin	53562-2212	(608) 203-8090
Welltopia Pharmacy	136 North Main Street	Thiensville	Wisconsin	53092-1606	(262) 429-9429
Yellow River Pharmacy	7438 Main Street West	Webster	Wisconsin	54893	(715) 866-8644
City Drug Pharmacy	1722 Carey Ave	Cheyenne	Wyoming	82001-4420	(307) 514-0200
Palace Pharmacy	1255 Main St	Lander	Wyoming	82520	(307) 332-2270
Powell Drug	140 North Bent Street	Powell	Wyoming	82435	(307) 754-2031
Ricker Pharmacy	1801 Big Horn Avenue	Worland	Wyoming	82401	(307) 347-2281
Shatto's Frontier Drug	1202 East Richards Street	Douglas	Wyoming	82633	(307) 358-5077

South Street Pharmacy	1456 South Street	Wheatland	Wyoming	82201	(307) 322-2486
-----------------------	-------------------	-----------	---------	-------	----------------

FRANCHISEES THAT LEFT THE SYSTEM (2025)

Transfers

Account Name	Business Address	Business Address City	Business Address State	Zip Code	Business Phone
Kilgore Express Pharmacy #6	1614 Glenn Blvd SW	Fort Payne	Alabama	35968-3522	(256) 845-3402
Medi-Quik Pharmacy	1531 East Main Street	Booneville	Arkansas	72927	(479) 675-3900
Oakdale Pharmacy	5400 Balboa Boulevard Suite 100	Encino	California	91316	(818) 788-0770
Newport Lido Pharmacy LTC	351 Hospital Road	Newport Beach	California	92663	(949) 764-6580
Orange Plaza Pharmacy	1010 West La Veta Avenue Suite 130	Orange	California	92868-4301	(714) 550-9798
Meiji Pharmacy	1630 W Redondo Bch Blvd Suite 14	Gardena	California	90247	(310) 538-2885
Hendricks Pharmacy	137 North Harvard Avenue	Claremont	California	91711-4717	(909) 624-1611
Jonathan's Pharmacy	19341 Bear Valley Road Suite 103	Apple Valley	California	92308	(760) 983-2599
Fullerton Pharmacy	1820 Fullerton Avenue Suite 105	Corona	California	92881-3160	(951) 496-4222
Danielson Pharmacy	77 Westcott Rd	Danielson	Connecticut	06239-2929	(860) 774-0050
ROTARY DRUG	1030 BARNUM AVE	STRATFORD	Connecticut	06614	(203) 378-9394
Danielson Pharmacy	77 Westcott Rd	Danielson	Connecticut	06239-2929	(860) 774-0050
Cypress Wellness Pharmacy	9451 Cypress Lake Dr	Fort Myers	Florida	33919	(239) 481-7322
Allcare Pharmacy & Healthcare Services	112 South Oxley Drive	Lyons	Georgia	30436	(912) 526-3200
Wyatt's Pharmacy	10671 Veterans Memorial Highway	Lithia Springs	Georgia	30122	(770) 948-8825
Curry's Family Pharmacy	1275 North 7th Street	Riverton	Illinois	62561	(217) 629-7001
Seifert Drug	230 South Main Street	Elkhart	Indiana	46516	(574) 295-4333
Seifert Drug #2	100 N Elkhart St	Wakarusa	Indiana	46573	(574) 862-1454
Seifert Drug #3	2102 N Main St Suite 100	Nappanee	Indiana	46550	(574) 773-8280
Summit Pharmacy	300 West Burlington Avenue	Fairfield	Iowa	52556-3241	(641) 472-7987
Newman Community Rx 1430	1400 W 12th Ave	Emporia	Kansas	66801	(620) 342-1242

Walter's Family Pharmacy	604 South 12th Street	Murray	Kentucky	42071	(270) 753-7688
Care More Pharmacy	151 Dorton-Jenkins Highway	Dorton	Kentucky	41520	(606) 639-2273
TYLERTOWN PHARMACY LLC	201 HOSPITAL DR	TYLERTOWN	Mississippi	39667-2019	(601) 222-1770
Olssons Pharmacy	576 Lafayette Avenue	Hawthorne	New Jersey	07506-2400	(973) 427-1700
Galloway-Sands Pharmacy #2	1513 North Howe Street Suite 8	Southport	North Carolina	28461	(910) 454-9090
Kratzer's Hometown Pharmacy Mt Orab	155 North Point Drive	Mount Orab	Ohio	45154	(937) 444-0135
Zeigler Pharmacy	159 W Main St	Wilmington	Ohio	45177	(937) 382-0921
Delta of Ellore	2611 Cleveland St	Ellore	South Carolina	29047	(843) 761-5255
Delta of Moncks Corner	402 East Main St	Moncks Corner	South Carolina	29461	(843) 761-5255
Delta of Charleston #3	346 East Bay St	Charleston	South Carolina	29401	(843) 937-0960
Dottie's Pharmacy	325 Folly Road Suite 101	Charleston	South Carolina	29412	(843) 501-9500
Belew Drugs Asheville Highway	8622 Asheville Highway	Knoxville	Tennessee	37924-4107	(865) 933-3441
Belew Drug Choto	1616 Choto Markets Way	Knoxville	Tennessee	37922-5760	(865) 766-4424
Belew Drugs	2021 N Broadway St	Knoxville	Tennessee	37917	(865) 525-4189
Thornhill's Pharmacy	6823 82nd Street Suite 600	Lubbock	Texas	79424	(806) 368-8400
Thornhill's Pharmacy	600 8th Street	Shallowater	Texas	79363	(806) 832-0300
English Pharmacy	2600 10th Street	Wichita Falls	Texas	76309	(940) 723-6060
Denbigh Pharmacy	13349 Warwick Boulevard	Newport News	Virginia	23602	(757) 877-0253
*Elkton Family Pharmacy	111 South Stuart Avenue	Elkton	Virginia	22827	(540) 298-9090
Orange Pharmacy	130 West Main Street	Orange	Virginia	22960	(540) 661-5006
Davenport Good Neighbor Pharmacy	525 Morgan Street	Davenport	Washington	99122	(509) 725-1151
FAMILY PHARMACY	7315 212th Street Southwest Suite 100	Edmonds	Washington	98026	(425) 778-7778
Riverside Pharmacy	22 Larry Joe Harless Drive	Gilbert	West Virginia	25621	(304) 664-3343
Riverside Pharmacy	22 Larry Joe Harless Drive	Gilbert	West Virginia	25621	(304) 664-3343

Terminations

Account Name	Business Street Address	Business Address City	Business Address State	Zip Code	Business Phone
Blood Pharmacy	410 Main Street	Neligh	Nebraska	68756	(402) 887-5426

Blood Pharmacy Tilden	103 East 2nd Street	Tilden	Nebraska	68781	(402) 368-5385
Hazel's Compounding Rx Pharmacy	2404 Smith Ranch Rd Suite 100	Pearland	Texas	77584-5120	(713) 340-0202
Petrossian Pharmacy	2701 West Alameda Avenue Suite 100	Burbank	California	91505	(818) 433-7166
Memorial Medical Center Pharmacy	9806 Venice Boulevard	Culver City	California	90232	(310) 837-6158
PharmaRx	11382 Miramar Parkway	Miramar	Florida	33025-5805	(786) 418-5383
Clark County Pharmacy	716 Boone Avenue	Winchester	Kentucky	40391	(859) 744-3350
BestRx	1103 North Main Street Suite E	Fountain Inn	South Carolina	29644-1336	(864) 210-1811
Eddie's Pharmacy	8408 Beverly Boulevard	Los Angeles	California	90048	(310) 358-2400
COLUMBINE DRUG	3515 Mountain Lion Drive	Loveland	Colorado	80537	(970) 663-4600
Health Plus Pharmacy	3104 West Mile 5 Road Suite 2	Mission	Texas	78574	(956) 424-3535
KwikRx Pharmacy	10322 South Harlem Avenue	Palos Hills	Illinois	60455	(708) 598-0808
Medical Arts Pharmacy	1320 Maricopa Highway	Ojai	California	93023	(805) 646-7211
Edmonds Pharmacy	7631 212th Street Southwest Suite D100	Edmonds	Washington	98026-7565	(425) 977-4880
Reeves Sain Drug Store	1801 Memorial Blvd.	Murfreesboro	Tennessee	37129	(615) 896-5731
Kilgore Express Pharmacy #6	1614 Glenn Blvd SW	Fort Payne	Alabama	35968-3522	(256) 845-3402
Bay Shore Pharmacy	93 A 4th Street	Suttons Bay	Michigan	49682	(231) 271-6111
Dilworth Drug	1300-B East Boulevard	Charlotte	North Carolina	28203	(704) 910-4288
Barrachina Pharmacy	2004 E Expressway 83 Suite 2	Weslaco	Texas	78599	(956) 405-3089
SALEM PHARMACY	3273 SALEM ROAD	COVINGTON	Georgia	30016	(770) 274-6561
RMC Pharmacy Day Street	6405 Day Street	Riverside	California	92507	(951) 899-8188
Kressaty's Pharmacy	1068 Ringwood Ave	Haskell	New Jersey	07420-1441	(973) 835-1627
Hometown Old Country Pharmacy Inc	8534 Ridge Rd	New Port Richey	Florida	34654	(727) 816-9770
Arrow Pharmacy	317 Bankhead Highway Suite A	Carrollton	Georgia	30117-2497	(770) 858-5767
Curex Pharmacy	900 Kern Ave Ste. A	Taft	California	93268	(661) 745-4115
A & O Peninsula Pharmacy	1860 El Camino Real Suite 108	Burlingame	California	94010	(650) 692-6569
Naples Pharmacy LLC	49 8th St N Suite A	Naples	Florida	34102	(239) 231-3026

Keller Apothecary	5346 Devonshire Avenue	Saint Louis	Missouri	63109	(314) 352-5201
Holly Springs Pharmacy	648 Holly Springs Road	Holly Springs	North Carolina	27540	(919) 346-6689
Akers United Drug	406 North Park Street	Chewelah	Washington	99109	(509) 935-8441
Royals Pharmacy	20727 Wyoming Street	Ferndale	Michigan	48220	(248) 566-0116
Sarasota Discount Pharmacy	110 North Lime Avenue	Sarasota	Florida	34237	(941) 444-6888
Cayucos Pharmacy	72 South Ocean Avenue	Cayucos	California	93430	(805) 995-3538
Spring Green Pharmacy	1443 FM 1463 Rd Suite 650	Katy	Texas	77494-5479	281-769-1444
Prescription Shop of Stuart	622 Colorado Avenue	Stuart	Florida	34994-3087	(772) 287-3443
FAMILY PHARMACY	7315 212th Street Southwest Suite 100	Edmonds	Washington	98026	(425) 778-7778
Chans Pharmacy Plus	2092 North University Drive	Pembroke Pines	Florida	33024	(954) 367-3296
Tustin Pharmacy	13400 Newport Avenue	Tustin	California	92780	(714) 731-1344
KEX RX	807 MAIN ST.	ATCHISON	Kansas	66002	9133675252
Lowe's Pharmacy	1536 East Broadway	Maryville	Tennessee	37804	(865) 982-3020
ElixRx	1090 Keolu Drive Suite 112/113	Kailua	Hawaii	96734	(808) 260-9894
Pharmax Pharmacy #1117	1117 Main Street	Imperial	Missouri	63052	(636) 464-1100
Carlisle Pharmacy	771 Central Avenue	Carlisle	Ohio	45005	(937) 806-8470
Belleville Pharmacy	338 Washington Avenue	Belleville	New Jersey	07109	(973) 759-1956
Pawleys Island Pharmacy of Litchfield	115 Willbrook Boulevard Unit A	Pawleys Island	South Carolina	29585	(843) 314-0498
Danielson Pharmacy	77 Westcott Rd	Danielson	Connecticut	06239-2929	(860) 774-0050
Northern Maine Medical Center Pharmacy	104 Main Street	Madawaska	Maine	04756	(207) 728-7200
St. Matthews Community Pharmacy	200 N Hurstbourne Pkwy Suite 174	Louisville	Kentucky	40222-5138	(502) 690-4462
Advanced Rx Pharmacy 060	1400 Donelson Pike Ste A15	Nashville	Tennessee	37217	(615) 866-6292
HCA Pharmacy & Medical Equipment	1113 West Lexington Avenue	Winchester	Kentucky	40391	(859) 745-4445
Galloway Sands Pharmacy	58 Physicians Drive Suite 5	Supply	North Carolina	28462	(910) 754-7200
Pharmax Pharmacy #1160	116 Walnut Street	Festus	Missouri	63028	(636) 937-7997
Seashore Drugs	1304 Highway 17 North	Little River	South Carolina	29566	(843) 281-9797
Trenton Avenue Pharmacy	3803 Ventnor Ave	Atlantic City	New Jersey	08401	(609) 345-8901

Arbor Lakes Pharmacy	1549 Holmes Road	Ypsilanti	Michigan	48198	(734) 340-6050
5 Minute Pharmacy Ala Moana	725 Kapiolani Boulevard Suite C111	Honolulu	Hawaii	96813-6016	(808) 797-2905
Corner Pharmacy	102 West Main Street	Barnesville	Ohio	43713	(740) 425-2651
Schwieterman Pharmacy	1302 Defiance Street	Wapakoneta	Ohio	45895	(419) 738-5959
Central Rx Pharmacy	50 Eagle Rock Way Suite C	Brentwood	California	94513-4941	(925) 240-9777
Acts Pharmacy and Healthcare Services	1901 South Union Avenue Building B Suite 2011	Tacoma	Washington	98405	(253) 272-0324
Denbigh Pharmacy	13349 Warwick Boulevard	Newport News	Virginia	23602	(757) 877-0253
Cano Pharmacy 5	5190 North West 167th Street Suite 100	Miami Lakes	Florida	33014	(786) 870-1170
Pharmax Pharmacy #1365	60 Nesbit Drive Ste A	Bonne Terre	Missouri	63628	(573) 358-3301
Habersham Drug	638 Historic Highway 441 Suite A	Demorest	Georgia	30535	(706) 754-4128
Riggs Drug	502 West Central Avenue	La Follette	Tennessee	37766	(423) 562-5235 Ext 223
Yorke Pharmacy	5524 New Falls Road	Levittown	Pennsylvania	19056	(215) 945-5700
Pharmax Pharmacy #1302	610 East High Street	Potosi	Missouri	63664	(573) 438-2189
Exton Pharmacy at Marchwood	1 Marchwood Road	Exton	Pennsylvania	19341	(610) 363-9444
Katy Medical Complex Pharmacy	21700 Kingsland, Suite 105	Katy	Texas	77450	(281) 829-6497
Coats Pharmacy Inc	393 N McKinley St	Coats	North Carolina	27521	(910) 897-8500
Cano Pharmacy	8300 West Flagler Street Suite 165	Miami	Florida	33144	(305) 456-3670
Hephzibah Pharmacy	4819 Windsor Spring Road	Hephzibah	Georgia	30815	(706) 592-4646
CornerstoneRx Pharmacy	1720 South McCall Road Suite J	Englewood	Florida	34223-4867	(941) 263-3331
Village Discount Pharmacy	3990 East State Road 44 Suite 207	Wildwood	Florida	34785-7480	(352) 492-9333
Florida Family Pharmacy	14889 Tamiami Trl	North Port	Florida	34287-2732	(941) 444-2215
Palm Care Pharmacy	4651 Babcock Street North East Suite 5A	Palm Bay	Florida	32905	(321) 914-0484
D&D Pharmacy	2903 Central Avenue Suite A	Charlotte	North Carolina	28205-6073	(980) 272-6988
Family Pharmacy	333 Newberry Street Northwest	Aiken	South Carolina	29801-3929	(803) 649-1776

Clearfork Pharmacy	1130 FM 1189 Suite 109	Millsap	Texas	76066	(817) 609-4992
Guy's Pharmacy of Summit	1121 Highway 98 and 51	Summit	Mississippi	39666	(601) 465-0777
Victory Pharmacy	1837 River Oaks Drive	Calumet City	Illinois	60409-5071	(708) 801-9626
Medical Arts Pharmacy	2102 Pecos Street	San Angelo	Texas	76901	(325) 949-4636
Newport Coast Pharmacy	400 Newport Center Drive	Newport Beach	California	92660	(949) 719-3707
River Pharmacy	124 Ames Street	Elk Rapids	Michigan	49629	(231) 264-8165
Wyatt's Pharmacy	10671 Veterans Memorial Highway	Lithia Springs	Georgia	30122	(770) 948-8825
Big Spring Pharmacy	91 South High Street	Newville	Pennsylvania	17241	(717) 776-0288
Frazier's Prater Drug	49 S. Church Street	Salyersville	Kentucky	41465	(606) 349-3135
Schwieterman Pharmacy	324 North Main Street	Minster	Ohio	45865	(419) 628-2305
Angier Family Pharmacy, LLC	50 East Depot Street	Angier	North Carolina	27501-6017	(919) 639-0155
Ann Arbor Pharmacy LLC	2418 East Stadium Boulevard	Ann Arbor	Michigan	48104	(734) 677-5555
Riverside Pharmacy	22 Larry Joe Harless Drive	Gilbert	West Virginia	25621	(304) 664-3343
Sixth Street Drugs	1020 Sixth Street	Traverse City	Michigan	49684	(231) 946-4570
Corner Pharmacy	504 Rocksylvana	Iowa Falls	Iowa	50126	(641) 648-5550
Cornersburg Family Discount Drug	3307 Canfield Road	Youngstown	Ohio	44511	(330) 792-7654
Abala Pharmacy	550 West Eaton Avenue, Suite B	Tracy	California	95376-3445	(209) 832-7080
Newark Pharmacy	635 Market Street Unit 1C	Newark	New Jersey	07105-3618	(973) 993-7510
Upper Darby Pharmacy	119 Long Lane	Upper Darby	Pennsylvania	19082-4103	(610) 352-3010
Schmidt & Sons Pharmacy of Blissfield LLC	616 W. Adrian Street	Blissfield	Michigan	49228	(517) 486-2145
Script Choice Pharmacy	9740 North 56th Street	Temple Terrace	Florida	33617	(813) 374-9944
Knolls Pharmacy	16630 Marquez Avenue	Pacific Palisades	California	90272	(310) 454-6000
SMITH BROTHERS DRUG	25 West Main Street	Maple Shade	New Jersey	08052	(856) 779-8300
Dunewood Pharmacy	1445 Sheldon Road Suite 104	Grand Haven	Michigan	49417	(616) 842-5193
Coast Hills Pharmacy	2610 San Miguel Rd	Newport Beach	California	92660	(949) 720-7044
Evans Prescription Pharmacy	310 North Dotsy Avenue	Odessa	Texas	79763	(432) 337-2361
Medicine Man Southwest Pharmacy	805 East Polston Avenue	Post Falls	Idaho	83854	(208) 777-7732
Campbell Drug	311 Main Street	Oshkosh	Nebraska	69154	(308) 772-3333

Global Pharmacy	926-B Montreal Road Suite 2	Clarkston	Georgia	30021	(404) 299-8255
Las Villas Pharmacy Discount and Medical Supplies	716 West 29th Street	Hialeah	Florida	33012	(305) 883-7476
Community Pharmacy of Plainwell	533 West Allegan Street	Plainwell	Michigan	49080	(269) 685-5847
Evergreen Park Pharmacy	2850 West 95th Street, Suite 100	Evergreen Park	Illinois	60805	(708) 423-4700
Farmacia Monte Verde	Carr 174 KM 10.2 La Morenita, Guaraguao	Bayamon	Puerto Rico	00956	(787) 780-7383
Seifert Drug	230 South Main Street	Elkhart	Indiana	46516	(574) 295-4333
Marcus Hook Pharmacy	46 E 10TH ST	Marcus Hook	Pennsylvania	19061	(610) 485-7750
McKinney Pharmacy	1601 West University Drive	McKinney	Texas	75069	(972) 562-8700
Riccio Family Pharmacy	2217 Bristol Pike, Suite 2	Bensalem	Pennsylvania	19020	(215) 639-6680
The Brown Drug Company	1121 Maine Street	Quincy	Illinois	62301	(217) 228-6400
Silverado Pharmacy	1473 Lincoln Avenue Suite D	Calistoga	California	94515	(707) 942-5115
Van Houten Pharmacy	669 Van Houten Avenue	Clifton	New Jersey	07013	(973) 779-1122
Schwieterman Pharmacy	404 West North Street	Coldwater	Ohio	45828	(419) 678-3435
St. John Valley Pharmacy	182 Market St Suite 2	Fort Kent	Maine	04743	(207) 834-2880
Batts Drug Company Mansfield, LLC	4424 Highway 213	Mansfield	Georgia	30055	(678) 712-7055
Northern Maine Medical Center Pharmacy	194 East Main Street	Fort Kent	Maine	04743-1428	(207) 834-1690
Banner Drug Downtown Statesville	307 N Center St	Statesville	North Carolina	28677	(704) 872-0880
Medicine Man West Pharmacy	802 East Medical Court	Post Falls	Idaho	83854	(208) 773-3566
Oakdale Pharmacy	5400 Balboa Boulevard Suite 100	Encino	California	91316	(818) 788-0770
Zeigler Pharmacy	159 W Main St	Wilmington	Ohio	45177	(937) 382-0921
Smith's St Helena Pharmacy	1390 Railroad Ave	Saint Helena	California	94574-1194	(707) 963-2794
Smith's Pharmacy	841 East Hunting Park Avenue	Philadelphia	Pennsylvania	19124-4800	(215) 537-3000
Country Market Pharmacy # 12	1255 South Main Street	Chelsea	Michigan	48118	(734) 433-0129
Economy Drug	1006 West Trimble Avenue	Berryville	Arkansas	72616	(870) 423-2094
Rushville Pharmacy	302 North Main Street	Rushville	Indiana	46173	(765) 561-5467

Bocage Pharmacy Centre	7150 Jefferson Highway Suite 680	Baton Rouge	Louisiana	70806	(225) 364-2847
Hassler's Drug	401 Front Street	Spring City	Tennessee	37381	(423) 365-9202
Pharmax Pharmacy #1343	113 St. Francois Plaza	Leadington	Missouri	63601	(573) 431-5040
Orange Pharmacy	130 West Main Street	Orange	Virginia	22960	(540) 661-5006
Schwieterman Pharmacy	2 North Washington Street	New Bremen	Ohio	45869	(419) 629-2336
Dalcoma Specialty Pharmacy	43337 Schoenherr Road	Sterling Heights	Michigan	48313	(586) 697-3877
GOOD RXS Pharmacy	5221 33rd Street East	Bradenton	Florida	34203-4330	(941) 900-4566
Hendricks Pharmacy	137 North Harvard Avenue	Claremont	California	91711-4717	(909) 624-1611
Key Drugs at Dexter	1007 West Business US Highway 60	Dexter	Missouri	63841	(573) 614-5900
WellnessRx Pharmacy	5971 University Avenue Suite 304	San Diego	California	92115	(619) 582-1933
Better Life Pharmacy	5621 Atlantic Avenue Suite 103	Raleigh	North Carolina	27615	(919) 891-9555
Country Market Pharmacy #11	1535 West Maumee Street	Adrian	Michigan	49221	(517) 265-9162
Gibbs Drug Store	216 Clay Street	Nocona	Texas	76255	(940) 825-3226
Southern Chester County Pharmacy	1011 West Baltimore Pike Suite 109	West Grove	Pennsylvania	19390	(610) 869-3200
Medicine Man Rathdrum Pharmacy	15837 North Westwood Drive	Rathdrum	Idaho	83858	(208) 687-5717
Olssons Pharmacy	576 Lafayette Avenue	Hawthorne	New Jersey	07506-2400	(973) 427-1700
Professional Pharmacy Services and Medical Equipment	10993 Southwest 186 Street	Miami	Florida	33157	(305) 253-6634
Colonial Pharmacy	1915 North Cleveland-Massillon Road	Bath	Ohio	44210	(330) 666-3569
Davenport Good Neighbor Pharmacy	525 Morgan Street	Davenport	Washington	99122	(509) 725-1151
Don Quijote Drugs	94-144 Farrington Highway	Waipahu	Hawaii	96797	(808) 973-6661
Ivan Pharmacy	691 Columbus Avenue	New York	New York	10025	(212) 222-4400
Munson Community Health Center Pharmacy	550 Munson Avenue Suite G-100	Traverse City	Michigan	49686	(231) 935-8730
River Oak Pharmacy	1080 West F Street, Suite D	Oakdale	California	95361	(209) 847-2226
Tidewater Drug and Health Care	30170 Three Notch Road Unit B	Charlotte Hall	Maryland	20622-4119	(301) 472-1720
SunScript LLC	7869 Pines Boulevard	Pembroke Pines	Florida	33024-6916	(954) 362-7645

Smith's Pharmacy	133 West Hunting Park Avenue Suite 200	Philadelphia	Pennsylvania	19140	(215) 324-5100
Oldens Pharmacy	101 Pleasant Street	South Weymouth	Massachusetts	02190	(781) 337-0187
Prescriptions Plus LTD	753 True Value Drive	Lebanon	Illinois	62254	(618) 537-6202
Topeka Pharmacy	101 N Main St	Topeka	Indiana	46571	(260) 593-2252
Spears Pharmacy	405 Becker Drive	Roanoke Rapids	North Carolina	27870	(252) 676-8399
Yinger Pharmacy Shoppe	1036 North Monroe Street	Monroe	Michigan	48162	(734) 384-7044
English Pharmacy	2600 10th Street	Wichita Falls	Texas	76309	(940) 723-6060
Cobb's Pharmacy	510 Houston St	George West	Texas	78022-2340	(361) 449-2631
Country Market Pharmacy #66	11301 Brooklyn Road	Brooklyn	Michigan	49230	(517) 592-2475
*Elkton Family Pharmacy	111 South Stuart Avenue	Elkton	Virginia	22827	(540) 298-9090
American Surgical Pharmacy	103 E Highland Ave	San Bernardino	California	92404	(909) 882-3353
Berry & Sweeney Pharmacy	1377 N Fair Oaks Ave	Pasadena	California	91103-2199	(626) 794-1124
Seifert Drug #2	100 N Elkhart St	Wakarusa	Indiana	46573	(574) 862-1454
Cox Family Pharmacy	1212 Garfield Avenue Suite 102	Parkersburg	West Virginia	26101	(304) 865-7600
Sterling Drug	1305 1st Avenue South West	Austin	Minnesota	55912	(507) 433-4586
EverCare Pharmacy	1903 East 9th Street	Trenton	Missouri	64683-2645	(660) 359-5700
Care More Pharmacy	151 Dorton-Jenkins Highway	Dorton	Kentucky	41520	(606) 639-2273
Saline Pharmacy	75 E Bennett St	Saline	Michigan	48176-1204	(734) 316-2162
GNO Pharmacy	1151 Barataria Blvd Suite 1200	Marrero	Louisiana	70072-3082	(504) 252-9686
Woodbury Family Pharmacy	160 North Broad Street	Woodbury	New Jersey	08096	(856) 251-1900
PALMYRA PHARMACY	1 East Broad Street	Palmyra	New Jersey	08065-1604	(856) 786-1615
Sterling Drug #19	430 2nd Avenue NW	Faribault	Minnesota	55021	(507) 333-5464
Cano Pharmacy	12600 Southwest 120th Street Suite 102	Miami	Florida	33186	(305) 506-1930
KEX RX PHARMACY & HOME CARE	120 E 18TH ST	FALLS CITY	Nebraska	68355	(402) 245-2029
Valley Pharmacy	791 Hamburg Turnpike	Wayne	New Jersey	07470-8416	(973) 832-7200
Pennington Apothecary	6 North Main Street	Pennington	New Jersey	08534	(609) 737-9297
South Fork Pharmacy	732 North Main St	Moorefield	West Virginia	26836	(304) 530-1044
Schroeder Drugs #1201	540 East Fifth Street	Washington	Missouri	63090-0227	(636) 239-4707

Times Pharmacy #8	1290 South Beretania Street	Honolulu	Hawaii	96814	(808) 522-5071
Rocky Top Pharmacy	702 Grove Street	Loudon	Tennessee	37774	(865) 657-3500
Thornhill's Pharmacy	600 8th Street	Shallowater	Texas	79363	(806) 832-0300
Pucci's Pharmacy	3257 Folsom Blvd	Sacramento	California	95816	(916) 442-5891
Allcare Pharmacy & Healthcare Services	112 South Oxley Drive	Lyons	Georgia	30436	(912) 526-3200
Mission Medical Pharmacy	27800 Medical Center Rd Suite 99	Mission Viejo	California	92691-6410	(949) 364-0122
Family Meds Inc	12114 Old Line Center R-7A	Waldorf	Maryland	20602	(301) 396-9277
Rancho Park Pharmacy	10587 (A) and (B) West Pico Boulevard	Los Angeles	California	90064	(310) 475-3040
Holland Center Pharmacy	621 Milford Warren Glen Road	Milford	New Jersey	08848	(908) 995-0015
Accokeek Drug and Health Care Inc	15789 Livingston Road Suite 108	Accokeek	Maryland	20607	(301) 203-7205
Whitesell Pharmacy	236 North Market Street	Frederick	Maryland	21701	(301) 662-4848
Holy Cross Pharmacy	11550 Indian Hills Road Suite 130	Mission Hills	California	91345	(818) 898-1628
KEX RX	101 SO. 6TH ST.	HIAWATHA	Kansas	66434	7857422125
Porter's Pharmacy & Compounding Lab	935 Beaver Grade Rd	Coraopolis	Pennsylvania	15108-2790	(412) 264-2230
Medicine Center Pharmacy	551 W High Ave	New Philadelphia	Ohio	44663	(330) 339-4466
WestSide Pharmacy	215 N Hermitage Ave Suite 9	Trenton	New Jersey	08618	(609) 394-0600
Rhine Drug Company	119 First Street	Rhine	Georgia	31077	(229) 385-5351
Community Pharmacy	1089 Elizabeth Avenue Store 5	Elizabeth	New Jersey	07201	(908) 469-6363
Ehrhardt Pharmacy	12930 Broxton Bridge Road	Ehrhardt	South Carolina	29081	(803) 267-2121
Elizabeth's Pharmacy on Main	52 Main Avenue North	Britt	Iowa	50423	(641) 843-3885
Mac's Edgemoor Pharmacy	643 Edgemoor Road	Powell	Tennessee	37849	(865) 945-3333
Harbor Drug #2	2046 Black River Street, Suite 2	Deckerville	Michigan	48427	(810) 376-8070
Beemans Lake Arrowhead Pharmacy	29099 Hospital Road	Lake Arrowhead	California	92352	(909) 337-0747
Innova Pharmacy	5830 Jameson Ct	Carmichael	California	95608	(916) 481-6900
Grove Harbor Medical Center Pharmacy	12555 Garden Grove Blvd Suite 102	Garden Grove	California	92843	(714) 636-0593
Southeast Pharmacy	400 Parker Ave N Suite 500A	Brooklet	Georgia	30415-9506	(912) 842-2040
Orange Plaza Pharmacy	1010 West La Veta Avenue Suite 130	Orange	California	92868-4301	(714) 550-9798

Newport Lido Pharmacy LTC	351 Hospital Road, Suite 107	Newport Beach	California	92663	(949) 764-6580
Pacific Pharmacy	11525 Brookshire Avenue, Suite 100	Downey	California	90241	(562) 862-1302
Grove Pharmacy	123 Grove Street	Montclair	New Jersey	07042	650-867-1408
Mayson's Pharmacy	4199 F1 Winchester Road	Marshall	Virginia	20115-3269	(540) 364-8291
Kennebec Pharmacy & Home Care	839 Commercial Street	Rockport	Maine	04856	(207) 594-0888
RYALS DRUG STORE	12 S 2ND AVE	MCRAE	Georgia	31055	(229) 868-6735
Ramsey Drug	401 College Dr S	Devils Lake	North Dakota	58301	(701) 662-3117
Seifert Drug #3	2102 N Main St Suite 100	Nappanee	Indiana	46550	(574) 773-8280
Drugs America	103 East 24Th St	Lumberton	North Carolina	28358	(910)739-4196
Hanger Drugs	207 Sparks Avenue Suite 1	Jeffersonville	Indiana	47130	(812) 283-3591
Greater Care Pharmacy	24800 HOOVER RD STE B	WARREN	Michigan	48089-1965	(586) 486-5008
Playa Pharmacy	8131 West Manchester Avenue	Playa Del Rey	California	90293	(310) 823-4500
Wyandotte Pharmacy	375 Eureka Road Suite A	Wyandotte	Michigan	48192-5839	(734) 720-0929
Cucamonga Community Pharmacy	8237 Rochester Ave Suite 140	Rancho Cucamonga	California	91730-0717	(909) 948-8377
Kratzer's Hometown Pharmacy Mt Orab	155 North Point Drive	Mount Orab	Ohio	45154	(937) 444-0135
Elwyn Pharmacy	5075 Edgmont Ave	Brookhaven	Pennsylvania	19015-1202	(610) 566-2226
Aalpha Pharmacy	174 S Alvarado St	Los Angeles	California	90057-2211	(213) 483-8741
St. Mary's Pharmacy	350 Boulevard	Passaic	New Jersey	07055	(973) 365-7143
Best Care Pharmacy	1040 S Pendleton St Suite C	Easley	South Carolina	29642	(864) 644-8494
Friendly City Pharmacy on 2nd	717 2ND ST W	TIFTON	Georgia	31794-4201	(229) 382-3711
AR-EX Drug Store	801 Broadway	Marysville	Kansas	66508	(785) 562-3196
Regions Pharmacy	999 N Tustin Ave Suite 216	Santa Ana	California	92705-6506	(714) 627-9190
Downtown Drug	8 2nd Street Northeast Suite 201B	Watertown	South Dakota	57201-3622	(605) 753-7847
Darlington Pharmacy	1115 Main Street	Darlington	Maryland	21034	(410) 457-5521
Regions Mission Viejo Pharmacy	26024 Acero Suite 110	Mission Viejo	California	92691	(949) 755-6443
Walter's Family Pharmacy	604 South 12th Street	Murray	Kentucky	42071	(270) 753-7688
Xpress Meds	4201 West 95th Street Suite G	Oak Lawn	Illinois	60453-2615	(708) 459-1800
AHCS Specialty Care Sacramento	1820 Tribute Road Suite G	Sacramento	California	95815	(916) 518-0659

Anderson Family Pharmacy	1142 Jackson Street	Anderson	South Carolina	29625-2760	(864) 642-0200
Seaway Pharmacy	1707 Cherry Street	Toledo	Ohio	43608	(419) 214-5197
Honest Pharmacy	7740 Garvey Avenue Unit A	Rosemead	California	91770-3061	(626) 703-4750
Honest Pharmacy	210 North Garfield Avenue Suite 101	Monterey Park	California	91754	(626) 545-2919
Pattie Drugs	868 Michigan Avenue	Baldwin	Michigan	49304	(231) 745-4697
FARMACIA AMERICA	CALLE SALAS TORRES 3, ESQUINA MUNOZ RIVERA	AGUAS BUENAS	Puerto Rico	00703	(787) 732-2241
Healthy Harlem Rx Corp	1875 Lexington Avenue	New York	New York	10035-4733	(212) 601-2661
North Rialto Drug	531 East Foothill Boulevard	Rialto	California	92376	(909) 875-2131
Nightingale Drug	1020 12th Avenue South East	Dyersville	Iowa	52040	(563) 875-7455
Fairmont Pharmacy	50 Bellefontaine St Suite 103	Pasadena	California	91105	(626) 793-1188
PRIME CARE DRUG & SURGICALS CORP	2066 FLATBUSH AVE	BROOKLYN	New York	11234	(718) 513-6644
Grand Care Pharmacy Inc	6656 Grand Ave	Maspeth	New York	11378-0009	(718) 446-6656
Boies Medical Center Pharmacy	828 Delbon Avenue	Turlock	California	95382	(209) 634-8511
Noubar's El Adobe Pharmacy	2010 Wilshire Boulevard, Suite F-2010	Los Angeles	California	90057	(213) 413-3999
Noubar's El Adobe Pharmacy Inc	5207 Hollywood Boulevard	Los Angeles	California	90027	(323) 461-9451
TYLERTOWN PHARMACY LLC	201 HOSPITAL DR	TYLERTOWN	Mississippi	39667-2019	(601) 222-1770
Medcare Medical Pharmacy	1661 Golden Rain Rd	Seal Beach	California	90740	(714) 557-2982
ROTARY DRUG	1030 BARNUM AVE	STRATFORD	Connecticut	06614	(203) 378-9394
WellCare Pharmacy	2130 West Poplar Avenue Suite 104	Collierville	Tennessee	38017	(901) 542-8001
Fisherville Pharmacy	219 Fisherville Rd Suite C	Penacook	New Hampshire	03303-2074	(603) 565-0210
Axtell's Pharmacy	1246 Highway 377 South Suite #100	Pilot Point	Texas	76258	(940) 686-2218
Drug Mart	1249 West 7th Street	South Plainfield	New Jersey	07080	(908) 561-5300
Town Pharmacy	4911 Bergenline Avenue	West New York	New Jersey	07093	(201) 766-1900
Quick Med Pharmacy	1221 Main Street	Asbury Park	New Jersey	07712-5940	(732) 897-1500
Harlingen Pharmacy	1616 North Ed Carey Drive	Harlingen	Texas	78550-8286	(956) 230-3200

**EXHIBIT E
FINANCIAL STATEMENTS
AND CENCORA GUARANTY**

FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

	<u>Page</u>
Report of Independent Registered Public Accounting Firm	1
Consolidated Financial Statements:	
Consolidated Balance Sheets as of September 30, 2025, and 2024	4
Consolidated Statements of Operations for the fiscal years ended September 30, 2025, 2024, and 2023	5
Consolidated Statements of Comprehensive Income for the fiscal years ended September 30, 2025, 2024, 2023	6
Consolidated Statements of Changes in Stockholders' Equity for the fiscal years ended September 30, 2025, 2024, 2023	7
Consolidated Statements of Cash Flows for the fiscal years ended September 30, 2025, 2024, and 2023	8
Notes to Consolidated Financial Statements	9

Report of Independent Registered Public Accounting Firm

To the Stockholders and the Board of Directors of Cencora, Inc.

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheets of Cencora, Inc. and subsidiaries (the Company) as of September 30, 2025 and 2024, the related consolidated statements of operations, comprehensive income, changes in stockholders' equity and cash flows for each of the three years in the period ended September 30, 2025, and the related notes (collectively referred to as the "consolidated financial statements"). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at September 30, 2025 and 2024, and the results of its operations and its cash flows for each of the three years in the period ended September 30, 2025, in conformity with U.S. generally accepted accounting principles.

Basis for Opinion

These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

Critical Audit Matters

The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.

Legal Matters and Contingencies - Opioid Lawsuits and Investigations

Description of the Matter

As discussed in Note 12 of the consolidated financial statements, the Company is involved in a significant number of lawsuits and government investigations relating to the distribution of prescription opioid pain medications and other controlled substances ("opioid litigation and investigations"). The Company recognizes a liability for those legal contingencies for which it is probable that a liability has been incurred at the date of the consolidated financial statements and the amount is reasonably estimable. As discussed in Note 4, in connection with the recognized liabilities for settled opioid lawsuits, the Company recognizes a related income tax benefit, which reflects an unrecognized tax benefit resulting from uncertainty in the amount that is more likely than not to be deductible for U.S. federal and state income tax purposes. The Company used significant judgment in measuring the amount of income tax benefit that may ultimately be deductible for U.S. federal and state purposes.

Auditing management's determination of whether the risk of loss related to opioid litigation and investigations is probable and reasonably estimable, and the related disclosures is highly subjective and requires significant judgment. Auditing management's judgments related to unsettled cases was challenging due to the significant judgment applied in determining the likelihood of resolution of matters through settlement or litigation and the magnitude of the liability. In addition, auditing management's estimate of the amount of income tax benefit related

to the Company's uncertain tax positions is challenging because the evaluation of the technical merits of income tax benefits that qualify for a deduction related to settled opioid lawsuits requires significant judgment.

*How We
Addressed the
Matter in Our
Audit*

We tested the Company's internal controls that address the risks of material misstatement related to the completeness and presentation and disclosure of the opioid litigation and investigations liability and uncertain tax position. This included testing controls related to the Company's process for identification, recognition, completeness, and disclosure of the opioid litigation and testing controls related to the Company's process to assess the technical merits of its tax position, including the Company's assessment as to the amount of benefit that is more likely than not to be realized upon ultimate settlement with taxing authorities. For example, we tested controls over management's review of the assessment of the completeness of the opioid litigation and investigations liability and whether a range of possible loss in excess of the amount accrued is reasonably estimable to determine the accuracy of the opioid litigation and investigations liability and the related financial statement disclosures.

To test the Company's opioid litigation and investigations liability, our substantive audit procedures included, among others, testing the completeness of the contingencies subject to evaluation by the Company and evaluating the Company's analysis of its assessment of the probability of outcome for each material legal contingency through inspection of responses to inquiry letters sent to both internal and external legal counsel, discussions with internal general counsel and external legal counsel to confirm our understanding of the allegations and any settlement discussions, inspection of proposed settlement agreements, and obtaining written representations from executives of the Company. We also compared the Company's assessment with its relevant history of similar legal contingencies that have been settled or otherwise resolved to evaluate the consistency of the Company's assessment for unsettled opioid litigation and investigations.

For those legal contingencies for which the Company has determined that a loss is probable and reasonably estimable and is therefore required to be recognized, we evaluated the method of measuring the amounts of the recorded and disclosed contingencies. For those legal contingencies for which the Company has determined that a loss is reasonably possible, and is therefore required to be disclosed, we evaluated the methods for determining whether a range of loss can be estimated and the related disclosures. We assessed the Company's estimate of the amount of the loss, for both contingencies that are probable and reasonably possible, through inspection of responses to inquiry letters sent to both internal and external legal counsel, discussions with internal general counsel and external legal counsel, inspection of proposed settlement agreements and obtaining written representations from executives of the Company. In addition, we evaluated the adequacy of the Company's financial statement disclosures.

To test the uncertain tax position, we involved our tax subject matter professionals in assessing the technical merits and measurement of the Company's tax positions related to the opioid litigation and investigation liability. We examined the Company's analyses and evaluated the underlying facts upon which the tax positions were based. We used our knowledge of historical settlement activity in similar matters involving legal settlements to evaluate the Company's measurement of the uncertain tax position associated with the opioid litigation and investigations. We also evaluated the adequacy of the Company's financial statement disclosures and obtained written representations from executives of the Company related to this income tax matter.

Goodwill Impairment Evaluation of the PharmaLex Reporting Unit

*Description of
the Matter*

At September 30, 2025, the Company's consolidated goodwill balance was \$13,677 million. As discussed in Note 1 to the consolidated financial statements, the Company's goodwill is tested for impairment at least annually, or whenever events or circumstances indicate that the value of goodwill may be impaired. If goodwill is determined to be impaired, an impairment loss is

measured at the amount by which the reporting unit's carrying amount exceeds its fair value, not to exceed the carrying amount of goodwill. The Company performed a quantitative analysis of the PharmaLex reporting unit as of its annual goodwill impairment assessment date of July 1, 2025. Based on the Company's assessment, the estimated fair value of the reporting unit was determined to be less than its carrying value. A pre-tax goodwill impairment charge of \$723.9 million was recognized, resulting in the PharmaLex reporting unit goodwill being fully impaired as of September 30, 2025.

Auditing the Company's goodwill impairment assessment for the PharmaLex reporting unit was complex and highly judgmental due to the significant judgments and estimation required by management in determining the fair value of the reporting unit, which is based on assumptions about future market or economic conditions and company-specific qualitative factors whose outcome is uncertain and will therefore be subject to change over time. In particular, the fair value estimate of the reporting unit involves the use of significant unobservable inputs and is sensitive to changes in significant assumptions, such as the discount rate and earnings before interest, taxes, depreciation and amortization ("EBITDA") margin.

*How We
Addressed the
Matter in Our
Audit*

We obtained an understanding, evaluated the design and tested the operating effectiveness of controls over the Company's annual goodwill impairment assessment process, which included the PharmaLex reporting unit. For example, we tested controls over management's review of the fair value of the PharmaLex reporting unit including review of the valuation model, the significant assumptions described above, and the completeness and accuracy of the data used in the valuation.

To test the estimated fair value of the PharmaLex reporting unit, we performed audit procedures that included, among others, assessing the methodologies used to develop the estimated fair value, testing the significant assumptions discussed above, and evaluating the completeness and accuracy of the underlying data used by the Company in its analyses. We compared the significant assumptions used by the Company to forecasted industry and economic trends and peer company information. We assessed the historical accuracy of management's estimates and performed sensitivity analyses of significant assumptions to evaluate the changes in the fair value of the reporting unit that would result from changes in the assumptions. We also involved valuation specialists to assist in our evaluation of the overall methodologies and significant assumptions used in the fair value estimate, including performing a comparative calculation of the discount rate.

/s/ Ernst & Young LLP

We have served as the Company's auditor since 1985.
Philadelphia, Pennsylvania
November 25, 2025

CENCORA, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS

(in thousands, except share and per share data)	September 30,	
	2025	2024
ASSETS		
Current assets:		
Cash and cash equivalents	\$ 4,356,138	\$ 3,132,648
Accounts receivable, less allowances for returns and credit losses: 2025 — \$1,796,172; 2024 — \$1,308,018	25,225,299	23,871,815
Inventories	20,492,480	18,998,833
Right to recover assets	1,625,817	1,175,871
Prepaid expenses and other	539,339	538,646
Total current assets	52,239,073	47,717,813
Property and equipment, net	2,539,076	2,181,410
Goodwill	13,676,520	9,318,027
Other intangible assets	3,774,181	4,001,046
Deferred income taxes	208,810	246,348
Other assets	4,152,452	3,637,023
TOTAL ASSETS	\$ 76,590,112	\$ 67,101,667
LIABILITIES AND STOCKHOLDERS' EQUITY		
Current liabilities:		
Accounts payable	\$ 54,719,761	\$ 50,942,162
Accrued expenses and other	2,982,993	2,758,560
Short-term debt	117,785	576,331
Total current liabilities	57,820,539	54,277,053
Long-term debt	7,542,988	3,811,745
Accrued income taxes	337,631	291,796
Deferred income taxes	1,620,724	1,643,746
Accrued litigation liability	3,881,283	4,296,902
Other liabilities	3,639,862	1,993,683
Commitments and contingencies (Note 12)		
Stockholders' equity:		
Common stock, \$0.01 par value — authorized, issued, and outstanding: 2025 — 600,000,000 shares, 297,401,863 shares and 193,937,673 shares; 2024 — 600,000,000 shares, 296,169,781 shares and 194,943,968 shares	2,974	2,962
Additional paid-in capital	6,204,302	6,030,790
Retained earnings	6,534,227	5,417,139
Accumulated other comprehensive loss	(901,378)	(989,118)
Treasury stock, at cost: 2025 — 103,464,190 shares; 2024 — 101,225,813 shares	(10,332,106)	(9,815,835)
Total Cencora, Inc. stockholders' equity	1,508,019	645,938
Noncontrolling interests	239,066	140,804
Total stockholders' equity	1,747,085	786,742
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	\$ 76,590,112	\$ 67,101,667

See notes to consolidated financial statements.

CENCORA, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except per share data)	Fiscal Year Ended September 30,		
	2025	2024	2023
Revenue	\$ 321,332,819	\$ 293,958,599	\$ 262,173,411
Cost of goods sold	309,854,280	284,048,570	253,213,918
Gross profit	11,478,539	9,910,029	8,959,493
Operating expenses:			
Distribution, selling, and administrative	6,493,842	5,661,106	5,309,984
Depreciation	494,141	428,500	410,341
Amortization	556,934	663,474	553,563
Litigation and opioid-related expenses (credit), net	60,671	227,070	(24,693)
Acquisition-related deal and integration expenses	291,044	103,001	139,683
Restructuring and other expenses	229,422	233,629	229,884
Goodwill impairment	723,884	418,000	—
Operating income	2,628,601	2,175,249	2,340,731
Other loss (income), net	78,717	14,283	(49,036)
Interest expense, net	291,548	156,991	228,931
Income before income taxes	2,258,336	2,003,975	2,160,836
Income tax expense	690,522	484,702	428,260
Net income	1,567,814	1,519,273	1,732,576
Net (income) loss attributable to noncontrolling interests	(13,645)	(10,153)	12,717
Net income attributable to Cencora, Inc.	\$ 1,554,169	\$ 1,509,120	\$ 1,745,293
Earnings per share:			
Basic	\$ 8.02	\$ 7.60	\$ 8.62
Diluted	\$ 7.96	\$ 7.53	\$ 8.53
Weighted average common shares outstanding:			
Basic	193,820	198,503	202,511
Diluted	195,214	200,284	204,591

See notes to consolidated financial statements.

CENCORA, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(in thousands)	Fiscal Year Ended September 30,		
	2025	2024	2023
Net income	\$ 1,567,814	\$ 1,519,273	\$ 1,732,576
Other comprehensive income:			
Foreign currency translation adjustments	91,788	405,099	353,439
Other, net	6,027	(272)	33,395
Total other comprehensive income	97,815	404,827	386,834
Total comprehensive income	1,665,629	1,924,100	2,119,410
Comprehensive (income) loss attributable to noncontrolling interests	(23,720)	(1,491)	54,246
Comprehensive income attributable to Cencora, Inc.	\$ 1,641,909	\$ 1,922,609	\$ 2,173,656

See notes to consolidated financial statements.

CENCORA, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY

(in thousands, except per share data)	Common Stock	Additional Paid-in Capital	Retained Earnings	Accumulated Other Comprehensive Loss	Treasury Stock	Non-controlling Interests	Total
September 30, 2022	\$ 2,927	\$ 5,658,733	\$ 2,977,646	\$ (1,830,970)	\$ (7,019,895)	\$ 282,832	\$ 71,273
Net income (loss)	—	—	1,745,293	—	—	(12,717)	1,732,576
Other comprehensive income (loss)	—	—	—	428,363	—	(41,529)	386,834
Cash dividends, \$1.94 per share	—	—	(398,752)	—	—	—	(398,752)
Exercises of stock options	8	61,144	—	—	—	—	61,152
Share-based compensation expense	—	124,624	—	—	—	—	124,624
Purchases of common stock	—	—	—	—	(1,155,929)	—	(1,155,929)
Employee tax withholdings related to restricted share vesting	—	—	—	—	(71,279)	—	(71,279)
Divestiture of business	—	—	—	—	—	(76,957)	(76,957)
Other, net	13	77	—	—	—	(7,345)	(7,255)
September 30, 2023	2,948	5,844,578	4,324,187	(1,402,607)	(8,247,103)	144,284	666,287
Net income	—	—	1,509,120	—	—	10,153	1,519,273
Other comprehensive income (loss)	—	—	—	413,489	—	(8,662)	404,827
Cash dividends, \$2.04 per share	—	—	(416,168)	—	—	—	(416,168)
Exercises of stock options	4	37,836	—	—	—	—	37,840
Share-based compensation expense	—	147,998	—	—	—	—	147,998
Purchases of common stock	—	—	—	—	(1,505,232)	—	(1,505,232)
Employee tax withholdings related to restricted share vesting	—	—	—	—	(63,500)	—	(63,500)
Other, net	10	378	—	—	—	(4,971)	(4,583)
September 30, 2024	2,962	6,030,790	5,417,139	(989,118)	(9,815,835)	140,804	786,742
Net income	—	—	1,554,169	—	—	13,645	1,567,814
Other comprehensive income	—	—	—	87,740	—	10,075	97,815
Cash dividends, \$2.20 per share	—	—	(437,081)	—	—	—	(437,081)
Exercises of stock options	4	29,129	—	—	—	—	29,133
Share-based compensation expense	—	147,963	—	—	—	—	147,963
Purchases of common stock	—	—	—	—	(438,488)	—	(438,488)
Employee tax withholdings related to restricted share vesting	—	—	—	—	(77,783)	—	(77,783)
Acquisitions	—	—	—	—	—	74,711	74,711
Other, net	8	(3,580)	—	—	—	(169)	(3,741)
September 30, 2025	<u>\$ 2,974</u>	<u>\$ 6,204,302</u>	<u>\$ 6,534,227</u>	<u>\$ (901,378)</u>	<u>\$ (10,332,106)</u>	<u>\$ 239,066</u>	<u>\$ 1,747,085</u>

See notes to consolidated financial statements.

CENCORA, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)	Fiscal Year Ended September 30,		
	2025	2024	2023
OPERATING ACTIVITIES			
Net income	\$ 1,567,814	\$ 1,519,273	\$ 1,732,576
Adjustments to reconcile net income to net cash provided by operating activities:			
Depreciation, including amounts charged to cost of goods sold	501,310	448,200	418,830
Amortization, including amounts charged to interest expense	567,106	670,642	562,018
Provision for credit losses	63,306	40,834	54,389
Provision (benefit) for deferred income taxes	59,864	(102,324)	(118,864)
Share-based compensation expense	147,963	147,998	124,624
LIFO (credit) expense	(76,875)	(52,168)	204,595
Impairment of assets, including goodwill	837,378	418,000	—
Loss (gain) on divestiture of businesses	35,539	—	(40,665)
Turkey highly inflationary impact	55,519	55,309	95,938
Adjustments to RCA equity units (Note 2)	121,666	—	—
Adjustments to contingent consideration (Note 2)	19,550	—	—
(Gain) loss on remeasurement of equity investment	(14,058)	16,201	(242)
Gain on divestiture of equity investment	(12,838)	—	—
Other, net	(33,548)	24,032	3,593
Changes in operating assets and liabilities, excluding the effects of acquisitions and divestitures:			
Accounts receivable	(1,923,411)	(2,784,339)	(2,711,786)
Inventories	(1,269,429)	(1,479,599)	(2,183,368)
Prepaid expenses and other assets	173,857	156,672	211,242
Accounts payable	3,693,364	4,968,093	6,103,451
Accrued expenses	(21,131)	148,533	51,112
Income taxes payable and other liabilities	(213,724)	(204,517)	(196,146)
Long-term accrued litigation liability	(404,102)	(506,155)	(399,963)
NET CASH PROVIDED BY OPERATING ACTIVITIES	3,875,120	3,484,685	3,911,334
INVESTING ACTIVITIES			
Capital expenditures	(667,981)	(487,173)	(458,359)
Cost of acquired companies, net of cash acquired	(4,095,630)	(69,771)	(1,409,835)
Cost of equity investments	(196,242)	(30,430)	(743,275)
Non-customer note receivable	(34,814)	(50,000)	—
Other, net	17,374	19,278	9,004
NET CASH USED IN INVESTING ACTIVITIES	(4,977,293)	(618,096)	(2,602,465)
FINANCING ACTIVITIES			
Senior notes and loan borrowings	4,508,482	688,321	157,547
Senior notes and loan repayments	(1,280,615)	(662,525)	(811,353)
Borrowings under revolving and securitization credit facilities	132,134,224	69,703,045	78,218,439
Repayments under revolving and securitization credit facilities	(132,166,423)	(70,114,293)	(78,187,891)
Purchases of common stock	(435,471)	(1,491,367)	(1,180,728)
Exercises of stock options	29,133	37,840	61,152
Cash dividends on common stock	(437,081)	(416,168)	(398,752)
Employee tax withholdings related to restricted share vesting	(77,783)	(63,500)	(71,279)
Other, net	(25,352)	(12,347)	(9,413)
NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES	2,249,114	(2,330,994)	(2,222,278)
EFFECT OF EXCHANGE RATE CHANGES ON CASH, CASH EQUIVALENTS, AND RESTRICTED CASH	(50,272)	9,396	72,759
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	1,096,669	544,991	(840,650)
Cash, cash equivalents, and restricted cash at beginning of year	3,297,880	2,752,889	3,593,539
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH AT END OF YEAR	\$ 4,394,549	\$ 3,297,880	\$ 2,752,889

See notes to consolidated financial statements.

CENCORA, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2025

Note 1. Summary of Significant Accounting Policies

Cencora, Inc. and its subsidiaries, including less-than-wholly-owned subsidiaries in which Cencora, Inc. has a controlling financial interest (the “Company”), is one of the largest global pharmaceutical sourcing and distribution services companies, helping both healthcare providers and pharmaceutical and biotech manufacturers improve patient access to products and enhance patient care. The Company delivers innovative programs and services designed to improve the effectiveness and efficiency of the pharmaceutical supply chain in both human and animal health.

Basis of Presentation

The accompanying financial statements present the consolidated financial position, results of operations, and cash flows of the Company as of the dates and for the periods indicated. All significant intercompany accounts and transactions have been eliminated in consolidation.

The preparation of financial statements in conformity with U.S. generally accepted accounting principles (“GAAP”) requires management to make estimates and assumptions that affect amounts reported in the financial statements and accompanying notes. Actual amounts could differ from these estimated amounts due to uncertainties inherent in such estimates. Management periodically evaluates estimates used in the preparation of the financial statements for continued reasonableness. Certain reclassifications have been made to prior-period amounts to conform to the current year presentation.

Recently Adopted Accounting Pronouncements

In November 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2023-07, “Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (“ASU 2023-07”).” ASU 2023-07 requires public entities to disclose significant segment expenses on an annual and interim basis and to provide in interim periods all disclosures about a reportable segment’s profit or loss that are currently required annually. ASU 2023-07 is effective for annual periods beginning after December 15, 2023 and interim periods beginning after December 15, 2024. The Company adopted ASU 2023-07 and retrospectively reflected segment cost of goods sold and segment operating expenses in Note 14. The adoption of ASU 2023-07 had no impact on the Company’s Consolidated Financial Statements.

Recently Issued Accounting Pronouncements Not Yet Adopted

In December 2023, the FASB issued ASU No. 2023-09, “Income Taxes (Topic 740): Improvements to Income Tax Disclosures (“ASU 2023-09”).” ASU 2023-09 requires entities to provide additional information in their tax rate reconciliation and additional disclosures about income taxes paid by jurisdiction. ASU 2023-09 is effective for annual reporting periods beginning after December 15, 2024, with early adoption permitted. The guidance should be applied prospectively, but entities have the option to apply it retrospectively for each period presented. The Company is evaluating the impact of adopting this new accounting guidance.

In November 2024, the FASB issued ASU No. 2024-03, “Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses (“ASU 2024-03”).” ASU 2024-03 requires disaggregated disclosures about specific types of expenses included in the expense captions presented on the face of the income statement as well as disclosures about selling expenses. Expense captions should be disaggregated to include expenses related to purchases of inventory, employee compensation, depreciation, and intangible asset amortization. ASU 2024-03 applies to public entities and is effective for annual periods beginning after December 15, 2026 and interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The guidance should be applied prospectively with the option for retrospective application. The Company is evaluating the impact of adopting this new accounting guidance.

Business Combinations

The assets acquired and liabilities assumed from an acquired business are recorded at estimated fair value, with the residual of the purchase price recorded as goodwill. The results of operations of an acquired businesses are included in the Company’s operating results from the date of acquisition.

Cash, Cash Equivalents, and Restricted Cash

The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. The carrying value of cash equivalents approximates fair value.

The Company is required to maintain certain cash deposits with banks mainly consisting of deposits restricted under contractual agency agreements and cash restricted by law and other obligations.

The following represents a reconciliation of cash and cash equivalents in the Consolidated Balance Sheets to cash, cash equivalents, and restricted cash in the Consolidated Statements of Cash Flows:

(amounts in thousands)	September 30,			
	2025	2024	2023	2022
Cash and cash equivalents	\$ 4,356,138	\$ 3,132,648	\$ 2,592,051	\$ 3,388,189
Restricted cash (included in Prepaid Expenses and Other)	38,411	98,596	97,722	144,980
Restricted cash (included in Other Assets)	—	66,636	63,116	60,370
Cash, cash equivalents, and restricted cash	\$ 4,394,549	\$ 3,297,880	\$ 2,752,889	\$ 3,593,539

Concentrations of Credit Risk and Allowance for Credit Losses

The Company has sales to a significant number of customers in the healthcare industry that include institutional and retail healthcare providers. Institutional healthcare providers include acute care hospitals, health systems, mail order pharmacies, long-term care and other alternate care pharmacies and providers of pharmacy services to such facilities, and physician offices. Retail healthcare providers include national and regional retail drugstore chains, independent community pharmacies, pharmacy departments of supermarkets and mass merchandisers, and veterinarians. The financial condition of the Company's customers can be affected by changes in government reimbursement policies as well as by other economic pressures in the healthcare industry.

The Company's trade accounts receivables are exposed to credit risk. Revenue from the various agreements and arrangements with Walgreens and Boots UK Ltd. collectively accounted for approximately 25% of revenue and represented approximately 38% of accounts receivable, net of incentives, as of September 30, 2025. Evernorth Health Services, the Company's second largest customer in fiscal 2025, accounted for approximately 13% of revenue and represented approximately 5% of accounts receivable as of September 30, 2025. The Company generally does not require collateral for trade receivables. The Company evaluates its receivables for risk of loss by grouping its receivables with similar risk characteristics. Expected losses are determined based on a combination of historical loss trends, current economic conditions, and forward-looking risk factors. Changes in these factors, among others, may lead to adjustments in the Company's allowance for credit losses. The calculation of the required allowance requires judgment by Company management as to the impact of those and other factors on the ultimate realization of its trade receivables. The Company performs ongoing credit evaluations of its customers' financial condition and maintains reserves for expected credit losses for specific credit problems when they arise. There were no significant changes to this process during fiscal 2025, 2024, and 2023, and bad debt expense was computed in a consistent manner during these periods.

The Company maintains cash, cash equivalents, and restricted cash with several financial institutions. Deposits held with banks may exceed the amount of insurance provided on such deposits. These deposits may be redeemed upon demand and are maintained with financial institutions with reputable credit and, therefore, bear minimal credit risk. The Company seeks to mitigate such risks by monitoring the risk profiles of these counterparties. The Company also seeks to mitigate risk by monitoring the investment strategy of money market accounts in which it is invested, which are classified as cash equivalents.

Contingencies

Loss Contingencies: In the ordinary course of its business, the Company becomes involved in lawsuits, administrative proceedings, government subpoenas, government investigations, stockholder demands, and other disputes, including antitrust, commercial, data privacy and security, product liability, intellectual property, regulatory, employment discrimination, and other matters. Significant damages or penalties may be sought from the Company in some matters, and some matters may require years for the Company to resolve. The Company records a reserve for these matters when it is both probable that a loss has been incurred and the amount can be reasonably estimated. The Company also performs an assessment of the materiality of loss contingencies where a loss is either not probable or it is reasonably possible that a loss could be incurred in excess of amounts accrued. If a loss or an additional loss has at least a reasonable possibility of occurring and the impact on the financial statements would be material, the Company provides disclosure of the loss contingency in the notes to its financial statements. The Company reviews all contingencies at least quarterly to determine whether the likelihood of loss has changed and to assess whether a reasonable estimate of the loss or the range of the loss can be made. Among the loss contingencies that the Company considered in accordance with the foregoing in connection with the preparation of the accompanying financial statements were the opioid matters described in Note 12.

Gain Contingencies: The Company records gain contingencies when they are realized. Gains from antitrust litigation settlements are realized upon the receipt of cash and recorded as a reduction to cost of goods sold because they represent a recovery of amounts historically paid to manufacturers to originally acquire the pharmaceuticals that were the subject of the antitrust litigation settlements (see Note 13).

Derivative Financial Instruments and Nonderivative Hedges

The Company utilizes derivative financial instruments to manage exposures to foreign currency. The Company records all derivative financial instruments on the balance sheet at fair value and complies with established criteria for designation and effectiveness of hedging relationships. The Company's policy prohibits it from entering into derivative financial instruments for speculative or trading purposes.

The Company uses foreign currency denominated debt held at the parent level to offset a portion of its foreign currency exchange rate exposure on its net investments in Euro-denominated subsidiaries. The Company's €1.0 billion of senior notes (Note 6) are designated as nonderivative hedging instruments that are remeasured each reporting period to reflect changes in the foreign currency exchange spot rate, with changes since the last remeasurement date recorded as foreign currency translation adjustments as a component of other comprehensive income/loss. The Company recorded losses on its nonderivative hedges of \$55.3 million in Foreign Currency Translation Adjustments in the Consolidated Statement of Comprehensive Income in fiscal 2025.

Foreign Currency

When the functional currency of the Company's foreign operations is the applicable local currency, assets and liabilities are translated into U.S. dollars using the current exchange rates in effect at the balance sheet date, while revenues and expenses are translated at the weighted average exchange rates for the period. The resulting asset and liability translation adjustments are recorded as a component of Accumulated Other Comprehensive Loss within Stockholders' Equity.

During the quarter ended March 31, 2022, Turkey became a highly inflationary economy, as defined under GAAP. As a result, effective April 1, 2022, and until such time as the applicable economy is no longer considered highly inflationary, Turkish Lira-denominated assets and liabilities are remeasured using the Company's reporting currency in accordance with Accounting Standards Codification ("ASC") 830, "Foreign Currency Matters." Turkish Lira denominated monetary assets and liabilities (primarily cash, accounts receivables, and accounts payables) are remeasured at each balance sheet date using the currency exchange rate then in effect, with currency remeasurement gains and losses recognized in Other Income in the Statement of Operations. Turkish Lira-denominated nonmonetary assets and liabilities (primarily inventories, goodwill, and other intangible assets) are translated at the currency exchange rate in effect prior to highly inflation accounting commencement or at the exchange rate in effect at their date of acquisition if subsequent to April 1, 2022. As such, nonmonetary assets and liabilities retain a higher historical basis when currencies are devalued. This higher historical basis results in incremental expense being recognized when nonmonetary assets are consumed (i.e., sale of inventory). During fiscal 2025, 2024, and 2023, the Company recorded incremental expenses of \$49.6 million, \$54.1 million, and \$87.0 million, respectively, in Cost of Goods Sold related to the consumption of inventory and expenses of \$5.9 million, \$1.2 million, and \$9.0 million, respectively, within Other Loss (Income), Net related to the currency remeasurement of monetary assets and liabilities.

Goodwill and Other Intangible Assets

Goodwill arises from acquisitions or consolidations of specific operating companies and is assigned to the reporting unit in which a particular operating company resides. The Company identifies its reporting units based upon the Company's management reporting structure, beginning with its operating segments. The Company evaluates whether the components within its operating segments have similar economic characteristics, which include the similarity of long-term gross margins, the nature of the components' products, services, and production processes, the types of customers and the methods by which products or services are delivered to customers, and the components' regulatory environment and aggregates two or more components within an operating segment that have similar economic characteristics. As of September 30, 2025, the Company's reporting units included U.S. Pharmaceutical Distribution Services, U.S. Consulting Services, MWI Animal Health, Alliance Healthcare, Innomar, World Courier, PharmaLex, and Profarma.

Goodwill and other intangible assets with indefinite lives, such as certain trademarks and trade names, are not amortized; rather, they are tested for impairment at least annually. For the purpose of these impairment tests, the Company can elect to perform a qualitative assessment to determine if it is more likely than not that the fair values of its reporting units and indefinite-lived intangible assets are less than the respective carrying values of those reporting units and indefinite-lived intangible assets, respectively. Such qualitative factors can include, among others, industry and market conditions, overall financial performance, and relevant entity-specific events. If the Company concludes based on its qualitative assessment that it is more likely than not that the fair value of a reporting unit is less than its carrying value, it performs a quantitative analysis. The Company elected to perform quantitative impairment assessments of goodwill for all its reporting units in fiscal 2025, 2024, and 2023 with the exception of its PharmaLex reporting unit in fiscal 2023 since it was acquired in fiscal 2023. The Company elected to perform qualitative impairment assessments of indefinite-lived intangible assets in fiscal 2025, 2024, and 2023.

The quantitative goodwill impairment test requires the Company to compare the carrying value of the reporting unit's net assets to the fair value of the reporting unit. If the fair value exceeds the carrying value, no further evaluation is required, and no impairment loss is recognized. If the carrying amount exceeds the fair value, the difference between the carrying value and the fair value is recorded as an impairment loss, the amount of which may not exceed the total amount of goodwill allocated to the reporting unit.

When performing a quantitative impairment assessment, the Company utilizes an income approach or a weighted average of an income and market approach to value its reporting units. The income approach relies on a discounted cash flow analysis, which considers forecasted cash flows discounted at an appropriate discount rate, to determine the fair value of each reporting unit. The Company generally believes that market participants would use a discounted cash flow analysis to determine the fair value of the Company's reporting units in a sale transaction. The annual goodwill impairment test requires the Company to make several assumptions and estimates concerning future levels of revenue growth, earnings before interest, taxes, depreciation and amortization ("EBITDA"), EBITDA margins, capital expenditures, and working capital requirements, which are based upon the Company's long-range plan. The discount rate is an estimate of the overall after-tax rate of return required by a market participant whose weighted average cost of capital includes both debt and equity, including a risk premium. While the Company uses the best available information to prepare its forecasted cash flows and discount rate assumptions, actual future cash flows and/or market conditions could differ significantly resulting in future impairment charges related to recorded goodwill balances. While there are always changes in assumptions to reflect changing business and market conditions, the Company's overall methodology and the population of assumptions used have remained unchanged.

The Company completed its required annual impairment assessments relating to goodwill and indefinite-lived intangible assets in fiscal 2025, 2024, and 2023 and, as a result, recorded goodwill impairments (see Note 5) of \$723.9 million and \$418.0 million in its PharmaLex reporting unit in fiscal 2025 and 2024, respectively. No goodwill impairments were recorded in fiscal 2023 and no indefinite-lived intangible asset impairments were recorded in fiscal 2025, 2024, or 2023.

Finite-lived intangible assets are amortized using the straight-line method over the estimated useful lives of the assets. The Company performs a recoverability assessment of its long-lived assets when impairment indicators are present. The Company performed a recoverability assessment of PharmaLex's long-lived asset group as of July 1, 2025, and it was determined to be recoverable.

Income Taxes

The Company accounts for income taxes using a method that requires recognition of deferred tax assets and liabilities for expected future tax consequences of temporary differences that currently exist between tax bases and financial reporting bases of the Company's assets and liabilities (commonly known as the asset and liability method). In assessing the need to establish a valuation allowance on deferred tax assets, the Company considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized.

The Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained upon examination by the taxing authorities, including settlements with tax authorities or resolutions of any related appeals or litigation processes, based upon the technical merits of the position. Tax benefits associated with uncertain tax positions that have met the recognition criteria are measured and recorded based upon the highest probable outcome that is more than 50% likely to be realized after full disclosure and resolution of a tax examination.

Inventories

Inventories are stated at the lower of cost or market. Cost for approximately 63% and 65% of the Company's inventories as of September 30, 2025 and 2024, respectively, has been determined using the last-in, first-out ("LIFO") method. If the Company had used the first-in, first-out method of inventory valuation, which approximates current replacement cost, inventories would have been approximately \$1,458.9 million and \$1,535.8 million higher than the amounts reported as of September 30, 2025 and 2024, respectively. The Company recorded LIFO credits of \$76.9 million and \$52.2 million in fiscal 2025 and 2024, respectively, and LIFO expense of \$204.6 million in fiscal 2023. The annual LIFO provision is affected by manufacturer pricing practices, which may be impacted by market and other external influences, changes in inventory quantities, and product mix, many of which are difficult to predict. Changes to any of the above factors can have a material impact on the Company's annual LIFO provision. Cost for the Company's inventory that is not determined using the LIFO method is stated at the lower of cost or market using the first-in, first-out method or moving average price method.

Investments

The Company first evaluates its investments in accordance with the variable interest model to determine whether it has a controlling financial interest in an investment. This evaluation is made as of the date on which the Company makes its initial investment, and subsequent evaluations are made if the structure of the investment changes. If it has determined that an investment is a variable interest entity ("VIE"), the Company evaluates whether the VIE is required to be consolidated. When the Company holds rights that give it the power to direct the activities of an entity that most significantly impact the entity's economic performance, combined with the obligation to absorb an entity's losses and the right to receive benefits, the Company consolidates a VIE. If it is determined that an investment is not a VIE, the Company then evaluates its investments under the voting interest model and generally consolidates investments in which it holds an ownership interest of greater than 50%. When the Company consolidates less-than-wholly-owned subsidiaries, it records its noncontrolling interest in its consolidated financial statements.

For equity securities without a readily determinable fair value, the Company uses the fair value measurement alternative and measures the securities at cost less impairment, if any, including adjustments for observable price changes in orderly transactions for an identical or similar investment of the same issuer. For investments in which the Company can exercise significant influence but does not control, it uses the equity method of accounting. The Company's share of earnings and losses of its investments is recorded in Other Loss (Income), Net in the Consolidated Statements of Operations. The Company monitors its investments for impairment by considering factors such as the operating performance of the investment and current economic and market conditions. In fiscal 2025, the Company recorded a \$113.5 million impairment of an equity investment that was made in fiscal 2021 in Other Loss (Income), Net in its Consolidated Statement of Operations.

Leases

At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the facts and circumstances present. Leases are classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. At the lease commencement date, operating and finance lease liabilities and their corresponding right-of-use ("ROU") assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable and, as such, the Company uses its incremental borrowing rate to discount the lease liabilities, which is the rate incurred to borrow on a collateralized basis over a similar term in a similar economic environment. Certain adjustments to the ROU asset may be required for items such as incentives received. The Company does not recognize on the balance sheet leases with terms of one year or less.

The Company has operating leases that are primarily comprised of buildings, office equipment, distribution center equipment, and vehicles. Some of the Company's leases include options to extend or early terminate the lease, which are included in the lease term when it is reasonably certain to exercise and there is a significant economic incentive to exercise that option. Certain lease agreements contain provisions for future rent increases. Lease payments included in the measurement of the lease liability comprise fixed payments. The Company combines lease and non-lease components as a single component. Operating lease cost is recognized over the expected lease term on a straight-line basis and is recorded in Distribution, Selling, and Administrative in the Company's Consolidated Statements of Operations. Variable lease payments, which are primarily comprised of maintenance, taxes, and other payments based on usage, are recognized when the expense is incurred. The Company's leases do not contain residual value guarantees.

Manufacturer Incentives

The Company considers fees and other incentives received from its suppliers relating to the purchase and distribution of inventory to represent product discounts, and, as a result, they are recognized within cost of goods sold upon the sale of the related inventory.

Property and Equipment

Property and equipment are stated at cost and depreciated using the straight-line method over the estimated useful lives of the assets, which range from 3 to 40 years for buildings and improvements and from 3 to 10 years for machinery, equipment, and other. The costs of repairs and maintenance are charged to expense as incurred.

The Company capitalizes project costs relating to computer software developed or obtained for internal use when the activities related to the project reach the application development stage. Costs that are associated with preliminary stage activities, training, maintenance, and all other post-implementation stage activities are expensed as they are incurred. Software development costs are depreciated using the straight-line method over the estimated useful lives, which range from 3 to 10 years.

The following table summarizes the Company's property and equipment balances for the periods indicated:

(in thousands)	September 30,	
	2025	2024
Property and equipment, at cost:		
Land	\$ 124,999	\$ 117,128
Buildings and improvements	1,128,433	893,694
Machinery, equipment, and other	4,479,886	4,204,268
Total property and equipment	5,733,318	5,215,090
Less accumulated depreciation	(3,194,242)	(3,033,680)
Property and equipment, net	<u>\$ 2,539,076</u>	<u>\$ 2,181,410</u>

Revenue Recognition

The Company's revenues are primarily generated from the distribution of pharmaceutical products. The Company also generates revenues from global commercialization services, which include clinical trial support, post-approval and commercialization support, and global specialty transportation and logistics for the biopharmaceutical industry. See Note 14 for the Company's disaggregated revenue.

The Company recognizes revenue related to the distribution of products at a point in time when title and control transfers to customers and there is no further obligation to provide services related to such products. Service revenue is recognized over the period that services are provided to the customer. The Company is generally the principal in a transaction; therefore, revenue is primarily recorded on a gross basis. When the Company is the principal in a transaction, it has determined that it controls the ability to direct the use of the product or service prior to the transfer to a customer, it is primarily responsible for fulfilling the promise to provide the product or service to its customer, it has discretion in establishing pricing, and it controls the relationship with the customer. Revenue is recognized at the amount of consideration expected to be received. For the distribution business, revenue is primarily generated from a contract related to a confirmed purchase order with a customer in a distribution arrangement and is net of estimated sales returns and allowances, other customer incentives, and sales tax.

When the Company is the agent in a transaction, the fee received from a manufacturer customer is recognized within revenue as the service is performed.

The Company's customer sales return policy generally allows customers to return products only if the products can be resold at full value or returned to suppliers for full credit. The Company records an accrual for estimated customer sales returns at the time of sale to the customer based upon historical return trends. As of September 30, 2025 and 2024, the Company's accrual for estimated customer sales returns was \$1,625.8 million and \$1,175.9 million, respectively.

Share-Based Compensation

The Company accounts for the compensation cost of all share-based payments at fair value. The fair value of restricted stock units and performance stock units is based upon the grant date market price of the Company's common stock.

Share-based compensation expense is recognized over the requisite service period within Distribution, Selling, and Administrative in the Consolidated Statements of Operations to correspond with the same line item as the cash compensation paid to employees. Compensation expense associated with nonvested performance stock units is dependent upon the Company's periodic assessment of the probability of the targets being achieved and its estimate of the number of shares that will ultimately be issued.

The income tax effects of awards are recognized when the awards vest or are settled and are recognized in Income Tax Expense in the Company's Consolidated Statements of Operations.

Shipping and Handling Costs

Shipping and handling costs include all costs to warehouse, pick, pack, and deliver inventory to customers. These costs, which were \$1,294.4 million, \$1,265.7 million, and \$1,200.0 million for fiscal 2025, 2024, and 2023, respectively, are included in Distribution, Selling, and Administrative in the Company's Consolidated Statements of Operations.

Supplier Reserves

The Company establishes reserves against amounts due from its suppliers relating to various price and rebate incentives, including deductions or billings taken against payments otherwise due to them from the Company. These reserve estimates are established based upon the judgment of Company management after carefully considering the status of current outstanding claims, historical experience with the suppliers, the specific incentive programs, and any other pertinent information available to the Company. The Company evaluates the amounts due from its suppliers on a continual basis and adjusts the reserve estimates when appropriate based upon changes in circumstances. The ultimate outcome of any outstanding claim may be different than the Company's estimate.

Note 2. Acquisitions and Equity Method Investment

RCA Acquisition

On January 2, 2025, the Company acquired an 85% interest in Retina Consultants of America ("RCA") for \$4,042.0 million in cash, \$694.4 million of contingent consideration related to equity units for certain RCA physicians and members of management that retained the remaining 15% interest in RCA, \$545.7 million for the settlement of a net receivable resulting from a pre-existing commercial relationship between the Company and RCA, and \$393.1 million for contingent consideration payable to the sellers associated with RCA's achievement of certain predefined business objectives in fiscal 2027 and fiscal 2028. The Company funded the cash purchase price through a combination of cash on hand and new debt financing (see Note 6). The Company believes the acquisition of RCA allows it to broaden its relationships with community providers and to build on its leadership in specialty pharmaceuticals within its U.S. Healthcare Solutions reportable segment.

As part of the acquisition, certain RCA physicians and members of management retained equity in RCA. The Company evaluated the equity unit arrangements to determine if the contingent payments were part of the purchase price or post-acquisition compensation expense, which would be recognized over any future service period. The \$694.4 million of contingent consideration for the retained equity units was concluded to be a part of the purchase price and initially recorded at its fair value at the time of the acquisition based on the unit price that the Company paid to acquire RCA times the number of equity units retained by RCA physicians and members of management, and represents a Level 3 fair value measurement. The equity units retained by RCA physicians have an embedded option feature that is a liability classified compensation arrangement and is being expensed ratably over a period of 1.5 years. The fair value of the embedded option feature was determined using a Black-Scholes model that included assumptions for the equity unit value, expected life, and volatility and represents a Level 3 fair value measurement. During fiscal 2025, the Company recognized an expense of \$121.7 million related to this embedded option feature and other incentive units granted in conjunction with the acquisition of RCA in Acquisition-Related Deal and Integration Expenses in its Consolidated Statement of Operations. The liability and associated future expenses may vary based on the change in the estimated fair value and payments made. The Company's estimated liability related to the equity units is \$815.2 million and is recorded in Other Liabilities on the Company's Consolidated Balance Sheet, as of September 30, 2025.

The \$393.1 million of contingent consideration represented an initial estimate for RCA's achievement of certain predefined business objectives in fiscal 2027 and fiscal 2028 and provides for the potential payment to the sellers of up to \$500 million in the aggregate. The fair value of this liability was determined based on a weighted probability of the achievement of these objectives and represents a Level 3 fair value measurement. During the fourth quarter of fiscal 2025, the Company increased the estimated fair value of the liability related to the achievement of the predetermined business objectives from the initial estimated value and recorded an expense of \$19.6 million in Acquisition-Related Deal and Integration Expenses in its Consolidated Statement of Operations. The Company's estimated liability related to the achievement of the predetermined business objectives is \$412.6 million and is recorded in Other Liabilities on the Company's Consolidated Balance Sheet, as of September 30, 2025.

The purchase price has been preliminarily allocated to the underlying assets acquired and liabilities assumed based upon their estimated fair values at the date of the acquisition in the table that follows. The allocation as of September 30, 2025 is pending the finalization of working capital and tax account balances. There can be no assurance that the estimated amounts recorded will represent the final purchase price allocation.

(in thousands)		
Consideration		
Cash	\$	4,042,007
Total estimated contingent consideration		1,087,450
Settlement of a net receivable resulting from a pre-existing commercial relationship		545,738
Estimated fair value of total consideration	\$	5,675,195
Recognized amounts of identifiable assets acquired and liabilities assumed		
Cash and cash equivalents	\$	143,312
Accounts receivable		450,744
Inventories		110,564
Prepaid expenses and other		12,866
Property and equipment		173,098
Goodwill		4,774,338
Other intangible assets		178,000
Deferred income taxes		46,380
Other assets		182,307
Total assets acquired	\$	6,071,609
Accounts payable	\$	72,385
Accrued expenses and other		163,272
Accrued income taxes		4,258
Other liabilities		156,164
Total liabilities assumed	\$	396,079
Net assets acquired	\$	5,675,530
Total estimated contingent consideration		(1,087,450)
Settlement of a net receivable resulting from a pre-existing commercial relationship		(545,738)
Noncontrolling interest		(335)
Total cash paid		4,042,007
Cash acquired		(143,312)
Net cash paid	\$	3,898,695

The estimated fair value of the trade name acquired is \$178.0 million and the estimated useful life is 15 years.

Goodwill reflects the intangible assets that do not qualify for separate recognition. Approximately \$1,071 million of goodwill resulting from this acquisition is expected to be deductible for income tax purposes.

The Company incurred \$65.1 million of acquisition-related costs in connection with this acquisition. These costs are included in Acquisition-Related Deal and Integration Expenses in the Company's Consolidated Statements of Operations.

The Company's consolidated results of operations since the acquisition date include RCA revenue of \$2.1 billion. RCA's results of operations are included in the U.S. Healthcare Solutions reportable segment within the Company's business segment information (see Note 14).

Investment in OneOncology

In June 2023, the Company and TPG, a global alternative asset management firm, acquired OneOncology, LLC ("OneOncology"), a network of leading oncology practices. Including all direct transaction costs, the Company invested \$718.4 million (representing 34.9%) in a joint venture formed to acquire OneOncology for approximately \$2.1 billion, and TPG acquired the majority interest in the joint venture. The Company accounts for its interest in the joint venture as an equity method investment, which is included in Other Assets on its Consolidated Balance Sheet.

The Company and TPG Inc. (“TPG”) are party to a series of put and call options governing the remaining interests in the joint venture, including TPG’s interest. The Company owns a call option that, on the date that is the third anniversary of the closing, allows it to purchase the remaining interests in the joint venture at the greater of 19 times OneOncology’s adjusted earnings before interest, taxes, depreciation and amortization for the most recently ended 12-month period (“OneOncology EBITDA”) or 2.5 times a Multiple on Invested Capital, all of which is subject to various adjustments and qualifications. TPG owns a put option that, beginning on the third anniversary of the closing and ending on the day before the fourth anniversary of the closing, allows it to require the Company to purchase the remaining interests in the joint venture at a price equal to 19 times OneOncology EBITDA, subject to various adjustments and qualifications. The Company owns a call option that, beginning on the fourth anniversary of the closing and ending on the day before the fifth anniversary of the closing, allows it to purchase the remaining interests in the joint venture, also at a price equal to 19 times OneOncology EBITDA. The fair value of the net put option, which is a Level 3 fair value measurement, was determined using a Monte Carlo simulation, which relies on assumptions, including cash flow projections, risk-free rates, volatility, and details specific to the put and call options. The Company recorded the net fair value of the net put option of \$872.9 million, which is recorded within Other Liabilities with a corresponding offset in Other Assets in the Company’s Consolidated Balance Sheets. Given the Company has elected to not mark the net put option to market, the fair value of the net put option at the time of the investment will remain on the balance sheet until its final resolution.

Upon the joint venture’s acquisition of OneOncology, it was determined that there was a \$625.2 million difference between the carrying value of the Company’s investment in OneOncology and its underlying equity in net assets, which has been allocated to intangible assets of \$305.6 million, a related deferred tax liability of \$20.5 million, and goodwill of \$340.0 million. The intangible assets and related deferred tax liability are being amortized over a weighted-average life of 23 years.

PharmaLex Acquisition

The Company acquired and assumed control of PharmaLex Holding GmbH (“PharmaLex”) effective January 1, 2023 for \$1.473 billion, subject to customary adjustments, including a \$29.3 million cash holdback. PharmaLex is a component of the Company’s International Healthcare Solutions reportable segment.

The Company completed the purchase price allocations as of December 31, 2023. The purchase price was allocated to the underlying assets acquired, including \$37.4 million of cash and cash equivalents, and liabilities assumed based upon their estimated fair values as of the date of the acquisition.

The purchase price exceeded the estimated fair value of the net tangible and intangible assets acquired by \$1,010.2 million, which was allocated to goodwill. Goodwill resulting from this acquisition is not deductible for income tax purposes.

The estimated fair value of the intangible assets acquired of \$558.9 million, and the estimated useful lives are as follows:

(in thousands, except useful lives)	Fair Value	Useful Lives
Customer relationships	\$ 522,634	12
Trade names	30,931	5
Software technology	5,333	6
Total	<u>\$ 558,898</u>	

The Company established an estimated deferred tax liability of \$146.0 million primarily in connection with the intangible assets acquired.

Note 3. Variable Interest Entity

The Company has substantial governance rights that allow it to direct the activities that significantly impact Profarma's economic performance. As such, the Company consolidates the operating results of Profarma in its consolidated financial statements. The Company is not obligated to provide future financial support to Profarma.

The following assets and liabilities of Profarma are included in the Company's Consolidated Balance Sheet for the periods indicated:

(in thousands)	September 30,	
	2025	2024
Cash and cash equivalents	\$ 70,796	\$ 58,082
Accounts receivables, net	260,759	236,930
Inventories	303,480	259,299
Prepaid expenses and other	55,981	68,612
Property and equipment, net	65,410	49,869
Other intangible assets	53,861	58,116
Other long-term assets	99,519	83,765
Total assets	<u>\$ 909,806</u>	<u>\$ 814,673</u>
Accounts payable	\$ 349,876	\$ 307,201
Accrued expenses and other	71,383	56,597
Short-term debt	116,361	76,308
Long-term debt	65,390	91,246
Deferred income taxes	11,986	19,227
Other long-term liabilities	75,132	61,690
Total liabilities	<u>\$ 690,128</u>	<u>\$ 612,269</u>

Profarma's assets can only be used to settle its obligations, and its creditors do not have recourse to the general credit of the Company.

Note 4. Income Taxes

Income Before Income Taxes

The following table summarizes the Company's income before income taxes for the periods indicated:

(in thousands)	Fiscal Year Ended September 30,		
	2025	2024	2023
Domestic	\$ 1,611,725	\$ 1,288,983	\$ 1,418,457
Foreign	646,611	714,992	742,379
Total	<u>\$ 2,258,336</u>	<u>\$ 2,003,975</u>	<u>\$ 2,160,836</u>

Income Tax Expense

The components of the Company's consolidated income tax expense are summarized in the following table for the periods indicated:

(in thousands)	Fiscal Year Ended September 30,		
	2025	2024	2023
Current provision:			
Federal	\$ 331,272	\$ 309,380	\$ 259,126
State and local	99,084	80,040	42,933
Foreign	200,302	197,606	245,065
Total current provision	<u>630,658</u>	<u>587,026</u>	<u>547,124</u>
Deferred provision (benefit):			
Federal	57,967	(17,934)	(15,600)
State and local	24,335	1,392	19,445
Foreign	(22,438)	(85,782)	(122,709)
Total deferred provision (benefit)	<u>59,864</u>	<u>(102,324)</u>	<u>(118,864)</u>
Income tax expense	<u>\$ 690,522</u>	<u>\$ 484,702</u>	<u>\$ 428,260</u>

Tax Rate Reconciliation

A reconciliation of the statutory U.S. federal income tax rate to the Company's consolidated effective income tax rate is as follows for the periods indicated:

	Fiscal Year Ended September 30,		
	2025	2024	2023
Statutory U.S. federal income tax rate	21.0%	21.0%	21.0%
State and local income tax rate, net of federal tax benefit	3.4	3.0	2.3
Tax effect of foreign operations	(2.7)	(2.4)	(2.3)
Foreign-derived intangible income	(4.0)	(0.5)	(0.1)
Unrecognized tax benefits	3.4	0.9	(0.4)
Impairment of assets, including goodwill	8.2	4.9	—
RCA contingent consideration adjustments	1.3	—	—
Change in valuation allowance	0.2	(4.2)	0.1
Other, net	(0.2)	1.5	(0.8)
Effective income tax rate	<u>30.6%</u>	<u>24.2%</u>	<u>19.8%</u>

Deferred Tax Liabilities and Assets

Deferred income taxes reflect the future tax consequences of differences between the tax bases of assets and liabilities and their financial reporting amounts. Significant components of the Company's deferred tax liabilities (assets) are as follows:

(in thousands)	September 30,	
	2025	2024
Inventories	\$ 1,578,513	\$ 1,537,057
Property and equipment	109,649	103,959
Goodwill and other intangible assets	1,081,544	1,143,962
Right-of-use assets	384,884	285,434
Other	37,266	31,416
Gross deferred tax liabilities	3,191,856	3,101,828
Net operating loss carryforwards and other tax attributes	(623,370)	(530,024)
Allowance for credit losses	(25,670)	(18,949)
Accrued expenses	(17,047)	(9,419)
Accrued litigation liability	(771,912)	(855,962)
Employee and retiree benefits	(31,466)	(26,960)
Goodwill and other intangible assets	(379,401)	(401,822)
Lease liabilities	(416,718)	(312,357)
Share-based compensation	(27,247)	(23,161)
Other	(149,001)	(128,136)
Gross deferred tax assets	(2,441,832)	(2,306,790)
Valuation allowance for deferred tax assets	661,890	602,361
Deferred tax assets, net of valuation allowance	(1,779,942)	(1,704,429)
Net deferred tax liabilities	\$ 1,411,914	\$ 1,397,399

As of September 30, 2025, the Company had \$168.2 million of potential tax benefits from federal and state net operating loss and other tax attribute carryforwards and \$491.6 million of potential tax benefits from foreign loss carryforwards, both of which have varying expiration dates. The Company had \$1.5 million of federal tax credit carryforwards, \$1.0 million of state tax credit carryforwards, and \$3.1 million of foreign alternative minimum tax credit carryforwards.

The Company assesses the available positive and negative evidence to determine whether deferred tax assets are more likely than not to be realized. As a result of this assessment, valuation allowances have been recorded on certain deferred tax assets. For fiscal 2025, the Company increased the valuation allowance on deferred tax assets by \$59.5 million primarily due to the change in the valuation allowance against foreign net operating loss carryforwards. For fiscal 2024, the Company decreased the valuation allowance on deferred tax assets by \$35.0 million primarily due to the increase in the valuation allowance against tax deductible goodwill.

In fiscal 2025, 2024, and 2023, tax benefits of \$16.0 million, \$15.0 million, and \$24.6 million, respectively, related to the exercise of employee stock options and lapses of restricted stock units were recorded in Income Tax Expense in the Company's Consolidated Statements of Operations. The tax benefits recognized in fiscal 2025, 2024, and 2023 are not necessarily indicative of amounts that may arise in future periods.

Income tax payments, net of refunds, were \$571.2 million, \$603.9 million, and \$463.1 million in fiscal 2025, 2024, and 2023, respectively.

Cumulative undistributed earnings of international subsidiaries were \$4.3 billion as of September 30, 2025, \$2.3 billion of which is considered permanently reinvested. It is not practicable to estimate the taxes that would be due if such earnings were to be repatriated in the future.

The Company and its subsidiaries file income tax returns in the U.S. federal jurisdiction and various states and foreign jurisdictions. The Company is currently undergoing certain state and local income tax audits for various years. With few exceptions, the Company is no longer subject to U.S. federal, state and local, or foreign income tax examinations by tax authorities for years before 2020. The Company believes it has adequate tax reserves to cover potential federal, state or foreign tax exposures.

Unrecognized Tax Benefits

As of September 30, 2025 and 2024, the Company had unrecognized tax benefits, defined as the aggregate tax effect of differences between tax return positions and the benefits recognized in the Company's financial statements, of \$640.5 million and \$545.0 million, respectively (\$583.8 million and \$498.0 million, net of federal tax benefit, respectively). If recognized in fiscal 2025 and 2024, \$574.0 million and \$488.1 million, respectively, of these benefits would have reduced income tax expense and the effective tax rate. As of September 30, 2025 and 2024, included in the unrecognized tax benefits are \$72.3 million and \$43.9 million of interest and penalties, respectively, which the Company records in Income Tax Expense in the Company's Consolidated Statements of Operations.

A reconciliation of the beginning and ending amount of unrecognized tax benefits, excluding interest and penalties, for the periods indicated is as follows:

(in thousands)	Fiscal Year Ended September 30,		
	2025	2024	2023
Unrecognized tax benefits at beginning of period	\$ 501,064	\$ 525,933	\$ 526,522
Additions to tax positions of the current year	41,433	13,636	22,646
Additions to tax positions of the prior years	37,611	—	11,875
Reductions of tax positions of the prior years	—	(37,520)	(31,110)
Settlements and expiration of statutes of limitations	(12,406)	(2,410)	(3,457)
Effects of foreign currency translation	457	1,425	(543)
Unrecognized tax benefits at end of period	\$ 568,159	\$ 501,064	\$ 525,933

During the next 12 months, the Company does not anticipate any material change in unrecognized tax benefits due to tax audit resolutions and the expiration of statutes of limitations.

A significant portion of the Company's unrecognized tax benefits as of September 30, 2025 relates to the legal accrual for litigation related to the Distributor Settlement Agreement, as well as other opioid-related litigation, as disclosed in Note 12. The Company has applied significant judgment in estimating the amount of the opioid settlements that will be deductible for U.S. federal and state purposes. In estimating the amount that would be deductible, the Company considered prior U.S. tax case law, the amount and character of the damages sought in litigation, and other relevant factors.

Note 5. Goodwill and Other Intangible Assets

The following is a summary of the changes in the carrying value of goodwill, by reportable segment, for fiscal 2025 and 2024:

(in thousands)	U.S. Healthcare Solutions	International Healthcare Solutions	Total
Goodwill as of September 30, 2023	\$ 6,205,774	\$ 3,368,343	\$ 9,574,117
Purchase accounting adjustments	—	(12,904)	(12,904)
Goodwill recognized in connection with acquisitions	—	18,712	18,712
Goodwill impairment	—	(418,000)	(418,000)
Foreign currency translation	2,748	153,354	156,102
Goodwill as of September 30, 2024	6,208,522	3,109,505	9,318,027
Goodwill recognized in connection with acquisitions	4,896,085	123,112	5,019,197
Goodwill impairment	—	(723,884)	(723,884)
Foreign currency translation	383	62,797	63,180
Goodwill as of September 30, 2025	\$ 11,104,990	\$ 2,571,530	\$ 13,676,520

The Company continued to experience weakening demand for specialized services in the life sciences industry, which has negatively impacted the operating results of PharmaLex. In the fourth quarter of fiscal 2025 and in connection with the Company's annual budgeting process, the Company revised PharmaLex's long-range forecast. In connection with the Company's annual goodwill impairment assessment, it recorded a full impairment of the remaining goodwill of \$723.9 million in the PharmaLex reporting unit. The fair value of the reporting unit was determined based on a weighted average of income and market approaches. The income approach includes the Company's forecasted cash flows in its long-range plan as well as discount rate and income tax rate assumptions. This represents a Level 3 nonrecurring fair value measurement. The Company believes that its assumptions are representative of market participant assumptions; however, the forecasted cash flows used to estimate fair value and measure the related impairment are inherently uncertain and include assumptions that could differ from actual results in future periods.

The carrying values of goodwill as of September 30, 2025 and 2024 are net of the following accumulated impairments:

(in thousands)	U.S. Healthcare Solutions	International Healthcare Solutions
Accumulated impairment losses as of September 30, 2025	\$ —	\$ 1,217,820
Accumulated impairment losses as of September 30, 2024	\$ —	\$ 493,936

The Company performed a recoverability assessment of PharmaLex's long-lived assets as of July 1, 2025 using its revised long-range forecast. The recoverability assessment compared PharmaLex's undiscounted cash flows to the carrying value of the PharmaLex asset group, including goodwill, and it was determined to be recoverable.

The following is a summary of other intangible assets:

	September 30, 2025				September 30, 2024		
(dollars in thousands)	Weighted Average Remaining Useful Life	Gross Carrying Amount	Accumulated Amortization	Net Carrying Amount	Gross Carrying Amount	Accumulated Amortization	Net Carrying Amount
Indefinite-lived trade name		\$ 17,000	\$ —	\$ 17,000	\$ 17,000	\$ —	\$ 17,000
Finite-lived:							
Customer relationships	12 years	5,250,912	(1,860,484)	3,390,428	5,090,864	(1,536,081)	3,554,783
Trade names and other	11 years	1,457,176	(1,090,423)	366,753	1,259,954	(830,691)	429,263
Total other intangible assets		\$ 6,725,088	\$ (2,950,907)	\$ 3,774,181	\$ 6,367,818	\$ (2,366,772)	\$ 4,001,046

Amortization expense for finite-lived intangible assets was \$556.9 million, \$663.5 million, and \$553.6 million in fiscal 2025, 2024, and 2023, respectively. Amortization expense for finite-lived intangible assets is estimated to be \$401.0 million in fiscal 2026, \$341.9 million in fiscal 2027, \$330.0 million in fiscal 2028, \$314.9 million in fiscal 2029, \$294.1 million in fiscal 2030, and \$2,075.3 million thereafter.

Note 6. Debt

Debt consisted of the following:

(in thousands)	September 30,	
	2025	2024
Multi-currency revolving credit facility due in 2030	\$ —	\$ —
Receivables securitization facility due in 2028	—	—
Term loan due in 2027	799,043	—
Money market facility due in 2027	—	—
Working capital credit facility due in 2026	—	—
\$500,000, 3.250% senior notes due 2025	—	499,738
\$750,000, 3.450% senior notes due 2027	748,150	747,308
\$500,000, 4.625% senior notes due 2027	497,309	—
€500,000, 2.875% senior notes due 2028	583,903	—
\$600,000, 4.850% senior notes due 2029	596,603	—
\$500,000, 2.800% senior notes due 2030	497,174	496,564
\$1,000,000, 2.700% senior notes due 2031	993,838	992,718
€500,000, 3.625% senior notes due 2032	581,685	—
\$500,000, 5.125% senior notes due 2034	495,104	494,514
\$700,000, 5.150% senior notes due 2035	694,909	—
\$500,000, 4.250% senior notes due 2045	495,792	495,574
\$500,000, 4.300% senior notes due 2047	494,088	493,821
Alliance Healthcare debt	1,424	286
Nonrecourse debt	181,751	167,553
Total debt	7,660,773	4,388,076
Less current portion of senior notes	—	499,738
Less Alliance Healthcare current portion	1,424	286
Less nonrecourse current portion	116,361	76,307
Long-term debt	\$ 7,542,988	\$ 3,811,745

Multi-Currency Revolving Credit Facility

The Company had a \$2.4 billion multi-currency senior unsecured revolving credit facility (“Multi-Currency Revolving Credit Facility”) with a syndicate of lenders, which was scheduled to expire in October 2029. In June 2025, the Company amended and restated the Multi-Currency Revolving Credit Facility to extend the expiration to June 2030 and increase the aggregate amount of the commitments under this facility to \$4.5 billion. Interest on borrowings under the Multi-Currency Revolving Credit Facility accrues at specified rates based upon the Company’s debt rating. The Company pays facility fees to maintain the availability under the Multi-Currency Revolving Credit Facility at specified rates based on its debt rating. The Company may choose to repay or reduce its commitments under the Multi-Currency Revolving Credit Facility at any time. The Multi-Currency Revolving Credit Facility contains covenants, including compliance with a financial leverage ratio test, as well as others that impose limitations on, among other things, indebtedness of subsidiaries and asset sales, with which the Company was compliant as of September 30, 2025. There were no borrowings outstanding under the Multi-Currency Revolving Credit Facility as of September 30, 2025 and 2024.

Commercial Paper Program

The Company had a \$3.4 billion commercial paper program. In September 2025, the Company increased its commercial paper program to \$4.5 billion. The commercial paper program does not increase the Company’s borrowing capacity, and it is fully backed by its Multi-Currency Revolving Credit Facility. The Company may, from time to time, issue short-term promissory notes in an aggregate amount of up to \$4.5 billion at any one time. Amounts available under the program may be borrowed, repaid, and re-borrowed from time to time. The maturities on the notes will vary but may not exceed 365 days from the date of issuance. The notes will bear interest, if interest bearing, or will be sold at a discount from their face amounts. There were no borrowings outstanding under the commercial paper program as of September 30, 2025 and 2024.

364-Day Revolving Credit Facility

In November 2024, the Company entered into an agreement pursuant to which it obtained a \$1.0 billion senior unsecured revolving credit facility (the “364-Day Revolving Credit Facility”) with a syndicate of lenders, which was scheduled to expire 364 days after the January 2, 2025 closing of the RCA acquisition, the date on which borrowings under this facility became available to the Company. In June 2025, in conjunction with the amendment to the Multi-Currency Revolving Credit Facility, the Company terminated the 364-Day Revolving Credit Facility.

Receivables Securitization Facility

The Company had a \$1.45 billion receivables securitization facility (“Receivables Securitization Facility”), which was scheduled to expire in October 2027. In June 2025, the Company amended the Receivables Securitization Facility to extend the expiration to June 2028, increase the size of the facility to \$1.5 billion, and increase its accordion feature to \$500 million from \$250 million. This accordion feature allows the Company to increase the commitment on the Receivables Securitization Facility up to \$500 million, subject to lender approval. Interest rates are based on prevailing market rates for short-term commercial paper or 30-day Term SOFR, plus a program fee. The Company pays a customary unused fee at prevailing market rates, monthly, to maintain the availability under the Receivables Securitization Facility. The Receivables Securitization Facility contains similar covenants to the Multi-Currency Revolving Credit Facility, with which the Company was compliant as of September 30, 2025. There were no borrowings outstanding under the Receivables Securitization Facility as of September 30, 2025 and 2024.

In connection with the Receivables Securitization Facility, AmerisourceBergen Drug Corporation and a specialty distribution subsidiary sell on a revolving basis certain accounts receivable to Amerisource Receivables Financial Corporation, a wholly-owned special purpose entity, which in turn sells a percentage ownership interest in the receivables to financial institutions and commercial paper conduits sponsored by financial institutions. AmerisourceBergen Drug Corporation is the servicer of the accounts receivable under the Receivables Securitization Facility. As sold receivables are collected, additional receivables may be sold up to the maximum amount available under the facility. The Company uses the facility as a financing vehicle because it generally offers an attractive interest rate relative to other financing sources. The Company securitizes its trade accounts, which are generally non-interest bearing, in transactions that are accounted for as borrowings.

Money Market Facility

The Company has an uncommitted, unsecured line of credit available to it pursuant to a money market credit agreement (“Money Market Facility”). In September 2025, the Company entered into an amendment to the Money Market Facility pursuant to which it may request short-term unsecured revolving credit loans in a principal amount not to exceed \$500 million on or after April 1 and before December 1 of any year and increases to \$750 million on or after December 1 and before March 31 of any year. The Money Market Facility may be decreased or terminated by the bank or the Company at any time without prior notice. There were no borrowings outstanding under the Money Market Facility as September 30, 2025 and 2024.

Working Capital Credit Facility

In July 2025, the Company entered into an uncommitted, unsecured line of credit to support its working capital needs (“Working Capital Credit Facility”). The Working Capital Credit Facility provides the Company with the ability to request short-term, unsecured revolving credit loans from time to time in a principal amount not to exceed \$500 million. The Working Capital Credit Facility expires in July 2026 and may be decreased or terminated by the bank or the Company at any time without prior notice. There were no borrowings outstanding under the Working Capital Credit Facility as of September 30, 2025.

Term Loan

In January 2025, the Company borrowed \$1.5 billion on a variable-rate term loan (“Term Loan”) that was scheduled to mature in December 2027. In September 2025, the Company amended the Term Loan to shorten the maturity to October 2027. The Term Loan was used to finance a portion of the acquisition of RCA (see Note 2). The Term Loan bears interest at a rate equal to either an adjusted SOFR plus an applicable margin or an alternate base rate plus an applicable margin. The margins are based on the Company’s public debt ratings. The Term Loan contains similar covenants to the Multi-Currency Revolving Credit Facility. The Company has the right to prepay the borrowings under the Term Loan at any time, in whole or in part and without premium or penalty. Through September 30, 2025, the Company elected to make early principal payments of \$700 million on the Term Loan.

Senior Notes

In December 2024, the Company issued \$500 million of 4.625% senior notes due in December 2027 (the “2027 Notes”), \$600 million of 4.850% senior notes due in December 2029 (the “2029 Notes”), and \$700 million of 5.150% senior notes due in February 2035 (the “2035 Notes”). The 2027 Notes were sold at 99.815% of the principal amount with an effective yield of 4.634%. The 2029 Notes were sold at 99.968% of the principal amount with an effective yield of 4.852%. The 2035 Notes were sold at 99.945% of the principal amount with an effective yield of 5.153%. Interest on the 2027 Notes and the 2029 Notes is payable semi-annually in arrears on June 15 and December 15, which began on June 15, 2025. Interest on the 2035 Notes is payable semi-annually in arrears on February 15 and August 15, which began on February 15, 2025. The Company used the proceeds from the 2027 Notes, the 2029 Notes, and the 2035 Notes to finance a portion of the acquisition of RCA.

In May 2025, the Company issued €500 million of 2.875% senior notes due in May 2028 (the “2028 Notes”) and €500 million of 3.625% senior notes due in May 2032 (the “2032 Notes”). The 2028 Notes were sold at 99.960% of the principal amount with an effective yield of 2.876%. The 2032 Notes were sold at 99.757% of the principal amount with an effective yield of 3.634%. Interest on the 2028 Notes and the 2032 Notes is payable annually in arrears beginning on May 22, 2026. The Company used the proceeds from the 2028 Notes and the 2032 Notes for general corporate purposes.

The senior notes discussed above and also illustrated in the above debt table are collectively referred to as the “Notes.” Interest on the Notes is payable semiannually in arrears, with the exception of the 2028 Notes and the 2032 Notes, which are paid annually in arrears. Most of the Notes were sold at small discounts to the principal amounts and, therefore, have effective yields that are greater than the stated interest rates in the table above. Costs incurred in connection with the issuance of the Notes were deferred and are being amortized over the terms of the Notes. The indentures governing the Notes contain restrictions and covenants, which include limitations on additional indebtedness; distributions to stockholders; the repurchase of stock and the making of other restricted payments; issuance of preferred stock; creation of certain liens; transactions with subsidiaries and other affiliates; and certain corporate acts such as mergers, consolidations, and the sale of substantially all assets. An additional covenant requires compliance with a financial leverage ratio test. The Company was compliant with all covenants as of September 30, 2025.

In March 2025, the Company’s \$500 million of 3.250% senior notes matured and was repaid.

Alliance Healthcare Debt

Alliance Healthcare debt is comprised of uncommitted revolving credit facilities in various currencies with various rates. These facilities are used to fund its working capital needs.

Nonrecourse Debt

Nonrecourse debt is comprised of short-term and long-term debt belonging to the Brazil subsidiaries and is repaid solely from the Brazil subsidiaries’ cash flows and such debt agreements provide that the repayment of the loans (and interest thereon) is secured solely by the capital stock, physical assets, contracts, and cash flows of the Brazil subsidiaries.

Other Information

Scheduled future principal payments of debt are \$115.2 million in fiscal 2026, \$24.9 million in fiscal 2027, \$2.7 billion in fiscal 2028, \$8.7 million in fiscal 2029, \$1.1 billion in fiscal 2030, and \$3.8 billion thereafter.

Interest paid on the above indebtedness during fiscal 2025, 2024, and 2023 was \$356.5 million, \$250.1 million, and \$271.3 million, respectively.

Total amortization of financing fees and the accretion of original issue discounts, which are recorded as components of Interest Expense, Net on the Consolidated Statements of Operations, were \$10.2 million, \$7.2 million, and \$8.5 million, for fiscal 2025, 2024, and 2023, respectively.

Note 7. Stockholders’ Equity and Weighted Average Common Shares Outstanding

The authorized capital stock of the Company consists of 600,000,000 shares of common stock, par value \$0.01 per share (the “common stock”), and 10,000,000 shares of preferred stock, par value \$0.01 per share (the “preferred stock”).

The holders of the Company’s common stock are entitled to one vote per share and have the exclusive right to vote for the Board of Directors and for all other purposes as provided by law. Subject to the rights of holders of the Company’s preferred stock, holders of common stock are entitled to receive ratably on a per share basis such dividends and other distributions in cash, stock, or property of the Company as may be declared by the Board of Directors from time to time out of the legally available assets or funds of the Company.

The following illustrates the components of Accumulated Other Comprehensive Loss, net of income taxes:

(in thousands)	September 30,	
	2025	2024
Foreign currency translation	\$ (903,078)	\$ (988,484)
Other, net	1,700	(634)
Total accumulated other comprehensive loss	<u>\$ (901,378)</u>	<u>\$ (989,118)</u>

In May 2022, the Company's Board of Directors authorized a share repurchase program allowing the Company to purchase up to \$1.0 billion of its outstanding shares of common stock, subject to market conditions. During fiscal 2023, the Company purchased 6.0 million shares of its common stock for \$961.3 million to complete its authorization under this program.

In March 2023, the Company's Board of Directors authorized a share repurchase program allowing the Company to purchase up to \$1.0 billion of its outstanding shares of common stock, subject to market conditions. During fiscal 2023, the Company purchased 1.0 million shares of its common stock for \$191.0 million under this program. During fiscal 2024, the Company purchased 3.9 million shares of its common stock for \$809.0 million to complete its authorization under this program.

In March 2024, the Company's Board of Directors authorized a share repurchase program allowing the Company to purchase up to \$2.0 billion of its outstanding common stock, subject to market conditions. During fiscal 2024, the Company purchased 3.0 million shares of its common stock for \$682.3 million under this program. During fiscal 2025, the Company purchased 1.9 million shares of its common stock for \$435.4 million under this program. As of September 30, 2025, the Company had \$882.2 million availability under this program.

Common Shares Outstanding

Basic earnings per share is computed by dividing net income attributable to Cencora, Inc. by the weighted average number of shares of common stock outstanding during the periods presented. Diluted earnings per share is computed by dividing net income attributable to Cencora, Inc. by the weighted average number of shares of common stock outstanding, plus the dilutive effect of restricted stock units and stock options during the periods presented.

The following illustrates the components of diluted weighted average shares outstanding:

(in thousands)	Fiscal Year Ended September 30,		
	2025	2024	2023
Weighted average common shares outstanding - basic	193,820	198,503	202,511
Effect of dilutive securities - restricted stock units and stock options	1,394	1,781	2,080
Weighted average common shares outstanding - diluted	<u>195,214</u>	<u>200,284</u>	<u>204,591</u>

The potentially dilutive restricted stock units and stock options that were antidilutive were 69 thousand, 85 thousand, and 94 thousand for fiscal 2025, 2024 and 2023, respectively.

Note 8. Retirement and Other Benefit Plans

The Company sponsors various retirement benefit plans and a deferred compensation plan covering eligible employees.

The Compensation and Succession Planning Committee ("Compensation Committee") of the Company's Board of Directors has delegated the administration of the Company's retirement and other benefit plans to its Benefits Committee, an internal committee, comprised of senior finance, human resources, and legal executives. The Benefits Committee is responsible for the investment options under the Company's savings plans, as well as performance of the investment advisers and plan administrators.

Retirement Benefit Plans

The Company sponsors the Cencora, Inc. Employee Investment Plan (the “Plan”), which is a defined contribution 401(k) plan covering salaried and certain hourly employees. Eligible participants may contribute to the plan from 1% to 50% of their regular compensation before taxes. The Company contributes \$1.00 for each \$1.00 invested by the participant up to the first 3% of the participant’s salary and \$0.50 for each additional \$1.00 invested by the participant of up to an additional 2% of salary. An additional discretionary contribution, in an amount not to exceed the limits established by the Internal Revenue Code of 1986, as amended (the “IRC”), may also be made depending upon the Company’s performance. Based on the Company’s performance in fiscal 2025, 2024, and 2023, the Company recognized expenses for discretionary contributions to the Plan in fiscal 2025, 2024, and 2023. All contributions are invested at the direction of the employee in one or more funds. All company matching contributions vest immediately except for the discretionary contributions made by the Company, which vest in full after five years of credited service.

The Company’s international businesses sponsor various country-specific retirement plans.

Costs of above retirement benefit plans charged to expense for fiscal 2025, 2024, and 2023 were \$125.3 million, \$99.8 million, and \$89.4 million, respectively. The increase in the cost of the retirement benefit plans from fiscal 2024 to fiscal 2025 is primarily due to the January 2025 acquisition of RCA.

Deferred Compensation Plan

The Company sponsors the Cencora, Inc. Deferred Compensation Plan. This unfunded plan allows eligible officers, directors and key management employees to defer a portion of their annual compensation and provides for a benefit restoration feature to selected key management. The benefit restoration feature provides certain eligible participants, including the Company’s executive officers, with an annual amount equal to 4% of the participant’s total cash compensation to the extent that an employee’s compensation exceeds the annual compensation limit established by Section 401(a) (17) of the IRC. The Company’s liability relating to its deferred compensation plan, including the benefit restoration feature, as of September 30, 2025 and 2024 was \$63.1 million and \$57.9 million, respectively.

Note 9. Share-Based Compensation

The Company’s stockholders approved the AmerisourceBergen Corporation 2022 Omnibus Incentive Plan (the “2022 Plan”). As of September 30, 2025, there were 17.9 million shares available to be granted for employee and non-employee director stock restricted stock units, performance stock units, and stock options under the 2022 Plan.

Restricted Stock Units

The majority of restricted stock units granted vest ratably over a three-year period. The estimated fair value of restricted stock units under the Company’s restricted stock unit plan is determined by the product of the number of shares granted and the closing grant date market price of the Company’s common stock. The estimated fair value of restricted stock units is expensed on a straight-line basis over the requisite service period, net of estimated forfeitures. During fiscal 2025, 2024, and 2023, the Company recognized restricted stock unit expense of \$108.7 million, \$98.9 million, and \$84.3 million, respectively.

A summary of the status of the Company’s nonvested restricted stock units as of September 30, 2025 and changes during fiscal 2025 are presented below:

(in thousands, except grant date fair value)	Restricted Stock Units	Weighted Average Grant Date Fair Value
Nonvested as of September 30, 2024	1,208	\$173
Granted	522	\$242
Vested	(588)	\$159
Forfeited	(64)	\$206
Nonvested as of September 30, 2025	1,078	\$213

During fiscal 2025, 2024, and 2023, the total fair values of restricted stock units vested were \$93.6 million, \$83.2 million, and \$103.0 million, respectively. Expected future compensation expense relating to the 1.1 million restricted stock units outstanding as of September 30, 2025 is \$89.4 million, which will be recognized over a weighted average period of 1.4 years.

Performance Stock Units

Performance stock units are granted to certain executive employees under the Plan and represent common stock potentially issuable in the future. Performance stock units vest at the end of a three-year performance period based upon achievement of specific performance goals. Based upon the extent to which the targets are achieved, vested shares may range from 0% to 230% of the target award amount. The fair value of performance stock units is determined by the grant date market price of the Company's common stock. Compensation expense associated with nonvested performance stock units is recognized over the requisite service period and is dependent on the Company's periodic assessment of the probability of the targets being achieved and its estimate of the number of shares that will ultimately be issued. During fiscal 2025, 2024, and 2023, the Company recognized performance stock expense of \$38.9 million, \$48.7 million, and \$40.4 million, respectively.

A summary of the status of the Company's nonvested performance stock units as of September 30, 2025 and changes during fiscal 2025 is presented below (based upon target award amounts).

(in thousands, except grant date fair value)	Performance Stock Units	Weighted Average Grant Date Fair Value
Nonvested as of September 30, 2024	248	\$178
Granted	125	\$243
Vested	(120)	\$158
Forfeited	(7)	\$211
Nonvested as of September 30, 2025	246	\$220

Shares that vested over the three-year performance period ended September 30, 2025 were distributed to employees in November 2025.

Stock Options

The Company has not granted any stock options since fiscal 2020.

In fiscal 2025, employees exercised 387 thousand stock options at a weighted average exercise price of \$87 per stock option. There were 147 thousand stock options outstanding as of September 30, 2025, all of which are exercisable, with a weighted average exercise price of \$87 per option. The weighted average remaining contractual term for outstanding stock options was one year as of September 30, 2025.

Note 10. Leases

The Company has long-term leases for facilities and equipment. In the normal course of business, leases are generally renewed or replaced by other leases. Certain leases include escalation clauses.

The following illustrates the components of lease cost for the periods presented:

(in thousands)	Fiscal Year Ended September 30,		
	2025	2024	2023
Operating lease cost	\$ 303,822	\$ 245,415	\$ 234,567
Short-term lease cost	9,571	18,459	9,799
Variable lease cost	37,573	35,539	25,598
Total lease cost	\$ 350,966	\$ 299,413	\$ 269,964

The following summarizes balance sheet information related to operating leases:

(in thousands, except for lease term and discount rate)	September 30,	
	2025	2024
Right of use assets		
Other assets	\$ 1,548,478	\$ 1,141,622
Lease liabilities		
Accrued expenses and other	\$ 253,770	\$ 204,767
Other long-term liabilities	1,416,633	1,029,978
Total lease liabilities	\$ 1,670,403	\$ 1,234,745
Weighted-average remaining lease term	7.55 years	7.34 years
Weighted-average discount rate	4.63%	4.18%

Other cash flow information related to operating leases is as follows:

(in thousands)	Fiscal Year Ended September 30,		
	2025	2024	2023
Cash paid for amounts included in the measurement of lease liabilities			
Operating lease cash payments	\$ 294,430	\$ 247,862	\$ 229,203
Right-of-use assets obtained in exchange for lease liabilities			
New operating leases	\$ 655,991	\$ 305,882	\$ 271,096

Future minimum rental payments under noncancellable operating leases were as follows:

Payments Due by Fiscal Year (in thousands)	As of September 30, 2025
2026	\$ 319,915
2027	295,076
2028	269,676
2029	237,780
2030	190,742
Thereafter	668,804
Total future undiscounted lease payments	1,981,993
Less: Future payments for leases that have not yet commenced ¹	(13,071)
Less: Imputed interest	(298,519)
Total lease liabilities	\$ 1,670,403

¹ The Company has certain leases that it has executed of which it does not control the underlying assets; therefore, liabilities and ROU assets related to these leases were not recorded on the Company's Consolidated Balance Sheet as of September 30, 2025.

Note 11. Restructuring and Other Expenses

The following illustrates the expenses incurred by the Company relating to Restructuring and Other Expenses for the periods indicated:

(in thousands)	Fiscal Year Ended September 30,		
	2025	2024	2023
Restructuring and employee severance costs	\$ 101,562	\$ 69,968	\$ 105,220
Business transformation efforts	122,286	130,069	82,117
Other, net	5,574	33,592	42,547
Total restructuring and other expenses	\$ 229,422	\$ 233,629	\$ 229,884

Restructuring and employee severance costs in fiscal 2025 primarily included expenses incurred related to workforce reductions in both of the Company's reportable segments. Restructuring and employee severance costs in fiscal 2024 primarily included expenses incurred related to facility closures in connection with the Company's office optimization plan and workforce reductions in both of its reportable segments. Restructuring and employee severance costs in fiscal 2023 primarily included expenses incurred in connection with workforce reductions in both of the Company's reportable segments.

Business transformation efforts in fiscal 2025, 2024, and 2023 included rebranding costs associated with the Company's name change to Cencora and non-recurring expenses related to significant strategic initiatives to improve operational efficiency, including certain technology initiatives. The majority of these costs related to services provided by third-party consultants.

In fiscal 2024, the Company experienced a cybersecurity event where data from its information systems was exfiltrated. In connection with this event, the Company incurred costs that were recorded in Other, net in the above table. The majority of the costs included in Other, net in fiscal 2024 related to this cybersecurity event.

In fiscal 2023, one of the Company's foreign business units experienced a cybersecurity event that impacted a standalone legacy information technology platform in one country and the foreign business unit's ability to operate in that country for approximately two weeks. In connection with this event, the Company incurred costs to restore the foreign business unit's operations in that country, which were recorded in Other, net in the above table. The majority of the costs included in Other, net in fiscal 2023 related to this cybersecurity event.

Note 12. Legal Matters and Contingencies

In the ordinary course of its business, the Company becomes involved in lawsuits, administrative proceedings, government subpoenas, government investigations, stockholder demands, and other disputes, including antitrust, commercial, data privacy and security, employment discrimination, intellectual property, product liability, regulatory, and other matters. Significant damages or penalties may be sought from the Company in some matters, and some matters may require years for the Company to resolve. The Company records a reserve for these matters when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated.

For those matters for which the Company has not recognized a liability, the Company cannot predict the outcome of their impact on the Company as uncertainty remains, including with regard to whether such matters will proceed to trial, whether settlements will be reached, and the amount and terms of any such settlements. Outcomes may include settlements in significant amounts that are not currently estimable, limitations on the Company's conduct, the imposition of corporate integrity agreement obligations, consent decrees, and/or other civil and criminal penalties. From time to time, the Company is also involved in disputes with its customers, which the Company generally seeks to resolve through commercial negotiations. If negotiations are unsuccessful, the parties may litigate the dispute or otherwise attempt to settle the matter.

With respect to the specific legal proceedings and claims described below, unless otherwise noted, the amount or range of possible losses is not reasonably estimable. There can be no assurance that the settlement, resolution, or other outcome of one or more matters, including the matters set forth below, during any subsequent reporting period will not have a material adverse effect on the Company's results of operations or cash flows for that period or on the Company's financial condition.

Opioid Lawsuits and Investigations

A significant number of counties, municipalities, and other governmental entities in a majority of U.S. states and Puerto Rico, as well as numerous states and tribes, filed lawsuits in various federal, state and other courts against pharmaceutical wholesale distributors (including the Company and certain subsidiaries, such as AmerisourceBergen Drug

Corporation (“ABDC”) and H.D. Smith, LLC (“H.D. Smith”), pharmaceutical manufacturers, retail pharmacy chains, medical practices, and physicians relating to the distribution of prescription opioid pain medications.

Starting in December 2017, more than 2,000 cases were transferred to Multidistrict Litigation (“MDL”) proceedings before the United States District Court for the Northern District of Ohio (the “MDL Court”). Since then, several cases filed by government and tribal plaintiffs that were selected as bellwether cases in the MDL have been resolved through trial or settlement. Following trial in two consolidated cases in the United States District Court for the Southern District of West Virginia, the Court entered judgment in favor of the defendants, including the Company. The plaintiffs filed an appeal of the Court’s decision in the United States Court of Appeals for the Fourth Circuit on August 2, 2022. On October 28, 2025, the Fourth Circuit issued its opinion in the case, vacated the District Court’s judgment, and remanded the case back to the District Court for further proceedings consistent with the Fourth Circuit’s opinion.

On July 21, 2021, the Company announced that it and the two other national pharmaceutical distributors had negotiated a Distributor Settlement Agreement that, if all conditions were satisfied, would result in the resolution of a substantial majority of opioid lawsuits filed by state and local governmental entities. The Distributor Settlement Agreement became effective on April 2, 2022, and as of September 30, 2025, it included 48 of 49 eligible states (the “Settling States”) as well as 99% by population of the eligible political subdivisions in the Settling States. The Distributor Settlement Agreement requires the Company to comply with certain requirements, including the establishment of a clearinghouse that will consolidate data from all three national pharmaceutical distributors. The States of Alabama and West Virginia and their subdivisions and Native American tribes are not a part of the Distributor Settlement Agreement, and the Company has reached separate agreements with those groups.

The MDL Court selected four cases filed by third-party payors to serve as additional litigation bellwethers. On May 31, 2024, the MDL Court severed and stayed these four cases against the Company and the two other national pharmaceutical distributors, pursuant to ongoing settlement discussions to resolve litigation filed by a putative class of third-party payors. On August 29, 2024, the Company and two other national pharmaceutical distributors entered into a proposed class action settlement agreement to resolve the opioid-related claims of a proposed settlement class of third-party payors. Pursuant to the agreement, the Company recorded a \$93.0 million litigation expense accrual in Litigation and Opioid-Related Expenses (Credit), Net in its fiscal 2024 Consolidated Statement of Operations. The MDL Court granted a motion for preliminary approval of the proposed class action settlement on September 3, 2024. Following a time period for submission of any objections or requests to be excluded from the settlement, the MDL granted final approval of the settlement during a fairness hearing held on January 13, 2025 and entered a final approval order on January 15, 2025. On February 13, 2025, the sole objector to the settlement filed a notice of appeal of the final approval order. A settlement agreement with the sole objector was entered into on June 12, 2025. On June 16, 2025, the MDL Court ruled that it would approve the settlement with the sole objector if remanded for that purpose. On July 25, 2025, the United States Court of Appeals for the Sixth Circuit granted a motion for limited remand. The MDL Court approved the settlement with the sole objector on August 8, 2025. The class action settlement became effective as of September 9, 2025.

In Maryland, a trial commenced on September 16, 2024 in a case filed by the Mayor and City Council of Baltimore in the Circuit Court for Baltimore City. On November 12, 2024, the jury returned a verdict finding ABDC (and another national distributor) liable for public nuisance and assessing approximately \$274 million total in compensatory damages, approximately \$74 million of which was assessed against ABDC. A second phase of the trial began on December 11, 2024 related to the City of Baltimore’s request for an abatement remedy and proceeded as a bench trial. On June 12, 2025, the Court issued a ruling on the defendants’ post-trial motions relating to the first phase of the trial. The Court upheld the jury’s finding of liability, but granted the defendants a new trial on the extent of damages to correct certain errors and due to the excessive nature of the jury’s damages award. In the alternative, the Court granted remittitur, through which the Court reduced the compensatory damages assessed against ABDC to approximately \$14.4 million. The Court issued its ruling regarding the City of Baltimore’s request for abatement on August 8, 2025, assessing approximately \$28 million against ABDC for abatement measures, bringing the overall monetary award assessed against ABDC to approximately \$42.5 million. On August 14, 2025, the City of Baltimore informed the Court that it would accept the reduced damages award as reflected in the Court’s post-trial ruling, in lieu of a new trial. On September 2, 2025, the Court entered final judgment. In October 2025, ABDC (and the other national distributor) filed a notice of appeal to the Appellate Court of Maryland, and the City of Baltimore filed a notice of cross-appeal. In November 2025, both the City of Baltimore and ABDC (and the other national distributor) filed petitions for a writ of certiorari (bypass) with the Supreme Court of Maryland. If the Court grants the petitions, then the appeal will proceed directly in that Court, instead of in the Appellate Court. The \$42.4 million is a component of the Company’s \$4.3 billion litigation liability as of September 30, 2025, as described above.

On September 26, 2024, the Company and two other national pharmaceutical distributors entered into a proposed class action settlement agreement to resolve the opioid-related claims of a proposed settlement class of hospitals. The Company recorded a \$120.9 million litigation expense accrual in Litigation and Opioid-Related Expenses (Credit), Net in its fiscal 2024

Consolidated Statement of Operations, representing the Company's expected share of the potential class action settlement. On October 30, 2024, the United States District Court for the District of New Mexico granted a motion for preliminary approval of the proposed class action settlement. Following notice to class members, a time period for submission of any objections to the settlement or requests to be excluded from the settlement, and a fairness hearing on March 4, 2025, the Court granted final approval of the settlement and entered a final approval order. The settlement became effective on April 4, 2025.

The Company's accrued litigation liability related to the Distributor Settlement Agreement, including the State of Alabama and an estimate for non-participating government subdivisions (with whom the Company has not reached a settlement agreement), as well as other opioid-related litigation for which it has reached settlement agreements, as described above, was \$4.3 billion as of September 30, 2025 and \$4.9 billion as of September 30, 2024. The \$4.3 billion liability will be paid over 13 years. The Company currently estimates that \$416.0 million will be paid prior to September 30, 2026, which is recorded in Accrued Expenses and Other on the Company's Consolidated Balance Sheet. The remaining long-term liability of \$3.9 billion is recorded in Accrued Litigation Liability on the Company's Consolidated Balance Sheet. While the Company has accrued its estimated liability for opioid litigation, it is unable to estimate the range of possible loss associated with the matters that are not included in the accrual. Because loss contingencies are inherently unpredictable and unfavorable developments or resolutions can occur, the assessment is highly subjective and requires judgments about future events. The Company regularly reviews opioid litigation matters to determine whether its accrual is adequate. The amount of ultimate loss may differ materially from the amount accrued to date. Until such time as otherwise resolved, the Company will continue to litigate and prepare for trial and to vigorously defend itself in all such matters. Since these matters are still developing, the Company is unable to predict the outcome, but the result of these lawsuits could include excessive monetary verdicts and/or injunctive relief that may affect the Company's operations. Additional lawsuits regarding the distribution of prescription opioid pain medications have been filed and may continue to be filed by a variety of types of plaintiffs, including lawsuits filed by non-governmental or non-political entities and individuals, among others. The Company is vigorously defending itself in the pending lawsuits and intends to vigorously defend itself against any threatened lawsuits or enforcement proceedings.

Since July 2017, the Company has received subpoenas from several U.S. Attorney's Offices, including grand jury subpoenas from the U.S. Attorney's Office for the District of New Jersey ("USAO-NJ") and the U.S. Attorney's Office for the Eastern District of New York ("USAO-EDNY"). Those subpoenas requested the production of a broad range of documents pertaining to the Company's distribution of controlled substances through its various subsidiaries, including ABDC, and its diversion control programs. The Company produced documents in response to the subpoenas and engaged in discussions with the various U.S. Attorney's Offices, including the Health Care and Government Fraud Unit of the Criminal Division of the USAO-NJ, the U.S. Department of Justice Consumer Protection Branch and the U.S. Drug Enforcement Administration, in an attempt to resolve these matters. On December 29, 2022, the Department of Justice filed a civil complaint (the "Complaint") against the Company, ABDC, and Integrated Commercialization Services, LLC ("ICS"), a subsidiary of the Company, alleging violations of the Controlled Substances Act. Specifically, the Complaint alleges that the Company negligently failed to report suspicious orders to the Drug Enforcement Administration. In the Complaint, the Department of Justice seeks civil penalties and injunctive relief. This Complaint relates to the aforementioned and previously-disclosed investigations. On March 30, 2023, the Company filed a motion to dismiss the Complaint in its entirety on behalf of itself, ABDC, and ICS. On November 6, 2023, the United States District Court for the Eastern District of Pennsylvania granted in part and denied in part the motion, dismissing with prejudice all claims for civil penalties for Defendants' alleged violations of the suspicious order reporting requirement prior to October 24, 2018, but otherwise denying the motion. On December 18, 2023, the Company, ABDC and ICS filed an Answer and Affirmative Defenses to the Complaint. On July 15, 2025, the Court entered an Amended Scheduling Order setting the fact discovery deadline as June 12, 2026 and the expert discovery deadline as January 15, 2027. The Company denies the allegations in the Complaint and intends to defend itself vigorously in the litigation.

Shareholder Securities Litigation

On December 30, 2021, the Lebanon County Employees' Retirement Fund and Teamsters Local 443 Health Services & Insurance Plan filed a complaint for a purported derivative action in the Delaware Court of Chancery against the Company and certain of its current officers and directors. The complaint alleges claims for breach of fiduciary duty allegedly arising from the Board's and certain officers' oversight of the Company's controlled substance diversion control programs. The defendants moved to dismiss the complaint on March 29, 2022. On December 22, 2022, the Delaware Court of Chancery granted the motion to dismiss. On January 9, 2023, the Plaintiffs filed a Motion for Relief from Judgment and Order Pursuant to Rule 60(b) from the Delaware Chancery Court's judgment. On January 20, 2023, the Plaintiffs also appealed the ruling to the Delaware Supreme Court. On March 21, 2023, the Delaware Court of Chancery denied the Plaintiffs' Motion for Relief from Judgment and Order Pursuant to Rule 60(b). On December 18, 2023, the Delaware Supreme Court reversed the dismissal and remanded the case to the Delaware Court of Chancery for further proceedings. On January 12, 2024, the Company's Board of Directors established a Special Litigation Committee ("SLC") and delegated to the SLC the Board's full authority with respect to the litigation. On March 4, 2024, the Delaware Court of Chancery granted the SLC's consented-to motion to stay the action pending its investigation of the allegations of the complaint. On July 28, 2025, the SLC notified the Court of Chancery that the parties had reached an agreement in principle to settle all claims in the action following a successful mediation conducted on June 24, 2025, and filed a stipulation to stay the action pending the presentation of a stipulation of settlement for the Court's approval. The Court granted the stay on July 29, 2025. The parties filed a stipulation of settlement with the Court on August 15, 2025, and the Court held a fairness hearing on November 13, 2025. During the fairness hearing, the Court approved the settlement and dismissed the action with prejudice. Under this settlement, insurance carriers will pay the Company \$111.3 million, less \$24.8 million in attorneys' fees and expenses awarded by the court to plaintiffs' counsel.

Subpoenas, Ongoing Investigations, and Other Contingencies

From time to time, the Company receives subpoenas or requests for information from various government agencies relating to the Company's business or to the business of a customer, supplier, or other industry participant. The Company's responses often require time and effort and can result in considerable costs being incurred. Most of these matters are resolved without incident; however, such subpoenas or requests can lead to the assertion of claims or the commencement of civil or criminal legal proceedings against the Company and other members of the healthcare industry, as well as to substantial settlements.

In January 2017, U.S. Bioservices Corporation, a former subsidiary of the Company, received a subpoena for information from the USAO-EDNY relating to its activities in connection with billing for products and making returns of potential overpayments to government payers. A filed qui tam complaint related to the investigation was unsealed in April 2019 and the relator filed an amended complaint under seal in the U.S. District Court for the Eastern District of New York. In December 2019, the government filed a notice that it was declining to intervene. The court ordered that the relator's complaint against the Company and other defendants, including AmerisourceBergen Specialty Group, LLC, be unsealed. The relator's complaint alleged violations of the federal False Claims Act and the false claims acts of various states. The relator filed a second amended complaint, removing one state false claims act count. The Company filed a motion to dismiss the second amended complaint and all briefs on the motion were filed with the Court on October 9, 2020. The motion to dismiss was granted on December 22, 2022. The False Claims Act claims were dismissed with prejudice, and the state claims were dismissed without prejudice. On January 24, 2023, the relator filed Motions to Reconsider Dismissal and For Leave to Amend the Complaint. Response briefs on those motions were filed by the Company and all briefing was completed on February 15, 2023. On October 17, 2025, the Court denied the relator's motions. On November 13, 2025, the relator filed a notice of appeal of such denial to the United States Court of Appeals for the Second Circuit.

On March 3, 2022, the United States Attorney's Office for the Western District of Virginia notified the Company of the existence of a criminal investigation into MWI Veterinary Supply Co. ("MWI"), the Company's animal health subsidiary, in connection with grand jury subpoenas to which MWI previously responded relating to compliance with state and federal regulatory requirements governing wholesale shipments of animal health products to customers. In October 2024, the Company reached an agreement in principle to resolve these claims. While no agreement has been finalized, pursuant to the agreement in principle the Company recorded a \$49.1 million litigation expense accrual in Litigation and Opioid-Related Expenses (Credit), Net in its fiscal 2024 Consolidated Statement of Operations. This liability is included in Accrued Expenses and Other on the Company's Consolidated Balance Sheet as of September 30, 2025.

Note 13. Antitrust Litigation Settlements

Numerous lawsuits have been filed against certain brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs from entering the market. These lawsuits are generally brought as class actions. The Company has not been named a plaintiff in any of these lawsuits but has been a member of the direct purchasers' class (i.e., those purchasers who purchase directly from these pharmaceutical manufacturers). None of the lawsuits has gone to trial, but some have settled in the past with the Company receiving proceeds from the settlement funds. During fiscal 2025, 2024, and 2023, the Company recognized gains relating to these lawsuits of \$236.4 million, \$170.9 million, and \$239.1 million, respectively. These gains, which are net of attorney fees and estimated payments due to other parties, were recorded as reductions to cost of goods sold in the Company's Consolidated Statements of Operations.

Note 14. Business Segment Information

The Company is organized geographically based upon the products and services it provides to its customer and reports its results under two reportable segments: U.S. Healthcare Solutions and International Healthcare Solutions.

The chief operating decision maker ("CODM") of the Company is its President & Chief Executive Officer, whose function is to allocate resources to, and assess the performance of, the Company's operating segments. The CODM does not review assets by operating segment for the purpose of assessing performance or allocating resources.

The U.S. Healthcare Solutions reportable segment distributes a comprehensive offering of brand-name, specialty brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to a wide variety of healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers. The U.S. Healthcare Solutions reportable segment also provides pharmaceutical distribution (including plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty pharmaceutical products) and additional services to physicians who specialize in a variety of disease states, especially oncology and retina, and to other healthcare providers, including hospitals, specialty retinal practices, and dialysis clinics. The U.S. Healthcare Solutions reportable segment also provides pharmacy management, staffing and additional patient access and adherence support, and supply management software to a variety of retail and institutional healthcare providers. Additionally, it delivers packaging solutions to institutional and retail healthcare providers. Through its animal health business, the U.S. Healthcare Solutions reportable segment sells pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and various other products to customers in both the companion animal and production animal markets. It also offers demand-creating sales force services to manufacturers.

The International Healthcare Solutions reportable segment consists of businesses that focus on international pharmaceutical wholesale and related service operations and global commercialization services. The International Healthcare Solutions reportable segment distributes pharmaceuticals and other healthcare products and provides related services to healthcare providers, including pharmacies, doctors, health centers and hospitals primarily in Europe. It is a leading global specialty transportation and logistics provider for the biopharmaceutical industry. It also is a provider of specialized services, including regulatory affairs, market access, pharmacovigilance, development consulting and scientific affairs, and quality management and compliance, for the life sciences industry. In Canada, the business drives innovative partnerships with manufacturers, providers, and pharmacies to improve product access and efficiency throughout the healthcare supply chain.

[Table of Contents](#)

The following illustrates reportable segment and disaggregated revenue as required by ASC 606, “Revenue from Contracts with Customers,” for the periods indicated:

(in thousands)	Fiscal Year Ended September 30,		
	2025	2024	2023
U.S. Healthcare Solutions			
Human Health	\$ 285,287,506	\$ 259,973,909	\$ 229,716,669
Animal Health	5,694,517	5,365,518	5,042,549
Total U.S. Healthcare Solutions	290,982,023	265,339,427	234,759,218
International Healthcare Solutions			
Alliance Healthcare	24,394,833	23,061,721	22,349,278
Other Healthcare Solutions	5,971,490	5,565,821	5,069,401
Total International Healthcare Solutions	30,366,323	28,627,542	27,418,679
Intersegment eliminations	(15,527)	(8,370)	(4,486)
Revenue	\$ 321,332,819	\$ 293,958,599	\$ 262,173,411

The following illustrates reportable segment cost of goods sold information for the periods indicated:

(in thousands)	Fiscal Year Ended September 30,		
	2025	2024	2023
U.S. Healthcare Solutions	\$ 283,076,597	\$ 258,916,313	\$ 228,938,102
International Healthcare Solutions	27,050,982	25,306,564	24,227,832
Intersegment eliminations	(9,622)	(5,322)	(4,486)
Total segment cost of goods sold	\$ 310,117,957	\$ 284,217,555	\$ 253,161,448

The following illustrates reportable segment operating expenses information for the periods indicated:

(in thousands)	Fiscal Year Ended September 30,		
	2025	2024	2023
U.S. Healthcare Solutions	\$ 4,330,727	\$ 3,488,237	\$ 3,224,557
International Healthcare Solutions	2,667,067	2,607,599	2,498,285
Intersegment eliminations	(5,905)	(3,048)	—
Total segment operating expenses	\$ 6,991,889	\$ 6,092,788	\$ 5,722,842

The following illustrates reportable segment operating income information for the periods indicated:

(in thousands)	Fiscal Year Ended September 30,		
	2025	2024	2023
U.S. Healthcare Solutions	\$ 3,574,699	\$ 2,934,877	\$ 2,596,559
International Healthcare Solutions	648,274	713,379	692,562
Total segment operating income	\$ 4,222,973	\$ 3,648,256	\$ 3,289,121

The following reconciles total segment operating income to income before income taxes for the periods indicated:

(in thousands)	Fiscal Year Ended September 30,		
	2025	2024	2023
Total segment operating income	\$ 4,222,973	\$ 3,648,256	\$ 3,289,121
Gains from antitrust litigation settlements	236,372	170,904	239,092
LIFO credit (expense)	76,876	52,168	(204,595)
Turkey highly inflationary impact	(49,571)	(54,087)	(86,967)
Acquisition-related intangibles amortization	(553,028)	(660,292)	(551,046)
Litigation and opioid-related (expenses) credit, net	(60,671)	(227,070)	24,693
Acquisition-related deal and integration expenses	(291,044)	(103,001)	(139,683)
Restructuring and other expenses	(229,422)	(233,629)	(229,884)
Goodwill impairment	(723,884)	(418,000)	—
Operating income	2,628,601	2,175,249	2,340,731
Other loss (income), net	78,717	14,283	(49,036)
Interest expense, net	291,548	156,991	228,931
Income before income taxes	\$ 2,258,336	\$ 2,003,975	\$ 2,160,836

Segment operating income is evaluated by the CODM of the Company and excludes gains from antitrust litigation settlements; LIFO credit (expense); Turkey highly inflationary impact; acquisition-related intangibles amortization; litigation and opioid-related (expenses) credit, net; acquisition-related deal and integration expenses; restructuring and other expenses; and goodwill impairment. All corporate office expenses are allocated to the operating segment level.

Litigation and opioid-related (expenses) credit, net in fiscal 2024 includes \$263.1 million of litigation expense accruals (see Note 12), offset in part by a net \$92.2 million opioid litigation settlement accrual reduction primarily as a result of the Company's prepayment of the net present value of a future obligation as permitted under its opioid settlement agreements.

Litigation and opioid-related (expenses) credit, net in fiscal 2023 includes the receipt of \$83.4 million from the H.D. Smith opioid litigation indemnity escrow.

Other loss (income), net includes a \$113.5 million impairment of an equity investment that was made in fiscal 2021 and a \$35.5 million loss on the divestiture of non-core businesses, offset in part by the Company's portion of an equity method investment's gain on the sale of a business of \$39.7 million and a \$14.1 million gain on the remeasurement of an equity investment in fiscal 2025.

Other loss (income), net, includes a \$40.7 million net gain on the divestiture of non-core businesses in fiscal 2023.

The following illustrates depreciation and amortization by reportable segment for the periods indicated:

(in thousands)	Fiscal Year Ended September 30,		
	2025	2024	2023
U.S. Healthcare Solutions	\$ 352,602	\$ 298,683	\$ 292,814
International Healthcare Solutions	145,445	132,999	120,044
Acquisition-related intangibles amortization	553,028	660,292	551,046
Total depreciation and amortization	\$ 1,051,075	\$ 1,091,974	\$ 963,904

Depreciation and amortization related to property and equipment and intangible assets excludes amortization of deferred financing costs and other debt-related items, which are included in interest expense, net.

The following illustrates capital expenditures by reportable segment for the periods indicated:

(in thousands)	Fiscal Year Ended September 30,		
	2025	2024	2023
U.S. Healthcare Solutions	\$ 399,518	\$ 273,715	\$ 268,069
International Healthcare Solutions	268,463	213,458	190,290
Total capital expenditures	\$ 667,981	\$ 487,173	\$ 458,359

Note 15. Fair Value of Financial Instruments

The recorded amounts of the Company's cash and cash equivalents, accounts receivable, and accounts payable as of September 30, 2025 and 2024 approximate fair value based upon the relatively short-term nature of these financial instruments. Within Cash and Cash Equivalents, the Company had \$1,864.0 million and \$1,190.0 million of investments in money market accounts as of September 30, 2025 and 2024, respectively. The fair value of the money market accounts was determined based upon unadjusted quoted prices in active markets for identical assets, otherwise known as Level 1 inputs.

The recorded amount of long-term debt (see Note 6) and the corresponding fair value as of September 30, 2025 were \$7,543.0 million and \$7,361.4 million, respectively. The recorded amount of long-term debt and the corresponding fair value as of September 30, 2024 were \$3,811.7 million and \$3,588.0 million, respectively. The fair value of long-term debt was determined based upon inputs other than quoted prices, otherwise known as Level 2 inputs.

Note 16. Subsequent Events

Dividend Increase

In November 2025, the Company's Board of Directors increased the quarterly dividend paid on common stock by 9% and declared a regular quarterly cash dividend of \$0.60 per share, payable on December 1, 2025 to shareholders of record on November 14, 2025.

Reportable Segments (revised as of October 1, 2025)

Recently, the Company undertook a strategic review of its business to ensure alignment with its growth priorities and strategic drivers. As a result of this review, the Company has reorganized certain business components within its reporting structure. Beginning in the first quarter of fiscal 2026, the Company's reporting structure will be comprised of U.S. Healthcare Solutions, International Healthcare Solutions, and Other. The U.S. Healthcare Solutions reportable segment will consist of U.S. Human Health (excluding legacy U.S. Consulting Services). The International Healthcare Solutions reportable segment will consist of Alliance Healthcare, Innomar, World Courier, and strategic components of PharmaLex. Other, which is not considered a reportable segment, will consist of businesses for which the Company has begun to explore strategic alternatives and includes MWI Animal Health, Profarma, U.S. Consulting Services and the other components of PharmaLex.

GUARANTEE OF PERFORMANCE

For value receive Cencora, Inc., a Delaware corporation (the "Guarantor"), located at 1 West First Avenue, Conshohocken, PA 19428, absolutely and unconditionally guarantees to assume the duties and obligations of AmerisourceBergen Drug Corporation, located at 1 West First Avenue Conshohocken, PA 19428 (the "Franchisor"), under its franchise registration in each state where the franchise is registered, and under its Franchise Agreement identified in the Franchise Disclosure Document issued 12/18/2025, as it may be amended, and as that Franchise Agreement may be entered into with franchisees and amended, modified or extended from time to time. This guarantee continues until all such obligations of the Franchisor under its franchise registrations and the Franchise Agreement are satisfied or until the liability of Franchisor to its franchisees under the Franchise Agreement has been completely discharged, whichever first occurs. The Guarantor is not discharged from liability if a claim by a franchisee against the Franchisor remains outstanding. Notice of acceptance is waived. The Guarantor does not waive receipt of notice of default on the part of the Franchisor. This guarantee is binding on the Guarantor and its successors and assigns.

The Guarantor executes this guarantee at Conshohocken, Pennsylvania on the 10th day of October, 2025.

Guarantor: Cencora, Inc.

By: 

Name: Elizabeth Campbell

Title: Executive Vice President and Chief legal Officer

EXHIBIT F
STATE SPECIFIC ADDENDA TO AMERISOURCEBERGEN DRUG CORPORATION
DISCLOSURE DOCUMENT
FOR THE STATE OF CALIFORNIA

1. Item 3 is amended to reflect that:

Neither AmerisourceBergen Drug Corporation nor any person identified in Item 2 of the Disclosure Document is subject to any current effective order of any national securities association or national securities exchange as defined in the Securities Exchange Act of 1934, U.S.C.A. 78a et seq., suspending or expelling such persons from membership in such association or exchange.

2. Item 5 is amended by the addition of the following language:

The release from claims does not include a release of any claims arising under the California Franchise Investment Act with respect to the offer or sale of the GNP Premier Agreement and the Premier Candidate Agreement.

3. Item 6 is amended by the addition of the following language:

The highest interest rate allowed in California may be 10% annually.

4. Item 17 is amended by the addition of the following language:

California Business and Professions Code Sections 20000 through 20043 provide rights to you concerning termination or nonrenewal of a franchise. If the GNP Premier Agreement contains a provision that is inconsistent with the law, the law will control.

The GNP Premier Agreement provides for termination upon bankruptcy. This provision may not be enforceable under federal bankruptcy law (11 U.S.C.A. Sec. 101 et seq.).

The GNP Premier Agreement does not contain any covenant not to compete which extend beyond expiration or termination of the Agreement but, to the extent it did, these provisions may not be enforceable under California law.

The California Corporations Code, Section 31125 requires AmerisourceBergen Drug Corporation to give you a Disclosure Document, approved by the Department of Corporations, prior to a solicitation of a proposed material modification of an existing franchise.

If the GNP Premier Agreement contains a liquidated damages clause, under California Civil Code Section 1671, certain liquidated damages clauses are unenforceable.

The GNP Premier Agreement requires the application of the laws of Pennsylvania. This provision may be unenforceable under California Law.

If you must sign a general release to renew or transfer your franchise, California Corporations Code Sec. 31512 voids a waiver of your rights under the Franchise Investment Law (California Corporations Code Sections 31000 through 31516). California Business and Professions Code Sec. 20010 voids a waiver of your rights under the Franchise Relations Act (Business and Professions Code Sections 20000 through 20043).

5. THE CALIFORNIA FRANCHISE INVESTMENT LAW REQUIRES THAT A COPY OF ALL PROPOSED AGREEMENTS RELATING TO THE SALE OF THE FRANCHISE BE DELIVERED TOGETHER WITH THE DISCLOSURE DOCUMENT.
6. OUR WEBSITE HAS NOT BEEN REVIEWED OR APPROVED BY THE CALIFORNIA DEPARTMENT OF BUSINESS OVERSIGHT. ANY COMPLAINTS CONCERNING THE CONTENT OF THIS WEBSITE MAY BE DIRECTED TO THE CALIFORNIA DEPARTMENT OF BUSINESS OVERSIGHT at WWW.DFPI.CA.GOV.
7. No statement, questionnaire, or acknowledgment signed or agreed to by a franchisee in connection with the commencement of the franchise relationship shall have the effect of (i) waiving any claims under any applicable state franchise law, including fraud in the inducement, or (ii) disclaiming reliance on any statement made by any franchisor, franchise seller, or other person acting on behalf of the franchisor. This provision supersedes any other term of any document executed in connection with the franchise.

**ADDENDUM TO AMERISOURCEBERGEN DRUG CORPORATION
DISCLOSURE DOCUMENT
FOR THE STATE OF HAWAII**

THESE FRANCHISES HAVE BEEN FILED UNDER THE FRANCHISE INVESTMENT LAW OF THE STATE OF HAWAII. FILING DOES NOT CONSTITUTE APPROVAL, RECOMMENDATION OR ENDORSEMENT BY THE DIRECTOR OF REGULATORY AGENCIES OR A FINDING BY THE DIRECTOR OF REGULATORY AGENCIES THAT THE INFORMATION PROVIDED HEREIN IS TRUE, COMPLETE AND NOT MISLEADING.

THE FRANCHISE INVESTMENT LAW MAKES IT UNLAWFUL TO OFFER OR SELL ANY FRANCHISE IN THIS STATE WITHOUT FIRST PROVIDING TO THE PROSPECTIVE FRANCHISEE, OR SUBFRANCHISOR, AT LEAST SEVEN (7) DAYS PRIOR TO THE EXECUTION BY THE PROSPECTIVE FRANCHISEE OF ANY BINDING FRANCHISE OR OTHER AGREEMENT, OR AT LEAST SEVEN (7) DAYS PRIOR TO THE PAYMENT OF ANY CONSIDERATION BY THE FRANCHISEE, OR SUBFRANCHISOR, WHICHEVER OCCURS FIRST, A COPY OF THE FRANCHISE DISCLOSURE DOCUMENT, TOGETHER WITH A COPY OF ALL PROPOSED AGREEMENTS RELATING TO THE SALE OF THE FRANCHISE.

THIS FRANCHISE DISCLOSURE DOCUMENT CONTAINS A SUMMARY ONLY OF CERTAIN MATERIAL PROVISIONS OF THE FRANCHISE AGREEMENT. THE CONTRACT OR AGREEMENT SHOULD BE REFERRED TO FOR A STATEMENT OF ALL RIGHTS, CONDITIONS, RESTRICTIONS AND OBLIGATIONS OF BOTH THE FRANCHISOR AND THE FRANCHISEE.

NOTWITHSTANDING ANYTHING CONTAINED IN THE FRANCHISE AGREEMENT OR AREA DEVELOPMENT AGREEMENT TO THE CONTRARY, YOU DO NOT HAVE TO PAY US THE INITIAL FRANCHISE FEE UNTIL WE PERFORM OUR PRE-OPENING OBLIGATIONS UNDER THE FRANCHISE AGREEMENT AND YOUR FIRST FRANCHISED BUSINESS IS OPEN. ONCE WE COMPLETE THIS OBLIGATION AND YOU ARE OPEN, YOU MUST IMMEDIATELY PAY US ALL INITIAL FEES WE DEFERRED.

**ADDENDUM TO AMERISOURCEBERGEN DRUG CORPORATION
DISCLOSURE DOCUMENT
FOR THE STATE OF ILLINOIS**

1. Illinois law governs the agreement(s) between the parties to this franchise.
2. Section 4 of the Illinois Franchise Disclosure Act provides that any provision in a franchise agreement that designates jurisdiction or venue outside the State of Illinois is void. However, a franchise agreement may provide for arbitration in a venue outside of Illinois.
3. Section 41 of the Illinois Franchise Disclosure Act provides that any condition, stipulation or provision purporting to bind any person acquiring any franchise to waive compliance with Illinois Franchise Disclosure Act or any other law of Illinois is void.
4. Your rights upon termination and non-renewal of a Franchise Agreement are set forth in sections 19 and 20 of the Illinois Franchise Disclosure Act.

No statement, questionnaire, or acknowledgment signed or agreed to by a franchisee in connection with the commencement of the franchise relationship shall have the effect of (i) waiving any claims under any applicable state franchise law, including fraud in the inducement, or (ii) disclaiming reliance on any statement made by any franchisor, franchise seller, or other person acting on behalf of the franchisor. This provision supersedes any other term of any document executed in connection with the franchise.

While the Franchisor's Parent company has guaranteed to assume the duties and obligations of the Participation (Franchise) Agreement if the Franchisor is unable to do so, the Parent company's financial condition calls into question its ability to fulfill such a guarantee.

There is no training program for this franchise opportunity.

**ADDENDUM TO AMERISOURCEBERGEN DRUG CORPORATION
DISCLOSURE DOCUMENT
FOR THE STATE OF MARYLAND**

1. Item 5 of the Disclosure Document is amended to reflect that, Based upon the financial information submitted, the Commissioner has determined that all fees paid to the franchisor by the franchisee, including payment for goods and services received from the franchisor before the business opens, shall be deferred pending satisfaction of all of the franchisor's pre-opening obligations to the franchisee.
2. Item 17 of the Disclosure Document is amended to reflect that, pursuant to the Code of Maryland Regulations, any general release required as a condition of renewal, sale and/or assignment/transfer will not apply to any liability or claims under the Maryland Franchise Registration and Disclosure Law resulting from the offer or sale of the franchise.
3. Item 17 of the Disclosure Document is amended to reflect that any claims arising under the Maryland Franchise Registration and Disclosure Law must be brought within 3 years after the grant of the franchise.
4. Item 17 of the Disclosure Document is amended to state that you may sue in Maryland for any claims arising under the Maryland Franchise Registration and Disclosure Law.

5. No statement, questionnaire, or acknowledgment signed or agreed to by a franchisee in connection with the commencement of the franchise relationship shall have the effect of (i) waiving any claims under any applicable state franchise law, including fraud in the inducement, or (ii) disclaiming reliance on any statement made by any franchisor, franchise seller, or other person acting on behalf of the franchisor. This provision supersedes any other term of any document executed in connection with the franchise.

**ADDENDUM TO AMERISOURCEBERGEN DRUG CORPORATION
DISCLOSURE DOCUMENT
FOR THE STATE OF MICHIGAN**

**NOTICE TO PROSPECTIVE FRANCHISEES IN THE STATE OF MICHIGAN
THE STATE OF MICHIGAN PROHIBITS CERTAIN UNFAIR PROVISIONS THAT ARE
SOMETIMES FOUND IN FRANCHISE DOCUMENTS. IF ANY OF THE FOLLOWING
PROVISIONS ARE IN THESE FRANCHISE DOCUMENTS, THE PROVISIONS ARE VOID AND
CANNOT BE ENFORCED AGAINST YOU.**

(A) A prohibition on the right of a franchisee to join an association of franchisees.

(B) A requirement that a franchisee assent to release, assignment, novation, waiver, or estoppel which deprives a franchisee of rights and protections provided in the Michigan Franchise Investment Law. This shall not preclude a franchisee, after entering into a franchise agreement, from settling any and all claims.

(C) A provision that permits a franchisor to terminate a franchise prior to the expiration of its term except for good cause. Good cause shall include the failure of the franchisee to comply with any lawful provision of the franchise agreement and to cure such failure after being given written notice thereof and a reasonable opportunity, which in no event need be more than 30 days, to cure such failure.

(D) A provision that permits a franchisor to refuse to renew a franchise without fairly compensating the franchisee by repurchase or other means for the fair market value at the time of expiration of the franchisee's inventory, supplies, equipment, fixtures, and furnishings. Personalized materials which have no value to the franchisor and inventory, supplies, equipment, fixtures and furnishings not reasonably required in the conduct of the franchise business are not subject to compensation. This subsection applies only if: (1) the term of the franchise is less than 5 years and (2) the franchisee is prohibited by the franchise or other agreement from continuing to conduct substantially the same business under another trademark, service mark, trade name, logotype, advertising, or other commercial symbol in the same area subsequent to the expiration of the franchise or the franchisee does not receive at least 6 months advance notice of the franchisor's intent not to renew the franchise.

(E) A provision that permits the franchisor to refuse to renew a franchise on terms generally available to other franchisees of the same class or type under similar circumstances. This section does not require a renewal provision.

(F) A provision requiring that arbitration or litigation be conducted outside this state. This shall not preclude the franchisee from entering into an agreement, at the time of arbitration, to conduct arbitration at a location outside this state.

(G) A provision which permits a franchisor to refuse to permit a transfer of ownership of a franchise, except for good cause. This subdivision does not prevent a franchisor from exercising a right of first refusal to purchase the franchise. Good cause shall include, but is not limited to:

- (1) the failure of the proposed transferee to meet the franchisor's then current reasonable qualifications or standards.
- (2) the fact that the proposed transferee is a competitor of the franchisor or subfranchisor.
- (3) the unwillingness of the proposed transferee to agree in writing to comply with all lawful obligations.
- (4) the failure of the franchisee or proposed transferee to pay any sums owing to the franchisor or to cure any default in the franchise agreement existing at the time of the proposed transfer.

(H) A provision that requires the franchisee to resell to the franchisor items that are not uniquely identified with the franchisor. This subdivision does not prohibit a provision that grants to a franchisor a right of first refusal to purchase the assets of a franchise on the same terms and conditions as a bona fide third party willing and able to purchase those assets, nor does this subdivision prohibit a provision that grants the franchisor the right to acquire the assets of a franchise for the market or appraised value of such assets if the franchisee has breached the lawful provision of the franchise agreement and has failed to cure the breach in the manner provided in subdivision (C).

(I) A provision which permits the franchisor to directly or indirectly convey, assign, or otherwise transfer its obligations to fulfill contractual obligations to the franchisee unless provision has been made for providing the required contractual services.

THE FACT THAT THERE IS A NOTICE OF THIS OFFERING ON FILE WITH THE ATTORNEY GENERAL DOES NOT CONSTITUTE APPROVAL, RECOMMENDATION, OR ENDORSEMENT BY THE ATTORNEY GENERAL.

ANY QUESTIONS REGARDING THIS NOTICE SHOULD BE ADDRESSED TO:
DEPARTMENT OF ATTORNEY GENERAL
CONSUMER PROTECTION DIVISION
670 LAW BUILDING, 525 W. OTTAWA STREET
LANSING, MICHIGAN 48913
Telephone (517) 373-7117

**ADDENDUM TO AMERISOURCEBERGEN DRUG CORPORATION
DISCLOSURE DOCUMENT
FOR THE STATE OF MINNESOTA**

1. The Commissioner of Commerce for the State of Minnesota requires that certain provisions in franchise documents be amended to be consistent with Minnesota Franchise Act, Minn. Stat. Section 80.01 et seq., and of the Rules and Regulations promulgated under the Act (collectively the "Minnesota Act"). To the extent that the Franchise Agreement and Franchise Disclosure Document have provisions that are inconsistent with the following, such provisions are hereby amended:

- a. The Minnesota Department of Commerce requires that ABDC indemnify Minnesota franchisees against liability to third parties resulting from claims by third parties that a franchisee's use of the Marks infringes trademark rights of the third party. ABDC does not indemnify against the consequences of Customer's use of the Marks except in accordance with the requirements of the Franchise Agreement, and, as a condition to indemnification, Customer must provide notice to ABDC of any such claim within ten (10) days after the earlier of (i) actual notice of the claim or (ii) receipt of written notice of the claim, and must therein tender the defense of the claim to ABDC. If ABDC accepts the tender of defense, ABDC has the right to manage the defense of the claim including the right to compromise, settle or otherwise resolve the claim, and to determine whether to appeal a final determination of the claim. If either the Franchise Agreement or the Franchise Disclosure Document has a provision that is inconsistent with the Minnesota Act, such provision will be superseded by the Minnesota Act's requirements and will have no force or effect.
- b. Minnesota Act, Sec. 80C.14, Subd. 4., requires, except in certain specified cases, that Customer be given written notice of ABDC's intention not to renew 180 days prior to expiration of the franchise and that Customer be given sufficient opportunity to operate the franchise in order to enable Customer the opportunity to recover the fair market value of the franchise as a going concern. If either the Franchise Agreement or the Franchise Disclosure Document has a provision that is inconsistent with the Minnesota Act, such provision will be superseded by the Minnesota Act's requirements and will have no force or effect.
- c. Minnesota Act, Sec. 80C.14, Subd. 3., requires, except in certain specified cases, that Customer be given 90 days' notice of termination (with 60 days to cure). If either the Franchise Agreement or the Franchise Disclosure Document has a provision that is inconsistent with the Minnesota Act, such provision will be superseded by the Minnesota Act's requirements and will have no force or effect.
- d. Minn. Rule 2860.4400(D) prohibits ABDC from requiring Customer to assent to a general release. If either the Franchise Agreement or the Franchise Disclosure Document requires Customer to execute a release of claims or to acknowledge facts that would negate or remove from judicial review any statement, misrepresentation or action that would violate the Franchise Act, such release will exclude claims arising under the Minnesota Act, and such acknowledgments will be void with respect to claims under the Minnesota Act.
- e. Minnesota Statutes, Section 80C.21 and Minn. Rule 2860.4400(J) prohibit ABDC from requiring litigation to be conducted outside Minnesota, requiring waiver of a jury trial or requiring Customer to consent to liquidated damages, termination penalties or judgment notes. In addition, nothing in the Franchise Agreement or the Franchise Disclosure Document can abrogate or reduce Customer's rights under Minnesota Statutes, Chapter 80C or Customer's rights to any procedure, forum or remedies provided for by the laws of the jurisdiction.

No statement, questionnaire, or acknowledgment signed or agreed to by a franchisee in connection with the commencement of the franchise relationship shall have the effect of (i) waiving any claims under any applicable state franchise law, including fraud in the inducement, or (ii) disclaiming reliance on any statement made by any franchisor, franchise seller, or other person acting on behalf of the franchisor. This provision supersedes any other term of any document executed in connection with the franchise.

Notwithstanding anything contained in the franchise agreement or area development agreement to the contrary, you do not have to pay us the initial franchise fee until we perform our pre-opening obligations under the franchise agreement, and your first franchised business is open. Once we complete this obligation and you are open, you must immediately pay us all initial fees we deferred.

**ADDENDUM TO AMERISOURCEBERGEN DRUG CORPORATION
DISCLOSURE DOCUMENT
FOR THE STATE OF NEW YORK**

1. Item 3 of the Disclosure Document is supplemented by the following language:
Except as described in Item 3:

Neither we nor any person identified in Item 2 above, has pending any administrative, criminal or material civil action (or a significant number of civil actions irrespective of materiality) alleging a violation of any franchise law, securities law, fraud, embezzlement, fraudulent conversion, restraint of trade, unfair or deceptive practices, misappropriation of property or comparable allegations.

Neither we nor any person identified in Item 2 above, has been convicted of a felony or pleaded nolo contendere to a felony charge or, within the ten-year period immediately preceding the date of this Disclosure Document, has been convicted of a misdemeanor or pleaded nolo contendere to a misdemeanor charge or been held liable in a civil action by final judgment or been the subject of a material complaint or other legal proceeding if such misdemeanor conviction or charge or civil action, complaint or other legal proceeding involved a violation of any franchise law, securities law, fraud, embezzlement, fraudulent conversion, restraint of trade, unfair or deceptive practices, misappropriation of property or comparable allegations.

Neither we nor any person identified in Item 2 above, is subject to any injunctive or restrictive order or decree relating to franchises or under any Federal, State or Canadian franchise, securities, antitrust, trade regulation or trade practice law as a result of a concluded or pending action or proceeding brought by a public agency, is subject to any currently effective order of any national securities association or national securities exchange, as defined in the Securities and Exchange Act of 1934, suspending or expelling such person from membership in such association or exchange; or is subject to a currently effective injunctive or restrictive order relating to any other business activity as a result of an action brought by a public agency or department, including, without limitation, actions affecting a license as a real estate broker or sales agent.

2. Item 4 of the Disclosure Document is supplemented by the following language:

Neither we, nor any of our affiliates or predecessors described in Item 1, or officers or general partners described in Item 2 have within the 10-year period immediately before the date of this Disclosure Document: (a) filed as a debtor (or had filed against it) a petition to start an action under U.S. Bankruptcy Code; (b) obtained a discharge of its debts under the U.S. Bankruptcy Code; or (c) was a principal officer of a company or general partner in a partnership that either filed as a debtor (or that had filed against it) a petition to start an action under U.S. Bankruptcy Code or that obtained a discharge of its debts under the U.S. Bankruptcy Code during or within 1 year after the officer or general partner held the position with the company or partnership.

3. Item 17, "Renewal, Termination, Transfer and Dispute Resolution", shall be supplemented under the categories entitled "Termination by Franchisee" and "Assignment of Contract by Franchisor" respectively, by the following language which shall be deemed an integral part thereof:

Any general release required under the GNP Premier Agreement shall be limited by the following, "All rights arising in your favor from the provisions of General Business Law of the State of New York, Article 33 and regulations issued thereunder shall remain in force; it being the intent of this proviso that the non-waiver provisions of GBL, Sections 687.4 and 687.5 be satisfied."

You have whatever rights you may have under applicable law to terminate the GNP Premier Agreement.

No assignment will be made except to an Assignee who, in our opinion, is willing and able to assume our obligations under the GNP Premier Agreement.

The GNP Premier Agreement requires the application of Pennsylvania law; however, the choice of law provision should not be considered a waiver of any right conferred on the franchisee by GBL, Article 33.

No statement, questionnaire, or acknowledgment signed or agreed to by a franchisee in connection with the commencement of the franchise relationship shall have the effect of (i) waiving any claims under any applicable state franchise law, including fraud in the inducement, or (ii) disclaiming reliance on any statement made by any franchisor, franchise seller, or other person acting on behalf of the franchisor. This provision supersedes any other term of any document executed in connection with the franchise.

**ADDENDUM TO AMERISOURCEBERGEN DRUG CORPORATION
DISCLOSURE DOCUMENT
FOR THE STATE OF NORTH DAKOTA**

1. Item 17(i) of the Disclosure Document is amended by the addition of the following language:

If the GNP Premier Agreement contains a liquidated damages clause, under Section 51-19-09 of the North Dakota Franchise Investment Law, certain liquidated damages clauses are unenforceable.

2. The State Cover Page and Item 17.w. are amended by the addition of the following language:

The GNP Premier Agreement requires the application of the laws of Pennsylvania. This provision may be unenforceable under North Dakota Law.

No statement, questionnaire, or acknowledgment signed or agreed to by a franchisee in connection with the commencement of the franchise relationship shall have the effect of (i) waiving any claims under any applicable state franchise law, including fraud in the inducement, or (ii) disclaiming reliance on any statement made by any franchisor, franchise seller, or other person acting on behalf of the franchisor. This provision supersedes any other term of any document executed in connection with the franchise.

**ADDENDUM TO AMERISOURCEBERGEN DRUG CORPORATION
DISCLOSURE DOCUMENT
FOR THE STATE OF RHODE ISLAND**

1. Item 17 of the Disclosure Document is amended to state that Section 19-28.1-14 of the Rhode Island Franchise Investment Act provides that any provision in the GNP Premier Agreement restricting jurisdiction or venue to a forum outside of Rhode Island or requiring the application of the laws of another state is void with respect to a claim otherwise enforceable under this Act.

**ADDENDUM TO AMERISOURCEBERGEN DRUG CORPORATION
DISCLOSURE DOCUMENT
FOR THE STATE OF VIRGINIA**

1. In recognition of the restrictions contained in Section 13.1-564 of the Virginia Retail Franchising Act, Items 17.e. and 17.h. of the Franchise Disclosure Document are supplemented by the following:

“Under Section 13.1-564 of the Virginia Retail Franchising Act, it is unlawful for a franchisor to cancel a franchise without reasonable cause. If any ground for default or termination stated in the GNP Premier Agreement do not constitute “reasonable cause”, as that term may be defined in the Virginia Retail Franchising Act or the laws of Virginia, that provision may not be enforceable.”

No statement, questionnaire, or acknowledgment signed or agreed to by a franchisee in connection with the commencement of the franchise relationship shall have the effect of (i) waiving any claims under any applicable state franchise law, including fraud in the inducement, or (ii) disclaiming reliance on any statement made by any franchisor, franchise seller, or other person acting on behalf of the franchisor. This provision supersedes any other term of any document executed in connection with the franchise.

The Virginia State Corporation Commission's Division of Securities and Retail Franchising requires us to defer payment of the initial franchise fee and other initial payments owed by franchisees to the franchisor until the franchisor has completed its pre-opening obligations under the franchise agreement.

**ADDENDUM TO AMERISOURCEBERGEN DRUG CORPORATION
DISCLOSURE DOCUMENT
FOR THE STATE OF WASHINGTON**

In the event of a conflict of laws, the provisions of the Washington Franchise Investment Protection Act, Chapter 19.100 RCW will prevail.

RCW 19.100.180 may supersede the franchise agreement in your relationship with the franchisor including the areas of termination and renewal of your franchise. There may also be court decisions which may supersede the franchise agreement in your relationship with the franchisor, including the areas of termination and renewal of your franchise.

In any arbitration or mediation involving a franchise purchased in Washington, the arbitration or mediation site will be either in the state of Washington, or in a place mutually agreed upon at the time of the arbitration or mediation, or as determined by the arbitrator or mediator at the time of arbitration or mediation. In addition, if litigation is not precluded by the franchise agreement, a

franchisee may bring an action or proceeding arising out of or in connection with the sale of franchises, or a violation of the Washington Franchise Investment Protection Act, in Washington.

A release or waiver of rights executed by a franchisee may not include rights under the Washington Franchise Investment Protection Act or any rule or order thereunder except when executed pursuant to a negotiated settlement after the agreement is in effect and where the parties are represented by independent counsel. Provisions such as those which unreasonably restrict or limit the statute of limitations period for claims under the Act, or rights or remedies under the Act such as a right to a jury trial, may not be enforceable.

Transfer fees are collectable to the extent that they reflect the franchisor's reasonable estimated or actual costs in effecting a transfer.

Pursuant to RCW 49.62.020, a noncompetition covenant is void and unenforceable against an employee, including an employee of a franchisee, unless the employee's earnings from the party seeking enforcement, when annualized, exceed \$100,000 per year (an amount that will be adjusted annually for inflation). In addition, a noncompetition covenant is void and unenforceable against an independent contractor of a franchisee under RCW 49.62.030 unless the independent contractor's earnings from the party seeking enforcement, when annualized, exceed \$250,000 per year (an amount that will be adjusted annually for inflation). As a result, any provisions contained in the franchise agreement or elsewhere that conflict with these limitations are void and unenforceable in Washington.

RCW 49.62.060 prohibits a franchisor from restricting, restraining, or prohibiting a franchisee from (i) soliciting or hiring any employee of a franchisee of the same franchisor or (ii) soliciting or hiring any employee of the franchisor. As a result, any such provisions contained in the franchise agreement or elsewhere are void and unenforceable in Washington. The undersigned does hereby acknowledge receipt of this addendum.

In lieu of an impound of franchise fees, the Franchisor will not require or accept the payment of any initial franchise fees until the franchisee has (a) received all initial training that it is entitled to under the franchise agreement or offering circular, and (b) is open for business.

No statement, questionnaire, or acknowledgment signed or agreed to by a franchisee in connection with the commencement of the franchise relationship shall have the effect of (i) waiving any claims under any applicable state franchise law, including fraud in the inducement, or (ii) disclaiming reliance on any statement made by any franchisor, franchise seller, or other person acting on behalf of the franchisor. This provision supersedes any other term of any document executed in connection with the franchise.

**ADDENDUM TO AMERISOURCEBERGEN DRUG CORPORATION
DISCLOSURE DOCUMENT
FOR THE STATE OF WISCONSIN**

1. Item 17 of the Disclosure Document is amended to state that the Wisconsin Fair Dealership Law (the "Wisconsin Act") supersedes any provisions contained in the Disclosure Document or the GNP Premier Agreement that are inconsistent with the Wisconsin Act.

State Effective Dates

The following states have franchise laws that require that the Franchise Disclosure Document be registered or filed with the states, or be exempt from registration: California, Hawaii, Illinois, Indiana, Maryland, Michigan, Minnesota, New York, North Dakota, Rhode Island, South Dakota, Virginia, Washington, and Wisconsin.

This document is effective and may be used in the following states, where the document is filed, registered, or exempt from registration, as of the Effective Date stated below:

State	Effective Date
California	
Florida	
Hawaii	
Illinois	
Indiana	
Maryland	
Michigan	
Minnesota	
New York	
North Dakota	
Rhode Island	
South Dakota	
Utah	
Virginia	
Washington	
Wisconsin	

Other states may require registration, filing, or exemption of a franchise under other laws, such as those that regulate the offer and sale of business opportunities or seller-assisted marketing plans.

In all other states, the effective date of this Franchise Disclosure Document is the Issuance Date of: December 18, 2025.

**ITEM 23
RECEIPT**

This Disclosure Document summarizes provisions of the GNP Premier Agreement and other information in plain language. Read this Disclosure Document and all agreements carefully.

If AmerisourceBergen Drug Corporation offers you a franchise, AmerisourceBergen Drug Corporation must provide this Disclosure Document to you 14 calendar days before you sign a binding agreement or make any payment to AmerisourceBergen Drug Corporation or an affiliate in connection with the proposed franchise sale. Under Michigan and Wisconsin law, AmerisourceBergen Drug Corporation must provide this Disclosure Document to you 10 business days before you sign any contract or make any payment relating to the franchise relationship. Under Oklahoma, New York and Rhode Island law, AmerisourceBergen Drug Corporation must provide this Disclosure Document to you at the earliest of the first personal meeting or 10 business days before you sign any contract or make any payment relating to the franchise relationship.

If AmerisourceBergen Drug Corporation does not deliver this Disclosure Document on time, or if it contains a false or misleading statement, or a material omission, a violation of federal and state law may have occurred and should be reported to the Federal Trade Commission, Washington, D.C. 20590 or the appropriate state agency listed in Exhibit A.

The name and address of our registered agent authorized to receive service of process is shown in Exhibit A.

The franchise seller's name(s), business address(es) and telephone number(s) is(are):

I have received a Franchise Disclosure Document with an issuance date of December 18, 2025. State registration effective dates are listed on the State Registrations Page. This Disclosure Document included the following Exhibits:

- A. State Administrators/Agents for Service of Process
- B. GNP Premier Agreement with Exhibits A-E and Term Sheets 1-10
- C. Table of Contents of GNP Manual
- D. List of Current, Transferred & Former Franchisees
- E. Financial Statements and Cencora Guaranty
- F. Addendum to Disclosure Document

PROSPECTIVE FRANCHISEE:

Signed by: _____

Print Name: _____

Date: _____

Please sign this Receipt and return it (fax or mail) to:

Good Neighbor Pharmacy Programs
1 West First Avenue, Conshohocken,
PA, 19428
Fax 610-862-3718.

**ITEM 23
RECEIPT**

This Disclosure Document summarizes provisions of the GNP Premier Agreement and other information in plain language. Read this Disclosure Document and all agreements carefully.

If AmerisourceBergen Drug Corporation offers you a franchise, AmerisourceBergen Drug Corporation must provide this Disclosure Document to you 14 calendar days before you sign a binding agreement or make any payment to AmerisourceBergen Drug Corporation or an affiliate in connection with the proposed franchise sale. Under Michigan and Wisconsin law, AmerisourceBergen Drug Corporation must provide this Disclosure Document to you 10 business days before you sign any contract or make any payment relating to the franchise relationship. Under Oklahoma, New York and Rhode Island law, AmerisourceBergen Drug Corporation must provide this Disclosure Document to you at the earliest of the first personal meeting or 10 business days before you sign any contract or make any payment relating to the franchise relationship.

If AmerisourceBergen Drug Corporation does not deliver this Disclosure Document on time, or if it contains a false or misleading statement, or a material omission, a violation of federal and state law may have occurred and should be reported to the Federal Trade Commission, Washington, D.C. 20590 or the appropriate state agency listed in Exhibit A.

The name and address of our registered agent authorized to receive service of process is shown in Exhibit A.

The franchise seller's name(s), business address(es) and telephone number(s) is(are):

I have received a Franchise Disclosure Document with an issuance date of December 18, 2025. State registration effective dates are listed on the State Registrations Page. This Disclosure Document included the following Exhibits:

- A. State Administrators/Agents for Service of Process
- B. GNP Premier Agreement with Exhibits A-E and Exhibits 1-10
- C. Table of Contents of GNP Manual
- D. List of Current, Transferred & Former Franchisees
- E. Financial Statements and Cencora Guaranty
- F. Addendum to Disclosure Document

PROSPECTIVE FRANCHISEE:

Signed by: _____

Print Name: _____

Date: _____

Please retain this Receipt for your records.